PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2557085-4	1989	Indicating that this may be an important cytotoxic lesion is the hypersensitivity to camptothecin of the yeast mutant rad52, which is deficient in double-strand-break-repair.	Camptothecin	85-97	recombinase RAD52	Saccharomyces cerevisiae S288C	118-123
2548490-2	1989	Inhibition of ribosomal RNA synthesis and processing by 5-fluorouridine or of general RNA synthesis by camptothecin, an inhibitor of topoisomerase I, does not affect the methylation pattern of core histones.	Camptothecin	103-115	Topoisomerase 1	Drosophila melanogaster	133-148
2555773-1	1989	Topoisomerase I cleavage sites have been mapped in vivo on the Hsp70 heat shock gene of Drosophila melanogaster cells using the drug camptothecin.	Camptothecin	133-145	Topoisomerase 1	Drosophila melanogaster	0-15
2555773-1	1989	Topoisomerase I cleavage sites have been mapped in vivo on the Hsp70 heat shock gene of Drosophila melanogaster cells using the drug camptothecin.	Camptothecin	133-145	Heat-shock-protein-70Ab	Drosophila melanogaster	63-68
2555773-6	1989	Camptothecin (100 microM) inhibited transcription of the Hsp70 gene greater than 95%.	Camptothecin	0-12	Heat-shock-protein-70Ab	Drosophila melanogaster	57-62
2552999-2	1989	Incubation of cultured rat aortic smooth muscle cells (A-10, ATCC CRL 1476) with [8-arginine]vasopressin (AVP) or thrombin increased the amount of DNA strand breakage induced by camptothecin, an inhibitor of topoisomerase I (DNA topoisomerase; EC 5.99.1.2) and transiently stimulated the extractable activity of this enzyme.	Camptothecin	178-190	arginine vasopressin	Rattus norvegicus	93-104
2552999-2	1989	Incubation of cultured rat aortic smooth muscle cells (A-10, ATCC CRL 1476) with [8-arginine]vasopressin (AVP) or thrombin increased the amount of DNA strand breakage induced by camptothecin, an inhibitor of topoisomerase I (DNA topoisomerase; EC 5.99.1.2) and transiently stimulated the extractable activity of this enzyme.	Camptothecin	178-190	coagulation factor II	Rattus norvegicus	114-122
2552999-6	1989	Pretreatment of the cells with pertussis toxin partially inhibited thrombin-mediated increases in camptothecin-induced strand breakage whereas AVP-mediated increases were unaffected.	Camptothecin	98-110	coagulation factor II	Rattus norvegicus	67-75
2545341-0	1989	DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.	Camptothecin	62-74	topoisomerase (DNA) I	Mus musculus	0-19
3031452-0	1987	Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin.	Camptothecin	134-146	Topoisomerase 1	Drosophila melanogaster	25-40
2478139-6	1989	Ten microM camptothecin inhibited Cd-induced accumulation of MT-II mRNA as well as induced and uninduced RNA synthesis in the resistant cells.	Camptothecin	11-23	metallothionein-2	Cricetulus griseus	61-66
3033639-3	1987	Inhibition of this topoisomerase activity by the selective inhibitor camptothecin markedly diminished transcription of supercoiled rDNA, and at a concentration of 150 microM, camptothecin almost completely inhibited DNA topoisomerase I activity and supercoiled rDNA transcription.	Camptothecin	175-187	DNA topoisomerase I	Rattus norvegicus	216-235
3033639-7	1987	The preferential inhibition of rRNA synthesis in vivo following treatment with camptothecin is probably due to selective camptothecin inhibition of DNA topoisomerase I activity.	Camptothecin	79-91	DNA topoisomerase I	Rattus norvegicus	148-167
3033639-7	1987	The preferential inhibition of rRNA synthesis in vivo following treatment with camptothecin is probably due to selective camptothecin inhibition of DNA topoisomerase I activity.	Camptothecin	121-133	DNA topoisomerase I	Rattus norvegicus	148-167
2819725-3	1987	Camptothecin stabilizes the topoisomerase I-DNA covalent intermediate that forms during the relaxation of torsionally strained DNA.	Camptothecin	0-12	Topoisomerase 1	Drosophila melanogaster	28-43
2846151-6	1988	Studies with DNA topoisomerase I purified from the wild-type and the mutant cells showed that the enzyme from the CptR cells was markedly resistant to camptothecin as assayed by the drug"s effects either on relaxation of supercoiled DNA or on stabilization of the covalent enzyme-DNA intermediate.	Camptothecin	151-163	DNA topoisomerase 1	Cricetulus griseus	13-32
2846151-7	1988	The presence of a camptothecin-resistant form of DNA topoisomerase I in the mutant cells provides further evidence that this enzyme is the cellular target of camptothecin.	Camptothecin	18-30	DNA topoisomerase 1	Cricetulus griseus	49-68
2846151-7	1988	The presence of a camptothecin-resistant form of DNA topoisomerase I in the mutant cells provides further evidence that this enzyme is the cellular target of camptothecin.	Camptothecin	158-170	DNA topoisomerase 1	Cricetulus griseus	49-68
2839226-8	1988	Dephosphorylation of DNA topoisomerase I appears to block formation of the initial enzyme-substrate complex on the basis of the failure of the dephosphorylated enzyme to nick DNA in the presence of camptothecin.	Camptothecin	198-210	DNA topoisomerase I, gene 1 L homeolog	Xenopus laevis	21-40
3028614-0	1987	Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.	Camptothecin	50-62	topoisomerase (DNA) I	Mus musculus	85-104
3031452-1	1987	Camptothecin stabilizes the topoisomerase I-DNA covalent intermediate that forms during the relaxation of torsionally strained DNA.	Camptothecin	0-12	Topoisomerase 1	Drosophila melanogaster	28-43
2819725-7	1987	Camptothecin only partially inhibits transcription of the hsp28 gene during heat shock, causing a reduced level of transcripts which are nonetheless full length.	Camptothecin	0-12	Heat shock protein 27	Drosophila melanogaster	58-63
2819731-0	1987	Camptothecin inhibits hsp 70 heat-shock transcription and induces DNA strand breaks in hsp 70 genes in Drosophila.	Camptothecin	0-12	Heat-shock-protein-70Ab	Drosophila melanogaster	22-28
2819731-0	1987	Camptothecin inhibits hsp 70 heat-shock transcription and induces DNA strand breaks in hsp 70 genes in Drosophila.	Camptothecin	0-12	Heat-shock-protein-70Ab	Drosophila melanogaster	87-93
3031452-6	1987	Camptothecin only partially inhibited transcription of the hsp28 gene during heat shock, causing a reduced level of transcripts which were nonetheless full length.	Camptothecin	0-12	Heat shock protein 27	Drosophila melanogaster	59-64
2819731-3	1987	Recent studies have demonstrated that camptothecin interferes with the DNA breakage and rejoining activity of the enzyme DNA topoisomerase I and stabilizes a cleavable complex between this enzyme and DNA.	Camptothecin	38-50	Topoisomerase 1	Drosophila melanogaster	125-140
2819731-5	1987	In this paper we have mapped the camptothecin-induced DNA breaks on the hsp 70 heat-shock gene in cultured Drosophila cells.	Camptothecin	33-45	Heat-shock-protein-70Ab	Drosophila melanogaster	72-78
2819731-7	1987	Camptothecin (20 microM) was also observed to inhibit heat-induced hsp 70 transcription greater than 70%.	Camptothecin	0-12	Heat-shock-protein-70Ab	Drosophila melanogaster	67-73
33785416-7	2021	The diffusion of camptothecin released from polymeric micelles revealed a significant decrease, which agrees with the increased expression of the P-gp observed with the increase in g-levels, responsible for pumping this drug out.	Camptothecin	17-29	phosphoglycolate phosphatase	Homo sapiens	146-150
1174509-6	1975	Since ornithine decarboxylase activity decays more rapidly in the presence of each polyamine after addition of camptothecin, the major locus of amine action appears to be in the cytoplasm.	Camptothecin	111-123	ornithine decarboxylase, structural 1	Mus musculus	6-29
33882408-4	2021	Here we report the novel interaction between the endogenous family member B-so-called ANP32B-and endogenous cytochrome c in cells undergoing camptothecin-induced DNA damage.	Camptothecin	141-153	acidic nuclear phosphoprotein 32 family member B	Homo sapiens	86-92
33882408-4	2021	Here we report the novel interaction between the endogenous family member B-so-called ANP32B-and endogenous cytochrome c in cells undergoing camptothecin-induced DNA damage.	Camptothecin	141-153	cytochrome c, somatic	Homo sapiens	108-120
7240210-5	1981	The action of NGF on acetylcholinesterase activity is abolished by low concentrations of the inhibitors of RNA synthesis, camptothecin and actinomycin D.	Camptothecin	122-134	acetylcholinesterase	Rattus norvegicus	21-41
988022-16	1976	The presence of camptothecin, or cordycepin, or cycloheximide in the incubation medium completely blocks the increase in number of 125I-insulin-binding sites resulting from serum starvation.	Camptothecin	16-28	insulin	Gallus gallus	136-143
5289246-2	1971	5 muM camptothecin inhibits the synthesis of heterogeneously sedimenting nuclear RNA by about 70%.	Camptothecin	6-18	latexin	Homo sapiens	2-5
33898327-0	2021	Camptothecin Inhibits Neddylation to Activate the Protective Autophagy Through NF-kappaB/AMPK/mTOR/ULK1 Axis in Human Esophageal Cancer Cells.	Camptothecin	0-12	nuclear factor kappa B subunit 1	Homo sapiens	79-88
33582946-11	2021	Leptin stimulated Akt activity and cell proliferation and inhibited camptothecin-induced apoptosis in an Akt-sensitive manner.	Camptothecin	68-80	leptin	Homo sapiens	0-6
33582946-11	2021	Leptin stimulated Akt activity and cell proliferation and inhibited camptothecin-induced apoptosis in an Akt-sensitive manner.	Camptothecin	68-80	AKT serine/threonine kinase 1	Homo sapiens	105-108
34049076-5	2021	We found that in cancer cells, tonicity-responsive enhancer-binding protein (TonEBP, also called NFAT5) interacted with PARP1 and localized to R-loops in response to DNA-damaging agent camptothecin (CPT), which is associated with R-loop formation.	Camptothecin	185-197	nuclear factor of activated T cells 5	Homo sapiens	31-75
34049076-5	2021	We found that in cancer cells, tonicity-responsive enhancer-binding protein (TonEBP, also called NFAT5) interacted with PARP1 and localized to R-loops in response to DNA-damaging agent camptothecin (CPT), which is associated with R-loop formation.	Camptothecin	185-197	nuclear factor of activated T cells 5	Homo sapiens	77-83
34049076-5	2021	We found that in cancer cells, tonicity-responsive enhancer-binding protein (TonEBP, also called NFAT5) interacted with PARP1 and localized to R-loops in response to DNA-damaging agent camptothecin (CPT), which is associated with R-loop formation.	Camptothecin	185-197	nuclear factor of activated T cells 5	Homo sapiens	97-102
34049076-5	2021	We found that in cancer cells, tonicity-responsive enhancer-binding protein (TonEBP, also called NFAT5) interacted with PARP1 and localized to R-loops in response to DNA-damaging agent camptothecin (CPT), which is associated with R-loop formation.	Camptothecin	185-197	poly(ADP-ribose) polymerase 1	Homo sapiens	120-125
33898327-0	2021	Camptothecin Inhibits Neddylation to Activate the Protective Autophagy Through NF-kappaB/AMPK/mTOR/ULK1 Axis in Human Esophageal Cancer Cells.	Camptothecin	0-12	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	89-93
33898327-0	2021	Camptothecin Inhibits Neddylation to Activate the Protective Autophagy Through NF-kappaB/AMPK/mTOR/ULK1 Axis in Human Esophageal Cancer Cells.	Camptothecin	0-12	mechanistic target of rapamycin kinase	Homo sapiens	94-98
33898327-0	2021	Camptothecin Inhibits Neddylation to Activate the Protective Autophagy Through NF-kappaB/AMPK/mTOR/ULK1 Axis in Human Esophageal Cancer Cells.	Camptothecin	0-12	unc-51 like autophagy activating kinase 1	Homo sapiens	99-103
33583643-16	2021	NAP1L4 knockdown inhibited apoptosis in camptothecin-induced DNA damage, induced cell cycle arrest at the G1/S phase, and inhibited cell proliferation.	Camptothecin	40-52	nucleosome assembly protein 1 like 4	Homo sapiens	0-6
33704464-6	2021	Moreover, DOCK7 is overexpressed in ovarian cancer and depleting DOCK7 sensitizes cancer cells to camptothecin.	Camptothecin	98-110	dedicator of cytokinesis 7	Homo sapiens	10-15
33704464-6	2021	Moreover, DOCK7 is overexpressed in ovarian cancer and depleting DOCK7 sensitizes cancer cells to camptothecin.	Camptothecin	98-110	dedicator of cytokinesis 7	Homo sapiens	65-70
33868235-0	2021	Camptothecin Regulates Microglia Polarization and Exerts Neuroprotective Effects via Activating AKT/Nrf2/HO-1 and Inhibiting NF-kappaB Pathways In Vivo and In Vitro.	Camptothecin	0-12	thymoma viral proto-oncogene 1	Mus musculus	96-99
33868235-0	2021	Camptothecin Regulates Microglia Polarization and Exerts Neuroprotective Effects via Activating AKT/Nrf2/HO-1 and Inhibiting NF-kappaB Pathways In Vivo and In Vitro.	Camptothecin	0-12	nuclear factor, erythroid derived 2, like 2	Mus musculus	100-104
33868235-0	2021	Camptothecin Regulates Microglia Polarization and Exerts Neuroprotective Effects via Activating AKT/Nrf2/HO-1 and Inhibiting NF-kappaB Pathways In Vivo and In Vitro.	Camptothecin	0-12	heme oxygenase 1	Mus musculus	105-109
33868235-0	2021	Camptothecin Regulates Microglia Polarization and Exerts Neuroprotective Effects via Activating AKT/Nrf2/HO-1 and Inhibiting NF-kappaB Pathways In Vivo and In Vitro.	Camptothecin	0-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	125-134
32981006-1	2021	Camptothecin (CPT) and its derivatives, irinotecan and topotecan are specific topoisomerase I (Top1) inhibitors and potent anticancer drugs.	Camptothecin	0-12	DNA topoisomerase I	Homo sapiens	95-99
32981006-1	2021	Camptothecin (CPT) and its derivatives, irinotecan and topotecan are specific topoisomerase I (Top1) inhibitors and potent anticancer drugs.	Camptothecin	14-17	DNA topoisomerase I	Homo sapiens	95-99
33536335-3	2021	We found that inactivation of Ataxia Telangiectasia- and Rad3-related (ATR), CHK1, BRCA2, and RPA1 overcome chemoresistance to camptothecin (CPT) in SLFN11-KO cells.	Camptothecin	127-139	ATR serine/threonine kinase	Homo sapiens	30-69
33359484-3	2021	Physical encapsulation is advantageous due to requiring no chemical modification of drug molecules, but many drugs, for instance, camptothecin (CPT) and curcumin (CCM), though very hydrophobic, can not be loaded in or form nanoformulations with albumin.	Camptothecin	130-142	albumin	Homo sapiens	245-252
33714537-10	2021	Both compounds suppressed HESC proliferation and induced apoptosis; ITPR1 expression was suppressed by camptothecin.	Camptothecin	103-115	inositol 1,4,5-trisphosphate receptor 1	Mus musculus	68-73
33536335-3	2021	We found that inactivation of Ataxia Telangiectasia- and Rad3-related (ATR), CHK1, BRCA2, and RPA1 overcome chemoresistance to camptothecin (CPT) in SLFN11-KO cells.	Camptothecin	127-139	ATR serine/threonine kinase	Homo sapiens	71-74
33536335-3	2021	We found that inactivation of Ataxia Telangiectasia- and Rad3-related (ATR), CHK1, BRCA2, and RPA1 overcome chemoresistance to camptothecin (CPT) in SLFN11-KO cells.	Camptothecin	127-139	checkpoint kinase 1	Homo sapiens	77-81
33536335-3	2021	We found that inactivation of Ataxia Telangiectasia- and Rad3-related (ATR), CHK1, BRCA2, and RPA1 overcome chemoresistance to camptothecin (CPT) in SLFN11-KO cells.	Camptothecin	127-139	BRCA2 DNA repair associated	Homo sapiens	83-88
33536335-3	2021	We found that inactivation of Ataxia Telangiectasia- and Rad3-related (ATR), CHK1, BRCA2, and RPA1 overcome chemoresistance to camptothecin (CPT) in SLFN11-KO cells.	Camptothecin	127-139	replication protein A1	Homo sapiens	94-98
33559345-0	2021	Camptothecin and topotecan, inhibitors of transcription factor Fli-1 and topoisomerase, markedly ameliorate lupus nephritis in NZBWF1 mice and reduce the production of inflammatory mediators in human renal cells.	Camptothecin	0-12	Friend leukemia integration 1	Mus musculus	63-68
33559345-0	2021	Camptothecin and topotecan, inhibitors of transcription factor Fli-1 and topoisomerase, markedly ameliorate lupus nephritis in NZBWF1 mice and reduce the production of inflammatory mediators in human renal cells.	Camptothecin	0-12	WD repeat and FYVE domain containing 3	Mus musculus	127-133
33559345-1	2021	OBJECTIVE: To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli-1 and topoisomerase, on lupus nephritis in NZBWF1 mice and their effects on inflammatory mediators in human renal cells.	Camptothecin	49-61	WD repeat and FYVE domain containing 3	Mus musculus	171-177
33536335-3	2021	We found that inactivation of Ataxia Telangiectasia- and Rad3-related (ATR), CHK1, BRCA2, and RPA1 overcome chemoresistance to camptothecin (CPT) in SLFN11-KO cells.	Camptothecin	127-139	schlafen family member 11	Homo sapiens	149-155
33414522-0	2021	FEN1 inhibitor synergizes with low-dose camptothecin to induce increased cell killing via the mitochondria mediated apoptotic pathway.	Camptothecin	40-52	flap structure-specific endonuclease 1	Homo sapiens	0-4
33563179-0	2021	In Vitro Metabolism of E2, G2: Novel Bile Acid-Coupling Camptothecin Analogues, in Rat Liver Microsomes.	Camptothecin	56-68	dihydrolipoamide S-succinyltransferase	Rattus norvegicus	23-29
33529438-6	2021	In combination with cytotoxic chemotherapy such as gemcitabine or camptothecin, Chk1 inhibition increased cytoplasmic dsDNA compared to the cytotoxic alone but attenuated the cytotoxic chemotherapy-induced increase in IRF1 protein and STAT1 phosphorylation through inhibition of nuclear RelB translocation.	Camptothecin	66-78	checkpoint kinase 1	Homo sapiens	80-84
33529438-6	2021	In combination with cytotoxic chemotherapy such as gemcitabine or camptothecin, Chk1 inhibition increased cytoplasmic dsDNA compared to the cytotoxic alone but attenuated the cytotoxic chemotherapy-induced increase in IRF1 protein and STAT1 phosphorylation through inhibition of nuclear RelB translocation.	Camptothecin	66-78	interferon regulatory factor 1	Homo sapiens	218-222
33529438-6	2021	In combination with cytotoxic chemotherapy such as gemcitabine or camptothecin, Chk1 inhibition increased cytoplasmic dsDNA compared to the cytotoxic alone but attenuated the cytotoxic chemotherapy-induced increase in IRF1 protein and STAT1 phosphorylation through inhibition of nuclear RelB translocation.	Camptothecin	66-78	signal transducer and activator of transcription 1	Homo sapiens	235-240
33529438-6	2021	In combination with cytotoxic chemotherapy such as gemcitabine or camptothecin, Chk1 inhibition increased cytoplasmic dsDNA compared to the cytotoxic alone but attenuated the cytotoxic chemotherapy-induced increase in IRF1 protein and STAT1 phosphorylation through inhibition of nuclear RelB translocation.	Camptothecin	66-78	RELB proto-oncogene, NF-kB subunit	Homo sapiens	287-291
33273058-6	2021	Payload release studies demonstrated that two camptothecins, CPT1 and the corresponding glycine analog (CPT2) were released from a cAC10 ADC by tumor cells.	Camptothecin	46-59	carnitine palmitoyltransferase 2	Rattus norvegicus	104-108
33141948-0	2021	Fun30 chromatin remodeler helps in dealing with torsional stress and camptothecin induced DNA damage.	Camptothecin	69-81	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	0-5
33141948-2	2021	Cells lacking Fun30 are moderately sensitive to the Topoisomerase inhibitor camptothecin and exhibit a delay in cell cycle progression in the presence of camptothecin.	Camptothecin	76-88	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	14-19
33141948-2	2021	Cells lacking Fun30 are moderately sensitive to the Topoisomerase inhibitor camptothecin and exhibit a delay in cell cycle progression in the presence of camptothecin.	Camptothecin	154-166	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	14-19
33141948-4	2021	Moreover, we show through genetic studies that Fun30 acts in a parallel pathway to Mus81 endonuclease but is epistatic to Tdp1 phosphodiesterase and Rad1 endonuclease in the repair of camptothecin induced DNA damage.	Camptothecin	184-196	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	47-52
33141948-4	2021	Moreover, we show through genetic studies that Fun30 acts in a parallel pathway to Mus81 endonuclease but is epistatic to Tdp1 phosphodiesterase and Rad1 endonuclease in the repair of camptothecin induced DNA damage.	Camptothecin	184-196	Mus81p	Saccharomyces cerevisiae S288C	83-88
33141948-4	2021	Moreover, we show through genetic studies that Fun30 acts in a parallel pathway to Mus81 endonuclease but is epistatic to Tdp1 phosphodiesterase and Rad1 endonuclease in the repair of camptothecin induced DNA damage.	Camptothecin	184-196	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	149-153
33141948-6	2021	We believe that, chromatin remodeling by Fun30 may be important in dealing with torsional stress and camptothecin induced DNA damage.	Camptothecin	101-113	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	41-46
33313823-5	2021	Here, we demonstrate that tonicity-responsive enhancer binding protein (TonEBP) recognizes R-loops generated by DNA damaging agents such as ultraviolet (UV) or camptothecin (CPT).	Camptothecin	160-172	nuclear factor of activated T cells 5	Homo sapiens	26-70
33313823-5	2021	Here, we demonstrate that tonicity-responsive enhancer binding protein (TonEBP) recognizes R-loops generated by DNA damaging agents such as ultraviolet (UV) or camptothecin (CPT).	Camptothecin	160-172	nuclear factor of activated T cells 5	Homo sapiens	72-78
33414522-3	2021	Here we found that FEN1 inhibitor greatly sensitizes cancer cells to low-dose camptothecin.	Camptothecin	78-90	flap structure-specific endonuclease 1	Homo sapiens	19-23
33022763-10	2021	In BPH1 cell line, SPOP mutant overexpression and CHD1 silencing synergistically sensitized the cells to DNA damage by camptothecin, an inducer of double-strand breaks.	Camptothecin	119-131	speckle type BTB/POZ protein	Homo sapiens	19-23
33268481-10	2021	Finally, we demonstrated that a low dose of a chemotherapeutic drug, camptothecin, inhibited expression of Fli-1 and reduced GM-CSF production in human T cells.	Camptothecin	69-81	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	107-112
33268481-10	2021	Finally, we demonstrated that a low dose of a chemotherapeutic drug, camptothecin, inhibited expression of Fli-1 and reduced GM-CSF production in human T cells.	Camptothecin	69-81	colony stimulating factor 2	Homo sapiens	125-131
33022763-10	2021	In BPH1 cell line, SPOP mutant overexpression and CHD1 silencing synergistically sensitized the cells to DNA damage by camptothecin, an inducer of double-strand breaks.	Camptothecin	119-131	chromodomain helicase DNA binding protein 1	Homo sapiens	50-54
33271982-5	2020	After inducing DSB by camptothecin, RB co-localizes with CtIP, which regulates DSB end resection.	Camptothecin	22-34	RB binding protein 8, endonuclease	Homo sapiens	57-61
33352117-7	2021	Thereby, camptothecins may leverage a physiological cysteine-based redox switch in Top1 to mediate their selective toxicity to rapidly proliferating cancer cells.	Camptothecin	9-22	DNA topoisomerase I	Homo sapiens	83-87
33510870-5	2021	Molecular docking simulations of known ABCB5 substrates such as taxanes, anthracyclines, camptothecin and etoposide were then used to identify at least three putative binding sites for chemotherapeutic drugs transported by ABCB5.	Camptothecin	89-101	ATP-binding cassette, sub-family B (MDR/TAP), member 5	Mus musculus	39-44
33510870-5	2021	Molecular docking simulations of known ABCB5 substrates such as taxanes, anthracyclines, camptothecin and etoposide were then used to identify at least three putative binding sites for chemotherapeutic drugs transported by ABCB5.	Camptothecin	89-101	ATP-binding cassette, sub-family B (MDR/TAP), member 5	Mus musculus	223-228
33352117-2	2021	The Top1 poison camptothecin targets cancer cells by trapping the enzyme in the covalent complex Top1cc, tethered to cleaved DNA by a tyrosine-3"-phosphate bond.	Camptothecin	16-28	DNA topoisomerase I	Homo sapiens	4-8
33352117-3	2021	In vitro mechanistic studies point to interfacial inhibition, where camptothecin binding to the Top1-DNA interface stabilizes Top1cc.	Camptothecin	68-80	DNA topoisomerase I	Homo sapiens	96-100
33352117-5	2021	We observed that camptothecins induce oxidative stress, leading to lipid peroxidation, lipid-derived electrophile accumulation, and Top1 poisoning via covalent modification.	Camptothecin	17-30	DNA topoisomerase I	Homo sapiens	132-136
32930615-6	2020	For example, graphene oxide incorporated with PEG and loaded with SN 38 for camptothecin analolgue as anticancer drug and revealed high cytotoxicity has an effect of 1000 times better effect than CPT in HCT-116 cells.	Camptothecin	76-88	choline phosphotransferase 1	Homo sapiens	196-199
33271982-8	2020	According to the synthetic lethality principle, based on the altered DSB repair pathway choice, after inducing DSBs by camptothecin, RB depleted cells are more sensitive to co-treatment with camptothecin and MMEJ blocker poly-ADP ribose polymerase 1 (PARP1) inhibitor.	Camptothecin	119-131	poly(ADP-ribose) polymerase 1	Homo sapiens	221-249
33271982-8	2020	According to the synthetic lethality principle, based on the altered DSB repair pathway choice, after inducing DSBs by camptothecin, RB depleted cells are more sensitive to co-treatment with camptothecin and MMEJ blocker poly-ADP ribose polymerase 1 (PARP1) inhibitor.	Camptothecin	191-203	poly(ADP-ribose) polymerase 1	Homo sapiens	251-256
33229317-7	2020	Based on the apoptosis model of MCF-7 cells induced by camptothecin, we used chromosome conformation capture (3C), quantitative real-time PCR (qRT-PCR) and the luciferase reporter gene technology to demonstrate that the NOXA promoter could function as an active enhancer and physically interact with the BCL2 promoter through chromatin looping.	Camptothecin	55-67	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	220-224
31870182-6	2020	As a vector, SPA could efficiently deliver camptothecin and plasmids into cells.	Camptothecin	43-55	surfactant protein A2	Homo sapiens	13-16
33229317-9	2020	Under weak apoptotic stimulation (1 mumol/L camptothecin treatment), the NOXA promoter mainly functioned as an enhancer; with the enhancement of apoptotic stimulation (10 mumol/L camptothecin treatment), the NOXA promoter activity increased and mainly regulated the expression of the gene itself to promote apoptosis.	Camptothecin	44-56	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	73-77
33229317-9	2020	Under weak apoptotic stimulation (1 mumol/L camptothecin treatment), the NOXA promoter mainly functioned as an enhancer; with the enhancement of apoptotic stimulation (10 mumol/L camptothecin treatment), the NOXA promoter activity increased and mainly regulated the expression of the gene itself to promote apoptosis.	Camptothecin	44-56	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	208-212
33229317-9	2020	Under weak apoptotic stimulation (1 mumol/L camptothecin treatment), the NOXA promoter mainly functioned as an enhancer; with the enhancement of apoptotic stimulation (10 mumol/L camptothecin treatment), the NOXA promoter activity increased and mainly regulated the expression of the gene itself to promote apoptosis.	Camptothecin	179-191	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	73-77
33229317-9	2020	Under weak apoptotic stimulation (1 mumol/L camptothecin treatment), the NOXA promoter mainly functioned as an enhancer; with the enhancement of apoptotic stimulation (10 mumol/L camptothecin treatment), the NOXA promoter activity increased and mainly regulated the expression of the gene itself to promote apoptosis.	Camptothecin	179-191	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	208-212
32882423-2	2020	In the current study, nucleolin-targeted co-delivery system, based on PEGylated rod-shaped mesoporous silica NPs was developed as a biocompatible nanocarrier for simultaneous delivery of camptothecin and survivin shRNA-expressing plasmid (iSur-DNA) to colon adenocarcinoma.	Camptothecin	187-199	nucleolin	Mus musculus	22-31
32882423-4	2020	Camptothecin was loaded into the rod-shaped MSN NPs with encapsulation efficiency of 32%.	Camptothecin	0-12	moesin	Mus musculus	44-47
32882423-5	2020	At the next stage, the prepared camptothecin-loaded system was PEGylated and then iSur-DNA was condensed with C/P ratio of 6 to form PEG@MSNR-CPT/Sur.	Camptothecin	32-44	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	Mus musculus	83-86
32882423-6	2020	Then, the prepared camptothecin-iSur-DNA loaded PEGylated rod-shaped mesoporous silica NPs were tagged with AS1411 DNA aptamer (Apt-PEG@MSNR-CPT/Sur) in order to provide selective therapy against colorectal adenocarcinoma.	Camptothecin	19-31	ATP-binding cassette, sub-family C (CFTR/MRP), member 8	Mus musculus	33-36
33017104-5	2020	TRIM29 triallelic knockout (TRIM29-/-/-/+) cells were sensitive to etoposide, but resistant to camptothecin.	Camptothecin	95-107	tripartite motif containing 29	Gallus gallus	0-6
32661832-0	2020	The integrin facilitated internalization of fibronectin-functionalized camptothecin-loaded DNA-nanofibers for high-efficiency anticancer effects.	Camptothecin	71-83	fibronectin 1	Homo sapiens	44-55
32674014-1	2020	It has recently been established that the marked sensitivity of ATM deficient cells to topoisomerase poisons like camptothecin (Cpt) results from unrestrained end-joining of DNA ends at collapsed replication forks that is mediated by the non-homologous end joining [NHEJ] pathway and results in the induction of copious numbers of genomic alterations, termed "toxic NHEJ".	Camptothecin	114-126	ATM serine/threonine kinase	Homo sapiens	64-67
33017104-7	2020	Interestingly, the kinetics of camptothecin-induced RAD51 foci formation of TRIM29-/-/-/+ cells was higher than that of WT cells.	Camptothecin	31-43	tripartite motif containing 29	Gallus gallus	76-82
32783654-3	2020	Here, we report that succinylation of FEN1 was stimulated in response to DNA replication fork-stalling agents, such as UV irradiation, hydroxyurea, camptothecin, and mitomycin C.	Camptothecin	148-160	flap structure-specific endonuclease 1	Homo sapiens	38-42
33017104-7	2020	Interestingly, the kinetics of camptothecin-induced RAD51 foci formation of TRIM29-/-/-/+ cells was higher than that of WT cells.	Camptothecin	31-43	RAD51 recombinase	Gallus gallus	52-57
32761833-0	2020	C1orf109L binding DHX9 promotes DNA damage depended on the R-loop accumulation and enhances camptothecin chemosensitivity.	Camptothecin	92-104	DExH-box helicase 9	Homo sapiens	18-22
32585151-0	2020	Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.	Camptothecin	0-12	DEAD-box helicase 5	Homo sapiens	21-25
32585151-0	2020	Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.	Camptothecin	52-64	DEAD-box helicase 5	Homo sapiens	21-25
32585151-4	2020	Here we reported that the resistance to camptothecin (cpt) therapy was driven by degradation of DDX5.	Camptothecin	40-52	DEAD-box helicase 5	Homo sapiens	96-100
32585151-4	2020	Here we reported that the resistance to camptothecin (cpt) therapy was driven by degradation of DDX5.	Camptothecin	54-57	DEAD-box helicase 5	Homo sapiens	96-100
32710950-0	2020	Liver injury in septic mice were suppressed by a camptothecin-bile acid conjugate via inhibiting NF-kappaB signaling pathway.	Camptothecin	49-61	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	97-106
31822580-12	2020	Hp also inhibits CPT-induced USF1/p53 nuclear complexes, exacerbating CPT-dependent DNA damaging effects.	Camptothecin	17-20	upstream transcription factor 1	Mus musculus	29-33
32652764-0	2020	MIB1-mediated degradation of WRN promotes cellular senescence in response to camptothecin treatment.	Camptothecin	77-89	MIB E3 ubiquitin protein ligase 1	Homo sapiens	0-4
32652764-0	2020	MIB1-mediated degradation of WRN promotes cellular senescence in response to camptothecin treatment.	Camptothecin	77-89	WRN RecQ like helicase	Homo sapiens	29-32
32652764-5	2020	Camptothecin (CPT) enhances the interaction between MIB1 and WRN, and promotes WRN degradation in a MIB1-dependent manner.	Camptothecin	0-12	MIB E3 ubiquitin protein ligase 1	Homo sapiens	52-56
32652764-5	2020	Camptothecin (CPT) enhances the interaction between MIB1 and WRN, and promotes WRN degradation in a MIB1-dependent manner.	Camptothecin	0-12	WRN RecQ like helicase	Homo sapiens	61-64
32652764-5	2020	Camptothecin (CPT) enhances the interaction between MIB1 and WRN, and promotes WRN degradation in a MIB1-dependent manner.	Camptothecin	0-12	WRN RecQ like helicase	Homo sapiens	79-82
32652764-5	2020	Camptothecin (CPT) enhances the interaction between MIB1 and WRN, and promotes WRN degradation in a MIB1-dependent manner.	Camptothecin	0-12	MIB E3 ubiquitin protein ligase 1	Homo sapiens	100-104
32652764-5	2020	Camptothecin (CPT) enhances the interaction between MIB1 and WRN, and promotes WRN degradation in a MIB1-dependent manner.	Camptothecin	14-17	MIB E3 ubiquitin protein ligase 1	Homo sapiens	52-56
32652764-5	2020	Camptothecin (CPT) enhances the interaction between MIB1 and WRN, and promotes WRN degradation in a MIB1-dependent manner.	Camptothecin	14-17	WRN RecQ like helicase	Homo sapiens	61-64
32652764-5	2020	Camptothecin (CPT) enhances the interaction between MIB1 and WRN, and promotes WRN degradation in a MIB1-dependent manner.	Camptothecin	14-17	WRN RecQ like helicase	Homo sapiens	79-82
32652764-5	2020	Camptothecin (CPT) enhances the interaction between MIB1 and WRN, and promotes WRN degradation in a MIB1-dependent manner.	Camptothecin	14-17	MIB E3 ubiquitin protein ligase 1	Homo sapiens	100-104
31822580-12	2020	Hp also inhibits CPT-induced USF1/p53 nuclear complexes, exacerbating CPT-dependent DNA damaging effects.	Camptothecin	70-73	upstream transcription factor 1	Mus musculus	29-33
33073191-5	2020	Furthermore, using camptothecin as the cytotoxic drug, camptothecin-MT-II (compound 1) can effectively inhibit A375 melanoma cell growth with an IC50 of 16 nM.	Camptothecin	19-31	metallothionein 2A	Homo sapiens	68-73
32504778-7	2020	Moreover, the DNA topoisomerase-1 inhibitor camptothecin (CPT) down-regulated FLIP in pancreatic cancer models and enhanced apoptosis induced by alphaDR5-NPs.	Camptothecin	44-56	DNA topoisomerase I	Homo sapiens	14-33
32504778-7	2020	Moreover, the DNA topoisomerase-1 inhibitor camptothecin (CPT) down-regulated FLIP in pancreatic cancer models and enhanced apoptosis induced by alphaDR5-NPs.	Camptothecin	58-61	DNA topoisomerase I	Homo sapiens	14-33
32505820-10	2020	CONCLUSIONS: These results indicate that Fas/FADD/caspase-8 activation plays an important role in CPT211-mediated tumor growth suppression in TNBC, and the novel camptothecin derivative, CPT211, can be exploited for specific targeted therapies and potentially improve approaches to combination treatments for human breast cancer.	Camptothecin	162-174	Fas associated via death domain	Homo sapiens	45-49
32306447-7	2020	Concurrent FAM35A and BRCA1 defects in mammalian cell lines cause resistance to PARP inhibitors and camptothecin.	Camptothecin	100-112	shieldin complex subunit 2	Homo sapiens	11-17
32387702-7	2020	Rats treated with camptothecin subsequent to a brain tumor graft survived longer when the drug was delivered by Bom/PEG-PCL-Tat mixed micelles than by PEG-PCL-Tat micelles.	Camptothecin	18-30	tyrosine aminotransferase	Rattus norvegicus	116-127
31504230-0	2020	Synergistic anti-breast cancer effect of pulsatilla saponin D and camptothecin through interrupting autophagic-lysosomal function and promoting p62-mediated ubiquitinated protein aggregation.	Camptothecin	66-78	nucleoporin 62	Homo sapiens	144-147
31504230-6	2020	However, PSD alone and particularly co-treatment with camptothecin remarkably increased p62 protein levels, indicating that PSD strongly inhibited the autophagic cargo degradation.	Camptothecin	54-66	nucleoporin 62	Homo sapiens	88-91
31828718-8	2020	The apoptosis imaging capacity of Al[18F]F-NOTA-PEG3-duramycin was evaluated using in vitro cell uptake assay with camptothecin-treated Jurkat cells, along with in vivo PET imaging using erlotinib-treated nude mice.	Camptothecin	115-127	paternally expressed 3	Homo sapiens	43-52
31828718-10	2020	Compared with the control cells, the binding of Al[18F]F-NOTA-PEG3-duramycin with camptothecin-induced apoptotic cells resulted in a tripling increase.	Camptothecin	82-94	paternally expressed 3	Mus musculus	62-66
32640219-2	2020	In this study, we report that ZGRF1 null cells accumulate chromosome aberrations following replication perturbation and show sensitivity to two potent replication-blocking anticancer drugs: mitomycin C and camptothecin.	Camptothecin	206-218	zinc finger GRF-type containing 1	Homo sapiens	30-35
32857718-9	2020	In addition to increasing cell proliferation, OXT significantly blunted the rise in reactive oxygen species induced by H2O2, and antagonized the reductions in cell viability induced by H2O2 and camptothecin.	Camptothecin	194-206	oxytocin/neurophysin I prepropeptide	Homo sapiens	46-49
32387702-7	2020	Rats treated with camptothecin subsequent to a brain tumor graft survived longer when the drug was delivered by Bom/PEG-PCL-Tat mixed micelles than by PEG-PCL-Tat micelles.	Camptothecin	18-30	tyrosine aminotransferase	Rattus norvegicus	124-127
32577161-6	2020	Olaparib also sensitized MYCN expressing cells to camptothecin- and temozolomide-induced cell death to a greater degree than non-expressing cells.	Camptothecin	50-62	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	25-29
32297953-6	2020	We show that ATAD5 deficiency leads to hypersensitivity to methyl methanesulphonate (MMS), camptothecin (CPT) and mitomycin C (MMC), agents that hinder the progression of replication forks.	Camptothecin	91-103	ATPase family, AAA domain containing 5	Mus musculus	13-18
32211858-9	2020	The contribution of FXR1 to DNA double-strand break damage responses seemed minor and limited to HR repair, considering that depletion of FXR1 perturbed chromatin association of homologous recombination repair factors and sensitized cells to camptothecin.	Camptothecin	242-254	FMR1 autosomal homolog 1	Homo sapiens	138-142
32297953-6	2020	We show that ATAD5 deficiency leads to hypersensitivity to methyl methanesulphonate (MMS), camptothecin (CPT) and mitomycin C (MMC), agents that hinder the progression of replication forks.	Camptothecin	105-108	ATPase family, AAA domain containing 5	Mus musculus	13-18
32551000-1	2020	A novel two-step in situ method for targeted antitumor drug release by supramolecular assembly (Fc-CPT@HACD) was constructed using camptothecin prodrug (Fc-CPT) and beta-cyclodextrin (beta-CD)-modified hyaluronic acid (HACD).	Camptothecin	131-143	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	184-191
32032660-5	2020	The investigation of additional innate immunity elements revealed that A + N (or camptothecin) stimulated the expression of NLRX1, STING (stimulator of interferon genes) and two antiviral proteins, IFIT1 and IFIT3.	Camptothecin	81-93	NLR family member X1	Homo sapiens	124-129
32032660-3	2020	The treatment with A + N (or camptothecin) strongly upregulated caspase-1 and its two activators: IFI16 and NLRP1, however, caspase-1 activation was not detected.	Camptothecin	29-41	caspase 1	Homo sapiens	64-73
32032660-5	2020	The investigation of additional innate immunity elements revealed that A + N (or camptothecin) stimulated the expression of NLRX1, STING (stimulator of interferon genes) and two antiviral proteins, IFIT1 and IFIT3.	Camptothecin	81-93	interferon induced protein with tetratricopeptide repeats 1	Homo sapiens	198-203
32032660-5	2020	The investigation of additional innate immunity elements revealed that A + N (or camptothecin) stimulated the expression of NLRX1, STING (stimulator of interferon genes) and two antiviral proteins, IFIT1 and IFIT3.	Camptothecin	81-93	interferon induced protein with tetratricopeptide repeats 3	Homo sapiens	208-213
32032660-3	2020	The treatment with A + N (or camptothecin) strongly upregulated caspase-1 and its two activators: IFI16 and NLRP1, however, caspase-1 activation was not detected.	Camptothecin	29-41	interferon gamma inducible protein 16	Homo sapiens	98-103
32032660-3	2020	The treatment with A + N (or camptothecin) strongly upregulated caspase-1 and its two activators: IFI16 and NLRP1, however, caspase-1 activation was not detected.	Camptothecin	29-41	NLR family pyrin domain containing 1	Homo sapiens	108-113
32286784-2	2020	To address this problem, we demonstrate a dendrimer-camptothecin (CPT) conjugate that actively penetrates deep into PDA tumor through gamma-glutamyl transpeptidase (GGT)-triggered cell endocytosis and transcytosis.	Camptothecin	52-64	inactive glutathione hydrolase 2	Homo sapiens	134-163
32036118-4	2020	Benefiting from the incorporated methyl-modified KCC-1 microparticles, the hybrid aerogels can load and deliver a payload of camptothecin (CPT), an anticancer drug with antitumor activity but limited clinical application due to its hydrophobicity.	Camptothecin	125-137	solute carrier family 12 member 4	Homo sapiens	49-54
32036118-4	2020	Benefiting from the incorporated methyl-modified KCC-1 microparticles, the hybrid aerogels can load and deliver a payload of camptothecin (CPT), an anticancer drug with antitumor activity but limited clinical application due to its hydrophobicity.	Camptothecin	139-142	solute carrier family 12 member 4	Homo sapiens	49-54
32062842-4	2020	CPT treatment induced cell cycle initiation of cortical neurons and elevated the expression of certain cell cycle components (e.g., cyclin D1, CDK4, E2F1) but failed to drive S phase entry or DNA synthesis.	Camptothecin	0-3	cyclin-dependent kinase 4 S homeolog	Xenopus laevis	143-147
31713291-8	2020	Moreover, prolonged replication stress induced by hydroxyurea or camptothecin resulted in a reduction of Chk1 protein levels, which was rescued by HUWE1 knockdown.	Camptothecin	65-77	checkpoint kinase 1	Homo sapiens	105-109
31713291-8	2020	Moreover, prolonged replication stress induced by hydroxyurea or camptothecin resulted in a reduction of Chk1 protein levels, which was rescued by HUWE1 knockdown.	Camptothecin	65-77	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	Homo sapiens	147-152
32062842-4	2020	CPT treatment induced cell cycle initiation of cortical neurons and elevated the expression of certain cell cycle components (e.g., cyclin D1, CDK4, E2F1) but failed to drive S phase entry or DNA synthesis.	Camptothecin	0-3	E2F transcription factor 1 L homeolog	Xenopus laevis	149-153
32062842-9	2020	Instead, in CPT-treated neurons, E2F1 preferentially regulated DNA repair related genes.	Camptothecin	12-15	E2F transcription factor 1 L homeolog	Xenopus laevis	33-37
32286784-2	2020	To address this problem, we demonstrate a dendrimer-camptothecin (CPT) conjugate that actively penetrates deep into PDA tumor through gamma-glutamyl transpeptidase (GGT)-triggered cell endocytosis and transcytosis.	Camptothecin	52-64	inactive glutathione hydrolase 2	Homo sapiens	165-168
31991288-5	2020	Additionally, we showed that POLE3/4-deficient cells displayed enhanced sensitivity to an ATR inhibitor, a PARP inhibitor, and camptothecin.	Camptothecin	127-139	DNA polymerase epsilon 3, accessory subunit	Homo sapiens	29-36
32490201-4	2020	We found that this carrier-free therapeutic system can serve as a reservoir for extended tumoral release of camptothecin and aPD1 antibody, resulting in an immune-stimulating tumor microenvironment for boosted PD-1 blockade immune response.	Camptothecin	108-120	programmed cell death 1	Homo sapiens	210-214
32068412-5	2020	Therefore, we designed and synthesized novel highly hydrophilic camptothecin-derivatives by conjugating SN38 with branched glycerol trimer (SN38-BGL), which we have been developing as a unique strategy to endow hydrophobic molecule with much hydrophilicity, to maximize the benefit of CPT-11 and minimize the adverse effects.	Camptothecin	64-76	galactosidase, beta 1	Mus musculus	145-148
32095815-0	2020	Involvement of Hus1 in the chain elongation step of DNA replication after exposure to camptothecin or ionizing radiation.	Camptothecin	86-98	HUS1 checkpoint clamp component	Homo sapiens	15-19
31927166-1	2020	Camptothecin (CPT), a potent inhibitor of topoisomerase I and HIF-1alpha, failed to demonstrate utility as an anti-cancer agent in early clinical trial investigations, primarily due to limited clinical activity and significant toxicity attributable to unfavorable physicochemical properties (e.g. low plasma solubility, pH-labile lactone ring).	Camptothecin	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	62-72
31970339-6	2020	Furthermore, the hydrophobic anticancer drug camptothecin (CPT) was selected as a model drug and successfully encapsulated into the CUR/beta-CD micelles.	Camptothecin	59-62	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	136-143
32209474-2	2020	Here, we show that SLFN11 increases chromatin accessibility genome wide, prominently at active promoters in response to replication stress induced by the checkpoint kinase 1 (CHK1) inhibitor prexasertib or the topoisomerase I (TOP1) inhibitor camptothecin.	Camptothecin	243-255	schlafen family member 11	Homo sapiens	19-25
32209474-5	2020	SLFN11-dependent IEG activation by camptothecin is also observed across 55 non-isogenic NCI-60 cell lines.	Camptothecin	35-47	schlafen family member 11	Homo sapiens	0-6
31970339-6	2020	Furthermore, the hydrophobic anticancer drug camptothecin (CPT) was selected as a model drug and successfully encapsulated into the CUR/beta-CD micelles.	Camptothecin	45-57	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	136-143
31861435-9	2019	The ectopic overexpression of p53 or camptothecin treatment induced maspin expression.	Camptothecin	37-49	serpin family B member 5	Homo sapiens	68-74
31729086-8	2020	The ATM pathway activation, attenuated in typical patients with NBS, appeared normal under camptothecin treatment in these new NBN-related infertile patients.	Camptothecin	91-103	nibrin	Homo sapiens	127-130
31995761-5	2020	We validate the ARK assay with genetic mutants with established deficiencies in DPC repair and demonstrate its robustness by using common DPC-inducing reagents, including formaldehyde, camptothecin, and etoposide.	Camptothecin	185-197	AXL receptor tyrosine kinase	Homo sapiens	16-19
31556849-6	2020	Recently, accumulating data indicates that the abnormal expression and function of SLCO1B3 are involved in resistance to anticancer drugs, such as taxanes, camptothecin and its analogs, SN-38, and androgen deprivation therapy (ADT) in breast, prostate, lung, hepatic, and colorectal cancer, respectively.	Camptothecin	156-168	solute carrier organic anion transporter family member 1B3	Homo sapiens	83-90
31927975-2	2020	CDN "S" composed of four constituents AA"", AB", BA", and BB", and two hairpin structures, H1 and H2, leads to the CDN "S"-guided unlocking of the MC-1/MC-2 carriers and the release of DOX-D and CPT-CMC or of the NMOF-1 and NMOF-2 carriers that release DOX and CPT, respectively.	Camptothecin	195-198	H1.5 linker histone, cluster member	Homo sapiens	91-100
31927975-2	2020	CDN "S" composed of four constituents AA"", AB", BA", and BB", and two hairpin structures, H1 and H2, leads to the CDN "S"-guided unlocking of the MC-1/MC-2 carriers and the release of DOX-D and CPT-CMC or of the NMOF-1 and NMOF-2 carriers that release DOX and CPT, respectively.	Camptothecin	261-264	H1.5 linker histone, cluster member	Homo sapiens	91-100
31927975-5	2020	The miRNA-155 stimulates the reconfiguration of CDN "S" to CDN "X", where AA" and BB" are upregulated, and AB" and BA" are downregulated, leading to the enhanced release of DOX-D or DOX from the microcapsule/NMOFs carriers, and to the concomitant inhibition of the release of CPT-CMC or CPT from the respective carriers.	Camptothecin	276-279	microRNA 155	Homo sapiens	4-13
31927975-5	2020	The miRNA-155 stimulates the reconfiguration of CDN "S" to CDN "X", where AA" and BB" are upregulated, and AB" and BA" are downregulated, leading to the enhanced release of DOX-D or DOX from the microcapsule/NMOFs carriers, and to the concomitant inhibition of the release of CPT-CMC or CPT from the respective carriers.	Camptothecin	287-290	microRNA 155	Homo sapiens	4-13
31330087-7	2020	Surprisingly, despite the critical role of POLbeta in alkylation damage repair, cells lacking POLbeta exhibited increased resistance to camptothecin (a topoisomerase I inhibitor that induces DNA single-strand breaks), irrespective of the presence or absence of LIG4.	Camptothecin	136-148	DNA polymerase beta	Homo sapiens	94-101
31626255-3	2019	Here we investigated the use of CTX as a targeting agent for camptothecin (CPT)-loaded polymeric nanoparticles (NPs) directed against KRAS mutant CTX-resistant cancer cells.	Camptothecin	61-73	KRAS proto-oncogene, GTPase	Homo sapiens	134-138
31794429-7	2019	Analyzing the effects of oxidizing (H2O2) and DNA-damaging (camptothecin) stressors on the interacting partners of RXFP3 using Affinity Purification-Mass Spectrometry, we found multiple proteins linked to DDR and cell cycle control.	Camptothecin	60-72	relaxin family peptide receptor 3	Mus musculus	115-120
31552432-5	2019	The sae2-S267A mutation is epistatic to mre11-nd for camptothecin (CPT) sensitivity and synergizes with sgs1Delta, whereas sae2-5A synergizes with mre11-nd and exhibits epistasis with sgs1Delta.	Camptothecin	53-65	RB binding protein 8, endonuclease	Homo sapiens	4-8
31552432-5	2019	The sae2-S267A mutation is epistatic to mre11-nd for camptothecin (CPT) sensitivity and synergizes with sgs1Delta, whereas sae2-5A synergizes with mre11-nd and exhibits epistasis with sgs1Delta.	Camptothecin	53-65	MRE11 homolog, double strand break repair nuclease	Homo sapiens	40-45
31552432-5	2019	The sae2-S267A mutation is epistatic to mre11-nd for camptothecin (CPT) sensitivity and synergizes with sgs1Delta, whereas sae2-5A synergizes with mre11-nd and exhibits epistasis with sgs1Delta.	Camptothecin	67-70	RB binding protein 8, endonuclease	Homo sapiens	4-8
31796101-3	2019	Depletion of MORC2 attenuates phosphorylated histone H2AX (gammaH2AX) focal formation, compromises the recruitment of DNA repair proteins, BRCA1, 53BP1, and Rad51, to sites of DNA damage, and consequently reduces cell survival following treatment with DNA-damaging chemotherapeutic drug camptothecin (CPT).	Camptothecin	287-299	MORC family CW-type zinc finger 2	Homo sapiens	13-18
31796101-3	2019	Depletion of MORC2 attenuates phosphorylated histone H2AX (gammaH2AX) focal formation, compromises the recruitment of DNA repair proteins, BRCA1, 53BP1, and Rad51, to sites of DNA damage, and consequently reduces cell survival following treatment with DNA-damaging chemotherapeutic drug camptothecin (CPT).	Camptothecin	301-304	MORC family CW-type zinc finger 2	Homo sapiens	13-18
31626255-3	2019	Here we investigated the use of CTX as a targeting agent for camptothecin (CPT)-loaded polymeric nanoparticles (NPs) directed against KRAS mutant CTX-resistant cancer cells.	Camptothecin	75-78	KRAS proto-oncogene, GTPase	Homo sapiens	134-138
31626255-6	2019	CTX successfully targeted CPT-loaded NPs to mutant KRAS PANC-1 tumours in vivo and reduced tumour growth.	Camptothecin	26-29	KRAS proto-oncogene, GTPase	Homo sapiens	51-55
31049660-6	2019	In this perspective, we discuss the cellular consequences of Top1-generated damage during DNA replication with focus on the differences between endogenous Top1-generated damage and Top1 damage generated due to the use of the drug camptothecin.	Camptothecin	230-242	DNA topoisomerase I	Homo sapiens	61-65
31049660-6	2019	In this perspective, we discuss the cellular consequences of Top1-generated damage during DNA replication with focus on the differences between endogenous Top1-generated damage and Top1 damage generated due to the use of the drug camptothecin.	Camptothecin	230-242	DNA topoisomerase I	Homo sapiens	155-159
31049660-6	2019	In this perspective, we discuss the cellular consequences of Top1-generated damage during DNA replication with focus on the differences between endogenous Top1-generated damage and Top1 damage generated due to the use of the drug camptothecin.	Camptothecin	230-242	DNA topoisomerase I	Homo sapiens	155-159
31030236-9	2019	In 3D Caco-2 cell model, Verapamil (P-gp inhibitor) and Gefitinib (BCRP inhibitor) more significantly increased the uptake of CPT and 9-Q20.	Camptothecin	126-129	phosphoglycolate phosphatase	Homo sapiens	36-40
31477700-3	2019	Here, we show that MSI and hypermutation are triggered by replication stress in an MMR-deficient background, enabling clonal expansion of cells harboring ARF/p53-module mutations and cells that are resistant to the anti-cancer drug camptothecin.	Camptothecin	232-244	transformation related protein 53, pseudogene	Mus musculus	158-161
31030236-9	2019	In 3D Caco-2 cell model, Verapamil (P-gp inhibitor) and Gefitinib (BCRP inhibitor) more significantly increased the uptake of CPT and 9-Q20.	Camptothecin	126-129	BCR pseudogene 1	Homo sapiens	67-71
31408463-7	2019	Under conditions of mild replication stress induced either by topoisomerase1 inhibition with camptothecin or nucleotide depletion by hydroxyurea, we found that the effect of acute PARP1/2 inhibition on replication fork progression is dependent on DEK expression.	Camptothecin	93-105	poly(ADP-ribose) polymerase family member 12	Homo sapiens	180-187
31482012-2	2019	In addition to doxorubicin, our results here indicated that camptothecin and bortezomib, which are a topoisomerase 1 poison and a 26 S proteasome inhibitor, respectively, could also induce apoptosis in a p53-dependent manner in prostate cancer.	Camptothecin	60-72	tumor protein p53	Homo sapiens	204-207
31482012-4	2019	By using dominant negative p53 to compete with wild-type p53 in transcription activity, we demonstrated that p53-mediated apoptosis in response to doxorubicin- or camptothecin-induced genotoxic stress is transcription-independent.	Camptothecin	163-175	tumor protein p53	Homo sapiens	27-30
31482012-4	2019	By using dominant negative p53 to compete with wild-type p53 in transcription activity, we demonstrated that p53-mediated apoptosis in response to doxorubicin- or camptothecin-induced genotoxic stress is transcription-independent.	Camptothecin	163-175	tumor protein p53	Homo sapiens	57-60
31482012-4	2019	By using dominant negative p53 to compete with wild-type p53 in transcription activity, we demonstrated that p53-mediated apoptosis in response to doxorubicin- or camptothecin-induced genotoxic stress is transcription-independent.	Camptothecin	163-175	tumor protein p53	Homo sapiens	57-60
31482012-6	2019	Interestingly, we also found that doxorubicin-induced p21 expression is activated by p53 in transcription-dependent manner, while camptothecin-induced p21 expression is p53-independent.	Camptothecin	130-142	H3 histone pseudogene 16	Homo sapiens	151-154
31482012-6	2019	Interestingly, we also found that doxorubicin-induced p21 expression is activated by p53 in transcription-dependent manner, while camptothecin-induced p21 expression is p53-independent.	Camptothecin	130-142	tumor protein p53	Homo sapiens	169-172
31482012-7	2019	We then investigated the p53 ratio of nucleus to cytosol corresponding to low and high dose doxorubicin, camptothecin, or bortezomib treatment.	Camptothecin	105-117	tumor protein p53	Homo sapiens	25-28
31361291-1	2019	Synergistic cancer starvation/ROS-mediated/chemo-therapy is developed through a cascade reaction with enzyme glucose oxidase (GOX) modified on the surface of an Fe-based metal organic framework (MOF(Fe)) and drug camptothecin (CPT) loaded into the cavities of MOF(Fe).	Camptothecin	213-225	hydroxyacid oxidase 1	Homo sapiens	109-124
31361291-1	2019	Synergistic cancer starvation/ROS-mediated/chemo-therapy is developed through a cascade reaction with enzyme glucose oxidase (GOX) modified on the surface of an Fe-based metal organic framework (MOF(Fe)) and drug camptothecin (CPT) loaded into the cavities of MOF(Fe).	Camptothecin	213-225	hydroxyacid oxidase 1	Homo sapiens	126-129
31361291-1	2019	Synergistic cancer starvation/ROS-mediated/chemo-therapy is developed through a cascade reaction with enzyme glucose oxidase (GOX) modified on the surface of an Fe-based metal organic framework (MOF(Fe)) and drug camptothecin (CPT) loaded into the cavities of MOF(Fe).	Camptothecin	227-230	hydroxyacid oxidase 1	Homo sapiens	109-124
31361291-1	2019	Synergistic cancer starvation/ROS-mediated/chemo-therapy is developed through a cascade reaction with enzyme glucose oxidase (GOX) modified on the surface of an Fe-based metal organic framework (MOF(Fe)) and drug camptothecin (CPT) loaded into the cavities of MOF(Fe).	Camptothecin	227-230	hydroxyacid oxidase 1	Homo sapiens	126-129
31020545-0	2019	Camptothecin activates SIRT1 to promote lipid catabolism through AMPK/FoxO1/ATGL pathway in C2C12 myogenic cells.	Camptothecin	0-12	sirtuin 1	Mus musculus	23-28
31020545-0	2019	Camptothecin activates SIRT1 to promote lipid catabolism through AMPK/FoxO1/ATGL pathway in C2C12 myogenic cells.	Camptothecin	0-12	forkhead box O1	Mus musculus	70-75
31020545-0	2019	Camptothecin activates SIRT1 to promote lipid catabolism through AMPK/FoxO1/ATGL pathway in C2C12 myogenic cells.	Camptothecin	0-12	patatin-like phospholipase domain containing 2	Mus musculus	76-80
31020545-3	2019	Using an in vitro fluorescence assay, the cancer therapeutic camptothecin increased SIRT1 enzymatic activity by 5.5-fold, indicating it to be a potent SIRT1 activator.	Camptothecin	61-73	sirtuin 1	Mus musculus	84-89
31020545-3	2019	Using an in vitro fluorescence assay, the cancer therapeutic camptothecin increased SIRT1 enzymatic activity by 5.5-fold, indicating it to be a potent SIRT1 activator.	Camptothecin	61-73	sirtuin 1	Mus musculus	151-156
31020545-4	2019	Camptothecin also elevated the nicotinamide adenine dinucleotide (NAD)+/NADH ratio and increased SIRT1 protein levels in differentiated C2C12 myogenic cells.	Camptothecin	0-12	sirtuin 1	Mus musculus	97-102
31020545-5	2019	Treatment of C2C12 myotubes with camptothecin increased phosphorylation of AMP-dependent kinase (AMPK) and acetyl-coenzyme A carboxylase, caused nuclear translocation and deacetylation of forkhead box O1 (FoxO1), increased transcription and protein expression of adipose triglyceride lipase (ATGL), decreased the amount of intracellular oil droplets, and significantly increased beta-oxidation of fatty acids.	Camptothecin	33-45	forkhead box O1	Mus musculus	188-203
31020545-5	2019	Treatment of C2C12 myotubes with camptothecin increased phosphorylation of AMP-dependent kinase (AMPK) and acetyl-coenzyme A carboxylase, caused nuclear translocation and deacetylation of forkhead box O1 (FoxO1), increased transcription and protein expression of adipose triglyceride lipase (ATGL), decreased the amount of intracellular oil droplets, and significantly increased beta-oxidation of fatty acids.	Camptothecin	33-45	forkhead box O1	Mus musculus	205-210
31020545-5	2019	Treatment of C2C12 myotubes with camptothecin increased phosphorylation of AMP-dependent kinase (AMPK) and acetyl-coenzyme A carboxylase, caused nuclear translocation and deacetylation of forkhead box O1 (FoxO1), increased transcription and protein expression of adipose triglyceride lipase (ATGL), decreased the amount of intracellular oil droplets, and significantly increased beta-oxidation of fatty acids.	Camptothecin	33-45	patatin-like phospholipase domain containing 2	Mus musculus	263-290
31020545-5	2019	Treatment of C2C12 myotubes with camptothecin increased phosphorylation of AMP-dependent kinase (AMPK) and acetyl-coenzyme A carboxylase, caused nuclear translocation and deacetylation of forkhead box O1 (FoxO1), increased transcription and protein expression of adipose triglyceride lipase (ATGL), decreased the amount of intracellular oil droplets, and significantly increased beta-oxidation of fatty acids.	Camptothecin	33-45	patatin-like phospholipase domain containing 2	Mus musculus	292-296
31020545-7	2019	All of the above camptothecin-induced alterations were attenuated by the SIRT1-specific inhibitor nicotinamide and/or 6-[4-(2-piperidin-1-ylethoxy) phenyl]-3-pyridin-4-ylpyrazolo [1,5-a]pyrimidin (compound C).	Camptothecin	17-29	sirtuin 1	Mus musculus	73-78
31020545-8	2019	Thus, camptothecin activation of SIRT1 promotes lipid catabolism through AMPK/FoxO1/ATGL signaling.	Camptothecin	6-18	sirtuin 1	Mus musculus	33-38
31020545-8	2019	Thus, camptothecin activation of SIRT1 promotes lipid catabolism through AMPK/FoxO1/ATGL signaling.	Camptothecin	6-18	forkhead box O1	Mus musculus	78-83
31020545-8	2019	Thus, camptothecin activation of SIRT1 promotes lipid catabolism through AMPK/FoxO1/ATGL signaling.	Camptothecin	6-18	patatin-like phospholipase domain containing 2	Mus musculus	84-88
30885713-7	2019	As expected, a caspase-9 inhibitor, z-LEHD-FMK, and an autophagy inhibitor, 3-methyladenine (3 MA), significantly diminished CPT-induced mitotic arrest.	Camptothecin	125-128	caspase 9	Homo sapiens	15-24
31324785-6	2019	We also find that radiation or camptothecin-induced DNA damage promotes RRM2 deacetylation by enhancing Sirt2-RRM2 interaction.	Camptothecin	31-43	ribonucleotide reductase regulatory subunit M2	Homo sapiens	72-76
31324785-6	2019	We also find that radiation or camptothecin-induced DNA damage promotes RRM2 deacetylation by enhancing Sirt2-RRM2 interaction.	Camptothecin	31-43	sirtuin 2	Homo sapiens	104-109
31324785-6	2019	We also find that radiation or camptothecin-induced DNA damage promotes RRM2 deacetylation by enhancing Sirt2-RRM2 interaction.	Camptothecin	31-43	ribonucleotide reductase regulatory subunit M2	Homo sapiens	110-114
31056253-7	2019	We provide evidence that depletion of PDCD11 decreased the formation of gamma-H2AX foci and the phosphorylation of DNA damage response (DDR) signaling intermediates in response to camptothecin or bleomycin, resulting in increased cellular resistance to DNA damage.	Camptothecin	180-192	programmed cell death 11	Homo sapiens	38-44
31117440-2	2019	Herein, we developed camptothecin (CPT)-conjugated prodrug (CPTP) micelles in which CPT was grafted to the poly(ethylene glycol)-poly(glutamic acid) block copolymer via a disulfide bond linker for a redox-triggered drug release.	Camptothecin	21-33	ceramide-1-phosphate transfer protein	Homo sapiens	60-64
31117440-2	2019	Herein, we developed camptothecin (CPT)-conjugated prodrug (CPTP) micelles in which CPT was grafted to the poly(ethylene glycol)-poly(glutamic acid) block copolymer via a disulfide bond linker for a redox-triggered drug release.	Camptothecin	35-38	ceramide-1-phosphate transfer protein	Homo sapiens	60-64
31062340-3	2019	Knockdown of RNase L reduces cell survival after induction of DSBs by ionizing radiation or camptothecin and causes a significant decrease in DSB repair, as evidenced by an increase in the extent of phosphorylation of histone H2AX on Ser139 (gammaH2AX) and gammaH2AX nuclear foci formation.	Camptothecin	92-104	ribonuclease L	Homo sapiens	13-20
30851366-0	2019	Camptothecin induces c-Myc- and Sp1-mediated hTERT expression in LNCaP cells: Involvement of reactive oxygen species and PI3K/Akt.	Camptothecin	0-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	21-26
30851366-0	2019	Camptothecin induces c-Myc- and Sp1-mediated hTERT expression in LNCaP cells: Involvement of reactive oxygen species and PI3K/Akt.	Camptothecin	0-12	telomerase reverse transcriptase	Homo sapiens	45-50
30851366-0	2019	Camptothecin induces c-Myc- and Sp1-mediated hTERT expression in LNCaP cells: Involvement of reactive oxygen species and PI3K/Akt.	Camptothecin	0-12	AKT serine/threonine kinase 1	Homo sapiens	126-129
31114910-0	2019	RAD51 and mitotic function of mus81 are essential for recovery from low-dose of camptothecin in the absence of the WRN exonuclease.	Camptothecin	80-92	RAD51 recombinase	Homo sapiens	0-5
31114910-0	2019	RAD51 and mitotic function of mus81 are essential for recovery from low-dose of camptothecin in the absence of the WRN exonuclease.	Camptothecin	80-92	MUS81 structure-specific endonuclease subunit	Homo sapiens	30-35
31114910-7	2019	We find that, upon treatment with clinically-relevant nanomolar doses of the Topoisomerase I inhibitor camptothecin, loss of WRN exonuclease stimulates fork inactivation and accumulation of parental gaps, which engages RAD51.	Camptothecin	103-115	WRN RecQ like helicase	Homo sapiens	125-128
31114910-7	2019	We find that, upon treatment with clinically-relevant nanomolar doses of the Topoisomerase I inhibitor camptothecin, loss of WRN exonuclease stimulates fork inactivation and accumulation of parental gaps, which engages RAD51.	Camptothecin	103-115	RAD51 recombinase	Homo sapiens	219-224
31269964-2	2019	RESULTS: In this study, we developed a MoS2-based hyaluronic acid (HA)-functionalized nanoplatform capable of achieving targeted delivery of camptothecin (CPT) and dual-stimuli-responsive drug release.	Camptothecin	141-153	mago homolog, exon junction complex core component	Mus musculus	39-43
31269964-2	2019	RESULTS: In this study, we developed a MoS2-based hyaluronic acid (HA)-functionalized nanoplatform capable of achieving targeted delivery of camptothecin (CPT) and dual-stimuli-responsive drug release.	Camptothecin	155-158	mago homolog, exon junction complex core component	Mus musculus	39-43
31242600-2	2019	As torsional stress is generated during transcription by progression of RNA polymerase II through the transcribed gene, we tested the effects of camptothecin and of the approved TOP1 inhibitors Topotecan and SN-38 on TNFalpha-induced gene expression.	Camptothecin	145-157	tumor necrosis factor	Homo sapiens	217-225
31242600-5	2019	TNFalpha stimulation led to inducible recruitment of TOP1 to the gene body of IL8, where its inhibition by camptothecin reduced transcription elongation and also led to altered histone H3 acetylation.	Camptothecin	107-119	tumor necrosis factor	Homo sapiens	0-8
31242600-5	2019	TNFalpha stimulation led to inducible recruitment of TOP1 to the gene body of IL8, where its inhibition by camptothecin reduced transcription elongation and also led to altered histone H3 acetylation.	Camptothecin	107-119	C-X-C motif chemokine ligand 8	Homo sapiens	78-81
31009828-9	2019	In contrast, the PML knock-out cells showed increased sensitivity to low doses of IR and DNA-damaging agents mitomycin C, cisplatin and camptothecin that all cause DNA lesions requiring repair by HR.	Camptothecin	136-148	PML nuclear body scaffold	Homo sapiens	17-20
30885713-0	2019	Camptothecin induces mitotic arrest through Mad2-Cdc20 complex by activating the JNK-mediated Sp1 pathway.	Camptothecin	0-12	mitotic arrest deficient 2 like 1	Homo sapiens	44-48
30885713-0	2019	Camptothecin induces mitotic arrest through Mad2-Cdc20 complex by activating the JNK-mediated Sp1 pathway.	Camptothecin	0-12	cell division cycle 20	Homo sapiens	49-54
30885713-0	2019	Camptothecin induces mitotic arrest through Mad2-Cdc20 complex by activating the JNK-mediated Sp1 pathway.	Camptothecin	0-12	mitogen-activated protein kinase 8	Homo sapiens	81-84
30778617-3	2019	CD151 ablation sensitized multiple tumor cell types to several anti-cancer drugs (e.g., gefitinib and camptothecin), thus increasing apoptosis, as seen using cleaved caspase-3, cleaved PARP (poly (ADP-ribose) polymerase), annexin V, and propidium iodide staining assays.	Camptothecin	102-114	CD151 molecule (Raph blood group)	Homo sapiens	0-5
30839063-5	2019	Furthermore, the knockdown of nucleolin by siRNA reduced the activation of ATM and RAD3-related (ATR) kinase and the formation of RAD51 and RPA32 foci after replication stress due to UV or camptothecin exposure, whereas nucleolin overexpression augmented ATR-dependent phosphorylation and RAD51 and RPA accumulation on chromatin.	Camptothecin	189-201	nucleolin	Homo sapiens	30-39
30839063-5	2019	Furthermore, the knockdown of nucleolin by siRNA reduced the activation of ATM and RAD3-related (ATR) kinase and the formation of RAD51 and RPA32 foci after replication stress due to UV or camptothecin exposure, whereas nucleolin overexpression augmented ATR-dependent phosphorylation and RAD51 and RPA accumulation on chromatin.	Camptothecin	189-201	ATR serine/threonine kinase	Homo sapiens	97-100
30839063-5	2019	Furthermore, the knockdown of nucleolin by siRNA reduced the activation of ATM and RAD3-related (ATR) kinase and the formation of RAD51 and RPA32 foci after replication stress due to UV or camptothecin exposure, whereas nucleolin overexpression augmented ATR-dependent phosphorylation and RAD51 and RPA accumulation on chromatin.	Camptothecin	189-201	RAD51 recombinase	Homo sapiens	130-135
30839063-5	2019	Furthermore, the knockdown of nucleolin by siRNA reduced the activation of ATM and RAD3-related (ATR) kinase and the formation of RAD51 and RPA32 foci after replication stress due to UV or camptothecin exposure, whereas nucleolin overexpression augmented ATR-dependent phosphorylation and RAD51 and RPA accumulation on chromatin.	Camptothecin	189-201	replication protein A2	Homo sapiens	140-145
31022845-0	2019	Camptothecin Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells.	Camptothecin	0-12	CD274 molecule	Homo sapiens	21-26
30676768-0	2019	RMI1 contributes to DNA repair and to the tolerance to camptothecin.	Camptothecin	55-67	RecQ mediated genome instability 1	Homo sapiens	0-4
30720231-4	2019	We found that DEHP impaired the effectiveness of camptothecin (CPT) and alleviated the CPT-induced formation of reactive oxygen species in ERalpha-positive MCF-7 cells, but not in ERalpha-negative MDA-MB-231 cells.	Camptothecin	87-90	estrogen receptor 1	Homo sapiens	139-146
30676768-3	2019	Herein, we report that RMI1 depletion increases cell sensitivity to camptothecin treatment, as shown by an elevation of genotoxic stress-induced DNA double-strand breaks, a stronger activation of the DNA damage response, and a greater G2/M cell cycle delay.	Camptothecin	68-80	RecQ mediated genome instability 1	Homo sapiens	23-27
30676768-6	2019	RMI1 contributes to DNA repair and to the tolerance to camptothecin.	Camptothecin	55-67	RecQ mediated genome instability 1	Homo sapiens	0-4
29262741-2	2019	In the present study, chemo-resistant proteins, including glucose-regulated protein 78 (GRP78)/clusterin (CLU) targeted 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) liposomes, were developed as a delivery system for co-delivery of camptothecin (CPT) and GRP78 siRNA/CLU siRNA.	Camptothecin	237-249	heat shock protein family A (Hsp70) member 5	Homo sapiens	58-86
30773277-6	2019	Moreover, functional studies revealed increased amounts of spontaneous replication fork stalling and chromosomal aberrations, as well as fewer camptothecin (CPT)-induced RAD51 foci in subject-derived cell lines.	Camptothecin	143-155	RAD51 recombinase	Mus musculus	170-175
30773277-6	2019	Moreover, functional studies revealed increased amounts of spontaneous replication fork stalling and chromosomal aberrations, as well as fewer camptothecin (CPT)-induced RAD51 foci in subject-derived cell lines.	Camptothecin	157-160	RAD51 recombinase	Mus musculus	170-175
29262741-2	2019	In the present study, chemo-resistant proteins, including glucose-regulated protein 78 (GRP78)/clusterin (CLU) targeted 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) liposomes, were developed as a delivery system for co-delivery of camptothecin (CPT) and GRP78 siRNA/CLU siRNA.	Camptothecin	237-249	heat shock protein family A (Hsp70) member 5	Homo sapiens	88-93
29262741-2	2019	In the present study, chemo-resistant proteins, including glucose-regulated protein 78 (GRP78)/clusterin (CLU) targeted 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) liposomes, were developed as a delivery system for co-delivery of camptothecin (CPT) and GRP78 siRNA/CLU siRNA.	Camptothecin	237-249	clusterin	Homo sapiens	106-109
29262741-2	2019	In the present study, chemo-resistant proteins, including glucose-regulated protein 78 (GRP78)/clusterin (CLU) targeted 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) liposomes, were developed as a delivery system for co-delivery of camptothecin (CPT) and GRP78 siRNA/CLU siRNA.	Camptothecin	251-254	heat shock protein family A (Hsp70) member 5	Homo sapiens	58-86
29262741-2	2019	In the present study, chemo-resistant proteins, including glucose-regulated protein 78 (GRP78)/clusterin (CLU) targeted 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) liposomes, were developed as a delivery system for co-delivery of camptothecin (CPT) and GRP78 siRNA/CLU siRNA.	Camptothecin	251-254	heat shock protein family A (Hsp70) member 5	Homo sapiens	88-93
29262741-2	2019	In the present study, chemo-resistant proteins, including glucose-regulated protein 78 (GRP78)/clusterin (CLU) targeted 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) liposomes, were developed as a delivery system for co-delivery of camptothecin (CPT) and GRP78 siRNA/CLU siRNA.	Camptothecin	251-254	clusterin	Homo sapiens	106-109
30061364-1	2018	PURPOSE: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used.	Camptothecin	91-104	DNA topoisomerase I	Canis lupus familiaris	36-51
30497009-2	2019	The aim of this study was to develop and assess a simple procedure for surface functionalization of ZnO NPs by N-acetyl-l-cysteine (NAC) for anticancer camptothecin (CPT) delivery.	Camptothecin	152-164	X-linked Kx blood group	Homo sapiens	132-135
30497009-2	2019	The aim of this study was to develop and assess a simple procedure for surface functionalization of ZnO NPs by N-acetyl-l-cysteine (NAC) for anticancer camptothecin (CPT) delivery.	Camptothecin	166-169	X-linked Kx blood group	Homo sapiens	132-135
30663574-4	2019	OBJECTIVE: Camptothecin and norcantharidin were thus chosen to construct a dual anticancer drugs assemblies mainly because CPT was the DNA-topoisomerase I inhibitor and norcantharidin could also suppress the cancer cell growth by inhibiting protein phosphatase.	Camptothecin	11-23	choline phosphotransferase 1	Homo sapiens	123-126
31930190-1	2019	Topoisomerases are well-validated targets for cancer chemotherapy and DNA topoisomerase 1 (Top1) is the sole target of the camptothecin (CPT) class of anticancer drugs.	Camptothecin	123-135	DNA topoisomerase I	Homo sapiens	70-89
31930190-1	2019	Topoisomerases are well-validated targets for cancer chemotherapy and DNA topoisomerase 1 (Top1) is the sole target of the camptothecin (CPT) class of anticancer drugs.	Camptothecin	137-140	DNA topoisomerase I	Homo sapiens	70-89
30775805-9	2019	SRSF1 was essential for the camptothecin-induced clearance from the nucleolus.	Camptothecin	28-40	serine and arginine rich splicing factor 1	Homo sapiens	0-5
30061364-3	2018	Indenoisoquinoline non-camptothecin topoisomerase I (TOP1) inhibitors overcome chemical instability and drug resistance that limit camptothecin use.	Camptothecin	23-35	DNA topoisomerase I	Canis lupus familiaris	36-51
30061364-3	2018	Indenoisoquinoline non-camptothecin topoisomerase I (TOP1) inhibitors overcome chemical instability and drug resistance that limit camptothecin use.	Camptothecin	23-35	DNA topoisomerase I	Canis lupus familiaris	53-57
30061364-3	2018	Indenoisoquinoline non-camptothecin topoisomerase I (TOP1) inhibitors overcome chemical instability and drug resistance that limit camptothecin use.	Camptothecin	131-143	DNA topoisomerase I	Canis lupus familiaris	36-51
30061364-1	2018	PURPOSE: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used.	Camptothecin	91-104	DNA topoisomerase I	Canis lupus familiaris	53-57
30061364-3	2018	Indenoisoquinoline non-camptothecin topoisomerase I (TOP1) inhibitors overcome chemical instability and drug resistance that limit camptothecin use.	Camptothecin	131-143	DNA topoisomerase I	Canis lupus familiaris	53-57
30096294-0	2018	PIM2 survival kinase is upregulated in a p53-dependent manner in cells treated with camptothecin or co-treated with actinomycin D and nutlin-3a.	Camptothecin	84-96	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	0-4
30266318-0	2018	Camptothecin enhances c-Myc-mediated endoplasmic reticulum stress and leads to autophagy by activating Ca2+-mediated AMPK.	Camptothecin	0-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	22-27
30266318-0	2018	Camptothecin enhances c-Myc-mediated endoplasmic reticulum stress and leads to autophagy by activating Ca2+-mediated AMPK.	Camptothecin	0-12	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	117-121
30106130-6	2018	In addition, the results of a viability assay and Annexin V staining revealed that CPT-induced autophagy could protect lung cancer cells from programmed cell death.	Camptothecin	83-86	annexin A5	Homo sapiens	50-59
30347770-0	2018	PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates.	Camptothecin	122-134	folate hydrolase 1	Homo sapiens	0-4
30138703-1	2018	A carrier-free and reduction-degradable Janus prodrug, termed as CPT-SS-GEM, was fabricated by redox-sensitive disulfide bond linked gemcitabine and camptothecin.	Camptothecin	149-161	choline phosphotransferase 1	Homo sapiens	65-68
30333500-6	2018	HORMAD1-depleted cells are sensitive to IR and camptothecin.	Camptothecin	47-59	HORMA domain containing 1	Homo sapiens	0-7
30096294-0	2018	PIM2 survival kinase is upregulated in a p53-dependent manner in cells treated with camptothecin or co-treated with actinomycin D and nutlin-3a.	Camptothecin	84-96	tumor protein p53	Homo sapiens	41-44
30209297-0	2018	PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.	Camptothecin	113-125	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
30274183-0	2018	Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules.	Camptothecin	73-85	poly(ADP-ribose) polymerase 1	Homo sapiens	106-110
30209297-0	2018	PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.	Camptothecin	113-125	Rho family GTPase 1	Homo sapiens	17-21
30209297-7	2018	We further demonstrated that camptothecin increases RND1 gene transcription and mRNA stability.	Camptothecin	29-41	Rho family GTPase 1	Homo sapiens	52-56
30209297-4	2018	Here we used camptothecin, a selective topoisomerase I (TOP1) inhibitor that stabilizes TOP1 cleavage complexes (TOP1cc), to search for other potential early DNA damage-inducible RHO GTPase genes.	Camptothecin	13-25	DNA topoisomerase I	Homo sapiens	56-60
30209297-8	2018	Camptothecin also increases poly(ADP-ribose) polymerase 1 (PARP-1) activity, whose inhibition reduces RND1 transcription.	Camptothecin	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	28-57
30209297-4	2018	Here we used camptothecin, a selective topoisomerase I (TOP1) inhibitor that stabilizes TOP1 cleavage complexes (TOP1cc), to search for other potential early DNA damage-inducible RHO GTPase genes.	Camptothecin	13-25	DNA topoisomerase I	Homo sapiens	88-92
30209297-8	2018	Camptothecin also increases poly(ADP-ribose) polymerase 1 (PARP-1) activity, whose inhibition reduces RND1 transcription.	Camptothecin	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	59-65
30209297-5	2018	We identified that an atypical RHO GTPase, RND1, is rapidly induced by camptothecin.	Camptothecin	71-83	Rho family GTPase 1	Homo sapiens	43-47
30209297-8	2018	Camptothecin also increases poly(ADP-ribose) polymerase 1 (PARP-1) activity, whose inhibition reduces RND1 transcription.	Camptothecin	0-12	Rho family GTPase 1	Homo sapiens	102-106
30209297-6	2018	RND1 induction is closely associated with the presence of TOP1cc induced by camptothecin or by DNA lesions that elevate TOP1cc levels such as UV and hydrogen peroxide.	Camptothecin	76-88	Rho family GTPase 1	Homo sapiens	0-4
30209297-10	2018	Finally, RND1 protects cells against camptothecin-induced apoptosis, and hence favors cellular resistance to camptothecin.	Camptothecin	37-49	Rho family GTPase 1	Homo sapiens	9-13
30209297-10	2018	Finally, RND1 protects cells against camptothecin-induced apoptosis, and hence favors cellular resistance to camptothecin.	Camptothecin	109-121	Rho family GTPase 1	Homo sapiens	9-13
30209297-6	2018	RND1 induction is closely associated with the presence of TOP1cc induced by camptothecin or by DNA lesions that elevate TOP1cc levels such as UV and hydrogen peroxide.	Camptothecin	76-88	DNA topoisomerase I	Homo sapiens	58-62
30209297-11	2018	Together, these findings highlight RND1 as an atypical RHO GTPase early induced by TOP1cc, and show that the TOP1cc-PARP-1-RND1 pathway protects cells against apoptosis induced by camptothecin.	Camptothecin	180-192	Rho family GTPase 1	Homo sapiens	35-39
30209297-11	2018	Together, these findings highlight RND1 as an atypical RHO GTPase early induced by TOP1cc, and show that the TOP1cc-PARP-1-RND1 pathway protects cells against apoptosis induced by camptothecin.	Camptothecin	180-192	DNA topoisomerase I	Homo sapiens	83-87
30209297-11	2018	Together, these findings highlight RND1 as an atypical RHO GTPase early induced by TOP1cc, and show that the TOP1cc-PARP-1-RND1 pathway protects cells against apoptosis induced by camptothecin.	Camptothecin	180-192	poly(ADP-ribose) polymerase 1	Homo sapiens	116-122
30209297-11	2018	Together, these findings highlight RND1 as an atypical RHO GTPase early induced by TOP1cc, and show that the TOP1cc-PARP-1-RND1 pathway protects cells against apoptosis induced by camptothecin.	Camptothecin	180-192	Rho family GTPase 1	Homo sapiens	123-127
30338760-2	2018	The fluorescence anisotropy method was used to examine the interactions of commercial human serum albumin (HSA) and human plasma proteins with ochratoxin A (OTA) or carboxylate form of camptothecin (CPT-C).	Camptothecin	185-197	albumin	Homo sapiens	92-111
30233218-3	2018	The effect of Sirt1 overexpression on camptothecin-induced apoptosis of NSCs was evaluated.	Camptothecin	38-50	sirtuin 1	Rattus norvegicus	14-19
30115492-0	2018	A series of camptothecin prodrugs exhibit HDAC inhibition activity.	Camptothecin	12-24	histone deacetylase 9	Homo sapiens	42-46
30115492-2	2018	Herein, we have designed a series of camptothecin prodrugs that exhibit histone deacetylase (HDAC) inhibition activity based on the synergy effect between HDAC inhibitors and camptothecin derivatives.	Camptothecin	37-49	histone deacetylase 9	Homo sapiens	72-91
30115492-2	2018	Herein, we have designed a series of camptothecin prodrugs that exhibit histone deacetylase (HDAC) inhibition activity based on the synergy effect between HDAC inhibitors and camptothecin derivatives.	Camptothecin	37-49	histone deacetylase 9	Homo sapiens	93-97
30115492-2	2018	Herein, we have designed a series of camptothecin prodrugs that exhibit histone deacetylase (HDAC) inhibition activity based on the synergy effect between HDAC inhibitors and camptothecin derivatives.	Camptothecin	37-49	histone deacetylase 9	Homo sapiens	155-159
30115492-2	2018	Herein, we have designed a series of camptothecin prodrugs that exhibit histone deacetylase (HDAC) inhibition activity based on the synergy effect between HDAC inhibitors and camptothecin derivatives.	Camptothecin	175-187	histone deacetylase 9	Homo sapiens	72-91
30115492-2	2018	Herein, we have designed a series of camptothecin prodrugs that exhibit histone deacetylase (HDAC) inhibition activity based on the synergy effect between HDAC inhibitors and camptothecin derivatives.	Camptothecin	175-187	histone deacetylase 9	Homo sapiens	93-97
30338760-2	2018	The fluorescence anisotropy method was used to examine the interactions of commercial human serum albumin (HSA) and human plasma proteins with ochratoxin A (OTA) or carboxylate form of camptothecin (CPT-C).	Camptothecin	199-204	albumin	Homo sapiens	92-111
29901986-5	2018	Most importantly, it was found that the PCF-MB-mediated photodynamic therapy could significantly reduce the expression of adenosine-triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2), which is responsible for the drug resistance in chemotherapy, resulting in a prominent intracellular camptothecin increase.	Camptothecin	299-311	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	122-188
30111719-1	2018	As part of our initial efforts into developing a tumor-targeting therapy, C-10 substituted derivatives of a camptothecin analog (SN-38) have been synthesized (2-, 3- and 4-nitrobenzyl) for use as potential hypoxia-activated prodrugs and evaluated for their cytotoxicity, topoisomerase I inhibition and electrochemical (reductive) properties.	Camptothecin	108-120	homeobox C10	Homo sapiens	74-78
29901986-5	2018	Most importantly, it was found that the PCF-MB-mediated photodynamic therapy could significantly reduce the expression of adenosine-triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2), which is responsible for the drug resistance in chemotherapy, resulting in a prominent intracellular camptothecin increase.	Camptothecin	299-311	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	190-195
30288239-3	2018	This dual and traceless prodrug activation strategy takes advantage of the INVDA chemistry of tetrazines (here a prodrug), generating a pyridazine-based miR21 inhibitor and the anti-cancer drug camptothecin and offers a new concept in prodrug activation.	Camptothecin	194-206	microRNA 21	Homo sapiens	153-158
29684847-6	2018	In p53+ group, the expression of Ser20 significantly increased after camptothecin and paclitaxel (p < 0.05).	Camptothecin	69-81	tumor protein p53	Homo sapiens	3-6
29963130-0	2018	Camptothecin inhibits the progression of NPC by regulating TGF-beta-induced activation of the PI3K/AKT signaling pathway.	Camptothecin	0-12	transforming growth factor, beta 1	Mus musculus	59-67
29963130-0	2018	Camptothecin inhibits the progression of NPC by regulating TGF-beta-induced activation of the PI3K/AKT signaling pathway.	Camptothecin	0-12	thymoma viral proto-oncogene 1	Mus musculus	99-102
29963130-7	2018	Camptothecin administration downregulated the expression levels of cell-cycle-associated proteins including cyclin 1, cyclin-dependent kinase (CDK)1 and CDK2 in NPC cells.	Camptothecin	0-12	cyclin-dependent kinase 1	Mus musculus	118-148
29963130-7	2018	Camptothecin administration downregulated the expression levels of cell-cycle-associated proteins including cyclin 1, cyclin-dependent kinase (CDK)1 and CDK2 in NPC cells.	Camptothecin	0-12	cyclin-dependent kinase 2	Mus musculus	153-157
29963130-8	2018	Expression levels of migration-associated proteins including vimentin, fibronectin and epithelial cadherin were regulated by camptothecin treatment in NPC cells.	Camptothecin	125-137	vimentin	Mus musculus	61-69
29963130-8	2018	Expression levels of migration-associated proteins including vimentin, fibronectin and epithelial cadherin were regulated by camptothecin treatment in NPC cells.	Camptothecin	125-137	fibronectin 1	Mus musculus	71-82
29873288-1	2018	BACKGROUND: Irinotecan (IRN) (CPT-11) is a camptothecin derivative with low oral bioavailability due to active efflux by intestinal P-glycoprotein (p-gp) receptors.	Camptothecin	43-55	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
29371029-2	2018	Modification of MAGED2 intracellular localization during cell cycle phases and following treatment with camptothecin (CPT) and phosphorylation by ATM/ATR following ionizing irradiation led us to investigate the molecular functions of MAGED2 in the cellular response to DNA damage.	Camptothecin	104-116	MAGE family member D2	Homo sapiens	16-22
29371029-2	2018	Modification of MAGED2 intracellular localization during cell cycle phases and following treatment with camptothecin (CPT) and phosphorylation by ATM/ATR following ionizing irradiation led us to investigate the molecular functions of MAGED2 in the cellular response to DNA damage.	Camptothecin	118-121	MAGE family member D2	Homo sapiens	16-22
29963130-9	2018	Additionally, camptothecin inhibited the expression of transforming growth factor-beta (TGF-beta), phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT), whereas TGF-beta overexpression abrogated camptothecin-mediated inhibition of PI3K and AKT expression and camptothecin-mediated inhibition of the viability and aggressiveness of NPC cells.	Camptothecin	14-26	transforming growth factor, beta 1	Mus musculus	88-96
29963130-9	2018	Additionally, camptothecin inhibited the expression of transforming growth factor-beta (TGF-beta), phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT), whereas TGF-beta overexpression abrogated camptothecin-mediated inhibition of PI3K and AKT expression and camptothecin-mediated inhibition of the viability and aggressiveness of NPC cells.	Camptothecin	14-26	thymoma viral proto-oncogene 1	Mus musculus	154-157
29963130-9	2018	Additionally, camptothecin inhibited the expression of transforming growth factor-beta (TGF-beta), phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT), whereas TGF-beta overexpression abrogated camptothecin-mediated inhibition of PI3K and AKT expression and camptothecin-mediated inhibition of the viability and aggressiveness of NPC cells.	Camptothecin	14-26	thymoma viral proto-oncogene 1	Mus musculus	247-250
29963130-9	2018	Additionally, camptothecin inhibited the expression of transforming growth factor-beta (TGF-beta), phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT), whereas TGF-beta overexpression abrogated camptothecin-mediated inhibition of PI3K and AKT expression and camptothecin-mediated inhibition of the viability and aggressiveness of NPC cells.	Camptothecin	202-214	transforming growth factor, beta 1	Mus musculus	168-176
29963130-9	2018	Additionally, camptothecin inhibited the expression of transforming growth factor-beta (TGF-beta), phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT), whereas TGF-beta overexpression abrogated camptothecin-mediated inhibition of PI3K and AKT expression and camptothecin-mediated inhibition of the viability and aggressiveness of NPC cells.	Camptothecin	202-214	transforming growth factor, beta 1	Mus musculus	168-176
29963130-11	2018	In conclusion, these results indicate that camptothecin treatment may inhibit the viability of NPC cells and aggressiveness by regulating the TGF-beta-induced PI3K/AKT signaling pathways, which in turn may be a potential molecular target for the treatment of NPC.	Camptothecin	43-55	transforming growth factor, beta 1	Mus musculus	142-150
29963130-11	2018	In conclusion, these results indicate that camptothecin treatment may inhibit the viability of NPC cells and aggressiveness by regulating the TGF-beta-induced PI3K/AKT signaling pathways, which in turn may be a potential molecular target for the treatment of NPC.	Camptothecin	43-55	thymoma viral proto-oncogene 1	Mus musculus	164-167
29789392-5	2018	In a BRCA1-mutant cell line, however, depletion of FAM35A increased resistance to camptothecin, suggesting that FAM35A participates in processing of DNA ends to allow more efficient DNA repair.	Camptothecin	82-94	BRCA1 DNA repair associated	Homo sapiens	5-10
29789392-5	2018	In a BRCA1-mutant cell line, however, depletion of FAM35A increased resistance to camptothecin, suggesting that FAM35A participates in processing of DNA ends to allow more efficient DNA repair.	Camptothecin	82-94	shieldin complex subunit 2	Homo sapiens	51-57
29789392-5	2018	In a BRCA1-mutant cell line, however, depletion of FAM35A increased resistance to camptothecin, suggesting that FAM35A participates in processing of DNA ends to allow more efficient DNA repair.	Camptothecin	82-94	shieldin complex subunit 2	Homo sapiens	112-118
29684847-5	2018	RESULTS: Cell lines and tumor cells p53+, p53- revealed a significant decrease in cell survival after camptothecin, paclitaxel, cisplatin treatment, compared to the control group (p < 0.01).	Camptothecin	102-114	tumor protein p53	Homo sapiens	36-39
29684847-5	2018	RESULTS: Cell lines and tumor cells p53+, p53- revealed a significant decrease in cell survival after camptothecin, paclitaxel, cisplatin treatment, compared to the control group (p < 0.01).	Camptothecin	102-114	tumor protein p53	Homo sapiens	42-45
29451722-8	2018	Notably, based on the direct adsorption of GSH, MOF-2 showed a comparable effect with the commercial antitumor drug camptothecin in a mouse breast cancer model.	Camptothecin	116-128	mesenteric and omental fat pad weight 2	Mus musculus	48-53
29875999-0	2018	Transcriptional activation of p21Waf1 contributes to suppression of HR by p53 in response to replication arrest induced by camptothecin.	Camptothecin	123-135	tumor protein p53	Homo sapiens	74-77
29432724-11	2018	We also found similar results in a distinct model of neuronal death: primary cultures of cortical neurons treated with the topoisomerase I inhibitor camptothecin, in which guanabenz limited camptothecin-induced neuronal death in an ATF4- and parkin-dependent manner.	Camptothecin	149-161	activating transcription factor 4	Rattus norvegicus	232-236
29432724-11	2018	We also found similar results in a distinct model of neuronal death: primary cultures of cortical neurons treated with the topoisomerase I inhibitor camptothecin, in which guanabenz limited camptothecin-induced neuronal death in an ATF4- and parkin-dependent manner.	Camptothecin	190-202	activating transcription factor 4	Rattus norvegicus	232-236
29731842-9	2018	The sensitivities of the cells to three drugs, camptothecin, cisplatin and olaparib, significantly increased following RAD51C gene knockdown.	Camptothecin	47-59	RAD51 paralog C	Homo sapiens	119-125
29774099-8	2018	These findings suggest that CPT-induced G2/M phase arrest through the ROS-ATM-Chk2-Cdc25C axis is accompanied by the activation of autophagy.	Camptothecin	28-31	checkpoint kinase 2	Homo sapiens	78-82
29774099-8	2018	These findings suggest that CPT-induced G2/M phase arrest through the ROS-ATM-Chk2-Cdc25C axis is accompanied by the activation of autophagy.	Camptothecin	28-31	cell division cycle 25C	Homo sapiens	83-89
29899822-0	2018	Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells.	Camptothecin	0-12	SUV39H1 histone lysine methyltransferase	Homo sapiens	49-54
29786670-9	2018	We found that USP47 contributes to cell viability and chemoresistance in NCI-N87 gastric carcinoma cells treated with etoposide and camptothecin.	Camptothecin	132-144	ubiquitin specific peptidase 47	Homo sapiens	14-19
29774099-0	2018	Camptothecin induces G2/M phase arrest through the ATM-Chk2-Cdc25C axis as a result of autophagy-induced cytoprotection: Implications of reactive oxygen species.	Camptothecin	0-12	ATM serine/threonine kinase	Homo sapiens	51-54
29774099-0	2018	Camptothecin induces G2/M phase arrest through the ATM-Chk2-Cdc25C axis as a result of autophagy-induced cytoprotection: Implications of reactive oxygen species.	Camptothecin	0-12	checkpoint kinase 2	Homo sapiens	55-59
29774099-0	2018	Camptothecin induces G2/M phase arrest through the ATM-Chk2-Cdc25C axis as a result of autophagy-induced cytoprotection: Implications of reactive oxygen species.	Camptothecin	0-12	cell division cycle 25C	Homo sapiens	60-66
29774099-1	2018	In the present study, we report that camptothecin (CPT) caused irreversible cell cycle arrest at the G2/M phase, and was associated with decreased levels of cell division cycle 25C (Cdc25C) and increased levels of cyclin B1, p21, and phospho-H3.	Camptothecin	37-49	cell division cycle 25C	Homo sapiens	182-188
29391350-4	2018	In cancer cells not expressing SLFN11, transfection of SLFN11 sensitized the cells to camptothecin, topotecan, hydroxyurea, and cisplatin but not to paclitaxel.	Camptothecin	86-98	schlafen family member 11	Homo sapiens	55-61
29774099-1	2018	In the present study, we report that camptothecin (CPT) caused irreversible cell cycle arrest at the G2/M phase, and was associated with decreased levels of cell division cycle 25C (Cdc25C) and increased levels of cyclin B1, p21, and phospho-H3.	Camptothecin	37-49	cyclin B1	Homo sapiens	214-223
29774099-1	2018	In the present study, we report that camptothecin (CPT) caused irreversible cell cycle arrest at the G2/M phase, and was associated with decreased levels of cell division cycle 25C (Cdc25C) and increased levels of cyclin B1, p21, and phospho-H3.	Camptothecin	37-49	cyclin dependent kinase inhibitor 1A	Homo sapiens	225-228
29774099-1	2018	In the present study, we report that camptothecin (CPT) caused irreversible cell cycle arrest at the G2/M phase, and was associated with decreased levels of cell division cycle 25C (Cdc25C) and increased levels of cyclin B1, p21, and phospho-H3.	Camptothecin	51-54	cell division cycle 25C	Homo sapiens	182-188
29774099-1	2018	In the present study, we report that camptothecin (CPT) caused irreversible cell cycle arrest at the G2/M phase, and was associated with decreased levels of cell division cycle 25C (Cdc25C) and increased levels of cyclin B1, p21, and phospho-H3.	Camptothecin	51-54	cyclin B1	Homo sapiens	214-223
29774099-1	2018	In the present study, we report that camptothecin (CPT) caused irreversible cell cycle arrest at the G2/M phase, and was associated with decreased levels of cell division cycle 25C (Cdc25C) and increased levels of cyclin B1, p21, and phospho-H3.	Camptothecin	51-54	cyclin dependent kinase inhibitor 1A	Homo sapiens	225-228
29774099-4	2018	We also found that CPT-induced G2/M phase arrest increased, along with the ataxia telangiectasia-mutated (ATM)-checkpoint kinase 2 (Chk2)-Cdc25C axis.	Camptothecin	19-22	ATM serine/threonine kinase	Homo sapiens	106-109
29774099-4	2018	We also found that CPT-induced G2/M phase arrest increased, along with the ataxia telangiectasia-mutated (ATM)-checkpoint kinase 2 (Chk2)-Cdc25C axis.	Camptothecin	19-22	checkpoint kinase 2	Homo sapiens	132-136
29774099-4	2018	We also found that CPT-induced G2/M phase arrest increased, along with the ataxia telangiectasia-mutated (ATM)-checkpoint kinase 2 (Chk2)-Cdc25C axis.	Camptothecin	19-22	cell division cycle 25C	Homo sapiens	138-144
29774099-7	2018	Finally, we found that CPT-induced G2/M phase arrest circumvented apoptosis by activating autophagy through ATM activation.	Camptothecin	23-26	ATM serine/threonine kinase	Homo sapiens	108-111
29774099-8	2018	These findings suggest that CPT-induced G2/M phase arrest through the ROS-ATM-Chk2-Cdc25C axis is accompanied by the activation of autophagy.	Camptothecin	28-31	ATM serine/threonine kinase	Homo sapiens	74-77
29643533-8	2018	MICB mRNA expression also increased slightly in another breast cancer cell SK-BR-3 treated by topoisomerase II inhibitors etoposide and camptothecin (P<0.05).	Camptothecin	136-148	MHC class I polypeptide-related sequence B	Homo sapiens	0-4
29643533-9	2018	Furthermore, etoposide and camptothecin upregulated MICA/B surface protein expression in MCF-7 cells (P<0.05), and the upregulation was found in both living and apoptotic cells.	Camptothecin	27-39	MHC class I polypeptide-related sequence A	Homo sapiens	52-56
29643533-5	2018	RESULTS: Three topoisomerase inhibitors etoposide, camptothecin and doxorubicine upregulated MICA and MICB mRNA expressions in breast cancer cell MCF-7.	Camptothecin	51-63	MHC class I polypeptide-related sequence A	Homo sapiens	93-97
29643533-5	2018	RESULTS: Three topoisomerase inhibitors etoposide, camptothecin and doxorubicine upregulated MICA and MICB mRNA expressions in breast cancer cell MCF-7.	Camptothecin	51-63	MHC class I polypeptide-related sequence B	Homo sapiens	102-106
29643533-7	2018	MICA and MICB mRNA levels also increased significantly when MCF-7 cells were incubated with camptothecin or doxorubicine at the specific concentrations (P<0.05).	Camptothecin	92-104	MHC class I polypeptide-related sequence A	Homo sapiens	0-4
29643533-7	2018	MICA and MICB mRNA levels also increased significantly when MCF-7 cells were incubated with camptothecin or doxorubicine at the specific concentrations (P<0.05).	Camptothecin	92-104	MHC class I polypeptide-related sequence B	Homo sapiens	9-13
29391350-7	2018	Consistent with the epigenetic regulation of SLFN11, camptothecin and class I HDAC inhibitors were synergistic in many of the cell lines tested.Conclusions: This study reports the prevalent epigenetic regulation of SLFN11 and the dominant stimulatory effect of HDAC inhibitors on SLFN11 expression.	Camptothecin	53-65	schlafen family member 11	Homo sapiens	215-221
29391350-7	2018	Consistent with the epigenetic regulation of SLFN11, camptothecin and class I HDAC inhibitors were synergistic in many of the cell lines tested.Conclusions: This study reports the prevalent epigenetic regulation of SLFN11 and the dominant stimulatory effect of HDAC inhibitors on SLFN11 expression.	Camptothecin	53-65	schlafen family member 11	Homo sapiens	215-221
29420790-4	2018	By assessing the impact of these mutations at the cellular and structural levels, we found that all the mre11 alleles that restore sae2Delta resistance to both camptothecin and phleomycin affect the Mre11 N-terminus and suppress the resection defect of sae2Delta cells by lowering MRX and Tel1 association to DSBs.	Camptothecin	160-172	MRE11 homolog, double strand break repair nuclease	Homo sapiens	104-109
29420790-4	2018	By assessing the impact of these mutations at the cellular and structural levels, we found that all the mre11 alleles that restore sae2Delta resistance to both camptothecin and phleomycin affect the Mre11 N-terminus and suppress the resection defect of sae2Delta cells by lowering MRX and Tel1 association to DSBs.	Camptothecin	160-172	MRE11 homolog, double strand break repair nuclease	Homo sapiens	199-204
29369435-6	2018	This concept is first demonstrated without drugs, and is further improved with the suitable loading of hydrophobic drugs, curcumin (CUR) and camptothecin (CPT), which are retained between the CNTs and human serum albumin (HSA) layer.	Camptothecin	141-153	albumin	Homo sapiens	207-220
29369435-6	2018	This concept is first demonstrated without drugs, and is further improved with the suitable loading of hydrophobic drugs, curcumin (CUR) and camptothecin (CPT), which are retained between the CNTs and human serum albumin (HSA) layer.	Camptothecin	155-158	albumin	Homo sapiens	207-220
29145770-1	2018	A novel pH-sensitive polymeric prodrug of camptothecin (CPT) by polymerizing gamma-camptothecin-glutamate N-carboxyanhydride (Glu (CPT)-NCA) on boronate ester-linked poly (ethyleneglycol) (PEG) directly via the amine-initiated ring open polymerization (ROP) has been developed.	Camptothecin	42-54	CEA cell adhesion molecule 6	Homo sapiens	136-139
29298824-3	2018	Here we demonstrate that cells depleted of MOF and under replicative stress induced by cisplatin, hydroxyurea, or camptothecin have reduced survival, a higher frequency of S-phase-specific chromosome damage, and increased R-loop formation.	Camptothecin	114-126	lysine acetyltransferase 8	Homo sapiens	43-46
29415984-3	2018	Here, we show that stable knockdown of UHRF1 renders retinoblastoma cells sensitized to conventional chemotherapeutic drugs such as etoposide and camptothecin, resulting in enhanced DNA damage and apoptotic cell death.	Camptothecin	146-158	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	39-44
29435049-7	2018	In addition, ZNF224 was rapidly degraded upon treatment with the DNA-damaging agent camptothecin (CPT).	Camptothecin	84-96	zinc finger protein 224	Homo sapiens	13-19
29435049-7	2018	In addition, ZNF224 was rapidly degraded upon treatment with the DNA-damaging agent camptothecin (CPT).	Camptothecin	98-101	zinc finger protein 224	Homo sapiens	13-19
29145770-1	2018	A novel pH-sensitive polymeric prodrug of camptothecin (CPT) by polymerizing gamma-camptothecin-glutamate N-carboxyanhydride (Glu (CPT)-NCA) on boronate ester-linked poly (ethyleneglycol) (PEG) directly via the amine-initiated ring open polymerization (ROP) has been developed.	Camptothecin	56-59	CEA cell adhesion molecule 6	Homo sapiens	136-139
29395061-2	2018	Here we show that, in response to replication stress induced by camptothecin, SLFN11 tightly binds chromatin at stressed replication foci via RPA1 together with the replication helicase subunit MCM3.	Camptothecin	64-76	schlafen family member 11	Homo sapiens	78-84
29395061-2	2018	Here we show that, in response to replication stress induced by camptothecin, SLFN11 tightly binds chromatin at stressed replication foci via RPA1 together with the replication helicase subunit MCM3.	Camptothecin	64-76	replication protein A1	Homo sapiens	142-146
29395061-2	2018	Here we show that, in response to replication stress induced by camptothecin, SLFN11 tightly binds chromatin at stressed replication foci via RPA1 together with the replication helicase subunit MCM3.	Camptothecin	64-76	minichromosome maintenance complex component 3	Homo sapiens	194-198
29335415-6	2018	USP48 repression confers a survival benefit to cells treated with camptothecin and its activity acts to restrain gene conversion and mutagenic single-strand annealing.	Camptothecin	66-78	ubiquitin specific peptidase 48	Homo sapiens	0-5
28991226-10	2018	Notably, cotreatment of chemotherapeutic agent camptothecin enhanced LSD1 inhibitor-induced senescence and growth inhibition of cancer cells in vitro and in mice.	Camptothecin	47-59	lysine (K)-specific demethylase 1A	Mus musculus	69-73
29239139-9	2018	Camptothecin and doxorubicin treatments in RT-4 cells or transient overexpression of p53 into p53-mutant HT1376 cells induced p53 and BTG2 expression.	Camptothecin	0-12	BTG anti-proliferation factor 2	Homo sapiens	134-138
27840168-7	2018	These understanding enabled the rational to conjugate LHRH with various cytotoxic drugs (doxorubicin, DOX; camptothecin etc.	Camptothecin	107-119	gonadotropin releasing hormone 1	Homo sapiens	54-58
29210480-6	2018	Moreover, camptothecin (CPT) is used as the anticancer drug and modified into a dimer (CPT)2 -ss-Mal, in which two CPT molecules are connected by a reduction-labile maleimide thioether bond.	Camptothecin	10-22	carnitine palmitoyltransferase 2	Homo sapiens	87-92
29210480-6	2018	Moreover, camptothecin (CPT) is used as the anticancer drug and modified into a dimer (CPT)2 -ss-Mal, in which two CPT molecules are connected by a reduction-labile maleimide thioether bond.	Camptothecin	24-27	carnitine palmitoyltransferase 2	Homo sapiens	87-92
29553100-0	2018	FL118, a novel camptothecin analogue, suppressed migration and invasion of human breast cancer cells by inhibiting epithelial-mesenchymal transition via the Wnt/beta-catenin signaling pathway.	Camptothecin	15-27	catenin beta 1	Homo sapiens	161-173
29116428-0	2017	Bromoethylindole (BEI-9) redirects NF-kappaB signaling induced by camptothecin and TNFalpha to promote cell death in colon cancer cells.	Camptothecin	66-78	nuclear factor kappa B subunit 1	Homo sapiens	35-44
29031818-0	2017	Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.	Camptothecin	0-12	far upstream element binding protein 1	Homo sapiens	137-142
29031818-0	2017	Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.	Camptothecin	0-12	Polykaryocytosis inducer	Homo sapiens	170-174
29031818-3	2017	In this study, we screened an FDA-approved drug library and discovered that the Topoisomerase I (TOP1) inhibitor camptothecin (CPT) and its derivative 7-ethyl-10-hydroxycamptothecin (SN-38), the active irinotecan metabolite that is used in the clinics in combination with other chemotherapeutics to treat carcinoma, inhibit FUBP1 activity.	Camptothecin	113-125	far upstream element binding protein 1	Homo sapiens	324-329
29031818-3	2017	In this study, we screened an FDA-approved drug library and discovered that the Topoisomerase I (TOP1) inhibitor camptothecin (CPT) and its derivative 7-ethyl-10-hydroxycamptothecin (SN-38), the active irinotecan metabolite that is used in the clinics in combination with other chemotherapeutics to treat carcinoma, inhibit FUBP1 activity.	Camptothecin	127-130	far upstream element binding protein 1	Homo sapiens	324-329
29031818-5	2017	Our results suggest the interference with the FUBP1/FUSE interaction as a further molecular mechanism that, in addition to the inactivation of TOP1, may contribute to the therapeutic potential of CPT/SN-38.	Camptothecin	196-199	far upstream element binding protein 1	Homo sapiens	46-51
29031818-5	2017	Our results suggest the interference with the FUBP1/FUSE interaction as a further molecular mechanism that, in addition to the inactivation of TOP1, may contribute to the therapeutic potential of CPT/SN-38.	Camptothecin	196-199	Polykaryocytosis inducer	Homo sapiens	52-56
28968864-8	2017	Not only silica but also rotenone, camptothecin and H2O2 activated ATX via ATM, suggesting that ATX is part of a generalized ATM response to double-strand breaks (DSBs).	Camptothecin	35-47	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	67-70
28968864-8	2017	Not only silica but also rotenone, camptothecin and H2O2 activated ATX via ATM, suggesting that ATX is part of a generalized ATM response to double-strand breaks (DSBs).	Camptothecin	35-47	ATM serine/threonine kinase	Homo sapiens	75-78
28968864-8	2017	Not only silica but also rotenone, camptothecin and H2O2 activated ATX via ATM, suggesting that ATX is part of a generalized ATM response to double-strand breaks (DSBs).	Camptothecin	35-47	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	96-99
28968864-8	2017	Not only silica but also rotenone, camptothecin and H2O2 activated ATX via ATM, suggesting that ATX is part of a generalized ATM response to double-strand breaks (DSBs).	Camptothecin	35-47	ATM serine/threonine kinase	Homo sapiens	125-128
29150335-0	2018	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.	Camptothecin	0-12	histone deacetylase 9	Homo sapiens	57-61
28910823-0	2017	Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs.	Camptothecin	0-12	NFE2 like bZIP transcription factor 2	Homo sapiens	24-28
28599178-12	2017	LTEP-P/DDP-1.0 cell-based sensor responses demonstrate that gemcitabine, vinorelbine, and camptothecin are ideal second-line drugs for clinical post-cisplatin therapy than other drugs according to MTT test results.	Camptothecin	90-102	translocase of inner mitochondrial membrane 8A	Homo sapiens	7-12
28822081-5	2017	The inducibility of DUSP1 in response to hypoxia, dexamethasone, or the chemotherapeutic agent camptothecin was confirmed in GB cell lines and tumor-derived stem cells (TSCs).	Camptothecin	95-107	dual specificity phosphatase 1	Homo sapiens	20-25
29100039-9	2017	Xrcc1-/- cells are hypersensitive to the DNA-protein cross-link inducing agent camptothecin (CPT) and the DNA oxidative agent H2O2 due in part to compromised PNKP-mediated repair.	Camptothecin	79-91	X-ray repair cross complementing 1	Homo sapiens	0-5
29100039-9	2017	Xrcc1-/- cells are hypersensitive to the DNA-protein cross-link inducing agent camptothecin (CPT) and the DNA oxidative agent H2O2 due in part to compromised PNKP-mediated repair.	Camptothecin	93-96	X-ray repair cross complementing 1	Homo sapiens	0-5
29100039-9	2017	Xrcc1-/- cells are hypersensitive to the DNA-protein cross-link inducing agent camptothecin (CPT) and the DNA oxidative agent H2O2 due in part to compromised PNKP-mediated repair.	Camptothecin	93-96	polynucleotide kinase 3'-phosphatase	Homo sapiens	158-162
29387807-8	2017	Results: We demonstrate that a small-cell lung cancer (SCLC)-associated T413S mutation in PALB2 impairs its chromatin association and confers reduced resistance to CPT, the only FDA-approved drug for relapsed SCLC.	Camptothecin	164-167	partner and localizer of BRCA2	Homo sapiens	90-95
28910823-3	2017	The current study focusses on camptothecin as a novel NRF2 inhibitor to sensitise HCC to chemotherapy.	Camptothecin	30-42	NFE2 like bZIP transcription factor 2	Homo sapiens	54-58
28910823-3	2017	The current study focusses on camptothecin as a novel NRF2 inhibitor to sensitise HCC to chemotherapy.	Camptothecin	30-42	HCC	Homo sapiens	82-85
28910823-7	2017	In searching chemicals targeting NRF2 for chemotherapy, we discovered that camptothecin is a potent NRF2 inhibitor.	Camptothecin	75-87	NFE2 like bZIP transcription factor 2	Homo sapiens	33-37
28910823-7	2017	In searching chemicals targeting NRF2 for chemotherapy, we discovered that camptothecin is a potent NRF2 inhibitor.	Camptothecin	75-87	NFE2 like bZIP transcription factor 2	Homo sapiens	100-104
28910823-8	2017	Camptothecin markedly suppressed NRF2 expression and transcriptional activity in different types of cancer cells including HepG2, SMMC-7721 and A549.	Camptothecin	0-12	NFE2 like bZIP transcription factor 2	Homo sapiens	33-37
28910823-10	2017	CONCLUSIONS: Camptothecin is a novel NRF2 inhibitor that may be repurposed in combination with other chemotherapeutics to enhance their efficacy in treating high NRF2-expressing cancers.	Camptothecin	13-25	NFE2 like bZIP transcription factor 2	Homo sapiens	37-41
28910823-10	2017	CONCLUSIONS: Camptothecin is a novel NRF2 inhibitor that may be repurposed in combination with other chemotherapeutics to enhance their efficacy in treating high NRF2-expressing cancers.	Camptothecin	13-25	NFE2 like bZIP transcription factor 2	Homo sapiens	162-166
28697309-2	2017	TDP1 plays a role in reversing inhibition of topoisomerase I by camptothecins, a series of potent and effective inhibitors used in the treatment of colorectal, ovarian, and small-cell lung cancers.	Camptothecin	64-77	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-4
28950297-3	2017	CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1alpha and 2alpha.	Camptothecin	58-70	hypoxia inducible factor 1 subunit alpha	Homo sapiens	118-161
28888997-7	2017	One peptide (P12) which specifically targeted PC-3 tumors in vivo was incorporated into mono-drug (Chlorambucil, Combretastatin or Camptothecin) and dual-drug (Chlorambucil/Combretastatin or Chlorambucil/Camptothecin) PDCs and the cytotoxic efficacy of these conjugates for target cells was tested.	Camptothecin	131-143	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	13-16
28888997-7	2017	One peptide (P12) which specifically targeted PC-3 tumors in vivo was incorporated into mono-drug (Chlorambucil, Combretastatin or Camptothecin) and dual-drug (Chlorambucil/Combretastatin or Chlorambucil/Camptothecin) PDCs and the cytotoxic efficacy of these conjugates for target cells was tested.	Camptothecin	204-216	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	13-16
28618148-1	2017	BACKGROUND: Recently, the nature of the lipid-ligand of Pru p 3, one of the most common plant food allergens in southern Europe, has been identified as a derivative of the alkaloid camptothecin bound to phytosphingosine.	Camptothecin	181-193	solute carrier family 10 (sodium/bile acid cotransporter family), member 3	Mus musculus	60-63
28977560-5	2017	Treatment with camptothecin which transiently stabilized nucleolar R-loops recruited RNase H1 to the nucleoli.	Camptothecin	15-27	ribonuclease H1	Homo sapiens	85-93
28082170-6	2017	Notably, the hybrid CPT-Cap prodrug showed a synergistic effect and significantly enhanced potency against three esophageal adenocarcinoma cell lines compared with the two homo-prodrugs (dCPT-Sup35 and dCap-Sup35) as well as free parent drugs (CPT, 5-Fu and CPT/5-FU mixture (1:1)).	Camptothecin	20-23	CAP	Drosophila melanogaster	24-27
28082170-6	2017	Notably, the hybrid CPT-Cap prodrug showed a synergistic effect and significantly enhanced potency against three esophageal adenocarcinoma cell lines compared with the two homo-prodrugs (dCPT-Sup35 and dCap-Sup35) as well as free parent drugs (CPT, 5-Fu and CPT/5-FU mixture (1:1)).	Camptothecin	20-23	CAP	Drosophila melanogaster	202-206
28383762-8	2017	Changes in the expression level of ATM and Nbs1 were minimal; however, ATM expression showed a slight gradual increase in normal cells which reached its peak at 2 hours after exposure to camptothecin.	Camptothecin	187-199	ATM serine/threonine kinase	Homo sapiens	71-74
28697309-3	2017	It is hypothesized that inhibition of TDP1 activity may enhance camptothecin sensitivity in tumors.	Camptothecin	64-76	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	38-42
28592488-5	2017	Although the topoisomerase I inhibitor camptothecin also activated ATR in non-cycling cells, other transcription inhibitors that do not directly damage DNA failed to do so.	Camptothecin	39-51	ATR serine/threonine kinase	Homo sapiens	67-70
28831158-3	2017	Temporary functional inactivation of the 60S ribosome assembly factor Bop1 in a 3T3 cell model markedly increased cell recovery after exposure to camptothecin or methotrexate.	Camptothecin	146-158	block of proliferation 1	Mus musculus	70-74
28831158-6	2017	By temporarily inactivating Bop1 function, we further demonstrate selective killing of p53-deficient cells with camptothecin while sparing isogenic p53-positive cells.	Camptothecin	112-124	block of proliferation 1	Mus musculus	28-32
28831158-6	2017	By temporarily inactivating Bop1 function, we further demonstrate selective killing of p53-deficient cells with camptothecin while sparing isogenic p53-positive cells.	Camptothecin	112-124	transformation related protein 53, pseudogene	Mus musculus	87-90
28785063-4	2017	Using a cell-based GR activity assay that measures Dexamethasone (Dex)-mediated NF-kappaB repression, we have screened ~8,000 compounds and identified several compounds that suppressed GR activity, including multiple GSK3beta inhibitors and anti-cancer agent camptothecin.	Camptothecin	259-271	nuclear receptor subfamily 3 group C member 1	Homo sapiens	185-187
28592488-6	2017	Interestingly, genetic and pharmacological inhibition of the XPB subunit of transcription factor IIH prevented the accumulation of the single-stranded DNA binding protein replication protein A (RPA) on damaged chromatin and severely abrogated ATR signaling in response to NA-AAF and camptothecin.	Camptothecin	283-295	general transcription factor IIH subunit 2	Homo sapiens	76-100
28401412-0	2017	Study of the Binding between Camptothecin Analogs and FTO by Spectroscopy and Molecular Docking.	Camptothecin	29-41	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	54-57
28059467-3	2017	The association between MYH and TRADD is reversed during tumor necrosis factor alpha (TNF-alpha)- and camptothecin (CPT)-induced apoptosis, and enhanced during TNF-alpha-induced survival.	Camptothecin	102-114	mutY DNA glycosylase	Mus musculus	24-27
28059467-3	2017	The association between MYH and TRADD is reversed during tumor necrosis factor alpha (TNF-alpha)- and camptothecin (CPT)-induced apoptosis, and enhanced during TNF-alpha-induced survival.	Camptothecin	102-114	TNFRSF1A-associated via death domain	Mus musculus	32-37
28059467-3	2017	The association between MYH and TRADD is reversed during tumor necrosis factor alpha (TNF-alpha)- and camptothecin (CPT)-induced apoptosis, and enhanced during TNF-alpha-induced survival.	Camptothecin	116-119	mutY DNA glycosylase	Mus musculus	24-27
28059467-3	2017	The association between MYH and TRADD is reversed during tumor necrosis factor alpha (TNF-alpha)- and camptothecin (CPT)-induced apoptosis, and enhanced during TNF-alpha-induced survival.	Camptothecin	116-119	TNFRSF1A-associated via death domain	Mus musculus	32-37
28673974-5	2017	Missense mutations that ablate PALB2 binding to MRG15 confer elevated sensitivity to the topoisomerase inhibitor camptothecin (CPT) and increased levels of aberrant metaphase chromosomes and DNA stress in gene bodies, which were suppressed by preventing DNA replication.	Camptothecin	113-125	partner and localizer of BRCA2	Homo sapiens	31-36
28673974-5	2017	Missense mutations that ablate PALB2 binding to MRG15 confer elevated sensitivity to the topoisomerase inhibitor camptothecin (CPT) and increased levels of aberrant metaphase chromosomes and DNA stress in gene bodies, which were suppressed by preventing DNA replication.	Camptothecin	113-125	mortality factor 4 like 1	Homo sapiens	48-53
28673974-5	2017	Missense mutations that ablate PALB2 binding to MRG15 confer elevated sensitivity to the topoisomerase inhibitor camptothecin (CPT) and increased levels of aberrant metaphase chromosomes and DNA stress in gene bodies, which were suppressed by preventing DNA replication.	Camptothecin	127-130	partner and localizer of BRCA2	Homo sapiens	31-36
28673974-5	2017	Missense mutations that ablate PALB2 binding to MRG15 confer elevated sensitivity to the topoisomerase inhibitor camptothecin (CPT) and increased levels of aberrant metaphase chromosomes and DNA stress in gene bodies, which were suppressed by preventing DNA replication.	Camptothecin	127-130	mortality factor 4 like 1	Homo sapiens	48-53
27677603-1	2017	Camptothecin (CPT) is a naturally occurring cytotoxic alkaloid having a broad spectrum of antitumor activity.	Camptothecin	0-12	dehydrodolichyl diphosphate synthase subunit	Homo sapiens	14-17
28401412-1	2017	In this work, the interaction between camptothecin (CPT) analogs and fat mass and obesity associated (FTO) was investigated using spectroscopy and molecular docking.	Camptothecin	38-50	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	102-105
28401412-1	2017	In this work, the interaction between camptothecin (CPT) analogs and fat mass and obesity associated (FTO) was investigated using spectroscopy and molecular docking.	Camptothecin	52-55	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	102-105
29137250-4	2017	This chaperone-mediated mutated p53-TAp73alpha complex induced chemoresistance to DNA damaging reagents, like Cisplatin, Doxorubicin, Etoposide or Camptothecin.	Camptothecin	147-159	tumor protein p53	Homo sapiens	32-35
27677293-0	2017	A Quinone-Containing Compound Enhances Camptothecin-Induced Apoptosis of Lung Cancer Through Modulating Endogenous ROS and ERK Signaling.	Camptothecin	39-51	mitogen-activated protein kinase 1	Homo sapiens	123-126
30023678-4	2017	Herein, a new class of nanotheranostic agents, Pnr-Cbt-Cpt-Pg-Bn, is proposed for the effective delivery of camptothecin.	Camptothecin	108-120	trace amine associated receptor 5	Homo sapiens	47-50
28389464-3	2017	Through synthetic viability screening, we discovered that histone H4 K16 deacetylation drives the sensitivity of yeast cells to camptothecin and that inactivation of this pathway by mutating H4 K16 or the genes SIR1-4 suppresses much of the hypersensitivity of tof1  strains towards this agent.	Camptothecin	128-140	Sir1p	Saccharomyces cerevisiae S288C	211-215
28064403-0	2017	Knockdown of clusterin alters mitochondrial dynamics, facilitates necrosis in camptothecin-induced cancer stem cells.	Camptothecin	78-90	clusterin	Homo sapiens	13-22
28389464-4	2017	We show that disruption of rDNA or telomeric silencing does not mediate camptothecin resistance but that disruption of Sir1-dependent chromatin domains is sufficient to suppress camptothecin sensitivity in wild-type and tof1  cells.	Camptothecin	178-190	Sir1p	Saccharomyces cerevisiae S288C	119-123
28212429-7	2017	We then show that, by inhibiting RhoB activity, delta133p53ss protects cells from camptothecin-induced apoptosis.	Camptothecin	82-94	ras homolog family member B	Homo sapiens	33-37
27841863-8	2017	Moreover, the overabundant RNF168 and the ensuing unorthodox recruitment patterns of 53BP1, RIF1 and REV7 (monitored on laser micro-irradiation-induced DNA damage) shift the DSB repair balance from HR toward NHEJ, a scenario accompanied by enhanced chromosomal instability/micronuclei formation and sensitivity under replication stress-inducing treatments with camptothecin or poly(ADP-ribose) polymerase (PARP) inhibitor.	Camptothecin	361-373	ring finger protein 168	Homo sapiens	27-33
27841863-8	2017	Moreover, the overabundant RNF168 and the ensuing unorthodox recruitment patterns of 53BP1, RIF1 and REV7 (monitored on laser micro-irradiation-induced DNA damage) shift the DSB repair balance from HR toward NHEJ, a scenario accompanied by enhanced chromosomal instability/micronuclei formation and sensitivity under replication stress-inducing treatments with camptothecin or poly(ADP-ribose) polymerase (PARP) inhibitor.	Camptothecin	361-373	tumor protein p53 binding protein 1	Homo sapiens	85-90
27841863-8	2017	Moreover, the overabundant RNF168 and the ensuing unorthodox recruitment patterns of 53BP1, RIF1 and REV7 (monitored on laser micro-irradiation-induced DNA damage) shift the DSB repair balance from HR toward NHEJ, a scenario accompanied by enhanced chromosomal instability/micronuclei formation and sensitivity under replication stress-inducing treatments with camptothecin or poly(ADP-ribose) polymerase (PARP) inhibitor.	Camptothecin	361-373	replication timing regulatory factor 1	Homo sapiens	92-96
27841863-8	2017	Moreover, the overabundant RNF168 and the ensuing unorthodox recruitment patterns of 53BP1, RIF1 and REV7 (monitored on laser micro-irradiation-induced DNA damage) shift the DSB repair balance from HR toward NHEJ, a scenario accompanied by enhanced chromosomal instability/micronuclei formation and sensitivity under replication stress-inducing treatments with camptothecin or poly(ADP-ribose) polymerase (PARP) inhibitor.	Camptothecin	361-373	mitotic arrest deficient 2 like 2	Homo sapiens	101-105
27841863-8	2017	Moreover, the overabundant RNF168 and the ensuing unorthodox recruitment patterns of 53BP1, RIF1 and REV7 (monitored on laser micro-irradiation-induced DNA damage) shift the DSB repair balance from HR toward NHEJ, a scenario accompanied by enhanced chromosomal instability/micronuclei formation and sensitivity under replication stress-inducing treatments with camptothecin or poly(ADP-ribose) polymerase (PARP) inhibitor.	Camptothecin	361-373	poly(ADP-ribose) polymerase 1	Homo sapiens	377-404
27841863-8	2017	Moreover, the overabundant RNF168 and the ensuing unorthodox recruitment patterns of 53BP1, RIF1 and REV7 (monitored on laser micro-irradiation-induced DNA damage) shift the DSB repair balance from HR toward NHEJ, a scenario accompanied by enhanced chromosomal instability/micronuclei formation and sensitivity under replication stress-inducing treatments with camptothecin or poly(ADP-ribose) polymerase (PARP) inhibitor.	Camptothecin	361-373	poly(ADP-ribose) polymerase 1	Homo sapiens	406-410
28131940-7	2017	Under normal plasma conditions (pH 7.4), both types of camptothecin-loaded mesoporous silica nanoparticles (i.e., MSN-Me-CPT and MSN-Et-CPT) did not release the model drug.	Camptothecin	55-67	moesin	Homo sapiens	114-117
28131940-7	2017	Under normal plasma conditions (pH 7.4), both types of camptothecin-loaded mesoporous silica nanoparticles (i.e., MSN-Me-CPT and MSN-Et-CPT) did not release the model drug.	Camptothecin	55-67	choline phosphotransferase 1	Homo sapiens	121-124
28131940-7	2017	Under normal plasma conditions (pH 7.4), both types of camptothecin-loaded mesoporous silica nanoparticles (i.e., MSN-Me-CPT and MSN-Et-CPT) did not release the model drug.	Camptothecin	55-67	moesin	Homo sapiens	129-132
28131940-7	2017	Under normal plasma conditions (pH 7.4), both types of camptothecin-loaded mesoporous silica nanoparticles (i.e., MSN-Me-CPT and MSN-Et-CPT) did not release the model drug.	Camptothecin	55-67	choline phosphotransferase 1	Homo sapiens	136-139
28131940-8	2017	However, under in vitro acidic conditions (pH 4.0), based on a comparison of the release rates, camptothecin was released from MSN-Me-CPT more rapidly than from MSN-Et-CPT.	Camptothecin	96-108	moesin	Homo sapiens	127-130
28131940-8	2017	However, under in vitro acidic conditions (pH 4.0), based on a comparison of the release rates, camptothecin was released from MSN-Me-CPT more rapidly than from MSN-Et-CPT.	Camptothecin	96-108	choline phosphotransferase 1	Homo sapiens	134-137
28131940-8	2017	However, under in vitro acidic conditions (pH 4.0), based on a comparison of the release rates, camptothecin was released from MSN-Me-CPT more rapidly than from MSN-Et-CPT.	Camptothecin	96-108	moesin	Homo sapiens	161-164
28131940-13	2017	At pH 4.0, the release of camptothecin from MSN-Et-CPT occurred after 2h, whereas MSN-Me-CPT showed immediate drug release.	Camptothecin	26-38	moesin	Homo sapiens	44-47
28131940-13	2017	At pH 4.0, the release of camptothecin from MSN-Et-CPT occurred after 2h, whereas MSN-Me-CPT showed immediate drug release.	Camptothecin	26-38	choline phosphotransferase 1	Homo sapiens	51-54
28126548-1	2017	In the current study camptothecin-loaded pegylated PAMAM dendrimer were synthesized and were functionalized with AS1411 anti-nucleolin aptamers for site-specific targeting against colorectal cancer cells which over expresses nucleolin receptors.	Camptothecin	21-33	nucleolin	Mus musculus	125-134
28126548-1	2017	In the current study camptothecin-loaded pegylated PAMAM dendrimer were synthesized and were functionalized with AS1411 anti-nucleolin aptamers for site-specific targeting against colorectal cancer cells which over expresses nucleolin receptors.	Camptothecin	21-33	nucleolin	Mus musculus	225-234
28126548-5	2017	Comparative in vitro cytotoxicity experiments demonstrated that the targeted camptothecin loaded-pegylated dendrimers had higher antiproliferation activity, towards nucleolin-positive HT29 and C26 colorectal cancer cells than nucleolin-negative CHO cell line.	Camptothecin	77-89	nucleolin	Mus musculus	165-174
28126548-5	2017	Comparative in vitro cytotoxicity experiments demonstrated that the targeted camptothecin loaded-pegylated dendrimers had higher antiproliferation activity, towards nucleolin-positive HT29 and C26 colorectal cancer cells than nucleolin-negative CHO cell line.	Camptothecin	77-89	nucleolin	Mus musculus	226-235
28126548-9	2017	These results suggested that the new nucleolin-targeted pegylated PAMAM dendrimer as a delivery system for camptothecin have the potential for the treatment of nucleolin-overexpressed colorectal cancer.	Camptothecin	107-119	nucleolin	Mus musculus	37-46
28126548-9	2017	These results suggested that the new nucleolin-targeted pegylated PAMAM dendrimer as a delivery system for camptothecin have the potential for the treatment of nucleolin-overexpressed colorectal cancer.	Camptothecin	107-119	nucleolin	Mus musculus	160-169
30549897-3	2017	3-Methoxybenzensulfonic acid 4-Omicron-beta-D- glucopyranoside (1) and methyl salicylate 2-rutinoside (5) showed strong cytotoxicity against EGFR-TKI-resistant human lung cancer A549 cells in comparison with camptothecin.	Camptothecin	208-220	epidermal growth factor receptor	Homo sapiens	141-145
28242760-6	2017	AIRE-mediated transcription was not only enhanced by TOP2 inhibition but also by the TOP1 inhibitor camptothecin.	Camptothecin	100-112	autoimmune regulator	Homo sapiens	0-4
28361991-5	2017	The anti-cancer agent camptothecin specifically suppressed p53beta induction.	Camptothecin	22-34	tumor protein p53	Homo sapiens	59-62
28075474-5	2017	We demonstrated that CLS-354/DX cells overexpressing multidrug resistance-associated protein 1 (MRP1) were resistant to anticancer drugs cisplatin and camptothecin.	Camptothecin	151-163	ATP binding cassette subfamily C member 1	Homo sapiens	53-94
28089177-1	2017	The evolutionally conserved Fun30 chromatin remodeler in Saccharomyces cerevisiae has been shown to contribute to cellular resistance to genotoxic stress inflicted by camptothecin (CPT), methyl methanesulfonate (MMS) and hydroxyurea (HU).	Camptothecin	167-179	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	28-33
28089177-1	2017	The evolutionally conserved Fun30 chromatin remodeler in Saccharomyces cerevisiae has been shown to contribute to cellular resistance to genotoxic stress inflicted by camptothecin (CPT), methyl methanesulfonate (MMS) and hydroxyurea (HU).	Camptothecin	181-184	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	28-33
28241406-4	2017	The expression of interferon-stimulated gene 15 (ISG15), the first identified ubiquitin-like protein, has recently been shown to be induced under various DNA damage conditions, such as exposure to UV, camptothecin, and doxorubicin.	Camptothecin	201-213	ISG15 ubiquitin like modifier	Homo sapiens	18-47
28241406-4	2017	The expression of interferon-stimulated gene 15 (ISG15), the first identified ubiquitin-like protein, has recently been shown to be induced under various DNA damage conditions, such as exposure to UV, camptothecin, and doxorubicin.	Camptothecin	201-213	ISG15 ubiquitin like modifier	Homo sapiens	49-54
28075474-5	2017	We demonstrated that CLS-354/DX cells overexpressing multidrug resistance-associated protein 1 (MRP1) were resistant to anticancer drugs cisplatin and camptothecin.	Camptothecin	151-163	ATP binding cassette subfamily C member 1	Homo sapiens	96-100
27878250-2	2017	This study aimed to examine the effects and mechanisms of action of SN38 (a metabolite of the camptothecin derivative, CPT-11) on IL-8 expression in HCT8 cells, using ELISA, CCK-8 and western blot analysis.	Camptothecin	94-106	C-X-C motif chemokine ligand 8	Homo sapiens	130-134
27977417-10	2017	Combination treatments using CPT and TTZ decreased the HER-2 positive BT-474 breast cancer cell growth by 66.9 +- 5.3% in vitro.	Camptothecin	29-32	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-60
28033467-4	2017	The designed MOF probe can realize cathepsin B-activated cancer cell imaging and chemo-photodynamic dual-therapy combining Ce6 as the photosensitizer and the camptothecine drug.	Camptothecin	158-171	cathepsin B	Homo sapiens	35-46
27721159-0	2017	Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways.	Camptothecin	46-58	mitogen-activated protein kinase 14	Homo sapiens	111-114
27721159-0	2017	Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways.	Camptothecin	46-58	mitogen-activated protein kinase 1	Homo sapiens	121-124
27721159-0	2017	Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways.	Camptothecin	46-58	AKT serine/threonine kinase 1	Homo sapiens	130-133
27721159-4	2017	Mechanism study indicated that PSI improved the CPT/HCPT induced apoptosis in lung cancer cells through mitochondria pathway including cytochrome C release and activation of caspase-9 and -3 cascades.	Camptothecin	48-51	cytochrome c, somatic	Homo sapiens	135-147
27721159-4	2017	Mechanism study indicated that PSI improved the CPT/HCPT induced apoptosis in lung cancer cells through mitochondria pathway including cytochrome C release and activation of caspase-9 and -3 cascades.	Camptothecin	48-51	caspase 9	Homo sapiens	174-190
27721159-6	2017	Moreover, PSI enhanced CPT/HCPT-mediated inhibition of p38 MAPK and activation of phosphorylation of p38 MAPK in H1299 cells, and suppression of Akt and ERK pathways activation in H460 cells as well as in H446 cells.	Camptothecin	23-26	mitogen-activated protein kinase 14	Homo sapiens	55-58
27721159-6	2017	Moreover, PSI enhanced CPT/HCPT-mediated inhibition of p38 MAPK and activation of phosphorylation of p38 MAPK in H1299 cells, and suppression of Akt and ERK pathways activation in H460 cells as well as in H446 cells.	Camptothecin	23-26	mitogen-activated protein kinase 14	Homo sapiens	101-104
27721159-6	2017	Moreover, PSI enhanced CPT/HCPT-mediated inhibition of p38 MAPK and activation of phosphorylation of p38 MAPK in H1299 cells, and suppression of Akt and ERK pathways activation in H460 cells as well as in H446 cells.	Camptothecin	23-26	mitogen-activated protein kinase 1	Homo sapiens	59-63
27768593-3	2017	Coupling ALOS4 to the topoisomerase I inhibitor Camptothecin (ALOS4-CPT) increases the cytotoxicity of CPT against human metastatic melanoma cells while reduces dramatically the cytotoxicity against non-cancerous cells as measured by the levels of gammaH2A.X, active caspase 3 and cell viability.	Camptothecin	48-60	caspase 3	Homo sapiens	267-276
27998073-3	2016	In this study, we describe an easy method to construct a novel matrix metalloproteinase-2 (MMP-2) responsive nanocarrier, which can load hydrophobic agents (camptothecin and sorafenib) with high efficiency to exert synergistic efficacy for CRC treatment.	Camptothecin	157-169	matrix metallopeptidase 2	Homo sapiens	63-89
27964702-7	2017	The expression of Chk2 phosphorylation (pT68-Chk2) was measured after administration of different dosages of siMCM2 (0.5 mug, 1 mug, and 2.5 mug) and camptothecin (CPT).	Camptothecin	150-162	checkpoint kinase 2	Homo sapiens	18-22
27964702-7	2017	The expression of Chk2 phosphorylation (pT68-Chk2) was measured after administration of different dosages of siMCM2 (0.5 mug, 1 mug, and 2.5 mug) and camptothecin (CPT).	Camptothecin	164-167	checkpoint kinase 2	Homo sapiens	18-22
27998073-3	2016	In this study, we describe an easy method to construct a novel matrix metalloproteinase-2 (MMP-2) responsive nanocarrier, which can load hydrophobic agents (camptothecin and sorafenib) with high efficiency to exert synergistic efficacy for CRC treatment.	Camptothecin	157-169	matrix metallopeptidase 2	Homo sapiens	91-96
27869268-1	2016	A novel amphiphilic camptothecin prodrug, CPT-ss-Ir, consisting of CPT, Ir and a disulfide bond linker, was synthesized, and it could self-assemble into nanowires in aqueous solution.	Camptothecin	20-32	choline phosphotransferase 1	Homo sapiens	42-45
27934922-7	2016	Boric acid coated nanocrystals of camptothecin, an anticancer drug with poor aqueous solubility and stability, demonstrated extreme cytotoxic activity (IC50 < 5.0 mug/mL) to cancer cells compared to synthetic polymer coated CPT nanocrystals and free CPT.	Camptothecin	34-46	choline phosphotransferase 1	Homo sapiens	227-230
27960424-2	2016	TP1, consisting of the antineoplastic camptothecin analogue SN-38, and the fluorescent dye rhodol green have been covalently conjugated through a disulfide bond.	Camptothecin	38-50	transition protein 1	Homo sapiens	0-3
27825797-0	2016	An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.	Camptothecin	13-25	Vif	Human immunodeficiency virus 1	114-117
27825797-0	2016	An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.	Camptothecin	13-25	apolipoprotein B mRNA editing enzyme catalytic subunit 3G	Homo sapiens	128-136
27869268-1	2016	A novel amphiphilic camptothecin prodrug, CPT-ss-Ir, consisting of CPT, Ir and a disulfide bond linker, was synthesized, and it could self-assemble into nanowires in aqueous solution.	Camptothecin	20-32	choline phosphotransferase 1	Homo sapiens	67-70
27933897-0	2016	Tyrosyl-DNA Phosphodiesterase 1 Inhibitors: Usnic Acid Enamines Enhance the Cytotoxic Effect of Camptothecin.	Camptothecin	96-108	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-31
27933897-6	2016	These new compounds enhanced the cytotoxicity of the established Top1 poison camptothecin by an order of magnitude.	Camptothecin	77-89	DNA topoisomerase I	Homo sapiens	65-69
27754664-0	2016	Anti-Fas Antibody Conjugated Nanoparticles Enhancing the Antitumor Effect of Camptothecin by Activating the Fas-FasL Apoptotic Pathway.	Camptothecin	77-89	Fas ligand	Homo sapiens	112-116
27687970-4	2016	Here, we designed and developed an antibody drug conjugate (CD123-CPT) by integrating anti-CD123 antibody with a chemotherapeutic agent, Camptothecin (CPT), via a disulfide linker.	Camptothecin	137-149	interleukin 3 receptor subunit alpha	Homo sapiens	60-65
27687970-4	2016	Here, we designed and developed an antibody drug conjugate (CD123-CPT) by integrating anti-CD123 antibody with a chemotherapeutic agent, Camptothecin (CPT), via a disulfide linker.	Camptothecin	137-149	interleukin 3 receptor subunit alpha	Homo sapiens	91-96
27687970-4	2016	Here, we designed and developed an antibody drug conjugate (CD123-CPT) by integrating anti-CD123 antibody with a chemotherapeutic agent, Camptothecin (CPT), via a disulfide linker.	Camptothecin	66-69	interleukin 3 receptor subunit alpha	Homo sapiens	60-65
27687970-4	2016	Here, we designed and developed an antibody drug conjugate (CD123-CPT) by integrating anti-CD123 antibody with a chemotherapeutic agent, Camptothecin (CPT), via a disulfide linker.	Camptothecin	66-69	interleukin 3 receptor subunit alpha	Homo sapiens	91-96
27608290-6	2016	Radiotracer 64Cu-NOTA-Ava-PSBP-6 was studied in camptothecin-induced apoptotic EL4 mouse lymphoma cells and in a murine EL4 tumor model of apoptosis using dynamic PET imaging.	Camptothecin	48-60	epilepsy 4	Mus musculus	79-82
28030910-0	2016	In Vitro and In Vivo Anticancer Activity of Gimatecan against Hepatocellular Carcinoma Objective: Gimatecan is a new camptothecin (CPT) analogue that inhibits tumor growth by targeting DNAtopoisomerase I (TOP I) and introducing strong and persistent DNA cleavage.	Camptothecin	117-129	topoisomerase (DNA) I	Mus musculus	185-203
27416553-5	2016	The most positive compounds 18f and 18g demonstrated as potent as camptothecin in Top I inhibition assay and MTT assay.	Camptothecin	66-78	DNA topoisomerase I	Homo sapiens	82-87
27608290-11	2016	A competitive radiometric cell binding assay confirmed binding of 64Cu-NOTA-Ava-PSBP-6 to camptothecin-induced apoptotic EL4 cells in a Ca2+-independent manner.	Camptothecin	90-102	epilepsy 4	Mus musculus	121-124
27608290-13	2016	Flow cytometry studies showed significantly higher binding of FITC-Ava-PSBP-6 to EL4 cells treated with camptothecin compared to untreated cells.	Camptothecin	104-116	epilepsy 4	Mus musculus	81-84
27877240-5	2016	To synthesize this novel compound, polyethylene glycol was functionalized with thioketal linker-modified camptothecin (TL-CPT) and triphenylphosphonium to form the block copolymer, TL-CPT-PEG1K-TPP.	Camptothecin	105-117	choline phosphotransferase 1	Homo sapiens	122-125
27877240-8	2016	We also show that the ZnPc loaded in ZnPc/CPT-TPPNPs absorbed the 633 nm laser to produce ROS, which could be utilized both in photodynamic therapy and to cleave the thioketal linker thereby releasing camptothecin for chemotherapy.	Camptothecin	201-213	choline phosphotransferase 1	Homo sapiens	42-45
27466387-4	2016	PARP inhibitors enhance the cytotoxicity of CPT in the clinical trials.	Camptothecin	44-47	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
27552991-12	2016	The same alternative splicing of CDC25C was detected by treating cells with DNA damaging drugs, such as cisplatin, camptothecin, and trichostatin A at appropriate dosage.	Camptothecin	115-127	cell division cycle 25C	Homo sapiens	33-39
26744836-10	2016	Our data revealed that CPT, 10-hydroxycamptothecin (HCPT), 10-methoxycamptothecin (MCPT) and 9-nitrocamptothecin (9NC) significantly inhibit the uptake activity of OAT3.	Camptothecin	23-26	solute carrier family 22 member 8	Homo sapiens	164-168
27634334-6	2016	Chemical and cytotoxic induction of replication stress, through aphidicolin, gemcitabine, camptothecin or hydroxyurea exposure, activates transcription of APOBEC3B via an ATR/Chk1-dependent pathway in vitro.	Camptothecin	90-102	apolipoprotein B mRNA editing enzyme catalytic subunit 3B	Homo sapiens	155-163
27634334-6	2016	Chemical and cytotoxic induction of replication stress, through aphidicolin, gemcitabine, camptothecin or hydroxyurea exposure, activates transcription of APOBEC3B via an ATR/Chk1-dependent pathway in vitro.	Camptothecin	90-102	ATR serine/threonine kinase	Homo sapiens	171-174
27634334-6	2016	Chemical and cytotoxic induction of replication stress, through aphidicolin, gemcitabine, camptothecin or hydroxyurea exposure, activates transcription of APOBEC3B via an ATR/Chk1-dependent pathway in vitro.	Camptothecin	90-102	checkpoint kinase 1	Homo sapiens	175-179
27457310-3	2016	CRLX101 is an investigational camptothecin-containing nanoparticle-drug conjugate (NDC), which durably inhibits HIF1alpha and HIF2alpha in preclinical models and in gastric cancer patients.	Camptothecin	30-42	hypoxia inducible factor 1 subunit alpha	Homo sapiens	112-121
27457310-3	2016	CRLX101 is an investigational camptothecin-containing nanoparticle-drug conjugate (NDC), which durably inhibits HIF1alpha and HIF2alpha in preclinical models and in gastric cancer patients.	Camptothecin	30-42	endothelial PAS domain protein 1	Homo sapiens	126-135
27536134-10	2016	Silencing RBBP6 followed by treatment with gamma-aminobutyric acid and camptothecin seems to sensitize cells to apoptosis induction rather than cell cycle arrest.	Camptothecin	71-83	RB binding protein 6, ubiquitin ligase	Homo sapiens	10-15
27536134-13	2016	Furthermore, sensitization of cells to camptothecin-induced apoptosis by RBBP6 targeting suggests a promising tool for halting cervical cancer progression.	Camptothecin	39-51	RB binding protein 6, ubiquitin ligase	Homo sapiens	73-78
27339653-4	2016	In this study, we found that restriction of protein synthesis, inhibition of ERK-signaling, and elimination of reactive oxygen species showed a combinatorial effect on suppression of cellular senescence induced by excess thymidine or camptothecin.	Camptothecin	234-246	mitogen-activated protein kinase 1	Homo sapiens	77-80
27404728-5	2016	Reduced sensitivity to hydrogen peroxide, paraquat and camptothecin, reactive oxygen species content, and intracellular retention of selenium after selenomethionine treatment were observed in SBP1 shRNA HeLa cells.	Camptothecin	55-67	selenium binding protein 1	Homo sapiens	192-196
27239795-7	2016	SMARCAD1 is required for 53BP1 repositioning, and the need for SMARCAD1 in olaparib or camptothecin resistance is alleviated by 53BP1 loss.	Camptothecin	87-99	SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1	Homo sapiens	63-71
27084940-2	2016	Namely, XAB2 is important for chromosomal double-strand break (DSB) repair via two pathways of HR that require end resection as an intermediate step, end resection of camptothecin (Cpt)-induced DNA damage, and RAD51 recruitment to ionizing radiation induced foci (IRIF), which requires end resection.	Camptothecin	167-179	XPA binding protein 2	Homo sapiens	8-12
27084940-2	2016	Namely, XAB2 is important for chromosomal double-strand break (DSB) repair via two pathways of HR that require end resection as an intermediate step, end resection of camptothecin (Cpt)-induced DNA damage, and RAD51 recruitment to ionizing radiation induced foci (IRIF), which requires end resection.	Camptothecin	181-184	XPA binding protein 2	Homo sapiens	8-12
26309154-0	2016	Biophysical and molecular docking insight into interaction mechanism and thermal stability of human serum albumin isoforms with a semi-synthetic water-soluble camptothecin analog irinotecan hydrochloride.	Camptothecin	159-171	albumin	Homo sapiens	100-113
26309154-1	2016	In the present work, we have examined the binding parameters, thermodynamics, and stability of human serum albumin (HSA) isoforms at pH 7.4 and 9.0, using spectroscopic, calorimetric, and molecular docking methods in the presence of water-soluble camptothecin analog irinotecan hydrochloride (CPT-11).	Camptothecin	247-259	albumin	Homo sapiens	101-114
27599509-1	2016	The effect of overexpression of Oct-1 protein isoforms on the cell response to two anticancer drugs camptothecin and dexamethasone was studied.	Camptothecin	100-112	solute carrier family 22 member 1	Homo sapiens	32-37
27239795-7	2016	SMARCAD1 is required for 53BP1 repositioning, and the need for SMARCAD1 in olaparib or camptothecin resistance is alleviated by 53BP1 loss.	Camptothecin	87-99	tumor protein p53 binding protein 1	Homo sapiens	128-133
27182942-0	2016	Quantitative evaluation of ABC transporter-mediated drug resistance based on the determination of the anticancer activity of camptothecin against breast cancer stem cells using TIRF.	Camptothecin	125-137	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	27-30
26810069-4	2016	Knockdown of TXNDC5 by siRNAs inhibits the cell growth, migration, and invasion of ccRCC cells as well as sensitizes ccRCC cells to chemotherapeutic drugs, such as Camptothecin and 5-Fluorouracil.	Camptothecin	164-176	thioredoxin domain containing 5	Homo sapiens	13-19
27311852-6	2016	Wnt5a increased proliferation of villous cytotrophoblasts and cell column trophoblasts, outgrowth on collagen I as well as cyclin A and D1 expression in floating explant cultures, but suppressed camptothecin-induced apoptosis.	Camptothecin	195-207	Wnt family member 5A	Homo sapiens	0-5
26928355-3	2016	The assay identified propyl gallate (PG) and 9-aminoacridine (9-AA) as inhibitors of camptothecin (CPT)-induced MDC1 foci formation.	Camptothecin	85-97	mediator of DNA damage checkpoint 1	Homo sapiens	112-116
27035096-6	2016	Combination of PA with Eto/Cpt promoted disruption of the dynamics of actin filaments, leading to subsequent enhancement of apoptotic cell death via induction of caspase-3, -8, and -9, accompanied by increased phosphorylation of p38.	Camptothecin	27-30	caspase 3	Homo sapiens	162-183
27035096-6	2016	Combination of PA with Eto/Cpt promoted disruption of the dynamics of actin filaments, leading to subsequent enhancement of apoptotic cell death via induction of caspase-3, -8, and -9, accompanied by increased phosphorylation of p38.	Camptothecin	27-30	mitogen-activated protein kinase 14	Homo sapiens	229-232
27096393-7	2016	Thirdly, we have shown that the tumor cells transformation by different Oct-1 isoforms retained those cells" sensitivity to the antitumor effect of combined dexamethasone and camptothecin.	Camptothecin	175-187	POU class 2 homeobox 1	Homo sapiens	72-77
27096393-8	2016	In contrast, in the non-transformed Namalwa cells, dexamethasone decreased the camptothecin effect on the cells survivorship, thus, emphasizing Oct-1 role in the regulation of cell response to different antitumor agents.	Camptothecin	79-91	POU class 2 homeobox 1	Homo sapiens	144-149
26928355-3	2016	The assay identified propyl gallate (PG) and 9-aminoacridine (9-AA) as inhibitors of camptothecin (CPT)-induced MDC1 foci formation.	Camptothecin	99-102	mediator of DNA damage checkpoint 1	Homo sapiens	112-116
26928355-4	2016	We demonstrated that the inhibition of CPT-induced MDC1 foci formation by PG was caused by the direct suppression of histone H2AX phosphorylation at Ser139 (gammaH2AX), which is required for MDC1 foci formation, by quantifying gammaH2AX in cells and in vitro 9-AA also directly suppressed H2AX Ser139-phosphorylation in vitro but the concentration was much higher than that required to suppress CPT-induced MDC1 foci formation in cells.	Camptothecin	39-42	mediator of DNA damage checkpoint 1	Homo sapiens	51-55
26928355-4	2016	We demonstrated that the inhibition of CPT-induced MDC1 foci formation by PG was caused by the direct suppression of histone H2AX phosphorylation at Ser139 (gammaH2AX), which is required for MDC1 foci formation, by quantifying gammaH2AX in cells and in vitro 9-AA also directly suppressed H2AX Ser139-phosphorylation in vitro but the concentration was much higher than that required to suppress CPT-induced MDC1 foci formation in cells.	Camptothecin	39-42	H2A.X variant histone	Homo sapiens	125-129
26928355-4	2016	We demonstrated that the inhibition of CPT-induced MDC1 foci formation by PG was caused by the direct suppression of histone H2AX phosphorylation at Ser139 (gammaH2AX), which is required for MDC1 foci formation, by quantifying gammaH2AX in cells and in vitro 9-AA also directly suppressed H2AX Ser139-phosphorylation in vitro but the concentration was much higher than that required to suppress CPT-induced MDC1 foci formation in cells.	Camptothecin	39-42	mediator of DNA damage checkpoint 1	Homo sapiens	191-195
26928355-4	2016	We demonstrated that the inhibition of CPT-induced MDC1 foci formation by PG was caused by the direct suppression of histone H2AX phosphorylation at Ser139 (gammaH2AX), which is required for MDC1 foci formation, by quantifying gammaH2AX in cells and in vitro 9-AA also directly suppressed H2AX Ser139-phosphorylation in vitro but the concentration was much higher than that required to suppress CPT-induced MDC1 foci formation in cells.	Camptothecin	39-42	H2A.X variant histone	Homo sapiens	162-166
26928355-4	2016	We demonstrated that the inhibition of CPT-induced MDC1 foci formation by PG was caused by the direct suppression of histone H2AX phosphorylation at Ser139 (gammaH2AX), which is required for MDC1 foci formation, by quantifying gammaH2AX in cells and in vitro 9-AA also directly suppressed H2AX Ser139-phosphorylation in vitro but the concentration was much higher than that required to suppress CPT-induced MDC1 foci formation in cells.	Camptothecin	39-42	mediator of DNA damage checkpoint 1	Homo sapiens	191-195
26905328-7	2016	RESULTS: In the carcinoma cell line, the PTEN knockdown enhanced sensitivity to cisplatin, rucaparib, doxorubicin, camptothecin, paclitaxel, and irradiation.	Camptothecin	115-127	phosphatase and tensin homolog	Homo sapiens	41-45
27146783-7	2016	While DNA damage elicited by camptothecin dramatically altered the ATF3 binding profile, most of the genes regulated by ATF3 upon DNA damage were pre-bound by ATF3 before the stress.	Camptothecin	29-41	activating transcription factor 3	Homo sapiens	67-71
27070848-0	2016	Design, Synthesis, and Biological Evaluation of New Cathepsin B-Sensitive Camptothecin Nanoparticles Equipped with a Novel Multifuctional Linker.	Camptothecin	74-86	cathepsin B	Homo sapiens	52-63
26843428-2	2016	Herein we report that exposure to DNA-damaging agents that generate replicative stress such as camptothecin (CPT), 5-fluoro-uracil (5FU) and ultraviolet radiation (UVC) causes downregulation of Stau2 in HCT116 colorectal cancer cells.	Camptothecin	95-107	staufen double-stranded RNA binding protein 2	Homo sapiens	194-199
26843428-2	2016	Herein we report that exposure to DNA-damaging agents that generate replicative stress such as camptothecin (CPT), 5-fluoro-uracil (5FU) and ultraviolet radiation (UVC) causes downregulation of Stau2 in HCT116 colorectal cancer cells.	Camptothecin	109-112	staufen double-stranded RNA binding protein 2	Homo sapiens	194-199
26843428-8	2016	Strikingly, Stau2 downregulation enhances levels of DNA damage and promotes apoptosis in CPT-treated cells.	Camptothecin	89-92	staufen double-stranded RNA binding protein 2	Homo sapiens	12-17
25728212-8	2016	In addition, overexpression of GDF10 promotes DNA damage-induced apoptosis and sensitizes the response to all-trans retinoic acid (ATRA) and camptothecin (CPT).	Camptothecin	141-153	growth differentiation factor 10	Homo sapiens	31-36
26936927-8	2016	sws-1 mutants exhibit sensitivity to DSB-inducing agents and fail to form mitotic RAD-51 foci following treatment with camptothecin.	Camptothecin	119-131	SWIM-type domain-containing protein	Caenorhabditis elegans	0-5
25728212-8	2016	In addition, overexpression of GDF10 promotes DNA damage-induced apoptosis and sensitizes the response to all-trans retinoic acid (ATRA) and camptothecin (CPT).	Camptothecin	155-158	growth differentiation factor 10	Homo sapiens	31-36
27211550-3	2016	We show that homozygous deletion of DNA2 sensitizes cells to ionizing radiation and camptothecin (CPT).	Camptothecin	84-96	DNA replication helicase/nuclease 2	Homo sapiens	36-40
26988802-3	2016	Among the tested compounds, 5h had a very strong topo-I activity of 97% (Camptothecin, 74%) at concentration of 100 muM.	Camptothecin	73-85	latexin	Homo sapiens	116-119
26988802-6	2016	All the compounds showed strong activity against HCT15 cell line with IC50 at the range of 1.9-10.4 muM (Adriamycin, 23.0; Etoposide, 6.9; and Camptothecin, 7.1 muM).	Camptothecin	143-155	latexin	Homo sapiens	161-164
27050524-4	2016	Starting with an unbiased proteomic analysis, we find that the chromatin remodeling complex BAZ1B-SMARCA5 accumulates near replication forks in camptothecin-exposed cells.	Camptothecin	144-156	bromodomain adjacent to zinc finger domain 1B	Homo sapiens	92-97
27050524-4	2016	Starting with an unbiased proteomic analysis, we find that the chromatin remodeling complex BAZ1B-SMARCA5 accumulates near replication forks in camptothecin-exposed cells.	Camptothecin	144-156	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5	Homo sapiens	98-105
27050524-6	2016	Single-molecule analyses of replication structures show that BAZ1B contributes to replication interference by camptothecin.	Camptothecin	110-122	bromodomain adjacent to zinc finger domain 1B	Homo sapiens	61-66
27050524-7	2016	A lack of BAZ1B confers increased cellular tolerance of camptothecin.	Camptothecin	56-68	bromodomain adjacent to zinc finger domain 1B	Homo sapiens	10-15
27211550-3	2016	We show that homozygous deletion of DNA2 sensitizes cells to ionizing radiation and camptothecin (CPT).	Camptothecin	98-101	DNA replication helicase/nuclease 2	Homo sapiens	36-40
26959889-0	2016	Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.	Camptothecin	0-12	WRN RecQ like helicase	Homo sapiens	21-24
26959889-2	2016	The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT).	Camptothecin	162-174	RecQ like helicase	Homo sapiens	31-37
26959889-2	2016	The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT).	Camptothecin	162-174	WRN RecQ like helicase	Homo sapiens	46-49
26959889-2	2016	The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT).	Camptothecin	162-174	RecQ like helicase 4	Homo sapiens	51-57
26959889-2	2016	The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT).	Camptothecin	162-174	RecQ like helicase 5	Homo sapiens	62-68
26959889-2	2016	The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT).	Camptothecin	176-179	RecQ like helicase	Homo sapiens	31-37
26959889-2	2016	The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT).	Camptothecin	176-179	WRN RecQ like helicase	Homo sapiens	46-49
26959889-2	2016	The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT).	Camptothecin	176-179	RecQ like helicase 4	Homo sapiens	51-57
26959889-2	2016	The five human RecQ helicases, RECQL1, Bloom, WRN, RECQL4 and RECQL5 play critical roles in DNA repair and cell survival after treatment with the anticancer drug camptothecin (CPT).	Camptothecin	176-179	RecQ like helicase 5	Homo sapiens	62-68
26959889-5	2016	In the cells treated with CPT, we observed distinct effects on WRN compared to other human RecQ helicases.	Camptothecin	26-29	WRN RecQ like helicase	Homo sapiens	63-66
25915850-7	2015	Moreover, administration of DSB-inducing chemicals, camptothecin (CPT) or irinotecan, to Myc-ELAS1-expressing U2OS cells also induced efficient apoptosis with only 1/100th (CPT) or 1/5th (irinotecan) of the amounts of drugs required for this effect in Myc-vector-expressing cells.	Camptothecin	52-64	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	89-92
26657505-5	2016	Here, we demonstrated that chemo- and radiotherapy agents such as camptothecin (CPT) and gamma irradiation decrease EZH2 expression in various PCa cell lines.	Camptothecin	66-78	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	116-120
26657505-5	2016	Here, we demonstrated that chemo- and radiotherapy agents such as camptothecin (CPT) and gamma irradiation decrease EZH2 expression in various PCa cell lines.	Camptothecin	80-83	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	116-120
26220042-3	2016	In cell line studies, both intrinsic (spontaneous or camptothecin-induced) and extrinsic (FasL- or anti-Fas-induced) apoptosis created a high percent of MEACs over time in a process associated with caspase-3 activation, leading to cytoplasmic myosin cleavage and trafficking to cell membranes.	Camptothecin	53-65	caspase 3	Homo sapiens	198-207
26903030-5	2016	We found that C. elegans brc-1 mutants were more sensitive to ionizing radiation and camptothecin than the N2 wild-type strain and repaired DNA strand breaks less efficiently than N2.	Camptothecin	85-97	Breast cancer type 1 susceptibility protein homolog	Caenorhabditis elegans	25-30
26578593-4	2016	Here, we use camptothecin (CPT)-treated serum-starved quiescent cells to induce transcription-blocking Top1cc and show that those DSBs are generated during Top1cc repair from Top1 peptide-linked DNA single-strand breaks generated after Top1 proteolysis and before excision by TDP1.	Camptothecin	13-25	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	276-280
26578593-4	2016	Here, we use camptothecin (CPT)-treated serum-starved quiescent cells to induce transcription-blocking Top1cc and show that those DSBs are generated during Top1cc repair from Top1 peptide-linked DNA single-strand breaks generated after Top1 proteolysis and before excision by TDP1.	Camptothecin	27-30	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	276-280
27008798-0	2016	INTERACTION OF CAMPTOTHECIN WITH HUMAN SERUM ALBUMIN DETERMINED BY FLUORESCENCE ANISOTROPY SPECTROSCOPY.	Camptothecin	15-27	albumin	Homo sapiens	39-52
27008798-2	2016	There are two forms of camptothecin (the carboxylate form (CPT-C) and the lactone form (CPT-L)) but only the lactone one is pharmacologically active.	Camptothecin	23-35	choline phosphotransferase 1	Homo sapiens	59-62
27008798-2	2016	There are two forms of camptothecin (the carboxylate form (CPT-C) and the lactone form (CPT-L)) but only the lactone one is pharmacologically active.	Camptothecin	23-35	choline phosphotransferase 1	Homo sapiens	88-91
26565033-6	2016	In cells treated with camptothecin (CPT), PIAS3 contributes to formation of DNA double-stranded breaks.	Camptothecin	22-34	protein inhibitor of activated STAT 3	Homo sapiens	42-47
26565033-6	2016	In cells treated with camptothecin (CPT), PIAS3 contributes to formation of DNA double-stranded breaks.	Camptothecin	36-39	protein inhibitor of activated STAT 3	Homo sapiens	42-47
27843533-0	2016	An Acetamide Derivative as a Camptothecin Sensitizer for Human Non-Small-Cell Lung Cancer Cells through Increased Oxidative Stress and JNK Activation.	Camptothecin	29-41	mitogen-activated protein kinase 8	Homo sapiens	135-138
25915850-7	2015	Moreover, administration of DSB-inducing chemicals, camptothecin (CPT) or irinotecan, to Myc-ELAS1-expressing U2OS cells also induced efficient apoptosis with only 1/100th (CPT) or 1/5th (irinotecan) of the amounts of drugs required for this effect in Myc-vector-expressing cells.	Camptothecin	52-64	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	252-255
26455329-2	2015	Here, we fabricated a series of hyaluronic acid (HA)-functionalized camptothecin (CPT)/curcumin (CUR)-loaded polymeric NPs (HA-CPT/CUR-NPs) with various weight ratios of CPT to CUR (1 : 1, 2 : 1 and 4 : 1).	Camptothecin	68-80	choline phosphotransferase 1	Homo sapiens	82-85
26275776-3	2015	Here, we show that, in response to replication perturbation induced by low doses of the TOP1 inhibitor camptothecin, loss of the WRN exonuclease resulted in enhanced degradation and ssDNA formation at nascent strands by the combined action of MRE11 and EXO1, as opposed to the limited processing of nascent strands performed by DNA2 in wild-type cells.	Camptothecin	103-115	WRN RecQ like helicase	Homo sapiens	129-132
26275776-3	2015	Here, we show that, in response to replication perturbation induced by low doses of the TOP1 inhibitor camptothecin, loss of the WRN exonuclease resulted in enhanced degradation and ssDNA formation at nascent strands by the combined action of MRE11 and EXO1, as opposed to the limited processing of nascent strands performed by DNA2 in wild-type cells.	Camptothecin	103-115	MRE11 homolog, double strand break repair nuclease	Homo sapiens	243-248
26275776-3	2015	Here, we show that, in response to replication perturbation induced by low doses of the TOP1 inhibitor camptothecin, loss of the WRN exonuclease resulted in enhanced degradation and ssDNA formation at nascent strands by the combined action of MRE11 and EXO1, as opposed to the limited processing of nascent strands performed by DNA2 in wild-type cells.	Camptothecin	103-115	exonuclease 1	Homo sapiens	253-257
26275776-3	2015	Here, we show that, in response to replication perturbation induced by low doses of the TOP1 inhibitor camptothecin, loss of the WRN exonuclease resulted in enhanced degradation and ssDNA formation at nascent strands by the combined action of MRE11 and EXO1, as opposed to the limited processing of nascent strands performed by DNA2 in wild-type cells.	Camptothecin	103-115	DNA replication helicase/nuclease 2	Homo sapiens	328-332
26490994-9	2015	Although, in the presence of NRG1, basal and camptothecin-induced trophoblast apoptosis was significantly repressed, this effect was abolished upon ErbB3 inhibition.	Camptothecin	45-57	neuregulin 1	Homo sapiens	29-33
26455329-2	2015	Here, we fabricated a series of hyaluronic acid (HA)-functionalized camptothecin (CPT)/curcumin (CUR)-loaded polymeric NPs (HA-CPT/CUR-NPs) with various weight ratios of CPT to CUR (1 : 1, 2 : 1 and 4 : 1).	Camptothecin	68-80	choline phosphotransferase 1	Homo sapiens	127-130
26722304-0	2015	Effect of camptothecin on inducible nitric oxide synthase expression in the colon cancer SW480 cell line.	Camptothecin	10-22	nitric oxide synthase 2	Homo sapiens	26-57
26437226-4	2015	V158411 potentiated the cytotoxicity of gemcitabine, cisplatin, SN38 and camptothecin in a variety of p53 deficient human tumor cell lines in vitro, p53 proficient cells were unaffected.	Camptothecin	73-85	tumor protein p53	Homo sapiens	102-105
26722304-2	2015	In an attempt to search for its novel anticancer mechanism, the present study evaluated the effects of CPT on inducible nitric oxide synthase (iNOS) in the human colon cancer SW480 cell line when stimulated with lipopolysaccharide (LPS) and interleukin (IL)-1beta.	Camptothecin	103-106	nitric oxide synthase 2	Homo sapiens	110-141
26722304-2	2015	In an attempt to search for its novel anticancer mechanism, the present study evaluated the effects of CPT on inducible nitric oxide synthase (iNOS) in the human colon cancer SW480 cell line when stimulated with lipopolysaccharide (LPS) and interleukin (IL)-1beta.	Camptothecin	103-106	nitric oxide synthase 2	Homo sapiens	143-147
25779942-7	2015	EWS-FLI1-mediated SLFN11 expression is responsible for high sensitivity of Ewing sarcoma to camptothecin and combinations of PARP inhibitors with temozolomide.	Camptothecin	92-104	EWS RNA binding protein 1	Homo sapiens	0-3
26282096-4	2015	Furthermore, The PEG layer would detach from the NPs due to the up-regulated extracellular MMP2 and MMP9 in tumors, resulting in the exposure of folate to enhance the cellular internalization via folate receptor mediated endocytosis, which accelerated the release rate of CPT in vivo.	Camptothecin	272-275	matrix metallopeptidase 2	Mus musculus	91-95
26282096-4	2015	Furthermore, The PEG layer would detach from the NPs due to the up-regulated extracellular MMP2 and MMP9 in tumors, resulting in the exposure of folate to enhance the cellular internalization via folate receptor mediated endocytosis, which accelerated the release rate of CPT in vivo.	Camptothecin	272-275	matrix metallopeptidase 9	Mus musculus	100-104
26315125-3	2015	SN-38, an active metabolite of camptothecin, conjugated to hyaluronic acid (HA) was used as the shell of chitosan nanoparticles decorated with MUC1 aptamer.	Camptothecin	31-43	mucin 1, cell surface associated	Homo sapiens	143-147
26187992-7	2015	Consistent with this suggestion we found that REV1 and FANCD2 are epistatic with respect to sensitivity to the double-strand break-inducer camptothecin.	Camptothecin	139-151	REV1 DNA directed polymerase	Homo sapiens	46-50
26187992-7	2015	Consistent with this suggestion we found that REV1 and FANCD2 are epistatic with respect to sensitivity to the double-strand break-inducer camptothecin.	Camptothecin	139-151	FA complementation group D2	Homo sapiens	55-61
26438292-4	2015	In this pathogen, Mms22p is important for recovery from DNA replication damage induced by agents including methylmethane sulfonate, camptothecin, and ionizing radiation.	Camptothecin	132-144	Mms22p	Saccharomyces cerevisiae S288C	18-24
26438292-9	2015	In C. albicans, although the loss of RAD57 greatly impairs response in the pathogen to many DNA-damaging agents, lethality due to camptothecin damage requires concomitant loss of Rad57p and Mms22p, suggesting that Mms22p is only essential for homologous recombination induced by camptothecin.	Camptothecin	130-142	Mms22p	Saccharomyces cerevisiae S288C	190-196
25779942-7	2015	EWS-FLI1-mediated SLFN11 expression is responsible for high sensitivity of Ewing sarcoma to camptothecin and combinations of PARP inhibitors with temozolomide.	Camptothecin	92-104	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	4-8
25779942-7	2015	EWS-FLI1-mediated SLFN11 expression is responsible for high sensitivity of Ewing sarcoma to camptothecin and combinations of PARP inhibitors with temozolomide.	Camptothecin	92-104	schlafen family member 11	Homo sapiens	18-24
26349035-5	2015	Wss1 is required for cell survival following UV irradiation, the smt3-331 mutation and Camptothecin-induced formation of covalent topoisomerase 1 complexes (Top1cc).	Camptothecin	87-99	metalloendopeptidase WSS1	Saccharomyces cerevisiae S288C	0-4
26716193-1	2015	Camptothecin (CPT) exerts very strong antitumor activities by suppressing the activity of DNA topoisomerase I, but its application is greatly limited owing to its low solubility and the instability of the active lactone form.	Camptothecin	0-12	topoisomerase (DNA) I	Mus musculus	90-109
26762090-9	2015	in the presence of Top 1 inhibitors, such as camptothecin, therefore Tdp1 is a very important target for the development of inhibitors--anticancer drugs.	Camptothecin	45-57	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	69-73
26716193-1	2015	Camptothecin (CPT) exerts very strong antitumor activities by suppressing the activity of DNA topoisomerase I, but its application is greatly limited owing to its low solubility and the instability of the active lactone form.	Camptothecin	14-17	topoisomerase (DNA) I	Mus musculus	90-109
26062578-9	2015	Furthermore, SW480 CRC cells, overexpressing HAX-1, exhibited increased resistance to camptothecin in vitro, and promoted proliferation in vitro and in vivo.	Camptothecin	86-98	HCLS1 associated protein X-1	Homo sapiens	45-50
26008972-5	2015	More importantly, genotoxic agents, such as camptothecin (CPT), induced SOD1 acetylation by disrupting its binding with SIRT1.	Camptothecin	44-56	superoxide dismutase 1	Homo sapiens	72-76
26008972-5	2015	More importantly, genotoxic agents, such as camptothecin (CPT), induced SOD1 acetylation by disrupting its binding with SIRT1.	Camptothecin	44-56	sirtuin 1	Homo sapiens	120-125
26008972-8	2015	Together, our findings gained mechanistic insights into how cytotoxic agents fine tune the intracellular ROS homeostasis to strengthen their anticancer effects, and suggested SOD1 acetylation as a candidate biomarker for predicting response to CPT-based chemotherapy.	Camptothecin	244-247	superoxide dismutase 1	Homo sapiens	175-179
26008972-5	2015	More importantly, genotoxic agents, such as camptothecin (CPT), induced SOD1 acetylation by disrupting its binding with SIRT1.	Camptothecin	58-61	superoxide dismutase 1	Homo sapiens	72-76
26008972-5	2015	More importantly, genotoxic agents, such as camptothecin (CPT), induced SOD1 acetylation by disrupting its binding with SIRT1.	Camptothecin	58-61	sirtuin 1	Homo sapiens	120-125
26008972-6	2015	CPT-induced SOD1 acetylation was stimulated by its provoked ROS, suggesting a positive feedback loop, in which ROS per se impairs the antioxidative defence of cancer cells and reinforces oxidative stress stimulated by anticancer agents.	Camptothecin	0-3	superoxide dismutase 1	Homo sapiens	12-16
26068472-4	2015	In response to camptothecin-mediated DNA DSBs, CHK1 and RPA2 phosphorylation, which are hallmarks of HR activation, was abrogated in SERBP1-depleted cells.	Camptothecin	15-27	checkpoint kinase 1	Homo sapiens	47-51
25417706-7	2015	Remarkably, deletion of Ku70, a protein essential for nonhomologous end joining (NHEJ) significantly restored tolerance of RAD18(-/-) and RNF8(-/-) cells to camptothecin and olaparib without affecting Rad51 focus formation.	Camptothecin	157-169	X-ray repair cross complementing 6	Gallus gallus	24-28
26079886-0	2015	Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARgamma.	Camptothecin	0-12	peroxisome proliferator activated receptor gamma	Mus musculus	88-97
26079886-4	2015	Following treatment with camptothecin, endogenous or overexpressed PPARgamma becomes destabilized; this was prevented in the presence of MG132, a proteasome inhibitor.	Camptothecin	25-37	peroxisome proliferator activated receptor gamma	Mus musculus	67-76
26079886-5	2015	Our findings suggest that camptothecin is able to induce proteasome-dependent degradation of PPARgamma.	Camptothecin	26-38	peroxisome proliferator activated receptor gamma	Mus musculus	93-102
26079886-6	2015	The ubiquitylation of PPARgamma increased in the presence of camptothecin.	Camptothecin	61-73	peroxisome proliferator activated receptor gamma	Mus musculus	22-31
26079886-8	2015	Our results suggest a possible role for camptothecin analogs in the regulation of PPARgamma.	Camptothecin	40-52	peroxisome proliferator activated receptor gamma	Mus musculus	82-91
26038195-5	2015	Previously, we demonstrated that neurotoxins N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4)- and camptothecin (CPT) induced the DNA damage response in SH-SY5Y cells, and DSP4 caused cell cycle arrest which was predominately in the S-phase.	Camptothecin	102-114	dual specificity phosphatase 26	Homo sapiens	175-179
26038195-5	2015	Previously, we demonstrated that neurotoxins N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4)- and camptothecin (CPT) induced the DNA damage response in SH-SY5Y cells, and DSP4 caused cell cycle arrest which was predominately in the S-phase.	Camptothecin	116-119	dual specificity phosphatase 26	Homo sapiens	175-179
26068472-4	2015	In response to camptothecin-mediated DNA DSBs, CHK1 and RPA2 phosphorylation, which are hallmarks of HR activation, was abrogated in SERBP1-depleted cells.	Camptothecin	15-27	replication protein A2	Homo sapiens	56-60
26068472-4	2015	In response to camptothecin-mediated DNA DSBs, CHK1 and RPA2 phosphorylation, which are hallmarks of HR activation, was abrogated in SERBP1-depleted cells.	Camptothecin	15-27	SERPINE1 mRNA binding protein 1	Homo sapiens	133-139
26055704-0	2015	hMSH5 Facilitates the Repair of Camptothecin-induced Double-strand Breaks through an Interaction with FANCJ.	Camptothecin	32-44	mutS homolog 5	Homo sapiens	0-5
25779651-11	2015	In combination with topo I and camptothecin, TDP-1 reversed the inhibitory effects of camptothecin on DNA relaxation and anti-dsDNA binding.	Camptothecin	31-43	tyrosyl-DNA phosphodiesterase 1	Mus musculus	45-50
26055704-0	2015	hMSH5 Facilitates the Repair of Camptothecin-induced Double-strand Breaks through an Interaction with FANCJ.	Camptothecin	32-44	BRCA1 interacting helicase 1	Homo sapiens	102-107
26055704-5	2015	In addition, CPT-treated hMSH5-deficient cells exhibit aberrant activation of Chk1 and Chk2 kinases and therefore abnormal cell cycle progression.	Camptothecin	13-16	mutS homolog 5	Homo sapiens	25-30
26055704-5	2015	In addition, CPT-treated hMSH5-deficient cells exhibit aberrant activation of Chk1 and Chk2 kinases and therefore abnormal cell cycle progression.	Camptothecin	13-16	checkpoint kinase 1	Homo sapiens	78-82
26055704-5	2015	In addition, CPT-treated hMSH5-deficient cells exhibit aberrant activation of Chk1 and Chk2 kinases and therefore abnormal cell cycle progression.	Camptothecin	13-16	checkpoint kinase 2	Homo sapiens	87-91
26199284-4	2015	The utility of this approach was demonstrated via the identification of the known CAN1 and TOP1 resistance targets for two compounds, canavanine and camptothecin, respectively.	Camptothecin	149-161	arginine permease CAN1	Saccharomyces cerevisiae S288C	82-86
25843524-7	2015	When evaluating the effects of TCDD on apoptosis induction by camptothecin, a genotoxic topoisomerase I inhibitor, we observed that the pre-treatment of WB-F344 cells with TCDD increased number of cells with apoptotic nuclear morphology, and it potentiated cleavage of both caspase-3 and poly(ADP-ribose) polymerase I.	Camptothecin	62-74	caspase 3	Rattus norvegicus	274-283
25935680-5	2015	The estimated number of molecules of gammaH2AX (ATQA(pS)QEY) per vehicle-treated HeLa S3 cell was 9.4 x 10(4) and increased to 6.2 x 10(5) molecules/cell after exposure to the DNA-damaging agent camptothecin (10 muM) for 1 h. The estimated total amount of H2AX (ATQA(pS)QEY + ATQASQEY) was 3.3-3.6 x 10(6) molecules/cell.	Camptothecin	195-207	H2A.X variant histone	Homo sapiens	42-46
25779651-11	2015	In combination with topo I and camptothecin, TDP-1 reversed the inhibitory effects of camptothecin on DNA relaxation and anti-dsDNA binding.	Camptothecin	86-98	tyrosyl-DNA phosphodiesterase 1	Mus musculus	45-50
26117979-5	2015	Overexpression of CD44, observed in many ovarian cancer cells, is used in creating carriers for selective delivery of various drugs (paclitaxel, doxorubicin, camptothecin or cisplatin) to cancer cells.	Camptothecin	158-170	CD44 molecule (Indian blood group)	Homo sapiens	18-22
25971544-1	2015	A DT-diaphorase-activatable theranostic prodrug, which contains camptothecin, a self-immolative linker and a trigger group, has been developed for the detection of DT-diaphorase, tracking of drug release and selectively killing cancer cells over-expressed with DT-diaphorase.	Camptothecin	64-76	NAD(P)H quinone dehydrogenase 1	Homo sapiens	2-15
25971544-1	2015	A DT-diaphorase-activatable theranostic prodrug, which contains camptothecin, a self-immolative linker and a trigger group, has been developed for the detection of DT-diaphorase, tracking of drug release and selectively killing cancer cells over-expressed with DT-diaphorase.	Camptothecin	64-76	NAD(P)H quinone dehydrogenase 1	Homo sapiens	164-177
25971544-1	2015	A DT-diaphorase-activatable theranostic prodrug, which contains camptothecin, a self-immolative linker and a trigger group, has been developed for the detection of DT-diaphorase, tracking of drug release and selectively killing cancer cells over-expressed with DT-diaphorase.	Camptothecin	64-76	NAD(P)H quinone dehydrogenase 1	Homo sapiens	164-177
25941985-0	2015	Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-kappaB activity and Nrf2-dependent induction of HO-1 expression.	Camptothecin	0-12	matrix metallopeptidase 9	Homo sapiens	38-64
25941985-0	2015	Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-kappaB activity and Nrf2-dependent induction of HO-1 expression.	Camptothecin	0-12	vascular endothelial growth factor A	Homo sapiens	69-103
25941985-0	2015	Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-kappaB activity and Nrf2-dependent induction of HO-1 expression.	Camptothecin	0-12	AKT serine/threonine kinase 1	Homo sapiens	132-135
25941985-0	2015	Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-kappaB activity and Nrf2-dependent induction of HO-1 expression.	Camptothecin	0-12	NFE2 like bZIP transcription factor 2	Homo sapiens	182-186
25941985-0	2015	Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-kappaB activity and Nrf2-dependent induction of HO-1 expression.	Camptothecin	0-12	heme oxygenase 1	Homo sapiens	210-214
25963854-3	2015	The mechanism of hTopI is specifically targeted in cancer treatment using camptothecin derivatives.	Camptothecin	74-86	DNA topoisomerase I	Homo sapiens	17-22
25963854-4	2015	These drugs convert the hTopI activity into a cellular poison, and hence the cytotoxic effects of camptothecin derivatives correlate with the hTopI activity.	Camptothecin	98-110	DNA topoisomerase I	Homo sapiens	24-29
25963854-4	2015	These drugs convert the hTopI activity into a cellular poison, and hence the cytotoxic effects of camptothecin derivatives correlate with the hTopI activity.	Camptothecin	98-110	DNA topoisomerase I	Homo sapiens	142-147
25963854-6	2015	Here we demonstrate potential applications of a fluorophore-quencher based DNA sensor designed for measurement of hTopI cleavage-ligation activities, which are the catalytic steps affected by camptothecin.	Camptothecin	192-204	DNA topoisomerase I	Homo sapiens	114-119
25798457-1	2015	We developed a real-time drug-reporting conjugate (CPT-SS-CyN) composed of a near-infrared (NIR) fluorescent cyanine-amine dye (CyN), a disulfide linker, and a model therapeutic drug (camptothecin, CPT).	Camptothecin	184-196	choline phosphotransferase 1	Homo sapiens	51-54
25776905-2	2015	It is a potent topoisomerase I inhibitor with potential therapeutic advantages over FDA-approved camptothecin derivatives.	Camptothecin	97-109	DNA topoisomerase I	Canis lupus familiaris	15-30
25760094-2	2015	Previously, we showed that recombinant BID fused with TAT cell penetrating peptide (TAT-BID) allowed for controlled delivery of BID to different cancer cell lines and moderately sensitized some of them to TRAIL or slightly to camptothecin.	Camptothecin	226-238	BH3 interacting domain death agonist	Homo sapiens	39-42
25760094-2	2015	Previously, we showed that recombinant BID fused with TAT cell penetrating peptide (TAT-BID) allowed for controlled delivery of BID to different cancer cell lines and moderately sensitized some of them to TRAIL or slightly to camptothecin.	Camptothecin	226-238	BH3 interacting domain death agonist	Homo sapiens	88-91
25760094-2	2015	Previously, we showed that recombinant BID fused with TAT cell penetrating peptide (TAT-BID) allowed for controlled delivery of BID to different cancer cell lines and moderately sensitized some of them to TRAIL or slightly to camptothecin.	Camptothecin	226-238	BH3 interacting domain death agonist	Homo sapiens	88-91
25578966-2	2015	However, we found that knockdown of DICER dramatically increased cell resistance to camptothecin that induced damage required ATM to facilitate HRR.	Camptothecin	84-96	dicer 1, ribonuclease III	Homo sapiens	36-41
25826089-0	2015	PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.	Camptothecin	183-196	polo like kinase 1	Mus musculus	0-4
25701040-2	2015	To circumvent this limitation, we fabricated a camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) nanoparticle (NP) with dual-surface functionalization-Pluronic F127 and chitosan-for inhibiting multi-drug resistant gene 1 (MDR1) expression and enhancing tumor uptake.	Camptothecin	47-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	199-226
25701040-2	2015	To circumvent this limitation, we fabricated a camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) nanoparticle (NP) with dual-surface functionalization-Pluronic F127 and chitosan-for inhibiting multi-drug resistant gene 1 (MDR1) expression and enhancing tumor uptake.	Camptothecin	47-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	228-232
25833208-5	2015	Breast cancer cells grown under hypoxic conditions were treated with the dual topoisomerase-1 (TOPO-1) and HIF-1alpha inhibitor camptothecin and assessed for their CSC content.	Camptothecin	128-140	hypoxia inducible factor 1, alpha subunit	Mus musculus	107-117
25806814-2	2015	This is believed to underlie the role of Fun30 in promoting cellular resistance to DSB inducing agent camptothecin.	Camptothecin	102-114	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	41-46
25906152-2	2015	We generated caspase-3 knockout (C3KO) and knockdown human colorectal cancer cells, and found that they are unexpectedly sensitized to DNA-damaging agents including 5-fluorouracil (5-FU), etoposide, and camptothecin.	Camptothecin	203-215	caspase 3	Homo sapiens	13-22
25578966-2	2015	However, we found that knockdown of DICER dramatically increased cell resistance to camptothecin that induced damage required ATM to facilitate HRR.	Camptothecin	84-96	ATM serine/threonine kinase	Homo sapiens	126-129
26252178-2	2015	We determined the kinetics of the mitochondrial translocation of p53 in HCT-116 and PA-1 cells exposed to different genotoxic stresses (doxorubicin, camptothecin, UVB).	Camptothecin	149-161	tumor protein p53	Homo sapiens	65-68
25945419-0	2015	MiR-15a and miR-16 induce autophagy and enhance chemosensitivity of Camptothecin.	Camptothecin	68-80	microRNA 15a	Homo sapiens	0-7
25096614-0	2015	Camptothecin and its analogs reduce amyloid-beta production and amyloid-beta42-induced IL-1beta production.	Camptothecin	0-12	interleukin 1 beta	Homo sapiens	87-95
25945419-0	2015	MiR-15a and miR-16 induce autophagy and enhance chemosensitivity of Camptothecin.	Camptothecin	68-80	glycerophosphodiester phosphodiesterase 1	Homo sapiens	12-18
25945419-5	2015	Moreover, miR-15a/16 dramatically enhances anticancer drug camptothecin (CPT)-induced autophagy and apoptotic cell death in HeLa cells.	Camptothecin	59-71	microRNA 15a	Homo sapiens	10-17
25945419-5	2015	Moreover, miR-15a/16 dramatically enhances anticancer drug camptothecin (CPT)-induced autophagy and apoptotic cell death in HeLa cells.	Camptothecin	73-76	microRNA 15a	Homo sapiens	10-17
25691521-6	2015	Both DIN7 and PLM2 systems are able to detect camptothecin while RNR2 and RAD54 systems are not.	Camptothecin	46-58	exodeoxyribonuclease DIN7	Saccharomyces cerevisiae S288C	5-9
25691521-6	2015	Both DIN7 and PLM2 systems are able to detect camptothecin while RNR2 and RAD54 systems are not.	Camptothecin	46-58	Plm2p	Saccharomyces cerevisiae S288C	14-18
25269479-3	2014	Depletion of ATR, the main transducer of replication stress, came as a top candidate gene for camptothecin synthetic lethality.	Camptothecin	94-106	ATR serine/threonine kinase	Homo sapiens	13-16
25520194-6	2015	We show that RECQL5, but not BLM, conferred resistance to mitomycin C (MMC, an interstrand crosslinker) and camptothecin (CPT, a type 1 topoisomerase inhibitor) in FANCB-defective cells.	Camptothecin	108-120	RecQ like helicase 5	Homo sapiens	13-19
25539742-0	2014	Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.	Camptothecin	81-93	Y-box binding protein 1	Homo sapiens	0-23
25539742-7	2014	Interactions between YB-1 and TOPO1 increased when cancer cells were treated with the TOPO1 inhibitor, camptothecin (CPT), but not with the TOPO2 inhibitor, adriamycin (ADM).	Camptothecin	103-115	Y-box binding protein 1	Homo sapiens	21-25
25539742-7	2014	Interactions between YB-1 and TOPO1 increased when cancer cells were treated with the TOPO1 inhibitor, camptothecin (CPT), but not with the TOPO2 inhibitor, adriamycin (ADM).	Camptothecin	117-120	Y-box binding protein 1	Homo sapiens	21-25
25520194-6	2015	We show that RECQL5, but not BLM, conferred resistance to mitomycin C (MMC, an interstrand crosslinker) and camptothecin (CPT, a type 1 topoisomerase inhibitor) in FANCB-defective cells.	Camptothecin	108-120	FA complementation group B	Homo sapiens	164-169
25331234-8	2014	UDCA (10 muM) reduced the apoptotic effects of camptothecin (0 5 muM) by 61%, (P < 0 001) and counteracted the apoptotic effects of LCA and bilirubin determined by DNA fragmentation (56% and 60%, respectively, P < 0 001), cytometry and caspase-3 activity in Saos-2, with lower effects in hOB.	Camptothecin	47-59	latexin	Homo sapiens	9-12
25331234-8	2014	UDCA (10 muM) reduced the apoptotic effects of camptothecin (0 5 muM) by 61%, (P < 0 001) and counteracted the apoptotic effects of LCA and bilirubin determined by DNA fragmentation (56% and 60%, respectively, P < 0 001), cytometry and caspase-3 activity in Saos-2, with lower effects in hOB.	Camptothecin	47-59	latexin	Homo sapiens	65-68
25331234-8	2014	UDCA (10 muM) reduced the apoptotic effects of camptothecin (0 5 muM) by 61%, (P < 0 001) and counteracted the apoptotic effects of LCA and bilirubin determined by DNA fragmentation (56% and 60%, respectively, P < 0 001), cytometry and caspase-3 activity in Saos-2, with lower effects in hOB.	Camptothecin	47-59	caspase 3	Homo sapiens	242-251
25117203-8	2014	We conclude that targeting Tdp1 in anticancer therapy preferentially enhances the sensitivity of some breast cancer cells to camptothecin and may be an effective adjuvant for breast cancer therapy.	Camptothecin	125-137	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	27-31
25253693-3	2014	Inhibition of Gli1 in tumor cells induced replication stress-mediated DNA damage response, attenuated their clonogenic potential, abrogated camptothecin (CPT)-induced Chk1 phosphorylation, and potentiated its cytotoxicity.	Camptothecin	140-152	GLI family zinc finger 1	Homo sapiens	14-18
25151090-3	2014	Synthetically, a significantly high dose of hydrophobic camptothecin (CPT) is first loaded into the porous structure of quantum dots (CdS) coupled mesoporous silica nanocomposite.	Camptothecin	56-68	CDP-diacylglycerol synthase 1	Homo sapiens	134-137
25151090-3	2014	Synthetically, a significantly high dose of hydrophobic camptothecin (CPT) is first loaded into the porous structure of quantum dots (CdS) coupled mesoporous silica nanocomposite.	Camptothecin	70-73	CDP-diacylglycerol synthase 1	Homo sapiens	134-137
25200008-5	2014	Using the HCT116 colorectal cancer model, we show that following binding to DR5, the nanoparticles activate caspase 8, enhancing the anti-tumor activity of the camptothecin payload both in vitro and in vivo.	Camptothecin	160-172	TNF receptor superfamily member 10b	Homo sapiens	76-79
25200008-5	2014	Using the HCT116 colorectal cancer model, we show that following binding to DR5, the nanoparticles activate caspase 8, enhancing the anti-tumor activity of the camptothecin payload both in vitro and in vivo.	Camptothecin	160-172	caspase 8	Homo sapiens	108-117
25200008-6	2014	Importantly, the combination of nanoparticle-induced DR5 clustering with camptothecin delivery overcomes resistance to DR5-induced apoptosis caused by loss of BAX or overexpression of anti-apoptotic FLIP.	Camptothecin	73-85	TNF receptor superfamily member 10b	Homo sapiens	119-122
25200008-6	2014	Importantly, the combination of nanoparticle-induced DR5 clustering with camptothecin delivery overcomes resistance to DR5-induced apoptosis caused by loss of BAX or overexpression of anti-apoptotic FLIP.	Camptothecin	73-85	BCL2 associated X, apoptosis regulator	Homo sapiens	159-162
25253693-3	2014	Inhibition of Gli1 in tumor cells induced replication stress-mediated DNA damage response, attenuated their clonogenic potential, abrogated camptothecin (CPT)-induced Chk1 phosphorylation, and potentiated its cytotoxicity.	Camptothecin	140-152	checkpoint kinase 1	Homo sapiens	167-171
25253693-3	2014	Inhibition of Gli1 in tumor cells induced replication stress-mediated DNA damage response, attenuated their clonogenic potential, abrogated camptothecin (CPT)-induced Chk1 phosphorylation, and potentiated its cytotoxicity.	Camptothecin	154-157	GLI family zinc finger 1	Homo sapiens	14-18
25253693-3	2014	Inhibition of Gli1 in tumor cells induced replication stress-mediated DNA damage response, attenuated their clonogenic potential, abrogated camptothecin (CPT)-induced Chk1 phosphorylation, and potentiated its cytotoxicity.	Camptothecin	154-157	checkpoint kinase 1	Homo sapiens	167-171
25240201-2	2014	Here we report that silkworm cells deficient for FA proteins FancD2 and FancM exhibit normal sensitivities to hydroxyurea (HU) and camptothecin (CPT), although FancM-dependent FancD2 monoubiquitination is induced upon these treatments.	Camptothecin	131-143	Fanconi anemia, complementation group D2	Bombyx mori	61-67
25240201-2	2014	Here we report that silkworm cells deficient for FA proteins FancD2 and FancM exhibit normal sensitivities to hydroxyurea (HU) and camptothecin (CPT), although FancM-dependent FancD2 monoubiquitination is induced upon these treatments.	Camptothecin	131-143	Fanconi anemia group M protein	Bombyx mori	72-77
25240201-2	2014	Here we report that silkworm cells deficient for FA proteins FancD2 and FancM exhibit normal sensitivities to hydroxyurea (HU) and camptothecin (CPT), although FancM-dependent FancD2 monoubiquitination is induced upon these treatments.	Camptothecin	145-148	Fanconi anemia, complementation group D2	Bombyx mori	61-67
25326334-3	2014	The aim of this work was to examine whether a fusion of BID with TAT cell penetrating peptide (TAT-BID) may be used for controlled sensitization of cancer cells to anticancer agents acting through death receptors (TRAIL) or DNA damage (camptothecin).	Camptothecin	236-248	BH3 interacting domain death agonist	Homo sapiens	56-59
25461556-0	2014	Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs.	Camptothecin	0-12	TNF superfamily member 10	Homo sapiens	54-59
25461556-0	2014	Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs.	Camptothecin	0-12	TNF receptor superfamily member 10b	Homo sapiens	97-113
25374083-6	2014	The cells expressing the lower caspase-14 were more sensitive to the treatment with either chemotherapy drugs camptothecin and cisplatin or radiotherapy than the ones expressing the higher caspase-14 (P<0.01).	Camptothecin	110-122	caspase 14	Homo sapiens	31-41
25333260-9	2014	Overexpression of miR-373 by transfection of MCF-7 cells showed downregulated protein expression of the estrogen receptor, and inhibition of apoptosis induced by camptothecin.	Camptothecin	162-174	microRNA 373	Homo sapiens	18-25
25327705-5	2014	Tdp1"s list of substrates has since grown and can be divided into two groups: protein-DNA adducts, such as camptothecin stabilized Topo1-DNA adducts, and modified nucleotides, including oxidized nucleotides and chain terminating nucleoside analogs.	Camptothecin	107-119	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-4
25326334-3	2014	The aim of this work was to examine whether a fusion of BID with TAT cell penetrating peptide (TAT-BID) may be used for controlled sensitization of cancer cells to anticancer agents acting through death receptors (TRAIL) or DNA damage (camptothecin).	Camptothecin	236-248	BH3 interacting domain death agonist	Homo sapiens	99-102
25326334-9	2014	Recombinant BID sensitized PC3 cells to TRAIL or, to lesser extent, to camptothecin.	Camptothecin	71-83	BH3 interacting domain death agonist	Homo sapiens	12-15
25326334-9	2014	Recombinant BID sensitized PC3 cells to TRAIL or, to lesser extent, to camptothecin.	Camptothecin	71-83	keratin 6A	Homo sapiens	27-30
24874432-6	2014	Exposure of HCC cells to diverse anticancer agents such as sorafenib, camptothecin, and doxorubicin increased linc-VLDLR expression in cells as well as within EVs released from these cells.	Camptothecin	70-82	very low density lipoprotein receptor	Homo sapiens	115-120
25299602-7	2014	Analysis of results obtained after treating these cells with aphidicolin and camptothecin revealed that Arp8 is involved in DNA repair.	Camptothecin	77-89	actin related protein 8	Homo sapiens	104-108
24988892-5	2014	Most importantly, lung cancer cells themselves upregulated IL-6 secretion by activating the p38/NF-kappaB pathway through treatment with cisplatin and camptothecin.	Camptothecin	151-163	interleukin 6	Homo sapiens	59-63
24988892-5	2014	Most importantly, lung cancer cells themselves upregulated IL-6 secretion by activating the p38/NF-kappaB pathway through treatment with cisplatin and camptothecin.	Camptothecin	151-163	mitogen-activated protein kinase 14	Homo sapiens	92-95
24988892-5	2014	Most importantly, lung cancer cells themselves upregulated IL-6 secretion by activating the p38/NF-kappaB pathway through treatment with cisplatin and camptothecin.	Camptothecin	151-163	nuclear factor kappa B subunit 1	Homo sapiens	96-105
25247114-1	2014	Camptothecin (CPT; (S)-(+)-4-ethyl-4-hydroxy-1H-pyrano[3",4":6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione) is a highly cytotoxic natural alkaloid that has not yet found use as chemotherapeutic agent due to its poor water-solubility and chemical instability and, as a consequence, no effective administration means have been designed.	Camptothecin	0-12	choline phosphotransferase 1	Homo sapiens	14-17
24786831-5	2014	PELP1-depleted p53 (wild-type) breast cancer cells were less sensitive to various genotoxic agents including etoposide, camptothecin or gamma-radiation.	Camptothecin	120-132	proline, glutamate and leucine rich protein 1	Homo sapiens	0-5
24786831-5	2014	PELP1-depleted p53 (wild-type) breast cancer cells were less sensitive to various genotoxic agents including etoposide, camptothecin or gamma-radiation.	Camptothecin	120-132	tumor protein p53	Homo sapiens	15-18
24794403-5	2014	Any compounds showing a synergistic effect with the Top1 inhibitor camptothecin (CPT) in hTDP1 cells should either be a TDP1-related pathway inhibitor or an inhibitor of alternate repair pathways for Top1cc.	Camptothecin	67-79	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	89-94
24794403-5	2014	Any compounds showing a synergistic effect with the Top1 inhibitor camptothecin (CPT) in hTDP1 cells should either be a TDP1-related pathway inhibitor or an inhibitor of alternate repair pathways for Top1cc.	Camptothecin	67-79	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	90-94
24794403-5	2014	Any compounds showing a synergistic effect with the Top1 inhibitor camptothecin (CPT) in hTDP1 cells should either be a TDP1-related pathway inhibitor or an inhibitor of alternate repair pathways for Top1cc.	Camptothecin	81-84	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	89-94
24794403-5	2014	Any compounds showing a synergistic effect with the Top1 inhibitor camptothecin (CPT) in hTDP1 cells should either be a TDP1-related pathway inhibitor or an inhibitor of alternate repair pathways for Top1cc.	Camptothecin	81-84	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	90-94
24794403-10	2014	We tested the compounds for their ability to inhibit poly(ADP-ribose)polymerase (PARP) because PARP inhibitors are known to potentiate the cytotoxicity of CPT by inhibiting the recruitment of TDP1 to Top1cc.	Camptothecin	155-158	poly(ADP-ribose) polymerase 1	Homo sapiens	53-79
24794403-10	2014	We tested the compounds for their ability to inhibit poly(ADP-ribose)polymerase (PARP) because PARP inhibitors are known to potentiate the cytotoxicity of CPT by inhibiting the recruitment of TDP1 to Top1cc.	Camptothecin	155-158	poly(ADP-ribose) polymerase 1	Homo sapiens	81-85
24794403-10	2014	We tested the compounds for their ability to inhibit poly(ADP-ribose)polymerase (PARP) because PARP inhibitors are known to potentiate the cytotoxicity of CPT by inhibiting the recruitment of TDP1 to Top1cc.	Camptothecin	155-158	poly(ADP-ribose) polymerase 1	Homo sapiens	95-99
24794403-10	2014	We tested the compounds for their ability to inhibit poly(ADP-ribose)polymerase (PARP) because PARP inhibitors are known to potentiate the cytotoxicity of CPT by inhibiting the recruitment of TDP1 to Top1cc.	Camptothecin	155-158	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	192-196
25247114-1	2014	Camptothecin (CPT; (S)-(+)-4-ethyl-4-hydroxy-1H-pyrano[3",4":6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione) is a highly cytotoxic natural alkaloid that has not yet found use as chemotherapeutic agent due to its poor water-solubility and chemical instability and, as a consequence, no effective administration means have been designed.	Camptothecin	19-111	choline phosphotransferase 1	Homo sapiens	14-17
24915421-9	2014	WJ35435 was less effective than camptothecin and etoposide in inducing the phosphorylation and activation of Chk1, Chk2 and RPA32 which were crucial coordinators in DNA repair pathway, indicating a low DNA repair activity to WJ35435 action.	Camptothecin	32-44	checkpoint kinase 1	Homo sapiens	109-113
25134433-4	2014	METHODS: NF-kappaB reporter cells were established and treated with 5-fluorouracil (5-FU, DNA/RNA damaging), oxaliplatin (DNA damaging), camptothecin (CTP, topoisomerase inhibitor), phleomycin (radiomimetic), or erlotinib (EGFR inhibitor).	Camptothecin	137-149	nuclear factor kappa B subunit 1	Homo sapiens	9-18
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	80-92	TSC complex subunit 2	Homo sapiens	170-174
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	80-92	mechanistic target of rapamycin kinase	Homo sapiens	175-179
24830551-4	2014	Most importantly, under in vitro cell culture conditions with the same amount of camptothecin (CPT) and therapeutic sonication, CPT-loaded CHC/SPIO NBs demonstrated more significant transcellular delivery and cytotoxicity than free CPT.	Camptothecin	81-93	clathrin, heavy polypeptide (Hc)	Mus musculus	139-142
24830551-4	2014	Most importantly, under in vitro cell culture conditions with the same amount of camptothecin (CPT) and therapeutic sonication, CPT-loaded CHC/SPIO NBs demonstrated more significant transcellular delivery and cytotoxicity than free CPT.	Camptothecin	95-98	clathrin, heavy polypeptide (Hc)	Mus musculus	139-142
24915421-9	2014	WJ35435 was less effective than camptothecin and etoposide in inducing the phosphorylation and activation of Chk1, Chk2 and RPA32 which were crucial coordinators in DNA repair pathway, indicating a low DNA repair activity to WJ35435 action.	Camptothecin	32-44	checkpoint kinase 2	Homo sapiens	115-119
24915421-9	2014	WJ35435 was less effective than camptothecin and etoposide in inducing the phosphorylation and activation of Chk1, Chk2 and RPA32 which were crucial coordinators in DNA repair pathway, indicating a low DNA repair activity to WJ35435 action.	Camptothecin	32-44	replication protein A2	Homo sapiens	124-129
24703106-0	2014	Silencing RBBP6 (Retinoblastoma Binding Protein 6) sensitises breast cancer cells MCF7 to staurosporine and camptothecin-induced cell death.	Camptothecin	108-120	RB binding protein 6, ubiquitin ligase	Homo sapiens	10-15
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	80-92	checkpoint kinase 2	Homo sapiens	196-200
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	80-92	tumor protein p53	Homo sapiens	201-204
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	80-92	H3 histone pseudogene 16	Homo sapiens	205-208
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	94-97	TSC complex subunit 2	Homo sapiens	170-174
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	94-97	mechanistic target of rapamycin kinase	Homo sapiens	175-179
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	94-97	checkpoint kinase 2	Homo sapiens	196-200
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	94-97	tumor protein p53	Homo sapiens	201-204
24858802-3	2014	In the present study, we found that, in human colorectal cancer cells, low-dose camptothecin (CPT) simultaneously induced autophagy and premature senescence through AMPK-TSC2-mTOR pathway and ATM-Chk2-p53-p21 pathway respectively.	Camptothecin	94-97	H3 histone pseudogene 16	Homo sapiens	205-208
24703106-0	2014	Silencing RBBP6 (Retinoblastoma Binding Protein 6) sensitises breast cancer cells MCF7 to staurosporine and camptothecin-induced cell death.	Camptothecin	108-120	RB binding protein 6, ubiquitin ligase	Homo sapiens	17-49
24703106-9	2014	These findings suggest that silencing RBBP6 may be a novel strategy to promote camptothecin-induced apoptosis in breast cancer cells.	Camptothecin	79-91	RB binding protein 6, ubiquitin ligase	Homo sapiens	38-43
24992598-3	2014	Through a chemical genetics screen with a luciferase-based DNA methylation reporter, LUCL, we found that camptothecin, a compound with anti-cancer properties that targets DNA topoisomerase 1alpha (TOP1alpha) was able to de-repress LUCL by reducing its DNA methylation and H3K9me2 levels.	Camptothecin	105-117	DNA topoisomerase I alpha	Arabidopsis thaliana	171-206
24912678-2	2014	Because inefficient repair of DNA double-strand breaks (DSBs) can lead to cancer, we investigated whether camptothecin, an anticancer drug that produces DSBs, induces RhoB expression and examined its role in the camptothecin-induced DNA damage response.	Camptothecin	106-118	ras homolog family member B	Homo sapiens	167-171
24912678-3	2014	We show that in camptothecin-treated cells, DSBs induce RhoB expression by a mechanism that depends notably on Chk2 and its substrate HuR, which binds to RhoB mRNA and protects it against degradation.	Camptothecin	16-28	ras homolog family member B	Homo sapiens	56-60
24912678-3	2014	We show that in camptothecin-treated cells, DSBs induce RhoB expression by a mechanism that depends notably on Chk2 and its substrate HuR, which binds to RhoB mRNA and protects it against degradation.	Camptothecin	16-28	checkpoint kinase 2	Homo sapiens	111-115
24912678-3	2014	We show that in camptothecin-treated cells, DSBs induce RhoB expression by a mechanism that depends notably on Chk2 and its substrate HuR, which binds to RhoB mRNA and protects it against degradation.	Camptothecin	16-28	ELAV like RNA binding protein 1	Homo sapiens	134-137
24912678-3	2014	We show that in camptothecin-treated cells, DSBs induce RhoB expression by a mechanism that depends notably on Chk2 and its substrate HuR, which binds to RhoB mRNA and protects it against degradation.	Camptothecin	16-28	ras homolog family member B	Homo sapiens	154-158
24912678-4	2014	RhoB-deficient cells fail to dephosphorylate gammaH2AX following camptothecin removal and show reduced efficiency of DSB repair by homologous recombination.	Camptothecin	65-77	ras homolog family member B	Homo sapiens	0-4
24996846-8	2014	Induction of gammaH2AX levels was chemotherapeutic dependent and correlated closely with potentiation of gemcitabine and camptothecin in p53 mutant colon cancer cells.	Camptothecin	121-133	tumor protein p53	Homo sapiens	137-140
24996846-9	2014	CONCLUSIONS: Our results suggest that Chk1 phosphorylation could be a useful biomarker for monitoring inhibition of Chk1 activity in clinical trials involving a range of V158411-chemotherapy combinations and gammaH2AX induction as a predictor of potentiation in combinations containing gemcitabine or camptothecin.	Camptothecin	301-313	checkpoint kinase 1	Homo sapiens	38-42
24996846-9	2014	CONCLUSIONS: Our results suggest that Chk1 phosphorylation could be a useful biomarker for monitoring inhibition of Chk1 activity in clinical trials involving a range of V158411-chemotherapy combinations and gammaH2AX induction as a predictor of potentiation in combinations containing gemcitabine or camptothecin.	Camptothecin	301-313	checkpoint kinase 1	Homo sapiens	116-120
24614819-5	2014	Cells expressing FHA-2D presented partially (but significantly) HR-deficient phenotypes, which were assayed by the reduction of gene conversion frequencies measured with a reporter assay, a decrease in radiation-induced Mre11 foci formation, and hypersensitivity to camptothecin treatments.	Camptothecin	266-278	FHII	Homo sapiens	17-22
24865427-7	2014	Deletion of Aldh1a1 exacerbated alpha-synuclein-mediated DA neurodegeneration and alpha-synuclein aggregation, whereas Aldh1a1-null and control DA neurons were comparably susceptible to 1-methyl-4-phenylpyridinium-, glutamate-, or camptothecin-induced cell death.	Camptothecin	231-243	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	12-19
24798329-3	2014	Top1mt cleavage complexes (Top1mtcc) can be stabilized in vitro by camptothecin (CPT).	Camptothecin	67-79	DNA topoisomerase 1, mitochondrial	Mus musculus	0-6
24798329-3	2014	Top1mt cleavage complexes (Top1mtcc) can be stabilized in vitro by camptothecin (CPT).	Camptothecin	81-84	DNA topoisomerase 1, mitochondrial	Mus musculus	0-6
24960044-2	2014	CD44+ cells were less sensitive to camptothecin than CD44- cells.	Camptothecin	35-47	CD44 molecule (Indian blood group)	Homo sapiens	0-4
24960044-3	2014	The relative resistance of CD44+ cells was correlated with (i) reduced activity of the nuclear enzyme topoisomerase I and (ii) insensitivity of this enzyme to camptothecin when analyzed in extracts.	Camptothecin	159-171	CD44 molecule (Indian blood group)	Homo sapiens	27-31
24960044-4	2014	In contrast, topoisomerase I activity was higher in extracts from CD44- cells and the enzyme was camptothecin sensitive.	Camptothecin	97-109	CD44 molecule (Indian blood group)	Homo sapiens	66-70
24960044-6	2014	This finding was further supported by the fact that phosphorylation of topoisomerase I in CD44+ cell extract by protein kinase CK2 converted the enzyme to a camptothecin sensitive, more active form mimicking topoisomerase I in extracts from CD44- cells.	Camptothecin	157-169	CD44 molecule (Indian blood group)	Homo sapiens	90-94
24960044-6	2014	This finding was further supported by the fact that phosphorylation of topoisomerase I in CD44+ cell extract by protein kinase CK2 converted the enzyme to a camptothecin sensitive, more active form mimicking topoisomerase I in extracts from CD44- cells.	Camptothecin	157-169	CD44 molecule (Indian blood group)	Homo sapiens	241-245
24960044-7	2014	Conversely, dephosphorylation of topoisomerase I in extracts from CD44- cells rendered the enzyme less active and camptothecin resistant.	Camptothecin	114-126	CD44 molecule (Indian blood group)	Homo sapiens	66-70
24779647-2	2014	To achieve that, we developed a drug delivery system (HCN) based on a polymer-drug conjugate of poly[2-(pyridin-2-yldisulfanyl)]-graft-poly(ethylene glycol) and camptothecin with an intracellularly cleavable linker and human epidermal growth factor receptor 2 (HER2) targeting ligands.	Camptothecin	161-173	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	54-57
24779647-0	2014	Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells.	Camptothecin	73-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93
24653001-0	2014	Synthetic cytotoxicity: digenic interactions with TEL1/ATM mutations reveal sensitivity to low doses of camptothecin.	Camptothecin	104-116	DNA-binding protein kinase TEL1	Saccharomyces cerevisiae S288C	50-54
24653001-0	2014	Synthetic cytotoxicity: digenic interactions with TEL1/ATM mutations reveal sensitivity to low doses of camptothecin.	Camptothecin	104-116	ATM serine/threonine kinase	Homo sapiens	55-58
24753408-7	2014	hSSB1 deficiency causes accumulation of DNA strand breaks and results in chromosome aberrations observed in mitosis, ultimately resulting in hSSB1 being required for survival to HU and camptothecin.	Camptothecin	185-197	nucleic acid binding protein 2	Homo sapiens	0-5
24214091-7	2014	Furthermore, simultaneous hNoxin knockdown and treatment with DNA-damaging agents, such as camptothecin (CPT) and UV irradiation, enhanced apoptosis, whereas Trichostatin A (TSA) did not.	Camptothecin	91-103	DNA damage induced apoptosis suppressor	Homo sapiens	26-32
24214091-7	2014	Furthermore, simultaneous hNoxin knockdown and treatment with DNA-damaging agents, such as camptothecin (CPT) and UV irradiation, enhanced apoptosis, whereas Trichostatin A (TSA) did not.	Camptothecin	105-108	DNA damage induced apoptosis suppressor	Homo sapiens	26-32
24650937-0	2014	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.	Camptothecin	88-101	poly(ADP-ribose) polymerase 1	Homo sapiens	14-41
24650937-0	2014	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.	Camptothecin	88-101	poly(ADP-ribose) polymerase 1	Homo sapiens	43-47
24650937-0	2014	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.	Camptothecin	88-101	poly(ADP-ribose) polymerase 1	Homo sapiens	127-131
24650937-5	2014	For camptothecin, both PARP inhibitors showed highly synergistic effects due to catalytic PARP inhibition, indicating the value of combining either veliparib or olaparib with topoisomerase I inhibitors.	Camptothecin	4-16	poly(ADP-ribose) polymerase 1	Homo sapiens	23-27
24650937-8	2014	Hence, we conclude that catalytic PARP inhibitors are highly effective in combination with camptothecins, whereas PARP inhibitors capable of PARP trapping are more effective with temozolomide.	Camptothecin	91-104	poly(ADP-ribose) polymerase 1	Homo sapiens	34-38
24753408-7	2014	hSSB1 deficiency causes accumulation of DNA strand breaks and results in chromosome aberrations observed in mitosis, ultimately resulting in hSSB1 being required for survival to HU and camptothecin.	Camptothecin	185-197	nucleic acid binding protein 2	Homo sapiens	141-146
24573676-8	2014	However, homologous recombination and replication checkpoint were activated normally, whereas DNA synthesis activity was markedly decreased in CPT-treated TIPIN KO cells.	Camptothecin	143-146	TIMELESS interacting protein	Gallus gallus	155-160
24569089-8	2014	In contrast, in cell lines lacking activating PI3KCA mutations, partial inhibition of Akt signaling synergized with camptothecin or etoposide, but higher A-443654 or MK-2206 concentrations (>80% inhibition of Akt signaling) or PDK1 siRNA antagonized the topoisomerase poisons by diminishing DNA synthesis, a process that contributes to effective DNA damage and killing by these agents.	Camptothecin	116-128	AKT serine/threonine kinase 1	Homo sapiens	86-89
24787137-7	2014	Importantly, increasing R-loop levels by treatment with DNA topoisomerase inhibitor camptothecin leads to up-regulation of repressive chromatin marks, resulting in FXN transcriptional silencing.	Camptothecin	84-96	frataxin	Homo sapiens	164-167
24327272-8	2014	Interestingly, when singly administered, the camptothecin was able to strongly decrease EGFR expression mainly by transcriptional inhibition.	Camptothecin	45-57	epidermal growth factor receptor	Homo sapiens	88-92
24700328-3	2014	Here we used conditional epistatic miniarray profiling to analyze the genetic interaction networks of the DDR genes RTT107, SLX4, and HRQ1 under three DNA-damaging conditions: camptothecin, hydroxyurea, and methyl methanesulfonate.	Camptothecin	176-188	Rtt107p	Saccharomyces cerevisiae S288C	116-122
24700328-3	2014	Here we used conditional epistatic miniarray profiling to analyze the genetic interaction networks of the DDR genes RTT107, SLX4, and HRQ1 under three DNA-damaging conditions: camptothecin, hydroxyurea, and methyl methanesulfonate.	Camptothecin	176-188	Slx4p	Saccharomyces cerevisiae S288C	124-128
24700328-3	2014	Here we used conditional epistatic miniarray profiling to analyze the genetic interaction networks of the DDR genes RTT107, SLX4, and HRQ1 under three DNA-damaging conditions: camptothecin, hydroxyurea, and methyl methanesulfonate.	Camptothecin	176-188	ATP-dependent 3'-5' DNA helicase	Saccharomyces cerevisiae S288C	134-138
24242862-2	2014	Camptothecin analogues, including SN-38, have been shown to reduce the expression and transcriptional activity of HIF-1alpha in preclinical models.	Camptothecin	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	114-124
24700328-7	2014	We observed that RTT107 had more genetic interactions under camptothecin conditions than SLX4 or HRQ1, suggesting that Rtt107 has an important role in response to this type of DNA lesion.	Camptothecin	60-72	Rtt107p	Saccharomyces cerevisiae S288C	17-23
24700328-7	2014	We observed that RTT107 had more genetic interactions under camptothecin conditions than SLX4 or HRQ1, suggesting that Rtt107 has an important role in response to this type of DNA lesion.	Camptothecin	60-72	Rtt107p	Saccharomyces cerevisiae S288C	119-125
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Camptothecin	98-110	BRCA1 DNA repair associated	Homo sapiens	112-117
24523556-5	2014	In mouse primary cortical neurons, Bif-1 knockdown exacerbated apoptosis induced by the DNA-damaging agent camptothecin.	Camptothecin	107-119	SH3-domain GRB2-like B1 (endophilin)	Mus musculus	35-40
23435429-6	2014	The functional relevance of NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappaB inhibition.	Camptothecin	87-99	nuclear factor kappa B subunit 1	Homo sapiens	28-37
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Camptothecin	98-110	nuclear factor kappa B subunit 1	Homo sapiens	152-173
23435429-6	2014	The functional relevance of NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappaB inhibition.	Camptothecin	87-99	BRCA1 DNA repair associated	Homo sapiens	52-57
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Camptothecin	98-110	nuclear factor kappa B subunit 1	Homo sapiens	175-184
23435429-6	2014	The functional relevance of NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappaB inhibition.	Camptothecin	87-99	BRCA1 DNA repair associated	Homo sapiens	157-162
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Camptothecin	98-110	BRCA1 DNA repair associated	Homo sapiens	196-201
23435429-6	2014	The functional relevance of NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappaB inhibition.	Camptothecin	87-99	nuclear factor kappa B subunit 1	Homo sapiens	184-193
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Camptothecin	98-110	nuclear factor kappa B subunit 1	Homo sapiens	206-215
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Camptothecin	98-110	nuclear factor kappa B subunit 1	Homo sapiens	206-215
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Camptothecin	98-110	BCL2 apoptosis regulator	Homo sapiens	292-296
23435429-2	2014	In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappaB (NF-kappaB), and that BRCA1 and NF-kappaB cooperate to regulate the expression of the NF-kappaB antiapoptotic targets BCL2 and XIAP.	Camptothecin	98-110	X-linked inhibitor of apoptosis	Homo sapiens	301-305
24285729-1	2014	BRCA1, BRCA2, and PALB2 are key players in cellular tolerance to chemotherapeutic agents, including camptothecin, cisplatin, and PARP inhibitor.	Camptothecin	100-112	BRCA1 DNA repair associated	Homo sapiens	0-5
24285729-1	2014	BRCA1, BRCA2, and PALB2 are key players in cellular tolerance to chemotherapeutic agents, including camptothecin, cisplatin, and PARP inhibitor.	Camptothecin	100-112	BRCA2 DNA repair associated	Homo sapiens	7-12
24285729-1	2014	BRCA1, BRCA2, and PALB2 are key players in cellular tolerance to chemotherapeutic agents, including camptothecin, cisplatin, and PARP inhibitor.	Camptothecin	100-112	partner and localizer of BRCA2	Homo sapiens	18-23
24584199-6	2014	In wild-type cells, HP1alpha was phosphorylated at Thr50, and the phosphorylation was maximized around 30 min, gradually dispersed 2 h after DNA damage induced by camptothecin.	Camptothecin	163-175	chromobox 5	Mus musculus	20-28
24286371-7	2014	Calcipotriol, camptothecin and tazarotene not only failed to inhibit this proliferation but also enhanced retinoic acid-related orphan receptor gamma (RORgamma) expression in IMQ-induced psoriasis-like inflammation.	Camptothecin	14-26	RAR-related orphan receptor gamma	Mus musculus	151-159
24388982-5	2014	We also found that prohibitin and prohibiton up-regulated PIG3 transcription independent of p53, although p53 obviously enhanced this process, and that the knock-down of prohibitin and prohibiton inhibited camptothecin-induced apoptosis.	Camptothecin	206-218	prohibitin 1	Homo sapiens	19-29
24388982-5	2014	We also found that prohibitin and prohibiton up-regulated PIG3 transcription independent of p53, although p53 obviously enhanced this process, and that the knock-down of prohibitin and prohibiton inhibited camptothecin-induced apoptosis.	Camptothecin	206-218	prohibitin 1	Homo sapiens	170-180
24252850-0	2014	The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1alpha activity by changing miR expression patterns in human cancer cells.	Camptothecin	46-58	hypoxia inducible factor 1 subunit alpha	Homo sapiens	70-80
24196441-4	2014	Concomitantly, ectopic expression of CtIP increased P21 promoter activity, and this increment was enhanced upon camptothecin treatment.	Camptothecin	112-124	RB binding protein 8, endonuclease	Homo sapiens	37-41
24252850-0	2014	The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1alpha activity by changing miR expression patterns in human cancer cells.	Camptothecin	46-58	myosin regulatory light chain interacting protein	Homo sapiens	102-105
24252850-2	2014	In the present work, we determined molecular aspects of the mechanism of camptothecin"s effects on hypoxia-inducible factor-1alpha (HIF-1alpha) activity in human cancer cells.	Camptothecin	73-85	hypoxia inducible factor 1 subunit alpha	Homo sapiens	99-130
24252850-2	2014	In the present work, we determined molecular aspects of the mechanism of camptothecin"s effects on hypoxia-inducible factor-1alpha (HIF-1alpha) activity in human cancer cells.	Camptothecin	73-85	hypoxia inducible factor 1 subunit alpha	Homo sapiens	132-142
24252850-3	2014	In particular, we provide evidence that low concentrations of camptothecin, without interfering with HIF-1alpha mRNA levels, can reduce HIF-1alpha protein expression and activity.	Camptothecin	62-74	hypoxia inducible factor 1 subunit alpha	Homo sapiens	136-146
24252850-4	2014	As luciferase assays demonstrated the involvement of the HIF-1alpha mRNA 3" untranslated region in camptothecin-induced impairment of HIF-1alpha protein regulation, we performed microarray analysis to identify camptothecin-induced modification of microRNAs (miRNA) targeting HIF-1alpha mRNA under hypoxic-mimetic conditions.	Camptothecin	99-111	hypoxia inducible factor 1 subunit alpha	Homo sapiens	57-67
24252850-4	2014	As luciferase assays demonstrated the involvement of the HIF-1alpha mRNA 3" untranslated region in camptothecin-induced impairment of HIF-1alpha protein regulation, we performed microarray analysis to identify camptothecin-induced modification of microRNAs (miRNA) targeting HIF-1alpha mRNA under hypoxic-mimetic conditions.	Camptothecin	99-111	hypoxia inducible factor 1 subunit alpha	Homo sapiens	134-144
24252850-4	2014	As luciferase assays demonstrated the involvement of the HIF-1alpha mRNA 3" untranslated region in camptothecin-induced impairment of HIF-1alpha protein regulation, we performed microarray analysis to identify camptothecin-induced modification of microRNAs (miRNA) targeting HIF-1alpha mRNA under hypoxic-mimetic conditions.	Camptothecin	210-222	hypoxia inducible factor 1 subunit alpha	Homo sapiens	57-67
24252850-5	2014	The selected miRNAs were then further analyzed, demonstrating a role for miR-17-5p and miR-155 in HIF-1alpha protein expression after camptothecin treatments.	Camptothecin	134-146	microRNA 17	Homo sapiens	73-82
24252850-5	2014	The selected miRNAs were then further analyzed, demonstrating a role for miR-17-5p and miR-155 in HIF-1alpha protein expression after camptothecin treatments.	Camptothecin	134-146	microRNA 155	Homo sapiens	87-94
24252850-5	2014	The selected miRNAs were then further analyzed, demonstrating a role for miR-17-5p and miR-155 in HIF-1alpha protein expression after camptothecin treatments.	Camptothecin	134-146	hypoxia inducible factor 1 subunit alpha	Homo sapiens	98-108
24252850-6	2014	The present findings establish miRNAs as key factors in a molecular pathway connecting Top1 inhibition and human HIF-1alpha protein regulation and activity, widening the biologic and molecular activity of camptothecin derivatives and the perspective for novel clinical interventions.	Camptothecin	205-217	hypoxia inducible factor 1 subunit alpha	Homo sapiens	113-123
24219989-2	2013	For example, activation of p53 by genotoxic agents, such as camptothecin (CPT), triggers apoptosis, while non-genotoxic activation of p53 by Nutlin-3 (Nut3) leads to cell-cycle arrest without significant apoptosis.	Camptothecin	60-72	tumor protein p53	Homo sapiens	27-30
24219989-2	2013	For example, activation of p53 by genotoxic agents, such as camptothecin (CPT), triggers apoptosis, while non-genotoxic activation of p53 by Nutlin-3 (Nut3) leads to cell-cycle arrest without significant apoptosis.	Camptothecin	74-77	tumor protein p53	Homo sapiens	27-30
24289229-9	2013	DSS1 knockdown, however, increased the susceptibility to the DNA-damaging drugs camptothecin and etoposide and caused early apoptosis in p53 wild type MCF7 and p53-insufficient MDA-MB-231 cells.	Camptothecin	80-92	SEM1 26S proteasome subunit	Homo sapiens	0-4
23838380-5	2013	Camptothecin (2.4A) and 9 amino camptothecin (2.0A) are clearly bound as the open lactone form (IBp).	Camptothecin	0-12	trafficking protein particle complex subunit 9	Homo sapiens	96-99
23997120-3	2013	Here we show that phosphorylated (pT371)TRF1 is recruited to sites of DNA damage, forming damage-induced foci in response to ionizing radiation (IR), etoposide and camptothecin.	Camptothecin	164-176	telomeric repeat binding factor 1	Homo sapiens	40-44
24136823-5	2013	However, [3H]choline labeling experiments in camptothecin-treated MCF7 cells and MCF7 cells expressing caspase 3 (MCF7-C3) revealed a global suppression of the CDP-choline pathway that was consistent with inhibition of a step prior to CCTalpha.	Camptothecin	45-57	phosphate cytidylyltransferase 1A, choline	Homo sapiens	235-243
24095863-7	2013	Nicotine addition to Caco-2 and HCT-8, treated with 5-FU or CPT, decreased the cleavage of substrate of caspase 3 and 7, poly-ADP-ribose polymerase (PARP).	Camptothecin	60-63	poly(ADP-ribose) polymerase 1	Homo sapiens	121-147
24095863-7	2013	Nicotine addition to Caco-2 and HCT-8, treated with 5-FU or CPT, decreased the cleavage of substrate of caspase 3 and 7, poly-ADP-ribose polymerase (PARP).	Camptothecin	60-63	poly(ADP-ribose) polymerase 1	Homo sapiens	149-153
23997120-7	2013	The lack of TRF1 phosphorylation at T371 also hampers the activation of the G2/M checkpoint and sensitizes cells to PARP inhibition, IR and camptothecin.	Camptothecin	140-152	telomeric repeat binding factor 1	Homo sapiens	12-16
24260486-5	2013	The miR-96 increased proliferation and impaired apoptosis induced by camptothecine in these cells.	Camptothecin	69-82	microRNA 96	Homo sapiens	4-10
24256432-1	2013	BACKGROUND: Camptothecin is a plant alkaloid that specifically binds topoisomerase I, inhibiting its activity and inducing double stranded breaks in DNA and activating the cell responses to DNA damage.	Camptothecin	12-24	topoisomerase I	Zea mays	69-84
24256432-7	2013	CONCLUSIONS: We have identified and characterized CaMNUC32, a 32 kDa Ca2+/Mg2+-dependent nuclease of the S1/P1 family induced by the topoisomerase I inhibitor camptothecin in maize cultured cells.	Camptothecin	159-171	topoisomerase I	Zea mays	133-148
23208500-11	2013	Consistent with p53 derepression, NF90/NF45-depleted HeLa cells displayed elevated poly ADP-ribose polymerase (PARP) cleavage and susceptibility to camptothecin-induced apoptosis.	Camptothecin	148-160	tumor protein p53	Homo sapiens	16-19
23918525-6	2013	RESULTS: RASFs displayed significantly higher caspase 3/7 activity upon camptothecin and FasL exposure when ADAM15 had been down-regulated by specific small interfering RNAs.	Camptothecin	72-84	caspase 3	Homo sapiens	46-55
23918525-6	2013	RESULTS: RASFs displayed significantly higher caspase 3/7 activity upon camptothecin and FasL exposure when ADAM15 had been down-regulated by specific small interfering RNAs.	Camptothecin	72-84	ADAM metallopeptidase domain 15	Homo sapiens	108-114
24005240-0	2013	Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death.	Camptothecin	128-140	dual specificity phosphatase 1	Homo sapiens	0-46
24005240-0	2013	Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death.	Camptothecin	128-140	mitogen-activated protein kinase 3	Homo sapiens	72-111
24005240-1	2013	Camptothecins are commonly used chemotherapeutics; in some models, they enhance signaling via the mitogen-activated protein kinase (MAPK) pathway through effects on upstream kinases.	Camptothecin	0-13	mitogen-activated protein kinase 3	Homo sapiens	132-136
24005240-6	2013	Treatment of HCT116 cells with CPT induced a sustained activation of nuclear ERK, which was required for CPT-induced apoptosis.	Camptothecin	31-34	mitogen-activated protein kinase 1	Homo sapiens	77-80
24005240-6	2013	Treatment of HCT116 cells with CPT induced a sustained activation of nuclear ERK, which was required for CPT-induced apoptosis.	Camptothecin	105-108	mitogen-activated protein kinase 1	Homo sapiens	77-80
24005240-8	2013	These results suggest that targeting dual-specificity MAPK phosphatases in colon cancer cells may be a viable strategy for optimizing camptothecin-based therapeutic protocols.	Camptothecin	134-146	mitogen-activated protein kinase 3	Homo sapiens	54-58
23850745-0	2013	Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation.	Camptothecin	90-102	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
23850745-1	2013	Irinotecan is a camptothecin derivative with low oral bioavailability due to active efflux by intestinal P-glycoprotein receptors.	Camptothecin	16-28	ATP binding cassette subfamily B member 1	Homo sapiens	105-119
24069881-6	2013	Interestingly, this study also provided a new structure-activity relationship for the C21-carbonyl group of camptothecin, which has been regarded as an essential pharmacophore.	Camptothecin	108-120	TBL1X/Y related 1	Homo sapiens	86-89
23208500-11	2013	Consistent with p53 derepression, NF90/NF45-depleted HeLa cells displayed elevated poly ADP-ribose polymerase (PARP) cleavage and susceptibility to camptothecin-induced apoptosis.	Camptothecin	148-160	interleukin enhancer binding factor 3	Homo sapiens	34-38
23208500-11	2013	Consistent with p53 derepression, NF90/NF45-depleted HeLa cells displayed elevated poly ADP-ribose polymerase (PARP) cleavage and susceptibility to camptothecin-induced apoptosis.	Camptothecin	148-160	interleukin enhancer binding factor 2	Homo sapiens	39-43
23208500-11	2013	Consistent with p53 derepression, NF90/NF45-depleted HeLa cells displayed elevated poly ADP-ribose polymerase (PARP) cleavage and susceptibility to camptothecin-induced apoptosis.	Camptothecin	148-160	poly(ADP-ribose) polymerase 1	Homo sapiens	111-115
24098947-0	2013	RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.	Camptothecin	74-86	phosphatidylethanolamine binding protein 1	Homo sapiens	0-4
24136229-1	2013	The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known regarding the effects of CPT on hypoxia-inducible factor-2alpha (HIF-2alpha) accumulation and activity in clear cell renal cell carcinoma (ccRCC).	Camptothecin	135-138	endothelial PAS domain protein 1	Homo sapiens	283-314
24136229-1	2013	The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known regarding the effects of CPT on hypoxia-inducible factor-2alpha (HIF-2alpha) accumulation and activity in clear cell renal cell carcinoma (ccRCC).	Camptothecin	135-138	endothelial PAS domain protein 1	Homo sapiens	316-326
24136229-1	2013	The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known regarding the effects of CPT on hypoxia-inducible factor-2alpha (HIF-2alpha) accumulation and activity in clear cell renal cell carcinoma (ccRCC).	Camptothecin	135-138	endothelial PAS domain protein 1	Homo sapiens	283-314
24136229-1	2013	The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known regarding the effects of CPT on hypoxia-inducible factor-2alpha (HIF-2alpha) accumulation and activity in clear cell renal cell carcinoma (ccRCC).	Camptothecin	135-138	endothelial PAS domain protein 1	Homo sapiens	316-326
24098947-0	2013	RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.	Camptothecin	74-86	signal transducer and activator of transcription 3	Homo sapiens	25-30
24098947-4	2013	The aim of this study was to evaluate the regulation of RKIP and STAT3 after treatment with clinically relevant chemotherapeutic agents (camptothecin (CPT) and oxaliplatin (OXP)) and the cytokine interleukin-6 (IL-6) in HCT116 colon cancer cells as well as evaluate the association between RKIP and STAT3 with clinical outcome of Stage II colon cancer patients.	Camptothecin	137-149	phosphatidylethanolamine binding protein 1	Homo sapiens	56-60
24098947-4	2013	The aim of this study was to evaluate the regulation of RKIP and STAT3 after treatment with clinically relevant chemotherapeutic agents (camptothecin (CPT) and oxaliplatin (OXP)) and the cytokine interleukin-6 (IL-6) in HCT116 colon cancer cells as well as evaluate the association between RKIP and STAT3 with clinical outcome of Stage II colon cancer patients.	Camptothecin	137-149	signal transducer and activator of transcription 3	Homo sapiens	65-70
24098947-4	2013	The aim of this study was to evaluate the regulation of RKIP and STAT3 after treatment with clinically relevant chemotherapeutic agents (camptothecin (CPT) and oxaliplatin (OXP)) and the cytokine interleukin-6 (IL-6) in HCT116 colon cancer cells as well as evaluate the association between RKIP and STAT3 with clinical outcome of Stage II colon cancer patients.	Camptothecin	151-154	phosphatidylethanolamine binding protein 1	Homo sapiens	56-60
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	MUS81 structure-specific endonuclease subunit	Gallus gallus	5-10
23791639-4	2013	Similarly to other camptothecin analogs, except for SN38, the activation energy for 9AC-lactone hydrolysis in the presence of Human Serum Albumin (HSA) was about 10 kJmol(-1) lower than that determined in plain PBS, whereas the equilibrium 9AC-lactone concentration was decreased in the presence of HSA as compared to that in plain PBS.	Camptothecin	19-31	albumin	Homo sapiens	132-145
23736154-10	2013	RESULTS: Four drug combinations had synergistic effects in at least one of the tested glioblastoma-derived cell lines; camptothecin combined with gefitinib (epidermal growth factor receptor inhibitor) or NSC 23766 (ras-related C3 botulinum toxin substrate 1 inhibitor) and imatinib combined with DAPT (Notch signaling inhibitor) or NSC 23766.	Camptothecin	119-131	Rac family small GTPase 1	Homo sapiens	215-257
24023853-7	2013	These experiments show that the expression of hMSH5 variants elicits different survival responses to anticancer drugs cisplatin, bleomycin, doxorubicin and camptothecin.	Camptothecin	156-168	mutS homolog 5	Homo sapiens	46-51
23750546-1	2013	The first synthesis and photophysical properties of a fluorecently labeled camptothecin derivative, namely, camptothecin-FI (CPT-FI), an antitumoral agent that targets topoisomerase I, are reported.	Camptothecin	75-87	choline phosphotransferase 1	Homo sapiens	125-128
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	essential meiotic structure-specific endonuclease 1	Gallus gallus	11-15
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	ERCC excision repair 4, endonuclease catalytic subunit	Gallus gallus	20-23
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	24-29
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	MUS81 structure-specific endonuclease subunit	Gallus gallus	114-119
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	essential meiotic structure-specific endonuclease 1	Gallus gallus	120-124
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	ERCC excision repair 4, endonuclease catalytic subunit	Gallus gallus	128-131
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	132-137
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	ERCC excision repair 4, endonuclease catalytic subunit	Gallus gallus	128-131
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	X-ray repair cross complementing 3	Gallus gallus	279-284
23576554-10	2013	Both Mus81-Eme1 and Xpf-Ercc1 contribute to the completion of HR, as evidenced by the data that the expression of Mus81-Eme1 or Xpf-Ercc1 diminished the number of camptothecin-induced chromosome breaks in Xpf-deficient DT40 cells, and to preventing early steps in HR by deleting XRCC3 suppressed the nonviability of Xpf-deficient DT40 cells.	Camptothecin	163-175	ERCC excision repair 4, endonuclease catalytic subunit	Gallus gallus	128-131
23470959-6	2013	However, caspase-7 activation induced by camptothecin was regulated by DDX3 in a manner dependent on the functional status of p53.	Camptothecin	41-53	caspase 7	Homo sapiens	9-18
23557481-7	2013	The effect of NKX3.1 on both Topo70 and the reconstituted enzyme was seen in the presence and absence of camptothecin.	Camptothecin	105-117	NK3 homeobox 1	Homo sapiens	14-20
23557481-10	2013	However, in cells the effect of NKX3.1 on topoisomerase binding to DNA sensitized the cells to cellular toxicity and the induction of apoptosis by low doses of CPT.	Camptothecin	160-163	NK3 homeobox 1	Homo sapiens	32-38
23770241-5	2013	The Ku mutants fail to regulate Exo1 activity, and bypass the requirement for Mre11 nuclease activity in the repair of camptothecin-induced single-ended DSBs.	Camptothecin	119-131	MRE11 homolog, double strand break repair nuclease	Homo sapiens	78-83
23416273-3	2013	Moreover, cancer cells expressing Nek6KM exhibited significantly increased premature senescence upon treatment with the anticancer drugs doxorubicin (DOX) and camptothecin (CPT).	Camptothecin	159-171	NIMA related kinase 6	Homo sapiens	34-40
23416273-3	2013	Moreover, cancer cells expressing Nek6KM exhibited significantly increased premature senescence upon treatment with the anticancer drugs doxorubicin (DOX) and camptothecin (CPT).	Camptothecin	173-176	NIMA related kinase 6	Homo sapiens	34-40
23470959-10	2013	Thus, DDX3 associates with p53, increases p53 accumulation, and positively regulates camptothecin-induced apoptotic signaling in cells expressing functional wild-type p53, whereas in cells expressing mutant or non-functional p53 DDX3 inhibits activation of the extrinsic apoptotic pathway to reduce caspase activation.	Camptothecin	85-97	DEAD-box helicase 3 X-linked	Homo sapiens	229-233
23470959-6	2013	However, caspase-7 activation induced by camptothecin was regulated by DDX3 in a manner dependent on the functional status of p53.	Camptothecin	41-53	DEAD-box helicase 3 X-linked	Homo sapiens	71-75
23470959-6	2013	However, caspase-7 activation induced by camptothecin was regulated by DDX3 in a manner dependent on the functional status of p53.	Camptothecin	41-53	tumor protein p53	Homo sapiens	126-129
23470959-7	2013	Depletion of DDX3 abrogated camptothecin-induced caspase-7 activation in MCF-7 cells expressing functional wild-type p53, but oppositely potentiated camptothecin-mediated caspase activation in cells expressing mutant or non-functional p53, which was accompanied by increased activation of the extrinsic apoptotic signaling initiator caspase-8.	Camptothecin	28-40	DEAD-box helicase 3 X-linked	Homo sapiens	13-17
23470959-7	2013	Depletion of DDX3 abrogated camptothecin-induced caspase-7 activation in MCF-7 cells expressing functional wild-type p53, but oppositely potentiated camptothecin-mediated caspase activation in cells expressing mutant or non-functional p53, which was accompanied by increased activation of the extrinsic apoptotic signaling initiator caspase-8.	Camptothecin	28-40	caspase 7	Homo sapiens	49-58
23470959-7	2013	Depletion of DDX3 abrogated camptothecin-induced caspase-7 activation in MCF-7 cells expressing functional wild-type p53, but oppositely potentiated camptothecin-mediated caspase activation in cells expressing mutant or non-functional p53, which was accompanied by increased activation of the extrinsic apoptotic signaling initiator caspase-8.	Camptothecin	28-40	tumor protein p53	Homo sapiens	117-120
23470959-7	2013	Depletion of DDX3 abrogated camptothecin-induced caspase-7 activation in MCF-7 cells expressing functional wild-type p53, but oppositely potentiated camptothecin-mediated caspase activation in cells expressing mutant or non-functional p53, which was accompanied by increased activation of the extrinsic apoptotic signaling initiator caspase-8.	Camptothecin	149-161	DEAD-box helicase 3 X-linked	Homo sapiens	13-17
23470959-8	2013	In MCF-7 cells, depletion of DDX3 reduced by more than 50% camptothecin-induced p53 accumulation, and this effect was blocked by inhibition of the proteasome with MG132, indicating that DDX3 regulates p53 not at expression level but rather its stabilization after DNA damage.	Camptothecin	59-71	DEAD-box helicase 3 X-linked	Homo sapiens	29-33
23470959-8	2013	In MCF-7 cells, depletion of DDX3 reduced by more than 50% camptothecin-induced p53 accumulation, and this effect was blocked by inhibition of the proteasome with MG132, indicating that DDX3 regulates p53 not at expression level but rather its stabilization after DNA damage.	Camptothecin	59-71	tumor protein p53	Homo sapiens	80-83
23470959-8	2013	In MCF-7 cells, depletion of DDX3 reduced by more than 50% camptothecin-induced p53 accumulation, and this effect was blocked by inhibition of the proteasome with MG132, indicating that DDX3 regulates p53 not at expression level but rather its stabilization after DNA damage.	Camptothecin	59-71	DEAD-box helicase 3 X-linked	Homo sapiens	186-190
23470959-8	2013	In MCF-7 cells, depletion of DDX3 reduced by more than 50% camptothecin-induced p53 accumulation, and this effect was blocked by inhibition of the proteasome with MG132, indicating that DDX3 regulates p53 not at expression level but rather its stabilization after DNA damage.	Camptothecin	59-71	tumor protein p53	Homo sapiens	201-204
23470959-10	2013	Thus, DDX3 associates with p53, increases p53 accumulation, and positively regulates camptothecin-induced apoptotic signaling in cells expressing functional wild-type p53, whereas in cells expressing mutant or non-functional p53 DDX3 inhibits activation of the extrinsic apoptotic pathway to reduce caspase activation.	Camptothecin	85-97	DEAD-box helicase 3 X-linked	Homo sapiens	6-10
23376743-1	2013	This research is aimed to develop a kind of hollow nanosphere based on beta-cyclodextrin-grafted alpha, beta-poly(aspartic acid) (beta-CD-graft-PAsp) as drug carrier to enhance the stability of camptothecin (CPT) in aqueous media.	Camptothecin	194-206	beta-carotene oxygenase 1	Mus musculus	130-137
23536184-8	2013	Treatment with camptothecin, a topoisomerase I inhibitor, caused normal cells to down-regulate H2AX and become quiescent, a process mediated by both Arf and p53.	Camptothecin	15-27	H2A.X variant histone	Homo sapiens	95-99
23536184-8	2013	Treatment with camptothecin, a topoisomerase I inhibitor, caused normal cells to down-regulate H2AX and become quiescent, a process mediated by both Arf and p53.	Camptothecin	15-27	tumor protein p53	Homo sapiens	157-160
23376743-1	2013	This research is aimed to develop a kind of hollow nanosphere based on beta-cyclodextrin-grafted alpha, beta-poly(aspartic acid) (beta-CD-graft-PAsp) as drug carrier to enhance the stability of camptothecin (CPT) in aqueous media.	Camptothecin	208-211	beta-carotene oxygenase 1	Mus musculus	130-137
23461902-0	2013	Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.	Camptothecin	115-127	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	0-5
23627586-7	2013	Recql5-deficient mouse embryonic fibroblasts are sensitive to camptothecin and display elevated levels of sister chromatid exchanges.	Camptothecin	62-74	RecQ protein-like 5	Mus musculus	0-6
23403232-2	2013	Mutation of RAD56 causes sensitivity to X-rays, methyl methanesulfonate, zeocin, camptothecin and hydroxyurea, but not to UV light, suggesting that N-terminal acetylation of specific DNA repair proteins is important for efficient DNA repair.	Camptothecin	81-93	peptide alpha-N-acetyltransferase complex B subunit NAT3	Saccharomyces cerevisiae S288C	12-17
23328306-0	2013	Camptothecin inhibits platelet-derived growth factor-BB-induced proliferation of rat aortic vascular smooth muscle cells through inhibition of PI3K/Akt signaling pathway.	Camptothecin	0-12	AKT serine/threonine kinase 1	Rattus norvegicus	148-151
23461902-0	2013	Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.	Camptothecin	115-127	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	20-25
23461902-0	2013	Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.	Camptothecin	115-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
23461902-7	2013	RESULTS: We found that additional deficiency of Abcc4 in Abcb1a/b;Abcg2(-/-) mice significantly increased the brain concentration of all camptothecin analogues by 1.2-fold (gimatecan) to 5.8-fold (SN-38).	Camptothecin	137-149	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	48-53
23461902-10	2013	CONCLUSION: Abcc4 limits the brain penetration of camptothecin analogues and teams up with Abcb1a/b and Abcg2 to form a robust cooperative drug efflux system.	Camptothecin	50-62	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	12-17
23461902-10	2013	CONCLUSION: Abcc4 limits the brain penetration of camptothecin analogues and teams up with Abcb1a/b and Abcg2 to form a robust cooperative drug efflux system.	Camptothecin	50-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
24716164-0	2013	Camptothecin-Loaded Liposomes with alpha-Melanocyte-Stimulating Hormone Enhance Cytotoxicity Toward and Cellular Uptake by Melanomas: An Application of Nanomedicine on Natural Product.	Camptothecin	0-12	proopiomelanocortin	Homo sapiens	35-71
22824799-7	2013	CD151 ablation, while minimally affecting normal cell and normal mouse functions, markedly sensitized mouse skin and epidermoid cells to chemicals/drugs including 7,12-dimethylbenz[alpha]anthracene (mutagen) and camptothecin (topoisomerase inhibitor), as well as to agents targeting epidermal growth factor receptor, PKC, Jak2/Tyk2 and STAT3.	Camptothecin	212-224	CD151 antigen	Mus musculus	0-5
23381786-0	2013	Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells.	Camptothecin	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	38-43
23381786-0	2013	Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells.	Camptothecin	0-12	ATP binding cassette subfamily C member 2	Homo sapiens	48-52
23381786-0	2013	Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells.	Camptothecin	0-12	ATM serine/threonine kinase	Homo sapiens	82-85
23381786-0	2013	Camptothecin and cisplatin upregulate ABCG2 and MRP2 expression by activating the ATM/NF-kappaB pathway in lung cancer cells.	Camptothecin	0-12	nuclear factor kappa B subunit 1	Homo sapiens	86-95
23381786-2	2013	Our study showed that both camptothecin and cisplatin could not only induce ATM and NF-kappaB activation but also upregulate expression of the MDR-related genes ABCG2, MRP2 in NCI-H446 cells.	Camptothecin	27-39	ATM serine/threonine kinase	Homo sapiens	76-79
23381786-2	2013	Our study showed that both camptothecin and cisplatin could not only induce ATM and NF-kappaB activation but also upregulate expression of the MDR-related genes ABCG2, MRP2 in NCI-H446 cells.	Camptothecin	27-39	nuclear factor kappa B subunit 1	Homo sapiens	84-93
23381786-2	2013	Our study showed that both camptothecin and cisplatin could not only induce ATM and NF-kappaB activation but also upregulate expression of the MDR-related genes ABCG2, MRP2 in NCI-H446 cells.	Camptothecin	27-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	161-166
23381786-2	2013	Our study showed that both camptothecin and cisplatin could not only induce ATM and NF-kappaB activation but also upregulate expression of the MDR-related genes ABCG2, MRP2 in NCI-H446 cells.	Camptothecin	27-39	ATP binding cassette subfamily C member 2	Homo sapiens	168-172
23381786-3	2013	Moreover, camptothecin and cisplatin-induced ABCG2 and MRP2 upregulation could be impaired by ATM and NF-kappaB inhibitors, indicating a relationship between ATM, NF-kappaB activation and MDR formation in lung cancer chemo-therapy.	Camptothecin	10-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	45-50
23381786-3	2013	Moreover, camptothecin and cisplatin-induced ABCG2 and MRP2 upregulation could be impaired by ATM and NF-kappaB inhibitors, indicating a relationship between ATM, NF-kappaB activation and MDR formation in lung cancer chemo-therapy.	Camptothecin	10-22	ATP binding cassette subfamily C member 2	Homo sapiens	55-59
23381786-3	2013	Moreover, camptothecin and cisplatin-induced ABCG2 and MRP2 upregulation could be impaired by ATM and NF-kappaB inhibitors, indicating a relationship between ATM, NF-kappaB activation and MDR formation in lung cancer chemo-therapy.	Camptothecin	10-22	ATM serine/threonine kinase	Homo sapiens	94-97
23381786-3	2013	Moreover, camptothecin and cisplatin-induced ABCG2 and MRP2 upregulation could be impaired by ATM and NF-kappaB inhibitors, indicating a relationship between ATM, NF-kappaB activation and MDR formation in lung cancer chemo-therapy.	Camptothecin	10-22	nuclear factor kappa B subunit 1	Homo sapiens	102-111
23381786-3	2013	Moreover, camptothecin and cisplatin-induced ABCG2 and MRP2 upregulation could be impaired by ATM and NF-kappaB inhibitors, indicating a relationship between ATM, NF-kappaB activation and MDR formation in lung cancer chemo-therapy.	Camptothecin	10-22	ATM serine/threonine kinase	Homo sapiens	158-161
23381786-3	2013	Moreover, camptothecin and cisplatin-induced ABCG2 and MRP2 upregulation could be impaired by ATM and NF-kappaB inhibitors, indicating a relationship between ATM, NF-kappaB activation and MDR formation in lung cancer chemo-therapy.	Camptothecin	10-22	nuclear factor kappa B subunit 1	Homo sapiens	163-172
24716164-11	2013	These findings demonstrate that alpha-MSH liposomes could enhance the anti-melanoma activity of camptothecin owing to their targeting ability and controlled drug delivery.	Camptothecin	96-108	proopiomelanocortin	Homo sapiens	32-41
23313858-0	2013	Sirt1 attenuates camptothecin-induced apoptosis through caspase-3 pathway in porcine preadipocytes.	Camptothecin	17-29	sirtuin 1	Homo sapiens	0-5
23313858-0	2013	Sirt1 attenuates camptothecin-induced apoptosis through caspase-3 pathway in porcine preadipocytes.	Camptothecin	17-29	caspase 3	Homo sapiens	56-65
23211717-7	2013	In FoxP3-transfected cells, apoptotic stimuli like Camptothecin, Temozolomide or tumor necrosis factor-alpha synergistically enhanced caspases-3/7-activities over controls.	Camptothecin	51-63	forkhead box P3	Homo sapiens	3-8
23313858-7	2013	Interestingly, silencing of Sirt1 significantly enhances sensitivity of porcine preadipocytes to camptothecin, which may be due to upregulation of p53, acetylated p53, Bax, cleaved caspase-3 and downregulation of Bcl-2.	Camptothecin	97-109	sirtuin 1	Homo sapiens	28-33
23313858-7	2013	Interestingly, silencing of Sirt1 significantly enhances sensitivity of porcine preadipocytes to camptothecin, which may be due to upregulation of p53, acetylated p53, Bax, cleaved caspase-3 and downregulation of Bcl-2.	Camptothecin	97-109	tumor protein p53	Homo sapiens	147-150
23313858-7	2013	Interestingly, silencing of Sirt1 significantly enhances sensitivity of porcine preadipocytes to camptothecin, which may be due to upregulation of p53, acetylated p53, Bax, cleaved caspase-3 and downregulation of Bcl-2.	Camptothecin	97-109	tumor protein p53	Homo sapiens	163-166
23313858-7	2013	Interestingly, silencing of Sirt1 significantly enhances sensitivity of porcine preadipocytes to camptothecin, which may be due to upregulation of p53, acetylated p53, Bax, cleaved caspase-3 and downregulation of Bcl-2.	Camptothecin	97-109	caspase 3	Homo sapiens	181-190
23313858-7	2013	Interestingly, silencing of Sirt1 significantly enhances sensitivity of porcine preadipocytes to camptothecin, which may be due to upregulation of p53, acetylated p53, Bax, cleaved caspase-3 and downregulation of Bcl-2.	Camptothecin	97-109	BCL2 apoptosis regulator	Homo sapiens	213-218
23313858-8	2013	On the contrary, under the Sirt1 overexpression condition viable cells" number significantly increases when challenging with camptothecin, and the protein levels of cleaved caspase-3, p53, acetylated p53 and Bax are downregulated.	Camptothecin	125-137	sirtuin 1	Homo sapiens	27-32
23313858-9	2013	We also find that hyperacetylated p53 is the major effect of Sirt1 knockdown by overexpression of a mutated p53, whereas Sirt1 overexpression prevents camptothecin-induced apoptosis through p53 deacetylation in preadipocytes.	Camptothecin	151-163	sirtuin 1	Homo sapiens	61-66
23313858-9	2013	We also find that hyperacetylated p53 is the major effect of Sirt1 knockdown by overexpression of a mutated p53, whereas Sirt1 overexpression prevents camptothecin-induced apoptosis through p53 deacetylation in preadipocytes.	Camptothecin	151-163	sirtuin 1	Homo sapiens	121-126
23006513-0	2013	Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.	Camptothecin	81-93	tumor protein p53	Homo sapiens	39-42
22410779-5	2013	SIRT1 knockdown also suppresses de novo genetic mutations of hypoxanthine phosphoribosyl transferase gene in CML and non-CML cells upon treatment with DNA damaging agent camptothecin.	Camptothecin	170-182	sirtuin 1	Homo sapiens	0-5
23344961-4	2013	First, quiescent mouse embryonic fibroblasts (MEFs) lacking Top2beta were shown to be hypersensitive to CPT with prominent induction of apoptosis.	Camptothecin	104-107	topoisomerase (DNA) II beta	Mus musculus	60-68
23161404-3	2013	In this study, we demonstrated that lithium and SB216763, which are pharmacological inhibitors of GSK3, attenuated p53 accumulation and caspase-3 activation, as shown by PARP cleavage induced by the DNA-damaging agents doxorubicin, etoposide and camptothecin.	Camptothecin	246-258	tumor protein p53	Homo sapiens	115-118
23161404-7	2013	GSK3 inhibition also reduced the phosphorylation of wild-type p53 at serine 33, which is induced by doxorubicin, etoposide and camptothecin in the mitochondria.	Camptothecin	127-139	tumor protein p53	Homo sapiens	62-65
23319047-4	2013	In response to treatment with ICL agents (cisplatin, camptothecin, and mitomycin), lamin A/C-deficient cells displayed normal gamma-H2AX focus formation but a higher frequency of cells with delayed gamma-H2AX removal, decreased recruitment of the FANCD2 repair factor, and a higher frequency of chromosome aberrations.	Camptothecin	53-65	lamin A/C	Homo sapiens	83-92
23259865-1	2013	Tyrosyl-DNA phosphodiesterase I (Tdp1) plays a key role in the repair of damaged DNA resulting from the topoisomerase I (Top1) inhibitor camptothecin and a variety of other DNA-damaging anticancer agents.	Camptothecin	137-149	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	33-37
23316441-0	2013	Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2.	Camptothecin	56-68	Cyp6d2	Drosophila melanogaster	43-49
23924470-5	2013	The binding of (99)Tc(m)-His10-Annexin V to apoptotic cells was validated in vitro using camptothecin-induced Jurkat cells.	Camptothecin	89-101	annexin A5	Homo sapiens	31-40
23724630-5	2013	METHODS: The extent of apoptosis induced by arsenic trioxide and camptothecin was evaluated by flow cytometry using annexin V and propidium iodide (PI) after selective labelling of plasma cells with CD38 and CD138 antibodies.	Camptothecin	65-77	CD38 molecule	Homo sapiens	199-203
23724630-5	2013	METHODS: The extent of apoptosis induced by arsenic trioxide and camptothecin was evaluated by flow cytometry using annexin V and propidium iodide (PI) after selective labelling of plasma cells with CD38 and CD138 antibodies.	Camptothecin	65-77	syndecan 1	Homo sapiens	208-213
23316441-3	2013	In this study, we focused on camptothecin and its derivatives, topotecan and irinotecan, which are type I topoisomerase inhibitors that create DNA double-strand breaks in rapidly dividing cells.	Camptothecin	29-41	Topoisomerase 1	Drosophila melanogaster	99-119
23316441-4	2013	Here, we describe two polymorphisms in Drosophila Cyp6d2 that result in extreme sensitivity to camptothecin but not topotecan or irinotecan.	Camptothecin	95-107	Cyp6d2	Drosophila melanogaster	50-56
23316441-6	2013	In addition, we showed that combining a cyp6d2 mutation with mutations in Drosophila brca2 results in extreme sensitivity to camptothecin.	Camptothecin	125-137	Cyp6d2	Drosophila melanogaster	40-46
23316441-6	2013	In addition, we showed that combining a cyp6d2 mutation with mutations in Drosophila brca2 results in extreme sensitivity to camptothecin.	Camptothecin	125-137	BRCA2, DNA repair associated	Drosophila melanogaster	85-90
23349734-11	2013	The cleaved caspase-3 expression was significantly decreased (2.09 and 2.47 folds respectively for 5-Fluorouracil and Camptothecin) in H460 spheroid cultures compared to 2D culture system.	Camptothecin	118-130	caspase 3	Homo sapiens	12-21
23796391-2	2013	The amino acid-linked carbamate derivatives (8-10) of the camptothecin-type natural product not only possessed good to excellent inhibitory activity against three human tumor cell lines K562, HepG2, and HT-29, but also showed significantly less cytotoxicity against normal human cell HEK293 (half maximal inhibiting concentration >10 muM).	Camptothecin	58-70	latexin	Homo sapiens	337-340
23555814-6	2013	However, flies carrying mutations in Smc5, Smc6 and MAGE are hypersensitive to genotoxic agents such as ionizing radiation, camptothecin, hydroxyurea and MMS, consistent with the Smc5/6 complex serving a conserved role in genome stability.	Camptothecin	124-136	Structural maintenance of chromosomes 5	Drosophila melanogaster	37-41
23555814-6	2013	However, flies carrying mutations in Smc5, Smc6 and MAGE are hypersensitive to genotoxic agents such as ionizing radiation, camptothecin, hydroxyurea and MMS, consistent with the Smc5/6 complex serving a conserved role in genome stability.	Camptothecin	124-136	java no jive	Drosophila melanogaster	43-47
23555814-6	2013	However, flies carrying mutations in Smc5, Smc6 and MAGE are hypersensitive to genotoxic agents such as ionizing radiation, camptothecin, hydroxyurea and MMS, consistent with the Smc5/6 complex serving a conserved role in genome stability.	Camptothecin	124-136	MAGE	Drosophila melanogaster	52-56
23157317-4	2012	In particular, camptothecin (CPT) induced rapid and efficient FANCJ hyperphosphorylation that was largely dependent on TopBP1 and ATM-Rad3 related (ATR) kinase.	Camptothecin	15-27	BRCA1 interacting helicase 1	Homo sapiens	62-67
20301284-8	1993	Agents/circumstances to avoid: Because TDP1 codes for a DNA repair enzyme, genotoxic anti-cancer drugs such as camptothecins (e.g., irinotecan and topotecan) and bleomycin are likely to be extremely harmful and possibly fatal; exposure to radiation is likely to be extremely harmful and possibly fatal.	Camptothecin	111-124	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	39-43
23157317-4	2012	In particular, camptothecin (CPT) induced rapid and efficient FANCJ hyperphosphorylation that was largely dependent on TopBP1 and ATM-Rad3 related (ATR) kinase.	Camptothecin	15-27	DNA topoisomerase II binding protein 1	Homo sapiens	119-125
23157317-4	2012	In particular, camptothecin (CPT) induced rapid and efficient FANCJ hyperphosphorylation that was largely dependent on TopBP1 and ATM-Rad3 related (ATR) kinase.	Camptothecin	15-27	ATR serine/threonine kinase	Homo sapiens	148-151
23157317-4	2012	In particular, camptothecin (CPT) induced rapid and efficient FANCJ hyperphosphorylation that was largely dependent on TopBP1 and ATM-Rad3 related (ATR) kinase.	Camptothecin	29-32	BRCA1 interacting helicase 1	Homo sapiens	62-67
23157317-4	2012	In particular, camptothecin (CPT) induced rapid and efficient FANCJ hyperphosphorylation that was largely dependent on TopBP1 and ATM-Rad3 related (ATR) kinase.	Camptothecin	29-32	DNA topoisomerase II binding protein 1	Homo sapiens	119-125
23157317-4	2012	In particular, camptothecin (CPT) induced rapid and efficient FANCJ hyperphosphorylation that was largely dependent on TopBP1 and ATM-Rad3 related (ATR) kinase.	Camptothecin	29-32	ATR serine/threonine kinase	Homo sapiens	148-151
22972498-2	2012	In this study, the interaction between TOPORS (topoisomerase I-binding protein) and H2AX was verified using mammalian cell extracts exposed to diverse DNA damaging stresses such as ionizing radiation, doxorubicin, camptothecin, and hydrogen peroxide.	Camptothecin	214-226	TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase	Homo sapiens	39-45
23010445-5	2012	However, we find that RNF8 and RNF168 knockout cell lines respond differently to treatment with camptothecin indicating that they do not function in a strictly linear manner.	Camptothecin	96-108	ring finger protein 8	Gallus gallus	22-26
23010445-5	2012	However, we find that RNF8 and RNF168 knockout cell lines respond differently to treatment with camptothecin indicating that they do not function in a strictly linear manner.	Camptothecin	96-108	ring finger protein 168	Gallus gallus	31-37
22970428-1	2012	A novel fluorescence derivatization method combined with HPLC was developed to detect the activity of caspase-3 and -8 in two cell lines (Hela cells and A549 cells) which were activated by low temperature-assisted ultraviolet irradiation (LT-UV), mitomycin C (MMC) and camptothecin during the apoptosis, respectively.	Camptothecin	269-281	caspase 3	Homo sapiens	102-118
22972498-2	2012	In this study, the interaction between TOPORS (topoisomerase I-binding protein) and H2AX was verified using mammalian cell extracts exposed to diverse DNA damaging stresses such as ionizing radiation, doxorubicin, camptothecin, and hydrogen peroxide.	Camptothecin	214-226	H2A.X variant histone	Homo sapiens	84-88
22983061-5	2012	Aberrations of the Mre11-Rad50-Nbs1 (MRN) complex sensitized cancer cells to PARP-1i, while p53 status was less predictive, even in response to PARP-1i combinations with camptothecin or ionizing radiation.	Camptothecin	170-182	MRE11 homolog, double strand break repair nuclease	Homo sapiens	19-24
22504023-6	2012	Human NAIP inhibited camptothecin-induced apoptosis in macrophages; however, it promoted cytotoxicity in L. pneumophila-infected cells.	Camptothecin	21-33	NLR family apoptosis inhibitory protein	Homo sapiens	6-10
22987307-4	2012	Using a primary hNPC culture system, we demonstrated that CXCL12 promotes hNPC survival in the events of camptothecin-induced apoptosis or growth factor deprivation, and that this effect requires both CXCR7 and CXCR4.	Camptothecin	105-117	C-X-C motif chemokine ligand 12	Homo sapiens	58-64
22983061-5	2012	Aberrations of the Mre11-Rad50-Nbs1 (MRN) complex sensitized cancer cells to PARP-1i, while p53 status was less predictive, even in response to PARP-1i combinations with camptothecin or ionizing radiation.	Camptothecin	170-182	RAD50 double strand break repair protein	Homo sapiens	25-30
22983061-5	2012	Aberrations of the Mre11-Rad50-Nbs1 (MRN) complex sensitized cancer cells to PARP-1i, while p53 status was less predictive, even in response to PARP-1i combinations with camptothecin or ionizing radiation.	Camptothecin	170-182	nibrin	Homo sapiens	31-35
22802092-5	2012	The potentiation of UPR was also detected in HEK293/tau cells treated with other ER stress inducers, including staurosporine, camptothecin and hydrogen peroxide, in which a suppressed apoptosis was also shown.	Camptothecin	126-138	microtubule associated protein tau	Homo sapiens	52-55
22976371-3	2012	This work therefore focuses on an exact evaluation of caspase-3 FMK inhibition dynamics in camptothecin-induced mesenchymal micromasses.	Camptothecin	91-103	caspase 3	Homo sapiens	54-63
23050233-7	2012	Strengthening the connections between NAB3 and ESA1, mutants of nab3 displayed several phenotypes similar to those of esa1 mutants, including increased sensitivity to the topoisomerase I inhibitor camptothecin and defects in rDNA silencing and cell-cycle progression.	Camptothecin	197-209	Nab3p	Saccharomyces cerevisiae S288C	64-68
23052275-13	2012	In this protocol we describe the use of 2- and 3-D live cell imaging to visualize the formation of 53BP1 foci in response to the DNA damaging agent camptothecin (CPT), as well as 53BP1"s behavior during mitosis.	Camptothecin	148-160	tumor protein p53 binding protein 1	Homo sapiens	99-104
22871320-4	2012	In this study, we demonstrate that genotoxic agents (doxorubicin, camptothecin, etoposide and cisplatin), alter the balance between CDC25C splice variants in human breast cancer cell lines both at the mRNA and protein levels.	Camptothecin	66-78	cell division cycle 25C	Homo sapiens	132-138
22960744-8	2012	The function of Fun30 in resection facilitates the repair of camptothecin-induced DNA lesions, although it becomes dispensable when Exo1 is ectopically overexpressed.	Camptothecin	61-73	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	16-21
23052275-13	2012	In this protocol we describe the use of 2- and 3-D live cell imaging to visualize the formation of 53BP1 foci in response to the DNA damaging agent camptothecin (CPT), as well as 53BP1"s behavior during mitosis.	Camptothecin	162-165	tumor protein p53 binding protein 1	Homo sapiens	99-104
22960744-8	2012	The function of Fun30 in resection facilitates the repair of camptothecin-induced DNA lesions, although it becomes dispensable when Exo1 is ectopically overexpressed.	Camptothecin	61-73	exonuclease 1	Homo sapiens	132-136
22565810-6	2012	Confirming these network data, we observed that cells with reduced levels of icb-1 exhibited an impaired response to the apoptosis inducers tamoxifen, staurosporine, actinomycin, and camptothecin.	Camptothecin	183-195	thymocyte selection associated family member 2	Homo sapiens	77-82
22960744-10	2012	The loss of SMARCAD1 impairs end resection and recombinational DNA repair, and renders cells hypersensitive to DNA damage resulting from camptothecin or poly(ADP-ribose) polymerase inhibitor treatments.	Camptothecin	137-149	SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1	Homo sapiens	12-20
22158045-5	2012	Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT).	Camptothecin	212-224	sulfatase 2	Homo sapiens	10-15
22158045-5	2012	Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT).	Camptothecin	212-224	ISG15 ubiquitin like modifier	Homo sapiens	132-137
22158045-5	2012	Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT).	Camptothecin	226-229	sulfatase 2	Homo sapiens	10-15
22701020-9	2012	p38 activation was found to mediate camptothecin-induced apoptosis.	Camptothecin	36-48	mitogen-activated protein kinase 14	Homo sapiens	0-3
22701020-10	2012	Finally, human coronary artery endothelial cells pretreated with EMP inhibited camptothecin-induced p38 activation.	Camptothecin	79-91	mitogen-activated protein kinase 14	Homo sapiens	100-103
22587838-9	2012	Camptothecin, which interrupts the regulation of Rad51 by HSF4, also affects DNA damage repair.	Camptothecin	0-12	RAD51 recombinase	Danio rerio	49-54
22587838-9	2012	Camptothecin, which interrupts the regulation of Rad51 by HSF4, also affects DNA damage repair.	Camptothecin	0-12	heat shock transcription factor 4	Danio rerio	58-62
22578086-5	2012	Treatment of cells with CPT (camptothecin) and HU (hydroxyurea), which cause DSB DNA damage and replication fork collapse respectively and also leads to the disruption of RPA-XPA complex.	Camptothecin	24-27	replication protein A1	Homo sapiens	171-174
22578086-5	2012	Treatment of cells with CPT (camptothecin) and HU (hydroxyurea), which cause DSB DNA damage and replication fork collapse respectively and also leads to the disruption of RPA-XPA complex.	Camptothecin	24-27	XPA, DNA damage recognition and repair factor	Homo sapiens	175-178
22578086-5	2012	Treatment of cells with CPT (camptothecin) and HU (hydroxyurea), which cause DSB DNA damage and replication fork collapse respectively and also leads to the disruption of RPA-XPA complex.	Camptothecin	29-41	replication protein A1	Homo sapiens	171-174
22578086-5	2012	Treatment of cells with CPT (camptothecin) and HU (hydroxyurea), which cause DSB DNA damage and replication fork collapse respectively and also leads to the disruption of RPA-XPA complex.	Camptothecin	29-41	XPA, DNA damage recognition and repair factor	Homo sapiens	175-178
22927825-4	2012	slx-1 mutants exhibit hypersensitivity to UV, nitrogen mustard, and camptothecin, but not gamma irradiation.	Camptothecin	68-80	Structure-specific endonuclease subunit SLX1 homolog	Caenorhabditis elegans	0-5
22691701-5	2012	We utilized ECSTASY to rapidly generate human beta-glucuronidase variants for cancer therapy by antibody-directed enzyme prodrug therapy with up to 30-fold greater potency to catalyze the hydrolysis of the clinically relevant camptothecin anti-cancer prodrug as compared with wild-type human beta-glucuronidase.	Camptothecin	226-238	glucuronidase beta	Homo sapiens	46-64
22645136-3	2012	Here, we identified a BRC repeat variant, named BRCv, in the RECQL5 helicase, which possesses anti-recombinase activity in vitro and suppresses HR and promotes cellular resistance to camptothecin-induced replication stress in vivo.	Camptothecin	183-195	RecQ like helicase 5	Homo sapiens	61-67
22645136-5	2012	Mutations of either motif compromised functions of RECQL5, including association with RAD51, inhibition of RAD51-mediated D-loop formation, suppression of sister chromatid exchange, and resistance to camptothecin-induced replication stress.	Camptothecin	200-212	RecQ like helicase 5	Homo sapiens	51-57
22647487-1	2012	Recently we have shown that the mitogen-activated protein kinase (MAPK) MAPK14/p38alpha is involved in resistance of colon cancer cells to camptothecin-related drugs.	Camptothecin	139-151	mitogen-activated protein kinase 14	Homo sapiens	72-78
22647487-1	2012	Recently we have shown that the mitogen-activated protein kinase (MAPK) MAPK14/p38alpha is involved in resistance of colon cancer cells to camptothecin-related drugs.	Camptothecin	139-151	mitogen-activated protein kinase 14	Homo sapiens	79-87
22647487-7	2012	Our results highlight the existence of a new mechanism of resistance to camptothecin-related drugs: upon SN38 induction, MAPK14/p38alpha is activated and triggers survival-promoting autophagy to protect tumor cells against the cytotoxic effects of the drug.	Camptothecin	72-84	mitogen-activated protein kinase 14	Homo sapiens	121-127
22647487-7	2012	Our results highlight the existence of a new mechanism of resistance to camptothecin-related drugs: upon SN38 induction, MAPK14/p38alpha is activated and triggers survival-promoting autophagy to protect tumor cells against the cytotoxic effects of the drug.	Camptothecin	72-84	mitogen-activated protein kinase 14	Homo sapiens	128-136
22792074-7	2012	This conclusion was based on the finding that FANCJ and its acetylation were required for robust RPA foci formation, RPA phosphorylation, and Rad51 foci formation in response to camptothecin (CPT).	Camptothecin	178-190	BRCA1 interacting helicase 1	Homo sapiens	46-51
22792074-7	2012	This conclusion was based on the finding that FANCJ and its acetylation were required for robust RPA foci formation, RPA phosphorylation, and Rad51 foci formation in response to camptothecin (CPT).	Camptothecin	178-190	RAD51 recombinase	Homo sapiens	142-147
22792074-7	2012	This conclusion was based on the finding that FANCJ and its acetylation were required for robust RPA foci formation, RPA phosphorylation, and Rad51 foci formation in response to camptothecin (CPT).	Camptothecin	192-195	BRCA1 interacting helicase 1	Homo sapiens	46-51
22792074-7	2012	This conclusion was based on the finding that FANCJ and its acetylation were required for robust RPA foci formation, RPA phosphorylation, and Rad51 foci formation in response to camptothecin (CPT).	Camptothecin	192-195	RAD51 recombinase	Homo sapiens	142-147
22490701-0	2012	Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCdelta-independent pathway.	Camptothecin	22-34	protein kinase C delta	Homo sapiens	194-202
22490701-10	2012	The combinatory treatment of camptothecin and rottlerin induced conformational change and activation of Bax and formation of truncated Bad, suggesting the contribution of mitochondria stress to apoptosis.	Camptothecin	29-41	BCL2 associated X, apoptosis regulator	Homo sapiens	104-107
22691701-5	2012	We utilized ECSTASY to rapidly generate human beta-glucuronidase variants for cancer therapy by antibody-directed enzyme prodrug therapy with up to 30-fold greater potency to catalyze the hydrolysis of the clinically relevant camptothecin anti-cancer prodrug as compared with wild-type human beta-glucuronidase.	Camptothecin	226-238	glucuronidase beta	Homo sapiens	292-310
22528748-6	2012	The FRET-based CE system is composed of a homemade CE system and a laser source for detecting the dynamics of caspase-3 in various cells expressing sensors of caspase-3 that have been treated with anticancer drugs, such as cell cycle-independent drug cisplatin and specific cell cycle drugs camptothecin and etoposide, as well as their combination with tumor necrosis factor (TNF).	Camptothecin	291-303	caspase 3	Homo sapiens	110-119
22056880-5	2012	In addition, Bax deficiency only provides partial protection against camptothecin and cisplatin-induced apoptosis and no protection against killing by Puma or ABT-737 plus Noxa overexpression.	Camptothecin	69-81	BCL2 associated X, apoptosis regulator	Homo sapiens	13-16
22544741-3	2012	Accordingly, an enhanced phosphorylation of FAK at Tyr-397, Tyr-576, and Tyr-861 was detected upon genotoxic stress by camptothecin in ADAM15-transfected T/C28a4 cells, but not in transfectants expressing an ADAM15 mutant without the cytoplasmic tail.	Camptothecin	119-131	protein tyrosine kinase 2	Homo sapiens	44-47
22544741-3	2012	Accordingly, an enhanced phosphorylation of FAK at Tyr-397, Tyr-576, and Tyr-861 was detected upon genotoxic stress by camptothecin in ADAM15-transfected T/C28a4 cells, but not in transfectants expressing an ADAM15 mutant without the cytoplasmic tail.	Camptothecin	119-131	ADAM metallopeptidase domain 15	Homo sapiens	135-141
22544741-3	2012	Accordingly, an enhanced phosphorylation of FAK at Tyr-397, Tyr-576, and Tyr-861 was detected upon genotoxic stress by camptothecin in ADAM15-transfected T/C28a4 cells, but not in transfectants expressing an ADAM15 mutant without the cytoplasmic tail.	Camptothecin	119-131	ADAM metallopeptidase domain 15	Homo sapiens	208-214
22544741-5	2012	In cells expressing full-length ADAM15, a concomitant activation of Src at Tyr-416 was detected upon camptothecin exposure.	Camptothecin	101-113	ADAM metallopeptidase domain 15	Homo sapiens	32-38
22544741-5	2012	In cells expressing full-length ADAM15, a concomitant activation of Src at Tyr-416 was detected upon camptothecin exposure.	Camptothecin	101-113	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	68-71
22619121-6	2012	At the end of the screening, we found that the compounds pinafide, ellipticine and camptothecin inhibited B-Myb transcriptional activity in luciferase assays.	Camptothecin	83-95	MYB proto-oncogene like 2	Homo sapiens	106-111
22619121-8	2012	We found that neuroblastoma cells with amplification of MYCN are more sensitive than MYCN negative cells to camptothecin and topotecan killing.	Camptothecin	108-120	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	56-60
22619121-8	2012	We found that neuroblastoma cells with amplification of MYCN are more sensitive than MYCN negative cells to camptothecin and topotecan killing.	Camptothecin	108-120	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	85-89
22619121-10	2012	Notably, forced overexpression of B-Myb could antagonize the killing effect of topotecan and camptothecin, demonstrating that the transcription factor is a key target of the drugs.	Camptothecin	93-105	MYB proto-oncogene like 2	Homo sapiens	34-39
22619121-11	2012	These results suggest that camptothecin and its analogues should be more effective in patients whose tumours feature amplification of MYCN and/or overexpression of B-MYB.	Camptothecin	27-39	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	134-138
22619121-11	2012	These results suggest that camptothecin and its analogues should be more effective in patients whose tumours feature amplification of MYCN and/or overexpression of B-MYB.	Camptothecin	27-39	MYB proto-oncogene like 2	Homo sapiens	164-169
22528748-6	2012	The FRET-based CE system is composed of a homemade CE system and a laser source for detecting the dynamics of caspase-3 in various cells expressing sensors of caspase-3 that have been treated with anticancer drugs, such as cell cycle-independent drug cisplatin and specific cell cycle drugs camptothecin and etoposide, as well as their combination with tumor necrosis factor (TNF).	Camptothecin	291-303	caspase 3	Homo sapiens	159-168
22537405-4	2012	SRF-VP16 suppressed active caspase 3 abundance in vitro and enhanced neuron survival upon camptothecin induced apoptosis.	Camptothecin	90-102	serum response factor	Homo sapiens	0-3
22537405-4	2012	SRF-VP16 suppressed active caspase 3 abundance in vitro and enhanced neuron survival upon camptothecin induced apoptosis.	Camptothecin	90-102	host cell factor C1	Homo sapiens	4-8
22524618-2	2012	PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT).	Camptothecin	134-146	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
21927023-4	2012	In this report, we demonstrate that ATF3 is required for efficient DR5 induction upon DNA damage by camptothecin (CPT) in colorectal cancer cells.	Camptothecin	100-112	activating transcription factor 3	Homo sapiens	36-40
21927023-4	2012	In this report, we demonstrate that ATF3 is required for efficient DR5 induction upon DNA damage by camptothecin (CPT) in colorectal cancer cells.	Camptothecin	100-112	TNF receptor superfamily member 10b	Homo sapiens	67-70
21927023-4	2012	In this report, we demonstrate that ATF3 is required for efficient DR5 induction upon DNA damage by camptothecin (CPT) in colorectal cancer cells.	Camptothecin	114-117	activating transcription factor 3	Homo sapiens	36-40
21927023-4	2012	In this report, we demonstrate that ATF3 is required for efficient DR5 induction upon DNA damage by camptothecin (CPT) in colorectal cancer cells.	Camptothecin	114-117	TNF receptor superfamily member 10b	Homo sapiens	67-70
22524618-2	2012	PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT).	Camptothecin	148-151	poly(ADP-ribose) polymerase 1	Homo sapiens	0-4
22524618-17	2012	The combination of olaparib and CPT had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor could be promising for clinical radiosensitization.	Camptothecin	32-35	poly(ADP-ribose) polymerase 1	Homo sapiens	104-108
22245938-1	2012	Camptothecin (CPT) exhibits very strong antitumor effects by inhibiting the activity of DNA topoisomerase I, but its application is greatly limited due to its low solubility and the instability of the active lactone form.	Camptothecin	0-12	topoisomerase (DNA) I	Mus musculus	88-107
22375014-4	2012	We found that Tdp1-/- cells were not only hypersensitive to camptothecin and bleomycin but also to etoposide, methyl methanesulfonate (MMS), H(2)O(2), and ionizing radiation.	Camptothecin	60-72	tyrosyl-DNA phosphodiesterase 1	Gallus gallus	14-18
22245938-1	2012	Camptothecin (CPT) exhibits very strong antitumor effects by inhibiting the activity of DNA topoisomerase I, but its application is greatly limited due to its low solubility and the instability of the active lactone form.	Camptothecin	14-17	topoisomerase (DNA) I	Mus musculus	88-107
22266724-0	2012	Differential sensitivity of RIP3-proficient and deficient murine fibroblasts to camptothecin anticancer drugs.	Camptothecin	80-92	receptor-interacting serine-threonine kinase 3	Mus musculus	28-32
22114138-11	2012	Clonogenic cell survival following a series of DNA damaging agents was variable: PTEN-deficient cells were sensitive to ionizing radiation, mitomycin-C, UV, H(2)O(2), and methyl methanesulfonate but not to cisplatin, camptothecin, or paclitaxel.	Camptothecin	217-229	phosphatase and tensin homolog	Homo sapiens	81-85
22194613-3	2012	Here we report that cellular exposure to UV irradiation, camptothecin, or hydroxyurea induces accumulation of HDHB on chromatin in a dose- and time-dependent manner, preferentially in S phase cells.	Camptothecin	57-69	DNA helicase B	Homo sapiens	110-114
22183159-6	2012	The platform was also used to determine the toxic impact of the alkaloid camptothecin on the intracellular enzyme glucose-6-phosphate dehydrogenase levels.	Camptothecin	73-85	glucose-6-phosphate dehydrogenase	Homo sapiens	114-147
22158865-3	2012	In this study we evaluated the ability of the PARP inhibitor veliparib to enhance the cytotoxicity of the topoisomerase I poisons topotecan and camptothecin (CPT).	Camptothecin	144-156	poly (ADP-ribose) polymerase family, member 1	Mus musculus	46-50
22158865-3	2012	In this study we evaluated the ability of the PARP inhibitor veliparib to enhance the cytotoxicity of the topoisomerase I poisons topotecan and camptothecin (CPT).	Camptothecin	158-161	poly (ADP-ribose) polymerase family, member 1	Mus musculus	46-50
22051412-0	2012	Binding interactions of water-soluble camptothecin derivatives with bovine serum albumin.	Camptothecin	38-50	albumin	Homo sapiens	75-88
21786128-3	2012	At the cellular level, WRN loss results in rapid replicative senescence, chromosomal instability and sensitivity to various DNA damaging agents including the topoisomerase inhibitor, camptothecin (CPT).	Camptothecin	183-195	WRN RecQ like helicase	Homo sapiens	23-26
21786128-3	2012	At the cellular level, WRN loss results in rapid replicative senescence, chromosomal instability and sensitivity to various DNA damaging agents including the topoisomerase inhibitor, camptothecin (CPT).	Camptothecin	197-200	WRN RecQ like helicase	Homo sapiens	23-26
21786128-6	2012	Such WS-like phenotypes are observed despite very limited decreases in total WRN protein, suggesting that levels of WRN protein are rate-limiting for the cellular response to camptothecin.	Camptothecin	175-187	WRN RecQ like helicase	Homo sapiens	116-119
21786128-0	2012	Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease.	Camptothecin	49-61	WRN RecQ like helicase	Homo sapiens	90-93
22051412-1	2012	In this study, the binding interactions of the water-soluble camptothecin derivatives hydroxycamptothecin (10-HCPT), topotecan (TPT), and camptothecin quaternary salt (CPT8), to bovine serum albumin (BSA) were determined using fluorescence spectra and UV-vis spectra.	Camptothecin	61-73	albumin	Homo sapiens	185-198
22359452-9	2012	Furthermore, higher tumor killing efficiency was observed in response to treatment with PEG-modified lipid nanoparticles encapsulating gold porphyrin or camptothecin when compared with free gold porphyrin or free camptothecin.	Camptothecin	153-165	progestagen associated endometrial protein	Homo sapiens	88-91
21901246-3	2012	Here, we show that DEXI methylation is implicated in mechanisms facilitating resistance             to camptothecin (CPT) via inhibition of apoptosis.	Camptothecin	103-115	Dexi homolog	Homo sapiens	19-23
21901246-3	2012	Here, we show that DEXI methylation is implicated in mechanisms facilitating resistance             to camptothecin (CPT) via inhibition of apoptosis.	Camptothecin	117-120	Dexi homolog	Homo sapiens	19-23
22359452-9	2012	Furthermore, higher tumor killing efficiency was observed in response to treatment with PEG-modified lipid nanoparticles encapsulating gold porphyrin or camptothecin when compared with free gold porphyrin or free camptothecin.	Camptothecin	213-225	progestagen associated endometrial protein	Homo sapiens	88-91
22510597-1	2012	Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase (DPYD), partially inhibits homologous recombination (HR) repair and has a radiosensitizing effect as well as enhanced sensitivity to Camptothecin (CPT).	Camptothecin	192-204	dihydropyrimidine dehydrogenase	Homo sapiens	60-64
22510597-1	2012	Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase (DPYD), partially inhibits homologous recombination (HR) repair and has a radiosensitizing effect as well as enhanced sensitivity to Camptothecin (CPT).	Camptothecin	206-209	dihydropyrimidine dehydrogenase	Homo sapiens	60-64
22510597-9	2012	DPYD depletion showed a radiosensitizing effect as well as enhanced sensitivity to CPT.	Camptothecin	83-86	dihydropyrimidine dehydrogenase	Homo sapiens	0-4
22675465-6	2012	Furthermore, treatment of U2OS cells with 15 microM of the Topoisomerase I inhibitor, camptothecin, causes the dissociation of the nucleolin-Werner complex in the nucleolus, followed by partial re-association in the nucleoplasm.	Camptothecin	86-98	nucleolin	Homo sapiens	131-140
22675468-5	2012	Upon loss of CLPTM1L accumulation in lung tumor cells, cisplatin and camptothecin induced apoptosis were increased in direct proportion to the level of CLPTM1L knockdown.	Camptothecin	69-81	CLPTM1 like	Homo sapiens	13-20
21756949-1	2011	Here we report the design, synthesis and biological evaluation of surface-modified silica nanoparticles (SNP) for the delivery of camptothecin (CPT).	Camptothecin	130-142	choline phosphotransferase 1	Homo sapiens	144-147
22039049-2	2011	Here, we show that MRE11-RAD50 cleaves the covalent 3"-phosphotyrosyl-DNA bonds that join topoisomerase 1 (Top1) to the DNA backbone and that are the hallmark of damage caused by Top1 poisons such as camptothecin.	Camptothecin	200-212	MRE11 homolog, double strand break repair nuclease	Homo sapiens	19-24
22039049-2	2011	Here, we show that MRE11-RAD50 cleaves the covalent 3"-phosphotyrosyl-DNA bonds that join topoisomerase 1 (Top1) to the DNA backbone and that are the hallmark of damage caused by Top1 poisons such as camptothecin.	Camptothecin	200-212	RAD50 double strand break repair protein	Homo sapiens	25-30
22071521-0	2011	Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.	Camptothecin	0-12	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	43-85
22071521-0	2011	Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.	Camptothecin	0-12	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	87-95
22071521-0	2011	Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.	Camptothecin	0-12	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	114-122
22071521-0	2011	Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.	Camptothecin	0-12	DNA topoisomerase I	Homo sapiens	123-138
22071521-0	2011	Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.	Camptothecin	14-17	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	43-85
22071521-0	2011	Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.	Camptothecin	14-17	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	87-95
22071521-0	2011	Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.	Camptothecin	14-17	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	114-122
22071521-0	2011	Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.	Camptothecin	14-17	DNA topoisomerase I	Homo sapiens	123-138
22071521-1	2011	Camptothecin (CPT) is an anti-tumor natural product that forms a ternary complex with topoisomerase I (top I) and DNA (CPT-top I-DNA).	Camptothecin	0-12	DNA topoisomerase I	Homo sapiens	86-101
22071521-1	2011	Camptothecin (CPT) is an anti-tumor natural product that forms a ternary complex with topoisomerase I (top I) and DNA (CPT-top I-DNA).	Camptothecin	0-12	DNA topoisomerase I	Homo sapiens	103-108
22071521-1	2011	Camptothecin (CPT) is an anti-tumor natural product that forms a ternary complex with topoisomerase I (top I) and DNA (CPT-top I-DNA).	Camptothecin	0-12	DNA topoisomerase I	Homo sapiens	123-128
22071521-1	2011	Camptothecin (CPT) is an anti-tumor natural product that forms a ternary complex with topoisomerase I (top I) and DNA (CPT-top I-DNA).	Camptothecin	14-17	DNA topoisomerase I	Homo sapiens	86-101
22071521-1	2011	Camptothecin (CPT) is an anti-tumor natural product that forms a ternary complex with topoisomerase I (top I) and DNA (CPT-top I-DNA).	Camptothecin	14-17	DNA topoisomerase I	Homo sapiens	103-108
22071521-1	2011	Camptothecin (CPT) is an anti-tumor natural product that forms a ternary complex with topoisomerase I (top I) and DNA (CPT-top I-DNA).	Camptothecin	14-17	DNA topoisomerase I	Homo sapiens	123-128
21943824-9	2011	Immunohistochemistry staining of tumor tissues with CD34 revealed that MVD positive cells were significantly reduced in CPT-loaded PCEC microspheres treated group in contrast to other groups (P<0.05).	Camptothecin	120-123	CD34 antigen	Mus musculus	52-56
22090490-5	2011	During apoptosis of NSC34 cells induced by camptothecin, levels of Dnmt1 and Dnmt3a increased fivefold and twofold, respectively, and 5-methylcytosine accumulated in nuclei.	Camptothecin	43-55	DNA methyltransferase (cytosine-5) 1	Mus musculus	67-72
21921034-8	2011	PP5(-/-) mouse embryonic fibroblasts demonstrated increased sensitivity to UV light, hydroxyurea, and camptothecin, which are known activators of ATR (ataxia-telangiectasia and Rad3-related) kinase.	Camptothecin	102-114	protein phosphatase 5, catalytic subunit	Mus musculus	0-3
21921034-8	2011	PP5(-/-) mouse embryonic fibroblasts demonstrated increased sensitivity to UV light, hydroxyurea, and camptothecin, which are known activators of ATR (ataxia-telangiectasia and Rad3-related) kinase.	Camptothecin	102-114	ataxia telangiectasia and Rad3 related	Mus musculus	146-149
21921034-8	2011	PP5(-/-) mouse embryonic fibroblasts demonstrated increased sensitivity to UV light, hydroxyurea, and camptothecin, which are known activators of ATR (ataxia-telangiectasia and Rad3-related) kinase.	Camptothecin	102-114	ataxia telangiectasia and Rad3 related	Mus musculus	151-190
22090490-5	2011	During apoptosis of NSC34 cells induced by camptothecin, levels of Dnmt1 and Dnmt3a increased fivefold and twofold, respectively, and 5-methylcytosine accumulated in nuclei.	Camptothecin	43-55	DNA methyltransferase 3A	Mus musculus	77-83
25419505-0	2011	Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles.	Camptothecin	77-89	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	14-19
22005580-4	2011	To this end, we examined Myc induction by the neurotoxic agents camptothecin and amyloid-beta peptide in a differentiated SH-SY5Y neuronal cell culture model.	Camptothecin	64-76	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	25-28
22059741-15	2011	The apoptotic inducers including actinomycin D, camptothecin and etoposide are also the chemotherapeutic drugs in clinical cancer therapy and PTMA siRNA can accelerate apoptotic progression in cells treated with those apoptosis inducers.	Camptothecin	48-60	prothymosin alpha	Homo sapiens	142-146
21809047-0	2011	Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells.	Camptothecin	0-12	tumor protein p53	Homo sapiens	21-24
21876003-3	2011	In this study, we show that yKu70 deficiency suppressed the camptothecin (CPT) and methyl methanesulfonate (MMS) sensitivity of nuclease-deficient mre11-3 and sae2Delta mutants in an Exo1-dependent manner.	Camptothecin	60-72	ATP-dependent DNA helicase YKU70	Saccharomyces cerevisiae S288C	28-33
21876003-3	2011	In this study, we show that yKu70 deficiency suppressed the camptothecin (CPT) and methyl methanesulfonate (MMS) sensitivity of nuclease-deficient mre11-3 and sae2Delta mutants in an Exo1-dependent manner.	Camptothecin	60-72	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	147-152
21876003-3	2011	In this study, we show that yKu70 deficiency suppressed the camptothecin (CPT) and methyl methanesulfonate (MMS) sensitivity of nuclease-deficient mre11-3 and sae2Delta mutants in an Exo1-dependent manner.	Camptothecin	74-77	ATP-dependent DNA helicase YKU70	Saccharomyces cerevisiae S288C	28-33
21876003-3	2011	In this study, we show that yKu70 deficiency suppressed the camptothecin (CPT) and methyl methanesulfonate (MMS) sensitivity of nuclease-deficient mre11-3 and sae2Delta mutants in an Exo1-dependent manner.	Camptothecin	74-77	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	147-152
21876003-4	2011	CPT-induced G(2)/M arrest, gamma-H2AX persistence, and chromosome breaks were elevated in mre11-3 mutants.	Camptothecin	0-3	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	90-95
21210765-0	2011	RECQL5 is an important determinant for camptothecin tolerance in human colorectal cancer cells.	Camptothecin	39-51	RecQ like helicase 5	Homo sapiens	0-6
25419505-0	2011	Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles.	Camptothecin	77-89	phosphatase and tensin homolog	Mus musculus	25-29
21875750-6	2011	We also demonstrate that DR5-targeted nanoparticles encapsulating the cytotoxic drug camptothecin are effectively targeted to the tumour cells, thereby producing enhanced cytotoxic effects through simultaneous drug delivery and apoptosis induction.	Camptothecin	85-97	TNF receptor superfamily member 10b	Homo sapiens	25-28
21914943-8	2011	Moreover, plain NOBs were biocompatible whereas CPT-loaded NOBs exerted a strong cytotoxic effect on HER2/neu-positive cells in vitro.	Camptothecin	48-51	erb-b2 receptor tyrosine kinase 2	Mus musculus	101-105
21698776-4	2011	Here, reversible hydrolysis to the ring-open carboxylate forms of CPT and TCPT was studied by HPLC, both in the presence and absence of human serum albumin (HSA).	Camptothecin	66-69	albumin	Homo sapiens	142-155
21064109-8	2011	Further, gal-4 sensitized the cells to camptothecin-induced apoptosis.	Camptothecin	39-51	galectin 4	Homo sapiens	9-14
21850716-0	2011	Total synthesis of 7-ethyl-10-hydroxycamptothecin (SN38) and its application to the development of C18-functionalized camptothecin derivatives.	Camptothecin	37-49	Bardet-Biedl syndrome 9	Homo sapiens	99-102
21710255-6	2011	When comparing exponentially growing Swiss3T3 cells to those synchronized to enter S-phase simultaneously and treated with the DNA damaging agent camptothecin, we found that with cells in S-phase, p53 protein levels increased earlier, Bax and p21 transcription was activated earlier and to a greater extent and apoptosis occurred earlier and to a greater extent.	Camptothecin	146-158	transformation related protein 53, pseudogene	Mus musculus	197-200
21710255-6	2011	When comparing exponentially growing Swiss3T3 cells to those synchronized to enter S-phase simultaneously and treated with the DNA damaging agent camptothecin, we found that with cells in S-phase, p53 protein levels increased earlier, Bax and p21 transcription was activated earlier and to a greater extent and apoptosis occurred earlier and to a greater extent.	Camptothecin	146-158	BCL2-associated X protein	Mus musculus	235-238
21710255-6	2011	When comparing exponentially growing Swiss3T3 cells to those synchronized to enter S-phase simultaneously and treated with the DNA damaging agent camptothecin, we found that with cells in S-phase, p53 protein levels increased earlier, Bax and p21 transcription was activated earlier and to a greater extent and apoptosis occurred earlier and to a greater extent.	Camptothecin	146-158	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	243-246
21843105-5	2011	Tdp1 inhibitors should synergize not only with Top1-targeting drugs (camptothecins, indenoisoquinolines), but also with bleomycin, topoisomerase II (Top2) inhibitors (etoposide, doxorubicin) and DNA alkylating agents.	Camptothecin	69-82	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-4
21807966-4	2011	The persistent DNA damage correlated to increased apoptosis and reduced survival of FIP200 knockout (KO) MEFs after treatments with camptothecin (CPT), a topoisomerase I inhibitor and chemotherapeutic agent.	Camptothecin	132-144	RB1 inducible coiled-coil 1	Homo sapiens	84-90
21820409-0	2011	Protein kinase Ceta activates NF-kappaB in response to camptothecin-induced DNA damage.	Camptothecin	55-67	nuclear factor kappa B subunit 1	Homo sapiens	30-39
21820409-5	2011	Furthermore, PKCeta enhances the nuclear translocation and transactivation of NF-kappaB under non-stressed conditions and in response to the anticancer drug camptothecin.	Camptothecin	157-169	nuclear factor kappa B subunit 1	Homo sapiens	78-87
21423215-0	2011	Camptothecin-induced downregulation of MLL5 contributes to the activation of tumor suppressor p53.	Camptothecin	0-12	lysine (K)-specific methyltransferase 2E	Danio rerio	39-43
21423215-0	2011	Camptothecin-induced downregulation of MLL5 contributes to the activation of tumor suppressor p53.	Camptothecin	0-12	tumor protein p53	Danio rerio	94-97
21423215-2	2011	In this study, we present evidence that MLL5 is involved in the camptothecin (CPT)-induced p53 activation.	Camptothecin	64-76	lysine (K)-specific methyltransferase 2E	Danio rerio	40-44
21423215-2	2011	In this study, we present evidence that MLL5 is involved in the camptothecin (CPT)-induced p53 activation.	Camptothecin	64-76	tumor protein p53	Danio rerio	91-94
21423215-2	2011	In this study, we present evidence that MLL5 is involved in the camptothecin (CPT)-induced p53 activation.	Camptothecin	78-81	lysine (K)-specific methyltransferase 2E	Danio rerio	40-44
21423215-2	2011	In this study, we present evidence that MLL5 is involved in the camptothecin (CPT)-induced p53 activation.	Camptothecin	78-81	tumor protein p53	Danio rerio	91-94
21086148-9	2011	Interestingly, calpain 2 appears to be involved in ionomycin-induced protection from camptothecin-induced cytotoxicity.	Camptothecin	85-97	calpain 2	Homo sapiens	15-24
21693595-9	2011	Reintroduction of histone H2AX in miR-138 overexpressing cells attenuated miR-138-mediated sensitization to cisplatin and camptothecin.	Camptothecin	122-134	H2A.X variant histone	Homo sapiens	18-30
21599019-3	2011	As a single compound, C3G (100 muM) decreased the DNA-damaging effects of CPT as well, but did not significantly affect those induced by DOX.	Camptothecin	74-77	latexin	Homo sapiens	31-34
21439410-5	2011	In the present study, this nanosystem is modified for targeted delivery of an anticancer agent (encapsulated camptothecin (CPT)) to cancer cells overexpressing epithelial growth factor receptor (EGFR) with accurate intracellular drug release.	Camptothecin	109-121	epidermal growth factor receptor	Homo sapiens	160-193
21439410-5	2011	In the present study, this nanosystem is modified for targeted delivery of an anticancer agent (encapsulated camptothecin (CPT)) to cancer cells overexpressing epithelial growth factor receptor (EGFR) with accurate intracellular drug release.	Camptothecin	109-121	epidermal growth factor receptor	Homo sapiens	195-199
21482670-6	2011	The hypersensitivity to both camptothecin and a PARP inhibitor suggests that the USP1/UAF1 complex promotes homologous recombination (HR)-mediated double-strand break (DSB) repair.	Camptothecin	29-41	ubiquitin specific peptidase 1	Gallus gallus	81-85
21709444-0	2011	A novel Rad18 ubiqitin ligase-mediated pathway for repair of camptothecin-induced DNA damage.	Camptothecin	61-73	RAD18 E3 ubiquitin protein ligase	Homo sapiens	8-13
21595014-4	2011	DNA damage in human pulmonary adenocarcinoma A549 cells was induced by treatment with the DNA topoisomerase I inhibitor camptothecin and phosphorylation of histone H2AX on Ser139 (gammaH2AX) and of ATM on Ser1981 was detected with phospho-specific Abs; cellular fluorescence was measured by laser scanning cytometry (LSC).	Camptothecin	120-132	ATM serine/threonine kinase	Homo sapiens	198-201
21515332-9	2011	Additive activity of proliferation inhibition and activation of caspase-3 by limonoids was observed when combined with camptothecin, demonstrating the induction of apoptosis.	Camptothecin	119-131	caspase 3	Homo sapiens	64-73
21478670-3	2011	We show here that the FA core complex protein FANCA and monoubiquitinated FANCD2 (an effector of the FA pathway) are rapidly mobilized to chromatin in response to CPT treatment in several human cancer cell lines and untransformed primary human dermal fibroblasts.	Camptothecin	163-166	FA complementation group A	Homo sapiens	46-51
21595924-1	2011	BACKGROUND: Camptothecin is a plant alkaloid that specifically binds topoisomerase I, inhibiting its activity and inducing double stranded breaks in DNA, activating the cell responses to DNA damage and, in response to severe treatments, triggering cell death.	Camptothecin	12-24	topoisomerase I	Zea mays	69-84
21539811-0	2011	Nek6 suppresses the premature senescence of human cancer cells induced by camptothecin and doxorubicin treatment.	Camptothecin	74-86	NIMA related kinase 6	Homo sapiens	0-4
21539811-4	2011	In this study, we examined the effect of Nek6 overexpression on the premature senescence of cancer cells induced by the anticancer drugs camptothecin (CPT) and doxorubicin (DOX).	Camptothecin	137-149	NIMA related kinase 6	Homo sapiens	41-45
21539811-4	2011	In this study, we examined the effect of Nek6 overexpression on the premature senescence of cancer cells induced by the anticancer drugs camptothecin (CPT) and doxorubicin (DOX).	Camptothecin	151-154	NIMA related kinase 6	Homo sapiens	41-45
21539811-5	2011	We found that CPT- and DOX-induced morphology changes and increases in senescence-associated beta-galactosidase staining were significantly inhibited in EJ human bladder cancer cells and H1299 human lung cancer cells overexpressing HA-Nek6.	Camptothecin	14-17	galactosidase beta 1	Homo sapiens	93-111
21539811-5	2011	We found that CPT- and DOX-induced morphology changes and increases in senescence-associated beta-galactosidase staining were significantly inhibited in EJ human bladder cancer cells and H1299 human lung cancer cells overexpressing HA-Nek6.	Camptothecin	14-17	NIMA related kinase 6	Homo sapiens	235-239
21478670-3	2011	We show here that the FA core complex protein FANCA and monoubiquitinated FANCD2 (an effector of the FA pathway) are rapidly mobilized to chromatin in response to CPT treatment in several human cancer cell lines and untransformed primary human dermal fibroblasts.	Camptothecin	163-166	FA complementation group D2	Homo sapiens	74-80
21333695-0	2011	Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells.	Camptothecin	121-133	mitogen-activated protein kinase 8	Homo sapiens	8-11
21398521-4	2011	Here, we show that GFP-tagged HEL308 localizes to replication forks following camptothecin treatment.	Camptothecin	78-90	helicase, POLQ like	Homo sapiens	30-36
21424556-1	2011	In the present study dopaminergic neuroblastoma B65 cells were exposed to Camptothecin (CPT) (0.5-10 muM), either alone or in the presence of roscovitine (ROSC).	Camptothecin	74-86	latexin	Homo sapiens	101-104
21424556-1	2011	In the present study dopaminergic neuroblastoma B65 cells were exposed to Camptothecin (CPT) (0.5-10 muM), either alone or in the presence of roscovitine (ROSC).	Camptothecin	88-91	latexin	Homo sapiens	101-104
21417227-2	2011	Initial biological studies indicate that psilostachyin C could enhance the sensitivity of the HeLa cell toward camptothecin (CPT) treatment via the activation of the caspase-3 mediated apoptosis pathway.	Camptothecin	125-128	caspase 3	Homo sapiens	166-175
21333695-0	2011	Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells.	Camptothecin	121-133	activating transcription factor 2	Homo sapiens	12-17
21333695-0	2011	Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells.	Camptothecin	121-133	thrombospondin 1	Homo sapiens	43-59
21333695-0	2011	Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells.	Camptothecin	121-133	thrombospondin 1	Homo sapiens	61-66
21333695-4	2011	The set of our data established that camptothecin- and doxorubicin-induced activation of Jun N-terminal kinase/activating transcription factor 2 pathway via de novo ceramide synthesis down-regulates thrombospondin-1 expression and apoptosis in human thyroid carcinoma FTC-133 cells.	Camptothecin	37-49	thrombospondin 1	Homo sapiens	199-215
21402778-5	2011	In vivo, Tel1 activation is enhanced in sae2Delta or mre11-3 mutants after camptothecin treatment; both of these mutants are defective in the removal of topoisomerase I from DNA.	Camptothecin	75-87	DNA-binding protein kinase TEL1	Saccharomyces cerevisiae S288C	9-13
21227924-5	2011	SiRNA knockdown for the endonuclease XPF-ERCC1 reduced the ABT-888-induced gammaH2AX response in non-replicating and replicating cells but enhanced the antiproliferative effect of ABT-888 in CPT-treated cells.	Camptothecin	191-194	ERCC excision repair 4, endonuclease catalytic subunit	Homo sapiens	37-40
21531294-3	2011	The binding of (99m)Tc-His(10)-annexin V to apoptosis was validated in vitro using camptothecin-induced Jurkat cells.	Camptothecin	83-95	annexin A5	Homo sapiens	31-40
21227924-5	2011	SiRNA knockdown for the endonuclease XPF-ERCC1 reduced the ABT-888-induced gammaH2AX response in non-replicating and replicating cells but enhanced the antiproliferative effect of ABT-888 in CPT-treated cells.	Camptothecin	191-194	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	41-46
21456053-5	2011	Luciferase activities were particularly enhanced in mutant strains with mms2 Delta and mag1 Delta by exposure to MMS, rad59 Delta and mlh1 Delta to camptothecin and mms2 Delta and mlh1 Delta to mitomycin C, respectively, compared with their parent strains.	Camptothecin	148-160	DNA-3-methyladenine glycosylase II	Saccharomyces cerevisiae S288C	87-91
21456053-5	2011	Luciferase activities were particularly enhanced in mutant strains with mms2 Delta and mag1 Delta by exposure to MMS, rad59 Delta and mlh1 Delta to camptothecin and mms2 Delta and mlh1 Delta to mitomycin C, respectively, compared with their parent strains.	Camptothecin	148-160	Rad59p	Saccharomyces cerevisiae S288C	118-123
21456053-5	2011	Luciferase activities were particularly enhanced in mutant strains with mms2 Delta and mag1 Delta by exposure to MMS, rad59 Delta and mlh1 Delta to camptothecin and mms2 Delta and mlh1 Delta to mitomycin C, respectively, compared with their parent strains.	Camptothecin	148-160	mismatch repair ATPase MLH1	Saccharomyces cerevisiae S288C	134-138
21456053-5	2011	Luciferase activities were particularly enhanced in mutant strains with mms2 Delta and mag1 Delta by exposure to MMS, rad59 Delta and mlh1 Delta to camptothecin and mms2 Delta and mlh1 Delta to mitomycin C, respectively, compared with their parent strains.	Camptothecin	148-160	mismatch repair ATPase MLH1	Saccharomyces cerevisiae S288C	180-184
21237216-6	2011	Treatment of cells with camptothecin was discovered to increase Snail protein levels, and this increase was diminished in cells with DDX3 knocked down.	Camptothecin	24-36	snail family transcriptional repressor 1	Homo sapiens	64-69
21464892-5	2011	Recombinant KLK6 was shown to significantly reduce cell death under resting conditions and in response to camptothecin, dexamethasone, staurosporine and Fas-ligand.	Camptothecin	106-118	kallikrein related peptidase 6	Homo sapiens	12-16
21237216-6	2011	Treatment of cells with camptothecin was discovered to increase Snail protein levels, and this increase was diminished in cells with DDX3 knocked down.	Camptothecin	24-36	DEAD-box helicase 3 X-linked	Homo sapiens	133-137
21237216-8	2011	Thus, DDX3 is required for basal Snail expression and increases in Snail induced by HDAC inhibitors or camptothecin, indicating that this action of DDX3 may contribute to its promotion of the progression of some cancers.	Camptothecin	103-115	DEAD-box helicase 3 X-linked	Homo sapiens	6-10
21237216-8	2011	Thus, DDX3 is required for basal Snail expression and increases in Snail induced by HDAC inhibitors or camptothecin, indicating that this action of DDX3 may contribute to its promotion of the progression of some cancers.	Camptothecin	103-115	snail family transcriptional repressor 1	Homo sapiens	67-72
21237216-8	2011	Thus, DDX3 is required for basal Snail expression and increases in Snail induced by HDAC inhibitors or camptothecin, indicating that this action of DDX3 may contribute to its promotion of the progression of some cancers.	Camptothecin	103-115	DEAD-box helicase 3 X-linked	Homo sapiens	148-152
21282053-0	2011	Improving anticancer activity and selectivity of camptothecin through conjugation with releasable substance P.	Camptothecin	49-61	tachykinin precursor 1	Homo sapiens	98-109
21145583-11	2011	ATF-3 expression was found only in the nuclear fraction of camptothecin-treated HeLa cultures.	Camptothecin	59-71	activating transcription factor 3	Homo sapiens	0-5
21145583-7	2011	The expression of p53 increased in HeLa cell cultures treated with camptothecin (positive control) for 24h, and the formation of p53Ser15 and p53Ser46 was detected in cell nuclei by Western blotting.	Camptothecin	67-79	tumor protein p53	Homo sapiens	18-21
21145583-7	2011	The expression of p53 increased in HeLa cell cultures treated with camptothecin (positive control) for 24h, and the formation of p53Ser15 and p53Ser46 was detected in cell nuclei by Western blotting.	Camptothecin	67-79	tumor protein p53	Homo sapiens	129-132
21145583-9	2011	Both camptothecin and TEGDMA increased p53 expression to some extent in the nuclear fraction in human transformed pulp-derived cells (tHPC), and similar effects were detected in RAW264.7 macrophages.	Camptothecin	5-17	tumor protein p53	Homo sapiens	39-42
21282053-2	2011	Therefore, we designed and synthesized the substance P targeted camptothecin (CPT) conjugates via a releasable disulfide carbonate linker.	Camptothecin	64-76	tachykinin precursor 1	Homo sapiens	43-54
21282053-2	2011	Therefore, we designed and synthesized the substance P targeted camptothecin (CPT) conjugates via a releasable disulfide carbonate linker.	Camptothecin	78-81	tachykinin precursor 1	Homo sapiens	43-54
22081768-3	2011	Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy.	Camptothecin	190-193	cut like homeobox 1	Homo sapiens	65-68
21135154-3	2011	Ethoxidine, a benzo[c]phenanthridines derivative, camptothecin analogue, has been identified as a potent inhibitor of Top I in various cancer cell lines.	Camptothecin	50-62	DNA topoisomerase I	Homo sapiens	118-123
22081768-3	2011	Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy.	Camptothecin	270-273	cut like homeobox 1	Homo sapiens	65-68
21278449-5	2011	In particular, current studies have revealed the presence of a novel Recql5/RECQL5-dependent mechanism for suppressing replication fork collapse in response to global replication fork stalling following exposure to camptothecin (CPT), a topoisomerase I inhibitor, and a potent inhibitor of DNA replication.	Camptothecin	215-227	RecQ like helicase 5	Homo sapiens	69-75
21182307-7	2011	Camptothecin-sensitive cancer cell lines display high CK2 activity, hyperphosphorylation of topo I, elevated topo I activity, and elevated phosphorylation-dependent complex formation between topo I and p14ARF, a topo I activator.	Camptothecin	0-12	cyclin dependent kinase inhibitor 2A	Homo sapiens	202-208
21082356-6	2011	Using this approach, we have been able to monitor caspase-3 activation and subsequent apoptosis induction after camptothecin and temozolomide treatment on xenograft mouse models of colon cancer and glioblastoma, respectively.	Camptothecin	112-124	caspase 3	Mus musculus	50-59
21266351-4	2011	The nucleolar localization of hPuf-A would redistribute to the nucleoplasm after the treatment of RNA polymerase inhibitors (actinomycin D and 5,6-dichlorobenzimidazole riboside) and topoisomerase inhibitors [camptothecin (CPT) and etoposide].	Camptothecin	209-221	pumilio RNA binding family member 3	Homo sapiens	30-36
21266351-4	2011	The nucleolar localization of hPuf-A would redistribute to the nucleoplasm after the treatment of RNA polymerase inhibitors (actinomycin D and 5,6-dichlorobenzimidazole riboside) and topoisomerase inhibitors [camptothecin (CPT) and etoposide].	Camptothecin	223-226	pumilio RNA binding family member 3	Homo sapiens	30-36
21278449-5	2011	In particular, current studies have revealed the presence of a novel Recql5/RECQL5-dependent mechanism for suppressing replication fork collapse in response to global replication fork stalling following exposure to camptothecin (CPT), a topoisomerase I inhibitor, and a potent inhibitor of DNA replication.	Camptothecin	215-227	RecQ like helicase 5	Homo sapiens	76-82
21278449-5	2011	In particular, current studies have revealed the presence of a novel Recql5/RECQL5-dependent mechanism for suppressing replication fork collapse in response to global replication fork stalling following exposure to camptothecin (CPT), a topoisomerase I inhibitor, and a potent inhibitor of DNA replication.	Camptothecin	229-232	RecQ like helicase 5	Homo sapiens	69-75
21278449-5	2011	In particular, current studies have revealed the presence of a novel Recql5/RECQL5-dependent mechanism for suppressing replication fork collapse in response to global replication fork stalling following exposure to camptothecin (CPT), a topoisomerase I inhibitor, and a potent inhibitor of DNA replication.	Camptothecin	229-232	RecQ like helicase 5	Homo sapiens	76-82
20813759-7	2011	In addition, SFPQ was demonstrated to mediate homology directed DNA repair and DNA damage response resulting from DNA crosslinking agents, alkylating agents and camptothecin.	Camptothecin	161-173	splicing factor proline and glutamine rich	Homo sapiens	13-17
21135129-6	2011	Cells lacking all three phosphatases Pph3, Ptc2, and Ptc3 exhibit synergistic sensitivities to the DNA-damaging agents camptothecin and methyl methanesulfonate, as well as hydroxyurea but not to UV light.	Camptothecin	119-131	type 2C protein phosphatase PTC2	Saccharomyces cerevisiae S288C	43-47
21135129-6	2011	Cells lacking all three phosphatases Pph3, Ptc2, and Ptc3 exhibit synergistic sensitivities to the DNA-damaging agents camptothecin and methyl methanesulfonate, as well as hydroxyurea but not to UV light.	Camptothecin	119-131	type 2C protein phosphatase PTC3	Saccharomyces cerevisiae S288C	53-57
20875401-3	2011	Recent findings showed that poly(ADP-ribosyl)ated PARP-1 and PARP-2 counteract camptothecin action facilitating resealing of DNA strand breaks.	Camptothecin	79-91	poly(ADP-ribose) polymerase 1	Homo sapiens	50-56
20875401-3	2011	Recent findings showed that poly(ADP-ribosyl)ated PARP-1 and PARP-2 counteract camptothecin action facilitating resealing of DNA strand breaks.	Camptothecin	79-91	poly(ADP-ribose) polymerase 2	Homo sapiens	61-67
21034425-3	2011	Accordingly, some potent chemotherapeutic agents such as camptothecin (CPT), methotrexate (MTX), paclitaxel (PTX) and doxorubicin (DOX) have been coupled to SSTR2-preferential somatostatin (SST) analogs.	Camptothecin	57-69	somatostatin receptor 2	Homo sapiens	157-162
21785230-6	2011	The XRCC4-deficient cells were highly sensitive to etoposide and 5-fluoro-2"-deoxyuridine as well as IR, and moderately sensitive to camptothecin, methyl methanesulfonate, cisplatin, mitomycin C, aphidicolin and hydroxyurea, compared to the parental HCT116 cells.	Camptothecin	133-145	X-ray repair cross complementing 4	Homo sapiens	4-9
21135129-6	2011	Cells lacking all three phosphatases Pph3, Ptc2, and Ptc3 exhibit synergistic sensitivities to the DNA-damaging agents camptothecin and methyl methanesulfonate, as well as hydroxyurea but not to UV light.	Camptothecin	119-131	phosphoprotein phosphatase PP4 catalytic subunit PPH3	Saccharomyces cerevisiae S288C	37-41
20812030-1	2011	Camptothecin (CPT) and Nutlin-3 caused apoptosis by increasing p53 protein and its activation in intestinal epithelial cells (IEC-6).	Camptothecin	0-12	tumor protein p53	Homo sapiens	63-66
20812030-1	2011	Camptothecin (CPT) and Nutlin-3 caused apoptosis by increasing p53 protein and its activation in intestinal epithelial cells (IEC-6).	Camptothecin	14-17	tumor protein p53	Homo sapiens	63-66
21174601-0	2011	Camptothecin induces apoptosis of human retinoblastoma cells via activation of FOXO1.	Camptothecin	0-12	forkhead box O1	Homo sapiens	79-84
21174601-1	2011	PURPOSE: The purpose of this study was to investigate the pro-apoptotic effect of camptothecin (CPT) on Y79 retinoblastoma cells and the role of Forkhead box, class O (FOXO1) in CPT-induced apoptosis.	Camptothecin	178-181	forkhead box O1	Homo sapiens	168-173
21174601-11	2011	CONCLUSIONS: Our study provides the evidence that a high level of endogenous FOXO1 expression in retinoblastoma cells contributes, at least in part, to CPT-induced apoptosis, which may help broad application of CPT in retinoblastoma therapy in the future.	Camptothecin	152-155	forkhead box O1	Homo sapiens	77-82
21174601-11	2011	CONCLUSIONS: Our study provides the evidence that a high level of endogenous FOXO1 expression in retinoblastoma cells contributes, at least in part, to CPT-induced apoptosis, which may help broad application of CPT in retinoblastoma therapy in the future.	Camptothecin	211-214	forkhead box O1	Homo sapiens	77-82
21660142-6	2011	We also found that the expression of the beta2 subunit increases the sensitivity to the camptothecin that induces DNA double-strand break (DSB).	Camptothecin	88-100	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	41-46
20600630-2	2010	Recently, camptothecin has been shown to activate the transcription of low-abundance antisense RNAs at the HIF-1alpha gene locus in human cancer cells in a Topoisomerase I-dependent manner.	Camptothecin	10-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	107-117
20600630-4	2010	Camptothecin readily inhibits Topoisomerase I in cells, and the enzyme inhibition activates transcriptional Cdk (Cdk9 and/or Cdk7) activity leading to the hyperphosphorylation of the CTD of the largest subunit of RNA polymerase II (RNAP II).	Camptothecin	0-12	cyclin dependent kinase 7	Homo sapiens	108-111
20600630-4	2010	Camptothecin readily inhibits Topoisomerase I in cells, and the enzyme inhibition activates transcriptional Cdk (Cdk9 and/or Cdk7) activity leading to the hyperphosphorylation of the CTD of the largest subunit of RNA polymerase II (RNAP II).	Camptothecin	0-12	cyclin dependent kinase 9	Homo sapiens	113-117
20600630-4	2010	Camptothecin readily inhibits Topoisomerase I in cells, and the enzyme inhibition activates transcriptional Cdk (Cdk9 and/or Cdk7) activity leading to the hyperphosphorylation of the CTD of the largest subunit of RNA polymerase II (RNAP II).	Camptothecin	0-12	cyclin dependent kinase 7	Homo sapiens	125-129
20600630-6	2010	Thus, the findings have documented that camptothecin can interfere with specific transcription regulatory steps, impairing the balance of cellular antisense and sense transcripts at the HIF-1alpha gene locus.	Camptothecin	40-52	hypoxia inducible factor 1 subunit alpha	Homo sapiens	186-196
21052091-4	2010	Finally, we show that on exposure to camptothecin, depletion of EXO1 in CtIP-deficient cells increases the frequency of DNA-PK-dependent radial chromosome formation.	Camptothecin	37-49	exonuclease 1	Homo sapiens	64-68
20872237-8	2010	We found that a clinically approved camptothecin analog, irinotecan suppressed the migration, Cdc42 activity, and autophosphorylation of FAK, and attenuated integrin beta1 distribution selectively in LM8 cells.	Camptothecin	36-48	cell division cycle 42	Mus musculus	94-99
20872237-8	2010	We found that a clinically approved camptothecin analog, irinotecan suppressed the migration, Cdc42 activity, and autophosphorylation of FAK, and attenuated integrin beta1 distribution selectively in LM8 cells.	Camptothecin	36-48	PTK2 protein tyrosine kinase 2	Mus musculus	137-140
20872237-8	2010	We found that a clinically approved camptothecin analog, irinotecan suppressed the migration, Cdc42 activity, and autophosphorylation of FAK, and attenuated integrin beta1 distribution selectively in LM8 cells.	Camptothecin	36-48	integrin beta 1 (fibronectin receptor beta)	Mus musculus	157-171
21052091-4	2010	Finally, we show that on exposure to camptothecin, depletion of EXO1 in CtIP-deficient cells increases the frequency of DNA-PK-dependent radial chromosome formation.	Camptothecin	37-49	RB binding protein 8, endonuclease	Homo sapiens	72-76
21052091-4	2010	Finally, we show that on exposure to camptothecin, depletion of EXO1 in CtIP-deficient cells increases the frequency of DNA-PK-dependent radial chromosome formation.	Camptothecin	37-49	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	120-126
20567954-0	2010	p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells.	Camptothecin	32-44	p21 (RAC1) activated kinase 5	Homo sapiens	0-22
20925107-6	2010	The induction of apoptosis by camptothecine increases the fluorescence lifetime, which means effective cleavage of the FRET sensor by caspase-3.	Camptothecin	30-43	caspase 3	Homo sapiens	134-143
20567954-5	2010	In the present study, we aim to investigate the role of PAK5 in camptothecin-induced apoptosis and its potential mechanism of action.	Camptothecin	64-76	p21 (RAC1) activated kinase 5	Homo sapiens	56-60
20567954-6	2010	Our results showed that overexpression of PAK5 inhibited camptothecin-induced apoptosis by inhibiting the activity of caspase-8 in CRC cells.	Camptothecin	57-69	p21 (RAC1) activated kinase 5	Homo sapiens	42-46
20567954-6	2010	Our results showed that overexpression of PAK5 inhibited camptothecin-induced apoptosis by inhibiting the activity of caspase-8 in CRC cells.	Camptothecin	57-69	caspase 8	Homo sapiens	118-127
20567954-9	2010	In conclusion, our study revealed previously unappreciated inhibitory role of PAK5 in camptothecin-induced apoptosis, thus suggesting PAK5 as a novel therapeutic target in CRC.	Camptothecin	86-98	p21 (RAC1) activated kinase 5	Homo sapiens	78-82
20567954-9	2010	In conclusion, our study revealed previously unappreciated inhibitory role of PAK5 in camptothecin-induced apoptosis, thus suggesting PAK5 as a novel therapeutic target in CRC.	Camptothecin	86-98	p21 (RAC1) activated kinase 5	Homo sapiens	134-138
20978201-7	2010	Marked increase in p53, a downstream target of the activated ATM pathway, was detected only in response to camptothecin and doxorubicin.	Camptothecin	107-119	tumor protein p53	Homo sapiens	19-22
21055985-0	2010	A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability.	Camptothecin	14-26	MMS22 like, DNA repair protein	Homo sapiens	69-75
21055985-0	2010	A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability.	Camptothecin	14-26	tonsoku like, DNA repair protein	Homo sapiens	76-83
21055985-1	2010	Replication stress involving collision of replisomes with camptothecin (CPT)-stabilized DNA-Topoisomerase I adducts activates an ATR-dependent pathway to promote repair by homologous recombination.	Camptothecin	58-70	ATR serine/threonine kinase	Homo sapiens	129-132
20978201-7	2010	Marked increase in p53, a downstream target of the activated ATM pathway, was detected only in response to camptothecin and doxorubicin.	Camptothecin	107-119	ATM serine/threonine kinase	Homo sapiens	61-64
20972445-2	2010	We report here that various genotoxic stress inducers, including camptothecin (CPT), inhibit the interaction between Ewing"s sarcoma proto-oncoprotein (EWS), an RNA polymerase II-associated factor, and YB-1, a spliceosome-associated factor.	Camptothecin	65-77	EWS RNA binding protein 1	Homo sapiens	117-150
20870738-4	2010	Suppression of GLUT3 expression determined by the real-time PCR was also evident with another DNA-damaging agent, camptothecin, which reduced the promoter"s activity as determined with a luciferase-linked assay.	Camptothecin	114-126	solute carrier family 2 member 3	Homo sapiens	15-20
20972445-2	2010	We report here that various genotoxic stress inducers, including camptothecin (CPT), inhibit the interaction between Ewing"s sarcoma proto-oncoprotein (EWS), an RNA polymerase II-associated factor, and YB-1, a spliceosome-associated factor.	Camptothecin	65-77	EWS RNA binding protein 1	Homo sapiens	152-155
23605487-6	2010	The specific topoisomerase poisons camptothecin and etoposide caused comparable effects, underlining that TDP1 plays an important role in the repair of topoisomerase-mediated DNA damage.	Camptothecin	35-47	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	106-110
20972445-2	2010	We report here that various genotoxic stress inducers, including camptothecin (CPT), inhibit the interaction between Ewing"s sarcoma proto-oncoprotein (EWS), an RNA polymerase II-associated factor, and YB-1, a spliceosome-associated factor.	Camptothecin	65-77	Y-box binding protein 1	Homo sapiens	161-239
20972445-2	2010	We report here that various genotoxic stress inducers, including camptothecin (CPT), inhibit the interaction between Ewing"s sarcoma proto-oncoprotein (EWS), an RNA polymerase II-associated factor, and YB-1, a spliceosome-associated factor.	Camptothecin	79-82	EWS RNA binding protein 1	Homo sapiens	117-150
20972445-2	2010	We report here that various genotoxic stress inducers, including camptothecin (CPT), inhibit the interaction between Ewing"s sarcoma proto-oncoprotein (EWS), an RNA polymerase II-associated factor, and YB-1, a spliceosome-associated factor.	Camptothecin	79-82	EWS RNA binding protein 1	Homo sapiens	152-155
20972445-2	2010	We report here that various genotoxic stress inducers, including camptothecin (CPT), inhibit the interaction between Ewing"s sarcoma proto-oncoprotein (EWS), an RNA polymerase II-associated factor, and YB-1, a spliceosome-associated factor.	Camptothecin	79-82	Y-box binding protein 1	Homo sapiens	161-239
21060845-3	2010	In S. cerevisiae, deficiency in MRE11, which encodes a highly conserved factor, greatly enhances sensitivity to treatment with CPT or ETP.	Camptothecin	127-130	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	32-37
21060845-5	2010	Here we report that an S. cerevisiae strain expressing the mre11-H59A allele, mutant at a conserved active site histidine, is sensitive to hydroxyurea and also to ionizing radiation, which induces DSBs, but not to CPT or ETP.	Camptothecin	214-217	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	59-64
20664928-8	2010	Upon induction of apoptosis by cytotoxin camptothecin, the percentages of apoptotic cells in G-Id3-1 and G-Id3-7 were, respectively >2.4-fold higher than that in control.	Camptothecin	41-53	inhibitor of DNA binding 3	Mus musculus	95-98
20976249-7	2010	Swi5(-/-) and Sfr1(-/-) cells are selectively sensitive to agents that cause DNA strand breaks, in particular ionizing radiation, camptothecin, and the Parp inhibitor olaparib.	Camptothecin	130-142	SWI5 homologous recombination repair protein	Homo sapiens	0-4
20976249-7	2010	Swi5(-/-) and Sfr1(-/-) cells are selectively sensitive to agents that cause DNA strand breaks, in particular ionizing radiation, camptothecin, and the Parp inhibitor olaparib.	Camptothecin	130-142	SWI5 dependent homologous recombination repair protein 1	Homo sapiens	14-18
20661218-9	2010	Restoration of p53 and silencing cyclin B1 render cervical carcinoma cells more susceptible to DNA damage agent camptothecin.	Camptothecin	112-124	tumor protein p53	Homo sapiens	15-18
20661218-9	2010	Restoration of p53 and silencing cyclin B1 render cervical carcinoma cells more susceptible to DNA damage agent camptothecin.	Camptothecin	112-124	cyclin B1	Homo sapiens	33-42
20693240-0	2010	The R438W polymorphism of human DNA polymerase lambda triggers cellular sensitivity to camptothecin by compromising the homologous recombination repair pathway.	Camptothecin	87-99	DNA polymerase lambda	Homo sapiens	32-53
20945128-9	2010	In the HepG2 cell line, 3, 5 and 7 showed cytotoxicity (IC(50): 4, 3 and 4 muM, respectively, with IC(50) of camptothecin: 0.3 muM).	Camptothecin	109-121	latexin	Homo sapiens	127-130
20603643-10	2010	We have also found that pharmacological interferences of TIP and RIP pathways distinctively modulated the CPT-induced cell killing with treatments at low and high dosages, respectively.	Camptothecin	106-109	receptor interacting serine/threonine kinase 1	Homo sapiens	65-68
20664928-8	2010	Upon induction of apoptosis by cytotoxin camptothecin, the percentages of apoptotic cells in G-Id3-1 and G-Id3-7 were, respectively >2.4-fold higher than that in control.	Camptothecin	41-53	ubiquitin-conjugating enzyme E2H	Mus musculus	105-112
20504912-0	2010	Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.	Camptothecin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-43
20504912-0	2010	Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.	Camptothecin	0-12	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-109
20504912-3	2010	Camptothecin (CPT) was demonstrated as a novel and potent inhibitor (IC(50) = 0.58 microM) of an hPXR-mediated transcriptional regulation on CYP3A4 in this study.	Camptothecin	0-12	nuclear receptor subfamily 1 group I member 2	Homo sapiens	97-101
20504912-3	2010	Camptothecin (CPT) was demonstrated as a novel and potent inhibitor (IC(50) = 0.58 microM) of an hPXR-mediated transcriptional regulation on CYP3A4 in this study.	Camptothecin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
20504912-3	2010	Camptothecin (CPT) was demonstrated as a novel and potent inhibitor (IC(50) = 0.58 microM) of an hPXR-mediated transcriptional regulation on CYP3A4 in this study.	Camptothecin	14-17	nuclear receptor subfamily 1 group I member 2	Homo sapiens	97-101
20504912-3	2010	Camptothecin (CPT) was demonstrated as a novel and potent inhibitor (IC(50) = 0.58 microM) of an hPXR-mediated transcriptional regulation on CYP3A4 in this study.	Camptothecin	14-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
19450997-7	2010	p21 Expression decreased basal caspase-3 expression compared with the untreated group, and reversed camptothecin-induced caspase-3 activity compared with camptothecin alone group.	Camptothecin	100-112	H3 histone pseudogene 16	Homo sapiens	0-3
19450997-7	2010	p21 Expression decreased basal caspase-3 expression compared with the untreated group, and reversed camptothecin-induced caspase-3 activity compared with camptothecin alone group.	Camptothecin	100-112	caspase 3	Homo sapiens	121-130
19450997-7	2010	p21 Expression decreased basal caspase-3 expression compared with the untreated group, and reversed camptothecin-induced caspase-3 activity compared with camptothecin alone group.	Camptothecin	154-166	H3 histone pseudogene 16	Homo sapiens	0-3
20662736-7	2010	Anthracycline (topoisomerase II inhibitors such as mitoxantrone and ellipticine) and camptothecin (topoisomerase I inhibitor) derivatives including topotecan induce DNA double strand breaks, which activate the p53 pathway through the ataxia telangiectasia mutated-checkpoint kinase 2 (ATM-CHK2) DNA damage response pathway.	Camptothecin	85-97	tumor protein p53	Homo sapiens	210-213
20516064-11	2010	Importantly, correct homomultimerization is required for WRN function in vivo as overexpression of this multimerization domain caused increased sensitivity to camptothecin and 4-nitroquinoline 1-oxide similar to that in cells lacking functional WRN protein.	Camptothecin	159-171	WRN RecQ like helicase	Homo sapiens	57-60
20662736-7	2010	Anthracycline (topoisomerase II inhibitors such as mitoxantrone and ellipticine) and camptothecin (topoisomerase I inhibitor) derivatives including topotecan induce DNA double strand breaks, which activate the p53 pathway through the ataxia telangiectasia mutated-checkpoint kinase 2 (ATM-CHK2) DNA damage response pathway.	Camptothecin	85-97	ATM serine/threonine kinase	Homo sapiens	285-293
20662736-8	2010	Although mitoxantrone, ellipticine, camptothecin, and topotecan all exhibited concentration-dependent disruption of the p53-hDM2 PPIB, they were much less potent than Nutlin-3.	Camptothecin	36-48	tumor protein p53	Homo sapiens	120-123
20662736-8	2010	Although mitoxantrone, ellipticine, camptothecin, and topotecan all exhibited concentration-dependent disruption of the p53-hDM2 PPIB, they were much less potent than Nutlin-3.	Camptothecin	36-48	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	124-128
20012292-9	2010	Aminoflavone-induced CYP1A1 induction was observed in the presence of camptothecin or paclitaxel.	Camptothecin	70-82	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	21-27
20394499-3	2010	In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells.	Camptothecin	101-113	TNF superfamily member 10	Homo sapiens	51-56
20663862-4	2010	We show that ectopic overexpression of CD133 in rat C6 glioma cells leads to significant reluctance to undergo apoptosis from camptothecin and doxorubicin.	Camptothecin	126-138	prominin 1	Rattus norvegicus	39-44
20206609-6	2010	By molecular docking, we found that camptothecin 20-N,N-glycinate (CPTg) and camptothecin (CPT) bind to the same pharmacophore at EGFR as erlotinib, albeit to partly different amino acids.	Camptothecin	36-48	epidermal growth factor receptor	Homo sapiens	130-134
20206609-6	2010	By molecular docking, we found that camptothecin 20-N,N-glycinate (CPTg) and camptothecin (CPT) bind to the same pharmacophore at EGFR as erlotinib, albeit to partly different amino acids.	Camptothecin	67-70	epidermal growth factor receptor	Homo sapiens	130-134
20680486-5	2010	Cytoplasmic expression of TrkA protein was differentially modulated during the camptothecin-induced DNA damage response in TrkA-expressing U2OS cells.	Camptothecin	79-91	neurotrophic receptor tyrosine kinase 1	Homo sapiens	26-30
20680486-5	2010	Cytoplasmic expression of TrkA protein was differentially modulated during the camptothecin-induced DNA damage response in TrkA-expressing U2OS cells.	Camptothecin	79-91	neurotrophic receptor tyrosine kinase 1	Homo sapiens	123-127
20206609-0	2010	Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.	Camptothecin	78-90	epidermal growth factor receptor	Homo sapiens	14-46
20394499-3	2010	In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells.	Camptothecin	101-113	TNF superfamily member 10	Homo sapiens	128-133
20394499-3	2010	In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells.	Camptothecin	101-113	TNF superfamily member 10	Homo sapiens	128-133
20394499-3	2010	In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells.	Camptothecin	101-113	CASP8 and FADD like apoptosis regulator	Homo sapiens	328-334
20394499-3	2010	In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells.	Camptothecin	101-113	caspase 8	Homo sapiens	352-361
20394499-3	2010	In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells.	Camptothecin	101-113	caspase 3	Homo sapiens	366-375
20179147-0	2010	Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins.	Camptothecin	57-70	insulin like growth factor 1	Homo sapiens	31-36
20479784-8	2010	Six of the Bcl-2 family members inhibited apoptosis induced by camptothecin in mammalian cells with HyBcl-2-like 4 showing an especially strong protective effect.	Camptothecin	63-75	BCL2 apoptosis regulator	Homo sapiens	11-16
20179147-0	2010	Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins.	Camptothecin	57-70	insulin like growth factor 1 receptor	Homo sapiens	41-47
20236666-6	2010	Apoptosis was induced after treatment with camptothecin and measured by release of caspase 3 and morphologic criteria.	Camptothecin	43-55	caspase 3	Mus musculus	83-92
20236666-13	2010	CONCLUSION: Survivin plays a critical role in TE7 cell resistance to camptothecin-induced apoptosis.	Camptothecin	69-81	baculoviral IAP repeat-containing 5	Mus musculus	12-20
20042274-0	2010	ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.	Camptothecin	64-76	ATM serine/threonine kinase	Homo sapiens	0-3
20042274-0	2010	ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.	Camptothecin	64-76	ATR serine/threonine kinase	Homo sapiens	9-12
20042274-3	2010	Following treatment with the camptothecin or ionizing radiation, both inducing double-strand DNA breaks, the ovarian carcinoma A2780 cells exhibited activation of the ATM-Chk2 pathway and early induction of apoptosis.	Camptothecin	29-41	ATM serine/threonine kinase	Homo sapiens	167-170
20042274-3	2010	Following treatment with the camptothecin or ionizing radiation, both inducing double-strand DNA breaks, the ovarian carcinoma A2780 cells exhibited activation of the ATM-Chk2 pathway and early induction of apoptosis.	Camptothecin	29-41	checkpoint kinase 2	Homo sapiens	171-175
20042274-7	2010	The susceptibility to camptothecin-induced apoptosis of A2780 cells was likely p53-dependent but not related to the activation of the ATM pathway.	Camptothecin	22-34	tumor protein p53	Homo sapiens	79-82
20042274-9	2010	Thus, depending on the biological context, the camptothecin activated ATM-Chk2 or ATR-Chk1 pathways, both having a protective role.	Camptothecin	47-59	ATM serine/threonine kinase	Homo sapiens	70-73
20042274-9	2010	Thus, depending on the biological context, the camptothecin activated ATM-Chk2 or ATR-Chk1 pathways, both having a protective role.	Camptothecin	47-59	checkpoint kinase 2	Homo sapiens	74-78
20042274-9	2010	Thus, depending on the biological context, the camptothecin activated ATM-Chk2 or ATR-Chk1 pathways, both having a protective role.	Camptothecin	47-59	ATR serine/threonine kinase	Homo sapiens	82-85
20042274-9	2010	Thus, depending on the biological context, the camptothecin activated ATM-Chk2 or ATR-Chk1 pathways, both having a protective role.	Camptothecin	47-59	checkpoint kinase 1	Homo sapiens	86-90
20528239-4	2010	Recently, a small molecule inhibitor of PNK has been developed that is able to sensitize cells to ionizing radiation and the topoisomerase I poison, camptothecin.	Camptothecin	149-161	polynucleotide kinase 3'-phosphatase	Homo sapiens	40-43
20138027-7	2010	This study identified five lead compounds such as thapsigargin, tunicamycine, MG132, kaempferol and camptothecin that could induce cytochrome C release in both wild type and Bax deficient cells with equal potency.	Camptothecin	100-112	cytochrome c, somatic	Homo sapiens	131-143
20138027-7	2010	This study identified five lead compounds such as thapsigargin, tunicamycine, MG132, kaempferol and camptothecin that could induce cytochrome C release in both wild type and Bax deficient cells with equal potency.	Camptothecin	100-112	BCL2 associated X, apoptosis regulator	Homo sapiens	174-177
20534341-2	2010	Camptothecins and novel noncamptothecins in clinical development (indenoisoquinolines and ARC-111) target eukaryotic type IB topoisomerases (Top1), whereas human type IIA topoisomerases (Top2alpha and Top2beta) are the targets of the widely used anticancer agents etoposide, anthracyclines (doxorubicin, daunorubicin), and mitoxantrone.	Camptothecin	0-13	DNA topoisomerase II alpha	Homo sapiens	187-196
20368354-4	2010	We report that camptothecin, an inhibitor of topoisomerase I, reversibly induced the unicellular to hyphal transition in S. japonicus at low concentrations of camptothecin that did not induce checkpoint arrest and the transition required the DNA checkpoint kinase Chk1.	Camptothecin	15-27	serine/threonine protein kinase CHK1	Saccharomyces cerevisiae S288C	264-268
20368354-5	2010	Furthermore, a mutation of chk1 induced hyphal transition without camptothecin.	Camptothecin	66-78	serine/threonine protein kinase CHK1	Saccharomyces cerevisiae S288C	27-31
20534341-2	2010	Camptothecins and novel noncamptothecins in clinical development (indenoisoquinolines and ARC-111) target eukaryotic type IB topoisomerases (Top1), whereas human type IIA topoisomerases (Top2alpha and Top2beta) are the targets of the widely used anticancer agents etoposide, anthracyclines (doxorubicin, daunorubicin), and mitoxantrone.	Camptothecin	0-13	DNA topoisomerase II beta	Homo sapiens	201-209
20213810-2	2010	METHODS: Caspase 3/7 activity was determined in primary OA and ADAM15-transfected T/C28a4 chondrocytes upon exposure to the DNA-damaging agent camptothecin or serum withdrawal.	Camptothecin	143-155	caspase 3	Homo sapiens	9-18
20223826-4	2010	The pro-apoptotic members Bak, Bad, Bim, and Noxa were required for apoptosis induced by DNA damaging agents camptothecin and UV.	Camptothecin	109-121	BCL2 antagonist/killer 1	Homo sapiens	26-29
20223826-4	2010	The pro-apoptotic members Bak, Bad, Bim, and Noxa were required for apoptosis induced by DNA damaging agents camptothecin and UV.	Camptothecin	109-121	BCL2 like 11	Homo sapiens	36-39
20223826-4	2010	The pro-apoptotic members Bak, Bad, Bim, and Noxa were required for apoptosis induced by DNA damaging agents camptothecin and UV.	Camptothecin	109-121	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	45-49
20479887-5	2010	Camptothecin is a reported inhibitor of HIF-1alpha translation, while mitomycin C has been reported to induce p53-dependent HIF-1alpha degradation.	Camptothecin	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	40-50
20479887-8	2010	However, we show here that even when eIF2alpha phosphorylation is prevented, the DNA damage inducing drugs mitomycin C, camptothecin and NSC-652287 still inhibit HIF-1alpha protein synthesis to the same extent.	Camptothecin	120-132	hypoxia inducible factor 1 subunit alpha	Homo sapiens	162-172
20479887-9	2010	The inhibitory effects of camptothecin on HIF-1alpha expression but not that of mitomycin C and NSC-652287 were dependent on cyclin-dependent kinase activity.	Camptothecin	26-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	42-52
20213810-2	2010	METHODS: Caspase 3/7 activity was determined in primary OA and ADAM15-transfected T/C28a4 chondrocytes upon exposure to the DNA-damaging agent camptothecin or serum withdrawal.	Camptothecin	143-155	ADAM metallopeptidase domain 15	Homo sapiens	63-69
20213810-8	2010	Apoptosis induction by camptothecin exposure also led to significantly elevated caspase 3/7 activity and reduced cell viability of the vector-transfected compared with ADAM15-transfected chondrocytes.	Camptothecin	23-35	caspase 3	Homo sapiens	80-89
20213810-8	2010	Apoptosis induction by camptothecin exposure also led to significantly elevated caspase 3/7 activity and reduced cell viability of the vector-transfected compared with ADAM15-transfected chondrocytes.	Camptothecin	23-35	ADAM metallopeptidase domain 15	Homo sapiens	168-174
20213810-10	2010	XIAP, an inhibitor of activated caspase 3, was significantly up-regulated ( approximately 3-fold) at the protein and mRNA levels in ADAM15-transfected chondrocytes upon camptothecin treatment.	Camptothecin	169-181	X-linked inhibitor of apoptosis	Homo sapiens	0-4
20213810-10	2010	XIAP, an inhibitor of activated caspase 3, was significantly up-regulated ( approximately 3-fold) at the protein and mRNA levels in ADAM15-transfected chondrocytes upon camptothecin treatment.	Camptothecin	169-181	caspase 3	Homo sapiens	32-41
20213810-10	2010	XIAP, an inhibitor of activated caspase 3, was significantly up-regulated ( approximately 3-fold) at the protein and mRNA levels in ADAM15-transfected chondrocytes upon camptothecin treatment.	Camptothecin	169-181	ADAM metallopeptidase domain 15	Homo sapiens	132-138
20213810-11	2010	Specific down-regulation of either ADAM15 or XIAP in OA chondrocytes led to significant sensitization to camptothecin-induced caspase 3/7 activity.	Camptothecin	105-117	ADAM metallopeptidase domain 15	Homo sapiens	35-41
20213810-11	2010	Specific down-regulation of either ADAM15 or XIAP in OA chondrocytes led to significant sensitization to camptothecin-induced caspase 3/7 activity.	Camptothecin	105-117	X-linked inhibitor of apoptosis	Homo sapiens	45-49
20213810-11	2010	Specific down-regulation of either ADAM15 or XIAP in OA chondrocytes led to significant sensitization to camptothecin-induced caspase 3/7 activity.	Camptothecin	105-117	caspase 3	Homo sapiens	126-135
20231364-5	2010	Fully functional RecQL5 requires both helicase activity and associations with the initiation polymerase, because mutants lacking either activity are partially defective in the suppression of sister chromatid exchange and resistance to camptothecin-induced DNA damage, and mutants lacking both activities are completely defective.	Camptothecin	235-247	RecQ like helicase 5	Homo sapiens	17-23
20372801-4	2010	Instead of being mitogenic, HGF confers anti-apoptotic properties upon serum starvation and moreover protects HB cells against strong apoptotic inducers such as cisplatin and camptothecin, thereby contributing to chemotherapeutic resistance.	Camptothecin	175-187	hepatocyte growth factor	Homo sapiens	28-31
20206136-3	2010	Camptothecin strikingly inhibited mutated and wild-type AR protein expression in LNCaP and PC-3/AR cells.	Camptothecin	0-12	androgen receptor	Homo sapiens	56-58
20400963-4	2010	The mutation results in loss of RAD51 focus formation in response to DNA damage and in increased cellular sensitivity to the DNA interstrand cross-linking agent mitomycin C and the topoisomerase-1 inhibitor camptothecin.	Camptothecin	207-219	RAD51 recombinase	Homo sapiens	32-37
20206136-0	2010	Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.	Camptothecin	0-12	androgen receptor	Homo sapiens	22-39
20206136-3	2010	Camptothecin strikingly inhibited mutated and wild-type AR protein expression in LNCaP and PC-3/AR cells.	Camptothecin	0-12	androgen receptor	Homo sapiens	96-98
20206136-5	2010	Additionally, camptothecin disrupted the association between AR and heat shock protein 90 and impeded binding of the synthetic androgen [3H]R1881 to AR in LNCaP cells.	Camptothecin	14-26	androgen receptor	Homo sapiens	61-63
20206136-5	2010	Additionally, camptothecin disrupted the association between AR and heat shock protein 90 and impeded binding of the synthetic androgen [3H]R1881 to AR in LNCaP cells.	Camptothecin	14-26	androgen receptor	Homo sapiens	149-151
20206136-6	2010	Camptothecin also blocked androgen-induced AR nuclear translocation, leading to downregulation of the AR target gene PSA.	Camptothecin	0-12	androgen receptor	Homo sapiens	43-45
20206136-6	2010	Camptothecin also blocked androgen-induced AR nuclear translocation, leading to downregulation of the AR target gene PSA.	Camptothecin	0-12	androgen receptor	Homo sapiens	102-104
20206136-8	2010	Collectively, our data reveal that camptothecin not only serves as a traditional genotoxic agent but, by virtue of its ability to target and disrupt AR, may also be a novel candidate for the treatment of prostate cancer.	Camptothecin	35-47	androgen receptor	Homo sapiens	149-151
20150439-5	2010	Apoptosis induced by camptothecin was significantly inhibited by IGFBP-2 overexpression in NCI-H522 cells.	Camptothecin	21-33	insulin like growth factor binding protein 2	Homo sapiens	65-72
20150439-6	2010	Conversely, selective knockdown of IGFBP-2 using small-interfering RNA resulted in an increase in procaspase-3 expression and sensitization to camptothecin-induced apoptosis in NCI-H522 cells.	Camptothecin	143-155	insulin like growth factor binding protein 2	Homo sapiens	35-42
20064923-0	2010	Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks.	Camptothecin	76-88	cullin 4B	Homo sapiens	13-22
20371676-5	2010	Moreover, using an isogenic in vitro system deficient in APTX, we show that aprataxin directly regulates the cellular sensitivity to camptothecin, suggesting that it could be used to predict patient response to irinotecan.	Camptothecin	133-145	aprataxin	Homo sapiens	76-85
20407862-2	2010	After incubation with transfected 16HBE cells, engulfment of apoptotic HL-60 cells induced by camptothecin was detected by myeloperoxidase (MPO) staining.	Camptothecin	94-106	myeloperoxidase	Homo sapiens	123-138
19940859-3	2010	On the cellular level, two principles of NF-kappaB inhibition, proteasome inhibition by bortezomib and IkappaB kinase-beta (IKKbeta) inhibition by the kinase inhibitor of NF-kappaB-1 (KINK-1), significantly increased the antitumoral efficacy of camptothecin.	Camptothecin	245-257	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	41-50
20407862-2	2010	After incubation with transfected 16HBE cells, engulfment of apoptotic HL-60 cells induced by camptothecin was detected by myeloperoxidase (MPO) staining.	Camptothecin	94-106	myeloperoxidase	Homo sapiens	140-143
20347418-3	2010	(2010) identify an evolutionarily conserved FANCM-associated histone-fold MHF heterodimer (MHF1-MHF2) that promotes the remodeling of artificial replication forks and confers cellular resistance to DNA crosslinks and camptothecin.	Camptothecin	217-229	FA complementation group M	Homo sapiens	44-49
20347429-3	2010	We show that suppression of MHF1 expression results in (1) destabilization of FANCM and MHF2, (2) impairment of DNA damage-induced monoubiquitination and foci formation of FANCD2, (3) defective chromatin localization of FA nuclear core complex proteins, (4) elevated MMC-induced chromosome aberrations, and (5) sensitivity to MMC and camptothecin.	Camptothecin	334-346	centromere protein S	Homo sapiens	28-32
30025429-1	2010	Human tyrosyl-DNA phosphodiesterase (hTdp1) inhibitors have become a major area of drug research and structure-based design since they have been shown to work synergistically with camptothecin (CPT) and selectively in cancer cells.	Camptothecin	180-192	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	37-42
30025429-1	2010	Human tyrosyl-DNA phosphodiesterase (hTdp1) inhibitors have become a major area of drug research and structure-based design since they have been shown to work synergistically with camptothecin (CPT) and selectively in cancer cells.	Camptothecin	194-197	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	37-42
20086100-7	2010	Furthermore, eIF4B silencing led to decreased proliferation rates, promoted caspase-dependent apoptosis, and further sensitized cells to camptothecin-induced cell death.	Camptothecin	137-149	eukaryotic translation initiation factor 4B	Homo sapiens	13-18
20015864-3	2010	By utilizing a proteomics-based approach, in this work, we identify that the human ANP32B protein is cleaved during apoptosis induction by NSC606985, a novel camptothecin analog.	Camptothecin	158-170	acidic nuclear phosphoprotein 32 family member B	Homo sapiens	83-89
20145617-3	2010	METHODS: hMEPE/OF45 expression in different human tumour cell lines and its relevance to the resistance of cell lines to DNA damage inducers such as ionising radiation (IR) or camptothecin (CPT) were assessed.	Camptothecin	190-193	matrix extracellular phosphoglycoprotein	Homo sapiens	15-19
20145154-5	2010	Stable FOXQ1-overexpressing cells (H1299/FOXQ1) exhibited elevated levels of p21 expression and inhibition of apoptosis induced by doxorubicin or camptothecin.	Camptothecin	146-158	forkhead box Q1	Homo sapiens	7-12
20145154-5	2010	Stable FOXQ1-overexpressing cells (H1299/FOXQ1) exhibited elevated levels of p21 expression and inhibition of apoptosis induced by doxorubicin or camptothecin.	Camptothecin	146-158	forkhead box Q1	Homo sapiens	41-46
19796682-6	2010	DNA damage by UV radiation, etoposide or camptothecin caused a preferential down-regulation of nuclear BARD1 at 6h post-treatment.	Camptothecin	41-53	BRCA1 associated RING domain 1	Homo sapiens	103-108
20107320-4	2010	In particular CAPNS1 depletion affects gamma-H2AX appearance or persistence in U2OS osteosarcoma cells 24 hours after MMC addition or UV light exposure; in HT1080 upon camptothecin treatment for 4 hours and 48 hours after addition of MMC; in MDA-MB-231, 24 hours after UV light exposure and 2 hours after bleomycin addition.	Camptothecin	168-180	calpain small subunit 1	Homo sapiens	14-20
19909561-6	2010	The expression % of neurons in camptothecin P38 group, after 24 hours (40%), compared to camptothecin ATF-2 group after 24hours (30%), have been significant lower (p<0.05).	Camptothecin	31-43	mitogen-activated protein kinase 14	Homo sapiens	44-47
19909561-6	2010	The expression % of neurons in camptothecin P38 group, after 24 hours (40%), compared to camptothecin ATF-2 group after 24hours (30%), have been significant lower (p<0.05).	Camptothecin	89-101	activating transcription factor 2	Homo sapiens	102-107
19909561-7	2010	This study revealed that camptothecin induces P38 expression and P38 in embryonic cortical neurons to determine the importance of the P38 pathway in neuronal death following DNA damage, and P38 is induce phosphorylation of ATF-2 in embryonic cortical neurons following DNA damage.	Camptothecin	25-37	mitogen-activated protein kinase 14	Homo sapiens	46-49
19909561-7	2010	This study revealed that camptothecin induces P38 expression and P38 in embryonic cortical neurons to determine the importance of the P38 pathway in neuronal death following DNA damage, and P38 is induce phosphorylation of ATF-2 in embryonic cortical neurons following DNA damage.	Camptothecin	25-37	mitogen-activated protein kinase 14	Homo sapiens	65-68
19909561-7	2010	This study revealed that camptothecin induces P38 expression and P38 in embryonic cortical neurons to determine the importance of the P38 pathway in neuronal death following DNA damage, and P38 is induce phosphorylation of ATF-2 in embryonic cortical neurons following DNA damage.	Camptothecin	25-37	mitogen-activated protein kinase 14	Homo sapiens	65-68
19909561-7	2010	This study revealed that camptothecin induces P38 expression and P38 in embryonic cortical neurons to determine the importance of the P38 pathway in neuronal death following DNA damage, and P38 is induce phosphorylation of ATF-2 in embryonic cortical neurons following DNA damage.	Camptothecin	25-37	mitogen-activated protein kinase 14	Homo sapiens	65-68
19909561-7	2010	This study revealed that camptothecin induces P38 expression and P38 in embryonic cortical neurons to determine the importance of the P38 pathway in neuronal death following DNA damage, and P38 is induce phosphorylation of ATF-2 in embryonic cortical neurons following DNA damage.	Camptothecin	25-37	activating transcription factor 2	Homo sapiens	223-228
20086182-6	2010	Furthermore, the number of the CASP8 -652 6N del (but not 302H) variant allele tended to correlate with increased levels of camptothecin-induced p53-mediated apoptosis in T lymphocytes from 170 cancer-free controls.	Camptothecin	124-136	caspase 8	Homo sapiens	31-36
20086182-6	2010	Furthermore, the number of the CASP8 -652 6N del (but not 302H) variant allele tended to correlate with increased levels of camptothecin-induced p53-mediated apoptosis in T lymphocytes from 170 cancer-free controls.	Camptothecin	124-136	tumor protein p53	Homo sapiens	145-148
20102612-6	2010	Supporting this crosstalk, the activation of NF-kappaB by retinoids in T47D cells antagonizes the apoptosis triggered by the chemotherapeutic drugs etoposide, camptothecin or doxorubicin.	Camptothecin	159-171	nuclear factor kappa B subunit 1	Homo sapiens	45-54
19963390-1	2010	Human tyrosyl-DNA phosphodiesterase (hTdp1) inhibitors have become a major area of drug research and structure-based design since they have been shown to work synergistically with camptothecin (CPT) and selectively in cancer cells.	Camptothecin	180-192	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	37-42
19963390-1	2010	Human tyrosyl-DNA phosphodiesterase (hTdp1) inhibitors have become a major area of drug research and structure-based design since they have been shown to work synergistically with camptothecin (CPT) and selectively in cancer cells.	Camptothecin	194-197	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	37-42
20166932-0	2010	Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothecin-based treatment.	Camptothecin	60-72	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-31
19488755-1	2010	PURPOSE: To develop quantitative structure property relationships (QSPR) for the pharmacokinetics and the susceptibility to BCRP-mediated efflux of ten drugs in the camptothecin family of topoisomerase I inhibitors.	Camptothecin	165-177	BCR pseudogene 1	Homo sapiens	124-128
19488755-8	2010	CONCLUSIONS: QSPR models were successfully constructed for the pharmacokinetics and the susceptibility to BCRP mediated efflux of the camptothecin analogs.	Camptothecin	134-146	BCR pseudogene 1	Homo sapiens	106-110
19495753-0	2010	A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.	Camptothecin	35-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-110
19495753-2	2010	METHODS: A novel camptothecin analog that is effective against breast cancer resistance protein (BCRP)-positive cells was screened, and a water soluble prodrug was generated.	Camptothecin	17-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	63-95
19495753-2	2010	METHODS: A novel camptothecin analog that is effective against breast cancer resistance protein (BCRP)-positive cells was screened, and a water soluble prodrug was generated.	Camptothecin	17-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	97-101
20166932-4	2010	Thus, a role for TDP1 in counteracting DNA damage induced by camptothecins has been proposed.	Camptothecin	61-74	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	17-21
19629643-5	2010	Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity.	Camptothecin	111-123	zinc finger protein 420	Homo sapiens	173-177
20157251-3	2010	Here, we observed that the cells bearing high level of the dephosphorylated tau at Tau-1 epitope were more vulnerable to the apoptosis induced by staurosporine, camptothecin, and hydrogen peroxide, though the general outcome of tau expression was still anti-apoptotic.	Camptothecin	161-173	microtubule associated protein tau	Homo sapiens	76-79
19895669-10	2010	Importantly, Pim-1 activity is critical for neuronal death in this paradigm and its deficiency blocks camptothecin-mediated neuronal death.	Camptothecin	102-114	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	13-18
19629643-5	2010	Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity.	Camptothecin	111-123	zinc finger protein 420	Homo sapiens	214-218
19629643-5	2010	Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity.	Camptothecin	111-123	tumor protein p53	Homo sapiens	224-227
19629643-5	2010	Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity.	Camptothecin	111-123	tumor protein p53	Homo sapiens	257-260
20429622-2	2010	A combination of camptothecin and etoposide (1 microg/ml + 10 microg/ml) proved to be efficient in both types of cell lines, although mutant p53 cells exhibited a higher resistance.	Camptothecin	17-29	tumor protein p53	Homo sapiens	141-144
19918932-10	2010	Finally, we observe an epistatic relationship in terms of sensitivity to camptothecin of mms4 or mus81 to mph1.	Camptothecin	73-85	Mms4p	Saccharomyces cerevisiae S288C	89-93
19548284-6	2010	Harmine reduced resistance to the anticancer drugs mitoxantrone and camptothecin mediated by BCRP and might be an interesting new reversal agent.	Camptothecin	68-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	93-97
19854946-0	2010	DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1alpha gene locus.	Camptothecin	34-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	179-189
19918932-10	2010	Finally, we observe an epistatic relationship in terms of sensitivity to camptothecin of mms4 or mus81 to mph1.	Camptothecin	73-85	3'-5' DNA helicase	Saccharomyces cerevisiae S288C	106-110
19502564-3	2009	Other chemotherapeutic inducers of apoptosis such as etoposide and camptothecin also led to a robust induction of Hsp70 surface expression.	Camptothecin	67-79	heat shock protein family A (Hsp70) member 4	Homo sapiens	114-119
19895853-3	2009	In this work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO), camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) in HeLa cells.	Camptothecin	208-220	zinc finger protein 330	Homo sapiens	104-109
19895853-3	2009	In this work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO), camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) in HeLa cells.	Camptothecin	208-220	zinc finger protein 330	Homo sapiens	110-116
19895853-3	2009	In this work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO), camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) in HeLa cells.	Camptothecin	222-225	zinc finger protein 330	Homo sapiens	104-109
19895853-3	2009	In this work we address its mitochondrial localization and we demonstrate that a blockage of endogenous NOA36/ZNF330 expression by small-interfering RNA (siRNA) reduced apoptotic response to etoposide (ETO), camptothecin (CPT) and staurosporine (STS) but not to CH11 anti-Fas antibody or tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) in HeLa cells.	Camptothecin	222-225	zinc finger protein 330	Homo sapiens	110-116
19912650-7	2009	Enforced expression of anti-apoptotic Bcl-2 protein provided protection against camptothecin-induced cell death and partly against khat toxicity.	Camptothecin	80-92	BCL2 apoptosis regulator	Homo sapiens	38-43
19912650-8	2009	Khat-induced cell death in MOLM-13 cells included reduced levels of anti-apoptotic Mcl-1 protein, while both khat and camptothecin induced c-FLIPL cleavage and procaspase-8 activation.	Camptothecin	118-130	CASP8 and FADD like apoptosis regulator	Homo sapiens	139-146
19777212-7	2009	Camptothecin and etoposide caused an increase of protein expression of several cell-cycle regulators and induced the cleavage of Bcl-2 family of proteins.	Camptothecin	0-12	BCL2 apoptosis regulator	Homo sapiens	129-134
19617005-6	2009	Camptothecin and other DNA damaging agents induced both TREX1 protein and its mRNA in a dose- and time-dependent manner.	Camptothecin	0-12	three prime repair exonuclease 1	Homo sapiens	56-61
19819763-5	2009	Loss of S. pombe Mms1 results in the accumulation of spontaneous DNA damage, mitotic delay, and hypersensitivity to genotoxins such as camptothecin that perturb replisome progression.	Camptothecin	135-147	Mms1p	Saccharomyces cerevisiae S288C	17-21
19956593-5	2009	We show that the deletion of FUN30 leads to sensitivity to the topoisomerase I poison camptothecin and to severe cell cycle progression defects when the Orc5 subunit is mutated.	Camptothecin	86-98	DNA-dependent ATPase FUN30	Saccharomyces cerevisiae S288C	29-34
19883083-4	2009	Tdp1 inhibitors have been regarded as potential therapeutics in combination with Top1 inhibitors, such as the camptothecin derivatives, topotecan, and irinotecan, which are used to treat human cancers.	Camptothecin	110-122	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-4
19883083-4	2009	Tdp1 inhibitors have been regarded as potential therapeutics in combination with Top1 inhibitors, such as the camptothecin derivatives, topotecan, and irinotecan, which are used to treat human cancers.	Camptothecin	110-122	DNA topoisomerase I	Homo sapiens	81-85
19442434-0	2009	PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.	Camptothecin	62-74	paired box 3	Homo sapiens	0-9
19442434-3	2009	Camptothecin more efficiently inhibited proliferation and induced apoptosis in Rh30 (ARMS) than RD (ERMS) cells.	Camptothecin	0-12	Rh blood group D antigen	Homo sapiens	79-83
19442434-4	2009	Ectopic expression of the PAX3-FKHR (PF) fusion protein in RD cells significantly increased sensitivity, whereas siRNA knockdown of PF decreased sensitivity of Rh30 cells to camptothecin.	Camptothecin	174-186	Rh blood group D antigen	Homo sapiens	160-164
19906104-9	2009	Moreover, the inhibition of ezrin expression clearly inhibited SGC-7901 cell migration and invasion, and improved cell adhesion as well as increased sensitivity to camptothecin-induced apoptosis.	Camptothecin	164-176	ezrin	Homo sapiens	28-33
19481069-3	2009	We assessed the combined effect of YC-1 on the camptothecin toxicity in the human epithelial ovarian carcinoma cell lines OVCAR-3 and SK-OV-3.	Camptothecin	47-59	RNA binding motif single stranded interacting protein 1	Homo sapiens	35-39
19481069-6	2009	Camptothecin decreased Bax protein levels, whereas YC-1 increased Bax levels.	Camptothecin	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	23-26
19481069-7	2009	YC-1 enhanced the camptothecin-induced changes in the apoptotic protein levels and increased apoptotic effect of camptothecin on ovarian carcinoma cell lines.	Camptothecin	18-30	RNA binding motif single stranded interacting protein 1	Homo sapiens	0-4
19481069-7	2009	YC-1 enhanced the camptothecin-induced changes in the apoptotic protein levels and increased apoptotic effect of camptothecin on ovarian carcinoma cell lines.	Camptothecin	113-125	RNA binding motif single stranded interacting protein 1	Homo sapiens	0-4
19481069-8	2009	The results suggested that YC-1 may enhance a camptothecin toxicity against ovarian carcinoma cell lines by increasing activation of the caspase-8 and Bid pathway as well as activation of the mitochondria-mediated apoptotic pathway, leading to cytochrome c release and subsequent caspase-3 activation.	Camptothecin	46-58	RNA binding motif single stranded interacting protein 1	Homo sapiens	27-31
19794960-4	2009	Camptothecin-induced DSBs promote PP2A to associate with Ku 70 and Ku 86.	Camptothecin	0-12	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	Mus musculus	34-38
19596235-4	2009	Depletion of SLX4 causes sensitivity to mitomycin C and camptothecin and reduces the efficiency of DSB repair in vivo.	Camptothecin	56-68	SLX4 structure-specific endonuclease subunit	Homo sapiens	13-17
26124677-4	2009	Here we show that stable expression of RTKN2 in HEK cells enhanced survival in response to intrinsic apoptotic agents; 25-hydroxy cholesterol and camptothecin, but not the extrinsic agent, TNFalpha.	Camptothecin	146-158	rhotekin 2	Homo sapiens	39-44
19641995-0	2009	Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells.	Camptothecin	28-40	BCL2 like 1	Homo sapiens	83-91
19641995-5	2009	Bcl-X(L) expression was induced in MCF-7 cells treated with camptothecin alone, but not in cells treated simultaneously with camptothecin and valproic acid.	Camptothecin	60-72	BCL2 like 1	Homo sapiens	0-8
19483192-3	2009	We here showed that inhibition of RIF1 expression by small interfering RNA led to defective homologous recombination-mediated DNA double-strand break repair and sensitized cancer cells to camptothecin or staurosporine treatment.	Camptothecin	188-200	replication timing regulatory factor 1	Homo sapiens	34-38
19557000-3	2009	We show the induction of DSBs and DDR activation in post-mitotic primary neurons and lymphocytes treated with camptothecin, with the induction of nuclear DDR foci containing activated ATM, gamma-H2AX (phosphorylated histone H2AX), activated CHK2 (checkpoint kinase 2), MDC1 (mediator of DNA damage checkpoint 1) and 53BP1 (p53 binding protein 1).	Camptothecin	110-122	ATM serine/threonine kinase	Homo sapiens	184-187
19557000-3	2009	We show the induction of DSBs and DDR activation in post-mitotic primary neurons and lymphocytes treated with camptothecin, with the induction of nuclear DDR foci containing activated ATM, gamma-H2AX (phosphorylated histone H2AX), activated CHK2 (checkpoint kinase 2), MDC1 (mediator of DNA damage checkpoint 1) and 53BP1 (p53 binding protein 1).	Camptothecin	110-122	checkpoint kinase 2	Homo sapiens	241-245
19557000-3	2009	We show the induction of DSBs and DDR activation in post-mitotic primary neurons and lymphocytes treated with camptothecin, with the induction of nuclear DDR foci containing activated ATM, gamma-H2AX (phosphorylated histone H2AX), activated CHK2 (checkpoint kinase 2), MDC1 (mediator of DNA damage checkpoint 1) and 53BP1 (p53 binding protein 1).	Camptothecin	110-122	checkpoint kinase 2	Homo sapiens	247-266
19557000-3	2009	We show the induction of DSBs and DDR activation in post-mitotic primary neurons and lymphocytes treated with camptothecin, with the induction of nuclear DDR foci containing activated ATM, gamma-H2AX (phosphorylated histone H2AX), activated CHK2 (checkpoint kinase 2), MDC1 (mediator of DNA damage checkpoint 1) and 53BP1 (p53 binding protein 1).	Camptothecin	110-122	mediator of DNA damage checkpoint 1	Homo sapiens	269-273
19557000-3	2009	We show the induction of DSBs and DDR activation in post-mitotic primary neurons and lymphocytes treated with camptothecin, with the induction of nuclear DDR foci containing activated ATM, gamma-H2AX (phosphorylated histone H2AX), activated CHK2 (checkpoint kinase 2), MDC1 (mediator of DNA damage checkpoint 1) and 53BP1 (p53 binding protein 1).	Camptothecin	110-122	mediator of DNA damage checkpoint 1	Homo sapiens	275-310
19557000-3	2009	We show the induction of DSBs and DDR activation in post-mitotic primary neurons and lymphocytes treated with camptothecin, with the induction of nuclear DDR foci containing activated ATM, gamma-H2AX (phosphorylated histone H2AX), activated CHK2 (checkpoint kinase 2), MDC1 (mediator of DNA damage checkpoint 1) and 53BP1 (p53 binding protein 1).	Camptothecin	110-122	tumor protein p53 binding protein 1	Homo sapiens	316-321
19557000-3	2009	We show the induction of DSBs and DDR activation in post-mitotic primary neurons and lymphocytes treated with camptothecin, with the induction of nuclear DDR foci containing activated ATM, gamma-H2AX (phosphorylated histone H2AX), activated CHK2 (checkpoint kinase 2), MDC1 (mediator of DNA damage checkpoint 1) and 53BP1 (p53 binding protein 1).	Camptothecin	110-122	tumor protein p53 binding protein 1	Homo sapiens	323-344
19106818-6	2009	It is striking that hypoxia-inducible factor 1alpha (HIF-1alpha) inhibitor, camptothecin, suppressed hypoxia-induced COX-2 expression rather than pyrrolidine dithiocarbamate, a nuclear factor kappaB inhibitor.	Camptothecin	76-88	hypoxia inducible factor 1, alpha subunit	Mus musculus	20-51
19106818-6	2009	It is striking that hypoxia-inducible factor 1alpha (HIF-1alpha) inhibitor, camptothecin, suppressed hypoxia-induced COX-2 expression rather than pyrrolidine dithiocarbamate, a nuclear factor kappaB inhibitor.	Camptothecin	76-88	hypoxia inducible factor 1, alpha subunit	Mus musculus	53-63
19106818-6	2009	It is striking that hypoxia-inducible factor 1alpha (HIF-1alpha) inhibitor, camptothecin, suppressed hypoxia-induced COX-2 expression rather than pyrrolidine dithiocarbamate, a nuclear factor kappaB inhibitor.	Camptothecin	76-88	cytochrome c oxidase II, mitochondrial	Mus musculus	117-122
19716789-5	2009	Further, we show that low levels of Fbx6 and consequent impairment of replication stress-induced Chk1 degradation are associated with cancer cell resistance to the chemotherapeutic agent, camptothecin.	Camptothecin	188-200	F-box protein 6	Homo sapiens	36-40
19716789-5	2009	Further, we show that low levels of Fbx6 and consequent impairment of replication stress-induced Chk1 degradation are associated with cancer cell resistance to the chemotherapeutic agent, camptothecin.	Camptothecin	188-200	checkpoint kinase 1	Homo sapiens	97-101
19433978-0	2009	Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.	Camptothecin	101-113	BRCA2 DNA repair associated	Homo sapiens	37-42
19494003-3	2009	We found that the Topo I inhibitor camptothecin and, to a lesser extent, the Topo II inhibitor etoposide are potent inhibitors of the transcription and replication function of the EBV-encoded immediate-early protein Zta (also referred to as ZEBRA, EB1, and BZLF1).	Camptothecin	35-47	protein Zta	Human gammaherpesvirus 4	257-262
19494003-8	2009	Treatment with camptothecin reduced both Zta and RecQL1 binding to OriLyt in vivo, suggesting that Topo I promotes replication protein assembly at OriLyt.	Camptothecin	15-27	RecQ like helicase	Homo sapiens	49-55
19604089-1	2009	AIMS: A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies.	Camptothecin	45-57	poly(ADP-ribose) polymerase 1	Homo sapiens	87-92
19416980-2	2009	Silencing of RRM1 and RRM2, which encode the large and small subunits of the human ribonucleotide reductase complex, respectively, markedly enhanced the cytotoxicity of the topoisomerase I inhibitor camptothecin (CPT).	Camptothecin	199-211	ribonucleotide reductase catalytic subunit M1	Homo sapiens	13-17
19416980-2	2009	Silencing of RRM1 and RRM2, which encode the large and small subunits of the human ribonucleotide reductase complex, respectively, markedly enhanced the cytotoxicity of the topoisomerase I inhibitor camptothecin (CPT).	Camptothecin	199-211	ribonucleotide reductase regulatory subunit M2	Homo sapiens	22-26
19416980-2	2009	Silencing of RRM1 and RRM2, which encode the large and small subunits of the human ribonucleotide reductase complex, respectively, markedly enhanced the cytotoxicity of the topoisomerase I inhibitor camptothecin (CPT).	Camptothecin	213-216	ribonucleotide reductase catalytic subunit M1	Homo sapiens	13-17
19416980-2	2009	Silencing of RRM1 and RRM2, which encode the large and small subunits of the human ribonucleotide reductase complex, respectively, markedly enhanced the cytotoxicity of the topoisomerase I inhibitor camptothecin (CPT).	Camptothecin	213-216	ribonucleotide reductase regulatory subunit M2	Homo sapiens	22-26
19549776-1	2009	PURPOSE: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I).	Camptothecin	9-21	DNA topoisomerase I	Homo sapiens	87-111
19549776-1	2009	PURPOSE: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I).	Camptothecin	23-26	DNA topoisomerase I	Homo sapiens	87-111
19423727-0	2009	Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M. FANCM is a component of the Fanconi anemia (FA) core complex and one FA patient (EUFA867) with biallelic mutations in FANCM has been described.	Camptothecin	59-71	FA complementation group M	Homo sapiens	134-139
19423727-3	2009	These cells were hypersensitive to mitomycin C, but unlike cells defective in other core complex members, FANCM(-/-) cells were proficient in monoubiquitinating FANCD2 and were sensitive to the topoisomerase inhibitor camptothecin, a feature shared only with the FA subtype D1 and N. In addition, FANCM(-/-) cells were sensitive to UV light.	Camptothecin	218-230	FA complementation group M	Homo sapiens	106-111
19604089-1	2009	AIMS: A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies.	Camptothecin	45-57	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	94-98
19604089-1	2009	AIMS: A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies.	Camptothecin	45-57	X-ray repair cross complementing 1	Homo sapiens	103-108
19469529-5	2009	The camptothecin drug linkers were conjugated to three antibodies: chimeric BR96, chimeric AC10, and humanized 1F6, which bind to the Lewis-Y antigen on carcinomas, CD30 on hematologic malignancies, and CD70 present on hematologic malignancies and renal cell carcinoma, respectively.	Camptothecin	4-16	TNF receptor superfamily member 8	Homo sapiens	165-169
19303373-8	2009	In contrast, camptothecin-induced Top1-SSBs accumulated to similar levels in Tdp1(-/-) and Tdp1(-/-)/Aptx(-/-) double knockout astrocytes.	Camptothecin	13-25	tyrosyl-DNA phosphodiesterase 1	Mus musculus	77-81
19303373-8	2009	In contrast, camptothecin-induced Top1-SSBs accumulated to similar levels in Tdp1(-/-) and Tdp1(-/-)/Aptx(-/-) double knockout astrocytes.	Camptothecin	13-25	tyrosyl-DNA phosphodiesterase 1	Mus musculus	91-95
19303373-8	2009	In contrast, camptothecin-induced Top1-SSBs accumulated to similar levels in Tdp1(-/-) and Tdp1(-/-)/Aptx(-/-) double knockout astrocytes.	Camptothecin	13-25	aprataxin	Mus musculus	101-105
19469529-5	2009	The camptothecin drug linkers were conjugated to three antibodies: chimeric BR96, chimeric AC10, and humanized 1F6, which bind to the Lewis-Y antigen on carcinomas, CD30 on hematologic malignancies, and CD70 present on hematologic malignancies and renal cell carcinoma, respectively.	Camptothecin	4-16	CD70 molecule	Homo sapiens	203-207
19483324-7	2009	The DNMT inhibitor 5-aza-2"-deoxycytidine (DAC) sensitized SMMC-7721 cells to the cytotoxic effect of CPT.	Camptothecin	102-105	DNA methyltransferase 1	Homo sapiens	4-8
19487283-7	2009	Up-regulation of CD and down-regulation of eEF1 seemed to be specific to senescence, as they were observed during cellular senescence induced by hydrogen peroxide or anticancer drugs (camptothecin, etoposide, or 50 ng doxorubicin) but not during apoptosis induced by Taxol or 10 microg doxorubicin or autophagy induced by tamoxifen.	Camptothecin	184-196	eukaryotic translation elongation factor 1 beta 2	Homo sapiens	43-47
19445707-0	2009	Increased susceptibility of spinal muscular atrophy fibroblasts to camptothecin is p53-independent.	Camptothecin	67-79	tumor protein p53	Homo sapiens	83-86
19445707-4	2009	Previously, we have shown that skin fibroblasts from SMA patients are more sensitive to the DNA topoisomerase I inhibitor camptothecin, supporting a role for SMN in cell survival.	Camptothecin	122-134	survival of motor neuron 1, telomeric	Homo sapiens	158-161
19445707-8	2009	Upon camptothecin treatment, levels of p53 were markedly increased.	Camptothecin	5-17	tumor protein p53	Homo sapiens	39-42
19445707-9	2009	To determine if p53 plays a role in the increased sensitivity of SMA fibroblasts to camptothecin, we analyzed the sensitivity of SMA fibroblasts to another DNA topoisomerase I inhibitor, beta-lapachone.	Camptothecin	84-96	tumor protein p53	Homo sapiens	16-19
19339209-0	2009	Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway.	Camptothecin	23-35	signal transducer and activator of transcription 5A	Homo sapiens	85-90
19360472-2	2009	By applying subcellular proteomic analysis, we identified that the DHFR protein was translocated from cytoplasm into the nucleus when apoptosis was induced by NSC606985, a camptothecin analogue.	Camptothecin	172-184	dihydrofolate reductase	Homo sapiens	67-71
19339209-0	2009	Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway.	Camptothecin	23-35	BCL2 like 1	Homo sapiens	91-97
19218244-3	2009	To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT).	Camptothecin	309-321	TBP-associated factor 1	Drosophila melanogaster	154-158
19027085-7	2009	Furthermore, blocking ceramide metabolism by inhibiting glucosylceramide synthase strengthened the camptothecin and doxorubicin-dependent effects.	Camptothecin	99-111	UDP-glucose ceramide glucosyltransferase	Homo sapiens	56-81
19218244-3	2009	To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT).	Camptothecin	309-321	TBP-associated factor 1	Drosophila melanogaster	160-183
19218244-3	2009	To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT).	Camptothecin	309-321	meiotic 41	Drosophila melanogaster	239-242
19218244-3	2009	To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT).	Camptothecin	309-321	meiotic 41	Drosophila melanogaster	244-260
19218244-3	2009	To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT).	Camptothecin	323-326	TBP-associated factor 1	Drosophila melanogaster	154-158
19218244-3	2009	To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT).	Camptothecin	323-326	TBP-associated factor 1	Drosophila melanogaster	160-183
19218244-3	2009	To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT).	Camptothecin	323-326	meiotic 41	Drosophila melanogaster	239-242
19218244-3	2009	To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT).	Camptothecin	323-326	meiotic 41	Drosophila melanogaster	244-260
19189942-3	2009	The combination of all suppressors, elevated temperature, srs2, rad51-I345T, and mating-type (MAT) heterozygosity resulted in almost complete suppression of the rad57 mutant defect in the recruitment of Rad51 to DNA-damaged sites, as well as survival in response to ionizing radiation and camptothecin.	Camptothecin	289-301	recombinase RAD51	Saccharomyces cerevisiae S288C	64-69
19305131-0	2009	Camptothecin releases P-TEFb from the inactive 7SK snRNP complex.	Camptothecin	0-12	LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated	Homo sapiens	51-56
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	19-31	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	82-85
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	19-31	MDM2 proto-oncogene	Rattus norvegicus	100-104
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	19-31	ATR serine/threonine kinase	Rattus norvegicus	153-156
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	19-31	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	165-168
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	19-31	MDM2 proto-oncogene	Rattus norvegicus	179-183
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	33-36	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	82-85
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	33-36	MDM2 proto-oncogene	Rattus norvegicus	100-104
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	33-36	ATR serine/threonine kinase	Rattus norvegicus	153-156
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	33-36	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	165-168
19136059-2	2009	Our data show that camptothecin (CPT)-induced apoptosis correlated with increased p53, p21Cip1, and Mdm2 protein levels, with a simultaneous increase in ATR Ser428, p53 Ser15 and Mdm2 Ser166 phosphorylation in IEC-6 cells.	Camptothecin	33-36	MDM2 proto-oncogene	Rattus norvegicus	179-183
19136059-10	2009	Inhibition of ornithine decarboxylase (ODC) with alpha-difluromethylornithine (DFMO) and subsequent depletion of intracellular polyamines increased p53 protein, Mdm2 Ser166 phosphorylation and conferred resistance to CPT-induced apoptosis.	Camptothecin	217-220	ornithine decarboxylase 1	Rattus norvegicus	14-37
19136059-10	2009	Inhibition of ornithine decarboxylase (ODC) with alpha-difluromethylornithine (DFMO) and subsequent depletion of intracellular polyamines increased p53 protein, Mdm2 Ser166 phosphorylation and conferred resistance to CPT-induced apoptosis.	Camptothecin	217-220	ornithine decarboxylase 1	Rattus norvegicus	39-42
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	122-151
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	153-167
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	67-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	176-181
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	67-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	183-215
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	293-298
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	67-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	303-308
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	81-84	ATP binding cassette subfamily B member 1	Homo sapiens	122-151
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	81-84	ATP binding cassette subfamily B member 1	Homo sapiens	153-167
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	81-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	176-181
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	81-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	183-215
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	81-84	ATP binding cassette subfamily B member 1	Homo sapiens	293-298
19139163-2	2009	Previous in vivo studies of the pharmacokinetics of the lipophilic camptothecin (CPT) analog gimatecan suggested that the ATP-binding cassette (ABC) B1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein) inhibitors elacridar and pantoprazole could inhibit transporters other than ABCB1 and ABCG2.	Camptothecin	81-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	303-308
19293287-9	2009	Interestingly, miR-125b is down-regulated when zebrafish embryos are treated with gamma-irradiation or camptothecin, corresponding to the rapid increase in p53 protein in response to DNA damage.	Camptothecin	103-115	microRNA 125b-1	Danio rerio	15-23
19189942-3	2009	The combination of all suppressors, elevated temperature, srs2, rad51-I345T, and mating-type (MAT) heterozygosity resulted in almost complete suppression of the rad57 mutant defect in the recruitment of Rad51 to DNA-damaged sites, as well as survival in response to ionizing radiation and camptothecin.	Camptothecin	289-301	putative DNA-dependent ATPase RAD57	Saccharomyces cerevisiae S288C	161-166
19293287-9	2009	Interestingly, miR-125b is down-regulated when zebrafish embryos are treated with gamma-irradiation or camptothecin, corresponding to the rapid increase in p53 protein in response to DNA damage.	Camptothecin	103-115	tumor protein p53	Danio rerio	156-159
19189942-3	2009	The combination of all suppressors, elevated temperature, srs2, rad51-I345T, and mating-type (MAT) heterozygosity resulted in almost complete suppression of the rad57 mutant defect in the recruitment of Rad51 to DNA-damaged sites, as well as survival in response to ionizing radiation and camptothecin.	Camptothecin	289-301	recombinase RAD51	Saccharomyces cerevisiae S288C	203-208
18923446-5	2009	In particular, pretreatment with LL-37 significantly decreased caspase-3 activity after CAM-treatment.	Camptothecin	88-91	cathelicidin antimicrobial peptide	Homo sapiens	33-38
18923446-5	2009	In particular, pretreatment with LL-37 significantly decreased caspase-3 activity after CAM-treatment.	Camptothecin	88-91	caspase 3	Homo sapiens	63-72
19530720-2	2009	A general synthetic protocol, based on "C-5 camptothecin (C-5-CPT) enolate chemistry", allows one to obtain various C5-substituted analogues.	Camptothecin	44-56	complement C5	Homo sapiens	39-43
19318631-12	2009	FASN overexpression protected iPrECs from apoptosis induced by camptothecin but did not protect iPrECs from Fas receptor-induced apoptosis.	Camptothecin	63-75	fatty acid synthase	Mus musculus	0-4
19885006-3	2009	Camptothecin caused apoptosis in SiHa cells by inducing mitochondrial membrane permeability changes that lead to the loss of mitochondrial membrane potential, decreased Bcl-2 levels, cytochrome c release, caspase-3 activation, formation of reactive oxygen species and depletion of GSH.	Camptothecin	0-12	BCL2 apoptosis regulator	Homo sapiens	169-174
19885006-3	2009	Camptothecin caused apoptosis in SiHa cells by inducing mitochondrial membrane permeability changes that lead to the loss of mitochondrial membrane potential, decreased Bcl-2 levels, cytochrome c release, caspase-3 activation, formation of reactive oxygen species and depletion of GSH.	Camptothecin	0-12	cytochrome c, somatic	Homo sapiens	183-195
19885006-3	2009	Camptothecin caused apoptosis in SiHa cells by inducing mitochondrial membrane permeability changes that lead to the loss of mitochondrial membrane potential, decreased Bcl-2 levels, cytochrome c release, caspase-3 activation, formation of reactive oxygen species and depletion of GSH.	Camptothecin	0-12	caspase 3	Homo sapiens	205-214
19049493-3	2009	Transient expression of ectopic p53, activation of endogenous p53 by the DNA-damaging drug camptothecin or Mdm2 (murine double minute 2) depletion decreases the intracellular levels of APP in murine N2abeta neuroblastoma cells.	Camptothecin	91-103	transformation related protein 53, pseudogene	Mus musculus	32-35
19049493-3	2009	Transient expression of ectopic p53, activation of endogenous p53 by the DNA-damaging drug camptothecin or Mdm2 (murine double minute 2) depletion decreases the intracellular levels of APP in murine N2abeta neuroblastoma cells.	Camptothecin	91-103	transformation related protein 53, pseudogene	Mus musculus	62-65
19049493-8	2009	Reduction of Sp1 binding after activation of p53 with camptothecin was also observed in chromatin immunoprecipitation assays.	Camptothecin	54-66	tumor protein p53	Homo sapiens	45-48
19261878-4	2009	Despite promoting nuclear p53 accumulation, Class I/II HDAC inhibitors (HDACIs) protected neurons from p53-dependent cell death induced by camptothecin, etoposide, heterologous p53 expression or the MDM2 inhibitor, nutlin-3a.	Camptothecin	139-151	tumor protein p53	Homo sapiens	103-106
19261878-4	2009	Despite promoting nuclear p53 accumulation, Class I/II HDAC inhibitors (HDACIs) protected neurons from p53-dependent cell death induced by camptothecin, etoposide, heterologous p53 expression or the MDM2 inhibitor, nutlin-3a.	Camptothecin	139-151	tumor protein p53	Homo sapiens	103-106
19144573-7	2009	Unmodified PARP-1 was first delocalized from the nucleolus using camptothecin.	Camptothecin	65-77	poly(ADP-ribose) polymerase 1	Homo sapiens	11-17
19212664-0	2009	Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells.	Camptothecin	17-29	cyclin dependent kinase inhibitor 1A	Homo sapiens	38-45
19212664-6	2009	The induction of p21CIP1 protein levels began at 3 h and was maximal at 6-8 h; however, it decreased to control levels by 30 h. In contrast, the anticancer drug, camptothecin (CPT) induced a steady accumulation of p21CIP1 protein.	Camptothecin	162-174	cyclin dependent kinase inhibitor 1A	Homo sapiens	17-24
19212664-6	2009	The induction of p21CIP1 protein levels began at 3 h and was maximal at 6-8 h; however, it decreased to control levels by 30 h. In contrast, the anticancer drug, camptothecin (CPT) induced a steady accumulation of p21CIP1 protein.	Camptothecin	162-174	cyclin dependent kinase inhibitor 1A	Homo sapiens	214-221
19212664-6	2009	The induction of p21CIP1 protein levels began at 3 h and was maximal at 6-8 h; however, it decreased to control levels by 30 h. In contrast, the anticancer drug, camptothecin (CPT) induced a steady accumulation of p21CIP1 protein.	Camptothecin	176-179	cyclin dependent kinase inhibitor 1A	Homo sapiens	17-24
19212664-6	2009	The induction of p21CIP1 protein levels began at 3 h and was maximal at 6-8 h; however, it decreased to control levels by 30 h. In contrast, the anticancer drug, camptothecin (CPT) induced a steady accumulation of p21CIP1 protein.	Camptothecin	176-179	cyclin dependent kinase inhibitor 1A	Homo sapiens	214-221
19885006-5	2009	These results suggest that camptothecin may cause cell death in SiHa cells by inducing changes in mitochondrial membrane permeability, which leads to cytochrome c release and activation of caspase-3.	Camptothecin	27-39	cytochrome c, somatic	Homo sapiens	150-162
19885006-5	2009	These results suggest that camptothecin may cause cell death in SiHa cells by inducing changes in mitochondrial membrane permeability, which leads to cytochrome c release and activation of caspase-3.	Camptothecin	27-39	caspase 3	Homo sapiens	189-198
19322780-0	2009	NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.	Camptothecin	64-76	N-myc downstream regulated 1	Homo sapiens	0-5
19322780-1	2009	We previously reported that NSC606985, a new camptothecin analog, induces apoptosis of acute myeloid leukemic cells, which is triggered by proteolytic activation of protein kinase C delta (PKC delta).	Camptothecin	45-57	protein kinase C delta	Homo sapiens	165-187
19322780-1	2009	We previously reported that NSC606985, a new camptothecin analog, induces apoptosis of acute myeloid leukemic cells, which is triggered by proteolytic activation of protein kinase C delta (PKC delta).	Camptothecin	45-57	protein kinase C delta	Homo sapiens	189-198
19322780-5	2009	The results demonstrated that the down-regulation of NDRG1 protein but not its mRNA was an early event prior to proteolytic activation of PKC delta in U937 cells under treatments of NSC606985 as well as other camptothecin analogs.	Camptothecin	209-221	N-myc downstream regulated 1	Homo sapiens	53-58
19322780-8	2009	In summary, our study suggests that the down-regulation of NDRG1 is involved in proteolytic activation of PKC delta during apoptosis induction, which would shed new light on the understanding the apoptotic process initiated by camptothecin.	Camptothecin	227-239	N-myc downstream regulated 1	Homo sapiens	59-64
19322780-8	2009	In summary, our study suggests that the down-regulation of NDRG1 is involved in proteolytic activation of PKC delta during apoptosis induction, which would shed new light on the understanding the apoptotic process initiated by camptothecin.	Camptothecin	227-239	protein kinase C delta	Homo sapiens	106-115
19094980-0	2009	A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.	Camptothecin	54-66	SBF complex DNA-binding subunit SWI4	Saccharomyces cerevisiae S288C	84-88
19060337-2	2009	A systematic screening of the protein kinase small interfering RNA library reveals that Chk1 and ataxia telangiectasia-mutated (ATM) and Rad3-related (ATR) are the main kinases responsible for intra-S-phase checkpoint upon topoisomerase I inhibitor camptothecin-induced DNA damage.	Camptothecin	249-261	checkpoint kinase 1	Homo sapiens	88-92
19060337-2	2009	A systematic screening of the protein kinase small interfering RNA library reveals that Chk1 and ataxia telangiectasia-mutated (ATM) and Rad3-related (ATR) are the main kinases responsible for intra-S-phase checkpoint upon topoisomerase I inhibitor camptothecin-induced DNA damage.	Camptothecin	249-261	ATM serine/threonine kinase	Homo sapiens	97-132
19060337-2	2009	A systematic screening of the protein kinase small interfering RNA library reveals that Chk1 and ataxia telangiectasia-mutated (ATM) and Rad3-related (ATR) are the main kinases responsible for intra-S-phase checkpoint upon topoisomerase I inhibitor camptothecin-induced DNA damage.	Camptothecin	249-261	ATR serine/threonine kinase	Homo sapiens	151-154
19060337-6	2009	In cells deficient in both Chk1 and p53, Cdc25A down-regulation upon camptothecin-induced DNA damage is completely abolished, leading to severe defects in cell cycle checkpoints and remarkable cell death in mitosis.	Camptothecin	69-81	checkpoint kinase 1	Homo sapiens	27-31
19060337-6	2009	In cells deficient in both Chk1 and p53, Cdc25A down-regulation upon camptothecin-induced DNA damage is completely abolished, leading to severe defects in cell cycle checkpoints and remarkable cell death in mitosis.	Camptothecin	69-81	tumor protein p53	Homo sapiens	36-39
19060337-6	2009	In cells deficient in both Chk1 and p53, Cdc25A down-regulation upon camptothecin-induced DNA damage is completely abolished, leading to severe defects in cell cycle checkpoints and remarkable cell death in mitosis.	Camptothecin	69-81	cell division cycle 25A	Homo sapiens	41-47
19073137-1	2009	Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette protein superfamily, confers resistance to nucleoside and nucleotide analogs as well as camptothecin derivatives.	Camptothecin	170-182	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
19073137-1	2009	Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette protein superfamily, confers resistance to nucleoside and nucleotide analogs as well as camptothecin derivatives.	Camptothecin	170-182	ATP binding cassette subfamily C member 4	Homo sapiens	37-42
18987662-5	2009	U-937 cells overexpressing VEGF were resistant to all-trans-retinoic acid-(ATRA) or camptothecin-induced apoptosis.	Camptothecin	84-96	vascular endothelial growth factor A	Homo sapiens	27-31
19094980-0	2009	A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.	Camptothecin	54-66	transcription factor MBP1	Saccharomyces cerevisiae S288C	93-97
19099450-0	2009	Camptothecins: a SAR/QSAR study.	Camptothecin	0-13	sarcosine dehydrogenase	Homo sapiens	17-20
19111545-0	2009	Down-regulation of adenine nucleotide translocase 3 and its role in camptothecin-induced apoptosis in human hepatoma QGY7703 cells.	Camptothecin	68-80	solute carrier family 25 member 6	Homo sapiens	19-49
18987339-0	2009	Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment.	Camptothecin	74-86	RecQ protein-like 5	Mus musculus	0-6
19470292-13	2009	This paper presents an overview of the investigations on the feasibility and application of flavonoids as P-gp modulators for improved efficacy of anti-cancer drugs like taxanes, anthracyclines, epipodophyllotoxins, camptothecins and vinca alkaloids.	Camptothecin	216-229	ATP binding cassette subfamily B member 1	Homo sapiens	106-110
18492021-9	2009	This inhibition of RFC4 expression correlated with a decrease in cellular proliferation, increased levels of apoptosis and a sensitizing of the cells to the DNA-damaging chemotherapeutic agents, doxorubicin and camptothecin.	Camptothecin	211-223	replication factor C subunit 4	Homo sapiens	19-23
19763947-2	2009	Using the topoisomerase I poison camptothecin and the topoisomerase II poison VP16, the precise sites of interaction of these enzymes around the lamin B2 origin have been identified at different points in the cell cycle.	Camptothecin	33-45	lamin B2	Homo sapiens	145-153
19887335-1	2009	Cancer being a leading cause of death, the development of anti-cancer drugs like Camptothecin (CPT) has been promoted.	Camptothecin	81-93	choline phosphotransferase 1	Homo sapiens	95-98
18987339-4	2009	Here, we report that the deletion of RecQ helicase Recql5 in mouse ES cells and embryonic fibroblast (MEF) cells resulted in a significant increase in CPT sensitivity and a profound reduction in DNA replication after the treatment with CPT, but not other DNA-damaging agents.	Camptothecin	151-154	RecQ protein-like 5	Mus musculus	51-57
18987339-6	2009	Furthermore, we show that Recql5 functions nonredundantly with Rad51, a key factor for HR to protect mouse ES cells from CPT-induced cytotoxicity.	Camptothecin	121-124	RecQ protein-like 5	Mus musculus	26-32
18987339-6	2009	Furthermore, we show that Recql5 functions nonredundantly with Rad51, a key factor for HR to protect mouse ES cells from CPT-induced cytotoxicity.	Camptothecin	121-124	RAD51 recombinase	Mus musculus	63-68
18834855-7	2008	Ectopic miR-34a expression resulted in cell cycle arrest and growth inhibition and attenuated chemoresistance to anticancer drug camptothecin by inducing apoptosis, suggesting a potential role of miR-34a for the treatment of p53-defective prostate cancer.	Camptothecin	129-141	microRNA 34a	Homo sapiens	8-15
18823950-1	2008	Structurally diverse chemotherapeutic and chemopreventive drugs, including camptothecin, doxorubicin, sanguinarine, and others, were found to cause covalent crosslinking of proliferating cell nuclear antigen (PCNA) trimers in mammalian cells exposed to fluorescent light.	Camptothecin	75-87	proliferating cell nuclear antigen	Homo sapiens	173-207
18823950-1	2008	Structurally diverse chemotherapeutic and chemopreventive drugs, including camptothecin, doxorubicin, sanguinarine, and others, were found to cause covalent crosslinking of proliferating cell nuclear antigen (PCNA) trimers in mammalian cells exposed to fluorescent light.	Camptothecin	75-87	proliferating cell nuclear antigen	Homo sapiens	209-213
18786657-3	2008	Using Xenopus cell-free extracts, we show that FANCL depletion results in defective DNA replication restart following treatment with camptothecin, a drug that results in DSBs during DNA replication.	Camptothecin	133-145	FA complementation group L L homeolog	Xenopus laevis	47-52
18693109-5	2008	Deletion of MRE11, part of the highly conserved RMX complex that aids in sensing and repairing double strand breaks in budding yeasts, enhanced sensitivity to gamma radiation (gamma-ray) (detection threshold of 50Gy) and camptothecin.	Camptothecin	221-233	MRX complex nuclease subunit	Saccharomyces cerevisiae S288C	12-17
19096507-6	2008	The top3alpha-2 line exhibits fragmented chromosomes during mitosis and sensitivity to camptothecin, suggesting an important role in chromosome segregation partly overlapping with that of type IB topoisomerases.	Camptothecin	87-99	topoisomerase 3alpha	Arabidopsis thaliana	4-13
19086848-3	2008	Repair-deficient cancers are likely to be Fhit-deficient and Fhit-deficient cells show enhanced resistance to ultraviolet C, mitomycin C, camptothecin and oxidative stress-induced cell killing.	Camptothecin	138-150	fragile histidine triad gene	Mus musculus	42-46
19086848-3	2008	Repair-deficient cancers are likely to be Fhit-deficient and Fhit-deficient cells show enhanced resistance to ultraviolet C, mitomycin C, camptothecin and oxidative stress-induced cell killing.	Camptothecin	138-150	fragile histidine triad gene	Mus musculus	61-65
18692478-4	2008	Np95 and Eme1 co-localize on nuclear chromatin following exposure of cells to camptothecin, an agent that promotes the collapse of replication forks.	Camptothecin	78-90	ubiquitin like with PHD and ring finger domains 1	Homo sapiens	0-4
18826252-8	2008	Moreover, we show that inhibition of Top1mt by camptothecin reduces the level of formation of the 7S DNA.	Camptothecin	47-59	DNA topoisomerase I mitochondrial	Homo sapiens	37-43
18692478-4	2008	Np95 and Eme1 co-localize on nuclear chromatin following exposure of cells to camptothecin, an agent that promotes the collapse of replication forks.	Camptothecin	78-90	essential meiotic structure-specific endonuclease 1	Homo sapiens	9-13
18716619-6	2008	We show that mutating Ser 267 of Sae2 to a non-phosphorylatable residue causes phenotypes comparable to those of a sae2Delta null mutant, including hypersensitivity to camptothecin, defective sporulation, reduced hairpin-induced recombination, severely impaired DNA-end processing and faulty assembly and disassembly of HR factors.	Camptothecin	168-180	ssDNA endodeoxyribonuclease SAE2	Saccharomyces cerevisiae S288C	33-37
18573234-4	2008	Treatment with a SIRT1 inhibitor, sirtinol, inhibited cell growth and increased sensitivity to camptothecin and cisplatin.	Camptothecin	95-107	sirtuin 1	Homo sapiens	17-22
18700866-7	2008	Camptothecin (CPT), however, triggered activation of caspase-3 without induction of caspase-12, and reduced cell proliferation.	Camptothecin	0-12	caspase 3	Homo sapiens	53-62
18700866-7	2008	Camptothecin (CPT), however, triggered activation of caspase-3 without induction of caspase-12, and reduced cell proliferation.	Camptothecin	14-17	caspase 3	Homo sapiens	53-62
18700866-8	2008	In addition, CPT-induced cell death was reversed by pre-treatment with z-DEVD, a caspase-3-specific inhibitor.	Camptothecin	13-16	caspase 3	Homo sapiens	81-90
18756267-7	2008	Furthermore, mutation of these Exo1 residues altered the DNA damage response to uncapped telomeres and camptothecin treatment, in a manner that suggests Exo1 phosphorylation inhibits its activity.	Camptothecin	103-115	Rad2 family nuclease EXO1	Saccharomyces cerevisiae S288C	31-35
18756267-7	2008	Furthermore, mutation of these Exo1 residues altered the DNA damage response to uncapped telomeres and camptothecin treatment, in a manner that suggests Exo1 phosphorylation inhibits its activity.	Camptothecin	103-115	Rad2 family nuclease EXO1	Saccharomyces cerevisiae S288C	153-157
18765539-0	2008	Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.	Camptothecin	61-73	phenylalkylamine Ca2+ antagonist (emopamil) binding protein	Mus musculus	88-91
18765539-0	2008	Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.	Camptothecin	61-73	MRE11A homolog A, double strand break repair nuclease	Mus musculus	135-140
18550533-5	2008	Treatment of chicken DT40 cells with various genotoxic agents, UV light, etoposide, or camptothecin induced Chk1 cleavage, which was inhibited by a pan-caspase inhibitor, benzyloxycarbonyl-VAD-fluoromethyl ketone.	Camptothecin	87-99	opsin, green sensitive (rhodopsin-like)	Gallus gallus	108-112
18718178-11	2008	The treatment of melanomas with the camptothecin-loaded SLN-C and NLC yielded cytotoxicity comparable to that of the free form.	Camptothecin	36-48	sarcolipin	Homo sapiens	56-59
18718178-13	2008	CONCLUSION: The results collectively suggest that the SLN-P may have the potential to serve as a delivery system for parenteral camptothecin administration because of the sustained drug release, strong cytotoxicity, limited hemolysis, and good storage stability.	Camptothecin	128-140	sarcolipin	Homo sapiens	54-57
18573234-5	2008	Silencing of SIRT1 expression by siRNA also suppressed cell proliferation and reduced camptothecin resistance in PC3 cells, mimicking the chemosensitizing effect caused by sirtinol.	Camptothecin	86-98	sirtuin 1	Homo sapiens	13-18
18573234-5	2008	Silencing of SIRT1 expression by siRNA also suppressed cell proliferation and reduced camptothecin resistance in PC3 cells, mimicking the chemosensitizing effect caused by sirtinol.	Camptothecin	86-98	proprotein convertase subtilisin/kexin type 1	Homo sapiens	113-116
18753379-7	2008	Primary cortical neurons prepared from paternal Ndn-deficient mice have high p53 acetylation levels and are sensitive to the DNA-damaging compounds camptothecin and hydrogen peroxide.	Camptothecin	148-160	necdin, MAGE family member	Mus musculus	48-51
18492797-0	2008	Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N"-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells.	Camptothecin	148-160	O-6-methylguanine-DNA methyltransferase	Homo sapiens	30-68
18515798-4	2008	Using quiescent (serum-starved) human WI-38 cells, camptothecin (CPT) was shown to induce Top1 down-regulation, which paralleled the induction of DNA single-strand breaks (SSBs) (assayed by comet assays) and ATM autophosphorylation (at Ser-1981).	Camptothecin	51-63	ATM serine/threonine kinase	Homo sapiens	208-211
18596254-2	2008	A model to address this issue is alternative splicing of Drosophila TAF1 pre-mRNA in response to camptothecin (CPT)-induced DNA damage signals.	Camptothecin	97-109	TBP-associated factor 1	Drosophila melanogaster	68-72
18596254-2	2008	A model to address this issue is alternative splicing of Drosophila TAF1 pre-mRNA in response to camptothecin (CPT)-induced DNA damage signals.	Camptothecin	111-114	TBP-associated factor 1	Drosophila melanogaster	68-72
18515798-4	2008	Using quiescent (serum-starved) human WI-38 cells, camptothecin (CPT) was shown to induce Top1 down-regulation, which paralleled the induction of DNA single-strand breaks (SSBs) (assayed by comet assays) and ATM autophosphorylation (at Ser-1981).	Camptothecin	65-68	ATM serine/threonine kinase	Homo sapiens	208-211
18452169-6	2008	Furthermore, prostate cancer cells overexpressing S100P were protected against camptothecin-induced apoptosis.	Camptothecin	79-91	S100 calcium binding protein P	Homo sapiens	50-55
18644996-4	2008	Importantly, pharmacologic SphK1 inhibition with the B-5354c compound sensitizes LNCaP and PC-3 cells to docetaxel and camptothecin, respectively.	Camptothecin	119-131	sphingosine kinase 1	Homo sapiens	27-32
18593932-7	2008	In contrast, ATM depletion sensitized the cancer cells to treatment with camptothecin, a topoisomerase inhibitor that induces DNA double-strand breaks.	Camptothecin	73-85	ATM serine/threonine kinase	Homo sapiens	13-16
18504617-5	2008	Previous studies have shown that BLM and WRN-deficient cells demonstrate increased sensitivity to hydroxyurea (HU), camptothecin (CPT), and 4-nitroquinoline 1-oxide (4NQO).	Camptothecin	116-128	WRN RecQ like helicase	Homo sapiens	41-44
18504617-5	2008	Previous studies have shown that BLM and WRN-deficient cells demonstrate increased sensitivity to hydroxyurea (HU), camptothecin (CPT), and 4-nitroquinoline 1-oxide (4NQO).	Camptothecin	130-133	WRN RecQ like helicase	Homo sapiens	41-44
18644996-5	2008	In vivo, camptothecin and B-5354c alone display a limited effect on tumor growth in PC-3 cells, whereas in combination there is a synergy of effect on tumor size with a significant increase in the ceramide to S1P sphingolipid ratio.	Camptothecin	9-21	membrane bound transcription factor peptidase, site 1	Homo sapiens	209-212
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Camptothecin	201-213	ATP binding cassette subfamily C member 4	Homo sapiens	0-30
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Camptothecin	201-213	ATP binding cassette subfamily C member 4	Homo sapiens	32-36
18559527-1	2008	Multidrug resistance protein 4 (MRP4; ABCC4) is a member of the ATP-binding cassette superfamily of membrane transport proteins and confers resistance to nucleoside and nucleotide analogues as well as camptothecin derivatives.	Camptothecin	201-213	ATP binding cassette subfamily C member 4	Homo sapiens	38-43
18445521-2	2008	The present study was designed to extend preclinical evaluation of the novel camptothecin in human squamous cell carcinoma (SCC) models.	Camptothecin	77-89	serpin family B member 3	Homo sapiens	124-127
18349103-1	2008	Poly(ADP-ribose) polymerase (PARP)-1 was reported to promote the religation activity of topoisomerase I in the presence of camptothecin by itself through the direct interaction with topoisomerase I or by the formation of poly(ADP-ribosyl)ated topoisomerase I.	Camptothecin	123-135	poly(ADP-ribose) polymerase 1	Homo sapiens	0-36
18315559-2	2008	Here we show that in cultured cortical neurons, the DNA damaging agent camptothecin (CPT) reduced transcription of rRNA and disrupted nucleolar staining for B23/nucleophosmin suggesting DNA damage-induced nucleolar stress.	Camptothecin	71-83	nucleophosmin 1	Homo sapiens	157-160
18315559-2	2008	Here we show that in cultured cortical neurons, the DNA damaging agent camptothecin (CPT) reduced transcription of rRNA and disrupted nucleolar staining for B23/nucleophosmin suggesting DNA damage-induced nucleolar stress.	Camptothecin	85-88	nucleophosmin 1	Homo sapiens	157-160
18645223-4	2008	Using immunocytochemistry we observed redistribution, enhanced upon treatment with camptothecin or valinomycin, of CIDEa to nucleus.	Camptothecin	83-95	cell death inducing DFFA like effector a	Homo sapiens	115-120
17943230-1	2008	Clinically relevant resistance to the currently approved camptothecins, irinotecan and topotecan, is poorly understood but may involve increased expression of ATP-dependent drug transporters such as ABCG2 (breast cancer resistant protein, BCRP).	Camptothecin	57-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	199-204
17943230-1	2008	Clinically relevant resistance to the currently approved camptothecins, irinotecan and topotecan, is poorly understood but may involve increased expression of ATP-dependent drug transporters such as ABCG2 (breast cancer resistant protein, BCRP).	Camptothecin	57-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	239-243
18349103-2	2008	We have demonstrated previously that ATP inhibited PARP-1/NAD-facilitated religation of topoisomerase I-linked DNA (TLD) in the presence of camptothecin.	Camptothecin	140-152	poly(ADP-ribose) polymerase 1	Homo sapiens	51-57
18349103-5	2008	In the presence of camptothecin or its derivative topotecan, ATP (at up to 2 mM) inhibited PARP-1/NAD-facilitated TLD religation in a dose-dependent manner.	Camptothecin	19-31	poly(ADP-ribose) polymerase 1	Homo sapiens	91-97
18495890-2	2008	Using the camptothecin-induced DNA damage model in neurons, we previously showed that cyclin D1-associated cell cycle cyclin-dependent kinases (Cdks) (Cdk4/6) and p53 activation are two major events leading to activation of the mitochondrial apoptotic pathway.	Camptothecin	10-22	cyclin D1	Homo sapiens	86-95
18566216-6	2008	Using RNA interference, we further showed that Chk2 was essential to G(2)-M arrest, whereas Chk1 was mainly required for HR repair in CPT-treated HCT116 cells.	Camptothecin	134-137	checkpoint kinase 1	Homo sapiens	92-96
18566216-0	2008	Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.	Camptothecin	150-163	checkpoint kinase 1	Homo sapiens	0-4
18566216-0	2008	Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.	Camptothecin	150-163	checkpoint kinase 2	Homo sapiens	9-13
18495890-2	2008	Using the camptothecin-induced DNA damage model in neurons, we previously showed that cyclin D1-associated cell cycle cyclin-dependent kinases (Cdks) (Cdk4/6) and p53 activation are two major events leading to activation of the mitochondrial apoptotic pathway.	Camptothecin	10-22	cyclin dependent kinase 4	Homo sapiens	144-148
18495890-2	2008	Using the camptothecin-induced DNA damage model in neurons, we previously showed that cyclin D1-associated cell cycle cyclin-dependent kinases (Cdks) (Cdk4/6) and p53 activation are two major events leading to activation of the mitochondrial apoptotic pathway.	Camptothecin	10-22	cyclin dependent kinase 4	Homo sapiens	151-157
18495890-2	2008	Using the camptothecin-induced DNA damage model in neurons, we previously showed that cyclin D1-associated cell cycle cyclin-dependent kinases (Cdks) (Cdk4/6) and p53 activation are two major events leading to activation of the mitochondrial apoptotic pathway.	Camptothecin	10-22	tumor protein p53	Homo sapiens	163-166
18384903-0	2008	In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.	Camptothecin	30-42	albumin	Mus musculus	115-128
18027847-6	2008	LNCaP cells overexpressing cyclin A1 are resistant to camptothecin-induced apoptosis.	Camptothecin	54-66	cyclin A1	Homo sapiens	27-36
18473721-7	2008	RNAi-mediated down-regulation of PNK renders cells more sensitive to ionizing radiation and camptothecin, a topoisomerase I inhibitor.	Camptothecin	92-104	polynucleotide kinase 3'-phosphatase	Homo sapiens	33-36
18473723-4	2008	Tdp1 has been regarded as a potential therapeutic co-target of Top1 in that it seemingly counteracts the effects of Top1 inhibitors, such as camptothecin and its clinically used derivatives.	Camptothecin	141-153	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	0-4
18418047-8	2008	However, HAUSP downregulation causes resistance to Camptothecin- and irradiation-induced apoptosis, which correlates with suppressed mitochondrial translocation of p53.	Camptothecin	51-63	ubiquitin specific peptidase 7	Homo sapiens	9-14
18418047-8	2008	However, HAUSP downregulation causes resistance to Camptothecin- and irradiation-induced apoptosis, which correlates with suppressed mitochondrial translocation of p53.	Camptothecin	51-63	tumor protein p53	Homo sapiens	164-167
18381071-0	2008	Protein arginine (N)-methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins.	Camptothecin	112-125	protein arginine N-methyltransferase 7	Cricetulus griseus	0-41
18381071-0	2008	Protein arginine (N)-methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins.	Camptothecin	112-125	protein arginine N-methyltransferase 7	Cricetulus griseus	43-48
18387845-10	2008	Camptothecin (1 mg/kg bw, day 6) induced a 3.6-fold increase in % MN-RET (P&lt;0.05) but was toxic at higher doses.	Camptothecin	0-12	ret proto-oncogene	Mus musculus	69-72
18311783-7	2008	By using camptothecin as a drug-induced apoptosis in vitro model, the authors demonstrated that the expression of AURKA provided protection against apoptosis to gastrointestinal cancer cells (AGS and RKO) (P= .006) and RIE-1 primary intestinal epithelial cells (P= .001).	Camptothecin	9-21	aurora kinase A	Rattus norvegicus	114-119
18307537-11	2008	An antisense RNA against YB-1 increased camptothecin sensitivity.	Camptothecin	40-52	Y-box binding protein 1	Homo sapiens	25-29
18027847-7	2008	Conversely, targeted knockdown of cyclin A1 via shRNA in LNCaP IL6+ cells resulted in decreased survival after treatment with camptothecin.	Camptothecin	126-138	cyclin A1	Homo sapiens	34-43
18027847-7	2008	Conversely, targeted knockdown of cyclin A1 via shRNA in LNCaP IL6+ cells resulted in decreased survival after treatment with camptothecin.	Camptothecin	126-138	interleukin 6	Homo sapiens	63-66
21892324-3	2008	The cytotoxic somatostatin (SST) conjugate JF-10-81 was developed by coupling camptothecin (CPT) to the N-terminus of a SST analog (JF-07-69) using an activated carbamate linker.	Camptothecin	78-90	somatostatin	Mus musculus	14-26
18480994-10	2008	It was suggested that transfection of mfn2 gene could significantly inhibit the proliferation of MCF-7 cells and promote their sensitivity to CAMP with a synergic effect.	Camptothecin	142-146	mitofusin 2	Homo sapiens	38-42
18285460-3	2008	The depletion of Rvb1 increases the amount and persistence of phosphorylation on chromatin-associated H2AX after the exposure of cells to UV irradiation or to mitomycin C, cisplatin, camptothecin, or etoposide, without increasing the amount of DNA damage.	Camptothecin	183-195	RuvB like AAA ATPase 1	Homo sapiens	17-21
18285460-3	2008	The depletion of Rvb1 increases the amount and persistence of phosphorylation on chromatin-associated H2AX after the exposure of cells to UV irradiation or to mitomycin C, cisplatin, camptothecin, or etoposide, without increasing the amount of DNA damage.	Camptothecin	183-195	H2A.X variant histone	Homo sapiens	102-106
18339864-2	2008	Here, we found that the Hsp72-depleted cells show defect in phosphorylation and activation of the protein kinase Chk1 by genotoxic stresses, such as UVC irradiation or camptothecin.	Camptothecin	168-180	heat shock protein family A (Hsp70) member 1A	Homo sapiens	24-29
18339864-2	2008	Here, we found that the Hsp72-depleted cells show defect in phosphorylation and activation of the protein kinase Chk1 by genotoxic stresses, such as UVC irradiation or camptothecin.	Camptothecin	168-180	checkpoint kinase 1	Homo sapiens	113-117
18208837-4	2008	Time-dependent decrease was observed in APE1 mRNA and protein levels in the human colorectal cancer line HCT116 p53(+/+), but not in the isogenic p53 null mutant after treatment with camptothecin, a DNA topoisomerase I inhibitor.	Camptothecin	183-195	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	40-44
18208837-4	2008	Time-dependent decrease was observed in APE1 mRNA and protein levels in the human colorectal cancer line HCT116 p53(+/+), but not in the isogenic p53 null mutant after treatment with camptothecin, a DNA topoisomerase I inhibitor.	Camptothecin	183-195	tumor protein p53	Homo sapiens	112-115
17617453-3	2008	We analysed programmed cell death pathways of v-myb-transformed BM2 monoblasts induced by arsenic trioxide, cycloheximide and camptothecin with U937 promonocytes as a reference cell line.	Camptothecin	126-138	MYB proto-oncogene, transcription factor	Homo sapiens	46-51
18177684-8	2008	Finally, treatment of uninfected cells with the topoisomerase I inhibitor camptothecin, to induce generation of free DNA ends, also resulted in Mre11 loss.	Camptothecin	74-86	MRE11 homolog, double strand break repair nuclease	Homo sapiens	144-149
18347181-3	2008	CDC45L, NFKB1, PARP1, TDP1, and XRCC1 have been shown to influence the cytotoxic action of camptothecins, including irinotecan.	Camptothecin	91-104	cell division cycle 45	Homo sapiens	0-6
18347181-3	2008	CDC45L, NFKB1, PARP1, TDP1, and XRCC1 have been shown to influence the cytotoxic action of camptothecins, including irinotecan.	Camptothecin	91-104	nuclear factor kappa B subunit 1	Homo sapiens	8-13
18347181-3	2008	CDC45L, NFKB1, PARP1, TDP1, and XRCC1 have been shown to influence the cytotoxic action of camptothecins, including irinotecan.	Camptothecin	91-104	poly(ADP-ribose) polymerase 1	Homo sapiens	15-20
18347181-3	2008	CDC45L, NFKB1, PARP1, TDP1, and XRCC1 have been shown to influence the cytotoxic action of camptothecins, including irinotecan.	Camptothecin	91-104	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	22-26
18347181-3	2008	CDC45L, NFKB1, PARP1, TDP1, and XRCC1 have been shown to influence the cytotoxic action of camptothecins, including irinotecan.	Camptothecin	91-104	X-ray repair cross complementing 1	Homo sapiens	32-37
18245364-3	2008	To examine the role of Esa1 in DNA damage repair, we isolated viable esa1 mutants with a range of hypersensitivities to the toposide camptothecin.	Camptothecin	133-145	NuA4 histone acetyltransferase complex catalytic subunit ESA1	Saccharomyces cerevisiae S288C	69-73
17977756-1	2008	In the present study, we investigated the role of recombinant human phospholipase D2 (rhPLD2) on proliferation and apoptosis in human leukemia HL-60 cells which induced by camptothecin.	Camptothecin	172-184	phospholipase D2	Homo sapiens	68-84
17977756-4	2008	Similarly, we show that both rhPLD2 and standard PLD were able to enhance camptothecin-induced apoptosis of HL-60 cells.	Camptothecin	74-86	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	31-34
17897832-0	2007	Identification of C10 biotinylated camptothecin (CPT-10-B) binding peptides using T7 phage display screen on a QCM device.	Camptothecin	35-47	dehydrodolichyl diphosphate synthase subunit	Homo sapiens	49-57
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Camptothecin	106-118	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	32-35
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Camptothecin	106-118	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	131-134
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Camptothecin	106-118	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	131-134
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Camptothecin	120-124	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	32-35
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Camptothecin	120-124	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	131-134
17897832-1	2007	A peptide sequence that can bind to camptothecin (CPT), a natural cytotoxic compound, was screened for using a T7 phage display system combined with a cuvette type quartz crystal microbalance (QCM) device.	Camptothecin	36-48	dehydrodolichyl diphosphate synthase subunit	Homo sapiens	50-53
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Camptothecin	120-124	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	131-134
17694514-4	2007	Our results show that activated Myc potentiated apoptosis induced by the cancer drugs etoposide (ETO) and camptothecin (CAMP) in v-Myc-expressing human U-937 monoblastic cells and in Rat1 cells containing a conditionally active Myc/estrogen receptor (MycER) fusion protein.	Camptothecin	120-124	estrogen receptor 1	Rattus norvegicus	232-249
17928296-4	2007	Robust phosphorylation of Ser(29) was also seen in interphase cells following treatment with the DNA-damaging agent camptothecin, a rare example of stress stimulating the modification of a repair factor by cyclin-Cdk.	Camptothecin	116-128	proliferating cell nuclear antigen	Homo sapiens	206-212
18074021-7	2007	Depletion of RECQ1 renders human cells sensitive to DNA damage induced by ionizing radiation or the topoisomerase inhibitor camptothecin, and results in spontaneous gamma-H2AX foci and elevated sister chromatid exchanges, indicating aberrant repair of DNA breaks.	Camptothecin	124-136	RecQ like helicase	Homo sapiens	13-18
18089724-1	2007	Lipophilic camptothecin derivatives are considered to have negligible affinity for breast cancer resistance protein (BCRP; ABCG2).	Camptothecin	11-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	83-115
17935989-3	2007	These compounds significantly sensitize tumor cells to the DNA-damaging antitumor agent doxorubicin in a cell-based assay and efficiently abrogate the doxorubicin-induced G2/M and camptothecin-induced S checkpoints, indicating that the potent biological activities of these compounds are mechanism-based through Chk1 inhibition.	Camptothecin	180-192	checkpoint kinase 1	Homo sapiens	312-316
18028422-6	2007	We further demonstrate that nuclear TFAM confers significant cytoprotection against the chemotherapeutic drugs etoposide, camptothecin, and cisplatin.	Camptothecin	122-134	transcription factor A, mitochondrial	Homo sapiens	36-40
18048937-10	2007	Infection of HeLa cells with GBS triggers pro-survival signalling and protects the HeLa cells from camptothecin-induced caspase-3 cleavage.	Camptothecin	99-111	caspase 3	Homo sapiens	120-129
18089724-1	2007	Lipophilic camptothecin derivatives are considered to have negligible affinity for breast cancer resistance protein (BCRP; ABCG2).	Camptothecin	11-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	117-121
18089724-1	2007	Lipophilic camptothecin derivatives are considered to have negligible affinity for breast cancer resistance protein (BCRP; ABCG2).	Camptothecin	11-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	123-128
17986860-7	2007	In human colon carcinoma cells treated with the topoisomerase I inhibitor camptothecin, DNA replication is inhibited both at the level of initiation and at the level of elongation through a Chk1-dependent checkpoint mechanism.	Camptothecin	74-86	checkpoint kinase 1	Homo sapiens	190-194
17942733-4	2007	Here we report that in this system, BDNF increased KSR1 association with activated ERK1/2, whereas KSR1 knockdown with a short hairpin (sh) RNA reduced BDNF-mediated activation of ERK1/2 and protection against a DNA-damaging drug, camptothecin (CPT).	Camptothecin	245-248	kinase suppressor of ras 1	Rattus norvegicus	99-103
17693058-9	2007	Treatment of the resistant cells with camptothecin, celecoxib and cisplatin resulted in the downregulation of c-FLIP and caused a synergistic apoptotic effect with TRAIL.	Camptothecin	38-50	CASP8 and FADD like apoptosis regulator	Homo sapiens	110-116
17693058-9	2007	Treatment of the resistant cells with camptothecin, celecoxib and cisplatin resulted in the downregulation of c-FLIP and caused a synergistic apoptotic effect with TRAIL.	Camptothecin	38-50	TNF superfamily member 10	Homo sapiens	164-169
17948061-5	2007	However, compared to wild-type mice, Tdp1-/- mice are hypersensitive to CPT and bleomycin but not to etoposide.	Camptothecin	72-75	tyrosyl-DNA phosphodiesterase 1	Mus musculus	37-41
17989286-7	2007	PUMA (p53-upregulated modulator of apoptosis) was one such gene induced by camptothecin, and its overexpression was sufficient to induce Bax (Bcl-2-associated X protein)-dependent neuronal death, whereas Noxa was not apoptogenic.	Camptothecin	75-87	transformation related protein 53, pseudogene	Mus musculus	6-9
17942733-4	2007	Here we report that in this system, BDNF increased KSR1 association with activated ERK1/2, whereas KSR1 knockdown with a short hairpin (sh) RNA reduced BDNF-mediated activation of ERK1/2 and protection against a DNA-damaging drug, camptothecin (CPT).	Camptothecin	231-243	kinase suppressor of ras 1	Rattus norvegicus	99-103
17942733-4	2007	Here we report that in this system, BDNF increased KSR1 association with activated ERK1/2, whereas KSR1 knockdown with a short hairpin (sh) RNA reduced BDNF-mediated activation of ERK1/2 and protection against a DNA-damaging drug, camptothecin (CPT).	Camptothecin	245-248	mitogen activated protein kinase 3	Rattus norvegicus	180-186
17942733-4	2007	Here we report that in this system, BDNF increased KSR1 association with activated ERK1/2, whereas KSR1 knockdown with a short hairpin (sh) RNA reduced BDNF-mediated activation of ERK1/2 and protection against a DNA-damaging drug, camptothecin (CPT).	Camptothecin	231-243	mitogen activated protein kinase 3	Rattus norvegicus	180-186
17565738-0	2007	Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling.	Camptothecin	0-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	46-49
17580098-2	2007	(Ala(2,8,9,19,24.25.27), Nle(17), Lys(28))VIP, (A-NL-K)VIP, was synthesized and Lys(28) was coupled to a linker, N-methyl-amino-ethyl-glycine, L2, which formed a carbamate bond with CPT.	Camptothecin	182-185	vasoactive intestinal polypeptide	Mus musculus	42-45
17565738-0	2007	Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling.	Camptothecin	0-12	protein kinase C delta	Homo sapiens	63-71
17942907-5	2007	Mgat5-/- tumor cells were comparatively hypersensitive to the ROS inducer 2,3-dimethoxy-1,4-naphthoquinone, hyposensitive to tyrosine kinase inhibitors, to Golgi disruption by brefeldin A, and to mitotic arrest by colcemid, hydroxyurea, and camptothecin.	Camptothecin	241-253	mannoside acetylglucosaminyltransferase 5	Mus musculus	0-5
17273826-5	2007	A decrease in Bcl-xL sensitised cells to the small molecule inhibitor of Bcl-xL, Antimycin A3 and the DNA topoisomerase I inhibitors, SN-38 and camptothecin, but not to doxorubicin.	Camptothecin	144-156	BCL2 like 1	Homo sapiens	14-20
17709397-6	2007	We observed that a treatment with the genotoxic stress inducer camptothecin for 6 h favored the production of the H-ras NMD-target transcript degraded in the cytosol by the NMD process.	Camptothecin	63-75	HRas proto-oncogene, GTPase	Homo sapiens	114-119
17709397-7	2007	Our data indicated that the NMD process allowed the elimination of transcripts produced in response to a short-term treatment with camptothecin from the major proto-oncogene H-ras, independently of PTCs induced by mutations.	Camptothecin	131-143	HRas proto-oncogene, GTPase	Homo sapiens	174-179
17709397-8	2007	The camptothecin effects on H-ras gene expression were p53 dependent and involved in part modulation of the SC35 splicing factor.	Camptothecin	4-16	HRas proto-oncogene, GTPase	Homo sapiens	28-33
17709397-8	2007	The camptothecin effects on H-ras gene expression were p53 dependent and involved in part modulation of the SC35 splicing factor.	Camptothecin	4-16	tumor protein p53	Homo sapiens	55-58
17709397-9	2007	Interestingly, a long-term treatment with camptothecin as well as p53 overexpression for 24 h resulted in the accumulation of the H-ras NMD target in the cytosol, although the NMD process was not completely inhibited as other NMD targets are not stabilized.	Camptothecin	42-54	HRas proto-oncogene, GTPase	Homo sapiens	130-135
17709397-10	2007	Finally, Upf1, a major NMD effector, was necessary for optimal p53 activation by camptothecin, which is consistent with recent data showing that NMD effectors are required for genome stability.	Camptothecin	81-93	UPF1 RNA helicase and ATPase	Homo sapiens	9-13
17709397-10	2007	Finally, Upf1, a major NMD effector, was necessary for optimal p53 activation by camptothecin, which is consistent with recent data showing that NMD effectors are required for genome stability.	Camptothecin	81-93	tumor protein p53	Homo sapiens	63-66
17917271-0	2007	Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase.	Camptothecin	39-51	WRN RecQ like helicase	Homo sapiens	98-101
17917271-4	2007	WRN silencing increased markedly the chemotherapeutic activity of camptothecin (CPT) on cancer cells in terms of the extent of efficacy and lowering effective drug dosage, accompanied by suppressing recovery from DNA damage caused by CPT.	Camptothecin	66-78	WRN RecQ like helicase	Homo sapiens	0-3
17917271-4	2007	WRN silencing increased markedly the chemotherapeutic activity of camptothecin (CPT) on cancer cells in terms of the extent of efficacy and lowering effective drug dosage, accompanied by suppressing recovery from DNA damage caused by CPT.	Camptothecin	80-83	WRN RecQ like helicase	Homo sapiens	0-3
17903171-6	2007	Intriguingly, Mus81 and FANCB act independently in surviving exposure to camptothecin (CPT).	Camptothecin	73-85	MUS81 structure-specific endonuclease subunit	Homo sapiens	14-19
17903171-6	2007	Intriguingly, Mus81 and FANCB act independently in surviving exposure to camptothecin (CPT).	Camptothecin	73-85	FA complementation group B	Homo sapiens	24-29
17903171-6	2007	Intriguingly, Mus81 and FANCB act independently in surviving exposure to camptothecin (CPT).	Camptothecin	87-90	MUS81 structure-specific endonuclease subunit	Homo sapiens	14-19
17903171-6	2007	Intriguingly, Mus81 and FANCB act independently in surviving exposure to camptothecin (CPT).	Camptothecin	87-90	FA complementation group B	Homo sapiens	24-29
17971907-0	2007	Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis.	Camptothecin	56-68	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	0-4
17971907-0	2007	Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis.	Camptothecin	56-68	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	5-10
17971907-10	2007	Cells coexpressing Noxa and Mcl-1 at different ratio correlates well with the extent of apoptosis, suggesting that the balance between Noxa and Mcl-1 may determine the susceptibility of HeLa cells to CPT-induced apoptosis.	Camptothecin	200-203	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	19-23
17971907-10	2007	Cells coexpressing Noxa and Mcl-1 at different ratio correlates well with the extent of apoptosis, suggesting that the balance between Noxa and Mcl-1 may determine the susceptibility of HeLa cells to CPT-induced apoptosis.	Camptothecin	200-203	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	28-33
17971907-10	2007	Cells coexpressing Noxa and Mcl-1 at different ratio correlates well with the extent of apoptosis, suggesting that the balance between Noxa and Mcl-1 may determine the susceptibility of HeLa cells to CPT-induced apoptosis.	Camptothecin	200-203	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	144-149
17660542-7	2007	Mms22 forms spontaneous nuclear foci and colocalizes with Rad22 in cells treated with camptothecin, suggesting that it has a direct role in repair of broken replication forks.	Camptothecin	86-98	Mms22p	Saccharomyces cerevisiae S288C	0-5
17548347-6	2007	Genotoxic stress induced by camptothecin treatment of NPCs stabilized p53, which formed a complex with GSK3beta and activated Bax and caspase-3.	Camptothecin	28-40	transformation related protein 53, pseudogene	Mus musculus	70-73
17349740-3	2007	The current study showed that a camptothecin (CPT)-selected human leukemia cell line (CPT-K5) had remarkably higher expression levels of Bcl-2 than its drug sensitive parental cell (RPMI 8402).	Camptothecin	32-44	BCL2 apoptosis regulator	Homo sapiens	137-142
17349740-3	2007	The current study showed that a camptothecin (CPT)-selected human leukemia cell line (CPT-K5) had remarkably higher expression levels of Bcl-2 than its drug sensitive parental cell (RPMI 8402).	Camptothecin	46-49	BCL2 apoptosis regulator	Homo sapiens	137-142
17548347-6	2007	Genotoxic stress induced by camptothecin treatment of NPCs stabilized p53, which formed a complex with GSK3beta and activated Bax and caspase-3.	Camptothecin	28-40	glycogen synthase kinase 3 beta	Mus musculus	103-111
17548347-6	2007	Genotoxic stress induced by camptothecin treatment of NPCs stabilized p53, which formed a complex with GSK3beta and activated Bax and caspase-3.	Camptothecin	28-40	BCL2-associated X protein	Mus musculus	126-129
17548347-6	2007	Genotoxic stress induced by camptothecin treatment of NPCs stabilized p53, which formed a complex with GSK3beta and activated Bax and caspase-3.	Camptothecin	28-40	caspase 3	Mus musculus	134-143
17548347-7	2007	Camptothecin-induced activation of caspase-3 was reduced by GSK3 inhibitors in both bax(+)(/)(+) and bax(-/-) NPCs.	Camptothecin	0-12	caspase 3	Mus musculus	35-44
17548347-7	2007	Camptothecin-induced activation of caspase-3 was reduced by GSK3 inhibitors in both bax(+)(/)(+) and bax(-/-) NPCs.	Camptothecin	0-12	glycogen synthase kinase 3 beta	Mus musculus	60-64
17548347-7	2007	Camptothecin-induced activation of caspase-3 was reduced by GSK3 inhibitors in both bax(+)(/)(+) and bax(-/-) NPCs.	Camptothecin	0-12	BCL2-associated X protein	Mus musculus	84-87
17548347-7	2007	Camptothecin-induced activation of caspase-3 was reduced by GSK3 inhibitors in both bax(+)(/)(+) and bax(-/-) NPCs.	Camptothecin	0-12	BCL2-associated X protein	Mus musculus	101-104
17462862-0	2007	NF-kappaB inhibition enhances caspase-3 degradation of Akt1 and apoptosis in response to camptothecin.	Camptothecin	89-101	nuclear factor kappa B subunit 1	Homo sapiens	0-9
17544271-6	2007	These compounds significantly potentiate the cytotoxicity of DNA-damaging antitumor agents in a cell-based assay and efficiently abrogate the doxorubicin-induced G2/M and the camptothecin-induced S checkpoints, suggesting that their potent biological activities are mechanism-based through Chk1 inhibition.	Camptothecin	175-187	checkpoint kinase 1	Homo sapiens	290-294
17522836-9	2007	Computational modelling, using the crystal structure of KirBac1.1, suggested that K332 is located on the intracellular domain of Kir6.2 and is accessible to intracellular modulators such as LC-CoA esters.	Camptothecin	82-86	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	129-135
17603121-4	2007	A possible role for this endonuclease in repairing double-strand breaks that arise during DNA replication is suggested by the finding that mus81 and mms4 mutants are hypersensitive to camptothecin; however, these mutants are not hypersensitive to other agents that generate lesions that slow or block DNA replication.	Camptothecin	184-196	mus81	Drosophila melanogaster	139-144
17603121-4	2007	A possible role for this endonuclease in repairing double-strand breaks that arise during DNA replication is suggested by the finding that mus81 and mms4 mutants are hypersensitive to camptothecin; however, these mutants are not hypersensitive to other agents that generate lesions that slow or block DNA replication.	Camptothecin	184-196	MMS-4	Drosophila melanogaster	149-153
17462862-0	2007	NF-kappaB inhibition enhances caspase-3 degradation of Akt1 and apoptosis in response to camptothecin.	Camptothecin	89-101	caspase 3	Homo sapiens	30-39
17462862-0	2007	NF-kappaB inhibition enhances caspase-3 degradation of Akt1 and apoptosis in response to camptothecin.	Camptothecin	89-101	AKT serine/threonine kinase 1	Homo sapiens	55-59
17462862-1	2007	DNA damaging agents, such as camptothecin, and ionizing radiation (IR), can induce both NF-kappaB activation and apoptosis, however, the mechanism of their inter-regulation is not yet clear.	Camptothecin	29-41	nuclear factor kappa B subunit 1	Homo sapiens	88-97
17464322-7	2007	It is interesting to note that inhibition of XIAP abolished the neuroprotective effects of PFT in cultured neurons exposed to camptothecin, glutamate, or oxygen glucose deprivation.	Camptothecin	126-138	X-linked inhibitor of apoptosis	Mus musculus	45-49
17634129-10	2007	Finally, primary human lymphocyte derived cell lines immortalized by a HTLV-1 proviral clone defective in p30 expression were more susceptible to camptothecin induced apoptosis.	Camptothecin	146-158	centromere protein V	Homo sapiens	106-109
17223257-0	2007	Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.	Camptothecin	0-12	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	90-97
17638872-8	2007	We also provide evidence that the action of hPNK in the repair of camptothecin-induced topoisomerase 1 "dead-end" complexes is independent of DNA-PKcs and that hPNK is not involved in the nucleotide excision repair pathway.	Camptothecin	66-78	polynucleotide kinase 3'-phosphatase	Homo sapiens	44-48
17896941-5	2007	Because of strong affinity of the carboxylate form of the parent drug camptothecin to human serum albumin (HSA), this protein promotes the deactivation of this compound.	Camptothecin	70-82	albumin	Homo sapiens	92-105
17555331-7	2007	When tumor cells treated with camptothecin or cisplatin were subsequently exposed to glutathione-enhancing agents, p53 underwent dethiolation accompanied by detectable increases in the level of p21waf1 expression, relative to the DNA-damaging drugs alone.	Camptothecin	30-42	tumor protein p53	Homo sapiens	115-118
17896945-4	2007	A serious limitation to the clinical application of CPT is the strong affinity of its carboxylate form to human serum albumin (HSA) which destabilizes its active lactone form.	Camptothecin	52-55	albumin	Homo sapiens	127-130
16983566-2	2007	Camptothecins exist in a pH dependent equilibrium between active lactone and inactive carboxy forms that can be altered by binding to human serum albumin (HSA).	Camptothecin	0-13	albumin	Homo sapiens	140-153
17603793-6	2007	In addition, depletion of XRCC1 resulted in a significantly increased sensitivity to the alkylating agent methyl methanesulfonate and the thymidine base analog 5-hydroxymethyl-2"-deoxyuridine, a slightly increased sensitivity to ethyl methanesulfonate and 1,3-bis(2-chloroethyl)-1-nitrosourea, and no change in the response to camptothecin.	Camptothecin	327-339	X-ray repair cross complementing 1	Homo sapiens	26-31
17562789-3	2007	AOA2 cells are sensitive to H2O2, camptothecin, and mitomycin C, but not to ionizing radiation, and sensitivity was rescued with full-length SETX cDNA.	Camptothecin	34-46	senataxin	Homo sapiens	141-145
17317670-8	2007	DNA damage caused by camptothecin treatment increases mRNA and protein levels of CDA1, accompanied by induction of p53.	Camptothecin	21-33	TSPY like 2	Homo sapiens	81-85
17258428-4	2007	Functionality of the p53 protein was verified by camptothecin treatment, known to induce p53-dependent apoptosis.	Camptothecin	49-61	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	21-24
17258428-4	2007	Functionality of the p53 protein was verified by camptothecin treatment, known to induce p53-dependent apoptosis.	Camptothecin	49-61	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	89-92
17258428-5	2007	Results showed that p53-expressing cells were significantly more sensitive to camptothecin induced cytotoxicity compared to non-expressing cells, and presented a significantly higher incidence of apoptosis.	Camptothecin	78-90	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	20-23
17378599-0	2007	Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.	Camptothecin	28-40	cathepsin B	Homo sapiens	108-119
17378599-4	2007	In the present work, we developed water-soluble camptothecin (CPT) and doxorubicin (DOXO) prodrugs that incorporate the peptide linker Ala-Leu-Ala-Leu that serves as a substrate for the tumor-associated protease, cathepsin B, which is overexpressed in several solid tumors.	Camptothecin	48-60	cathepsin B	Homo sapiens	213-224
17378599-4	2007	In the present work, we developed water-soluble camptothecin (CPT) and doxorubicin (DOXO) prodrugs that incorporate the peptide linker Ala-Leu-Ala-Leu that serves as a substrate for the tumor-associated protease, cathepsin B, which is overexpressed in several solid tumors.	Camptothecin	62-65	cathepsin B	Homo sapiens	213-224
17317670-8	2007	DNA damage caused by camptothecin treatment increases mRNA and protein levels of CDA1, accompanied by induction of p53.	Camptothecin	21-33	tumor protein p53	Homo sapiens	115-118
17181554-10	2007	Midkine did not influence the proliferation of meningioma cells in vitro, but it did protect meningioma cells from camptothecin-mediated apoptotic cell death through reduction in the amounts of active caspase-3.	Camptothecin	115-127	midkine	Homo sapiens	0-7
17303082-0	2007	WRN counteracts the NHEJ pathway upon camptothecin exposure.	Camptothecin	38-50	Werner syndrome RecQ like helicase	Gallus gallus	0-3
17303082-2	2007	When treated with camptothecin (CPT), an inhibitor of DNA topoisomerase I, WRN(-/-) cells showed higher sensitivity than wild-type cells, whereas KU70(-/-) and DNA-PKcs(-/-/-) cells showed hyper-resistance.	Camptothecin	18-30	DNA topoisomerase I	Gallus gallus	54-73
17303082-2	2007	When treated with camptothecin (CPT), an inhibitor of DNA topoisomerase I, WRN(-/-) cells showed higher sensitivity than wild-type cells, whereas KU70(-/-) and DNA-PKcs(-/-/-) cells showed hyper-resistance.	Camptothecin	18-30	Werner syndrome RecQ like helicase	Gallus gallus	75-78
17303082-2	2007	When treated with camptothecin (CPT), an inhibitor of DNA topoisomerase I, WRN(-/-) cells showed higher sensitivity than wild-type cells, whereas KU70(-/-) and DNA-PKcs(-/-/-) cells showed hyper-resistance.	Camptothecin	32-35	DNA topoisomerase I	Gallus gallus	54-73
17303082-2	2007	When treated with camptothecin (CPT), an inhibitor of DNA topoisomerase I, WRN(-/-) cells showed higher sensitivity than wild-type cells, whereas KU70(-/-) and DNA-PKcs(-/-/-) cells showed hyper-resistance.	Camptothecin	32-35	Werner syndrome RecQ like helicase	Gallus gallus	75-78
17169332-6	2007	As expected on the basis of the introduction of a hydrophilic substituent, the novel camptothecin was a substrate for BCRP.	Camptothecin	85-97	BCR pseudogene 1	Homo sapiens	118-122
17123873-8	2007	Upon repression of the wild-type H2AX transgene, XRCC3(-/-)/H2AX(-/S139A) cells failed to form Rad51 foci and exhibited markedly increased levels of chromosomal aberrations after CPT treatment.	Camptothecin	179-182	X-ray repair cross complementing 3	Gallus gallus	49-54
17118488-1	2007	Resistance to camptothecin (CPT), a topoisomerase I (Top1) inhibitor, is frequently encountered in non-small cell lung cancer (NSCLC) and CPT resistance is linked with TDP1, an enzyme capable of cleaving the covalent linkage between stabilized Top1 with DNA.	Camptothecin	14-26	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	168-172
17118488-1	2007	Resistance to camptothecin (CPT), a topoisomerase I (Top1) inhibitor, is frequently encountered in non-small cell lung cancer (NSCLC) and CPT resistance is linked with TDP1, an enzyme capable of cleaving the covalent linkage between stabilized Top1 with DNA.	Camptothecin	28-31	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	168-172
17169973-0	2007	Prolidase-independent mechanism of camptothecin-induced inhibition of collagen biosynthesis in cultured human skin fibroblasts.	Camptothecin	35-47	peptidase D	Homo sapiens	0-9
17352464-5	2007	Compounds 5b, 5c, 5f, 15, 16d, 17g, 17h, 17k, 18d, and 22 were identified as ideal Chk1 inhibitors, which showed little or no single-agent activity but significantly potentiate the cytotoxicities of the DNA-damaging antitumor agents doxorubicin and camptothecin.	Camptothecin	249-261	checkpoint kinase 1	Homo sapiens	83-87
17352464-6	2007	These novel Chk1 inhibitors abrogate the doxorubicin-induced G2 and camptothecin-induced S checkpoint arrests, confirming that their potent biological activities are mechanism-based through Chk1 inhibition.	Camptothecin	68-80	checkpoint kinase 1	Homo sapiens	12-16
17352464-6	2007	These novel Chk1 inhibitors abrogate the doxorubicin-induced G2 and camptothecin-induced S checkpoint arrests, confirming that their potent biological activities are mechanism-based through Chk1 inhibition.	Camptothecin	68-80	checkpoint kinase 1	Homo sapiens	190-194
17351391-9	2007	The GI50 values for melphalan and camptothecin correlated positively with the activity of glutathione-S-transferase, whereas GI50 values for methotrexate correlated positively with the cellular activities of both glutathione reductase and thioredoxin reductase.	Camptothecin	34-46	glutathione S-transferase kappa 1	Homo sapiens	90-115
17242200-2	2007	Accordingly, yeast rad18 mutants are tolerant of camptothecin (CPT), a topoisomerase I inhibitor, which induces DSBs by blocking replication.	Camptothecin	49-61	E3 ubiquitin-protein ligase RAD18	Saccharomyces cerevisiae S288C	19-24
17242200-2	2007	Accordingly, yeast rad18 mutants are tolerant of camptothecin (CPT), a topoisomerase I inhibitor, which induces DSBs by blocking replication.	Camptothecin	63-66	E3 ubiquitin-protein ligase RAD18	Saccharomyces cerevisiae S288C	19-24
17242200-6	2007	Concomitant deletion of Rad18 and PARP1 synergistically increased CPT sensitivity, and additional inactivation of NHEJ normalized this hypersensitivity, indicating their parallel actions.	Camptothecin	66-69	E3 ubiquitin-protein ligase RAD18	Saccharomyces cerevisiae S288C	24-29
17222391-1	2007	Deletion mutants of CHL1 or CTF4, which are required for sister chromatid cohesion, showed higher sensitivity to the DNA damaging agents methyl methanesulfonate (MMS), hydroxyurea (HU), phleomycin, and camptothecin, similar to the phenotype of mutants of RAD52, which is essential for recombination repair.	Camptothecin	202-214	cell adhesion molecule L1 like	Homo sapiens	20-24
17222391-1	2007	Deletion mutants of CHL1 or CTF4, which are required for sister chromatid cohesion, showed higher sensitivity to the DNA damaging agents methyl methanesulfonate (MMS), hydroxyurea (HU), phleomycin, and camptothecin, similar to the phenotype of mutants of RAD52, which is essential for recombination repair.	Camptothecin	202-214	WD repeat and HMG-box DNA binding protein 1	Homo sapiens	28-32
17264768-1	2007	The camptothecin-bombesin conjugate termed DC-51-43, as a novel targeted drug delivery system, was examined in over 10 human tumor cell lines and shows a potent antiproliferative activity.	Camptothecin	4-16	gastrin releasing peptide	Homo sapiens	17-25
17264768-4	2007	The camptothecin-bombesin conjugate and free camptothecin show potent in-vitro inhibitory activities of cell adhesion to various extracellular matrix components and integrins alphaVbeta3 and alphaVbeta5, not beta1/alphabeta1.	Camptothecin	4-16	gastrin releasing peptide	Homo sapiens	17-25
17264768-4	2007	The camptothecin-bombesin conjugate and free camptothecin show potent in-vitro inhibitory activities of cell adhesion to various extracellular matrix components and integrins alphaVbeta3 and alphaVbeta5, not beta1/alphabeta1.	Camptothecin	45-57	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	208-224
17264768-7	2007	These experimental results support the fact that the camptothecin-bombesin conjugate has therapeutic activities against angiogenesis.	Camptothecin	53-65	gastrin releasing peptide	Homo sapiens	66-74
16644105-0	2007	A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.	Camptothecin	15-27	thymoma viral proto-oncogene 1	Mus musculus	140-143
16644105-0	2007	A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.	Camptothecin	15-27	matrix metallopeptidase 2	Mus musculus	173-181
16644105-9	2007	Our results support that this conjugate could possibly inhibit prostate cancer PC-3 cell invasion through a signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9, and this SSA could be used as an efficient vector to deliver CPT or other cytotoxic agents to target sites for cancer therapy.	Camptothecin	245-248	thymoma viral proto-oncogene 1	Mus musculus	141-144
17297656-10	2007	Furthermore, new camptothecin analogs synthesized by our research group had potent effects in circumventing ABCG2-mediated drug resistance without any influence from major non-synonymous polymorphisms.	Camptothecin	17-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	108-113
17259077-4	2007	Pharmacological data demonstrate that the EP4 receptor is responsible for mediating the protection from camptothecin-induced apoptosis.	Camptothecin	104-116	prostaglandin E receptor 4	Homo sapiens	42-45
17314275-8	2007	Inhibition of endogenous parafibromin expression by RNA interference inhibits the basal rate of apoptosis and apoptosis resulting from DNA damage induced by camptothecin, a topoisomerase I inhibitor.	Camptothecin	157-169	cell division cycle 73	Homo sapiens	25-37
17259077-5	2007	Pre-treatment of the cells with the EP4 antagonist (EP4A) prior to PGE(2) and camptothecin abolished the increased survival effect of PGE(2).	Camptothecin	78-90	prostaglandin E receptor 4	Homo sapiens	36-39
17666167-0	2007	Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.	Camptothecin	141-153	diablo IAP-binding mitochondrial protein	Homo sapiens	33-37
17666167-0	2007	Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.	Camptothecin	141-153	diablo IAP-binding mitochondrial protein	Homo sapiens	38-44
17666167-0	2007	Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.	Camptothecin	141-153	caspase 8	Homo sapiens	52-61
17666167-0	2007	Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.	Camptothecin	141-153	BCL2 apoptosis regulator	Homo sapiens	84-89
17666167-3	2007	Present study is focused on the role of Bid in the control of Bax-GFP and Smac/DIABLO-GFP kinetics in breast cancer MCF-7 cells stimulated to apoptosis with camptothecin (CPT).	Camptothecin	157-169	BH3 interacting domain death agonist	Homo sapiens	40-43
17666167-3	2007	Present study is focused on the role of Bid in the control of Bax-GFP and Smac/DIABLO-GFP kinetics in breast cancer MCF-7 cells stimulated to apoptosis with camptothecin (CPT).	Camptothecin	171-174	BH3 interacting domain death agonist	Homo sapiens	40-43
17255282-6	2007	CHIR-124 interacts synergistically with topoisomerase poisons (e.g., camptothecin or SN-38) in causing growth inhibition in several p53-mutant solid tumor cell lines as determined by isobologram or response surface analysis.	Camptothecin	69-81	tumor protein p53	Homo sapiens	132-135
16860395-8	2007	We also showed that the induction of bcl-2 expression prevented NT2 astrocytes from camptothecin-induced cellular damage.	Camptothecin	84-96	BCL2 apoptosis regulator	Homo sapiens	37-42
17046751-7	2006	The EndoG-positive WDNI cells were more sensitive to etoposide- or camptothecin-induced cell death than EndoG-negative PDI cells.	Camptothecin	67-79	endonuclease G	Homo sapiens	4-9
18094537-5	2007	In this study, we examined the modulation of CD93 expression on a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances : an RNA-synthesis inhibitor, actinomycin D (ActD); a DNA topoisomerase I inhibitor, camptothecin (CPT); a protein-synthesis inhibitor, cycloheximide (CHX); a DNA topoisomerase II inhibitor, etoposide (EPS); and a DNA-synthesis inhibitor, mitomycin C (MMC).	Camptothecin	248-260	CD93 molecule	Homo sapiens	45-49
18094537-5	2007	In this study, we examined the modulation of CD93 expression on a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances : an RNA-synthesis inhibitor, actinomycin D (ActD); a DNA topoisomerase I inhibitor, camptothecin (CPT); a protein-synthesis inhibitor, cycloheximide (CHX); a DNA topoisomerase II inhibitor, etoposide (EPS); and a DNA-synthesis inhibitor, mitomycin C (MMC).	Camptothecin	262-265	CD93 molecule	Homo sapiens	45-49
16935573-2	2006	Using SCAN1 cells treated with the specific topoisomerase I (Top1) inhibitor camptothecin, we find enhanced levels of Top1 cleavage complexes (Top1cc) and defective reversal of Top1cc in SCAN1 Tdp1-deficient cells, indicating a direct involvement of Tdp1 in the repair of Top1cc.	Camptothecin	77-89	calcium activated nucleotidase 1	Homo sapiens	6-11
16935573-2	2006	Using SCAN1 cells treated with the specific topoisomerase I (Top1) inhibitor camptothecin, we find enhanced levels of Top1 cleavage complexes (Top1cc) and defective reversal of Top1cc in SCAN1 Tdp1-deficient cells, indicating a direct involvement of Tdp1 in the repair of Top1cc.	Camptothecin	77-89	DNA topoisomerase I	Homo sapiens	61-65
16935573-2	2006	Using SCAN1 cells treated with the specific topoisomerase I (Top1) inhibitor camptothecin, we find enhanced levels of Top1 cleavage complexes (Top1cc) and defective reversal of Top1cc in SCAN1 Tdp1-deficient cells, indicating a direct involvement of Tdp1 in the repair of Top1cc.	Camptothecin	77-89	DNA topoisomerase I	Homo sapiens	118-122
16935573-2	2006	Using SCAN1 cells treated with the specific topoisomerase I (Top1) inhibitor camptothecin, we find enhanced levels of Top1 cleavage complexes (Top1cc) and defective reversal of Top1cc in SCAN1 Tdp1-deficient cells, indicating a direct involvement of Tdp1 in the repair of Top1cc.	Camptothecin	77-89	calcium activated nucleotidase 1	Homo sapiens	187-192
16935573-2	2006	Using SCAN1 cells treated with the specific topoisomerase I (Top1) inhibitor camptothecin, we find enhanced levels of Top1 cleavage complexes (Top1cc) and defective reversal of Top1cc in SCAN1 Tdp1-deficient cells, indicating a direct involvement of Tdp1 in the repair of Top1cc.	Camptothecin	77-89	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	193-197
16935573-2	2006	Using SCAN1 cells treated with the specific topoisomerase I (Top1) inhibitor camptothecin, we find enhanced levels of Top1 cleavage complexes (Top1cc) and defective reversal of Top1cc in SCAN1 Tdp1-deficient cells, indicating a direct involvement of Tdp1 in the repair of Top1cc.	Camptothecin	77-89	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	250-254
16935573-3	2006	Because the defective removal of Top1cc and the hypersensitivity of SCAN1 cells to camptothecin are not affected by aphidicolin, we propose that Tdp1 is involved in the repair of Top1cc associated with transcription damage in SCAN1 cells.	Camptothecin	83-95	calcium activated nucleotidase 1	Homo sapiens	68-73
16935573-3	2006	Because the defective removal of Top1cc and the hypersensitivity of SCAN1 cells to camptothecin are not affected by aphidicolin, we propose that Tdp1 is involved in the repair of Top1cc associated with transcription damage in SCAN1 cells.	Camptothecin	83-95	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	145-149
17158148-5	2007	When compared with wild-type HCT116 cells, RAD18-/- cells, defective in the repair of X-ray-induced chromosomal aberrations, were significantly hypersensitive to X-ray-irradiation and also to the topoisomerase I inhibitor camptothecin (CPT) capable of inducing single-strand breaks but were not so sensitive to the topoisomerase II inhibitor etoposide capable of inducing double-strand breaks.	Camptothecin	222-234	RAD18 E3 ubiquitin protein ligase	Homo sapiens	43-48
17158148-5	2007	When compared with wild-type HCT116 cells, RAD18-/- cells, defective in the repair of X-ray-induced chromosomal aberrations, were significantly hypersensitive to X-ray-irradiation and also to the topoisomerase I inhibitor camptothecin (CPT) capable of inducing single-strand breaks but were not so sensitive to the topoisomerase II inhibitor etoposide capable of inducing double-strand breaks.	Camptothecin	236-239	RAD18 E3 ubiquitin protein ligase	Homo sapiens	43-48
17077513-5	2006	As reported, WRNIP1-/-/- cells and RAD18-/- cells are moderately and severely sensitive to camptothecin (CPT), respectively.	Camptothecin	105-108	Werner helicase interacting protein 1	Gallus gallus	13-19
16997331-7	2006	Cells deleted for Brca2 exon 27 are hypersensitive to gamma-radiation, streptonigrin, mitomycin C and camptothecin and mildly resistant to ICRF-193 which is similar to HR defective cells null for Rad54.	Camptothecin	102-114	breast cancer 2, early onset	Mus musculus	18-23
16997331-8	2006	By contrast, Blm-impaired cells are hypersensitive to ICRF-193, mildly resistant to camptothecin and mitomycin C and more strongly resistant to hydroxyurea.	Camptothecin	84-96	Bloom syndrome, RecQ like helicase	Mus musculus	13-16
16966326-4	2006	Moreover, the induction of c-Jun is observed following treatment with two other drugs that inhibit the cell cycle in S phase, aphidicolin and camptothecin.	Camptothecin	142-154	jun proto-oncogene	Mus musculus	27-32
17341614-5	2006	NF-kappaB was activated by TNF-alpha, IL-1beta, PMA, and camptothecin in a dose-dependent manner, but not by LPS.	Camptothecin	57-69	nuclear factor kappa B subunit 1	Homo sapiens	0-9
17341614-5	2006	NF-kappaB was activated by TNF-alpha, IL-1beta, PMA, and camptothecin in a dose-dependent manner, but not by LPS.	Camptothecin	57-69	tumor necrosis factor	Homo sapiens	27-36
17030624-5	2006	TAF1 alternative splicing was regulated in a tissue-specific manner and in response to DNA damage induced by ionizing radiation or camptothecin.	Camptothecin	131-143	TBP-associated factor 1	Drosophila melanogaster	0-4
17030624-7	2006	Similarly, camptothecin-induced upregulation of TAF1-3 and TAF1-4 splicing was mediated by ATR (ATM-RAD3 related) and CHK1.	Camptothecin	11-23	TBP-associated factor 13	Drosophila melanogaster	48-54
17030624-7	2006	Similarly, camptothecin-induced upregulation of TAF1-3 and TAF1-4 splicing was mediated by ATR (ATM-RAD3 related) and CHK1.	Camptothecin	11-23	TBP-associated factor 1	Drosophila melanogaster	59-65
17030624-7	2006	Similarly, camptothecin-induced upregulation of TAF1-3 and TAF1-4 splicing was mediated by ATR (ATM-RAD3 related) and CHK1.	Camptothecin	11-23	meiotic 41	Drosophila melanogaster	91-94
17030624-7	2006	Similarly, camptothecin-induced upregulation of TAF1-3 and TAF1-4 splicing was mediated by ATR (ATM-RAD3 related) and CHK1.	Camptothecin	11-23	meiotic 41	Drosophila melanogaster	96-112
17030624-7	2006	Similarly, camptothecin-induced upregulation of TAF1-3 and TAF1-4 splicing was mediated by ATR (ATM-RAD3 related) and CHK1.	Camptothecin	11-23	grapes	Drosophila melanogaster	118-122
16785996-0	2006	Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment.	Camptothecin	67-79	cyclin B1	Homo sapiens	12-21
16834570-4	2006	We have shown that the Kep1 protein is phosphorylated in ovaries induced to undergo apoptosis following treatment with the topoisomerase I inhibitor camptothecin.	Camptothecin	149-161	quaking related 58E-3	Drosophila melanogaster	23-27
16834570-4	2006	We have shown that the Kep1 protein is phosphorylated in ovaries induced to undergo apoptosis following treatment with the topoisomerase I inhibitor camptothecin.	Camptothecin	149-161	Topoisomerase 1	Drosophila melanogaster	123-138
16931176-0	2006	A novel Rad18 function involved in protection of the vertebrate genome after exposure to camptothecin.	Camptothecin	89-101	RAD18, E3 ubiquitin protein ligase	Gallus gallus	8-13
16931176-2	2006	Chicken DT40 RAD18(-/-) cells were found to be hypersensitive to camptothecin (CPT), while RAD30(-/-) and REV3(-/-) cells, which are defective in translesion DNA synthesis, were not.	Camptothecin	65-77	RAD18, E3 ubiquitin protein ligase	Gallus gallus	13-18
16931176-2	2006	Chicken DT40 RAD18(-/-) cells were found to be hypersensitive to camptothecin (CPT), while RAD30(-/-) and REV3(-/-) cells, which are defective in translesion DNA synthesis, were not.	Camptothecin	79-82	RAD18, E3 ubiquitin protein ligase	Gallus gallus	13-18
17077513-5	2006	As reported, WRNIP1-/-/- cells and RAD18-/- cells are moderately and severely sensitive to camptothecin (CPT), respectively.	Camptothecin	91-103	Werner helicase interacting protein 1	Gallus gallus	13-19
17077513-5	2006	As reported, WRNIP1-/-/- cells and RAD18-/- cells are moderately and severely sensitive to camptothecin (CPT), respectively.	Camptothecin	91-103	E3 ubiquitin-protein ligase RAD18	Saccharomyces cerevisiae S288C	35-40
17077513-5	2006	As reported, WRNIP1-/-/- cells and RAD18-/- cells are moderately and severely sensitive to camptothecin (CPT), respectively.	Camptothecin	105-108	E3 ubiquitin-protein ligase RAD18	Saccharomyces cerevisiae S288C	35-40
16905549-12	2006	Chk2 deficiency in HCT116 is associated with defective S-phase checkpoint, prolonged G2 arrest, and hypersensitivity to camptothecin.	Camptothecin	120-132	checkpoint kinase 2	Homo sapiens	0-4
16905549-13	2006	The high frequency of MRN and Chk2 deficiencies may contribute to genomic instability and therapeutic response to camptothecins in colorectal cancers.	Camptothecin	114-127	checkpoint kinase 2	Homo sapiens	30-34
16962673-0	2006	The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells.	Camptothecin	68-80	CD47 molecule	Homo sapiens	15-19
16962673-0	2006	The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells.	Camptothecin	68-80	CD47 molecule	Homo sapiens	20-23
16962673-0	2006	The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells.	Camptothecin	68-80	thrombospondin 1	Homo sapiens	42-58
16962673-3	2006	In this report, using Hoechst reagent staining, reactive oxygen species production and caspase-3 activity measurement, we determined that both camptothecin and doxorubicin induced apoptosis in human thyroid carcinoma cells (FTC-133).	Camptothecin	143-155	caspase 3	Homo sapiens	87-96
16962673-4	2006	On the one hand, we demonstrated that camptothecin and doxorubicin inhibited TSP-1 expression mainly occurring at the transcriptional level.	Camptothecin	38-50	thrombospondin 1	Homo sapiens	77-82
16962673-8	2006	These findings suggest that induction of apoptosis by camptothecin or doxorubicin in FTC-133 cells is greatly dependent by a down-regulation of TSP-1 expression and shed new light on a possible role for TSP-1 in drug resistance.	Camptothecin	54-66	thrombospondin 1	Homo sapiens	144-149
16962673-8	2006	These findings suggest that induction of apoptosis by camptothecin or doxorubicin in FTC-133 cells is greatly dependent by a down-regulation of TSP-1 expression and shed new light on a possible role for TSP-1 in drug resistance.	Camptothecin	54-66	thrombospondin 1	Homo sapiens	203-208
16505951-2	2006	ATP-binding cassette (ABC) transporters have been reported to modulate camptothecin analogues, are associated with camptothecin resistance, and might also affect 9NC and 9AC pharmacokinetics.	Camptothecin	71-83	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	0-20
16794010-8	2006	In LNCaP cells treated with camptothecin, an inhibitor of topoisomerase I, the interaction between Bcl-xL and Bak was absent after 36 h, Bcl-xL decreased gradually and Bak increased coincidentally with the progress of apoptosis.	Camptothecin	28-40	BCL2 like 1	Homo sapiens	99-105
16794010-8	2006	In LNCaP cells treated with camptothecin, an inhibitor of topoisomerase I, the interaction between Bcl-xL and Bak was absent after 36 h, Bcl-xL decreased gradually and Bak increased coincidentally with the progress of apoptosis.	Camptothecin	28-40	BCL2 like 1	Homo sapiens	137-143
16908529-2	2006	In addition to IR induction, we have previously shown that DNA-PKcs phosphorylation is increased upon camptothecin treatment, which induces replication stress and replication-associated double-strand breaks.	Camptothecin	102-114	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	59-67
16728456-17	2006	Additionally, we have found that this induced level of Hsp70 protected the Caco-2 cells against apoptosis caused by camptothecin.	Camptothecin	116-128	heat shock protein family A (Hsp70) member 4	Homo sapiens	55-60
17194031-4	2006	GSTs A1, P1 and M1 were inhibited by O6-benzylguanine (IC50s around 30 microM), GST P1-1 by sulphinpyrazone (IC50 = 66 microM), GST Al-1 by sulphasalazine, and camptothecin (34 and 74 microM respectively), and GST M1-1 by sulphasalazine, camptothecin and indomethacin (0.3, 29 and 30 microM respectively) using CDNB as a substrate.	Camptothecin	160-172	glutathione S-transferase kappa 1	Homo sapiens	0-4
17194031-4	2006	GSTs A1, P1 and M1 were inhibited by O6-benzylguanine (IC50s around 30 microM), GST P1-1 by sulphinpyrazone (IC50 = 66 microM), GST Al-1 by sulphasalazine, and camptothecin (34 and 74 microM respectively), and GST M1-1 by sulphasalazine, camptothecin and indomethacin (0.3, 29 and 30 microM respectively) using CDNB as a substrate.	Camptothecin	238-250	glutathione S-transferase kappa 1	Homo sapiens	0-4
16505951-2	2006	ATP-binding cassette (ABC) transporters have been reported to modulate camptothecin analogues, are associated with camptothecin resistance, and might also affect 9NC and 9AC pharmacokinetics.	Camptothecin	71-83	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	22-25
16505951-2	2006	ATP-binding cassette (ABC) transporters have been reported to modulate camptothecin analogues, are associated with camptothecin resistance, and might also affect 9NC and 9AC pharmacokinetics.	Camptothecin	115-127	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	0-20
16505951-2	2006	ATP-binding cassette (ABC) transporters have been reported to modulate camptothecin analogues, are associated with camptothecin resistance, and might also affect 9NC and 9AC pharmacokinetics.	Camptothecin	115-127	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	22-25
16766720-0	2006	In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.	Camptothecin	52-64	gastrin releasing peptide	Homo sapiens	65-73
16714402-8	2006	In conclusion, the vacuolar-H(+)-ATPase inhibitor NiK-12192 was able to potentiate the cytotoxic/antitumor effects of camptothecins, either in in vitro or in in vivo systems.	Camptothecin	118-131	mitogen-activated protein kinase kinase kinase 14	Homo sapiens	50-53
17048510-1	2006	Camptothecin (CPT) is a topoisomerase I inhibitor that acts against a broad spectrum of cancers.	Camptothecin	0-12	choline phosphotransferase 1	Homo sapiens	14-17
16766720-0	2006	In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.	Camptothecin	52-64	gastrin releasing peptide	Homo sapiens	136-144
16766720-3	2006	To address this question, we synthesized camptothecin (CPT) bombesin (Bn) analogs, in which CPT was coupled via a novel carbamate linker, L2 [N-(N-methyl-amino-ethyl)-glycine carbamate], that were chemically similar but differed markedly in their potency/affinity for human Bn receptors.	Camptothecin	41-53	gastrin releasing peptide	Homo sapiens	60-68
16766720-3	2006	To address this question, we synthesized camptothecin (CPT) bombesin (Bn) analogs, in which CPT was coupled via a novel carbamate linker, L2 [N-(N-methyl-amino-ethyl)-glycine carbamate], that were chemically similar but differed markedly in their potency/affinity for human Bn receptors.	Camptothecin	41-53	gastrin releasing peptide	Homo sapiens	70-72
16766720-6	2006	(125)I-CPT-L2-BA3 but not (125)I-D-Phe-CPT-L2-BA3 was internalized by Bn receptor subtype-containing cells.	Camptothecin	7-11	gastrin releasing peptide	Homo sapiens	70-72
17009856-1	2006	The chemotherapeutic agent camptothecin, 10-OH (CPT,10-OH), was shown to act synergistically with the epithelial growth factor receptor (EGFR) inhibitor (AG1478) against several transformed cell lines.	Camptothecin	27-39	epidermal growth factor receptor	Homo sapiens	102-135
17009856-1	2006	The chemotherapeutic agent camptothecin, 10-OH (CPT,10-OH), was shown to act synergistically with the epithelial growth factor receptor (EGFR) inhibitor (AG1478) against several transformed cell lines.	Camptothecin	27-39	epidermal growth factor receptor	Homo sapiens	137-141
17009856-1	2006	The chemotherapeutic agent camptothecin, 10-OH (CPT,10-OH), was shown to act synergistically with the epithelial growth factor receptor (EGFR) inhibitor (AG1478) against several transformed cell lines.	Camptothecin	48-51	epidermal growth factor receptor	Homo sapiens	102-135
16730650-6	2006	The mitochondrial enzymatic response to HGF was dose- and time-dependent with the maximum increase occurring in cells pre-treated with 30 ng/ml HGF for 48h prior to camptothecin exposure.	Camptothecin	165-177	hepatocyte growth factor	Homo sapiens	40-43
16928871-0	2006	The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin.	Camptothecin	85-97	checkpoint kinase 1	Homo sapiens	4-8
16928871-0	2006	The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin.	Camptothecin	85-97	cell division cycle 25A	Homo sapiens	9-15
16928871-11	2006	During camptothecin treatment of neurons, this activity is rapidly downregulated with a concomitant increase in Cdc25A activity.	Camptothecin	7-19	cell division cycle 25A	Homo sapiens	112-118
16928871-12	2006	Importantly, expression of wild-type Chk1, but not kinase-dead Chk1, inhibits the camptothecin-induced increase in Cdc25A activity.	Camptothecin	82-94	checkpoint kinase 1	Homo sapiens	37-41
16928871-12	2006	Importantly, expression of wild-type Chk1, but not kinase-dead Chk1, inhibits the camptothecin-induced increase in Cdc25A activity.	Camptothecin	82-94	cell division cycle 25A	Homo sapiens	115-121
16733081-4	2006	Treatment of SH-SY5Y cells with camptothecin increased RGS2 mRNA and decreased RGS4 mRNA levels.	Camptothecin	32-44	regulator of G protein signaling 2	Homo sapiens	55-59
16733081-4	2006	Treatment of SH-SY5Y cells with camptothecin increased RGS2 mRNA and decreased RGS4 mRNA levels.	Camptothecin	32-44	regulator of G protein signaling 4	Homo sapiens	79-83
16733081-6	2006	Cell cycle arrest was further implicated in regulating RGS mRNA levels because geldanamycin, which causes cell cycle arrest by inhibiting the actions of heat shock protein 90, caused changes in the mRNA levels of RGS2 and RGS4 similar to, and additive with, the effects of camptothecin.	Camptothecin	273-285	paired like homeodomain 2	Homo sapiens	55-58
16733081-6	2006	Cell cycle arrest was further implicated in regulating RGS mRNA levels because geldanamycin, which causes cell cycle arrest by inhibiting the actions of heat shock protein 90, caused changes in the mRNA levels of RGS2 and RGS4 similar to, and additive with, the effects of camptothecin.	Camptothecin	273-285	regulator of G protein signaling 2	Homo sapiens	213-217
16787641-5	2006	Up-regulation of caspase-3 protein was evident in manganese-treated PC12 cells and was moderate in cisplatin-, rotenone- and A23187-treated cells but was not observed in serum deprivation-, anisomycin-, camptothecin-, cycloheximide- or staurosporine-treated cells in which all treatments induced extensive DNA fragmentation.	Camptothecin	203-215	caspase 3	Rattus norvegicus	17-26
16469826-0	2006	Short-chain fatty acid mediated phosphorylation of heat shock protein 25: effects on camptothecin-induced apoptosis.	Camptothecin	85-97	heat shock protein family B (small) member 1	Rattus norvegicus	51-72
16928813-7	2006	Our result showed that only the down-regulation of Chk1, but not of Chk2 or MK2, abrogated camptothecin- or 5-fluorouracil-induced S-phase arrest or doxorubicin-induced G(2)-phase arrest.	Camptothecin	91-103	checkpoint kinase 1	Homo sapiens	51-55
16769258-4	2006	Moreover, while WRNIP1(-/-/-) and WRN(-/-) cells were moderately sensitive to camptothecin (CPT), double mutant cells showed a synergistic increase in CPT sensitivity.	Camptothecin	78-90	Werner helicase interacting protein 1	Gallus gallus	16-22
16769258-4	2006	Moreover, while WRNIP1(-/-/-) and WRN(-/-) cells were moderately sensitive to camptothecin (CPT), double mutant cells showed a synergistic increase in CPT sensitivity.	Camptothecin	78-90	Werner syndrome RecQ like helicase	Gallus gallus	16-19
16769258-4	2006	Moreover, while WRNIP1(-/-/-) and WRN(-/-) cells were moderately sensitive to camptothecin (CPT), double mutant cells showed a synergistic increase in CPT sensitivity.	Camptothecin	92-95	Werner syndrome RecQ like helicase	Gallus gallus	16-19
16730650-6	2006	The mitochondrial enzymatic response to HGF was dose- and time-dependent with the maximum increase occurring in cells pre-treated with 30 ng/ml HGF for 48h prior to camptothecin exposure.	Camptothecin	165-177	hepatocyte growth factor	Homo sapiens	144-147
16735025-5	2006	HAT1(-/-) cells had mild growth defect, conferring sensitivities to methyl methanesulfonate and camptothecin that enforce replication blocks creating DNA double strand breaks.	Camptothecin	96-108	histone acetyltransferase 1	Gallus gallus	0-4
16603354-3	2006	These compounds are potent cell permeable CHK-1 inhibitors and showed synergistic effect with a DNA-damaging agent, camptothecin.	Camptothecin	116-128	checkpoint kinase 1	Homo sapiens	42-47
16888206-4	2006	MCF-7 cells have VPAC1 receptors that bound the VIP chemotherapeutic conjugate, (Ala2,8,9,19,24,25,27 Nle17, Lys28)VIP-L2-camptothecin, with high affinity.	Camptothecin	122-134	vasoactive intestinal peptide receptor 1	Homo sapiens	17-22
16888206-4	2006	MCF-7 cells have VPAC1 receptors that bound the VIP chemotherapeutic conjugate, (Ala2,8,9,19,24,25,27 Nle17, Lys28)VIP-L2-camptothecin, with high affinity.	Camptothecin	122-134	vasoactive intestinal peptide	Homo sapiens	48-51
16888206-4	2006	MCF-7 cells have VPAC1 receptors that bound the VIP chemotherapeutic conjugate, (Ala2,8,9,19,24,25,27 Nle17, Lys28)VIP-L2-camptothecin, with high affinity.	Camptothecin	122-134	vasoactive intestinal peptide	Homo sapiens	115-118
16407843-2	2006	We report that defects of p21(CDKN1A) and p53 enhance camptothecin-induced histone H2AX phosphorylation (gammaH2AX), a marker for DNA DSBs.	Camptothecin	54-66	cyclin dependent kinase inhibitor 1A	Homo sapiens	26-29
16632474-3	2006	Capn4(-/-) MEFs displayed resistance to puromycin, camptothecin, etoposide, hydrogen peroxide, ultraviolet light, and serum starvation, which was consistent with pro-apoptotic roles for calpain.	Camptothecin	51-63	calpain, small subunit 1	Mus musculus	0-5
16458935-5	2006	The AML-2/DX100 cells were also resistant to other anticancer drugs, including daunorubicin and camptothecin, and the expression levels of the differentially regulated genes such as STMN1, MMP-2 and CTSG, were constantly maintained.	Camptothecin	96-108	RUNX family transcription factor 3	Homo sapiens	4-9
16407843-6	2006	The cell cycle checkpoint abrogator and Chk1/Chk2 inhibitor 7-hydroxystaurosporine (UCN-01) also increases camptothecin-induced gammaH2AX formation and inhibits camptothecin-induced p21(CDKN1A) upregulation in HCT116 wt cells.	Camptothecin	107-119	checkpoint kinase 1	Homo sapiens	40-44
16751265-5	2006	Cells lacking Tdp1 are hypersensitive to camptothecin, consistent with a role for Tdp1 in processing 3" phosphotyrosyl protein-DNA covalent complexes.	Camptothecin	41-53	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	14-18
16723399-9	2006	Most importantly, WRN hypermethylation in colorectal tumors was a predictor of good clinical response to the camptothecin analogue irinotecan, a topoisomerase inhibitor commonly used in the clinical setting for the treatment of this tumor type.	Camptothecin	109-121	WRN RecQ like helicase	Homo sapiens	18-21
16677834-5	2006	Treatment of cells with the apoptosis inducing drug camptothecin lowered Hsp70 levels but again had no effect on HspBP1 levels.	Camptothecin	52-64	heat shock protein family A (Hsp70) member 4	Homo sapiens	73-78
16598301-6	2006	Especially, AML1-ETO endows leukemic cells with the susceptibility to anti-Fas agonist antibody, ultraviolet light and camptothecin analog NSC606985-induced apoptosis with increased activation of caspase-3/8.	Camptothecin	119-131	caspase 3	Homo sapiens	196-205
16407843-6	2006	The cell cycle checkpoint abrogator and Chk1/Chk2 inhibitor 7-hydroxystaurosporine (UCN-01) also increases camptothecin-induced gammaH2AX formation and inhibits camptothecin-induced p21(CDKN1A) upregulation in HCT116 wt cells.	Camptothecin	107-119	checkpoint kinase 2	Homo sapiens	45-49
16407843-6	2006	The cell cycle checkpoint abrogator and Chk1/Chk2 inhibitor 7-hydroxystaurosporine (UCN-01) also increases camptothecin-induced gammaH2AX formation and inhibits camptothecin-induced p21(CDKN1A) upregulation in HCT116 wt cells.	Camptothecin	107-119	cyclin dependent kinase inhibitor 1A	Homo sapiens	186-192
16407843-2	2006	We report that defects of p21(CDKN1A) and p53 enhance camptothecin-induced histone H2AX phosphorylation (gammaH2AX), a marker for DNA DSBs.	Camptothecin	54-66	cyclin dependent kinase inhibitor 1A	Homo sapiens	30-36
16407843-6	2006	The cell cycle checkpoint abrogator and Chk1/Chk2 inhibitor 7-hydroxystaurosporine (UCN-01) also increases camptothecin-induced gammaH2AX formation and inhibits camptothecin-induced p21(CDKN1A) upregulation in HCT116 wt cells.	Camptothecin	161-173	checkpoint kinase 1	Homo sapiens	40-44
16407843-2	2006	We report that defects of p21(CDKN1A) and p53 enhance camptothecin-induced histone H2AX phosphorylation (gammaH2AX), a marker for DNA DSBs.	Camptothecin	54-66	tumor protein p53	Homo sapiens	42-45
16407843-6	2006	The cell cycle checkpoint abrogator and Chk1/Chk2 inhibitor 7-hydroxystaurosporine (UCN-01) also increases camptothecin-induced gammaH2AX formation and inhibits camptothecin-induced p21(CDKN1A) upregulation in HCT116 wt cells.	Camptothecin	161-173	checkpoint kinase 2	Homo sapiens	45-49
16407843-6	2006	The cell cycle checkpoint abrogator and Chk1/Chk2 inhibitor 7-hydroxystaurosporine (UCN-01) also increases camptothecin-induced gammaH2AX formation and inhibits camptothecin-induced p21(CDKN1A) upregulation in HCT116 wt cells.	Camptothecin	161-173	cyclin dependent kinase inhibitor 1A	Homo sapiens	182-185
16407843-3	2006	In human colon carcinoma HCT116 cells with wild-type (wt) p53, gammaH2AX reverses after camptothecin removal.	Camptothecin	88-100	tumor protein p53	Homo sapiens	58-61
16407843-6	2006	The cell cycle checkpoint abrogator and Chk1/Chk2 inhibitor 7-hydroxystaurosporine (UCN-01) also increases camptothecin-induced gammaH2AX formation and inhibits camptothecin-induced p21(CDKN1A) upregulation in HCT116 wt cells.	Camptothecin	161-173	cyclin dependent kinase inhibitor 1A	Homo sapiens	186-192
16365881-7	2006	Similar to CD95-induced cell death, apoptosis triggered by the DNA topoisomerase inhibitors, camptothecin or etoposide was shifted to necrosis when capsase activation was inhibited.	Camptothecin	93-105	Fas cell surface death receptor	Homo sapiens	11-15
16263807-4	2006	Camptothecin initiated the intrinsic pathway with activation of caspase-9 and caspase-dependent cleavage of procaspase-3.	Camptothecin	0-12	caspase 9	Rattus norvegicus	64-73
16205924-2	2006	In biological matrices, camptothecin analogues exist in equilibrium between the active-lactone (LAC) and inactive-hydroxy acid (HA) forms.	Camptothecin	24-36	lactase	Homo sapiens	96-99
16644697-4	2006	2) Overexpression of a constitutively active form of the antiapoptotic protein kinase Akt1 in 832/13 cells provides significant protection against cell killing induced by camptothecin and etoposide but no protection against cytokine-mediated damage.	Camptothecin	171-183	AKT serine/threonine kinase 1	Rattus norvegicus	86-90
16644697-7	2006	In contrast, camptothecin- and etoposide-induced killing is associated with robust increases in caspase 3 activation and annexin V staining.	Camptothecin	13-25	caspase 3	Rattus norvegicus	96-105
16516161-0	2006	High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation.	Camptothecin	120-132	sphingosine kinase 1	Homo sapiens	19-37
16516161-2	2006	A human prostate cancer cell line PC3 is resistant to camptothecin (CPT).	Camptothecin	54-66	proprotein convertase subtilisin/kexin type 1	Homo sapiens	34-37
16278671-2	2006	Cells lacking mouse Hus1 are hypersensitive to DNA damage inducers including UV and camptothecin (CPT).	Camptothecin	84-96	HUS1 checkpoint clamp component	Mus musculus	20-24
16278671-2	2006	Cells lacking mouse Hus1 are hypersensitive to DNA damage inducers including UV and camptothecin (CPT).	Camptothecin	98-101	HUS1 checkpoint clamp component	Mus musculus	20-24
16428803-1	2006	Human (h) DNA topoisomerase I has been identified as a major SUMO1 target in camptothecin-treated cells.	Camptothecin	77-89	small ubiquitin like modifier 1	Homo sapiens	61-66
16438941-7	2006	Potentiation of camptothecin-induced apoptosis by TRAIL appears dependent on cooperation between extrinsic and intrinsic pathways, as documented by loss of the sensitization to apoptosis following reduction of caspase 8 after small interfering RNA transfection.	Camptothecin	16-28	TNF superfamily member 10	Homo sapiens	50-55
16428803-2	2006	In response to TOP1-mediated DNA damage induced by camptothecin, multiple SUMO1 molecules are conjugated to the N-terminal domain of a single TOP1 molecule.	Camptothecin	51-63	small ubiquitin like modifier 1	Homo sapiens	74-79
16438941-7	2006	Potentiation of camptothecin-induced apoptosis by TRAIL appears dependent on cooperation between extrinsic and intrinsic pathways, as documented by loss of the sensitization to apoptosis following reduction of caspase 8 after small interfering RNA transfection.	Camptothecin	16-28	caspase 8	Homo sapiens	210-219
16309825-0	2006	Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.	Camptothecin	26-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	63-68
16483312-1	2006	Replication protein A2 (RPA2), a component of the RPA heterotrimer, is hyperphosphorylated and forms nuclear foci in response to camptothecin (CPT) that directly induces replication-mediated DNA double-strand breaks (DSBs).	Camptothecin	129-141	replication protein A2	Homo sapiens	0-22
16498404-7	2006	Moreover, we found deletion of Ligase IV, another NHEJ gene, suppressed the camptothecin of PARP-1(-/-) cells.	Camptothecin	76-88	poly(ADP-ribose) polymerase 1	Gallus gallus	92-98
16309825-3	2006	To circumvent the ABCG2-associated drug resistance, the structure-activity-relationship (SAR) of 14 new camptothecin (CPT) analogues has been studied with respect to the substrate specificity of ABCG2.	Camptothecin	104-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	195-200
16309825-3	2006	To circumvent the ABCG2-associated drug resistance, the structure-activity-relationship (SAR) of 14 new camptothecin (CPT) analogues has been studied with respect to the substrate specificity of ABCG2.	Camptothecin	118-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	195-200
16325482-6	2006	Surprisingly, mutants in slx5 or slx8 were not sensitive to transient replication fork stalling induced by hydroxyurea, nor were they sensitive to replication dependent double-strand breaks induced by camptothecin.	Camptothecin	201-213	SUMO-targeted ubiquitin ligase complex subunit SLX5	Saccharomyces cerevisiae S288C	25-29
16483312-1	2006	Replication protein A2 (RPA2), a component of the RPA heterotrimer, is hyperphosphorylated and forms nuclear foci in response to camptothecin (CPT) that directly induces replication-mediated DNA double-strand breaks (DSBs).	Camptothecin	129-141	replication protein A2	Homo sapiens	24-28
16483312-1	2006	Replication protein A2 (RPA2), a component of the RPA heterotrimer, is hyperphosphorylated and forms nuclear foci in response to camptothecin (CPT) that directly induces replication-mediated DNA double-strand breaks (DSBs).	Camptothecin	143-146	replication protein A2	Homo sapiens	0-22
16483312-1	2006	Replication protein A2 (RPA2), a component of the RPA heterotrimer, is hyperphosphorylated and forms nuclear foci in response to camptothecin (CPT) that directly induces replication-mediated DNA double-strand breaks (DSBs).	Camptothecin	143-146	replication protein A2	Homo sapiens	24-28
16489052-5	2006	We have previously observed a decrease of CD59 in camptothecin-induced apoptotic IMR32 cells, whereas expression was increased in the surviving fraction compared with untreated cells.	Camptothecin	50-62	CD59 molecule (CD59 blood group)	Homo sapiens	42-46
16319068-0	2006	Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism.	Camptothecin	0-12	prohibitin 1	Homo sapiens	39-49
16319068-0	2006	Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism.	Camptothecin	0-12	exportin 1	Homo sapiens	96-101
16319068-4	2006	We had found that treatment of cells with camptothecin, a topoisomerase 1 inhibitor, led to the export of prohibitin and p53 from the nucleus to the mitochondria.	Camptothecin	42-54	prohibitin 1	Homo sapiens	106-116
16319068-4	2006	We had found that treatment of cells with camptothecin, a topoisomerase 1 inhibitor, led to the export of prohibitin and p53 from the nucleus to the mitochondria.	Camptothecin	42-54	tumor protein p53	Homo sapiens	121-124
16319068-5	2006	Here we show that the camptothecin-induced export of prohibitin occurs preferentially in transformed cell lines, but not in untransformed or primary cells.	Camptothecin	22-34	prohibitin 1	Homo sapiens	53-63
16568373-9	2006	Furthermore, although 5-FU itself increased DPD mRNA expression, a mechanism considered to be related to the acquisition of 5-FU resistance, the addition of cisplatin or camptothecin significantly inhibited the 5-FU-induced elevation of DPD.	Camptothecin	170-182	dihydropyrimidine dehydrogenase	Homo sapiens	44-47
16568373-9	2006	Furthermore, although 5-FU itself increased DPD mRNA expression, a mechanism considered to be related to the acquisition of 5-FU resistance, the addition of cisplatin or camptothecin significantly inhibited the 5-FU-induced elevation of DPD.	Camptothecin	170-182	dihydropyrimidine dehydrogenase	Homo sapiens	237-240
16874058-3	2006	(1) Camptothecin (CPT)-induced apoptosis in breast cancer MCF-7 cells is associated with activation of cathepsin B and aggregation of BAX and BID on mitochondria.	Camptothecin	4-16	cathepsin B	Homo sapiens	103-114
16874058-3	2006	(1) Camptothecin (CPT)-induced apoptosis in breast cancer MCF-7 cells is associated with activation of cathepsin B and aggregation of BAX and BID on mitochondria.	Camptothecin	4-16	BCL2 associated X, apoptosis regulator	Homo sapiens	134-137
16874058-3	2006	(1) Camptothecin (CPT)-induced apoptosis in breast cancer MCF-7 cells is associated with activation of cathepsin B and aggregation of BAX and BID on mitochondria.	Camptothecin	4-16	BH3 interacting domain death agonist	Homo sapiens	142-145
16874058-3	2006	(1) Camptothecin (CPT)-induced apoptosis in breast cancer MCF-7 cells is associated with activation of cathepsin B and aggregation of BAX and BID on mitochondria.	Camptothecin	18-21	cathepsin B	Homo sapiens	103-114
16874058-3	2006	(1) Camptothecin (CPT)-induced apoptosis in breast cancer MCF-7 cells is associated with activation of cathepsin B and aggregation of BAX and BID on mitochondria.	Camptothecin	18-21	BCL2 associated X, apoptosis regulator	Homo sapiens	134-137
16874058-3	2006	(1) Camptothecin (CPT)-induced apoptosis in breast cancer MCF-7 cells is associated with activation of cathepsin B and aggregation of BAX and BID on mitochondria.	Camptothecin	18-21	BH3 interacting domain death agonist	Homo sapiens	142-145
16847561-0	2006	Camptothecin induces the transit of FasL trimers to the cell surface in apoptotic HEp-2 cells.	Camptothecin	0-12	Fas ligand	Homo sapiens	36-40
16847561-8	2006	In conclusion, camptothecin appears to perturb the Fas and FasL segregation in the cytoplasm by promoting the transit of FasL to the cell surface, thus fostering a process of autocrine or paracrine apoptosis.	Camptothecin	15-27	Fas ligand	Homo sapiens	59-63
16847561-8	2006	In conclusion, camptothecin appears to perturb the Fas and FasL segregation in the cytoplasm by promoting the transit of FasL to the cell surface, thus fostering a process of autocrine or paracrine apoptosis.	Camptothecin	15-27	Fas ligand	Homo sapiens	121-125
16454746-4	2006	To circumvent the ABCG2-associated drug resistance, we have synthesized and characterized a total of fourteen new camptothecin (CPT) analogues with respect to both the inhibition of Topo I and the substrate specificity of ABCG2.	Camptothecin	128-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	18-23
16374543-0	2006	Nuclear caspase-3 and caspase-7 activation, and poly(ADP-ribose) polymerase cleavage are early events in camptothecin-induced apoptosis.	Camptothecin	105-117	caspase 3	Homo sapiens	8-17
16374543-0	2006	Nuclear caspase-3 and caspase-7 activation, and poly(ADP-ribose) polymerase cleavage are early events in camptothecin-induced apoptosis.	Camptothecin	105-117	caspase 7	Homo sapiens	22-31
16374543-0	2006	Nuclear caspase-3 and caspase-7 activation, and poly(ADP-ribose) polymerase cleavage are early events in camptothecin-induced apoptosis.	Camptothecin	105-117	poly(ADP-ribose) polymerase 1	Homo sapiens	48-75
16374543-4	2006	Using cell fractionation, western blotting, and immunofluorescence assays, we show that the activation of nuclear caspases-7 and -3, and poly(ADP-ribose) polymerase (PARP) cleavage, are early events in camptothecin-induced apoptosis.	Camptothecin	202-214	caspase 7	Homo sapiens	114-131
16374543-4	2006	Using cell fractionation, western blotting, and immunofluorescence assays, we show that the activation of nuclear caspases-7 and -3, and poly(ADP-ribose) polymerase (PARP) cleavage, are early events in camptothecin-induced apoptosis.	Camptothecin	202-214	poly(ADP-ribose) polymerase 1	Homo sapiens	137-164
16374543-4	2006	Using cell fractionation, western blotting, and immunofluorescence assays, we show that the activation of nuclear caspases-7 and -3, and poly(ADP-ribose) polymerase (PARP) cleavage, are early events in camptothecin-induced apoptosis.	Camptothecin	202-214	poly(ADP-ribose) polymerase 1	Homo sapiens	166-170
16454746-0	2006	Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.	Camptothecin	55-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	92-97
16454746-4	2006	To circumvent the ABCG2-associated drug resistance, we have synthesized and characterized a total of fourteen new camptothecin (CPT) analogues with respect to both the inhibition of Topo I and the substrate specificity of ABCG2.	Camptothecin	114-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	18-23
16454746-4	2006	To circumvent the ABCG2-associated drug resistance, we have synthesized and characterized a total of fourteen new camptothecin (CPT) analogues with respect to both the inhibition of Topo I and the substrate specificity of ABCG2.	Camptothecin	114-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	222-227
16454746-4	2006	To circumvent the ABCG2-associated drug resistance, we have synthesized and characterized a total of fourteen new camptothecin (CPT) analogues with respect to both the inhibition of Topo I and the substrate specificity of ABCG2.	Camptothecin	128-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	222-227
16143529-1	2005	A biotinylated derivative of the anti-tumor agent camptothecin (CPT) was synthesized and used in a phage display assay to identify drug-binding sequences.	Camptothecin	50-62	dehydrodolichyl diphosphate synthase subunit	Homo sapiens	64-67
16793421-3	2006	It has also been proposed that Tdp1 may represent a novel anticancer target since known anticancer agents (e.g., camptothecin) act by stabilizing topoisomerase I-DNA covalent adducts.	Camptothecin	113-125	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	31-35
16357178-2	2005	We took advantage of the known differential effect of camptothecin and docetaxel on human PC-3 and LNCaP prostate cancer cells to determine their effect on sphingosine kinase-1 (SphK1) activity and subsequent ceramide/sphingosine 1-phosphate (S1P) balance in relation with cell survival.	Camptothecin	54-66	proprotein convertase subtilisin/kexin type 1	Homo sapiens	90-94
16357178-2	2005	We took advantage of the known differential effect of camptothecin and docetaxel on human PC-3 and LNCaP prostate cancer cells to determine their effect on sphingosine kinase-1 (SphK1) activity and subsequent ceramide/sphingosine 1-phosphate (S1P) balance in relation with cell survival.	Camptothecin	54-66	sphingosine kinase 1	Homo sapiens	156-176
16357178-2	2005	We took advantage of the known differential effect of camptothecin and docetaxel on human PC-3 and LNCaP prostate cancer cells to determine their effect on sphingosine kinase-1 (SphK1) activity and subsequent ceramide/sphingosine 1-phosphate (S1P) balance in relation with cell survival.	Camptothecin	54-66	sphingosine kinase 1	Homo sapiens	178-183
16357178-3	2005	In vitro, docetaxel and camptothecin induced strong inhibition of SphK1 and elevation of the ceramide/S1P ratio only in cell lines sensitive to these drugs.	Camptothecin	24-36	sphingosine kinase 1	Mus musculus	66-71
16357178-3	2005	In vitro, docetaxel and camptothecin induced strong inhibition of SphK1 and elevation of the ceramide/S1P ratio only in cell lines sensitive to these drugs.	Camptothecin	24-36	sphingosine-1-phosphate receptor 1	Mus musculus	102-105
15929725-4	2005	Using co-immunoprecipitation assays, we showed that cellular interaction of RPA with two DSB repair factors, Rad51 and Rad52, was predominantly mediated by the hyperphosphorylated species of RPA in cells after UV and camptothecin treatment.	Camptothecin	217-229	replication protein A1	Homo sapiens	76-79
15929725-4	2005	Using co-immunoprecipitation assays, we showed that cellular interaction of RPA with two DSB repair factors, Rad51 and Rad52, was predominantly mediated by the hyperphosphorylated species of RPA in cells after UV and camptothecin treatment.	Camptothecin	217-229	RAD51 recombinase	Homo sapiens	109-114
15929725-4	2005	Using co-immunoprecipitation assays, we showed that cellular interaction of RPA with two DSB repair factors, Rad51 and Rad52, was predominantly mediated by the hyperphosphorylated species of RPA in cells after UV and camptothecin treatment.	Camptothecin	217-229	RAD52 homolog, DNA repair protein	Homo sapiens	119-124
15929725-4	2005	Using co-immunoprecipitation assays, we showed that cellular interaction of RPA with two DSB repair factors, Rad51 and Rad52, was predominantly mediated by the hyperphosphorylated species of RPA in cells after UV and camptothecin treatment.	Camptothecin	217-229	replication protein A1	Homo sapiens	191-194
16234411-7	2006	We prepared an adenovirus encoding Hpr6(hbd) and found that adenovirus Hpr6(hbd) increases susceptibility of breast cancer cells to doxorubicin and camptothecin.	Camptothecin	148-160	DNA-directed DNA polymerase delta POL3	Saccharomyces cerevisiae S288C	35-44
16234411-7	2006	We prepared an adenovirus encoding Hpr6(hbd) and found that adenovirus Hpr6(hbd) increases susceptibility of breast cancer cells to doxorubicin and camptothecin.	Camptothecin	148-160	DNA-directed DNA polymerase delta POL3	Saccharomyces cerevisiae S288C	35-39
16234411-7	2006	We prepared an adenovirus encoding Hpr6(hbd) and found that adenovirus Hpr6(hbd) increases susceptibility of breast cancer cells to doxorubicin and camptothecin.	Camptothecin	148-160	DNA-directed DNA polymerase delta POL3	Saccharomyces cerevisiae S288C	40-43
17135786-0	2006	A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells.	Camptothecin	66-78	chromobox 8	Homo sapiens	89-92
17135786-2	2006	To detect some candidate marker proteins which may confer resistance to the anticancer drug camptothecin (CPT; DNA topoisomerase 1 inhibitor), the current study deals with the comparative proteomic profiling of CPT-resistant PC3 and CPT-sensitive LNCaP human prostate cancer cell lines which have been widely employed as a useful model to investigate prostate cancer cells.	Camptothecin	92-104	DNA topoisomerase I	Homo sapiens	111-130
17135786-2	2006	To detect some candidate marker proteins which may confer resistance to the anticancer drug camptothecin (CPT; DNA topoisomerase 1 inhibitor), the current study deals with the comparative proteomic profiling of CPT-resistant PC3 and CPT-sensitive LNCaP human prostate cancer cell lines which have been widely employed as a useful model to investigate prostate cancer cells.	Camptothecin	92-104	chromobox 8	Homo sapiens	225-228
17135786-2	2006	To detect some candidate marker proteins which may confer resistance to the anticancer drug camptothecin (CPT; DNA topoisomerase 1 inhibitor), the current study deals with the comparative proteomic profiling of CPT-resistant PC3 and CPT-sensitive LNCaP human prostate cancer cell lines which have been widely employed as a useful model to investigate prostate cancer cells.	Camptothecin	106-109	chromobox 8	Homo sapiens	225-228
16257398-8	2005	These results suggest that novel anticancer drugs could be synthesized that do not inhibit AChE, or alternatively, that novel AChE inhibitors could be designed based around the camptothecin scaffold.	Camptothecin	177-189	acetylcholinesterase (Cartwright blood group)	Homo sapiens	126-130
16150728-6	2005	Camptothecin and adriamycin also reduce the amount of chromatin-associated Chk2.	Camptothecin	0-12	checkpoint kinase 2	Homo sapiens	75-79
16132345-0	2005	Human multidrug resistance associated protein 4 confers resistance to camptothecins.	Camptothecin	70-83	ATP binding cassette subfamily C member 4	Homo sapiens	6-47
16211302-8	2005	The cytotoxicity of doxorubicin and camptothecin was augmented by the suppression of the XIAP in SK-Hep1 cells, whereas the suppression of survivin did not affect cytotoxicity.	Camptothecin	36-48	X-linked inhibitor of apoptosis	Homo sapiens	89-93
16211302-8	2005	The cytotoxicity of doxorubicin and camptothecin was augmented by the suppression of the XIAP in SK-Hep1 cells, whereas the suppression of survivin did not affect cytotoxicity.	Camptothecin	36-48	DNL-type zinc finger	Homo sapiens	100-104
16132345-3	2005	P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan.	Camptothecin	111-115	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
16132345-18	2005	Further studies are needed to explore the role of MRP4 in resistance, toxicity, and pharmacokinetics of CPTs and cyclophosphamide.	Camptothecin	104-108	ATP binding cassette subfamily C member 4	Homo sapiens	50-54
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Camptothecin	34-38	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
16132345-3	2005	P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan.	Camptothecin	111-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	16-48
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Camptothecin	34-38	glutamate-cysteine ligase catalytic subunit	Homo sapiens	132-165
16132345-3	2005	P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan.	Camptothecin	111-115	ATP binding cassette subfamily C member 1	Homo sapiens	50-54
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Camptothecin	34-38	ATP binding cassette subfamily C member 4	Homo sapiens	215-219
16132345-3	2005	P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan.	Camptothecin	111-115	ATP binding cassette subfamily C member 2	Homo sapiens	60-64
16230379-2	2005	In the current study, we investigated the role of Ku86 in DNA topoisomerase I-mediated radiosensitization induced by camptothecin in mammalian cells.	Camptothecin	117-129	X-ray repair cross complementing 5	Homo sapiens	50-54
16230379-3	2005	Interestingly, as examined by clonogenic survival assay, a 30-minute camptothecin treatment induced significantly higher levels of radiosensitization in the Ku86-deficient Chinese hamster ovary xrs-6 cells than in the hamster Ku86-complemented xrs-6+hamKu86 cells, albeit exhibiting similar drug toxicity in these two cell lines.	Camptothecin	69-81	X-ray repair cross-complementing protein 5	Cricetulus griseus	157-161
16230379-3	2005	Interestingly, as examined by clonogenic survival assay, a 30-minute camptothecin treatment induced significantly higher levels of radiosensitization in the Ku86-deficient Chinese hamster ovary xrs-6 cells than in the hamster Ku86-complemented xrs-6+hamKu86 cells, albeit exhibiting similar drug toxicity in these two cell lines.	Camptothecin	69-81	X-ray repair cross-complementing protein 5	Cricetulus griseus	226-230
16230379-6	2005	Again, significantly higher levels of camptothecin-induced radiosensitization were observed in the vector-alone sublines than in the Ku86-complemented XR-V15B sublines.	Camptothecin	38-50	X-ray repair cross complementing 5	Homo sapiens	133-137
16230379-7	2005	In contrast, camptothecin treatments, ranging from 0.5 to 24 hours, induced similar cytotoxicities in both vector-alone and Ku86-complemented sublines.	Camptothecin	13-25	X-ray repair cross complementing 5	Homo sapiens	124-128
16192386-6	2005	We find that apoptotic death induced by the DNA-damaging agent camptothecin is associated with early transcription-mediated loss of p35 and with late production of p25 that is dependent on Bax, Apaf1, and caspases.	Camptothecin	63-75	cyclin dependent kinase 5 regulatory subunit 1	Homo sapiens	132-135
16199871-5	2005	Fibroblasts without BLM showed an increased sensitivity to camptothecin, enhanced formation of Top1-DNA complexes, and delayed histone H2AX phosphorylation (gamma-H2AX).	Camptothecin	59-71	BLM RecQ like helicase	Homo sapiens	20-23
16199871-6	2005	Camptothecin also induced nuclear relocalization of BLM, Top3alpha, and PML protein and replication-dependent phosphorylation of BLM on threonine 99 (T99p-BLM).	Camptothecin	0-12	BLM RecQ like helicase	Homo sapiens	52-55
16199871-6	2005	Camptothecin also induced nuclear relocalization of BLM, Top3alpha, and PML protein and replication-dependent phosphorylation of BLM on threonine 99 (T99p-BLM).	Camptothecin	0-12	DNA topoisomerase III alpha	Homo sapiens	57-66
16199871-6	2005	Camptothecin also induced nuclear relocalization of BLM, Top3alpha, and PML protein and replication-dependent phosphorylation of BLM on threonine 99 (T99p-BLM).	Camptothecin	0-12	PML nuclear body scaffold	Homo sapiens	72-75
16199871-6	2005	Camptothecin also induced nuclear relocalization of BLM, Top3alpha, and PML protein and replication-dependent phosphorylation of BLM on threonine 99 (T99p-BLM).	Camptothecin	0-12	BLM RecQ like helicase	Homo sapiens	129-132
16199871-6	2005	Camptothecin also induced nuclear relocalization of BLM, Top3alpha, and PML protein and replication-dependent phosphorylation of BLM on threonine 99 (T99p-BLM).	Camptothecin	0-12	BLM RecQ like helicase	Homo sapiens	129-132
16199871-9	2005	Following camptothecin treatment, T99p-BLM colocalized with gamma-H2AX but not with Top3alpha or PML.	Camptothecin	10-22	BLM RecQ like helicase	Homo sapiens	39-42
16199871-9	2005	Following camptothecin treatment, T99p-BLM colocalized with gamma-H2AX but not with Top3alpha or PML.	Camptothecin	10-22	H2A.X variant histone	Homo sapiens	66-70
16199871-11	2005	A defect in gamma-H2AX signaling in response to unrepaired replication-mediated double-strand breaks might, at least in part, explain the camptothecin-sensitivity of BLM-deficient cells.	Camptothecin	138-150	H2A.X variant histone	Homo sapiens	18-22
16199871-11	2005	A defect in gamma-H2AX signaling in response to unrepaired replication-mediated double-strand breaks might, at least in part, explain the camptothecin-sensitivity of BLM-deficient cells.	Camptothecin	138-150	BLM RecQ like helicase	Homo sapiens	166-169
16181409-2	2005	In the present study, we demonstrate a neuroprotective role for SCF and its tyrosine kinase receptor, c-kit, against camptothecin-induced apoptosis and glutamate excitotoxicity in rat cortical neurons.	Camptothecin	117-129	KIT ligand	Rattus norvegicus	64-67
16160819-10	2005	In this review article, we present an overview on the genetic polymorphisms of human ABC transporter ABCG2 and new camptothecin analogues that can circumvent AGCG2-associated multidrug resistance of cancer.	Camptothecin	115-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	101-106
16192386-6	2005	We find that apoptotic death induced by the DNA-damaging agent camptothecin is associated with early transcription-mediated loss of p35 and with late production of p25 that is dependent on Bax, Apaf1, and caspases.	Camptothecin	63-75	cyclin dependent kinase 5 regulatory subunit 1	Homo sapiens	164-167
16192386-6	2005	We find that apoptotic death induced by the DNA-damaging agent camptothecin is associated with early transcription-mediated loss of p35 and with late production of p25 that is dependent on Bax, Apaf1, and caspases.	Camptothecin	63-75	BCL2 associated X, apoptosis regulator	Homo sapiens	189-192
16137618-5	2005	Treatment of cells with the anticancer agent camptothecin (CPT) triggers Chk1 destruction, which blocks recovery from drug-induced S phase arrest and leads to cell death.	Camptothecin	45-57	checkpoint kinase 1	Homo sapiens	73-77
16192386-6	2005	We find that apoptotic death induced by the DNA-damaging agent camptothecin is associated with early transcription-mediated loss of p35 and with late production of p25 that is dependent on Bax, Apaf1, and caspases.	Camptothecin	63-75	apoptotic peptidase activating factor 1	Homo sapiens	194-199
16137618-5	2005	Treatment of cells with the anticancer agent camptothecin (CPT) triggers Chk1 destruction, which blocks recovery from drug-induced S phase arrest and leads to cell death.	Camptothecin	59-62	checkpoint kinase 1	Homo sapiens	73-77
16137618-7	2005	Proteolysis of activated Chk1 may promote checkpoint termination under normal conditions, and may play an important role in the cytotoxic effects of CPT and related anticancer drugs.	Camptothecin	149-152	checkpoint kinase 1	Homo sapiens	25-29
15856005-2	2005	Here, we demonstrate that FGF-2 is also a potent stimulator of breast cancer cell survival, as it counteracts the apoptotic activity of the C2 ceramide analogue and various chemotherapeutic agents (5-fluorouracil, camptothecin, etoposide) in MCF-7, T47-D and BT-20 cells.	Camptothecin	214-226	fibroblast growth factor 2	Homo sapiens	26-31
16141196-2	2005	Cells lacking CAF-1 and RCAF are hypersensitive to DNA-damaging agents, such as methyl methanesulfonate and camptothecin, suggesting a possible defect in double-strand break (DSB) repair.	Camptothecin	108-120	chromatin assembly factor 1 subunit A	Homo sapiens	14-19
15856006-4	2005	The presence of RPA components in the immunoprecipitates was confirmed by immunoblotting, and we found that the association between 53BP1 and RPA2 was disrupted following DNA damage induced by treatment with camptothecin, a topoisomerase I inhibitor.	Camptothecin	208-220	tumor protein p53 binding protein 1	Homo sapiens	132-137
15856006-4	2005	The presence of RPA components in the immunoprecipitates was confirmed by immunoblotting, and we found that the association between 53BP1 and RPA2 was disrupted following DNA damage induced by treatment with camptothecin, a topoisomerase I inhibitor.	Camptothecin	208-220	replication protein A2	Homo sapiens	142-146
15856006-6	2005	We found that camptothecin-induced RPA2 phosphorylation was inhibited in these cells, and also following 53BP1 knockdown by siRNA transfection.	Camptothecin	14-26	replication protein A2	Homo sapiens	35-39
15856006-6	2005	We found that camptothecin-induced RPA2 phosphorylation was inhibited in these cells, and also following 53BP1 knockdown by siRNA transfection.	Camptothecin	14-26	tumor protein p53 binding protein 1	Homo sapiens	105-110
15856006-8	2005	Taken together, these results suggest that 53BP1 is involved in DNA damage-induced RPA2 hyperphosphorylation, and inhibition of 53BP1 function may sensitize cancer cells to camptothecin treatment.	Camptothecin	173-185	tumor protein p53 binding protein 1	Homo sapiens	43-48
15856006-8	2005	Taken together, these results suggest that 53BP1 is involved in DNA damage-induced RPA2 hyperphosphorylation, and inhibition of 53BP1 function may sensitize cancer cells to camptothecin treatment.	Camptothecin	173-185	replication protein A2	Homo sapiens	83-87
15856006-8	2005	Taken together, these results suggest that 53BP1 is involved in DNA damage-induced RPA2 hyperphosphorylation, and inhibition of 53BP1 function may sensitize cancer cells to camptothecin treatment.	Camptothecin	173-185	tumor protein p53 binding protein 1	Homo sapiens	128-133
16055725-8	2005	Furthermore, we show that gammaH2Ax, DSBs, and RAD51 foci are synergistically induced in EM9 cells with camptothecin, suggesting that lack of SSB repair in EM9 causes more collapsed forks and more recombination repair.	Camptothecin	104-116	RAD51 recombinase	Homo sapiens	47-52
16061638-4	2005	When Darpp-32 and t-Darpp were overexpressed in AGS and RKO gastrointestinal cells, up to a 4-fold reduction in the apoptosis rate was observed (terminal deoxynucleotidyl transferase-mediated nick-end labeling and Annexin V assays) in response to camptothecin, sodium butyrate, and ceramide.	Camptothecin	247-259	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	5-13
16055725-8	2005	Furthermore, we show that gammaH2Ax, DSBs, and RAD51 foci are synergistically induced in EM9 cells with camptothecin, suggesting that lack of SSB repair in EM9 causes more collapsed forks and more recombination repair.	Camptothecin	104-116	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	89-92
16055725-8	2005	Furthermore, we show that gammaH2Ax, DSBs, and RAD51 foci are synergistically induced in EM9 cells with camptothecin, suggesting that lack of SSB repair in EM9 causes more collapsed forks and more recombination repair.	Camptothecin	104-116	small RNA binding exonuclease protection factor La	Homo sapiens	142-145
16055725-8	2005	Furthermore, we show that gammaH2Ax, DSBs, and RAD51 foci are synergistically induced in EM9 cells with camptothecin, suggesting that lack of SSB repair in EM9 causes more collapsed forks and more recombination repair.	Camptothecin	104-116	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	156-159
15920477-0	2005	SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity.	Camptothecin	70-82	calcium activated nucleotidase 1	Homo sapiens	0-5
15908423-4	2005	Nuclear accumulation of p53 protein in mdm2 SNP309 cells results after 6 h of camptothecin, etoposide, or mitomycin C treatment, with the p53 protein phosphorylated at Ser15.	Camptothecin	78-90	tumor protein p53	Homo sapiens	24-27
15908423-4	2005	Nuclear accumulation of p53 protein in mdm2 SNP309 cells results after 6 h of camptothecin, etoposide, or mitomycin C treatment, with the p53 protein phosphorylated at Ser15.	Camptothecin	78-90	MDM2 proto-oncogene	Homo sapiens	39-43
15897895-5	2005	In addition, the cellular interaction of 9-1-1 with RPA or hyperphosphorylated RPA was stimulated by UV irradiation or camptothecin treatment in a dose-dependent manner.	Camptothecin	119-131	replication protein A1	Homo sapiens	52-55
15897895-5	2005	In addition, the cellular interaction of 9-1-1 with RPA or hyperphosphorylated RPA was stimulated by UV irradiation or camptothecin treatment in a dose-dependent manner.	Camptothecin	119-131	replication protein A1	Homo sapiens	79-82
16012946-9	2005	Camptothecin-induced apoptosis was monitored using caspase-3 and poly (ADP-ribose) polymerase [PARP]-specific antibodies and DNA Elisa +/- Hsp72 siRNA.	Camptothecin	0-12	caspase 3	Rattus norvegicus	51-93
16012946-9	2005	Camptothecin-induced apoptosis was monitored using caspase-3 and poly (ADP-ribose) polymerase [PARP]-specific antibodies and DNA Elisa +/- Hsp72 siRNA.	Camptothecin	0-12	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	139-144
16012946-13	2005	Reduced Hsp72 was associated with increased camptothecin-induced caspase-3 and PARP cleavage in glutamine-deficient cells.	Camptothecin	44-56	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	8-13
16012946-13	2005	Reduced Hsp72 was associated with increased camptothecin-induced caspase-3 and PARP cleavage in glutamine-deficient cells.	Camptothecin	44-56	caspase 3	Rattus norvegicus	65-74
15920477-0	2005	SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity.	Camptothecin	70-82	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	13-17
15958570-4	2005	Sublethal concentrations of camptothecin reduced the IC50 of agonistic anti-Fas antibody (CH-11) 10-fold, from 500 to 50 ng/mL, in human U87 glioblastoma cells (p53 wild-type).	Camptothecin	28-40	tumor protein p53	Homo sapiens	161-164
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	152-164	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	16-20
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	152-164	calcium activated nucleotidase 1	Homo sapiens	52-57
15958570-9	2005	Expression of Fas-associated death domain, and not Fas, Fas ligand, or caspase proteins, increased following cell treatment with camptothecin + CH-11.	Camptothecin	129-141	Fas ligand	Homo sapiens	56-66
15958570-10	2005	Camptothecin treatment enhanced c-jun-NH2-kinase activation in response to CH-11, but inhibition of c-jun-NH2-kinase did not prevent cell death induced by the combination treatment.	Camptothecin	0-12	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	32-37
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	152-164	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	184-188
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	166-169	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	16-20
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	166-169	calcium activated nucleotidase 1	Homo sapiens	52-57
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	166-169	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	184-188
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	206-209	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	16-20
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	206-209	calcium activated nucleotidase 1	Homo sapiens	52-57
15920477-5	2005	The analysis of Tdp1 mutant cell lines derived from SCAN1 patients reveals that they are hypersensitive to the topoisomerase I-specific anticancer drug camptothecin (CPT), implicating Tdp1 in the repair of CPT-induced topoisomerase I damage in human cells.	Camptothecin	206-209	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	184-188
15772291-9	2005	These studies may allow the design of both novel camptothecin analogs that would not inhibit AChE and new AChE inhibitors derived from the camptothecin scaffold.	Camptothecin	139-151	acetylcholinesterase (Cartwright blood group)	Homo sapiens	106-110
15834151-3	2005	Previous work has demonstrated that two structure-specific nucleases, Rad1 and Mus81, protect cells from camptothecin toxicity.	Camptothecin	105-117	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	70-74
15834151-3	2005	Previous work has demonstrated that two structure-specific nucleases, Rad1 and Mus81, protect cells from camptothecin toxicity.	Camptothecin	105-117	Mus81p	Saccharomyces cerevisiae S288C	79-84
15834151-5	2005	In addition to genes involved in DSB repair and recombination, we identified four genes with known or implicated nuclease activity, SLX1, SLX4, SAE2, and RAD27, that were also important for protection against camptothecin.	Camptothecin	209-221	endonuclease	Saccharomyces cerevisiae S288C	132-136
15834151-5	2005	In addition to genes involved in DSB repair and recombination, we identified four genes with known or implicated nuclease activity, SLX1, SLX4, SAE2, and RAD27, that were also important for protection against camptothecin.	Camptothecin	209-221	Slx4p	Saccharomyces cerevisiae S288C	138-142
15834151-5	2005	In addition to genes involved in DSB repair and recombination, we identified four genes with known or implicated nuclease activity, SLX1, SLX4, SAE2, and RAD27, that were also important for protection against camptothecin.	Camptothecin	209-221	ssDNA endodeoxyribonuclease SAE2	Saccharomyces cerevisiae S288C	144-148
15834151-5	2005	In addition to genes involved in DSB repair and recombination, we identified four genes with known or implicated nuclease activity, SLX1, SLX4, SAE2, and RAD27, that were also important for protection against camptothecin.	Camptothecin	209-221	multifunctional nuclease RAD27	Saccharomyces cerevisiae S288C	154-159
15834151-6	2005	Genetic analysis revealed that the flap endonucleases Slx4 and Sae2 represent new pathways parallel to Tdp1, Rad1, and Mus81 that protect cells from camptothecin toxicity.	Camptothecin	149-161	Slx4p	Saccharomyces cerevisiae S288C	54-58
15834151-6	2005	Genetic analysis revealed that the flap endonucleases Slx4 and Sae2 represent new pathways parallel to Tdp1, Rad1, and Mus81 that protect cells from camptothecin toxicity.	Camptothecin	149-161	ssDNA endodeoxyribonuclease SAE2	Saccharomyces cerevisiae S288C	63-67
15834151-6	2005	Genetic analysis revealed that the flap endonucleases Slx4 and Sae2 represent new pathways parallel to Tdp1, Rad1, and Mus81 that protect cells from camptothecin toxicity.	Camptothecin	149-161	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	103-107
15834151-6	2005	Genetic analysis revealed that the flap endonucleases Slx4 and Sae2 represent new pathways parallel to Tdp1, Rad1, and Mus81 that protect cells from camptothecin toxicity.	Camptothecin	149-161	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	109-113
15834151-6	2005	Genetic analysis revealed that the flap endonucleases Slx4 and Sae2 represent new pathways parallel to Tdp1, Rad1, and Mus81 that protect cells from camptothecin toxicity.	Camptothecin	149-161	Mus81p	Saccharomyces cerevisiae S288C	119-124
15834151-7	2005	We show further that the function of Sae2 is likely due to its interaction with the endonuclease Mre11 and that the latter acts on an independent branch to repair camptothecin-induced damage.	Camptothecin	163-175	ssDNA endodeoxyribonuclease SAE2	Saccharomyces cerevisiae S288C	37-41
15930305-1	2005	FdUMP[10], a 10mer of 5-fluoro-2"-deoxyuridine 5"-monophosphate (FdUMP), the thymidylate synthase inhibitory metabolite of 5-fluorouracil (FU), is most closely correlated with the DNA topoisomerase I (Top1) inhibitor camptothecin in the National Cancer Institute COMPARE analysis, but not with FU.	Camptothecin	217-229	thymidylate synthase	Mus musculus	77-97
15930305-3	2005	Camptothecin-resistant P388/CPT45 cells lacking Top1 are cross-resistant to FdUMP[10] as well as to FdUMP, FdU, and the thymidylate synthase inhibitor raltitrexed (Tomudex).	Camptothecin	0-12	thymidylate synthase	Mus musculus	120-140
16077201-0	2005	Cathepsins and BID are involved in the molecular switch between apoptosis and autophagy in breast cancer MCF-7 cells exposed to camptothecin.	Camptothecin	128-140	BH3 interacting domain death agonist	Homo sapiens	15-18
16077201-2	2005	This study focused on the role of cathepsin B and its substrate, BID as molecular links between apoptosis and autophagy in human breast cancer MCF-7 cells exposed to camptothecin.	Camptothecin	166-178	cathepsin B	Homo sapiens	34-45
16077201-2	2005	This study focused on the role of cathepsin B and its substrate, BID as molecular links between apoptosis and autophagy in human breast cancer MCF-7 cells exposed to camptothecin.	Camptothecin	166-178	BH3 interacting domain death agonist	Homo sapiens	65-68
16146333-4	2005	Overexpression of BCRP is associated with high levels of resistance to a variety of anticancer agents, including anthracyclines, mitoxantrone, and the camptothecins, by enhancing drug efflux.	Camptothecin	151-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	18-22
15735665-8	2005	The expression of topors is induced by exposure to the genotoxic reagents cisplatin and camptothecin, a DNA topoisomerase I inhibitor.	Camptothecin	88-100	TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase	Homo sapiens	18-24
15867389-0	2005	Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin.	Camptothecin	105-117	poly(ADP-ribose) polymerase 1	Homo sapiens	0-29
15671440-0	2005	Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms.	Camptothecin	40-52	protein kinase C delta	Homo sapiens	101-122
15846088-5	2005	The cell line that showed greatest reduction (85-90%) of p53 expression showed decreased p21 promoter activation after DNA damage with camptothecin, etoposide and MMS.	Camptothecin	135-147	tumor protein p53	Homo sapiens	57-60
15846088-5	2005	The cell line that showed greatest reduction (85-90%) of p53 expression showed decreased p21 promoter activation after DNA damage with camptothecin, etoposide and MMS.	Camptothecin	135-147	H3 histone pseudogene 16	Homo sapiens	89-92
15576186-5	2005	Animals treated with the polymer implants containing camptothecin had significantly longer TGDs compared to untreated animals as well as to animals treated systemically with camptothecin by intra-peritoneal injection with no evidence of toxicity in terms of loss of body weight.	Camptothecin	53-65	TDP-glucose 4,6-dehydratase	Mus musculus	91-95
15867389-1	2005	Poly(ADP-ribose) polymerase-1 (PARP-1) is known to have an important role in camptothecin sensitivity and interacts with topoisomerase I.	Camptothecin	77-89	poly(ADP-ribose) polymerase 1	Homo sapiens	0-29
15867389-1	2005	Poly(ADP-ribose) polymerase-1 (PARP-1) is known to have an important role in camptothecin sensitivity and interacts with topoisomerase I.	Camptothecin	77-89	poly(ADP-ribose) polymerase 1	Homo sapiens	31-37
15867389-2	2005	In the present study, the impact of PARP-1 on the topoisomerase I-DNA complex stabilized by camptothecin was assessed.	Camptothecin	92-104	poly(ADP-ribose) polymerase 1	Homo sapiens	36-42
15867389-4	2005	PARP-1 could prevent the action of camptothecin on the religation activity of full-length topoisomerase I, which is linked to DNA in a stoichiometrical manner.	Camptothecin	35-47	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
15867389-7	2005	This data suggests that PARP-1 destabilizes the topoisomerase I-camptothecin-DNA complex with the participation of the NH2-terminal domain of topoisomerase I. Poly(ADP-ribosyl)ation of topoisomerase I by PARP-1 in the presence its substrate, NAD, could also promote the religation activity of full-length topoisomerase I as well as NH2 terminus-truncated topoisomerase I.	Camptothecin	64-76	poly(ADP-ribose) polymerase 1	Homo sapiens	24-30
15867389-7	2005	This data suggests that PARP-1 destabilizes the topoisomerase I-camptothecin-DNA complex with the participation of the NH2-terminal domain of topoisomerase I. Poly(ADP-ribosyl)ation of topoisomerase I by PARP-1 in the presence its substrate, NAD, could also promote the religation activity of full-length topoisomerase I as well as NH2 terminus-truncated topoisomerase I.	Camptothecin	64-76	poly(ADP-ribose) polymerase 1	Homo sapiens	204-210
15867389-10	2005	This study also implies that PARP-1 and PARP-1/NAD actions need to be highly regulated by cellular factors for camptothecin to exert its cytotoxicity inside the cells.	Camptothecin	111-123	poly(ADP-ribose) polymerase 1	Homo sapiens	29-35
15867389-10	2005	This study also implies that PARP-1 and PARP-1/NAD actions need to be highly regulated by cellular factors for camptothecin to exert its cytotoxicity inside the cells.	Camptothecin	111-123	poly(ADP-ribose) polymerase 1	Homo sapiens	40-46
15862279-6	2005	Camptothecin treatment resulted in activation of caspase-3 with generation of the caspase-3 cleavage product, poly ADP-ribose polymerase (PARP).	Camptothecin	0-12	caspase 3	Homo sapiens	49-58
15809721-3	2005	CPT-11, a derivative of camptothecin, works as type-I DNA topoisomerase inhibitor and showed a major objective response rate in patients with metastatic colorectal cancer.	Camptothecin	24-36	DNA topoisomerase I	Homo sapiens	47-71
15759029-1	2005	A lysosomal pathway, characterized by partial rupture of lysosomal membranes and cathepsin B activation, is activated during camptothecin (CPT)-induced apoptosis in U937 and Namalwa cancer cells.	Camptothecin	125-137	cathepsin B	Homo sapiens	81-92
15759029-1	2005	A lysosomal pathway, characterized by partial rupture of lysosomal membranes and cathepsin B activation, is activated during camptothecin (CPT)-induced apoptosis in U937 and Namalwa cancer cells.	Camptothecin	139-142	cathepsin B	Homo sapiens	81-92
15862279-6	2005	Camptothecin treatment resulted in activation of caspase-3 with generation of the caspase-3 cleavage product, poly ADP-ribose polymerase (PARP).	Camptothecin	0-12	caspase 3	Homo sapiens	82-91
15862279-6	2005	Camptothecin treatment resulted in activation of caspase-3 with generation of the caspase-3 cleavage product, poly ADP-ribose polymerase (PARP).	Camptothecin	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	110-136
15862279-6	2005	Camptothecin treatment resulted in activation of caspase-3 with generation of the caspase-3 cleavage product, poly ADP-ribose polymerase (PARP).	Camptothecin	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	138-142
15803320-4	2005	In a yku70 mutant background, sgs1 mutations increased sensitivity to DNA breakage induced either by treatment with camptothecin or by the expression of the restriction enzyme EcoRI.	Camptothecin	116-128	ATP-dependent DNA helicase YKU70	Saccharomyces cerevisiae S288C	5-10
15843040-4	2005	While ERK1/2 activation was a general phenomenon, irrespective of the used cell type or antitumour drug, the MEK/ERK inhibitors only reduced cisplatin toxicity in human myeloid cells (THP-1, HL-60 and NB-4), but not in RAW 264.7 mouse macrophages and NRK-52E rat renal tubular cells; and failed to reduce the toxicity etoposide, camptothecin, melphalan and arsenic trioxide, in U-937 cells.	Camptothecin	329-341	mitogen-activated protein kinase kinase 7	Homo sapiens	109-112
15846298-5	2005	Treatment of cell lines in vitro with HGS-ETR1 enhanced the cytotoxicity of chemotherapeutic agents (camptothecin, cisplatin, carboplatin, or 5-fluorouracil) even in tumour cell lines that were not sensitive to HGS-ETR1 alone.	Camptothecin	101-113	CUGBP Elav-like family member 3	Homo sapiens	42-46
15699047-4	2005	To address this issue, we assessed the roles of ATR, Chk1, ATM, and Chk2 in cells treated with the topoisomerase I poisons camptothecin and 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan.	Camptothecin	123-135	checkpoint kinase 2	Homo sapiens	68-72
15699047-5	2005	Colony forming assays demonstrated that down-regulation of ATR or Chk1 sensitized cells to SN-38 and camptothecin.	Camptothecin	101-113	ATR serine/threonine kinase	Homo sapiens	59-62
15699047-5	2005	Colony forming assays demonstrated that down-regulation of ATR or Chk1 sensitized cells to SN-38 and camptothecin.	Camptothecin	101-113	checkpoint kinase 1	Homo sapiens	66-70
15653682-2	2005	The induction of replication stress by hydroxyurea (HU) or DNA damage by camptothecin (CAMPT), etoposide (ETOP), or mitomycin C (MMC) led to the formation of nuclear foci containing phosphorylated Nbs1.	Camptothecin	73-85	nibrin	Homo sapiens	197-201
15653682-2	2005	The induction of replication stress by hydroxyurea (HU) or DNA damage by camptothecin (CAMPT), etoposide (ETOP), or mitomycin C (MMC) led to the formation of nuclear foci containing phosphorylated Nbs1.	Camptothecin	87-92	nibrin	Homo sapiens	197-201
15653682-3	2005	HU and CAMPT treatment also led to the formation of RPA foci that co-localized with phospho-Nbs1 foci.	Camptothecin	7-12	replication protein A1	Homo sapiens	52-55
15653682-3	2005	HU and CAMPT treatment also led to the formation of RPA foci that co-localized with phospho-Nbs1 foci.	Camptothecin	7-12	nibrin	Homo sapiens	92-96
15653682-6	2005	Consistent with the presence or absence of RPA foci, RPA hyperphosphorylation was present following HU, CAMPT, and ETOP treatment but absent following MMC treatment.	Camptothecin	104-109	replication protein A1	Homo sapiens	53-56
15803320-4	2005	In a yku70 mutant background, sgs1 mutations increased sensitivity to DNA breakage induced either by treatment with camptothecin or by the expression of the restriction enzyme EcoRI.	Camptothecin	116-128	ATP-dependent DNA helicase SGS1	Saccharomyces cerevisiae S288C	30-34
15674334-6	2005	The camptothecin or etoposide-dependent p53-mediated repression was attenuated by trichostatin A (TSA), an inhibitor of histone deacetylases (HDACs).	Camptothecin	4-16	tumor protein p53	Homo sapiens	40-43
15766244-7	2005	Finally, certain TFO-CPT conjugates were able to induce sequence-specific DNA cleavage with the topo I mutants R364H and N722S that are resistant to camptothecin.	Camptothecin	149-161	choline phosphotransferase 1	Homo sapiens	21-24
15674334-8	2005	The simultaneous formation of a camptothecin-dependent p53-SP1 complex indicated its occurrence outside of the RECQ4 promoter.	Camptothecin	32-44	tumor protein p53	Homo sapiens	55-58
15674334-8	2005	The simultaneous formation of a camptothecin-dependent p53-SP1 complex indicated its occurrence outside of the RECQ4 promoter.	Camptothecin	32-44	RecQ like helicase 4	Homo sapiens	111-116
15743838-2	2005	Here we show that nucleolin-RPA complex formation is stimulated after genotoxic stresses such as treatment with camptothecin or exposure to ionizing radiation.	Camptothecin	112-124	nucleolin	Homo sapiens	18-27
15660100-5	2005	We found that NO donors ((+/-)-S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, and NONOates) dose-dependently inhibited caspase-3 and -9 activity induced by STS and camptothecin.	Camptothecin	172-184	caspase 3	Homo sapiens	127-143
15557337-9	2005	By contrast, HIF-1alpha-VP16-expressing HT22 cells were more resistant to DNA damage (induced by camptothecin) or endoplasmic reticulum stress (induced by thapsigargin and tunicamycin) than were VP16-expressing cells, and suppression of HIF-1alpha expression using RNA interference rendered HT22 cells more sensitive to death induced by DNA damage or endoplasmic reticulum stress.	Camptothecin	97-109	hypoxia inducible factor 1, alpha subunit	Mus musculus	13-23
15743838-2	2005	Here we show that nucleolin-RPA complex formation is stimulated after genotoxic stresses such as treatment with camptothecin or exposure to ionizing radiation.	Camptothecin	112-124	replication protein A1	Homo sapiens	28-31
15608676-2	2005	We have previously shown that inhibition of Chk1 sensitizes tumor cells to topoisomerase inhibitors such as camptothecin and doxorubicin through abrogation of cell-cycle arrest (S or G2/M checkpoints).	Camptothecin	108-120	checkpoint kinase 1	Homo sapiens	44-48
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Camptothecin	90-102	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	128-133
15719174-1	2005	The cells of an ataxia-oculomotor apraxia type 1 (AOA1) patient, homozygous for a new aprataxin mutation (T739C), were treated with camptothecin, an inhibitor of DNA topoisomerase I which induces DNA single-strand breaks.	Camptothecin	132-144	aprataxin	Homo sapiens	86-95
15665856-4	2005	Abrogation of Chk1 function with small interfering RNA or chemical antagonists inhibits HRR, leading to persistent unrepaired DNA double-strand breaks (DSBs) and cell death after replication inhibition with hydroxyurea or DNA-damage caused by camptothecin.	Camptothecin	243-255	checkpoint kinase 1	Homo sapiens	14-18
15551063-9	2005	Effects of Zn(2+) on bcl-2/bax ratio were confirmed in apoptotic camptothecin-treated SHE cells.	Camptothecin	65-77	apoptosis regulator Bcl-2	Mesocricetus auratus	21-26
15551063-9	2005	Effects of Zn(2+) on bcl-2/bax ratio were confirmed in apoptotic camptothecin-treated SHE cells.	Camptothecin	65-77	apoptosis regulator BAX	Mesocricetus auratus	27-30
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Camptothecin	90-102	tumor necrosis factor receptor superfamily, member 10b	Mus musculus	198-201
15389801-10	2005	Chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, doxorubicin, and camptothecin) significantly augmented TRAIL-induced apoptosis in cancer cells through up-regulation of DR4, DR5, Bax, and Bak, and induction of caspase activation.	Camptothecin	90-102	BCL2-associated X protein	Mus musculus	203-206
15561098-3	2005	Whereas exposure of human cells to topoisomerase inhibitors camptothecin, etoposide, or adriamycin resulted in rapid (within 1 h) activation of the pathway including degradation of the Cdc25A phosphatase and inhibition of cyclin E/CDK2 kinase activity, taxol failed to activate this checkpoint even after a prolonged treatment.	Camptothecin	60-72	cell division cycle 25A	Homo sapiens	185-191
15561098-3	2005	Whereas exposure of human cells to topoisomerase inhibitors camptothecin, etoposide, or adriamycin resulted in rapid (within 1 h) activation of the pathway including degradation of the Cdc25A phosphatase and inhibition of cyclin E/CDK2 kinase activity, taxol failed to activate this checkpoint even after a prolonged treatment.	Camptothecin	60-72	cyclin dependent kinase 2	Homo sapiens	231-235
15813675-2	2005	Cancer cells overexpressing the ABCG2 gene show multidrug resistance to mitoxantrone-, methotrexate-, doxorubicin-, and camptothecin-based anticancer drugs, such as topotecan and SN-38.	Camptothecin	120-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	32-37
15586228-7	2005	Stimulation by an anticancer drug (camptothecin) augmented cell surface expression of TWEAK and all human colonic adenocarcinoma tissue samples studied (n=59) demonstrated positive staining for TWEAK antigen.	Camptothecin	35-47	TNF superfamily member 12	Homo sapiens	86-91
15592449-7	2005	Human FEN-1, but not the GEN-deficient mutant, E178A, was shown to rescue the defect in resistance to UV and camptothecin in a yeast FEN-1 null mutant.	Camptothecin	109-121	flap structure-specific endonuclease 1	Homo sapiens	6-11
15586228-7	2005	Stimulation by an anticancer drug (camptothecin) augmented cell surface expression of TWEAK and all human colonic adenocarcinoma tissue samples studied (n=59) demonstrated positive staining for TWEAK antigen.	Camptothecin	35-47	TNF superfamily member 12	Homo sapiens	194-199
15448168-10	2004	In addition, loss of topo I phosphorylation in c-Abl-deficient cells conferred resistance to camptothecin-induced apoptosis.	Camptothecin	93-105	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	47-52
15494395-6	2004	Cells expressing GFP-tagged TDP1 &gt; 100-fold in excess of endogenous TDP1 exhibited a significant reduction of DNA damage induced by the topoisomerase I poison camptothecin and could be selected by that drug.	Camptothecin	162-174	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	28-32
15494395-6	2004	Cells expressing GFP-tagged TDP1 &gt; 100-fold in excess of endogenous TDP1 exhibited a significant reduction of DNA damage induced by the topoisomerase I poison camptothecin and could be selected by that drug.	Camptothecin	162-174	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	71-75
15604285-5	2004	Surprisingly, the RNase L-deficient cells were also highly resistant to apoptosis by combination treatments with a topoisomerase (Topo) I inhibitor (camptothecin, topotecan, or SN-38) and tumor necrosis factor-related apoptosis-inducing ligand [TRAIL (Apo2L)].	Camptothecin	149-161	ribonuclease L	Homo sapiens	18-25
15604285-7	2004	An inhibitor of c-Jun NH(2)-terminal kinases reduced apoptosis induced by treatment with either 2-5A or the combination of camptothecin and TRAIL, thus implicating c-Jun NH(2)-terminal kinase in the apoptotic signaling pathway.	Camptothecin	123-135	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-21
15604285-7	2004	An inhibitor of c-Jun NH(2)-terminal kinases reduced apoptosis induced by treatment with either 2-5A or the combination of camptothecin and TRAIL, thus implicating c-Jun NH(2)-terminal kinase in the apoptotic signaling pathway.	Camptothecin	123-135	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	164-169
15448168-0	2004	Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity.	Camptothecin	76-88	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	46-51
15585644-0	2004	pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol.	Camptothecin	56-68	proline rich protein BstNI subfamily 2	Homo sapiens	0-4
15500952-6	2004	These results suggest that GSTP1 has protective effects against camptothecin-induced necrosis in subset of human lung adenocarcinoma through glutathione conjugation.	Camptothecin	64-76	glutathione S-transferase pi 1	Homo sapiens	27-32
15500952-0	2004	GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells.	Camptothecin	38-50	glutathione S-transferase pi 1	Homo sapiens	0-5
15500952-2	2004	We intended to investigate whether GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells.	Camptothecin	73-85	glutathione S-transferase pi 1	Homo sapiens	35-40
15500952-3	2004	Camptothecin induced GSTP1 expression.	Camptothecin	0-12	glutathione S-transferase pi 1	Homo sapiens	21-26
15500952-4	2004	Downregulation of GSTP1 increased necrosis induced by camptothecin in A549 cells but not in PC-14 and RERF-LC-KJ cells.	Camptothecin	54-66	glutathione S-transferase pi 1	Homo sapiens	18-23
15585644-0	2004	pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol.	Camptothecin	56-68	RB transcriptional corepressor like 2	Homo sapiens	5-9
15585644-2	2004	The purpose of this study is to investigate the possible role of pRb2/p130 in the sensitivity of ovarian cancer to camptothecin, doxorubicin, and taxol.	Camptothecin	115-127	proline rich protein BstNI subfamily 2	Homo sapiens	65-69
15585644-2	2004	The purpose of this study is to investigate the possible role of pRb2/p130 in the sensitivity of ovarian cancer to camptothecin, doxorubicin, and taxol.	Camptothecin	115-127	RB transcriptional corepressor like 2	Homo sapiens	70-74
15585644-4	2004	RESULTS: The results reported in this study support the conclusion that overexpression of pRb2/p130 in the CAOV-3 ovarian cancer cell line lacking wild-type p53 is able to inhibit apoptosis triggered by camptothecin and doxorubicin through the c-Jun NH(2)-terminal kinase signaling transduction pathway.	Camptothecin	203-215	proline rich protein BstNI subfamily 2	Homo sapiens	90-94
15585644-4	2004	RESULTS: The results reported in this study support the conclusion that overexpression of pRb2/p130 in the CAOV-3 ovarian cancer cell line lacking wild-type p53 is able to inhibit apoptosis triggered by camptothecin and doxorubicin through the c-Jun NH(2)-terminal kinase signaling transduction pathway.	Camptothecin	203-215	RB transcriptional corepressor like 2	Homo sapiens	95-99
15634660-7	2004	In contrast, cotreatment of camptothecin or VP-16 with TWEAK or TL1A did not facilitate apoptosis in HL60 cells.	Camptothecin	28-40	TNF superfamily member 12	Homo sapiens	55-60
15700547-3	2004	Overexpression of SKP2 reduced the expression of p27Kip1, cyclin E, and p21Cip1, increased S-phase cells, rescued A549 cells from apoptosis due to adenoviral infection, and also increased chemoresistance against camptothecin, cisplatin, and AG1478.	Camptothecin	212-224	S-phase kinase associated protein 2	Homo sapiens	18-22
15634660-7	2004	In contrast, cotreatment of camptothecin or VP-16 with TWEAK or TL1A did not facilitate apoptosis in HL60 cells.	Camptothecin	28-40	TNF superfamily member 15	Homo sapiens	64-68
15634660-0	2004	Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.	Camptothecin	0-12	TNF receptor superfamily member 10a	Homo sapiens	93-116
15634660-8	2004	These findings suggest that DR4 aggregation mediated by camptothecin or VP-16 could represent a mean that accelerates TRAIL-induced apoptosis.	Camptothecin	56-68	TNF receptor superfamily member 10a	Homo sapiens	28-31
15634660-0	2004	Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.	Camptothecin	0-12	TNF superfamily member 10	Homo sapiens	145-200
15634660-8	2004	These findings suggest that DR4 aggregation mediated by camptothecin or VP-16 could represent a mean that accelerates TRAIL-induced apoptosis.	Camptothecin	56-68	TNF superfamily member 10	Homo sapiens	118-123
15634660-1	2004	During camptothecin- and etoposide (VP-16)-induced apoptosis in HL-60 cells, the expression level of cell death receptor-3 (DR3), cell death receptor-4 (DR4), and FAS remained mostly unchanged, whereas the expression of silencers of death domain (SODD) and FLICE inhibitory proteins, inhibitors of the cell death receptor signaling pathways, decreased substantially.	Camptothecin	7-19	host cell factor C1	Homo sapiens	36-41
15475000-7	2004	Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene.	Camptothecin	118-130	glycogen synthase kinase 3 beta	Homo sapiens	47-56
15634660-1	2004	During camptothecin- and etoposide (VP-16)-induced apoptosis in HL-60 cells, the expression level of cell death receptor-3 (DR3), cell death receptor-4 (DR4), and FAS remained mostly unchanged, whereas the expression of silencers of death domain (SODD) and FLICE inhibitory proteins, inhibitors of the cell death receptor signaling pathways, decreased substantially.	Camptothecin	7-19	TNF receptor superfamily member 25	Homo sapiens	106-122
15634660-1	2004	During camptothecin- and etoposide (VP-16)-induced apoptosis in HL-60 cells, the expression level of cell death receptor-3 (DR3), cell death receptor-4 (DR4), and FAS remained mostly unchanged, whereas the expression of silencers of death domain (SODD) and FLICE inhibitory proteins, inhibitors of the cell death receptor signaling pathways, decreased substantially.	Camptothecin	7-19	TNF receptor superfamily member 10a	Homo sapiens	135-151
15634660-4	2004	The high expression level of SODD or of dominant negative forms of FADD (FADD-DN) and DAP3 (DAP3-DN), or of NH2-terminal deletion mutant of TRADD (TRADD-ND) achieved by transient transfection experiments, did not impair the kinetics of apoptosis after camptothecin and VP-16 treatment in HL-60 and U937 cells.	Camptothecin	252-264	TNFRSF1A associated via death domain	Homo sapiens	147-155
15634660-5	2004	Taken together, these observations suggested that camptothecin and VP-16 induced rapid aggregation of DR4 and DR3, but paradoxically, the importance of these events in signaling apoptosis is uncertain, because the kinetics of apoptosis were unaffected, even in the presence of a high expression level of SODD, FADD-DN, TRADD-ND, and DAP3-DN.	Camptothecin	50-62	TNF receptor superfamily member 10a	Homo sapiens	102-105
15634660-5	2004	Taken together, these observations suggested that camptothecin and VP-16 induced rapid aggregation of DR4 and DR3, but paradoxically, the importance of these events in signaling apoptosis is uncertain, because the kinetics of apoptosis were unaffected, even in the presence of a high expression level of SODD, FADD-DN, TRADD-ND, and DAP3-DN.	Camptothecin	50-62	TNF receptor superfamily member 25	Homo sapiens	110-113
15634660-6	2004	However, camptothecin or VP-16 treatment in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) substantially accelerated kinetics of apoptosis than treatment with camptothecin, VP-16, or TRAIL alone.	Camptothecin	9-21	TNF superfamily member 10	Homo sapiens	118-123
15505424-1	2004	In the p53-deficient human B lymphoma Namalwa cell line that quickly undergoes apoptosis after DNA topoisomerase I inhibitor (camptothecin, CPT) treatment, we observed rapid and slight induction of the pro-apoptotic BH3-only Bik, Bim-EL, Bim-L and Bim-S proteins.	Camptothecin	126-138	tumor protein p53	Homo sapiens	7-10
15475000-7	2004	Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene.	Camptothecin	118-130	tumor protein p53	Homo sapiens	176-179
15475000-7	2004	Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene.	Camptothecin	118-130	Fas cell surface death receptor	Homo sapiens	209-213
15452064-4	2004	Expression of eIF5A protein in response to camptothecin or a combination of camptothecin and TNF-alpha was determined by Western blot analysis.	Camptothecin	43-55	eukaryotic translation initiation factor 5A	Homo sapiens	14-19
15684817-0	2004	Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon.	Camptothecin	0-12	ISG15 ubiquitin like modifier	Homo sapiens	49-54
15684817-0	2004	Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon.	Camptothecin	0-12	ISG15 ubiquitin like modifier	Homo sapiens	69-74
15684817-6	2004	CPT induced free ISG15 and conjugates in a dose-dependent and time-dependent manner.	Camptothecin	0-3	ISG15 ubiquitin like modifier	Homo sapiens	17-22
15684817-8	2004	CPT-induced ISG15 conjugates were distinct from those induced by IFN; however, CPT treatment dramatically enhanced ISG15 conjugation in response to IFN.	Camptothecin	0-3	ISG15 ubiquitin like modifier	Homo sapiens	12-17
15684817-8	2004	CPT-induced ISG15 conjugates were distinct from those induced by IFN; however, CPT treatment dramatically enhanced ISG15 conjugation in response to IFN.	Camptothecin	0-3	interferon alpha 1	Homo sapiens	148-151
15684817-8	2004	CPT-induced ISG15 conjugates were distinct from those induced by IFN; however, CPT treatment dramatically enhanced ISG15 conjugation in response to IFN.	Camptothecin	79-82	ISG15 ubiquitin like modifier	Homo sapiens	115-120
15684817-8	2004	CPT-induced ISG15 conjugates were distinct from those induced by IFN; however, CPT treatment dramatically enhanced ISG15 conjugation in response to IFN.	Camptothecin	79-82	interferon alpha 1	Homo sapiens	148-151
15492260-4	2004	In two melanomas with wild-type p53 but with differential expression of APAF-1, treatment with camptothecin, celecoxib, or an nitric oxide synthase inhibitor (1400W) significantly modulated expression of 36 of 96 genes in an apoptosis-specific cDNA macroarray, but APAF-1 mRNA levels were not induced (in APAF-1(-) cells) nor up-regulated (in APAF-1(+) cells), a finding confirmed at the protein level.	Camptothecin	95-107	tumor protein p53	Homo sapiens	32-35
15492260-4	2004	In two melanomas with wild-type p53 but with differential expression of APAF-1, treatment with camptothecin, celecoxib, or an nitric oxide synthase inhibitor (1400W) significantly modulated expression of 36 of 96 genes in an apoptosis-specific cDNA macroarray, but APAF-1 mRNA levels were not induced (in APAF-1(-) cells) nor up-regulated (in APAF-1(+) cells), a finding confirmed at the protein level.	Camptothecin	95-107	apoptotic peptidase activating factor 1	Homo sapiens	72-78
15492260-4	2004	In two melanomas with wild-type p53 but with differential expression of APAF-1, treatment with camptothecin, celecoxib, or an nitric oxide synthase inhibitor (1400W) significantly modulated expression of 36 of 96 genes in an apoptosis-specific cDNA macroarray, but APAF-1 mRNA levels were not induced (in APAF-1(-) cells) nor up-regulated (in APAF-1(+) cells), a finding confirmed at the protein level.	Camptothecin	95-107	apoptotic peptidase activating factor 1	Homo sapiens	265-271
15492260-4	2004	In two melanomas with wild-type p53 but with differential expression of APAF-1, treatment with camptothecin, celecoxib, or an nitric oxide synthase inhibitor (1400W) significantly modulated expression of 36 of 96 genes in an apoptosis-specific cDNA macroarray, but APAF-1 mRNA levels were not induced (in APAF-1(-) cells) nor up-regulated (in APAF-1(+) cells), a finding confirmed at the protein level.	Camptothecin	95-107	apoptotic peptidase activating factor 1	Homo sapiens	265-271
15492260-4	2004	In two melanomas with wild-type p53 but with differential expression of APAF-1, treatment with camptothecin, celecoxib, or an nitric oxide synthase inhibitor (1400W) significantly modulated expression of 36 of 96 genes in an apoptosis-specific cDNA macroarray, but APAF-1 mRNA levels were not induced (in APAF-1(-) cells) nor up-regulated (in APAF-1(+) cells), a finding confirmed at the protein level.	Camptothecin	95-107	apoptotic peptidase activating factor 1	Homo sapiens	265-271
15492260-5	2004	Treatment with cisplatin, camptothecin, etoposide, betulinic acid, celecoxib, 1400W, and staurosporine promoted enzymatic activity not only of caspases -2, -8, and -3 but also of caspase-9 in both APAF-1(+) and APAF-1(-) tumor cells.	Camptothecin	26-38	caspase 2	Homo sapiens	143-166
15492260-5	2004	Treatment with cisplatin, camptothecin, etoposide, betulinic acid, celecoxib, 1400W, and staurosporine promoted enzymatic activity not only of caspases -2, -8, and -3 but also of caspase-9 in both APAF-1(+) and APAF-1(-) tumor cells.	Camptothecin	26-38	caspase 9	Homo sapiens	179-188
15492260-5	2004	Treatment with cisplatin, camptothecin, etoposide, betulinic acid, celecoxib, 1400W, and staurosporine promoted enzymatic activity not only of caspases -2, -8, and -3 but also of caspase-9 in both APAF-1(+) and APAF-1(-) tumor cells.	Camptothecin	26-38	apoptotic peptidase activating factor 1	Homo sapiens	197-203
15492260-5	2004	Treatment with cisplatin, camptothecin, etoposide, betulinic acid, celecoxib, 1400W, and staurosporine promoted enzymatic activity not only of caspases -2, -8, and -3 but also of caspase-9 in both APAF-1(+) and APAF-1(-) tumor cells.	Camptothecin	26-38	apoptotic peptidase activating factor 1	Homo sapiens	211-217
15452064-10	2004	TUNEL of transfected LC cells treated with TNF-alpha and camptothecin revealed an 80% reduction in apoptosis with siRNA against eIF5A.	Camptothecin	57-69	eukaryotic translation initiation factor 5A	Homo sapiens	128-133
15452064-4	2004	Expression of eIF5A protein in response to camptothecin or a combination of camptothecin and TNF-alpha was determined by Western blot analysis.	Camptothecin	76-88	eukaryotic translation initiation factor 5A	Homo sapiens	14-19
15452064-7	2004	Expression of eIF5A protein increased significantly after 8 hours of exposure to TNF-alpha and camptothecin, but not in response to camptothecin alone.	Camptothecin	95-107	eukaryotic translation initiation factor 5A	Homo sapiens	14-19
15452064-7	2004	Expression of eIF5A protein increased significantly after 8 hours of exposure to TNF-alpha and camptothecin, but not in response to camptothecin alone.	Camptothecin	132-144	eukaryotic translation initiation factor 5A	Homo sapiens	14-19
15452064-8	2004	siRNAs directed against eIF5A reduced apoptosis of LC cells in response to TNF-alpha and camptothecin by between 35% and 69%, as determined by Hoechst staining.	Camptothecin	89-101	eukaryotic translation initiation factor 5A	Homo sapiens	24-29
15135727-3	2004	The phenotypes of yeast strains that express this mutant show that the contribution of TDP1 to the repair of two kinds of damaged termini-induced, respectively, by camptothecin (CPT) and by bleomycin-strongly depends on enzyme activity.	Camptothecin	164-176	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	87-91
15724841-3	2004	Subsequent studies from our laboratory also revealed that the combined use of both UCN-01 and camptothecin induced DNA double strand breaks in p53 mutant tumor cells but not in normal or p53 negative epithelial cells.	Camptothecin	94-106	tumor protein p53	Homo sapiens	143-146
15371552-6	2004	Finally, this PNA acted cooperatively with camptothecin treatment both with regard to p53 activity induction as well as cell viability.	Camptothecin	43-55	tumor protein p53	Homo sapiens	86-89
15075385-1	2004	One activity potentially limiting the efficacy of camptothecin anticancer agents is their cellular efflux by the ATP-binding cassette half-transporter, ABCG2.	Camptothecin	50-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	152-157
15075385-4	2004	We report herein that, like camptothecins, homocamptothecin and its difluoro derivative BN80915 are substrates for ABCG2.	Camptothecin	28-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	115-120
15170677-0	2004	Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.	Camptothecin	6-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	45-50
15170677-3	2004	In the present study, we have characterized a total of 14 new camptothecin (CPT) analogues with respect to both the inhibition of Topo I and the substrate specificity of ABCG2.	Camptothecin	62-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	170-175
15170677-3	2004	In the present study, we have characterized a total of 14 new camptothecin (CPT) analogues with respect to both the inhibition of Topo I and the substrate specificity of ABCG2.	Camptothecin	76-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	170-175
15170677-6	2004	We have examined ATP-dependent transport of those CPT analogues by using plasma membrane vesicles prepared from both PC-6/SN2-5H2 cells and ABCG2-transfected HEK-293 cells.	Camptothecin	50-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	140-145
15105421-5	2004	SIVA is induced following direct p53 gene delivery, treatment with a DNA-damaging agent camptothecin, and stroke injury in vivo.	Camptothecin	88-100	SIVA1 apoptosis inducing factor	Homo sapiens	0-4
15475475-4	2004	Camptothecin activated p53 in A549 lung carcinoma cells pretreated with scrambled siRNA, exhibited concentration-dependent cell cycle blocks, and induced moderate microtubule stabilization.	Camptothecin	0-12	tumor protein p53	Homo sapiens	23-26
15475475-5	2004	Knockdown of camptothecin-induced p53 protein expression with p53 siRNA inhibited the G1/S blocking activity of the drug and diminished its microtubule-stabilizing activity.	Camptothecin	13-25	tumor protein p53	Homo sapiens	34-37
15475475-5	2004	Knockdown of camptothecin-induced p53 protein expression with p53 siRNA inhibited the G1/S blocking activity of the drug and diminished its microtubule-stabilizing activity.	Camptothecin	13-25	tumor protein p53	Homo sapiens	62-65
15367606-8	2004	Although Tax1 and Tax2 expression mediated elevated resistance to apoptosis in Jurkat cells after serum deprivation, Tax1 was unique in protection from apoptosis after exposure to camptothecin and etoposide, inhibitors of topoisomerase I and II, respectively.	Camptothecin	180-192	contactin 2	Homo sapiens	117-121
15208667-4	2004	We have studied here the p53 response to DNA-damaging agents (camptothecin, mitomycin C) in individual cells.	Camptothecin	62-74	tumor protein p53	Homo sapiens	25-28
15368659-1	2004	Some antitumor agents, including tumor necrosis factor-alpha (TNF-alpha) and camptothecin (CPT), often cause resistance of tumor cells to antitumor agents through activation of the nuclear factor-kappa B (NF-kappa B) pathway that leads to up-regulation of anti-apoptotic proteins.	Camptothecin	77-89	nuclear factor kappa B subunit 1	Homo sapiens	181-203
15368659-1	2004	Some antitumor agents, including tumor necrosis factor-alpha (TNF-alpha) and camptothecin (CPT), often cause resistance of tumor cells to antitumor agents through activation of the nuclear factor-kappa B (NF-kappa B) pathway that leads to up-regulation of anti-apoptotic proteins.	Camptothecin	77-89	nuclear factor kappa B subunit 1	Homo sapiens	205-215
15368659-1	2004	Some antitumor agents, including tumor necrosis factor-alpha (TNF-alpha) and camptothecin (CPT), often cause resistance of tumor cells to antitumor agents through activation of the nuclear factor-kappa B (NF-kappa B) pathway that leads to up-regulation of anti-apoptotic proteins.	Camptothecin	91-94	nuclear factor kappa B subunit 1	Homo sapiens	181-203
15368659-1	2004	Some antitumor agents, including tumor necrosis factor-alpha (TNF-alpha) and camptothecin (CPT), often cause resistance of tumor cells to antitumor agents through activation of the nuclear factor-kappa B (NF-kappa B) pathway that leads to up-regulation of anti-apoptotic proteins.	Camptothecin	91-94	nuclear factor kappa B subunit 1	Homo sapiens	205-215
15470521-4	2004	RESULTS: Apoptotic changes in HEp-2 cells appeared by 24 hours of camptothecin exposure, meanwhile the necrotic features become visible earlier.	Camptothecin	66-78	DNL-type zinc finger	Homo sapiens	30-33
15149862-1	2004	Mutations in the WRN or the TP53 genes lead to spontaneous genetic instability, an elevated risk of tumor formation, and sensitivity to compounds that interfere with DNA replication, such as camptothecin and DNA interstrand cross-linking drugs.	Camptothecin	191-203	WRN RecQ like helicase	Homo sapiens	17-20
15149862-1	2004	Mutations in the WRN or the TP53 genes lead to spontaneous genetic instability, an elevated risk of tumor formation, and sensitivity to compounds that interfere with DNA replication, such as camptothecin and DNA interstrand cross-linking drugs.	Camptothecin	191-203	tumor protein p53	Homo sapiens	28-32
15135727-3	2004	The phenotypes of yeast strains that express this mutant show that the contribution of TDP1 to the repair of two kinds of damaged termini-induced, respectively, by camptothecin (CPT) and by bleomycin-strongly depends on enzyme activity.	Camptothecin	178-181	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	87-91
15135730-4	2004	We show here that antisense suppression of WRN in two human glioma cell lines reproduces hallmarks of the drug cytotoxicity profile of WS cells, namely, hypersensitivity to 4-nitroquinoline 1-oxide, camptothecin and hydroxyurea.	Camptothecin	199-211	WRN RecQ like helicase	Homo sapiens	43-46
15161627-5	2004	The appearance of diminished FRET was inhibited by a pan-caspase inhibitor z-VAD or D-&gt;A mutations in the LEVD sequence and was markedly increased by apoptosis-inducing agents, etoposide and camptothecin, or overexpression of a caspase 8-red fluorescent protein fusion protein.	Camptothecin	194-206	caspase 4	Homo sapiens	57-64
15161627-5	2004	The appearance of diminished FRET was inhibited by a pan-caspase inhibitor z-VAD or D-&gt;A mutations in the LEVD sequence and was markedly increased by apoptosis-inducing agents, etoposide and camptothecin, or overexpression of a caspase 8-red fluorescent protein fusion protein.	Camptothecin	194-206	caspase 8	Homo sapiens	231-240
14729579-8	2004	HIP expression in HCT-116 cells was also significantly decreased in parallel with apoptosis after treatment with 50 micro M camptothecin and 20 micro M 5-fluorouracil.	Camptothecin	124-136	ribosomal protein L29	Homo sapiens	0-3
15122760-0	2004	Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.	Camptothecin	24-36	tumor necrosis factor	Mus musculus	90-93
15125776-0	2004	Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).	Camptothecin	22-34	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
15125776-0	2004	Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).	Camptothecin	22-34	ATP binding cassette subfamily B member 1	Homo sapiens	74-79
15125776-0	2004	Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).	Camptothecin	22-34	ATP binding cassette subfamily C member 2	Homo sapiens	85-115
15125776-0	2004	Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).	Camptothecin	22-34	ATP binding cassette subfamily C member 2	Homo sapiens	117-122
14754875-6	2004	RT-PCR analysis and western blot analysis revealed that ascorbic acid specifically blocked the decrease of bcl-X(L) by camptothecin or flavone.	Camptothecin	119-131	BCL2 like 1	Homo sapiens	107-115
14754875-8	2004	precedes the down-regulation of bcl-X(L) by camptothecin and flavone and ascorbic acid at a concentration of 1 mM prevented the generation of this reactive oxygen species.	Camptothecin	44-56	BCL2 like 1	Homo sapiens	32-40
15153331-3	2004	On the contrary, topoisomerase inhibitors, adriamycin and camptothecin, induce apoptosis to the same extent regardless of c-Myc expression.	Camptothecin	58-70	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	122-127
15141020-9	2004	The camptothecin-induced intra-S checkpoint is partially dependent on ATM, and is associated with inhibitory phosphorylation of cyclin-dependent kinase 2 and reduction of BrdUrd incorporation after mid-S phase.	Camptothecin	4-16	ATM serine/threonine kinase	Homo sapiens	70-73
15141020-9	2004	The camptothecin-induced intra-S checkpoint is partially dependent on ATM, and is associated with inhibitory phosphorylation of cyclin-dependent kinase 2 and reduction of BrdUrd incorporation after mid-S phase.	Camptothecin	4-16	cyclin dependent kinase 2	Homo sapiens	128-153
15059881-3	2004	Previously, 4-anilinoquinazoline TKIs have been shown to inhibit the function of the breast cancer resistance-associated drug transporter (ABCG2), reversing resistance to camptothecin derivatives topotecan and SN-38.	Camptothecin	171-183	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	139-144
15069724-8	2004	RESULTS: Topoisomerase inhibitors, including camptothecin and etoposide, were found to increase the endostatin expression level in vitro.	Camptothecin	45-57	collagen, type XVIII, alpha 1	Mus musculus	100-110
14715657-0	2004	Camptothecin-sensitive relaxation of supercoiled DNA by the topoisomerase I-like activity associated with poly(ADP-ribose) polymerase-1.	Camptothecin	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	106-135
15013706-0	2004	Enhanced stimulation of chromosomal translocations by radiomimetic DNA damaging agents and camptothecin in Saccharomyces cerevisiae rad9 checkpoint mutants.	Camptothecin	91-103	chromatin-binding protein RAD9	Saccharomyces cerevisiae S288C	132-136
15013706-5	2004	DNA damage-associated frequencies of translocations after exposure to hydrogen peroxide (H(2)O(2)), bleomycin, phleomycin, cisplatin, and camptothecin are higher in the rad9 diploid than in wild type.	Camptothecin	138-150	chromatin-binding protein RAD9	Saccharomyces cerevisiae S288C	169-173
15060176-3	2004	Previously, we reported that DNA-PK phosphorylates Thr21 of the 32 kDa subunit of replication protein A (RPA32) in response to camptothecin.	Camptothecin	127-139	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	29-35
15060176-3	2004	Previously, we reported that DNA-PK phosphorylates Thr21 of the 32 kDa subunit of replication protein A (RPA32) in response to camptothecin.	Camptothecin	127-139	replication protein A2	Homo sapiens	105-110
15060176-4	2004	In this report we demonstrate that the camptothecin-induced phosphorylation of RPA32 on Thr21 is inhibited by 2 mM caffeine.	Camptothecin	39-51	replication protein A2	Homo sapiens	79-84
14999078-4	2004	To accomplish this goal, we used an established experimental paradigm in which BDNF protects postnatal cortical neurons against both trophic deprivation and camptothecin-induced DNA damage.	Camptothecin	157-169	brain derived neurotrophic factor	Homo sapiens	79-83
14999078-5	2004	BDNF protection against camptothecin is mediated primarily by ERK1/2 activation, whereas its protection against trophic deprivation is mainly through stimulation of the PI3K pathway (Hetman et al., 1999).	Camptothecin	24-36	brain derived neurotrophic factor	Homo sapiens	0-4
14999078-6	2004	Here we demonstrate that expression of a wild-type SRF is sufficient to protect postnatal cortical neurons against camptothecin or trophic deprivation.	Camptothecin	115-127	serum response factor	Homo sapiens	51-54
14999078-9	2004	In addition, protection against camptothecin by expression of constitutive active mitogen-activated protein kinase kinase 1, an upstream kinase that activates ERK1/2, was also blocked by expression of the dominant-negative SRF.	Camptothecin	32-44	mitogen-activated protein kinase kinase 1	Homo sapiens	82-123
14999078-9	2004	In addition, protection against camptothecin by expression of constitutive active mitogen-activated protein kinase kinase 1, an upstream kinase that activates ERK1/2, was also blocked by expression of the dominant-negative SRF.	Camptothecin	32-44	mitogen-activated protein kinase 3	Homo sapiens	159-165
14999078-9	2004	In addition, protection against camptothecin by expression of constitutive active mitogen-activated protein kinase kinase 1, an upstream kinase that activates ERK1/2, was also blocked by expression of the dominant-negative SRF.	Camptothecin	32-44	serum response factor	Homo sapiens	223-226
14762204-3	2004	In this study, we showed that Hus1-deficient mouse cells had an impaired S checkpoint after exposure to DNA strand break-inducing agents such as camptothecin (CPT) (&gt;or=1.0 micro M), or ionizing radiation (IR) (&gt;or=15 Gy).	Camptothecin	145-157	HUS1 checkpoint clamp component	Mus musculus	30-34
14983893-1	2004	We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells.	Camptothecin	34-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	116-142
14983893-1	2004	We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells.	Camptothecin	34-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	144-149
14983893-1	2004	We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells.	Camptothecin	34-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	180-190
14983893-3	2004	In addition, we demonstrate that Top 1 is required for the inhibition of HIF-1alpha protein accumulation by TPT as shown by experiments performed using camptothecin-resistant cell lines with known Top 1 alterations.	Camptothecin	152-164	hypoxia inducible factor 1 subunit alpha	Homo sapiens	73-83
14872059-6	2004	Ionizing radiation (IR)-induced phosphorylation of RPA32 on Thr21 was defective in ATM-deficient cells, while camptothecin (CPT)-induced phosphorylation of RPA32 on Thr21 was defective in cells lacking functional DNA-PK.	Camptothecin	110-122	replication protein A2	Homo sapiens	156-161
14872059-6	2004	Ionizing radiation (IR)-induced phosphorylation of RPA32 on Thr21 was defective in ATM-deficient cells, while camptothecin (CPT)-induced phosphorylation of RPA32 on Thr21 was defective in cells lacking functional DNA-PK.	Camptothecin	110-122	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	213-219
14872059-6	2004	Ionizing radiation (IR)-induced phosphorylation of RPA32 on Thr21 was defective in ATM-deficient cells, while camptothecin (CPT)-induced phosphorylation of RPA32 on Thr21 was defective in cells lacking functional DNA-PK.	Camptothecin	124-127	replication protein A2	Homo sapiens	156-161
14872059-6	2004	Ionizing radiation (IR)-induced phosphorylation of RPA32 on Thr21 was defective in ATM-deficient cells, while camptothecin (CPT)-induced phosphorylation of RPA32 on Thr21 was defective in cells lacking functional DNA-PK.	Camptothecin	124-127	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	213-219
14762204-3	2004	In this study, we showed that Hus1-deficient mouse cells had an impaired S checkpoint after exposure to DNA strand break-inducing agents such as camptothecin (CPT) (&gt;or=1.0 micro M), or ionizing radiation (IR) (&gt;or=15 Gy).	Camptothecin	159-162	HUS1 checkpoint clamp component	Mus musculus	30-34
14993467-10	2004	In addition to acting as an antirecombinase, we also show that Srs2 can aid the recombinational repair of camptothecin-induced collapsed replication forks, independently of PRR.	Camptothecin	106-118	DNA helicase SRS2	Saccharomyces cerevisiae S288C	63-67
14662759-7	2004	Consistent with this increased expression of cell survival genes, MEKK3 stable cells showed reduced activation of caspases 3 and 8 and poly(ADP-ribose) polymerase cleavage and dramatically increased resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand, doxorubicin, daunorubicin, camptothecin, and paclitaxel.	Camptothecin	318-330	mitogen-activated protein kinase kinase kinase 3	Homo sapiens	66-71
14973057-7	2004	A decrease in copy numbers of genes encoding deoxycytidine kinase, DNA topoisomerase I, and DNA topoisomerase II alpha reduced their expression levels in one cytosine arabinoside-resistant line, two of three camptothecin-resistant lines, and two of five VP-16-resistant cell lines, respectively.	Camptothecin	208-220	deoxycytidine kinase	Homo sapiens	45-65
14762204-0	2004	Involvement of Hus1 in the chain elongation step of DNA replication after exposure to camptothecin or ionizing radiation.	Camptothecin	86-98	HUS1 checkpoint clamp component	Mus musculus	15-19
14605862-0	2004	Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.	Camptothecin	25-37	thymidylate synthase	Mus musculus	120-140
14732228-0	2004	Glutathione S-transferase P1 has protective effects on cell viability against camptothecin.	Camptothecin	78-90	glutathione S-transferase pi 1	Homo sapiens	0-28
14750127-2	2004	METHODS: Cells of the human promyelocytic HL-60 line treated with camptothecin (CPT) or ultraviolet light (UV) were labeled with fluorescein isothiocyanate-conjugated annexin V and prefixed with 1% methanol-free formaldehyde on ice, and their DNA was stained stoichiometrically with propidium iodide in the presence of digitonin.	Camptothecin	66-78	annexin A5	Homo sapiens	167-176
14750127-2	2004	METHODS: Cells of the human promyelocytic HL-60 line treated with camptothecin (CPT) or ultraviolet light (UV) were labeled with fluorescein isothiocyanate-conjugated annexin V and prefixed with 1% methanol-free formaldehyde on ice, and their DNA was stained stoichiometrically with propidium iodide in the presence of digitonin.	Camptothecin	80-83	annexin A5	Homo sapiens	167-176
14732228-3	2004	We carried out transfection of GSTP1 sense and antisense vectors to examine effects of GSTP1 on cell cycle arrest and apoptosis induced by camptothecin in HeLa cells.	Camptothecin	139-151	glutathione S-transferase pi 1	Homo sapiens	87-92
14732228-5	2004	Camptothecin-induced S- or G2/M arrest was intensified by transfection of GSTP1 antisense vector, and subsequent apoptosis was attenuated by transfection of GSTP1 sense vector.	Camptothecin	0-12	glutathione S-transferase pi 1	Homo sapiens	74-79
14732228-5	2004	Camptothecin-induced S- or G2/M arrest was intensified by transfection of GSTP1 antisense vector, and subsequent apoptosis was attenuated by transfection of GSTP1 sense vector.	Camptothecin	0-12	glutathione S-transferase pi 1	Homo sapiens	157-162
14732228-6	2004	These results suggest that GSTP1 has protective effects against camptothecin-induced cytotoxicity.	Camptothecin	64-76	glutathione S-transferase pi 1	Homo sapiens	27-32
14618629-1	2004	Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan.	Camptothecin	134-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-32
15366785-10	2004	This assay was validated using reference compounds such as camptothecin and actinomycin D, known inducers of p21(Waf1/Cip1) protein.	Camptothecin	59-71	cyclin dependent kinase inhibitor 1A	Homo sapiens	109-112
15366785-10	2004	This assay was validated using reference compounds such as camptothecin and actinomycin D, known inducers of p21(Waf1/Cip1) protein.	Camptothecin	59-71	cyclin dependent kinase inhibitor 1A	Homo sapiens	113-117
15366785-10	2004	This assay was validated using reference compounds such as camptothecin and actinomycin D, known inducers of p21(Waf1/Cip1) protein.	Camptothecin	59-71	cyclin dependent kinase inhibitor 1A	Homo sapiens	118-122
14618629-1	2004	Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan.	Camptothecin	134-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	34-38
14618629-1	2004	Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan.	Camptothecin	134-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	39-44
14618629-1	2004	Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan.	Camptothecin	134-146	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	52-89
14566974-8	2003	These results suggest that the ability of P2P-R to promote camptothecin-induced apoptosis in MCF-7 cells involves a specific region (1156-1314 aa) that exists within P2P-R.	Camptothecin	59-71	RB binding protein 6, ubiquitin ligase	Homo sapiens	166-171
14757846-8	2004	In addition, the splicing reaction brought about by camptothecin was hampered in human CEM/C2 and in murine P388-45R leukemic deficient in topoisomerase I activity.	Camptothecin	52-64	complement C2	Homo sapiens	87-93
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Camptothecin	53-65	glycogen synthase kinase 3 beta	Homo sapiens	92-101
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Camptothecin	53-65	glycogen synthase kinase 3 beta	Homo sapiens	178-187
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Camptothecin	53-65	glycogen synthase kinase 3 beta	Homo sapiens	178-187
14739609-4	2003	We also compared the effects of non-selective and isoenzyme selective COX-2 inhibitors on camptothecin-induced apoptosis in these three cell lines.	Camptothecin	90-102	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	70-75
14566974-0	2003	Stable overexpression of specific segments of the P2P-R protein in human MCF-7 cells promotes camptothecin-induced apoptosis.	Camptothecin	94-106	RB binding protein 6, ubiquitin ligase	Homo sapiens	50-55
14566974-4	2003	Since segments of P2P-R were found not to induce apoptosis independently, the ability of three different P2P-R segments to promote camptothecin-induced apoptosis was evaluated following their stable transfection and expression in MCF-7 cells.	Camptothecin	131-143	RB binding protein 6, ubiquitin ligase	Homo sapiens	105-110
14566974-10	2003	Therefore, P2P-R-promoted apoptosis induced by camptothecin may be influenced by such interactions.	Camptothecin	47-59	RB binding protein 6, ubiquitin ligase	Homo sapiens	11-16
14566974-6	2003	The results document that overexpression of P2P-R-2 and P2P-R-3 promotes camptothecin-induced apoptosis by three to fivefold when assayed by flow cytometric analysis of apoptotic sub 2n cell populations or by TUNEL assays.	Camptothecin	73-85	RB binding protein 6, ubiquitin ligase	Homo sapiens	44-49
14566974-6	2003	The results document that overexpression of P2P-R-2 and P2P-R-3 promotes camptothecin-induced apoptosis by three to fivefold when assayed by flow cytometric analysis of apoptotic sub 2n cell populations or by TUNEL assays.	Camptothecin	73-85	RB binding protein 6, ubiquitin ligase	Homo sapiens	56-61
14645680-4	2003	In clear contrast, the antitumor drug camptothecin potently induces apoptosis in NCOL-1 cells associated with a specific down-regulation of the antiapoptotic factor bcl-XL at the mRNA and protein levels and with the activation of the mitochondrial apoptosis pathway.	Camptothecin	38-50	BCL2 like 1	Homo sapiens	165-171
14566974-8	2003	These results suggest that the ability of P2P-R to promote camptothecin-induced apoptosis in MCF-7 cells involves a specific region (1156-1314 aa) that exists within P2P-R.	Camptothecin	59-71	RB binding protein 6, ubiquitin ligase	Homo sapiens	42-47
14647467-6	2003	In differentiated progenitor cells, nuclear localization of ectopic cyclin D1 induced apoptosis, and the DNA-damaging compound camptothecin caused nuclear accumulation of endogenous cyclin D1, accompanied by Rb phosphorylation.	Camptothecin	127-139	cyclin D1	Homo sapiens	182-191
14500729-4	2003	Upon apoptotic stimulation by camptothecin, prohibitin is exported to perinuclear regions where it localizes to mitochondria.	Camptothecin	30-42	prohibitin 1	Homo sapiens	44-54
14647467-6	2003	In differentiated progenitor cells, nuclear localization of ectopic cyclin D1 induced apoptosis, and the DNA-damaging compound camptothecin caused nuclear accumulation of endogenous cyclin D1, accompanied by Rb phosphorylation.	Camptothecin	127-139	RB transcriptional corepressor 1	Homo sapiens	208-210
14583781-0	2003	c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis.	Camptothecin	54-66	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5
14597418-0	2003	Cell-cycle-dependent three-dimensional redistribution of nuclear proteins, P 120, pKi-67, and SC 35 splicing factor, in the presence of the topoisomerase I inhibitor camptothecin.	Camptothecin	166-178	catenin delta 1	Homo sapiens	75-88
14597418-4	2003	In this study we demonstrated that treatment of KB cells with camptothecin for only 30 min induced the 3D reorganization and redistribution of three proteins involved in the nucleus machinery, P 120, pKi-67, and SC 35, and this occurred in a cell cycle-dependent manner.	Camptothecin	62-74	catenin delta 1	Homo sapiens	193-206
14597418-6	2003	In the presence of camptothecin, P 120, which occupied the nucleolar volume, lost its reticulation and pKi-67 was redistributed within the nucleoplasm and even into the cytoplasm.	Camptothecin	19-31	catenin delta 1	Homo sapiens	33-38
14583781-6	2003	Importantly, although camptothecin treatment markedly increased p21(Waf1/Cip1) levels in parental LoVo cells, this effect was abrogated in c-Myc-overexpressing derivatives.	Camptothecin	22-34	cyclin dependent kinase inhibitor 1A	Homo sapiens	73-77
14583781-6	2003	Importantly, although camptothecin treatment markedly increased p21(Waf1/Cip1) levels in parental LoVo cells, this effect was abrogated in c-Myc-overexpressing derivatives.	Camptothecin	22-34	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	139-144
14583781-7	2003	Targeted inactivation of p21(Waf1/Cip1) in HCT116 colon cancer cells resulted in significantly increased levels of apoptosis following treatment with camptothecin, demonstrating the importance of p21(Waf1/Cip1) in the response to this agent.	Camptothecin	150-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	25-28
14583781-7	2003	Targeted inactivation of p21(Waf1/Cip1) in HCT116 colon cancer cells resulted in significantly increased levels of apoptosis following treatment with camptothecin, demonstrating the importance of p21(Waf1/Cip1) in the response to this agent.	Camptothecin	150-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	29-33
14583781-7	2003	Targeted inactivation of p21(Waf1/Cip1) in HCT116 colon cancer cells resulted in significantly increased levels of apoptosis following treatment with camptothecin, demonstrating the importance of p21(Waf1/Cip1) in the response to this agent.	Camptothecin	150-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	34-38
14583781-7	2003	Targeted inactivation of p21(Waf1/Cip1) in HCT116 colon cancer cells resulted in significantly increased levels of apoptosis following treatment with camptothecin, demonstrating the importance of p21(Waf1/Cip1) in the response to this agent.	Camptothecin	150-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	196-199
14583781-7	2003	Targeted inactivation of p21(Waf1/Cip1) in HCT116 colon cancer cells resulted in significantly increased levels of apoptosis following treatment with camptothecin, demonstrating the importance of p21(Waf1/Cip1) in the response to this agent.	Camptothecin	150-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	200-204
14583781-7	2003	Targeted inactivation of p21(Waf1/Cip1) in HCT116 colon cancer cells resulted in significantly increased levels of apoptosis following treatment with camptothecin, demonstrating the importance of p21(Waf1/Cip1) in the response to this agent.	Camptothecin	150-162	cyclin dependent kinase inhibitor 1A	Homo sapiens	205-209
14583781-2	2003	Using an isogenic cell system, we demonstrate that c-Myc overexpression in colon carcinoma LoVo cells resulted in sensitisation to camptothecin-induced apoptosis, thus identifying c-Myc as a potential marker predicting response of colorectal tumour cells to camptothecin.	Camptothecin	131-143	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
14583781-8	2003	Finally, cDNA microarray analysis was used to identify genes that are modulated in expression by c-Myc upregulation that could serve as additional markers predicting response to camptothecin.	Camptothecin	178-190	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	97-102
14583781-2	2003	Using an isogenic cell system, we demonstrate that c-Myc overexpression in colon carcinoma LoVo cells resulted in sensitisation to camptothecin-induced apoptosis, thus identifying c-Myc as a potential marker predicting response of colorectal tumour cells to camptothecin.	Camptothecin	131-143	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	180-185
14583781-2	2003	Using an isogenic cell system, we demonstrate that c-Myc overexpression in colon carcinoma LoVo cells resulted in sensitisation to camptothecin-induced apoptosis, thus identifying c-Myc as a potential marker predicting response of colorectal tumour cells to camptothecin.	Camptothecin	258-270	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
14583781-2	2003	Using an isogenic cell system, we demonstrate that c-Myc overexpression in colon carcinoma LoVo cells resulted in sensitisation to camptothecin-induced apoptosis, thus identifying c-Myc as a potential marker predicting response of colorectal tumour cells to camptothecin.	Camptothecin	258-270	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	180-185
14583781-3	2003	Both camptothecin exposure and c-Myc overexpression in LoVo cells resulted in elevation of p53 protein levels, suggesting a role of p53 in the c-Myc-imposed sensitisation to the apoptotic effects of camptothecin.	Camptothecin	5-17	tumor protein p53	Homo sapiens	91-94
14583781-3	2003	Both camptothecin exposure and c-Myc overexpression in LoVo cells resulted in elevation of p53 protein levels, suggesting a role of p53 in the c-Myc-imposed sensitisation to the apoptotic effects of camptothecin.	Camptothecin	5-17	tumor protein p53	Homo sapiens	132-135
14583781-3	2003	Both camptothecin exposure and c-Myc overexpression in LoVo cells resulted in elevation of p53 protein levels, suggesting a role of p53 in the c-Myc-imposed sensitisation to the apoptotic effects of camptothecin.	Camptothecin	5-17	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	143-148
14583781-3	2003	Both camptothecin exposure and c-Myc overexpression in LoVo cells resulted in elevation of p53 protein levels, suggesting a role of p53 in the c-Myc-imposed sensitisation to the apoptotic effects of camptothecin.	Camptothecin	199-211	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	31-36
14583781-3	2003	Both camptothecin exposure and c-Myc overexpression in LoVo cells resulted in elevation of p53 protein levels, suggesting a role of p53 in the c-Myc-imposed sensitisation to the apoptotic effects of camptothecin.	Camptothecin	199-211	tumor protein p53	Homo sapiens	91-94
14583781-3	2003	Both camptothecin exposure and c-Myc overexpression in LoVo cells resulted in elevation of p53 protein levels, suggesting a role of p53 in the c-Myc-imposed sensitisation to the apoptotic effects of camptothecin.	Camptothecin	199-211	tumor protein p53	Homo sapiens	132-135
14583781-3	2003	Both camptothecin exposure and c-Myc overexpression in LoVo cells resulted in elevation of p53 protein levels, suggesting a role of p53 in the c-Myc-imposed sensitisation to the apoptotic effects of camptothecin.	Camptothecin	199-211	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	143-148
14583781-4	2003	This was confirmed by the ability of PFT-alpha, a specific inhibitor of p53, to attenuate camptothecin-induced apoptosis.	Camptothecin	90-102	tumor protein p53	Homo sapiens	72-75
14583781-6	2003	Importantly, although camptothecin treatment markedly increased p21(Waf1/Cip1) levels in parental LoVo cells, this effect was abrogated in c-Myc-overexpressing derivatives.	Camptothecin	22-34	cyclin dependent kinase inhibitor 1A	Homo sapiens	64-67
14583781-6	2003	Importantly, although camptothecin treatment markedly increased p21(Waf1/Cip1) levels in parental LoVo cells, this effect was abrogated in c-Myc-overexpressing derivatives.	Camptothecin	22-34	cyclin dependent kinase inhibitor 1A	Homo sapiens	68-72
14576842-8	2003	The spectrum of anticancer drugs effluxed by BCRP includes mitoxantrone, camptothecin-derived and indolocarbazole topoisomerase I inhibitors, methotrexate, flavopiridol, and quinazoline ErbB1 inhibitors.	Camptothecin	73-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	45-49
14504478-9	2003	Following treatment with TPT, CPT or MTX the peak of H2AX phosphorylation preceded caspase-3 activation and the appearance of apoptosis-associated DNA fragmentation, both selective to S-phase cells.	Camptothecin	30-33	H2A.X variant histone	Homo sapiens	53-57
14504478-9	2003	Following treatment with TPT, CPT or MTX the peak of H2AX phosphorylation preceded caspase-3 activation and the appearance of apoptosis-associated DNA fragmentation, both selective to S-phase cells.	Camptothecin	30-33	caspase 3	Homo sapiens	83-92
14617791-0	2003	Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.	Camptothecin	16-28	carboxylesterase 1	Homo sapiens	49-66
14617791-1	2003	7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan, CPT-11) is a camptothecin prodrug that is metabolized by carboxylesterases (CE) to the active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), a topoisomerase I inhibitor.	Camptothecin	53-65	carboxylesterase 1	Homo sapiens	136-153
12866025-3	2003	Caspase-3 activation as well as nuclear fragmentation, both indicative of apoptosis, were dose dependently inhibited by the NO-liberating agents sodium nitroprusside (SNP) or S-nitroso-N-acetyl-D,L-penicillamine (SNAP) when apoptosis was initiated by flavone with only minor effects on apoptosis when initiated by camptothecin.	Camptothecin	314-326	caspase 3	Homo sapiens	0-9
12937274-5	2003	Importantly, the nucleolar WRNp/VCP complex was dissociated by treatment with camptothecin, an inhibitor of topoisomerase I, whereas other WRNp-associated protein complexes, such as WRNp/Ku 80, were not dissociated by this drug.	Camptothecin	78-90	WRN RecQ like helicase	Homo sapiens	27-31
12937274-5	2003	Importantly, the nucleolar WRNp/VCP complex was dissociated by treatment with camptothecin, an inhibitor of topoisomerase I, whereas other WRNp-associated protein complexes, such as WRNp/Ku 80, were not dissociated by this drug.	Camptothecin	78-90	valosin containing protein	Homo sapiens	32-35
14505797-3	2003	The carboxy form of many CPTs, including 9AC, preferentially binds to human serum albumin (HSA), which further reduces the equilibrium amount of active lactone and greatly decreases antitumor efficacy.	Camptothecin	25-29	albumin	Homo sapiens	76-89
14655759-4	2003	TRAIL also triggered apoptosis in resistant glioma cell lines through the same pathways, but only if the cells were pretreated with chemotherapeutic agents, cisplatin, camptothecin and etoposide.	Camptothecin	168-180	TNF superfamily member 10	Homo sapiens	0-5
12963987-4	2003	Cell viability analysis revealed that IkappaBalpha-SR- or IKKbeta-DN-transfected cells were more resistant to peplomycin, mitomycin C, and camptothecin.	Camptothecin	139-151	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	38-50
12963987-4	2003	Cell viability analysis revealed that IkappaBalpha-SR- or IKKbeta-DN-transfected cells were more resistant to peplomycin, mitomycin C, and camptothecin.	Camptothecin	139-151	inhibitor of kappaB kinase beta	Mus musculus	58-65
12955088-0	2003	Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray.	Camptothecin	102-114	MRE11 homolog, double strand break repair nuclease	Homo sapiens	32-38
12928501-4	2003	In this study, we show that c-Abl mediates a second pathway by which adhesion to extracellular matrix regulates cell killing by chemotherapeutic agents 5-arabinofuranosylcytosine, cisplatin, and camptothecin.	Camptothecin	195-207	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	28-33
12955088-0	2003	Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray.	Camptothecin	102-114	RAD50 double strand break repair protein	Homo sapiens	39-45
12955088-0	2003	Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray.	Camptothecin	102-114	nibrin	Homo sapiens	46-50
12955088-0	2003	Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray.	Camptothecin	102-114	mutL homolog 1	Homo sapiens	70-74
12955088-0	2003	Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray.	Camptothecin	102-114	nuclear factor kappa B subunit 1	Homo sapiens	78-87
12955088-4	2003	NBS- and hMRE11-deficient cells present a classical kinetic of NF-kappaB induction after camptothecin treatment.	Camptothecin	89-101	MRE11 homolog, double strand break repair nuclease	Homo sapiens	9-15
12874005-1	2003	ABCG2 is a plasma membrane efflux pump that is able to confer resistance to several anticancer agents, including mitoxantrone, camptothecins, anthracyclines, and flavopiridol.	Camptothecin	127-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-5
14579240-4	2003	The substrate profile of ABCG2 includes the antineoplastic drugs primarily targeting topoisomerases, including anthracyclines and camptothecins.	Camptothecin	130-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-30
12869632-5	2003	The role of the ATP-dependent drug transporter ABCG2 in CPT-11 cytotoxicity is unclear because some ABCG2 mutants confer camptothecin resistance, whereas others do not.	Camptothecin	121-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	100-105
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Camptothecin	77-89	TNF receptor superfamily member 10a	Homo sapiens	137-153
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Camptothecin	77-89	TNF receptor superfamily member 10a	Homo sapiens	154-157
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Camptothecin	77-89	TNF superfamily member 10	Homo sapiens	137-142
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Camptothecin	77-89	TNF receptor superfamily member 10b	Homo sapiens	179-182
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Camptothecin	77-89	TNF superfamily member 10	Homo sapiens	162-167
14500373-4	2003	The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells.	Camptothecin	77-89	TNF superfamily member 10	Homo sapiens	162-167
12777465-3	2003	Here we show that treatment of thioglycollate-elicited mouse peritoneal macrophages with various unrelated apoptotic agents, including simvastatin, camptothecin, or glucose deprivation, is associated with a specific and large increase in caveolin-1 expression.	Camptothecin	148-160	caveolin 1, caveolae protein	Mus musculus	238-248
12783868-3	2003	The phenotypes of nat3-Delta and mdm20-Delta mutants are identical or nearly the same and include the following: diminished growth at elevated temperatures and on hyperosmotic and nonfermentable media; diminished mating; defective actin cables formation; abnormal mitochondrial and vacuolar inheritance; inhibition of growth by DNA-damaging agents such as methyl methanesulfonate, bleomycin, camptothecin, and hydroxyurea; and inhibition of growth by the antimitotic drugs benomyl and thiabendazole.	Camptothecin	392-404	peptide alpha-N-acetyltransferase complex B subunit NAT3	Saccharomyces cerevisiae S288C	18-22
12721303-2	2003	Previous evidence has shown that apoptotic death of embryonic cortical neurons treated with the DNA damaging agent camptothecin is dependent upon the tumor suppressor p53, an upstream death mediator, and more distal death effectors such as caspases.	Camptothecin	115-127	tumor protein p53	Homo sapiens	167-170
12765196-7	2003	The results demonstrated that both taxol and CPT could inhibit the migration of B16F10 cells, and inhibit the adhesion of B16F10 to fibronectin and laminin.	Camptothecin	45-48	fibronectin 1	Mus musculus	132-143
12807744-6	2003	Furthermore, caffeine also inhibited the accumulation of p53 by a variety of stress-inducing agents in vivo, such as 5-fluorouracil, doxorubicin, mitomycin C, camptothecin and roscovitine.	Camptothecin	159-171	tumor protein p53	Homo sapiens	57-60
12787881-2	2003	BPR0Y007 was less potent than camptothecin (CPT) in the inhibition of Top I in vitro.	Camptothecin	30-42	DNA topoisomerase I	Homo sapiens	70-75
12787881-2	2003	BPR0Y007 was less potent than camptothecin (CPT) in the inhibition of Top I in vitro.	Camptothecin	44-47	DNA topoisomerase I	Homo sapiens	70-75
12676925-8	2003	Herein, we show that camptothecin and doxorubicin, two widely used topoisomerase inhibitors conferring S and G2 arrest, respectively, cause the degradation of Cdc25A.	Camptothecin	21-33	cell division cycle 25A	Homo sapiens	159-165
12665508-3	2003	We report here that without the use of endoplasmic reticulum (ER) stress inducers, specific overexpression of GRP78 results in reduced apoptosis and higher colony survival when challenged with topoisomerase II inhibitors, etoposide and doxorubicin, and topoisomerase I inhibitor, camptothecin.	Camptothecin	280-292	heat shock protein family A (Hsp70) member 5	Homo sapiens	110-115
12839962-2	2003	Here we demonstrate that overexpression of human Spy1 enhances mammalian cell viability during cellular responses to DNA damage induced by genotoxic agents such as camptothecin, cisplatin, and hydroxyurea.	Camptothecin	164-176	speedy/RINGO cell cycle regulator family member A	Homo sapiens	49-53
12839962-4	2003	Consistent with Spy1 having a role in the DNA damage response, endogenous Spy1 protein levels are up-regulated in response to DNA damage induced by camptothecin, cisplatin, or hydroxyurea.	Camptothecin	148-160	speedy/RINGO cell cycle regulator family member A	Homo sapiens	16-20
12839962-4	2003	Consistent with Spy1 having a role in the DNA damage response, endogenous Spy1 protein levels are up-regulated in response to DNA damage induced by camptothecin, cisplatin, or hydroxyurea.	Camptothecin	148-160	speedy/RINGO cell cycle regulator family member A	Homo sapiens	74-78
12826051-0	2003	TNF increases camptothecin-induced apoptosis by inhibition of NF-kappaB.	Camptothecin	14-26	tumor necrosis factor	Homo sapiens	0-3
12826051-0	2003	TNF increases camptothecin-induced apoptosis by inhibition of NF-kappaB.	Camptothecin	14-26	nuclear factor kappa B subunit 1	Homo sapiens	62-71
12871905-2	2003	Mutations in scaA(NBS1), which encodes the apparent homolog of human nibrin in Aspergillus nidulans, inhibit growth in the presence of the antitopoisomerase I drug camptothecin.	Camptothecin	164-176	nibrin	Homo sapiens	18-22
12787912-3	2003	Here, we demonstrate that a recently developed two-hybrid based plate assay that visualizes the DNA damage-induced homomeric complex formation of the yeast checkpoint protein Rad17 correctly predicts the biological activity of the tested camptothecin derivatives.	Camptothecin	238-250	Rad17p	Saccharomyces cerevisiae S288C	175-180
12660252-6	2003	However, H2AX-/- mouse embryonic fibroblasts exposed to camptothecin fail to form Mre11, Rad50, and Nbs1 foci and are hypersensitive to camptothecin.	Camptothecin	56-68	H2A.X variant histone	Mus musculus	9-13
12791148-2	2003	Mutations in scaANBS1, which encodes the apparent homologue of human Nbs1 in Aspergillus nidulans, inhibit growth in the presence of the anti-topoisomerase I drug camptothecin.	Camptothecin	163-175	nibrin	Homo sapiens	69-73
12660252-6	2003	However, H2AX-/- mouse embryonic fibroblasts exposed to camptothecin fail to form Mre11, Rad50, and Nbs1 foci and are hypersensitive to camptothecin.	Camptothecin	56-68	MRE11A homolog A, double strand break repair nuclease	Mus musculus	82-87
12660252-6	2003	However, H2AX-/- mouse embryonic fibroblasts exposed to camptothecin fail to form Mre11, Rad50, and Nbs1 foci and are hypersensitive to camptothecin.	Camptothecin	56-68	RAD50 double strand break repair protein	Mus musculus	89-94
12660252-6	2003	However, H2AX-/- mouse embryonic fibroblasts exposed to camptothecin fail to form Mre11, Rad50, and Nbs1 foci and are hypersensitive to camptothecin.	Camptothecin	56-68	nibrin	Mus musculus	100-104
12660252-6	2003	However, H2AX-/- mouse embryonic fibroblasts exposed to camptothecin fail to form Mre11, Rad50, and Nbs1 foci and are hypersensitive to camptothecin.	Camptothecin	136-148	H2A.X variant histone	Mus musculus	9-13
12538580-2	2003	Exposure of human neuroblastoma SH-SY5Y cells to the DNA-damaging agent camptothecin increased p53 levels, activated caspase-3, and caused cell death.	Camptothecin	72-84	tumor protein p53	Homo sapiens	95-98
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Camptothecin	291-303	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Camptothecin	291-303	erb-b2 receptor tyrosine kinase 3	Homo sapiens	62-66
12761490-4	2003	Transfection of HER2 in MCF7 breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).	Camptothecin	291-303	AKT serine/threonine kinase 1	Homo sapiens	132-135
12684213-10	2003	These data indicate that LPA protects IEC-6 cells from camptothecin-induced apoptosis through G(i)-coupled inhibition of caspase-3 activation mediated by the attenuation of caspase-9 activation due to diminished cytochrome c release, involving upregulation of Bcl-2 protein expression and prevention of Bax translocation.	Camptothecin	55-67	caspase 3	Rattus norvegicus	121-130
12684213-10	2003	These data indicate that LPA protects IEC-6 cells from camptothecin-induced apoptosis through G(i)-coupled inhibition of caspase-3 activation mediated by the attenuation of caspase-9 activation due to diminished cytochrome c release, involving upregulation of Bcl-2 protein expression and prevention of Bax translocation.	Camptothecin	55-67	BCL2, apoptosis regulator	Rattus norvegicus	260-265
12684213-10	2003	These data indicate that LPA protects IEC-6 cells from camptothecin-induced apoptosis through G(i)-coupled inhibition of caspase-3 activation mediated by the attenuation of caspase-9 activation due to diminished cytochrome c release, involving upregulation of Bcl-2 protein expression and prevention of Bax translocation.	Camptothecin	55-67	BCL2 associated X, apoptosis regulator	Rattus norvegicus	303-306
12687290-6	2003	RESULTS: Ketotifen was found to restore the sensitivity of P-glycoprotein-overexpressing multidrug-resistant MCF-7/adr cells to doxorubicin, mitoxantrone, VP-16 and vinblastine, but not to methotrexate or camptothecin.	Camptothecin	205-217	ATP binding cassette subfamily B member 1	Homo sapiens	59-73
12684687-4	2003	We report that Brca1-deficiency in p53-null cells was associated with increased sensitivity to the topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons doxorubicin, mitoxantrone and etoposide, and to the platinum compounds carboplatin and oxaliplatin, but not to the antimetabolites 5-fluorouracil and gemcitabine and the taxanes docetaxel and paclitaxel.	Camptothecin	123-135	tumor protein p53	Homo sapiens	35-38
12694869-8	2003	In spite of an apparent cytostatic response and apoptosis resistance, the PC3 tumor was more responsive to in vivo treatment with camptothecins than the DU145 model.	Camptothecin	130-143	chromobox 8	Homo sapiens	74-77
12847914-0	2003	Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.	Camptothecin	117-130	protein tyrosine kinase 2	Homo sapiens	14-35
12847914-1	2003	This study shows a strong association between cell attachment to substratum and activation of beta 1-integrin-signaling with resistance to the camptothecin derivative topotecan (TPT) in breast cancer cells.	Camptothecin	143-155	integrin subunit beta 1	Homo sapiens	94-109
12847914-4	2003	Because p125 focal adhesion kinase (FAK) is a transducer in the beta 1-integrin signaling pathway, it is essential to cell adhesion and it is overexpressed in metastatic breast cancer, we hypothesized that attenuation of FAK might enhance the sensitivity of breast cancer cells to camptothecins.	Camptothecin	281-294	protein tyrosine kinase 2	Homo sapiens	13-34
12847914-4	2003	Because p125 focal adhesion kinase (FAK) is a transducer in the beta 1-integrin signaling pathway, it is essential to cell adhesion and it is overexpressed in metastatic breast cancer, we hypothesized that attenuation of FAK might enhance the sensitivity of breast cancer cells to camptothecins.	Camptothecin	281-294	protein tyrosine kinase 2	Homo sapiens	36-39
12847914-4	2003	Because p125 focal adhesion kinase (FAK) is a transducer in the beta 1-integrin signaling pathway, it is essential to cell adhesion and it is overexpressed in metastatic breast cancer, we hypothesized that attenuation of FAK might enhance the sensitivity of breast cancer cells to camptothecins.	Camptothecin	281-294	protein tyrosine kinase 2	Homo sapiens	221-224
12724407-5	2003	Genetically, we show that both mus81 and sgs1 mutants are sensitive to camptothecin-induced DNA damage.	Camptothecin	71-83	Mus81p	Saccharomyces cerevisiae S288C	31-36
12724407-5	2003	Genetically, we show that both mus81 and sgs1 mutants are sensitive to camptothecin-induced DNA damage.	Camptothecin	71-83	ATP-dependent DNA helicase SGS1	Saccharomyces cerevisiae S288C	41-45
12538580-2	2003	Exposure of human neuroblastoma SH-SY5Y cells to the DNA-damaging agent camptothecin increased p53 levels, activated caspase-3, and caused cell death.	Camptothecin	72-84	caspase 3	Homo sapiens	117-126
12538580-7	2003	The mechanism of protection afforded by muscarinic receptor activation from camptothecin-induced apoptotic signaling involved blockade of mitochondrial cytochrome c release associated with a bolstering of mitochondrial bcl-2 levels and blockade of the translocation of Bax to mitochondria.	Camptothecin	76-88	cytochrome c, somatic	Homo sapiens	152-164
12538580-7	2003	The mechanism of protection afforded by muscarinic receptor activation from camptothecin-induced apoptotic signaling involved blockade of mitochondrial cytochrome c release associated with a bolstering of mitochondrial bcl-2 levels and blockade of the translocation of Bax to mitochondria.	Camptothecin	76-88	BCL2 apoptosis regulator	Homo sapiens	219-224
12538580-7	2003	The mechanism of protection afforded by muscarinic receptor activation from camptothecin-induced apoptotic signaling involved blockade of mitochondrial cytochrome c release associated with a bolstering of mitochondrial bcl-2 levels and blockade of the translocation of Bax to mitochondria.	Camptothecin	76-88	BCL2 associated X, apoptosis regulator	Homo sapiens	269-272
12642871-5	2003	In p53-null Saos2 cells, cyclin G inhibited p73 induction in response to genotoxic stress and delayed the camptothecin-mediated cell cycle arrest.	Camptothecin	106-118	cyclin G1	Homo sapiens	25-33
12603831-5	2003	Surprisingly, activation of procaspase-3 preceded activation of the initiator procaspases 2, 8, 9 and 10 during CT-induced apoptosis of Y79 cells.	Camptothecin	112-114	caspase 3	Homo sapiens	28-40
12637937-0	2003	E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.	Camptothecin	59-71	E2F transcription factor 1	Homo sapiens	0-5
12637937-4	2003	Therefore, the present study was designed to investigate the effect of adenovirus-mediated E2F-1 gene transfer on chemosensitivity of colorectal cancer to camptothecin, in vitro and in vivo.	Camptothecin	155-167	E2F transcription factor 1	Homo sapiens	91-96
12637937-7	2003	Ad-E2F-1 gene transfer at low doses (less than the LD(20) dose) markedly increased the sensitivity of human colorectal cancer cells to camptothecin in vitro, which is because of induction of apoptosis.	Camptothecin	135-147	E2F transcription factor 1	Homo sapiens	0-8
12626594-5	2003	MIF suppressed camptothecin-induced apoptosis in HeLa and Kym cells and HL-60 promyeloblasts.	Camptothecin	15-27	macrophage migration inhibitory factor	Homo sapiens	0-3
12506112-5	2003	Here, we report our findings that UV irradiation or camptothecin treatment of U937 cells induced apoptosis and caused a significant change in the levels and localization of nucleolin within the nucleus.	Camptothecin	52-64	nucleolin	Homo sapiens	173-182
12475977-7	2003	NFBD1 foci are also detected in response to camptothecin, etoposide, and methylmethanesulfonate treatments.	Camptothecin	44-56	mediator of DNA damage checkpoint 1	Homo sapiens	0-5
12606765-2	2003	The administration of the H(2)O(2)-specific scavenger catalase attenuated the generation of apoptosis by the antitumor drugs etoposide, camptothecin, doxorubicin, and cisplatin in U-937 human promonocytic cells.	Camptothecin	136-148	catalase	Homo sapiens	54-62
12610517-6	2003	We show that genotoxic agents such as cisplatin, doxorubicin and camptothecin, in addition to UV radiation, can induce TRAIL-R2 on the cell surface of TRAIL receptor-negative tumour cells.	Camptothecin	65-77	TNF receptor superfamily member 10b	Homo sapiens	119-127
12581860-6	2003	The DNA damaging agents camptothecin and etoposide enhanced IFN-gamma-induced NO production and showed I-kappaB degradation, indicating that the increase in NO production was due to direct DNA damage.	Camptothecin	24-36	interferon gamma	Mus musculus	60-69
12584174-0	2003	Reduced apoptotic response to camptothecin in CHO cells deficient in XRCC3.	Camptothecin	30-42	DNA repair protein XRCC3	Cricetulus griseus	69-74
12584174-4	2003	In the work reported here we investigated the possible role of the Rad51-like HR proteins XRCC2, XRCC3 and Rad51C in apoptosis following the induction of DSBs by camptothecin.	Camptothecin	162-174	DNA repair protein RAD51 homolog 1	Cricetulus griseus	67-72
12584174-4	2003	In the work reported here we investigated the possible role of the Rad51-like HR proteins XRCC2, XRCC3 and Rad51C in apoptosis following the induction of DSBs by camptothecin.	Camptothecin	162-174	DNA repair protein XRCC2	Cricetulus griseus	90-95
12584174-4	2003	In the work reported here we investigated the possible role of the Rad51-like HR proteins XRCC2, XRCC3 and Rad51C in apoptosis following the induction of DSBs by camptothecin.	Camptothecin	162-174	DNA repair protein XRCC3	Cricetulus griseus	97-102
12584174-4	2003	In the work reported here we investigated the possible role of the Rad51-like HR proteins XRCC2, XRCC3 and Rad51C in apoptosis following the induction of DSBs by camptothecin.	Camptothecin	162-174	DNA repair protein RAD51 homolog 3	Cricetulus griseus	107-113
12584174-5	2003	We show that a hamster cell line (irs1SF) deficient in the HR repair gene XRCC3 exhibits altered death and cell-cycle checkpoint responses following treatment with growth inhibitory concentrations of camptothecin.	Camptothecin	200-212	DNA repair protein XRCC3	Cricetulus griseus	74-79
12610517-6	2003	We show that genotoxic agents such as cisplatin, doxorubicin and camptothecin, in addition to UV radiation, can induce TRAIL-R2 on the cell surface of TRAIL receptor-negative tumour cells.	Camptothecin	65-77	TNF superfamily member 10	Homo sapiens	119-124
12432233-10	2002	Finally, we found that IGF-I prevented the apoptosis of CE81T/VGH cells induced by chemotherapeutic drugs, such as cisplatin, 5-fluorouracil and camptothecin.	Camptothecin	145-157	insulin like growth factor 1	Homo sapiens	23-28
12502373-1	2003	Poly-alpha-(l-glutamic acid) (PG) conjugates of 20(S)-camptothecin (1, CPT) displayed improved aqueous solubility compared to CPT, were stable in aqueous solution at neutral pH, and were potent antitumor agents in vivo.	Camptothecin	50-66	choline phosphotransferase 1	Homo sapiens	71-74
12521296-0	2002	MAPK signaling is involved in camptothecin-induced cell death.	Camptothecin	30-42	mitogen-activated protein kinase 3	Homo sapiens	0-4
12521296-4	2002	Z-VAD-fmk, pan-caspase inhibitor, blocked apoptotic phenotypes induced by camptothecin suggesting that caspases are involved in camptothecin-induced cell death.	Camptothecin	74-86	caspase 6	Homo sapiens	15-22
12521296-4	2002	Z-VAD-fmk, pan-caspase inhibitor, blocked apoptotic phenotypes induced by camptothecin suggesting that caspases are involved in camptothecin-induced cell death.	Camptothecin	74-86	caspase 6	Homo sapiens	103-111
12521296-4	2002	Z-VAD-fmk, pan-caspase inhibitor, blocked apoptotic phenotypes induced by camptothecin suggesting that caspases are involved in camptothecin-induced cell death.	Camptothecin	128-140	caspase 6	Homo sapiens	15-22
12521296-4	2002	Z-VAD-fmk, pan-caspase inhibitor, blocked apoptotic phenotypes induced by camptothecin suggesting that caspases are involved in camptothecin-induced cell death.	Camptothecin	128-140	caspase 6	Homo sapiens	103-111
12521296-7	2002	These results suggest that only few caspases are involved in camptothecin-induced cell death.	Camptothecin	61-73	caspase 6	Homo sapiens	36-44
12521296-8	2002	Camptothecin induced phosphorylation of ERK1/2, JNK, and p38 MAPK, in a dose and time-dependent manner in AGS.	Camptothecin	0-12	mitogen-activated protein kinase 3	Homo sapiens	40-46
12521296-8	2002	Camptothecin induced phosphorylation of ERK1/2, JNK, and p38 MAPK, in a dose and time-dependent manner in AGS.	Camptothecin	0-12	mitogen-activated protein kinase 8	Homo sapiens	48-51
12477391-6	2002	p53 deficiency also markedly decreased DNA damage-induced apoptosis, elicited by ultraviolet irradiation or by the anti-cancer compound camptothecin.	Camptothecin	136-148	transformation related protein 53, pseudogene	Mus musculus	0-3
12397185-5	2002	In contrast, assays of growth in the presence of the Top1 poison camptothecin (CPT) indicate that the structure-specific nucleases dependent on RAD1 and MUS81 can contribute independently of TDP1 to repair, presumably by cutting off a segment of DNA along with the topoisomerase.	Camptothecin	65-77	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	144-148
12397185-5	2002	In contrast, assays of growth in the presence of the Top1 poison camptothecin (CPT) indicate that the structure-specific nucleases dependent on RAD1 and MUS81 can contribute independently of TDP1 to repair, presumably by cutting off a segment of DNA along with the topoisomerase.	Camptothecin	65-77	Mus81p	Saccharomyces cerevisiae S288C	153-158
12397185-5	2002	In contrast, assays of growth in the presence of the Top1 poison camptothecin (CPT) indicate that the structure-specific nucleases dependent on RAD1 and MUS81 can contribute independently of TDP1 to repair, presumably by cutting off a segment of DNA along with the topoisomerase.	Camptothecin	79-82	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	144-148
12397185-5	2002	In contrast, assays of growth in the presence of the Top1 poison camptothecin (CPT) indicate that the structure-specific nucleases dependent on RAD1 and MUS81 can contribute independently of TDP1 to repair, presumably by cutting off a segment of DNA along with the topoisomerase.	Camptothecin	79-82	Mus81p	Saccharomyces cerevisiae S288C	153-158
12485664-8	2003	The biological activity of radiolabelled annexin-V was tested in control and camptothecin-treated (i.e. apoptotic) human leukaemic HL60 cells.	Camptothecin	77-89	annexin A5	Homo sapiens	41-50
12485664-10	2003	The binding of [125I]m-SIB labelled annexin-V to camptothecin treated cells was blocked (68%) by a 100-fold excess of unlabelled annexin-V.	Camptothecin	49-61	annexin A5	Homo sapiens	36-45
12485664-10	2003	The binding of [125I]m-SIB labelled annexin-V to camptothecin treated cells was blocked (68%) by a 100-fold excess of unlabelled annexin-V.	Camptothecin	49-61	annexin A5	Homo sapiens	129-138
12608644-5	2003	Camptothecin and all of the topoisomerase II inhibitors induced neutrophil apoptosis, even in the presence of the CPPD crystals that normally repress TNF-alpha-induced and spontaneous apoptosis.	Camptothecin	0-12	tumor necrosis factor	Homo sapiens	150-159
12521296-10	2002	Blocking of p38 MAPK, but not ERK1/2, resulted in partial inhibition of cell death and PARP cleavage by camptothecin in AGS.	Camptothecin	104-116	collagen type XI alpha 2 chain	Homo sapiens	87-91
12521296-11	2002	Taken together, MAPK signaling is associated with apoptotic cell death by camptothecin.	Camptothecin	74-86	mitogen-activated protein kinase 3	Homo sapiens	16-20
12439742-0	2002	SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin.	Camptothecin	98-110	small ubiquitin like modifier 1	Homo sapiens	0-6
12530505-0	2002	Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.	Camptothecin	0-12	plasminogen activator, urokinase	Homo sapiens	21-57
12368472-3	2002	Thus, tdp1 rad1 cells (including the catalytic point mutant rad1-D869A) not only are highly sensitive to the Top1 poison camptothecin but also exhibit a TOP1-dependent growth delay.	Camptothecin	121-133	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	6-10
12368472-3	2002	Thus, tdp1 rad1 cells (including the catalytic point mutant rad1-D869A) not only are highly sensitive to the Top1 poison camptothecin but also exhibit a TOP1-dependent growth delay.	Camptothecin	121-133	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	11-15
12368472-3	2002	Thus, tdp1 rad1 cells (including the catalytic point mutant rad1-D869A) not only are highly sensitive to the Top1 poison camptothecin but also exhibit a TOP1-dependent growth delay.	Camptothecin	121-133	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	60-64
12368472-7	2002	Finally, we show that yeast lacking the Rad1-Rad10-related proteins Mus81-Mms4 display a unique pattern of camptothecin sensitivity and suggest a concerted model for the action of these endonucleases.	Camptothecin	107-119	ssDNA endodeoxyribonuclease RAD1	Saccharomyces cerevisiae S288C	40-44
12368472-7	2002	Finally, we show that yeast lacking the Rad1-Rad10-related proteins Mus81-Mms4 display a unique pattern of camptothecin sensitivity and suggest a concerted model for the action of these endonucleases.	Camptothecin	107-119	DNA repair protein RAD10	Saccharomyces cerevisiae S288C	45-50
12368472-7	2002	Finally, we show that yeast lacking the Rad1-Rad10-related proteins Mus81-Mms4 display a unique pattern of camptothecin sensitivity and suggest a concerted model for the action of these endonucleases.	Camptothecin	107-119	Mus81p	Saccharomyces cerevisiae S288C	68-73
12368472-7	2002	Finally, we show that yeast lacking the Rad1-Rad10-related proteins Mus81-Mms4 display a unique pattern of camptothecin sensitivity and suggest a concerted model for the action of these endonucleases.	Camptothecin	107-119	Mms4p	Saccharomyces cerevisiae S288C	74-78
12677090-9	2002	Vincristine (VIN), camptothecin (CPT), and actinomycin D were found to have a cooperative (&gt;38% over the additive single therapy values) effect on E2F-1-mediated apoptosis.	Camptothecin	19-31	E2F transcription factor 1	Homo sapiens	150-155
12677090-9	2002	Vincristine (VIN), camptothecin (CPT), and actinomycin D were found to have a cooperative (&gt;38% over the additive single therapy values) effect on E2F-1-mediated apoptosis.	Camptothecin	33-36	E2F transcription factor 1	Homo sapiens	150-155
12677090-11	2002	Ad-E2F-1 treatment alone results in 3.4-fold increase of cyclin A kinase activity compared to Ad-LacZ control (p &lt; 0.05); when combined with chemotherapeutic agents, cyclin A kinase activity was inhibited significantly by VIN, actinomycin D, and etoposide (p &lt; 0.005), but not with CPT, CIS, and 5-FU (p &gt; 0.1) compared to Ad-E2F-1 treatment alone.	Camptothecin	288-291	E2F transcription factor 1	Homo sapiens	3-8
12677090-11	2002	Ad-E2F-1 treatment alone results in 3.4-fold increase of cyclin A kinase activity compared to Ad-LacZ control (p &lt; 0.05); when combined with chemotherapeutic agents, cyclin A kinase activity was inhibited significantly by VIN, actinomycin D, and etoposide (p &lt; 0.005), but not with CPT, CIS, and 5-FU (p &gt; 0.1) compared to Ad-E2F-1 treatment alone.	Camptothecin	288-291	cyclin A2	Homo sapiens	57-65
12677090-11	2002	Ad-E2F-1 treatment alone results in 3.4-fold increase of cyclin A kinase activity compared to Ad-LacZ control (p &lt; 0.05); when combined with chemotherapeutic agents, cyclin A kinase activity was inhibited significantly by VIN, actinomycin D, and etoposide (p &lt; 0.005), but not with CPT, CIS, and 5-FU (p &gt; 0.1) compared to Ad-E2F-1 treatment alone.	Camptothecin	288-291	cyclin A2	Homo sapiens	169-177
12530505-2	2002	In screening other uPA-inducible anti-cancer agents, we found that camptothecin (CPT) and its derivative, SN38, could induce uPA in RC-K8 and H69 cells.	Camptothecin	67-79	plasminogen activator, urokinase	Homo sapiens	19-22
12530505-2	2002	In screening other uPA-inducible anti-cancer agents, we found that camptothecin (CPT) and its derivative, SN38, could induce uPA in RC-K8 and H69 cells.	Camptothecin	67-79	plasminogen activator, urokinase	Homo sapiens	125-128
12530505-2	2002	In screening other uPA-inducible anti-cancer agents, we found that camptothecin (CPT) and its derivative, SN38, could induce uPA in RC-K8 and H69 cells.	Camptothecin	81-84	plasminogen activator, urokinase	Homo sapiens	19-22
12530505-2	2002	In screening other uPA-inducible anti-cancer agents, we found that camptothecin (CPT) and its derivative, SN38, could induce uPA in RC-K8 and H69 cells.	Camptothecin	81-84	plasminogen activator, urokinase	Homo sapiens	125-128
12369998-3	2002	When overexpressed in cell lines, ABCG2 has the ability to confer high levels of resistance to anthracyclines, mitoxantrone, bisantrene, and the camptothecins topotecan and SN-38.	Camptothecin	145-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	34-39
12384558-6	2002	Constitutive PHLDA1 expression greatly enhances the sensitivity of human melanoma cells to the chemotherapeutic agents doxorubicin and camptothecin.	Camptothecin	135-147	pleckstrin homology like domain family A member 1	Homo sapiens	13-19
12237769-0	2002	A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.	Camptothecin	85-97	choline phosphotransferase 1	Homo sapiens	43-46
12225847-2	2002	Encoded by the ABCG2 gene, overexpression confers resistance to camptothecins, as well as to mitoxantrone.	Camptothecin	64-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	15-20
12237778-0	2002	Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.	Camptothecin	53-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	13-45
12237769-2	2002	The antineoplastic drug camptothecin was linked to a water-soluble polymeric backbone (MAG-CPT) and administrated as a 30 min infusion over 3 consecutive days every 4 weeks to patients with malignant solid tumours.	Camptothecin	24-36	choline phosphotransferase 1	Homo sapiens	91-94
12101394-10	2002	Similar effects were observed for another DNA crosslinking agent, cis-platinum, and to a lesser extent, for DNA topoisomerase I inhibitor, camptothecin.	Camptothecin	139-151	topoisomerase (DNA) I	Mus musculus	108-127
12161136-0	2002	Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin.	Camptothecin	38-50	plasminogen	Homo sapiens	120-127
12161136-1	2002	The first prodrugs of camptothecin and 9-aminocamptothecin that are activated by the tumour-associated protease plasmin are reported.	Camptothecin	22-34	plasminogen	Homo sapiens	112-119
12161136-2	2002	The tripartate prodrugs consist of a tripeptide sequence recognised by plasmin, which is linked to the 20-hydroxyl group of the camptothecins via a 1,6-elimination spacer.	Camptothecin	128-141	plasminogen	Homo sapiens	71-78
12218071-8	2002	Increased expression of TRAIL on tumor cells was observed by flow cytometry after cytokine stimulation (IFN-gamma, TNF-alpha) or the addition of chemotherapeutic agents (camptothecin, doxolubicin hydrochloride).	Camptothecin	170-182	TNF superfamily member 10	Homo sapiens	24-29
12138209-2	2002	We report that nucleolin mobilization also occurs following exposure to ionizing radiation (IR) and treatment with camptothecin.	Camptothecin	115-127	nucleolin	Homo sapiens	15-24
12115804-0	2002	Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.	Camptothecin	88-100	ATP binding cassette subfamily C member 3	Homo sapiens	12-51
12115804-7	2002	The cytotoxic effect of CPT was modulated in cells expressing MRP1 (MCF7/VP, HT29 cells) by the specific MRP1 modulators, probenecid and MK571.	Camptothecin	24-27	ATP binding cassette subfamily C member 1	Homo sapiens	62-66
12115804-7	2002	The cytotoxic effect of CPT was modulated in cells expressing MRP1 (MCF7/VP, HT29 cells) by the specific MRP1 modulators, probenecid and MK571.	Camptothecin	24-27	ATP binding cassette subfamily C member 1	Homo sapiens	105-109
12138192-8	2002	Interestingly, the zinc finger domain is also required for NF-kappa B activation by two other slow and weak inducers, camptothecin and etoposide.	Camptothecin	118-130	nuclear factor kappa B subunit 1	Homo sapiens	59-69
11994275-7	2002	Calpeptin treatment also blocked 9-amino camptothecin-induced DNA ligase III proteolysis and simultaneously protected the cells from death.	Camptothecin	41-53	DNA ligase 3	Homo sapiens	62-76
12048243-3	2002	DNA damage induced by camptothecin, which activates the tumor suppressor p53, was found to activate GSK3beta.	Camptothecin	22-34	tumor protein p53	Homo sapiens	73-76
12083797-6	2002	These results identify topors as a new member of the group of proteins that associate dynamically with PML nuclear bodies and suggest that topors may be involved in the cellular response to camptothecin.	Camptothecin	190-202	PML nuclear body scaffold	Homo sapiens	103-106
12085232-0	2002	Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis.	Camptothecin	68-80	prohibitin 1	Homo sapiens	50-60
12085232-3	2002	We now find that prohibitin protects cells from apoptosis mediated by camptothecin, a topoisomerase I inhibitor.	Camptothecin	70-82	prohibitin 1	Homo sapiens	17-27
12085232-4	2002	Camptothecin treatment of Ramos B cells leads to the degradation of Rb protein and phosphorylation of its family members, p107 and p130.	Camptothecin	0-12	RB transcriptional corepressor like 1	Homo sapiens	122-126
12085232-4	2002	Camptothecin treatment of Ramos B cells leads to the degradation of Rb protein and phosphorylation of its family members, p107 and p130.	Camptothecin	0-12	nucleolar and coiled-body phosphoprotein 1	Homo sapiens	131-135
12135490-0	2002	SF2/ASF protein inhibits camptothecin-induced DNA cleavage by human topoisomerase I.	Camptothecin	25-37	serine and arginine rich splicing factor 1	Homo sapiens	0-3
12135490-0	2002	SF2/ASF protein inhibits camptothecin-induced DNA cleavage by human topoisomerase I.	Camptothecin	25-37	serine and arginine rich splicing factor 1	Homo sapiens	4-7
12135490-2	2002	This study demonstrates that SF2/ASF inhibits DNA cleavage by human topoisomerase I induced by the anti-cancer agent camptothecin.	Camptothecin	117-129	serine and arginine rich splicing factor 1	Homo sapiens	29-32
12135490-2	2002	This study demonstrates that SF2/ASF inhibits DNA cleavage by human topoisomerase I induced by the anti-cancer agent camptothecin.	Camptothecin	117-129	serine and arginine rich splicing factor 1	Homo sapiens	33-36
12048243-3	2002	DNA damage induced by camptothecin, which activates the tumor suppressor p53, was found to activate GSK3beta.	Camptothecin	22-34	glycogen synthase kinase 3 beta	Homo sapiens	100-108
11997243-0	2002	Polyamine depletion prevents camptothecin-induced apoptosis by inhibiting the release of cytochrome c.	Camptothecin	29-41	cytochrome c, somatic	Homo sapiens	89-101
11997243-7	2002	Depletion of polyamines prevented camptothecin-induced release of cytochrome c from mitochondria and decreased the activity of caspase-9 and caspase-3.	Camptothecin	34-46	cytochrome c, somatic	Homo sapiens	66-78
11997243-7	2002	Depletion of polyamines prevented camptothecin-induced release of cytochrome c from mitochondria and decreased the activity of caspase-9 and caspase-3.	Camptothecin	34-46	caspase 9	Rattus norvegicus	127-136
11997243-7	2002	Depletion of polyamines prevented camptothecin-induced release of cytochrome c from mitochondria and decreased the activity of caspase-9 and caspase-3.	Camptothecin	34-46	caspase 3	Rattus norvegicus	141-150
11877436-0	2002	Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin.	Camptothecin	81-93	H3 histone pseudogene 16	Homo sapiens	8-11
12036943-7	2002	Subtoxic concentrations of camptothecin (which stabilizes topoisomerase I cleavage complexes, mediating nonhomologous recombination) produced a dose-dependent increase in PALA(R) colonies, and combining expression of mutant p53 with exposure to camptothecin produced a greater than additive increase in PALA(R) colony formation.	Camptothecin	27-39	tumor protein p53	Homo sapiens	224-227
12513785-9	2002	Bcr-abl fusion gene prevented apoptosis induced by etoposide or camptothecin, but did not prevent apoptosis induced by CIK cells.	Camptothecin	64-76	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	0-7
12052248-0	2002	Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin.	Camptothecin	127-139	annexin A5	Homo sapiens	11-20
12052248-5	2002	In contrast, induction of apoptosis with 5 microM camptothecin, documented by 60-70% desquamation of HUVEC culture, annexin V-binding to the cells and DNA-fragmentation, led to a release of annexin V-binding microparticles (approximately 80,000 MP/103 cells).	Camptothecin	50-62	annexin A5	Homo sapiens	116-125
12052248-5	2002	In contrast, induction of apoptosis with 5 microM camptothecin, documented by 60-70% desquamation of HUVEC culture, annexin V-binding to the cells and DNA-fragmentation, led to a release of annexin V-binding microparticles (approximately 80,000 MP/103 cells).	Camptothecin	50-62	annexin A5	Homo sapiens	190-199
12052248-10	2002	CONCLUSIONS: Camptothecin treated HUVEC released different populations of annexin V-binding membrane microparticles at early stage after proapoptotic stimulation before detection of phosphatidylserine exposure on the cells or DNA fragmentation.	Camptothecin	13-25	annexin A5	Homo sapiens	74-83
11877436-6	2002	These observations demonstrated that p21 was required for senescence development of HCT116 cells following treatment with low concentrations of CPT.	Camptothecin	144-147	H3 histone pseudogene 16	Homo sapiens	37-40
12088114-1	2002	The multidrug-resistance (MDR) status of a novel camptothecin analogue, homocamptothecin (hCPT), was investigated in human colon adenocarcinoma HT29 cells, myelogenous leukemia K562 cells and breast carcinoma MCF7 cells.	Camptothecin	49-61	choline phosphotransferase 1	Homo sapiens	90-94
11980637-0	2002	Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment.	Camptothecin	89-101	checkpoint kinase 1	Homo sapiens	40-44
11956509-9	2002	In vitro, the activity of acetylcholinesterase was inhibited by 100-micromol/L irinotecan (-24.8%) and markedly reduced by 1-micromol/L physostigmine (-86.7%), whereas neither SN-38 nor camptothecin had an effect.	Camptothecin	186-198	acetylcholinesterase (Cartwright blood group)	Homo sapiens	26-46
11894136-1	2002	Topoisomerase I inhibitors of the camptothecin (CPT) family have emerged as potent clinical chemotherapeutic agents in first-line treatment of solid colorectal cancer and in second-line for 5-fluorouracil resistant patients.	Camptothecin	34-46	choline phosphotransferase 1	Homo sapiens	48-51
11729194-7	2002	Expression of human PNKP in pnk1delta cells restores resistance to gamma-radiation or camptothecin, suggesting that the functions of yeast Pnk1 and human PNKP have been conserved.	Camptothecin	86-98	polynucleotide kinase 3'-phosphatase	Homo sapiens	20-24
11925121-13	2002	An intact cytochrome c pathway was demonstrated in C33A cells leading to cleavage of caspase 3 after camptothecin treatment.	Camptothecin	101-113	cytochrome c, somatic	Homo sapiens	10-22
11925121-13	2002	An intact cytochrome c pathway was demonstrated in C33A cells leading to cleavage of caspase 3 after camptothecin treatment.	Camptothecin	101-113	caspase 3	Homo sapiens	85-94
11891718-15	2002	About 50% of cells in the TNF-alpha-treated cultures underwent apoptosis during the initial 6 h at a rate of approximately 8% of cells per hour; the remaining cells were undergoing apoptosis at a rate of approximately 2.5% of cells per hour for up to 24 h. Also, about 50% of the CPT-treated cells, predominantly those in S phase of the cell cycle, underwent apoptosis within the initial 8 h of CPT exposure, at a rate of approximately 7% of cells per hour.	Camptothecin	280-283	tumor necrosis factor	Homo sapiens	26-35
11891718-15	2002	About 50% of cells in the TNF-alpha-treated cultures underwent apoptosis during the initial 6 h at a rate of approximately 8% of cells per hour; the remaining cells were undergoing apoptosis at a rate of approximately 2.5% of cells per hour for up to 24 h. Also, about 50% of the CPT-treated cells, predominantly those in S phase of the cell cycle, underwent apoptosis within the initial 8 h of CPT exposure, at a rate of approximately 7% of cells per hour.	Camptothecin	395-398	tumor necrosis factor	Homo sapiens	26-35
11840341-6	2002	WRN-/- cells showed hypersensitivities to genotoxic agents, such as 4-nitroquinoline 1-oxide, camptothecin and methyl methanesulfonate.	Camptothecin	94-106	Werner syndrome RecQ like helicase	Gallus gallus	0-3
11755358-1	2002	The first immunoconjugate of camptothecin has been synthesized wherein the drug is attached to the tumor-recognizing antibody BR96 via a Cathepsin B cleavable linker.	Camptothecin	29-41	cathepsin B	Homo sapiens	137-148
11918083-7	2002	We found that stromal ECM protected LiM6 cells from the toxicity of etoposide and LS174T, but not LiM6 cells, from the toxicity of camptothecin.	Camptothecin	131-143	multimerin 1	Homo sapiens	22-25
11756244-7	2002	This frequency is even more elevated in WRN mutant mice treated with camptothecin.	Camptothecin	69-81	Werner syndrome RecQ like helicase	Mus musculus	40-43
11918083-10	2002	Stromal-derived ECM may protect colon cancer cells from etoposide and camptothecin-induced apotosis, through a mechanism that is not bcl-2 or bcl-x(L) dependant.	Camptothecin	70-82	multimerin 1	Homo sapiens	16-19
11810260-4	2002	Furthermore, the mms1 Delta cells are sensitive to killing by conditions that induce replication-dependent double-strand breaks, such as treatment with camptothecin, and incubation of a cdc2-2 strain at the restrictive temperature.	Camptothecin	152-164	Mms1p	Saccharomyces cerevisiae S288C	17-21
11752162-3	2002	By transfecting cells with a construct expressing the Pst-Mlu segment of the LAT, encompassing the LAT exon 1, the stable 2.0-kb intron, and 5" part of exon 2, we confirmed that this region was able to diminish the onset of programmed cell death initiated by anti-Fas and camptothecin treatment.	Camptothecin	272-284	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4	Homo sapiens	54-57
11802813-0	2002	O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.	Camptothecin	82-94	O-6-methylguanine-DNA methyltransferase	Homo sapiens	0-40
11802813-0	2002	O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.	Camptothecin	82-94	O-6-methylguanine-DNA methyltransferase	Homo sapiens	42-46
11810260-5	2002	rad52 Delta is epistatic to mms1 Delta for MMS and camptothecin sensitivity, indicating that Mms1 acts in concert with Rad52.	Camptothecin	51-63	recombinase RAD52	Saccharomyces cerevisiae S288C	0-5
11810260-5	2002	rad52 Delta is epistatic to mms1 Delta for MMS and camptothecin sensitivity, indicating that Mms1 acts in concert with Rad52.	Camptothecin	51-63	Mms1p	Saccharomyces cerevisiae S288C	28-32
11810260-5	2002	rad52 Delta is epistatic to mms1 Delta for MMS and camptothecin sensitivity, indicating that Mms1 acts in concert with Rad52.	Camptothecin	51-63	Mms1p	Saccharomyces cerevisiae S288C	93-97
11741290-8	2001	This is the first demonstration that camptothecin and Zeocin can differentially signal for increased levels of modified p53 during all stages of the cell cycle.	Camptothecin	37-49	tumor protein p53	Homo sapiens	120-123
12415191-7	2002	CPT induced cell cycle arrest at the G2/M phase and enhanced the expression of human RAD9 (hRAD9) in MKN-45 cells.	Camptothecin	0-3	RAD9 checkpoint clamp component A	Homo sapiens	85-89
12415191-7	2002	CPT induced cell cycle arrest at the G2/M phase and enhanced the expression of human RAD9 (hRAD9) in MKN-45 cells.	Camptothecin	0-3	RAD9 checkpoint clamp component A	Homo sapiens	91-96
11740913-10	2001	The in vitro activity of human erythrocyte acetylcholinesterase was significantly inhibited by irinotecan (-21.5% at 100 microM) or physostigmine (-84.8% at 1 microM), whereas SN-38 or camptothecin had no effect.	Camptothecin	185-197	acetylcholinesterase	Rattus norvegicus	43-63
11741290-0	2001	Camptothecin and Zeocin can increase p53 levels during all cell cycle stages.	Camptothecin	0-12	tumor protein p53	Homo sapiens	37-40
11741290-7	2001	The p53 induced by both drugs was able to bind to DNA; however, only the p53 induced by camptothecin was phosphorylated at serine-392.	Camptothecin	88-100	tumor protein p53	Homo sapiens	4-7
11741290-7	2001	The p53 induced by both drugs was able to bind to DNA; however, only the p53 induced by camptothecin was phosphorylated at serine-392.	Camptothecin	88-100	tumor protein p53	Homo sapiens	73-76
11720709-5	2001	Treatment of the differentiated SH-SY5Y cells with camptothecin resulted in a time and concentration dependent activation of caspase-3 with a concomitant increase in the presence of apoptotic nuclei.	Camptothecin	51-63	caspase 3	Homo sapiens	125-134
11720709-6	2001	Immunoblotting revealed that camptothecin treatment resulted in a significant increase in tau phosphorylation.	Camptothecin	29-41	microtubule associated protein tau	Homo sapiens	90-93
11720709-7	2001	Addition of a cyclin-dependent kinase inhibitor reduced camptothecin-induced cell death in the differentiated SH-SY5Y cells and decreased the effects of camptothecin on tau phosphorylation.	Camptothecin	153-165	microtubule associated protein tau	Homo sapiens	169-172
11688982-1	2001	Overexpression of breast cancer resistance protein (BCRP) ABCG2 reportedly confers cancer cell resistance to camptothecin-based anticancer drugs, such as topotecan and 7-ethyl-10-hydroxycamptothecin (SN-38: the active metabolite of irinotecan).	Camptothecin	109-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	18-50
11718848-4	2001	Overexpression of TERT in PC12 cells increases their resistance to the topoisomerase inhibitors camptothecin and etoposide.	Camptothecin	96-108	telomerase reverse transcriptase	Rattus norvegicus	18-22
11753682-8	2001	Camptothecin increased caspase 3 activity twice as much in the IEX-HaCaT cells when compared to HaCaT cells.	Camptothecin	0-12	caspase 3	Homo sapiens	23-32
11688982-1	2001	Overexpression of breast cancer resistance protein (BCRP) ABCG2 reportedly confers cancer cell resistance to camptothecin-based anticancer drugs, such as topotecan and 7-ethyl-10-hydroxycamptothecin (SN-38: the active metabolite of irinotecan).	Camptothecin	109-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	58-63
11688982-1	2001	Overexpression of breast cancer resistance protein (BCRP) ABCG2 reportedly confers cancer cell resistance to camptothecin-based anticancer drugs, such as topotecan and 7-ethyl-10-hydroxycamptothecin (SN-38: the active metabolite of irinotecan).	Camptothecin	109-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	52-56
11704644-15	2001	These results revealed that P-glycoprotein might modulate hepatobiliary excretion and BBB penetration of camptothecin.	Camptothecin	105-117	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	28-42
11546768-6	2001	In addition, transcription inhibitors such as 5,6-dichlorobenzimidazole riboside and camptothecin can substantially block VM-26-induced TOP2beta degradation.	Camptothecin	85-97	DNA topoisomerase II beta	Homo sapiens	136-144
11704644-0	2001	Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis.	Camptothecin	63-75	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	10-24
11698339-7	2001	Furthermore, MSH2(-/-) cells displayed an elevated spontaneous RAD51 focus-forming activity and a higher induction of RAD51 foci following camptothecin treatment.	Camptothecin	139-151	mutS homolog 2	Mus musculus	13-17
11698339-0	2001	Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair.	Camptothecin	20-32	mutS homolog 2	Mus musculus	36-40
11698339-7	2001	Furthermore, MSH2(-/-) cells displayed an elevated spontaneous RAD51 focus-forming activity and a higher induction of RAD51 foci following camptothecin treatment.	Camptothecin	139-151	RAD51 recombinase	Mus musculus	118-123
11698339-0	2001	Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair.	Camptothecin	20-32	mutS homolog 2	Mus musculus	87-91
11591730-5	2001	Induction of neuronal cell death by camptothecin, a DNA-damaging agent that functions through a p53-dependent mechanism, resulted in increased Apaf1 mRNA in p53-positive, but not p53-deficient neurons.	Camptothecin	36-48	tumor protein p53	Homo sapiens	96-99
11605011-3	2001	Since the activity of the camptothecines (CPTs) depends on local pH conditions, we investigated, whether PB/PA modulate CPT effects indirectly by affecting intracellular pH in SW620 and SW480 colon cancer cells.	Camptothecin	26-40	choline phosphotransferase 1	Homo sapiens	42-45
11585902-5	2001	The triple mutant was also deficient in the repair of 3" phosphate lesions left by Tdp1-mediated cleavage of camptothecin-stabilized Top1-DNA covalent complexes.	Camptothecin	109-121	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	83-87
11709009-9	2001	Following exposure to camptothecin, keratocytes from patients with Fuchs dystrophy responded with an increased level of Bax and a low level of Bcl-2.	Camptothecin	22-34	BCL2 associated X, apoptosis regulator	Homo sapiens	120-123
11709009-9	2001	Following exposure to camptothecin, keratocytes from patients with Fuchs dystrophy responded with an increased level of Bax and a low level of Bcl-2.	Camptothecin	22-34	BCL2 apoptosis regulator	Homo sapiens	143-148
11591730-5	2001	Induction of neuronal cell death by camptothecin, a DNA-damaging agent that functions through a p53-dependent mechanism, resulted in increased Apaf1 mRNA in p53-positive, but not p53-deficient neurons.	Camptothecin	36-48	apoptotic peptidase activating factor 1	Homo sapiens	143-148
11591730-5	2001	Induction of neuronal cell death by camptothecin, a DNA-damaging agent that functions through a p53-dependent mechanism, resulted in increased Apaf1 mRNA in p53-positive, but not p53-deficient neurons.	Camptothecin	36-48	tumor protein p53	Homo sapiens	157-160
11591730-5	2001	Induction of neuronal cell death by camptothecin, a DNA-damaging agent that functions through a p53-dependent mechanism, resulted in increased Apaf1 mRNA in p53-positive, but not p53-deficient neurons.	Camptothecin	36-48	tumor protein p53	Homo sapiens	157-160
11591730-11	2001	Neurons treated with camptothecin were significantly protected in the absence of Apaf1 relative to those derived from wild-type littermates.	Camptothecin	21-33	apoptotic peptidase activating factor 1	Homo sapiens	81-86
11593403-3	2001	In contrast, agents that inhibit the elongation phase of transcription, such as UV light, camptothecin or actinomycin D, induced the accumulation of nuclear p53 proteins that were modified at both of these sites.	Camptothecin	90-102	tumor protein p53	Homo sapiens	157-160
11562548-9	2001	The Rep protein can be classified as a type-I topoisomerase because of its nicking activity and sensitivity towards camptothecin, a topoisomerase type-I inhibitor.	Camptothecin	116-128	replication protein	Escherichia coli	4-7
11557032-4	2001	Cells that express Chk2AS display defective S-phase delay in response to DNA replication-mediated DNA damage induced by the topoisomerase I inhibitor camptothecin.	Camptothecin	150-162	checkpoint kinase 2	Homo sapiens	19-23
11557032-6	2001	Enhanced apoptosis was observed in Chk2AS cells after exposure to gamma-radiation or camptothecin.	Camptothecin	85-97	checkpoint kinase 2	Homo sapiens	35-39
12049482-0	2001	The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.	Camptothecin	65-78	acetylcholinesterase (Cartwright blood group)	Homo sapiens	18-38
11473362-5	2001	We found that the activating transcription factor 3 (ATF3) protein, a repressor of cyclic-AMP responsive element (CRE)-dependent transcription, was strongly induced among CRE-BP/ATF members and subsequently accumulated in nuclei following camptothecin or etoposide treatment.	Camptothecin	239-251	activating transcription factor 3	Homo sapiens	18-51
11473362-5	2001	We found that the activating transcription factor 3 (ATF3) protein, a repressor of cyclic-AMP responsive element (CRE)-dependent transcription, was strongly induced among CRE-BP/ATF members and subsequently accumulated in nuclei following camptothecin or etoposide treatment.	Camptothecin	239-251	activating transcription factor 3	Homo sapiens	53-57
11533143-3	2001	In monolayers of human colonic HT-29/B6 cells, apoptosis induced by camptothecin was assessed by poly-(ADP-ribose)-polymerase (PARP) cleavage, histone ELISA and DNA-specific fluorochrome staining (with 4",6"-diamidino-2"-phenylindoladihydrochloride (DAPI)).	Camptothecin	68-80	poly(ADP-ribose) polymerase 1	Homo sapiens	97-125
11533143-3	2001	In monolayers of human colonic HT-29/B6 cells, apoptosis induced by camptothecin was assessed by poly-(ADP-ribose)-polymerase (PARP) cleavage, histone ELISA and DNA-specific fluorochrome staining (with 4",6"-diamidino-2"-phenylindoladihydrochloride (DAPI)).	Camptothecin	68-80	poly(ADP-ribose) polymerase 1	Homo sapiens	127-131
11522300-5	2001	Activities of caspase-1, -3, -8 and -9 were increased by treatment of the cells with camptothecin, but not with PS.	Camptothecin	85-97	caspase-1	Cricetulus griseus	14-38
11487718-3	2001	In the present study subcellular BAX translocations in human colon adenocarcinoma COLO 205 cells exposed to various anticancer drugs [camptothecin (CPT), etoposide (ETO), staurosporine (STP), 2-chloro-2"-deoxyadenosine (2CdA) and nimesulide (NIM)] was examined.	Camptothecin	134-146	BCL2 associated X, apoptosis regulator	Homo sapiens	33-36
11487718-3	2001	In the present study subcellular BAX translocations in human colon adenocarcinoma COLO 205 cells exposed to various anticancer drugs [camptothecin (CPT), etoposide (ETO), staurosporine (STP), 2-chloro-2"-deoxyadenosine (2CdA) and nimesulide (NIM)] was examined.	Camptothecin	148-151	BCL2 associated X, apoptosis regulator	Homo sapiens	33-36
11487718-15	2001	Immunoelectron microscopy revealed that CPT-induced apoptosis was associated with translocation of BAX from the cytosol to organellar membranes (mitochondrial, Golgi apparatus and endoplasmic reticulum) and via nuclear envelope pores to the nucleus, occurring within 60-180 min of cell exposure to the drug.	Camptothecin	40-43	BCL2 associated X, apoptosis regulator	Homo sapiens	99-102
12049482-3	2001	Attachment of heterocyclic and branched amino groups onto the camptothecin back-bone continues to be a strategy for the synthesis of water-soluble analogues, but this may lead to undesirable inhibition of AChE.	Camptothecin	62-74	acetylcholinesterase (Cartwright blood group)	Homo sapiens	205-209
12049482-4	2001	In this study, we screened a range of camptothecin analogues, degradation products and metabolites for their ability to inhibit AChE.	Camptothecin	38-50	acetylcholinesterase (Cartwright blood group)	Homo sapiens	128-132
12049482-10	2001	Overall, our experiments reveal that nitrogenous substitutions at the permissive C-10 of the camptothecin backbone may lead to AchE inhibition, particularly if they involve a quaternary nitrogen.	Camptothecin	93-105	acetylcholinesterase (Cartwright blood group)	Homo sapiens	127-131
11356855-3	2001	In a novel application of the yeast two-hybrid system and by immunoprecipitation, we show here that Rad17p is capable of increased self-interaction following DNA damage introduced by 4-nitroquinoline-N-oxide, camptothecin or partial inactivation of DNA ligase I.	Camptothecin	209-221	Rad17p	Saccharomyces cerevisiae S288C	100-106
11532027-7	2001	In the absence of RAD9, inactivation of TDP1 has a significant effect on the survival of cells following exposure to camptothecin but is without consequence for the survival of agents that do not target topoisomerase I.	Camptothecin	117-129	tyrosyl-DNA phosphodiesterase 1	Saccharomyces cerevisiae S288C	40-44
11438577-3	2001	Previous evidence has shown that the death of embryonic cortical neurons treated with the DNA-damaging agent camptothecin is dependent on the tumor suppressor p53 and cyclin-dependent kinase (CDK) activity and that the inhibition of either pathway alone leads to enhanced and prolonged survival.	Camptothecin	109-121	tumor protein p53	Homo sapiens	159-162
11489830-7	2001	These cells showed an increased resistance to undergo camptothecin-induced apoptosis, which was overcome by effective Dap-3-antisense treatment.	Camptothecin	54-66	death associated protein 3	Homo sapiens	118-123
11509123-5	2001	Significantly enhanced gene expression of the majority of PKC isozyme genes was found after treatment with camptothecin.	Camptothecin	107-119	protein kinase C zeta	Homo sapiens	58-61
11514625-3	2001	With the use of two drugs, camptothecin and hydroxyurea, which produce replication-associated DNA damage and/or inhibit replication fork progression, we find that WS cells have a slower rate of repair associated with DNA damage induced in the S-phase and a reduced induction of RAD51 foci.	Camptothecin	27-39	recombinase RAD51	Saccharomyces cerevisiae S288C	278-283
11476184-2	2001	The present study was conducted to evaluate whether camptothecin (CPT), a topoisomerase I inhibitor, exhibits antitumor activity through regulation the inducible nitric oxide synthase (iNOS) biosynthesis pathway.	Camptothecin	52-64	nitric oxide synthase 2, inducible	Mus musculus	152-183
11494133-5	2001	In addition, we found that p73 can cooperate with the DNA damaging agent camptothecin to activate the initiator caspase 2.	Camptothecin	73-85	caspase 2	Homo sapiens	112-121
11485202-3	2001	As a result, the new tomato gene Le-pirin was isolated, whose mRNA levels dramatically increase during camptothecin-induced PCD.	Camptothecin	103-115	pirin	Homo sapiens	36-41
11485202-5	2001	The caspase inhibitor Z-Asp-CH2-DCB and the calcium channel blocker LaCl3 effectively delayed whereas ethylene greatly stimulated camptothecin-induced PCD and the accumulation of Le-pirin mRNA.	Camptothecin	130-142	pirin	Homo sapiens	182-187
11457508-4	2001	Here we demonstrate increased expression and co-localization of p53 and Mdm2 in the nuclei of degenerating neurons following treatment with either the excitotoxin, kainic acid, or the topoisomerase I inhibitor, camptothecin.	Camptothecin	211-223	tumor protein p53	Homo sapiens	64-67
11457508-4	2001	Here we demonstrate increased expression and co-localization of p53 and Mdm2 in the nuclei of degenerating neurons following treatment with either the excitotoxin, kainic acid, or the topoisomerase I inhibitor, camptothecin.	Camptothecin	211-223	MDM2 proto-oncogene	Homo sapiens	72-76
11476184-2	2001	The present study was conducted to evaluate whether camptothecin (CPT), a topoisomerase I inhibitor, exhibits antitumor activity through regulation the inducible nitric oxide synthase (iNOS) biosynthesis pathway.	Camptothecin	52-64	nitric oxide synthase 2, inducible	Mus musculus	185-189
11476184-2	2001	The present study was conducted to evaluate whether camptothecin (CPT), a topoisomerase I inhibitor, exhibits antitumor activity through regulation the inducible nitric oxide synthase (iNOS) biosynthesis pathway.	Camptothecin	66-69	nitric oxide synthase 2, inducible	Mus musculus	152-183
11476184-2	2001	The present study was conducted to evaluate whether camptothecin (CPT), a topoisomerase I inhibitor, exhibits antitumor activity through regulation the inducible nitric oxide synthase (iNOS) biosynthesis pathway.	Camptothecin	66-69	nitric oxide synthase 2, inducible	Mus musculus	185-189
11334569-1	2001	Eleven A-ring modified hexacyclic analogues of camptothecin (CPT) containing a 1,4-oxazine ring were synthesized from 10-hydroxycamptothecin (11a) and 7-ethyl-10-hydroxycamptothecin (3) (SN-38) in four to five steps and were subjected to the biological tests such as cytotoxicity, topoisomerase I (Topo I) inhibitory activity, acetylcholinesterase (AChE) inhibition, and stability in human plasma.	Camptothecin	47-59	acetylcholinesterase (Cartwright blood group)	Homo sapiens	327-347
11423970-8	2001	Low concentrations of roscovitine cooperate with the DNA-damaging agent camptothecin to activate p53 in a synergistic fashion.	Camptothecin	72-84	tumor protein p53	Homo sapiens	97-100
11418138-0	2001	pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase.	Camptothecin	15-27	RB transcriptional corepressor 1	Homo sapiens	0-3
11418138-0	2001	pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase.	Camptothecin	15-27	mitogen-activated protein kinase 8	Homo sapiens	95-118
11418138-1	2001	This paper studies the cytotoxic effect induced by the topoisomerase I inhibitor camptothecin in human osteosarcoma Saos-2 cells, which lack p53 and contain a non-functional form of the product of the retinoblastoma gene, pRb.	Camptothecin	81-93	tumor protein p53	Homo sapiens	141-144
11418138-1	2001	This paper studies the cytotoxic effect induced by the topoisomerase I inhibitor camptothecin in human osteosarcoma Saos-2 cells, which lack p53 and contain a non-functional form of the product of the retinoblastoma gene, pRb.	Camptothecin	81-93	RB transcriptional corepressor 1	Homo sapiens	201-215
11418138-1	2001	This paper studies the cytotoxic effect induced by the topoisomerase I inhibitor camptothecin in human osteosarcoma Saos-2 cells, which lack p53 and contain a non-functional form of the product of the retinoblastoma gene, pRb.	Camptothecin	81-93	RB transcriptional corepressor 1	Homo sapiens	222-225
11418138-5	2001	Treatment with camptothecin caused a threefold increase in the activity of c-Jun N-terminal kinase (JNK) and an eightfold increase in the level of phosphorylated c-Jun.	Camptothecin	15-27	mitogen-activated protein kinase 8	Homo sapiens	75-98
11418138-5	2001	Treatment with camptothecin caused a threefold increase in the activity of c-Jun N-terminal kinase (JNK) and an eightfold increase in the level of phosphorylated c-Jun.	Camptothecin	15-27	mitogen-activated protein kinase 8	Homo sapiens	100-103
11418138-5	2001	Treatment with camptothecin caused a threefold increase in the activity of c-Jun N-terminal kinase (JNK) and an eightfold increase in the level of phosphorylated c-Jun.	Camptothecin	15-27	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	75-80
11418138-8	2001	Exposure to 100 nM camptothecin for 72 h reduced the viability of transfected cells by only 10%; moreover, very modest effects were observed on the activity of JNK as well as on the level of phosphorylated c-Jun.	Camptothecin	19-31	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	206-211
11459199-5	2001	By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents.	Camptothecin	187-199	epidermal growth factor receptor	Homo sapiens	94-98
11459199-5	2001	By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents.	Camptothecin	187-199	tumor necrosis factor	Homo sapiens	116-119
11459199-5	2001	By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents.	Camptothecin	187-199	epidermal growth factor receptor	Homo sapiens	94-98
11459199-5	2001	By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents.	Camptothecin	201-204	epidermal growth factor receptor	Homo sapiens	94-98
11459199-5	2001	By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents.	Camptothecin	201-204	tumor necrosis factor	Homo sapiens	116-119
11459199-5	2001	By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents.	Camptothecin	201-204	epidermal growth factor receptor	Homo sapiens	94-98
11334569-1	2001	Eleven A-ring modified hexacyclic analogues of camptothecin (CPT) containing a 1,4-oxazine ring were synthesized from 10-hydroxycamptothecin (11a) and 7-ethyl-10-hydroxycamptothecin (3) (SN-38) in four to five steps and were subjected to the biological tests such as cytotoxicity, topoisomerase I (Topo I) inhibitory activity, acetylcholinesterase (AChE) inhibition, and stability in human plasma.	Camptothecin	47-59	acetylcholinesterase (Cartwright blood group)	Homo sapiens	349-353
11336984-0	2001	Molecular characterisation of camptothecin-induced mutations at the hprt locus in Chinese hamster cells.	Camptothecin	30-42	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	68-72
11336984-1	2001	The capacity of the topoisomerase I inhibitor camptothecin (CPT) to induce single locus mutations at the hypoxanthine-guanine phosphoribosyltransferase (hprt) gene and the DNA changes underlying induced mutations were analysed in Chinese hamster ovary cells.	Camptothecin	46-58	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	105-151
11336984-1	2001	The capacity of the topoisomerase I inhibitor camptothecin (CPT) to induce single locus mutations at the hypoxanthine-guanine phosphoribosyltransferase (hprt) gene and the DNA changes underlying induced mutations were analysed in Chinese hamster ovary cells.	Camptothecin	46-58	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	153-157
11336984-1	2001	The capacity of the topoisomerase I inhibitor camptothecin (CPT) to induce single locus mutations at the hypoxanthine-guanine phosphoribosyltransferase (hprt) gene and the DNA changes underlying induced mutations were analysed in Chinese hamster ovary cells.	Camptothecin	60-63	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	105-151
11336984-1	2001	The capacity of the topoisomerase I inhibitor camptothecin (CPT) to induce single locus mutations at the hypoxanthine-guanine phosphoribosyltransferase (hprt) gene and the DNA changes underlying induced mutations were analysed in Chinese hamster ovary cells.	Camptothecin	60-63	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	153-157
11334569-1	2001	Eleven A-ring modified hexacyclic analogues of camptothecin (CPT) containing a 1,4-oxazine ring were synthesized from 10-hydroxycamptothecin (11a) and 7-ethyl-10-hydroxycamptothecin (3) (SN-38) in four to five steps and were subjected to the biological tests such as cytotoxicity, topoisomerase I (Topo I) inhibitory activity, acetylcholinesterase (AChE) inhibition, and stability in human plasma.	Camptothecin	61-64	acetylcholinesterase (Cartwright blood group)	Homo sapiens	327-347
11336984-2	2001	Camptothecin treatments increased hprt mutations up to 50-fold over the spontaneous levels at highly cytotoxic doses.	Camptothecin	0-12	hypoxanthine-guanine phosphoribosyltransferase	Cricetulus griseus	34-38
11334569-1	2001	Eleven A-ring modified hexacyclic analogues of camptothecin (CPT) containing a 1,4-oxazine ring were synthesized from 10-hydroxycamptothecin (11a) and 7-ethyl-10-hydroxycamptothecin (3) (SN-38) in four to five steps and were subjected to the biological tests such as cytotoxicity, topoisomerase I (Topo I) inhibitory activity, acetylcholinesterase (AChE) inhibition, and stability in human plasma.	Camptothecin	61-64	acetylcholinesterase (Cartwright blood group)	Homo sapiens	349-353
11230497-2	2001	With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I-interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer.	Camptothecin	150-162	DNA topoisomerase I	Homo sapiens	26-41
11145960-2	2001	A change in the degree of phosphorylation of HMGA1a has been observed during apoptosis induced in four leukemic cell lines (HL60, K562, NB4, and U937) by drugs (etoposide, camptothecin) or herpes simplex virus type-1.	Camptothecin	172-184	high mobility group AT-hook 1	Homo sapiens	45-51
11313933-6	2001	Treatment of HT29 cells with FasL or with the CH-11 agonistic anti-Fas antibody potentiated the apoptotic response of cells treated with CPT.	Camptothecin	137-140	Fas ligand	Homo sapiens	29-33
11309344-0	2001	Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.	Camptothecin	80-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	17-49
11309344-0	2001	Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.	Camptothecin	80-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	51-55
11309344-0	2001	Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.	Camptothecin	80-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	136-140
11309344-1	2001	This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918.	Camptothecin	138-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	51-55
11309344-1	2001	This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918.	Camptothecin	138-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	56-59
11309344-1	2001	This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918.	Camptothecin	138-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	60-64
11309344-1	2001	This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918.	Camptothecin	138-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	66-70
11309344-1	2001	This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918.	Camptothecin	138-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	66-70
11309344-3	2001	Notably, DX8951f and BNP1350 appeared to be very poor substrates for BCRP, with much lower resistance factors observed both in T8 and MX3 cells than observed for the other camptothecins tested.	Camptothecin	172-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	69-73
11309344-8	2001	Furthermore, GF120918 appears to be a potent reversal agent of BCRP-mediated resistance to camptothecins, with almost complete reversal noted at 100 nM.	Camptothecin	91-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	63-67
11430427-5	2001	During camptothecin-induced PCD tomato DAD1 mRNA levels roughly halve, while tomato HSR203 mRNA levels increase 5-fold.	Camptothecin	7-19	dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1	Solanum lycopersicum	39-43
11380620-5	2001	RESULTS: Using immunocytochemistry, we found that WRNp forms distinct nuclear foci in response to DNA damaging agents, including camptothecin (CPT), etoposide, 4-nitroquinolin-N-oxide and bleomycin.	Camptothecin	129-141	WRN RecQ like helicase	Homo sapiens	50-54
11380620-5	2001	RESULTS: Using immunocytochemistry, we found that WRNp forms distinct nuclear foci in response to DNA damaging agents, including camptothecin (CPT), etoposide, 4-nitroquinolin-N-oxide and bleomycin.	Camptothecin	143-146	WRN RecQ like helicase	Homo sapiens	50-54
11380620-6	2001	The presence of aphidicolin inhibited CPT-induced WRNp foci strongly but not bleomycin-induced foci.	Camptothecin	38-41	WRN RecQ like helicase	Homo sapiens	50-54
11331310-6	2001	53BP1 foci formation is not restricted to gamma-radiation but is also detected in response to UV radiation as well as hydroxyurea, camptothecin, etoposide, and methylmethanesulfonate treatment.	Camptothecin	131-143	tumor protein p53 binding protein 1	Homo sapiens	0-5
11313933-0	2001	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells.	Camptothecin	86-98	Fas ligand	Homo sapiens	47-57
11313933-0	2001	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells.	Camptothecin	86-98	tumor protein p53	Homo sapiens	102-105
11313933-1	2001	The present study explored the role of the cell surface receptor Fas (CD95/APO-1) in apoptosis induced by camptothecin (CPT) in the HT29 colon carcinoma cell line.	Camptothecin	106-118	Fas cell surface death receptor	Homo sapiens	70-74
11313933-1	2001	The present study explored the role of the cell surface receptor Fas (CD95/APO-1) in apoptosis induced by camptothecin (CPT) in the HT29 colon carcinoma cell line.	Camptothecin	106-118	Fas cell surface death receptor	Homo sapiens	75-80
11313933-1	2001	The present study explored the role of the cell surface receptor Fas (CD95/APO-1) in apoptosis induced by camptothecin (CPT) in the HT29 colon carcinoma cell line.	Camptothecin	120-123	Fas cell surface death receptor	Homo sapiens	70-74
11313933-1	2001	The present study explored the role of the cell surface receptor Fas (CD95/APO-1) in apoptosis induced by camptothecin (CPT) in the HT29 colon carcinoma cell line.	Camptothecin	120-123	Fas cell surface death receptor	Homo sapiens	75-80
11313865-0	2001	p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.	Camptothecin	147-159	tumor protein p53	Homo sapiens	0-3
11313865-0	2001	p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.	Camptothecin	147-159	tumor protein p53	Homo sapiens	85-88
11313865-2	2001	Several cell lines expressing wild-type p53 protein were treated with increasing concentrations of DNA-damaging drug camptothecin.	Camptothecin	117-129	tumor protein p53	Homo sapiens	40-43
11313865-7	2001	We demonstrate here that transcriptional activation of p53 after the treatment of camptothecin is not sufficient to cause p53-dependent G1 cell cycle arrest.	Camptothecin	82-94	tumor protein p53	Homo sapiens	55-58
11230497-2	2001	With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I-interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer.	Camptothecin	150-162	DNA topoisomerase I	Homo sapiens	43-48
11230497-2	2001	With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I-interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer.	Camptothecin	150-162	DNA topoisomerase I	Homo sapiens	132-137
11762642-1	2001	We report the synthesis and pharmacological evaluation of a novel homocamptothecin (hCPT) derivative, 12-Cl-hCPT, which contains a seven-membered beta-hydroxylactone in place of the conventional six-membered alpha-hydroxylactone found in camptothecin (CPT) and bears a chloro substituent at position 12.	Camptothecin	70-82	choline phosphotransferase 1	Homo sapiens	84-88
11136718-4	2001	We provide evidence for the in vivo significance of the topo II-HDAC1 association, showing that inhibition of HDAC activity with trichostatin A suppresses apoptosis induced by the topo II poison etoposide, but not by the topoisomerase I inhibitor camptothecin.	Camptothecin	247-259	histone deacetylase 1	Homo sapiens	64-69
11162657-2	2001	BCRP-overexpressing cells show cross-resistance to camptothecin derivatives such as irinotecan, SN-38 (the active metabolite of irinotecan), and topotecan.	Camptothecin	51-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-4
11762642-1	2001	We report the synthesis and pharmacological evaluation of a novel homocamptothecin (hCPT) derivative, 12-Cl-hCPT, which contains a seven-membered beta-hydroxylactone in place of the conventional six-membered alpha-hydroxylactone found in camptothecin (CPT) and bears a chloro substituent at position 12.	Camptothecin	70-82	choline phosphotransferase 1	Homo sapiens	108-112
11762642-1	2001	We report the synthesis and pharmacological evaluation of a novel homocamptothecin (hCPT) derivative, 12-Cl-hCPT, which contains a seven-membered beta-hydroxylactone in place of the conventional six-membered alpha-hydroxylactone found in camptothecin (CPT) and bears a chloro substituent at position 12.	Camptothecin	70-82	choline phosphotransferase 1	Homo sapiens	85-88
11561692-1	2001	PURPOSE: To evaluate the role of 9-aminocamptothecin (9-AC), a synthetic camptothecin analog, in advanced cutaneous T-cell lymphoma (CTCL).	Camptothecin	40-52	TSPY like 2	Homo sapiens	133-137
11482896-1	2001	The unique combination of immunocytochemistry with embedment-free electron microscopy was applied for precise and specific localisation of BAX in the human colon adenocarcinoma COLO 205 cell line stimulated to undergo apoptosis by camptothecin (DNA topoisomerase I inhibitor).	Camptothecin	231-243	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
11482896-2	2001	Camptothecin-induced apoptosis was associated with redistribution of BAX from cytosol to organelle membranes: mitochondria, Golgi apparatus, endoplasmic reticulum and via nuclear envelope pores to the nucleus, occurring within 60-180 min of cell exposure to the drug.	Camptothecin	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	69-72
11482896-4	2001	The increase in BAX expression in the nuclear area of camptothecin-treated COLO 205 cells was confirmed by quantitative analysis using laser scanning cytometry.	Camptothecin	54-66	BCL2 associated X, apoptosis regulator	Homo sapiens	16-19
11139322-4	2001	Camptothecin-induced DNA strand breaks were also increased 2.5-fold by NU1025 and exposure to camptothecin-activated PARP.	Camptothecin	0-12	poly (ADP-ribose) polymerase family, member 1	Mus musculus	117-121
11139322-4	2001	Camptothecin-induced DNA strand breaks were also increased 2.5-fold by NU1025 and exposure to camptothecin-activated PARP.	Camptothecin	94-106	poly (ADP-ribose) polymerase family, member 1	Mus musculus	117-121
11139322-7	2001	Taken together, these data suggest that potentiation of camptothecin cytotoxicity by NU1025 is a direct result of increased DNA strand breakage, and that activation of PARP by camptothecin-induced DNA damage contributes to its repair and consequently cell survival.	Camptothecin	176-188	poly (ADP-ribose) polymerase family, member 1	Mus musculus	168-172
11118036-1	2000	Homocamptothecin (hCPT), which differs from camptothecin (CPT) by the presence of an additional methylene group in the E-ring, was evaluated in CPT-resistant cell lines.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	18-22
11123279-3	2001	We report that in CD4(+) human lymphoblastoid cell lines transfected with the nef cDNA obtained from three different HIV-1 strains, expression of the Nef protein enhances and accelerates the response to four unrelated apoptotic agents (staurosporine, anisomycin, camptothecin, and etoposide) but not to an anti-Fas agonist Ab.	Camptothecin	263-275	S100 calcium binding protein B	Homo sapiens	78-81
11123279-3	2001	We report that in CD4(+) human lymphoblastoid cell lines transfected with the nef cDNA obtained from three different HIV-1 strains, expression of the Nef protein enhances and accelerates the response to four unrelated apoptotic agents (staurosporine, anisomycin, camptothecin, and etoposide) but not to an anti-Fas agonist Ab.	Camptothecin	263-275	Nef	Human immunodeficiency virus 1	150-153
11305412-0	2001	Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.	Camptothecin	103-115	cyclin B1	Homo sapiens	10-19
11103783-7	2000	In this report, we have presented the novel observation that the transcription factor Oct-1 is induced after cells are exposed to multiple DNA-damaging agents and therapeutic agents, including UV radiation, methylmethane sulfonate, ionizing radiation, etoposide, cisplatin, and camptothecin.	Camptothecin	278-290	POU class 2 homeobox 1	Homo sapiens	86-91
10967121-6	2000	Moreover, deletion of NSR1 reduces sensitivity to camptothecin, an antineoplastic topoisomerase I inhibitor.	Camptothecin	50-62	scavenger receptor class F member 2	Homo sapiens	22-26
11029511-0	2000	UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells.	Camptothecin	11-23	tumor protein p53	Homo sapiens	59-62
11205246-4	2000	Down-regulation of TOP2 alpha gene expression by the camptothecin induced DNA damage response may adversely affect the effectiveness of sequential therapy.	Camptothecin	53-65	DNA topoisomerase II alpha	Homo sapiens	19-29
11205246-8	2000	These results demonstrated that induction of p53 by camptothecin treatment can lead to a decreased level of TOP2 alpha and should be considered in design of combination therapy.	Camptothecin	52-64	tumor protein p53	Homo sapiens	45-48
11205246-8	2000	These results demonstrated that induction of p53 by camptothecin treatment can lead to a decreased level of TOP2 alpha and should be considered in design of combination therapy.	Camptothecin	52-64	DNA topoisomerase II alpha	Homo sapiens	108-118
11139283-0	2000	Increased mitochondrial cytochrome c levels and mitochondrial hyperpolarization precede camptothecin-induced apoptosis in Jurkat cells.	Camptothecin	88-100	cytochrome c, somatic	Homo sapiens	24-36
11139283-2	2000	In the present study, we showed that, in Jurkat human T cells, camptothecin-induced apoptosis is preceded by (i) an increase in cytochrome c and subunit IV of cytochrome c oxidase (COX IV) levels in mitochondria; and (ii) an elevation of the mitochondrial membrane potential (Delta(Psi)m).	Camptothecin	63-75	cytochrome c, somatic	Homo sapiens	128-140
11139283-2	2000	In the present study, we showed that, in Jurkat human T cells, camptothecin-induced apoptosis is preceded by (i) an increase in cytochrome c and subunit IV of cytochrome c oxidase (COX IV) levels in mitochondria; and (ii) an elevation of the mitochondrial membrane potential (Delta(Psi)m).	Camptothecin	63-75	cytochrome c, somatic	Homo sapiens	159-171
11139283-2	2000	In the present study, we showed that, in Jurkat human T cells, camptothecin-induced apoptosis is preceded by (i) an increase in cytochrome c and subunit IV of cytochrome c oxidase (COX IV) levels in mitochondria; and (ii) an elevation of the mitochondrial membrane potential (Delta(Psi)m).	Camptothecin	63-75	cytochrome c oxidase subunit 4I1	Homo sapiens	181-187
11035919-4	2000	This separation, which appears to be initiated by the nucleolar segregation, was observed in HL-60 cells that were undergoing spontaneous apoptosis in cultures or were treated with the DNA-damaging drug, DNA topoisomerase I inhibitor camptothecin (CPT), or with the cell death ligand, tumor necrosis factor-alpha.	Camptothecin	248-251	tumor necrosis factor	Homo sapiens	285-312
11023999-6	2000	Importantly, cells derived from WS patients exhibit an attenuated and delayed induction of p53 by UV or by the topoisomerase I inhibitor camptothecin.	Camptothecin	137-149	tumor protein p53	Homo sapiens	91-94
11054676-5	2000	The YKL-1 and DNA damaging agent, camptothecin effectively induced p53 in H460 and HepG2 as well as in normal cells.	Camptothecin	34-46	tumor protein p53	Homo sapiens	67-70
11029511-1	2000	Previous research has shown synergistic growth inhibition between UCN-01 and camptothecin (CPT) in tumor cells with mutant p53 versus tumor cells with wild-type p53.	Camptothecin	77-89	tumor protein p53	Homo sapiens	123-126
11029511-1	2000	Previous research has shown synergistic growth inhibition between UCN-01 and camptothecin (CPT) in tumor cells with mutant p53 versus tumor cells with wild-type p53.	Camptothecin	91-94	tumor protein p53	Homo sapiens	123-126
10915781-8	2000	As a corollary, the cytosolic levels of cytochrome c were significantly higher in AS versus C cells, which correlated with approximately 2- and approximately 3-fold higher activation of caspase-9 and -3, respectively, in AS versus C cells in response to camptothecin.	Camptothecin	254-266	cytochrome c, somatic	Homo sapiens	40-52
11006574-6	2000	The addition of MG132 to sodium butyrate counteracted the effect on p53 only, while the addition of camptothecin to sodium butyrate counteracted the effect on both p53 and E2F-1.	Camptothecin	100-112	tumor protein p53 L homeolog	Xenopus laevis	164-167
11006574-6	2000	The addition of MG132 to sodium butyrate counteracted the effect on p53 only, while the addition of camptothecin to sodium butyrate counteracted the effect on both p53 and E2F-1.	Camptothecin	100-112	E2F transcription factor 1 L homeolog	Xenopus laevis	172-177
10915781-8	2000	As a corollary, the cytosolic levels of cytochrome c were significantly higher in AS versus C cells, which correlated with approximately 2- and approximately 3-fold higher activation of caspase-9 and -3, respectively, in AS versus C cells in response to camptothecin.	Camptothecin	254-266	caspase 9	Homo sapiens	186-202
11059771-6	2000	Lines lacking both P-gp and Mrp1 were (compared with wild-type lines) hypersensitive to an even broader array of drugs, including epipodophyllotoxins (4-7-fold), anthracyclines (6-7-fold), camptothecins (3-fold), arsenite (4-fold) and Vinca alkaloids, especially vincristine (28-fold).	Camptothecin	189-202	phosphoglycolate phosphatase	Mus musculus	19-23
11059771-6	2000	Lines lacking both P-gp and Mrp1 were (compared with wild-type lines) hypersensitive to an even broader array of drugs, including epipodophyllotoxins (4-7-fold), anthracyclines (6-7-fold), camptothecins (3-fold), arsenite (4-fold) and Vinca alkaloids, especially vincristine (28-fold).	Camptothecin	189-202	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	Mus musculus	28-32
11062698-2	2000	At present, an MDR-1 product, the P-170 glycoprotein, is the best known of the P-170 family and is involved in resistance to natural product-based chemotherapeutics, including taxanes, anthracyclines, vinca alkaloids, podophyllotoxins and camptothecins.	Camptothecin	239-252	ATP binding cassette subfamily B member 1	Homo sapiens	15-20
10984607-4	2000	For IAP-expressing cells treated with camptothecin, survival correlated with their intrinsic anti-caspase-3 activity.	Camptothecin	38-50	caspase 3	Homo sapiens	98-107
10924353-4	2000	HGF-transfected clones showed modestly increased proliferation rates and became more resistant to cell death and apoptosis caused by two anticancer drugs, adriamycin (ADR) and camptothecin (CPT), compared to controlvector-transfected clones.	Camptothecin	176-188	hepatocyte growth factor	Cricetulus griseus	0-3
10960439-9	2000	In addition, we found that treatment with conventional chemotherapeutic agents, doxorubicin and camptothecin, dramatically augmented TRAIL-induced cytotoxicity in most of the HCC cell lines.	Camptothecin	96-108	TNF superfamily member 10	Homo sapiens	133-138
10960439-10	2000	Actinomycin D and camptothecin almost completely suppressed NF-kappaB induction by TRAIL, whereas doxorubicin had little effect.	Camptothecin	18-30	nuclear factor kappa B subunit 1	Homo sapiens	60-69
10960439-10	2000	Actinomycin D and camptothecin almost completely suppressed NF-kappaB induction by TRAIL, whereas doxorubicin had little effect.	Camptothecin	18-30	TNF superfamily member 10	Homo sapiens	83-88
10862613-1	2000	Topoisomerase I-mediated DNA damage induced by camptothecin has been shown to induce rapid small ubiquitin-related modifier (SUMO)-1 conjugation to topoisomerase I.	Camptothecin	47-59	small ubiquitin like modifier 1	Homo sapiens	97-132
10924353-4	2000	HGF-transfected clones showed modestly increased proliferation rates and became more resistant to cell death and apoptosis caused by two anticancer drugs, adriamycin (ADR) and camptothecin (CPT), compared to controlvector-transfected clones.	Camptothecin	190-193	hepatocyte growth factor	Cricetulus griseus	0-3
10945642-4	2000	Pretreating U373 human glioblastoma cells with recombinant SF/HGF partially abrogated their cytotoxic responses to gamma irradiation, cisplatin, camptothecin, Adriamycin, and Taxol in vitro.	Camptothecin	145-157	hepatocyte growth factor	Homo sapiens	59-65
10754512-3	2000	There have been some conflicting results concerning whether annexin V binds to camptothecin (CAM)-treated HL-60 cells, a commonly used model for apoptosis.	Camptothecin	79-91	annexin A5	Homo sapiens	60-69
10839298-0	2000	Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis.	Camptothecin	26-38	mitogen-activated protein kinase 8	Homo sapiens	19-22
10839298-2	2000	Here, we provide evidence that SAPK/JNK activity is required for camptothecin sensitization to anti-Fas-induced apoptosis.	Camptothecin	65-77	mitogen-activated protein kinase 8	Homo sapiens	36-39
10839298-3	2000	Camptothecin, but not Fas ligation, was shown to activate SAPK/JNK in a time-dependent manner, and to induce c-Jun expression.	Camptothecin	0-12	mitogen-activated protein kinase 8	Homo sapiens	63-66
10839298-3	2000	Camptothecin, but not Fas ligation, was shown to activate SAPK/JNK in a time-dependent manner, and to induce c-Jun expression.	Camptothecin	0-12	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	109-114
10839298-7	2000	Antisense oligonucleotides targeted to JNK1 and JNK2 reversed the effect of camptothecin.	Camptothecin	76-88	mitogen-activated protein kinase 8	Homo sapiens	39-43
10839298-7	2000	Antisense oligonucleotides targeted to JNK1 and JNK2 reversed the effect of camptothecin.	Camptothecin	76-88	mitogen-activated protein kinase 9	Homo sapiens	48-52
10891498-7	2000	Furthermore, we found that the level of the poly(C) binding MCG10 protein is increased in cells treated with the DNA-damaging agent camptothecin in a p53-dependent manner.	Camptothecin	132-144	poly(rC) binding protein 4	Homo sapiens	60-65
10891498-7	2000	Furthermore, we found that the level of the poly(C) binding MCG10 protein is increased in cells treated with the DNA-damaging agent camptothecin in a p53-dependent manner.	Camptothecin	132-144	tumor protein p53	Homo sapiens	150-153
10887218-0	2000	Isolation of camptothecin-sensitive chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group.	Camptothecin	13-25	insulin receptor substrate 2	Cricetulus griseus	136-140
10912951-4	2000	The etoposide-resistant line with the highest P-gp level was cross-resistant also to SN-38, CPT-11 and topotecan (TPT), but not to 9-aminocamptothecin (9-AC), CPT and DX-8951f.	Camptothecin	92-95	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
10841808-1	2000	Homocamptothecin (hCPT) is an E-ring modified camptothecin (CPT) analogue bearing a methylene spacer between the alcohol and carboxyl functions of the CPT lactone.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	19-22
10841808-1	2000	Homocamptothecin (hCPT) is an E-ring modified camptothecin (CPT) analogue bearing a methylene spacer between the alcohol and carboxyl functions of the CPT lactone.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	60-63
10754512-3	2000	There have been some conflicting results concerning whether annexin V binds to camptothecin (CAM)-treated HL-60 cells, a commonly used model for apoptosis.	Camptothecin	93-96	annexin A5	Homo sapiens	60-69
10835501-1	2000	In previous studies, we established two camptothecin (CPT)-resistant sublines, HT-29 / CPT and St-4 / CPT, from the human colon cancer cell line HT-29 and the human stomach cancer cell line St-4, respectively.	Camptothecin	40-52	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	Homo sapiens	95-99
10777774-3	2000	Camptothecin induced rapid pRb and p107 phosphorylation at a Cdk4/6 phosphorylation site followed by selective loss of Rb and p107.	Camptothecin	0-12	RB transcriptional corepressor 1	Homo sapiens	27-30
10777774-3	2000	Camptothecin induced rapid pRb and p107 phosphorylation at a Cdk4/6 phosphorylation site followed by selective loss of Rb and p107.	Camptothecin	0-12	RB transcriptional corepressor like 1	Homo sapiens	35-39
10777774-3	2000	Camptothecin induced rapid pRb and p107 phosphorylation at a Cdk4/6 phosphorylation site followed by selective loss of Rb and p107.	Camptothecin	0-12	cyclin dependent kinase 6	Homo sapiens	61-67
10777774-3	2000	Camptothecin induced rapid pRb and p107 phosphorylation at a Cdk4/6 phosphorylation site followed by selective loss of Rb and p107.	Camptothecin	0-12	RB transcriptional corepressor like 1	Homo sapiens	126-130
10777774-7	2000	Finally, expression of dominant-negative versions of DP1, known to compromise E2F transcriptional activity, protects cortical neurons from death induced by camptothecin and sympathetic neurons from death evoked by UV treatment.	Camptothecin	156-168	prostaglandin D2 receptor	Homo sapiens	53-56
10937621-8	2000	Treatment of the cells with camptothecin or tumor necrosis factor-alpha plus cycloheximide significantly inhibited COL2A1 transcriptional activity.	Camptothecin	28-40	collagen type II alpha 1 chain	Homo sapiens	115-121
10835501-1	2000	In previous studies, we established two camptothecin (CPT)-resistant sublines, HT-29 / CPT and St-4 / CPT, from the human colon cancer cell line HT-29 and the human stomach cancer cell line St-4, respectively.	Camptothecin	40-52	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	Homo sapiens	190-194
10835501-1	2000	In previous studies, we established two camptothecin (CPT)-resistant sublines, HT-29 / CPT and St-4 / CPT, from the human colon cancer cell line HT-29 and the human stomach cancer cell line St-4, respectively.	Camptothecin	54-57	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	Homo sapiens	95-99
10835501-1	2000	In previous studies, we established two camptothecin (CPT)-resistant sublines, HT-29 / CPT and St-4 / CPT, from the human colon cancer cell line HT-29 and the human stomach cancer cell line St-4, respectively.	Camptothecin	54-57	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	Homo sapiens	190-194
10811474-3	2000	Over a 2-4 day treatment period with GCV or the other four drugs, protein levels of the apoptosis agonist Bak increased 1.5- to 3-fold, whereas a corresponding decrease in the levels of the apoptosis antagonist, Bcl-X(L), was observed in butyrate-, CPT-, and 7-hydroxystaurosporine (UCN-01)-treated cells.	Camptothecin	249-252	BCL2 like 1	Homo sapiens	212-220
10757806-5	2000	Although normal cells and wild-type p53-expressing tumor cells showed similar responses to actinomycin D and camptothecin treatment, the transcriptional activity of stabilized p53 induced by deferoxamine mesylate, which mimics hypoxia, in normal cells was lost in all three tumor cell lines tested.	Camptothecin	109-121	tumor protein p53	Homo sapiens	36-39
10772918-10	2000	Furthermore, Bax-sigma overexpression increased cell death induced by various concentrations of genotoxic agents with the most pronounced effect occurring at low camptothecin and vinblastine dose levels.	Camptothecin	162-174	BCL2 associated X, apoptosis regulator	Homo sapiens	13-16
10759568-2	2000	In the current study, we show that treatment of mammalian cells or yeast cells expressing human DNA TOP1 with camptothecin (CPT) induces covalent modification of the TOP1 by SUMO-1/Smt3p, a ubiquitin-like protein.	Camptothecin	110-122	small ubiquitin like modifier 1	Homo sapiens	174-180
10759568-2	2000	In the current study, we show that treatment of mammalian cells or yeast cells expressing human DNA TOP1 with camptothecin (CPT) induces covalent modification of the TOP1 by SUMO-1/Smt3p, a ubiquitin-like protein.	Camptothecin	110-122	small ubiquitin like modifier 1	Homo sapiens	181-186
10759568-2	2000	In the current study, we show that treatment of mammalian cells or yeast cells expressing human DNA TOP1 with camptothecin (CPT) induces covalent modification of the TOP1 by SUMO-1/Smt3p, a ubiquitin-like protein.	Camptothecin	124-127	small ubiquitin like modifier 1	Homo sapiens	174-180
10759568-2	2000	In the current study, we show that treatment of mammalian cells or yeast cells expressing human DNA TOP1 with camptothecin (CPT) induces covalent modification of the TOP1 by SUMO-1/Smt3p, a ubiquitin-like protein.	Camptothecin	124-127	small ubiquitin like modifier 1	Homo sapiens	181-186
10811474-3	2000	Over a 2-4 day treatment period with GCV or the other four drugs, protein levels of the apoptosis agonist Bak increased 1.5- to 3-fold, whereas a corresponding decrease in the levels of the apoptosis antagonist, Bcl-X(L), was observed in butyrate-, CPT-, and 7-hydroxystaurosporine (UCN-01)-treated cells.	Camptothecin	249-252	BCL2 antagonist/killer 1	Homo sapiens	106-109
10749144-3	2000	Activation of the gadd45 gene was observed when camptothecin was added to cells containing p53 in the absence of a further increase in the p53 level.	Camptothecin	48-60	growth arrest and DNA damage inducible alpha	Homo sapiens	18-24
10722720-1	2000	We found that antitumor drugs such as cytotrienin A, camptothecin, taxol, and 5-fluorouracil induced the activation of a 36-kDa protein kinase (p36 myelin basic protein (MBP) kinase) during apoptosis in human promyelocytic leukemia HL-60 cells.	Camptothecin	53-65	myelin basic protein	Homo sapiens	170-173
10778981-1	2000	The transcription factor complex E2F-1/DP-1 regulates the G1-to-S-phase transition and has been associated with sensitivity to the S-phase-specific anticancer agents camptothecin and etoposide, which poison DNA topoisomerase I and II, respectively.	Camptothecin	166-178	E2F transcription factor 1	Homo sapiens	33-38
10778981-1	2000	The transcription factor complex E2F-1/DP-1 regulates the G1-to-S-phase transition and has been associated with sensitivity to the S-phase-specific anticancer agents camptothecin and etoposide, which poison DNA topoisomerase I and II, respectively.	Camptothecin	166-178	transcription factor Dp-1	Homo sapiens	39-43
10778981-5	2000	This indicates that camptothecin-induced toxicity in this model is due to the activation of an E2F-1/ DP-1-induced post-DNA damage pathway rather than an increase in the number of replication forks caused by the S-phase initiation.	Camptothecin	20-32	E2F transcription factor 1	Homo sapiens	95-100
10778981-5	2000	This indicates that camptothecin-induced toxicity in this model is due to the activation of an E2F-1/ DP-1-induced post-DNA damage pathway rather than an increase in the number of replication forks caused by the S-phase initiation.	Camptothecin	20-32	transcription factor Dp-1	Homo sapiens	102-106
10749144-3	2000	Activation of the gadd45 gene was observed when camptothecin was added to cells containing p53 in the absence of a further increase in the p53 level.	Camptothecin	48-60	tumor protein p53	Homo sapiens	91-94
10749144-7	2000	Interestingly, after camptothecin treatment, increased DNase I sensitivity was detected at the gadd45 promoter, suggesting that an undetermined DNA damage signal is involved in inducing chromatin remodeling at the gadd45 promoter while cooperating with p53 to activate gadd45 transcription.	Camptothecin	21-33	growth arrest and DNA damage inducible alpha	Homo sapiens	95-101
10749144-7	2000	Interestingly, after camptothecin treatment, increased DNase I sensitivity was detected at the gadd45 promoter, suggesting that an undetermined DNA damage signal is involved in inducing chromatin remodeling at the gadd45 promoter while cooperating with p53 to activate gadd45 transcription.	Camptothecin	21-33	growth arrest and DNA damage inducible alpha	Homo sapiens	214-220
10749144-7	2000	Interestingly, after camptothecin treatment, increased DNase I sensitivity was detected at the gadd45 promoter, suggesting that an undetermined DNA damage signal is involved in inducing chromatin remodeling at the gadd45 promoter while cooperating with p53 to activate gadd45 transcription.	Camptothecin	21-33	tumor protein p53	Homo sapiens	253-256
10749144-7	2000	Interestingly, after camptothecin treatment, increased DNase I sensitivity was detected at the gadd45 promoter, suggesting that an undetermined DNA damage signal is involved in inducing chromatin remodeling at the gadd45 promoter while cooperating with p53 to activate gadd45 transcription.	Camptothecin	21-33	growth arrest and DNA damage inducible alpha	Homo sapiens	214-220
10692111-0	2000	p53-dependent apoptosis in melanoma cells after treatment with camptothecin.	Camptothecin	63-75	tumor protein p53	Homo sapiens	0-3
10845773-2	2000	We show here that this cleavage activity is lacking in camptothecin-treated caspase 3-deficient neurons.	Camptothecin	55-67	caspase 3	Homo sapiens	76-85
10845773-3	2000	Moreover, we report that death of camptothecin-treated caspase 3-deficient neurons cultured from E16 embryos is delayed and that no significant increase in survival is observed with cotreatment with the general caspase inhibitor BAF.	Camptothecin	34-46	caspase 3	Homo sapiens	55-64
10845773-3	2000	Moreover, we report that death of camptothecin-treated caspase 3-deficient neurons cultured from E16 embryos is delayed and that no significant increase in survival is observed with cotreatment with the general caspase inhibitor BAF.	Camptothecin	34-46	BAF nuclear assembly factor 1	Homo sapiens	229-232
10845773-4	2000	These results indicate that caspase-dependent death of camptothecin-treated cortical neurons requires caspase 3 activity.	Camptothecin	55-67	caspase 3	Homo sapiens	102-111
10845773-6	2000	However, Bax-dependent cytochrome c release still occurs in camptothecin-treated caspase 3-deficient cortical neurons.	Camptothecin	60-72	BCL2 associated X, apoptosis regulator	Homo sapiens	9-12
10845773-6	2000	However, Bax-dependent cytochrome c release still occurs in camptothecin-treated caspase 3-deficient cortical neurons.	Camptothecin	60-72	cytochrome c, somatic	Homo sapiens	23-35
10845773-6	2000	However, Bax-dependent cytochrome c release still occurs in camptothecin-treated caspase 3-deficient cortical neurons.	Camptothecin	60-72	caspase 3	Homo sapiens	81-90
10712236-3	2000	This study examines the involvement of polyamines in the induction of apoptosis by the DNA topoisomerase I inhibitor, camptothecin.	Camptothecin	118-130	DNA topoisomerase I	Rattus norvegicus	87-106
10692111-8	2000	Our results indicate that overexpression of the mutant p53 increased the growth rate of MMAN cells, reduced the sensitivity to camptothecin, and lowered drug-induced apoptosis by 2-3-fold.	Camptothecin	127-139	tumor protein p53	Homo sapiens	55-58
10692111-10	2000	Furthermore, camptothecin treatment reduced bcl-2 and P-glycoprotein expression in wild-type p53 MMAN cells, but not cells overexpressing mutant p53.	Camptothecin	13-25	BCL2 apoptosis regulator	Homo sapiens	44-49
10692111-10	2000	Furthermore, camptothecin treatment reduced bcl-2 and P-glycoprotein expression in wild-type p53 MMAN cells, but not cells overexpressing mutant p53.	Camptothecin	13-25	ATP binding cassette subfamily B member 1	Homo sapiens	54-68
10692111-10	2000	Furthermore, camptothecin treatment reduced bcl-2 and P-glycoprotein expression in wild-type p53 MMAN cells, but not cells overexpressing mutant p53.	Camptothecin	13-25	tumor protein p53	Homo sapiens	93-96
10774745-4	2000	They were also slightly more resistant than the parental cell (AML-2/WT) to etoposide, camptothecin and daunorubicin.	Camptothecin	87-99	RUNX family transcription factor 3	Homo sapiens	63-68
10666341-3	2000	The aim of the present study was to reveal cell cycle phase specificity as well as the temporal and sequence relationships of PARP cleavage vis-a-vis DNA fragmentation in two model systems of apoptosis, one induced by DNA damage via cell treatment with camptothecin (CPT) (mitochondria-induced pathway) and another by the cytotoxic ligand tumor necrosis factor alpha (TNF-alpha) (cell surface death receptor pathway).	Camptothecin	253-265	poly(ADP-ribose) polymerase 1	Homo sapiens	126-130
10666341-3	2000	The aim of the present study was to reveal cell cycle phase specificity as well as the temporal and sequence relationships of PARP cleavage vis-a-vis DNA fragmentation in two model systems of apoptosis, one induced by DNA damage via cell treatment with camptothecin (CPT) (mitochondria-induced pathway) and another by the cytotoxic ligand tumor necrosis factor alpha (TNF-alpha) (cell surface death receptor pathway).	Camptothecin	253-265	tumor necrosis factor	Homo sapiens	368-377
10666341-3	2000	The aim of the present study was to reveal cell cycle phase specificity as well as the temporal and sequence relationships of PARP cleavage vis-a-vis DNA fragmentation in two model systems of apoptosis, one induced by DNA damage via cell treatment with camptothecin (CPT) (mitochondria-induced pathway) and another by the cytotoxic ligand tumor necrosis factor alpha (TNF-alpha) (cell surface death receptor pathway).	Camptothecin	267-270	poly(ADP-ribose) polymerase 1	Homo sapiens	126-130
10713734-0	2000	The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes.	Camptothecin	29-41	Fas cell surface death receptor	Homo sapiens	65-69
10713734-5	2000	Although etoposide and camptothecin induced CD95-ligand mRNA expression, drug-induced apoptosis of activated human lymphocytes was not inhibited by CD95 antagonists.	Camptothecin	23-35	Fas ligand	Homo sapiens	44-55
10713734-5	2000	Although etoposide and camptothecin induced CD95-ligand mRNA expression, drug-induced apoptosis of activated human lymphocytes was not inhibited by CD95 antagonists.	Camptothecin	23-35	Fas cell surface death receptor	Homo sapiens	44-48
11012087-5	2000	Consistent with a partial G1 arrest, the ZF87/MAZ-expressing cells show a reduced sensitivity to the S phase specific chemotherapeutic agent camptothecin.	Camptothecin	141-153	MYC associated zinc finger protein	Homo sapiens	41-45
11193908-0	2000	Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance.	Camptothecin	31-43	small ubiquitin like modifier 1	Homo sapiens	11-17
11193908-0	2000	Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance.	Camptothecin	31-43	CLRN1 antisense RNA 1	Homo sapiens	23-27
11012087-5	2000	Consistent with a partial G1 arrest, the ZF87/MAZ-expressing cells show a reduced sensitivity to the S phase specific chemotherapeutic agent camptothecin.	Camptothecin	141-153	MYC associated zinc finger protein	Homo sapiens	46-49
10597196-0	1999	p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line.	Camptothecin	76-88	cyclin dependent kinase inhibitor 1A	Homo sapiens	8-12
10663644-5	2000	RESULTS: UCN-01, a specific inhibitor of protein kinase C (PKC) presently in clinical trials, abrogated CPT-induced activation of S and G(2) checkpoints in human MDA-MB-231 and GI 101A breast carcinoma cells, both of which are mutants for the p53 gene.	Camptothecin	104-107	tumor protein p53	Homo sapiens	243-246
10626806-5	1999	Colon carcinoma cell lines could be further sensitized to TRAIL-induced apoptosis in vitro by the addition of the chemotherapeutic agent camptothecin.	Camptothecin	137-149	TNF superfamily member 10	Homo sapiens	58-63
10626806-6	1999	Moreover, the combination of TRAIL and CPT-11, a water-soluble analogue of camptothecin, greatly enhanced the antitumor activity of TRAIL in vivo.	Camptothecin	75-87	TNF superfamily member 10	Homo sapiens	29-34
10626806-6	1999	Moreover, the combination of TRAIL and CPT-11, a water-soluble analogue of camptothecin, greatly enhanced the antitumor activity of TRAIL in vivo.	Camptothecin	75-87	TNF superfamily member 10	Homo sapiens	132-137
10803925-2	2000	A COMPARE analysis using the NCI 60 cell line drug-screening panel suggested that there were similarities in the mechanisms of action of camptothecin analogs and TS inhibitors.	Camptothecin	137-149	thymidylate synthetase	Homo sapiens	162-164
10644891-7	2000	The representative cell line NCI-H1437 cells transfected with wild-type p53 gene (H1437/wtp53) showed a dramatic increase in susceptibility to three anticancer agents (7-fold to cisplatin, 21-fold to etoposide, and 20-fold to camptothecin) compared to untransfected or neotransfected H1437 cells.	Camptothecin	226-238	tumor protein p53	Homo sapiens	72-75
10597196-0	1999	p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line.	Camptothecin	76-88	BCL2 apoptosis regulator	Homo sapiens	34-39
10562548-6	1999	Importantly, restoration of Par-4 levels to normal in Ras-transformed cells makes these cells sensitive to the pro-apoptotic actions of tumor necrosis factor-alpha under conditions in which PI 3-kinase is inhibited and also severely impairs colony formation in soft agar and tumor development in nude mice, as well as increases the sensitivity of these tumors to camptothecin.	Camptothecin	363-375	PRKC, apoptosis, WT1, regulator	Mus musculus	28-33
10585266-5	1999	p53(V143A) inhibited the camptothecin-induced accumulation of p21(WAF1/CIP1) in cell lines with p53 functional wild-type activity, but not in cell lines lacking p53 activity, consistent with a transdominant-negative effect of p53(V143A).	Camptothecin	25-37	tumor protein p53	Homo sapiens	0-3
10585266-5	1999	p53(V143A) inhibited the camptothecin-induced accumulation of p21(WAF1/CIP1) in cell lines with p53 functional wild-type activity, but not in cell lines lacking p53 activity, consistent with a transdominant-negative effect of p53(V143A).	Camptothecin	25-37	cyclin dependent kinase inhibitor 1A	Homo sapiens	62-65
10585266-5	1999	p53(V143A) inhibited the camptothecin-induced accumulation of p21(WAF1/CIP1) in cell lines with p53 functional wild-type activity, but not in cell lines lacking p53 activity, consistent with a transdominant-negative effect of p53(V143A).	Camptothecin	25-37	cyclin dependent kinase inhibitor 1A	Homo sapiens	66-70
10585266-5	1999	p53(V143A) inhibited the camptothecin-induced accumulation of p21(WAF1/CIP1) in cell lines with p53 functional wild-type activity, but not in cell lines lacking p53 activity, consistent with a transdominant-negative effect of p53(V143A).	Camptothecin	25-37	cyclin dependent kinase inhibitor 1A	Homo sapiens	71-75
10585266-5	1999	p53(V143A) inhibited the camptothecin-induced accumulation of p21(WAF1/CIP1) in cell lines with p53 functional wild-type activity, but not in cell lines lacking p53 activity, consistent with a transdominant-negative effect of p53(V143A).	Camptothecin	25-37	tumor protein p53	Homo sapiens	96-99
10585266-5	1999	p53(V143A) inhibited the camptothecin-induced accumulation of p21(WAF1/CIP1) in cell lines with p53 functional wild-type activity, but not in cell lines lacking p53 activity, consistent with a transdominant-negative effect of p53(V143A).	Camptothecin	25-37	tumor protein p53	Homo sapiens	96-99
10585266-5	1999	p53(V143A) inhibited the camptothecin-induced accumulation of p21(WAF1/CIP1) in cell lines with p53 functional wild-type activity, but not in cell lines lacking p53 activity, consistent with a transdominant-negative effect of p53(V143A).	Camptothecin	25-37	tumor protein p53	Homo sapiens	96-99
10606239-0	1999	Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.	Camptothecin	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	107-110
10606239-0	1999	Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.	Camptothecin	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	150-153
10606239-13	1999	The lack of selection for higher levels of UGT capacity in the colon cells suggests that high levels of expression of MXR alone are sufficient to confer resistance to the camptothecins.	Camptothecin	171-184	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	118-121
10569939-1	1999	Homocamptothecin (hCPT) contains a seven-membered beta-hydroxylactone in place of the conventional six-membered alpha-hydroxylactone ring found in camptothecin and its tumor active analogues, including topotecan and irinotecan.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	18-22
10544019-5	1999	Treating SNB-78 cells with antisense oligonucleotide against Apollon reduced the expression of Apollon protein, and significantly sensitized the cells to apoptosis induced by cisplatin and camptothecin.	Camptothecin	189-201	baculoviral IAP repeat containing 6	Homo sapiens	61-68
10544019-5	1999	Treating SNB-78 cells with antisense oligonucleotide against Apollon reduced the expression of Apollon protein, and significantly sensitized the cells to apoptosis induced by cisplatin and camptothecin.	Camptothecin	189-201	baculoviral IAP repeat containing 6	Homo sapiens	95-102
10536167-0	1999	Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.	Camptothecin	115-127	tumor protein p53	Homo sapiens	28-31
10536167-4	1999	The initial transient cell arrest at the G1 checkpoint seen at 8-16 h of treatment with 0.15 microM CPT was accompanied by the rapid accumulation of p53 (preventable by cycloheximide) in the nucleus; the rise (&gt;20-fold) in p53 was maximal for S phase cells.	Camptothecin	100-103	tumor protein p53	Homo sapiens	149-152
10536167-4	1999	The initial transient cell arrest at the G1 checkpoint seen at 8-16 h of treatment with 0.15 microM CPT was accompanied by the rapid accumulation of p53 (preventable by cycloheximide) in the nucleus; the rise (&gt;20-fold) in p53 was maximal for S phase cells.	Camptothecin	100-103	tumor protein p53	Homo sapiens	226-229
10428835-3	1999	Here, we report that brain-derived neurotrophic factor (BDNF) protects cortical neurons against apoptosis induced by camptothecin or serum deprivation and activates the extracellular-signal-regulated kinase (ERK) and the phosphatidylinositol 3-kinase (PI 3-kinase) pathways.	Camptothecin	117-129	brain derived neurotrophic factor	Homo sapiens	21-54
10527882-6	1999	GFP-NPM(N) dissociates from nucleoli after treatments with daunomycin, actinomycin D, camptothecin, and toyocamycin.	Camptothecin	86-98	nucleophosmin 1	Homo sapiens	4-7
10523305-8	1999	Finally, we observed that Ref-1 cooperates with a DNA-damaging compound, camptothecin, to stimulate the transcriptional activity of p53.	Camptothecin	73-85	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	26-31
10523305-8	1999	Finally, we observed that Ref-1 cooperates with a DNA-damaging compound, camptothecin, to stimulate the transcriptional activity of p53.	Camptothecin	73-85	tumor protein p53	Homo sapiens	132-135
10573208-8	1999	After 24 h, TT2 induces as much DNA cleavage as camptothecin and DAU, two anti-cancer drugs producing DNA strand breaks and known to respectively inhibit DNA topoisomerase I and II activities.	Camptothecin	48-60	topoisomerase (DNA) I	Mus musculus	154-173
10428835-4	1999	Using pharmacological agents and transient transfection with dominant interfering or constitutive active components of the ERK or the PI 3-kinase pathway, we demonstrate that the ERK pathway plays a major role in BDNF neuroprotection against camptothecin.	Camptothecin	242-254	mitogen-activated protein kinase 1	Homo sapiens	179-182
10428835-4	1999	Using pharmacological agents and transient transfection with dominant interfering or constitutive active components of the ERK or the PI 3-kinase pathway, we demonstrate that the ERK pathway plays a major role in BDNF neuroprotection against camptothecin.	Camptothecin	242-254	brain derived neurotrophic factor	Homo sapiens	213-217
10428835-3	1999	Here, we report that brain-derived neurotrophic factor (BDNF) protects cortical neurons against apoptosis induced by camptothecin or serum deprivation and activates the extracellular-signal-regulated kinase (ERK) and the phosphatidylinositol 3-kinase (PI 3-kinase) pathways.	Camptothecin	117-129	brain derived neurotrophic factor	Homo sapiens	56-60
10428835-5	1999	Furthermore, ERK is activated in cortical neurons during camptothecin-induced apoptosis, and inhibition of ERK increases apoptosis.	Camptothecin	57-69	mitogen-activated protein kinase 1	Homo sapiens	13-16
20654516-6	1999	Following incubation of rat primary hepatocytes with camptothecin (CPT), a time- and concentration-dependent increase of mRNA expression was measured for bax at approximately 350% and p53 at approximately 600%.	Camptothecin	53-65	BCL2 associated X, apoptosis regulator	Rattus norvegicus	154-157
10455888-11	1999	CONCLUSIONS: Treatment with CPT effectively inhibited the growth of the human gastric cancer SIIA; the mechanism involved was induction of apoptosis mediated by up-regulation of p53, p21Waf1/Cip1, and p27Kip1 and the down-regulation of Bcl-2 and Bcl-XL.	Camptothecin	28-31	tumor protein p53	Homo sapiens	178-181
10455888-11	1999	CONCLUSIONS: Treatment with CPT effectively inhibited the growth of the human gastric cancer SIIA; the mechanism involved was induction of apoptosis mediated by up-regulation of p53, p21Waf1/Cip1, and p27Kip1 and the down-regulation of Bcl-2 and Bcl-XL.	Camptothecin	28-31	cyclin dependent kinase inhibitor 1A	Homo sapiens	191-195
20654516-6	1999	Following incubation of rat primary hepatocytes with camptothecin (CPT), a time- and concentration-dependent increase of mRNA expression was measured for bax at approximately 350% and p53 at approximately 600%.	Camptothecin	53-65	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	184-187
10455888-11	1999	CONCLUSIONS: Treatment with CPT effectively inhibited the growth of the human gastric cancer SIIA; the mechanism involved was induction of apoptosis mediated by up-regulation of p53, p21Waf1/Cip1, and p27Kip1 and the down-regulation of Bcl-2 and Bcl-XL.	Camptothecin	28-31	cyclin dependent kinase inhibitor 1B	Homo sapiens	201-208
10455888-11	1999	CONCLUSIONS: Treatment with CPT effectively inhibited the growth of the human gastric cancer SIIA; the mechanism involved was induction of apoptosis mediated by up-regulation of p53, p21Waf1/Cip1, and p27Kip1 and the down-regulation of Bcl-2 and Bcl-XL.	Camptothecin	28-31	BCL2 apoptosis regulator	Homo sapiens	236-241
10455888-11	1999	CONCLUSIONS: Treatment with CPT effectively inhibited the growth of the human gastric cancer SIIA; the mechanism involved was induction of apoptosis mediated by up-regulation of p53, p21Waf1/Cip1, and p27Kip1 and the down-regulation of Bcl-2 and Bcl-XL.	Camptothecin	28-31	BCL2 like 1	Homo sapiens	246-252
20654516-6	1999	Following incubation of rat primary hepatocytes with camptothecin (CPT), a time- and concentration-dependent increase of mRNA expression was measured for bax at approximately 350% and p53 at approximately 600%.	Camptothecin	67-70	BCL2 associated X, apoptosis regulator	Rattus norvegicus	154-157
20654516-6	1999	Following incubation of rat primary hepatocytes with camptothecin (CPT), a time- and concentration-dependent increase of mRNA expression was measured for bax at approximately 350% and p53 at approximately 600%.	Camptothecin	67-70	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	184-187
20654516-7	1999	Further, camptothecin and topotecan (TPT) were compared for their effect on bax mRNA expression.	Camptothecin	9-21	BCL2 associated X, apoptosis regulator	Rattus norvegicus	76-79
20654516-8	1999	Whereas camptothecin induced a continuous increase in bax transcription from 0.1 mum to 10 mum, only the highest concentration of topotecan (10 mum) led to a comparable increase of bax transcription.	Camptothecin	8-20	BCL2 associated X, apoptosis regulator	Rattus norvegicus	54-57
10383158-1	1999	Homocamptothecin (hCPT) is a semisynthetic analogue of camptothecin (CPT) with a seven-membered beta-hydroxylactone resulting from the insertion of a methylene spacer between the alcohol moiety and the carboxyl function of the naturally occurring six-membered alpha-hydroxylactone of CPT.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	18-22
10383158-1	1999	Homocamptothecin (hCPT) is a semisynthetic analogue of camptothecin (CPT) with a seven-membered beta-hydroxylactone resulting from the insertion of a methylene spacer between the alcohol moiety and the carboxyl function of the naturally occurring six-membered alpha-hydroxylactone of CPT.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	19-22
10383158-1	1999	Homocamptothecin (hCPT) is a semisynthetic analogue of camptothecin (CPT) with a seven-membered beta-hydroxylactone resulting from the insertion of a methylene spacer between the alcohol moiety and the carboxyl function of the naturally occurring six-membered alpha-hydroxylactone of CPT.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	69-72
10205159-4	1999	Caspase-6 was found to co-purify with caspase-3 as part of a multiprotein activation complex from extracts of camptothecin-treated Jurkat cells.	Camptothecin	110-122	caspase 6	Homo sapiens	0-9
10408840-4	1999	Indeed, poly(ADP-Ribose) polymerase was shown to be proteolytically cleaved in cells treated with camptothecin plus anti-Fas, but not in cells treated with anti-Fas only.	Camptothecin	98-110	poly(ADP-ribose) polymerase 1	Homo sapiens	8-35
10344722-5	1999	RESULTS: Of 26 agents screened, BRCA1 and BRCA2 mRNA reductions were observed in both cell lines after exposure to adriamycin (ADR), camptothecin (CPT), sodium selenite (SLN), and ultraviolet radiation (UV), while nitrogen mustard (HN2) caused mRNA reduction in DU-145 but not in Tsu-Prl.	Camptothecin	133-145	BRCA1 DNA repair associated	Homo sapiens	32-37
10344722-5	1999	RESULTS: Of 26 agents screened, BRCA1 and BRCA2 mRNA reductions were observed in both cell lines after exposure to adriamycin (ADR), camptothecin (CPT), sodium selenite (SLN), and ultraviolet radiation (UV), while nitrogen mustard (HN2) caused mRNA reduction in DU-145 but not in Tsu-Prl.	Camptothecin	133-145	BRCA2 DNA repair associated	Homo sapiens	42-47
10344722-5	1999	RESULTS: Of 26 agents screened, BRCA1 and BRCA2 mRNA reductions were observed in both cell lines after exposure to adriamycin (ADR), camptothecin (CPT), sodium selenite (SLN), and ultraviolet radiation (UV), while nitrogen mustard (HN2) caused mRNA reduction in DU-145 but not in Tsu-Prl.	Camptothecin	147-150	BRCA1 DNA repair associated	Homo sapiens	32-37
10344722-5	1999	RESULTS: Of 26 agents screened, BRCA1 and BRCA2 mRNA reductions were observed in both cell lines after exposure to adriamycin (ADR), camptothecin (CPT), sodium selenite (SLN), and ultraviolet radiation (UV), while nitrogen mustard (HN2) caused mRNA reduction in DU-145 but not in Tsu-Prl.	Camptothecin	147-150	BRCA2 DNA repair associated	Homo sapiens	42-47
10472781-3	1999	(2) Camptothecin elicited similar trends on Bcl-2 and Bax as Adriamycin, while etoposide, at 50-100 fold (1-5 microM) the effective concentration of Adriamycin and camptothecin, only resulted in an increase in Bax mRNA levels.	Camptothecin	4-16	BCL2 apoptosis regulator	Homo sapiens	44-49
10472781-3	1999	(2) Camptothecin elicited similar trends on Bcl-2 and Bax as Adriamycin, while etoposide, at 50-100 fold (1-5 microM) the effective concentration of Adriamycin and camptothecin, only resulted in an increase in Bax mRNA levels.	Camptothecin	4-16	BCL2 associated X, apoptosis regulator	Homo sapiens	54-57
10472781-4	1999	(3) Adriamycin and camptothecin, but not etoposide, were effective in suppressing estradiol-stimulated increases in Bcl-2 mRNA levels.	Camptothecin	19-31	BCL2 apoptosis regulator	Homo sapiens	116-121
10205159-4	1999	Caspase-6 was found to co-purify with caspase-3 as part of a multiprotein activation complex from extracts of camptothecin-treated Jurkat cells.	Camptothecin	110-122	caspase 3	Homo sapiens	38-47
10327072-5	1999	We found that cells from Ataxia Telangiectasia patients exhibit a defect in NF-kappaB activation in response to treatment with camptothecin, a topoisomerase I poison.	Camptothecin	127-139	nuclear factor kappa B subunit 1	Homo sapiens	76-85
10101025-1	1999	DNA topoisomerase I (top I) is the target of the antitumor drug camptothecin (CPT) and its analogs.	Camptothecin	64-76	DNA topoisomerase I	Homo sapiens	4-19
10101025-1	1999	DNA topoisomerase I (top I) is the target of the antitumor drug camptothecin (CPT) and its analogs.	Camptothecin	64-76	DNA topoisomerase I	Homo sapiens	21-26
10101025-1	1999	DNA topoisomerase I (top I) is the target of the antitumor drug camptothecin (CPT) and its analogs.	Camptothecin	78-81	DNA topoisomerase I	Homo sapiens	4-19
10101025-1	1999	DNA topoisomerase I (top I) is the target of the antitumor drug camptothecin (CPT) and its analogs.	Camptothecin	78-81	DNA topoisomerase I	Homo sapiens	21-26
10206278-2	1999	HL-60 cells exposed to okadaic acid and camptothecin underwent morphological and biochemical changes typical of apoptosis, including internucleosomal DNA fragmentation and PAI-2 cleavage.	Camptothecin	40-52	serpin family B member 2	Homo sapiens	172-177
10206278-4	1999	In camptothecin-treated cells, PAI-2 cleavage was an early event, detectable after 2 h of treatment, and preceding internucleosomal DNA fragmentation.	Camptothecin	3-15	serpin family B member 2	Homo sapiens	31-36
10206278-5	1999	The caspase I selective protease inhibitor, YVAD-cmk, inhibited internucleosomal DNA fragmentation and PAI-2 cleavage of okadaic acid and camptothecin-induced apoptotic cells.	Camptothecin	138-150	C-X-C motif chemokine ligand 9	Homo sapiens	49-52
10206278-5	1999	The caspase I selective protease inhibitor, YVAD-cmk, inhibited internucleosomal DNA fragmentation and PAI-2 cleavage of okadaic acid and camptothecin-induced apoptotic cells.	Camptothecin	138-150	serpin family B member 2	Homo sapiens	103-108
10206278-6	1999	YVAD-cmk rather sensitively and non-toxically inhibited camptothecin-induced morphology, but not okadaic acid-induced morphology.	Camptothecin	56-68	C-X-C motif chemokine ligand 9	Homo sapiens	5-8
10327072-7	1999	Ectopic expression of the ATM protein in AT cells increases the activation of NF-kappaB in response to camptothecin.	Camptothecin	103-115	ATM serine/threonine kinase	Homo sapiens	26-29
10327072-7	1999	Ectopic expression of the ATM protein in AT cells increases the activation of NF-kappaB in response to camptothecin.	Camptothecin	103-115	nuclear factor kappa B subunit 1	Homo sapiens	78-87
9927052-8	1999	Only the expression of MEKK1-DN, not Vit C treatment, blocked the JNK activity induced by CPT, Vbeta-16, or GL331.	Camptothecin	90-93	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	23-28
10066379-1	1999	Treatment of 26L cells, a subclone obtained from U937 cells, with TNF-alpha or DNA-damaging agents such as teniposide (VM26) and camptothecin (CPT) induced morphologically and biochemically typical apoptotic changes, including the activation of procaspase-3.	Camptothecin	129-141	caspase 3	Homo sapiens	245-257
10066379-1	1999	Treatment of 26L cells, a subclone obtained from U937 cells, with TNF-alpha or DNA-damaging agents such as teniposide (VM26) and camptothecin (CPT) induced morphologically and biochemically typical apoptotic changes, including the activation of procaspase-3.	Camptothecin	143-146	tumor necrosis factor	Homo sapiens	66-75
10066379-1	1999	Treatment of 26L cells, a subclone obtained from U937 cells, with TNF-alpha or DNA-damaging agents such as teniposide (VM26) and camptothecin (CPT) induced morphologically and biochemically typical apoptotic changes, including the activation of procaspase-3.	Camptothecin	143-146	caspase 3	Homo sapiens	245-257
10066793-0	1999	The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin.	Camptothecin	97-109	terminal nucleotidyltransferase 4A	Homo sapiens	40-44
10066793-3	1999	We report here that two genes required for sister chromatid cohesion, TRF4 and MCD1/SCC1, are also required to repair camptothecin-mediated damage to DNA.	Camptothecin	118-130	terminal nucleotidyltransferase 4A	Homo sapiens	70-74
10066793-3	1999	We report here that two genes required for sister chromatid cohesion, TRF4 and MCD1/SCC1, are also required to repair camptothecin-mediated damage to DNA.	Camptothecin	118-130	RAD21 cohesin complex component	Homo sapiens	79-83
10066793-3	1999	We report here that two genes required for sister chromatid cohesion, TRF4 and MCD1/SCC1, are also required to repair camptothecin-mediated damage to DNA.	Camptothecin	118-130	RAD21 cohesin complex component	Homo sapiens	84-88
10066793-4	1999	The hypersensitivity to camptothecin in the trf4 mutant does not result from elevated expression of DNA topoisomerase I.	Camptothecin	24-36	terminal nucleotidyltransferase 4A	Homo sapiens	44-48
10066793-6	1999	Suppression of camptothecin hypersensitivity in the trf4 mutant by gene overexpression resulted in the isolation of three genes: another member of the TRF4 gene family, TRF5, and two genes that may influence higher order chromosome structure, ZDS1 and ZDS2.	Camptothecin	15-27	terminal nucleotidyltransferase 4A	Homo sapiens	52-56
10066793-6	1999	Suppression of camptothecin hypersensitivity in the trf4 mutant by gene overexpression resulted in the isolation of three genes: another member of the TRF4 gene family, TRF5, and two genes that may influence higher order chromosome structure, ZDS1 and ZDS2.	Camptothecin	15-27	terminal nucleotidyltransferase 4A	Homo sapiens	151-155
10066793-9	1999	The evolutionary conservation of TRF4 suggests that it may also influence mammalian cell sensitivity to camptothecin.	Camptothecin	104-116	terminal nucleotidyltransferase 4A	Homo sapiens	33-37
10359142-4	1999	To explore the molecular basis for synergy in glioma cells, we focused on one glioma cell line (U87) in which even sub-cytotoxic doses of CPT potentiated the action of VP-16.	Camptothecin	138-141	host cell factor C1	Homo sapiens	168-173
10064605-0	1999	Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.	Camptothecin	35-47	replication protein A1	Homo sapiens	75-78
10064605-0	1999	Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.	Camptothecin	35-47	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	82-110
10064605-0	1999	Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.	Camptothecin	35-47	replication protein A1	Homo sapiens	127-130
10064605-0	1999	Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.	Camptothecin	35-47	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	131-137
10064605-2	1999	In human cells treated with the topoisomerase inhibitors camptothecin or etoposide (VP-16), we find that RPA2, the middle-sized subunit of RPA, becomes rapidly phosphorylated.	Camptothecin	57-69	replication protein A2	Homo sapiens	105-109
10064605-2	1999	In human cells treated with the topoisomerase inhibitors camptothecin or etoposide (VP-16), we find that RPA2, the middle-sized subunit of RPA, becomes rapidly phosphorylated.	Camptothecin	57-69	replication protein A1	Homo sapiens	105-108
10064605-4	1999	RPA2 phosphorylation in response to camptothecin required ongoing DNA replication.	Camptothecin	36-48	replication protein A2	Homo sapiens	0-4
10064605-5	1999	Camptothecin itself partially inhibited DNA synthesis, and this inhibition followed the same kinetics as DNA-PK activation and RPA2 phosphorylation.	Camptothecin	0-12	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	105-111
10064605-5	1999	Camptothecin itself partially inhibited DNA synthesis, and this inhibition followed the same kinetics as DNA-PK activation and RPA2 phosphorylation.	Camptothecin	0-12	replication protein A2	Homo sapiens	127-131
10064605-6	1999	DNA-PK activation and RPA2 phosphorylation were prevented by the cell-cycle checkpoint abrogator 7-hydroxystaurosporine (UCN-01), which markedly potentiates camptothecin cytotoxicity.	Camptothecin	157-169	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	0-6
10064605-6	1999	DNA-PK activation and RPA2 phosphorylation were prevented by the cell-cycle checkpoint abrogator 7-hydroxystaurosporine (UCN-01), which markedly potentiates camptothecin cytotoxicity.	Camptothecin	157-169	replication protein A2	Homo sapiens	22-26
10064605-7	1999	The DNA-PK catalytic subunit (DNA-PKcs) was found to bind RPA which was replaced by the Ku autoantigen upon camptothecin treatment.	Camptothecin	108-120	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	4-28
10064605-7	1999	The DNA-PK catalytic subunit (DNA-PKcs) was found to bind RPA which was replaced by the Ku autoantigen upon camptothecin treatment.	Camptothecin	108-120	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	30-38
10064605-7	1999	The DNA-PK catalytic subunit (DNA-PKcs) was found to bind RPA which was replaced by the Ku autoantigen upon camptothecin treatment.	Camptothecin	108-120	replication protein A1	Homo sapiens	58-61
9927052-8	1999	Only the expression of MEKK1-DN, not Vit C treatment, blocked the JNK activity induced by CPT, Vbeta-16, or GL331.	Camptothecin	90-93	mitogen-activated protein kinase 8	Homo sapiens	66-69
10071186-3	1999	We have found similar S-phase arrest in both WRN and control cells after treatment with the DNA-topoisomerase-I-trapping drug camptothecin; this may be responsible for the drug-exposure-related growth inhibition seen in both cell types.	Camptothecin	126-138	WRN RecQ like helicase	Homo sapiens	45-48
10194547-3	1999	Camptothecin is a DNA topoisomerase I poison.	Camptothecin	0-12	DNA topoisomerase 1	Cricetulus griseus	18-37
10071186-5	1999	The mechanism of camptothecin-induced cell death in WRN-deficient LCLs appears to be through apoptosis, a phenotype that strongly differentiates WRN-deficient from wild-type LCLs.	Camptothecin	17-29	WRN RecQ like helicase	Homo sapiens	52-55
9794234-4	1998	Forced expression of temperature-sensitive p53val135 in mutant conformation failed to prevent accumulation of endogenous wild-type p53 but acted in a transdominant negative manner to inhibit p53-mediated, camptothecin-induced p21WAF1/CIP1 expression.	Camptothecin	205-217	tumor protein p53	Homo sapiens	43-46
9876111-1	1998	Homocamptothecin (hCPT), a camptothecin (CPT) analogue with a seven membered beta-hydroxylactone which combines enhanced plasma stability and potent topoisomerase I (Topo I)-mediated activity, is an attractive template for the elaboration of new anticancer agents.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	18-22
9876111-2	1998	Like CPT, hCPT carries an asymmetric tertiary alcohol and displays stereoselective inhibition of Topo I.	Camptothecin	5-8	choline phosphotransferase 1	Homo sapiens	10-14
9842975-2	1998	Here, we asked whether alterations in the p53 and RB pathways and the expression of six BCL-2 family proteins predicted acute cytotoxicity and clonogenic cell death induced by BCNU, vincristine, cytarabine, teniposide, doxorubicin, camptothecin or beta-lapachone in 12 human malignant glioma cell lines.	Camptothecin	232-244	BCL2 apoptosis regulator	Homo sapiens	88-93
9841888-1	1998	We studied the inhibition of tumour necrosis factor alpha (TNFalpha)- and camptothecin-induced apoptosis by Bcl-2 and Bcl-xL as they relate to the ceramide pathway.	Camptothecin	74-86	BCL2 apoptosis regulator	Homo sapiens	108-113
9841888-1	1998	We studied the inhibition of tumour necrosis factor alpha (TNFalpha)- and camptothecin-induced apoptosis by Bcl-2 and Bcl-xL as they relate to the ceramide pathway.	Camptothecin	74-86	BCL2 like 1	Homo sapiens	118-124
9841888-2	1998	Expression of either Bcl-2 or Bcl-xL provided significant protection from the apoptotic effects of TNFalpha or camptothecin.	Camptothecin	111-123	BCL2 apoptosis regulator	Homo sapiens	21-26
9841888-2	1998	Expression of either Bcl-2 or Bcl-xL provided significant protection from the apoptotic effects of TNFalpha or camptothecin.	Camptothecin	111-123	BCL2 like 1	Homo sapiens	30-36
9841888-4	1998	On the other hand, Bcl-xL prevented the accumulation of endogenous ceramide in response to TNFalpha or camptothecin, whereas Bcl-2 showed little effect on ceramide formation.	Camptothecin	103-115	BCL2 like 1	Homo sapiens	19-25
9756937-5	1998	Anticancer drugs such as camptothecin, vinblastine, inostamycin, and adriamycin induced activation of caspase-3(-like) proteases and apoptosis.	Camptothecin	25-37	caspase 3	Homo sapiens	102-117
9841888-6	1998	These results identify a different mechanism of action for Bcl-xL compared with Bcl-2 and they demonstrate that Bcl-xL targets a point upstream of ceramide generation, whereas Bcl-2 functions downstream of ceramide in the TNFalpha- and camptothecin-activated pathways of apoptosis.	Camptothecin	236-248	BCL2 like 1	Homo sapiens	59-65
9823324-1	1998	After administration of CTP-11, a camptothecin derivative exhibiting a wide spectrum of antitumor activity, dose-limiting gastrointestinal toxicity with great interpatient variability is observed.	Camptothecin	34-46	SPANX family member C	Homo sapiens	24-30
9878214-5	1998	Camptothecin, but not beta-lapachone, induced accumulation of p53 and the major growth arrest-associated p53 response protein, p21.	Camptothecin	0-12	tumor protein p53	Homo sapiens	62-65
9878214-5	1998	Camptothecin, but not beta-lapachone, induced accumulation of p53 and the major growth arrest-associated p53 response protein, p21.	Camptothecin	0-12	tumor protein p53	Homo sapiens	105-108
9878214-5	1998	Camptothecin, but not beta-lapachone, induced accumulation of p53 and the major growth arrest-associated p53 response protein, p21.	Camptothecin	0-12	H3 histone pseudogene 16	Homo sapiens	127-130
9878214-7	1998	Camptothecin, but not beta-lapachone, synergistically enhanced RPE cell apoptosis induced by the cytotoxic cytokine, CD95 ligand (CD95L).	Camptothecin	0-12	Fas ligand	Homo sapiens	117-128
9878214-7	1998	Camptothecin, but not beta-lapachone, synergistically enhanced RPE cell apoptosis induced by the cytotoxic cytokine, CD95 ligand (CD95L).	Camptothecin	0-12	Fas ligand	Homo sapiens	130-135
9786955-6	1998	We also demonstrate that the CKIs p16 and p27 as well as DN-Cdk4 and 6 but not DN-Cdk2 or 3 protect cortical neurons from the DNA damaging agent camptothecin.	Camptothecin	145-157	cyclin dependent kinase inhibitor 2A	Homo sapiens	34-37
9786955-6	1998	We also demonstrate that the CKIs p16 and p27 as well as DN-Cdk4 and 6 but not DN-Cdk2 or 3 protect cortical neurons from the DNA damaging agent camptothecin.	Camptothecin	145-157	interferon alpha inducible protein 27	Homo sapiens	42-45
9786955-6	1998	We also demonstrate that the CKIs p16 and p27 as well as DN-Cdk4 and 6 but not DN-Cdk2 or 3 protect cortical neurons from the DNA damaging agent camptothecin.	Camptothecin	145-157	cyclin dependent kinase 4	Homo sapiens	60-64
9786955-7	1998	Finally, in consonance with our hypothesis and these results, cyclin D1-associated kinase activity is rapidly and highly elevated in cortical neurons upon camptothecin treatment.	Camptothecin	155-167	proliferating cell nuclear antigen	Homo sapiens	62-68
9794234-4	1998	Forced expression of temperature-sensitive p53val135 in mutant conformation failed to prevent accumulation of endogenous wild-type p53 but acted in a transdominant negative manner to inhibit p53-mediated, camptothecin-induced p21WAF1/CIP1 expression.	Camptothecin	205-217	cyclin dependent kinase inhibitor 1A	Homo sapiens	226-238
9823429-0	1998	Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-kappa B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells.	Camptothecin	46-58	nuclear factor kappa B subunit 1	Homo sapiens	111-121
9823429-0	1998	Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-kappa B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells.	Camptothecin	46-58	tumor necrosis factor	Homo sapiens	169-190
10200532-10	1998	Furthermore, as observed with DXR and VP-16, both the CD95L-sensitive and the CD95L-resistant cell lines resulted equally sensitive to the cytotoxic effects of a number of different cytotoxic drugs (vincristine, camptothecin, 5-fluorouracil and methotrexate).	Camptothecin	212-224	Fas ligand	Homo sapiens	78-83
9743293-8	1998	Thus, although p53-dependent apoptosis is induced by camptothecin, topotecan and SN-38 in this human ovarian carcinoma cell line, these drugs induce p53-independent death, as measured by clonogenic assay.	Camptothecin	53-65	tumor protein p53	Homo sapiens	15-18
9745438-8	1998	Camptothecin-induced apoptosis is inhibited by the addition of IGF-I and -II (500 ng/mL).	Camptothecin	0-12	insulin like growth factor 1	Homo sapiens	63-76
9683792-4	1998	Treatment of cells cultured on fibronectin with a short pulse of the S phase chemotherapeutic agent camptothecin, resulted in a relative protection from cell death when compared to cells cultured on tissue culture plastic.	Camptothecin	100-112	fibronectin 1	Mus musculus	31-42
9739812-0	1998	The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication.	Camptothecin	94-106	DNA repair protein XRCC1	Cricetulus griseus	8-13
9739812-11	1998	These results suggest that EM9 cells are sensitized to camptothecin by a mechanism that is independent of DNA replication and may be a consequence of the XRCC1 mutation or the associated deficiency in DNA ligase III activity.	Camptothecin	55-67	DNA repair protein XRCC1	Cricetulus griseus	154-159
9758415-0	1998	Camptothecin induces differentiation, tissue transglutaminase and apoptosis in cultured keratinocytes.	Camptothecin	0-12	transglutaminase 2	Homo sapiens	38-61
9714845-2	1998	To elucidate the suppression mechanism of the TIS mRNA by camptothecin, we characterized the structures of the TIS gene.	Camptothecin	58-70	programmed cell death 4	Mus musculus	46-49
9714845-2	1998	To elucidate the suppression mechanism of the TIS mRNA by camptothecin, we characterized the structures of the TIS gene.	Camptothecin	58-70	programmed cell death 4	Mus musculus	111-114
9714845-8	1998	The present study showed that the expression of the TIS is suppressed at the transcriptional level by camptothecin.	Camptothecin	102-114	programmed cell death 4	Mus musculus	52-55
9714845-9	1998	Considering that topoisomerase I is an essential enzyme in mammalian cells, the TIS protein may have an important role in camptothecin toxicity.	Camptothecin	122-134	programmed cell death 4	Mus musculus	80-83
9673414-0	1998	Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.	Camptothecin	44-56	tumor protein p53	Homo sapiens	18-21
9658339-6	1998	Using a model motor neuronal cell line, NSC19, which we have shown undergoes apoptosis after treatment with classic apoptosis inducers such as the topoisomerase inhibitors camptothecin and etoposide, we unambiguously found that nanomolar thrombin induced characteristic signs of apoptosis.	Camptothecin	172-184	coagulation factor II, thrombin	Homo sapiens	238-246
9660477-9	1998	Camptothecin and etoposide increased the p53 level after 4 hours of treatment, before the onset of apoptosis.	Camptothecin	0-12	tumor protein p53	Homo sapiens	41-44
9673414-1	1998	The role of wild-type human p53 protein in enhancing camptothecin cytotoxicity was examined by infecting human prostate PC3 cells with adenovirus expressing human wild-type p53 gene (Adwtp53).	Camptothecin	53-65	tumor protein p53	Homo sapiens	28-31
9673414-4	1998	In the presence of camptothecin, an inhibitor of topoisomerase 1, significant increases in both p53 and p21 proteins were detected in Adwtp53-infected PC3 cells.	Camptothecin	19-31	tumor protein p53	Homo sapiens	96-99
9673414-4	1998	In the presence of camptothecin, an inhibitor of topoisomerase 1, significant increases in both p53 and p21 proteins were detected in Adwtp53-infected PC3 cells.	Camptothecin	19-31	cyclin dependent kinase inhibitor 1A	Homo sapiens	104-107
9506459-4	1998	Concomitant treatment with (1000 U/ml) IFN-beta counteracted the inhibitory effect of etoposide and camptothecin but had no consistent effect on the inhibition mediated by the other drugs.	Camptothecin	100-112	interferon beta 1	Homo sapiens	39-47
9719482-0	1998	Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells.	Camptothecin	124-136	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	73-78
9719482-5	1998	At camptothecin concentrations of 5, 10, and 25 microM, where suppression of c-myc expression was observed, strand breaks in bulk DNA were also detected.	Camptothecin	3-15	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	77-82
9719482-7	1998	In contrast to the absence of detectable damage to bulk DNA or suppression of c-myc expression at the lower concentrations of camptothecin, DNA synthesis was inhibited over the entire range of drug concentrations and demonstrated a strong correspondence with growth inhibition.	Camptothecin	126-138	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	78-83
9499438-0	1998	Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.	Camptothecin	159-171	cyclin dependent kinase inhibitor 1A	Homo sapiens	16-28
9499438-0	1998	Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.	Camptothecin	159-171	tumor protein p53	Homo sapiens	197-200
9499438-7	1998	The levels of p21WAF1/CIP1 protein also increased in a dose- and time-dependent manner in MDA-MB-468 cells treated with HCPT or CPT, whereas the mutated p53 protein levels had no significant change.	Camptothecin	121-124	cyclin dependent kinase inhibitor 1A	Homo sapiens	22-26
9499438-9	1998	The elevation of p21WAF1/CIP1 in MDA-MB-468 cells treated with CPT was not inhibited by aphidicolin.	Camptothecin	63-66	cyclin dependent kinase inhibitor 1A	Homo sapiens	25-29
9619832-4	1998	We found that several agents, including adriamycin (a DNA intercalator and inhibitor of topoisomerase II), camptothecin (a topoisomerase I inhibitor), and ultraviolet radiation induced significant decreases in BRCA1 and BRCA2 mRNA levels.	Camptothecin	107-119	BRCA1 DNA repair associated	Homo sapiens	210-215
9619832-4	1998	We found that several agents, including adriamycin (a DNA intercalator and inhibitor of topoisomerase II), camptothecin (a topoisomerase I inhibitor), and ultraviolet radiation induced significant decreases in BRCA1 and BRCA2 mRNA levels.	Camptothecin	107-119	BRCA2 DNA repair associated	Homo sapiens	220-225
9570926-2	1998	Preventive effect of Bcl-xL on cell death induced by various concentrations of camptothecin (DNA topoisomerase I inhibitor; CPT) was observed in the three lines with most pronounced effect in cells containing the highest level of Bcl-xL expression.	Camptothecin	79-91	BCL2 like 1	Homo sapiens	21-27
9570926-2	1998	Preventive effect of Bcl-xL on cell death induced by various concentrations of camptothecin (DNA topoisomerase I inhibitor; CPT) was observed in the three lines with most pronounced effect in cells containing the highest level of Bcl-xL expression.	Camptothecin	79-91	BCL2 like 1	Homo sapiens	230-236
9506459-11	1998	Camptothecin inhibited the expression of mRNA for granzyme B, a lytic protein involved in lymphoid-mediated cytotoxicity.	Camptothecin	0-12	granzyme B	Homo sapiens	50-60
9398050-0	1997	Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone.	Camptothecin	151-163	Fas cell surface death receptor	Homo sapiens	124-128
9446803-6	1998	Furthermore, when PC3 cells were treated with a panel of apoptosis-inducing agents, it was found that camptothecin, bleomycin, VP16 and TNF-alpha induced varying amounts of cytosolic accumulation of cytochrome c either prior to or concurrent with PARP cleavage while vinblastine and BHPP did not.	Camptothecin	102-114	tumor necrosis factor	Homo sapiens	136-145
9398050-6	1997	LN-229 cells which have partial p53-wild-type activity show enhanced expression of p53, p21 and bax protein, whereas bcl-2 levels decrease, after exposure to camptothecin.	Camptothecin	158-170	BCL2 apoptosis regulator	Homo sapiens	117-122
9398050-12	1997	Camptothecin, but not beta-lapachone, sensitizes human malignant glioma cells to apoptosis induced by the cytotoxic cytokines, tumor necrosis factor-alpha and CD95 ligand.	Camptothecin	0-12	tumor necrosis factor	Homo sapiens	127-154
9398050-12	1997	Camptothecin, but not beta-lapachone, sensitizes human malignant glioma cells to apoptosis induced by the cytotoxic cytokines, tumor necrosis factor-alpha and CD95 ligand.	Camptothecin	0-12	Fas cell surface death receptor	Homo sapiens	159-163
9508372-5	1998	After treatment with 40 nM, 200 nM or 1 microM of camptothecin the survival rates were, on average, 16%, 8% and 4% for the wild-type p53 melanoma cells, compared with 89%, 67% and 38% for the mutant p53 cells, respectively (P = 0.00004, P = 0.003 and P = 0.04, respectively).	Camptothecin	50-62	tumor protein p53	Homo sapiens	133-136
9508372-5	1998	After treatment with 40 nM, 200 nM or 1 microM of camptothecin the survival rates were, on average, 16%, 8% and 4% for the wild-type p53 melanoma cells, compared with 89%, 67% and 38% for the mutant p53 cells, respectively (P = 0.00004, P = 0.003 and P = 0.04, respectively).	Camptothecin	50-62	tumor protein p53	Homo sapiens	199-202
9508372-8	1998	Cisplatin, camptothecin and vincristine all induced apoptosis in wild-type p53 melanoma cells, but not in mutant p53 cells.	Camptothecin	11-23	tumor protein p53	Homo sapiens	75-78
9446803-6	1998	Furthermore, when PC3 cells were treated with a panel of apoptosis-inducing agents, it was found that camptothecin, bleomycin, VP16 and TNF-alpha induced varying amounts of cytosolic accumulation of cytochrome c either prior to or concurrent with PARP cleavage while vinblastine and BHPP did not.	Camptothecin	102-114	cytochrome c, somatic	Homo sapiens	199-211
9446803-6	1998	Furthermore, when PC3 cells were treated with a panel of apoptosis-inducing agents, it was found that camptothecin, bleomycin, VP16 and TNF-alpha induced varying amounts of cytosolic accumulation of cytochrome c either prior to or concurrent with PARP cleavage while vinblastine and BHPP did not.	Camptothecin	102-114	collagen type XI alpha 2 chain	Homo sapiens	247-251
9395460-0	1997	Activation of PKCalpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells.	Camptothecin	132-144	protein kinase C alpha	Homo sapiens	14-22
9395460-6	1997	Camptothecin (CPT) and etoposide (VP-16) also markedly enhanced PKCalpha activity during apoptosis in HL60 cells.	Camptothecin	0-12	protein kinase C alpha	Homo sapiens	64-72
9395460-6	1997	Camptothecin (CPT) and etoposide (VP-16) also markedly enhanced PKCalpha activity during apoptosis in HL60 cells.	Camptothecin	14-17	protein kinase C alpha	Homo sapiens	64-72
9398050-14	1997	Camptothecin-like agents are particularly promising for immunochemotherapy of malignant glioma using cytotoxic drugs and CD95 ligand.	Camptothecin	0-12	Fas cell surface death receptor	Homo sapiens	121-125
9398050-6	1997	LN-229 cells which have partial p53-wild-type activity show enhanced expression of p53, p21 and bax protein, whereas bcl-2 levels decrease, after exposure to camptothecin.	Camptothecin	158-170	tumor protein p53	Homo sapiens	32-35
9398050-6	1997	LN-229 cells which have partial p53-wild-type activity show enhanced expression of p53, p21 and bax protein, whereas bcl-2 levels decrease, after exposure to camptothecin.	Camptothecin	158-170	H3 histone pseudogene 16	Homo sapiens	88-91
9398050-6	1997	LN-229 cells which have partial p53-wild-type activity show enhanced expression of p53, p21 and bax protein, whereas bcl-2 levels decrease, after exposure to camptothecin.	Camptothecin	158-170	BCL2 associated X, apoptosis regulator	Homo sapiens	96-99
9259410-8	1997	Our data suggest that PC-6/SN2-5 cells may have acquired resistance to camptothecin analogs by a decrease in intracellular drug accumulation and that DX-8951f may have the potency to overcome such a type of resistance mechanism induced by camptothecin compounds.	Camptothecin	71-83	proprotein convertase subtilisin/kexin type 5	Homo sapiens	22-26
9307289-0	1997	Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.	Camptothecin	56-68	tumor protein p53	Homo sapiens	168-171
9307289-2	1997	In this study, we found that nanomolar concentrations of camptothecin (CPT), a topoisomerase I inhibitor, arrest or delay cell cycle progression during the S and G2 phases in p53 mutant human colon carcinoma HT29 cells and that UCN-01 abrogates the S-phase arrest or delay induced by CPT.	Camptothecin	57-69	tumor protein p53	Homo sapiens	175-178
9307289-2	1997	In this study, we found that nanomolar concentrations of camptothecin (CPT), a topoisomerase I inhibitor, arrest or delay cell cycle progression during the S and G2 phases in p53 mutant human colon carcinoma HT29 cells and that UCN-01 abrogates the S-phase arrest or delay induced by CPT.	Camptothecin	71-74	tumor protein p53	Homo sapiens	175-178
9413228-12	1997	For CPT and SN-22 but not for SN-38 and NB-506, the moderate resistance levels observed in the Pgp-expressing cell line could be negated by prolongation of exposure duration.	Camptothecin	4-7	ATP binding cassette subfamily B member 1	Homo sapiens	95-98
9815856-0	1997	Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.	Camptothecin	50-62	tumor protein p53	Homo sapiens	16-19
9264376-0	1997	Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases.	Camptothecin	0-12	tumor protein p53	Homo sapiens	34-37
9264376-4	1997	We found that CPP32 is activated during camptothecin-induced apoptosis, and that N-benzyloxycarbony-Val-Ala-Asp (O-methyl) -fluoromethyketone (Z-VAD-fmk), a cell permeable caspase inhibitor blocks all features of apoptosis: morphological changes, cleavage of caspase 3 (CPP32/Yama/Apopain) and poly(ADP-ribose) polymerase, lamin B degradation and DNA fragmentation.	Camptothecin	40-52	caspase 3	Homo sapiens	14-19
9264376-8	1997	Taken together, these results suggest that in HL60 cells, both CPP32 and serine proteases are activated in camptothecin-induced apoptosis.	Camptothecin	107-119	caspase 3	Homo sapiens	63-68
9157988-1	1997	We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats.	Camptothecin	227-239	ATP binding cassette subfamily C member 2	Rattus norvegicus	35-86
9271208-1	1997	Circular dichroism (CD) and Raman spectroscopy were employed in order to locate a camptothecin (CPT)-binding site within human serum albumin (HSA) and to identify protein structural transformations induced by CPT binding.	Camptothecin	82-94	albumin	Homo sapiens	142-145
9271208-1	1997	Circular dichroism (CD) and Raman spectroscopy were employed in order to locate a camptothecin (CPT)-binding site within human serum albumin (HSA) and to identify protein structural transformations induced by CPT binding.	Camptothecin	96-99	albumin	Homo sapiens	142-145
9271208-2	1997	A competitive binding of CPT and 3"-azido-3"-deoxythymidine (a ligand occupying IIIA structural sub-domain of the protein) to HSA does not show any competition and demonstrates that the ligands are located in the different binding sites, whereas a HSA-bound CPT may be replaced by warfarin, occupying IIA structural sub-domain of the protein.	Camptothecin	25-28	albumin	Homo sapiens	126-129
9271208-2	1997	A competitive binding of CPT and 3"-azido-3"-deoxythymidine (a ligand occupying IIIA structural sub-domain of the protein) to HSA does not show any competition and demonstrates that the ligands are located in the different binding sites, whereas a HSA-bound CPT may be replaced by warfarin, occupying IIA structural sub-domain of the protein.	Camptothecin	25-28	albumin	Homo sapiens	248-251
9205078-2	1997	IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil (antimetabolite), methotrexate (antimetabolite), tamoxifen (antiestrogen/antiproliferative), or camptothecin (topoisomerase 1 inhibitor) and after serum withdrawal.	Camptothecin	170-182	insulin like growth factor 1	Homo sapiens	0-5
11596273-1	1997	The effects of differentiation of human leukemia HL60 cells on harringtonine(Har) and camptothecin(Cam) induced apoptosis(in these cells) were studied.	Camptothecin	86-98	calmodulin 3	Homo sapiens	99-102
9157988-1	1997	We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats.	Camptothecin	227-239	ATP binding cassette subfamily C member 2	Rattus norvegicus	88-93
9155159-2	1997	Topo I and II targeting anticancer agents such as camptothecins (CPT-II), epipodophyllotoxins (VP16 and VM26), and amsarcine are widely used in cancer chemotherapy.	Camptothecin	50-63	carnitine palmitoyltransferase 2	Homo sapiens	65-71
9115278-3	1997	Yeast SCT1 mutants were isolated in a screen for mutations in genes other than TOP1 that result in camptothecin resistance.	Camptothecin	99-111	bifunctional glycerol-3-phosphate/glycerone-phosphate O-acyltransferase SCT1	Saccharomyces cerevisiae S288C	6-10
9115278-7	1997	Deletion of PDR1 or the downstream effector SNQ2 increased cell sensitivity to camptothecin, whereas deletion of YOR1 or PDR5 had little effect on camptothecin sensitivity.	Camptothecin	79-91	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	12-16
9115278-7	1997	Deletion of PDR1 or the downstream effector SNQ2 increased cell sensitivity to camptothecin, whereas deletion of YOR1 or PDR5 had little effect on camptothecin sensitivity.	Camptothecin	79-91	ATP-binding cassette transporter SNQ2	Saccharomyces cerevisiae S288C	44-48
9115278-8	1997	However, the camptothecin resistance accompanying GAL1-promoted overexpression of PDR5 suggests some substrate promiscuity among the ATP-binding cassette transporters.	Camptothecin	13-25	galactokinase	Saccharomyces cerevisiae S288C	50-54
9115278-8	1997	However, the camptothecin resistance accompanying GAL1-promoted overexpression of PDR5 suggests some substrate promiscuity among the ATP-binding cassette transporters.	Camptothecin	13-25	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	82-86
9115278-9	1997	These data underscore the role of the pleiotropic drug resistance network in regulating camptothecin toxicity and are consistent with a model of decreased intracellular concentrations of camptothecin resulting from the increased expression of the SNQ2 transporter.	Camptothecin	88-100	ATP-binding cassette transporter SNQ2	Saccharomyces cerevisiae S288C	247-251
9115278-9	1997	These data underscore the role of the pleiotropic drug resistance network in regulating camptothecin toxicity and are consistent with a model of decreased intracellular concentrations of camptothecin resulting from the increased expression of the SNQ2 transporter.	Camptothecin	187-199	ATP-binding cassette transporter SNQ2	Saccharomyces cerevisiae S288C	247-251
9062409-20	1997	Similarly, camptothecin and topotecan were correlated to cisplatin but inversely correlated to VP-16 and other topo II poisons.	Camptothecin	11-23	host cell factor C1	Homo sapiens	95-100
9108456-0	1997	Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.	Camptothecin	84-96	DNA topoisomerase 1	Cricetulus griseus	10-29
9108456-1	1997	The role of DNA topoisomerase I as a biochemical mediator of radiosensitization in cultured mammalian cells by camptothecin derivatives was studied.	Camptothecin	111-123	DNA topoisomerase 1	Cricetulus griseus	12-31
9106619-0	1997	Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation.	Camptothecin	117-129	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	0-28
9106619-0	1997	Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation.	Camptothecin	117-129	5'-aminolevulinate synthase 2	Homo sapiens	69-103
9106619-6	1997	Camptothecin-induced expression of beta-globin or ALAS-E transcript levels was inhibited in the presence of cycloheximide or vanadate.	Camptothecin	0-12	5'-aminolevulinate synthase 2	Homo sapiens	50-56
9074631-3	1997	Preincubation of HL-60 cells with the hydrogen peroxide-scavenging enzyme catalase (500 U/ml) inhibited apoptosis due to UV irradiation or low concentrations of camptothecin, etoposide or melphalan, but did not protect against higher concentrations.	Camptothecin	161-173	catalase	Homo sapiens	74-82
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	57-69	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-91
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	57-69	mitogen-activated protein kinase 8	Homo sapiens	145-149
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	57-69	mitogen-activated protein kinase 9	Homo sapiens	150-154
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	57-69	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-172
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	57-69	caspase 1	Homo sapiens	189-192
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	57-69	caspase 1	Homo sapiens	194-229
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	57-69	intraflagellar transport 43	Homo sapiens	231-236
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	71-74	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-91
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	71-74	mitogen-activated protein kinase 8	Homo sapiens	145-149
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	71-74	mitogen-activated protein kinase 9	Homo sapiens	150-154
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	71-74	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-172
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	71-74	caspase 1	Homo sapiens	189-192
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	71-74	caspase 1	Homo sapiens	194-229
9020192-2	1997	In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells.	Camptothecin	71-74	intraflagellar transport 43	Homo sapiens	231-236
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Camptothecin	67-79	nuclear factor kappa B subunit 1	Homo sapiens	121-130
9054963-1	1997	PURPOSE: 20(S)-Camptothecin (CAM), topotecan (TPT, active ingredient in Hycamtin) and 9-amino-20(S)-camptothecin (9AC) are topoisomerase I inhibitors that cause similar dose-limiting toxicities to rapidly renewing tissues, such as hematopoietic tissues, in humans, mice, and dogs.	Camptothecin	11-27	calmodulin 3	Homo sapiens	29-32
9121221-0	1996	Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo.	Camptothecin	48-60	chromobox 8	Homo sapiens	76-97
20650253-1	1996	CPT-11, a derivative of camptothecin (CPT) that interacts with type-I DNA topoisomerase, induced apoptosis in HL60 and Daudi cells in vitro.	Camptothecin	24-36	DNA topoisomerase I	Homo sapiens	63-87
20650253-1	1996	CPT-11, a derivative of camptothecin (CPT) that interacts with type-I DNA topoisomerase, induced apoptosis in HL60 and Daudi cells in vitro.	Camptothecin	0-3	DNA topoisomerase I	Homo sapiens	63-87
8903483-2	1996	In this study, we found that GRP-inducing conditions in culture led to induction of resistance to the topoisomerase I-targeted drug camptothecin in human colon cancer HT-29 and ovarian cancer A2780 cells.	Camptothecin	132-144	gastrin releasing peptide	Homo sapiens	29-32
9272121-0	1997	Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.	Camptothecin	50-62	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
9495454-3	1997	MRP-expressing 250-fold doxorubicin-resistant human fibrosarcoma HT1080/DR4 tumor cells were drug sensitive to NB-506 and camptothecin (CPT) (resistance factor: 0.7 and 0.8, respectively) with no alterations of TOP-I parameters including DNA relaxation, expression of TOP-I protein and mRNA.	Camptothecin	122-134	ATP binding cassette subfamily C member 1	Homo sapiens	0-3
8967975-0	1996	Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.	Camptothecin	11-23	transformation related protein 53, pseudogene	Mus musculus	63-66
8967975-2	1996	However, these mutant p53-transfected cell lines retained sensitivity to taxol and camptothecin.	Camptothecin	83-95	transformation related protein 53, pseudogene	Mus musculus	22-25
8967975-5	1996	Camptothecin also induced apoptosis in a p53-independent manner in thymocytes at low doses but in a p53-dependent manner at high doses.	Camptothecin	0-12	transformation related protein 53, pseudogene	Mus musculus	41-44
8967975-5	1996	Camptothecin also induced apoptosis in a p53-independent manner in thymocytes at low doses but in a p53-dependent manner at high doses.	Camptothecin	0-12	transformation related protein 53, pseudogene	Mus musculus	100-103
8967975-6	1996	These data suggest that taxoids and camptothecin analogs could have activity in tumors that have aberrant p53 function and provide a rationale for the clinical observations of responsiveness of refractory ovarian cancer to these drugs.	Camptothecin	36-48	transformation related protein 53, pseudogene	Mus musculus	106-109
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Camptothecin	67-79	nuclear factor kappa B subunit 1	Homo sapiens	132-137
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Camptothecin	67-79	RELA proto-oncogene, NF-kB subunit	Homo sapiens	138-142
8932379-5	1996	We now show that a series of topoisomerase poisons (actinomycin D, camptothecin, daunomycin and etoposide) also activate NF-kappaB (NFKB1/RelA dimer) in ACH-2 and CEM cells.	Camptothecin	67-79	acyl-CoA thioesterase 1	Homo sapiens	153-158
8932379-7	1996	In ACH-2 cells latently infected by HIV-1, camptothecin, daunomycin and etoposide are able to enhance virus production.	Camptothecin	43-55	acyl-CoA thioesterase 1	Homo sapiens	3-8
8891470-2	1996	Irinotecan (CPT-II) is a semisynthetic derivative of camptothecin.	Camptothecin	53-65	carnitine palmitoyltransferase 2	Homo sapiens	12-18
8895510-2	1996	Exposure of HeLa cells to camptothecin, etoposide or nitrogen mustard for 1 h in S phase resulted in delayed expression of cyclin B1 mRNA during the G2 arrest.	Camptothecin	26-38	cyclin B1	Homo sapiens	123-132
8895510-5	1996	However, with camptothecin or etoposide treatment, while the accumulation of cyclin B1 protein was delayed, its levels eventually surpassed peak levels seen in control cells, in spite of the fact that cells were still blocked in G2.	Camptothecin	14-26	cyclin B1	Homo sapiens	77-86
8875976-7	1996	Moreover, when the DNA damage-inducing drugs etoposide or camptothecin were added to the cells, a further stimulation of kinase activity was observed following growth at 28 degrees C, but not 38 degrees C. These data are consistent with a regulatory model in which p53 is sensitive to stress or DNA damage through phosphorylation at its N-terminus.	Camptothecin	58-70	tumor protein p53	Homo sapiens	265-268
8922198-1	1996	BACKGROUND: CPT-11 (irinotecan), a camptothecin-derived anticancer agent with DNA topoisomerase 1 inhibitory activity, has demonstrated a broad spectrum of in vitro and in vivo activity in solid tumour models including multidrug-resistant tumours.	Camptothecin	35-47	DNA topoisomerase I	Homo sapiens	78-97
8917343-0	1996	Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in mice and human mononuclear cells.	Camptothecin	40-52	tumor necrosis factor	Mus musculus	13-34
9816112-7	1996	We also find that induction of wild-type p53 potentiates the cytotoxicity of topotecan, a member of the camptothecin family of drugs that also has clinical activity against colon cancer.	Camptothecin	104-116	tumor protein p53	Homo sapiens	41-44
8706020-0	1996	Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.	Camptothecin	103-115	glucuronidase, beta	Rattus norvegicus	15-33
8806433-0	1996	DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies.	Camptothecin	163-175	tumor protein p53	Homo sapiens	52-55
8806433-2	1996	HL60 cells are p53 null and extremely sensitive to a variety of apoptotic stimuli including DNA damage induced by the topoisomerase I inhibitor, camptothecin.	Camptothecin	145-157	tumor protein p53	Homo sapiens	15-18
8634449-6	1996	The results also demonstrate the activation and cleavage of PKCdelta (1) is inhibited by expression of antiapoptotic proteins, and (2) is induced by camptothecin (CAM) and mitomycin C (MMC).	Camptothecin	149-161	protein kinase C delta	Homo sapiens	60-68
8707853-0	1996	Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.	Camptothecin	35-47	DNA topoisomerase I	Rattus norvegicus	65-84
8695747-9	1996	The expression of p330d/CENP-F and PCNA was also assessed in the growth inhibition of HT-29 cells induced by various concentrations of camptothecin (CPT), etoposide (VP-16), and aphidicolin (APH).	Camptothecin	135-147	centromere protein F	Homo sapiens	24-30
8695747-9	1996	The expression of p330d/CENP-F and PCNA was also assessed in the growth inhibition of HT-29 cells induced by various concentrations of camptothecin (CPT), etoposide (VP-16), and aphidicolin (APH).	Camptothecin	135-147	proliferating cell nuclear antigen	Homo sapiens	35-39
8707853-1	1996	Camptothecin is an S-phase-specific anticancer agent that inhibits the activity of the enzyme DNA topoisomerase-I (topo-I).	Camptothecin	0-12	DNA topoisomerase I	Rattus norvegicus	94-113
8741673-3	1996	A serine protease inhibitor TPCK and an ICE-like protease inhibitor VAD-FMK prevented etoposide, camptothecin and ara-C-induced internucleosomal DNA cleavage in human myeloid leukemia HL-60 and U937 cells.	Camptothecin	97-109	coagulation factor II, thrombin	Homo sapiens	2-17
8779771-2	1996	A serine protease inhibitor TPCK and an ICE-like protease inhibitor VAD-FMK prevented etoposide, camptothecin and ara-C-induced internucleosomal DNA cleavage.	Camptothecin	97-109	coagulation factor II, thrombin	Homo sapiens	2-17
8635865-1	1996	20(S)-Camptothecin (CPT), a topoisomerase I inhibitor specifically toxic toward S-phase cells, was tested topically for its ability to inhibit the biochemical markers of skin tumor promotion.	Camptothecin	20-23	DNA segment, 20S	Mus musculus	0-18
8639538-5	1996	In vitro experiments with purified recombinant proteins show that p53 increases the catalytic activities of topoisomerase I as measured by relaxation of supercoiled DNA, stabilization of the covalent topoisomerase I-DNA complex (in the presence of camptothecin), and phosphorylation of SR protein splicing factor ASF/SF2.	Camptothecin	248-260	tumor protein p53	Homo sapiens	66-69
8634449-6	1996	The results also demonstrate the activation and cleavage of PKCdelta (1) is inhibited by expression of antiapoptotic proteins, and (2) is induced by camptothecin (CAM) and mitomycin C (MMC).	Camptothecin	163-166	protein kinase C delta	Homo sapiens	60-68
8838651-9	1996	When HL60 cells were stimulated by diverse apoptosis inducers such as camptothecin, staurosporine, cycloheximide, and A23187, the extent of NuMA cleavage to produce a 180 kDa product was comparable with the degree of oligonucleosomal laddering.	Camptothecin	70-82	nuclear mitotic apparatus protein 1	Homo sapiens	140-144
8695922-1	1996	Comparison between five human leukemic lines (BV173, HL60, U937, K562, KCL22) suggest that the main determinant of their sensitivity to topoisomerase I (camptothecin) and II (VP-16) inhibitors is their ability to regulate cell cycle progression in response to specific DNA damage, then to die through apoptosis: the more the cells inhibit cell cycle progression, the less sensitive they are.	Camptothecin	153-165	host cell factor C1	Homo sapiens	175-180
8632759-0	1996	Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.	Camptothecin	130-143	interleukin 1 alpha	Homo sapiens	0-19
8632759-2	1996	We found that interleukin-1 alpha potentiated cytotoxicity of camptothecin (4-5-fold) during simultaneous drug exposure in human ovarian NIH:OVCAR-3 cancer cells in vitro.	Camptothecin	62-74	interleukin 1 alpha	Homo sapiens	14-33
8632759-3	1996	Studies indicated that IL-1 alpha significantly increased topoisomerase I-catalyzed camptothecin-induced DNA cleavable complexes in the ovarian cell line, which was not due increased intracellular camptothecin as IL-1 alpha failed to effect cellular uptake of camptothecin.	Camptothecin	84-96	interleukin 1 alpha	Homo sapiens	23-33
8632759-6	1996	Because camptothecins are active against solid tumors in vivo, combinations of IL-1 alpha with these active drugs may lead to more effective treatment of ovarian cancers in the clinic.	Camptothecin	8-21	interleukin 1 alpha	Homo sapiens	79-89
8565133-1	1996	Camptothecin is a widely used anti-tumor drug that specifically inhibits DNA topoisomerase I.	Camptothecin	0-12	DNA topoisomerase 1	Cricetulus griseus	73-92
8565133-3	1996	We have assessed the effects of camptothecin on RNA polymerase II transcription from the dihydrofolate reductase (DHFR) gene in Chinese hamster ovary (CHO) cells.	Camptothecin	32-44	dihydrofolate reductase	Cricetulus griseus	89-112
8565133-3	1996	We have assessed the effects of camptothecin on RNA polymerase II transcription from the dihydrofolate reductase (DHFR) gene in Chinese hamster ovary (CHO) cells.	Camptothecin	32-44	dihydrofolate reductase	Cricetulus griseus	114-118
8565133-4	1996	Using in vivo [3H]uridine pulse labeling and in vitro nuclear run-on techniques to estimate relative rates of transcription, it was found that camptothecin stimulated RNA synthesis from promoter-proximal sequences of the DHFR gene, while transcription from promoter-distal sequences was reduced.	Camptothecin	143-155	dihydrofolate reductase	Cricetulus griseus	221-225
8565133-6	1996	The effect of camptothecin on transcription was reversible, resulting in a wave of RNA synthesis recovery in a 5" to 3" direction through the DHFR gene following a chase with camptothecin-free medium.	Camptothecin	14-26	dihydrofolate reductase	Cricetulus griseus	142-146
8565133-6	1996	The effect of camptothecin on transcription was reversible, resulting in a wave of RNA synthesis recovery in a 5" to 3" direction through the DHFR gene following a chase with camptothecin-free medium.	Camptothecin	175-187	dihydrofolate reductase	Cricetulus griseus	142-146
8565133-7	1996	We conclude that camptothecin stimulates initiation but inhibits elongation of the RNA polymerase II transcribed DHFR gene.	Camptothecin	17-29	dihydrofolate reductase	Cricetulus griseus	113-117
8938795-0	1996	Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.	Camptothecin	115-127	tumor protein p53	Homo sapiens	161-164
7603986-0	1995	SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I.	Camptothecin	26-38	bifunctional glycerol-3-phosphate/glycerone-phosphate O-acyltransferase SCT1	Saccharomyces cerevisiae S288C	0-4
7603986-3	1995	Following ethyl methanesulfonate mutagenesis of top1 delta yeast cells expressing plasmid-borne wild-type DNA topoisomerase I, six dominant suppressors of camptothecin toxicity were isolated that define a single genetic locus, sct1.	Camptothecin	155-167	bifunctional glycerol-3-phosphate/glycerone-phosphate O-acyltransferase SCT1	Saccharomyces cerevisiae S288C	227-231
7603986-4	1995	Mutant SCT1 cells expressed DNA topoisomerase I protein of similar specific activity and camptothecin sensitivity to that of congenic, drug-sensitive sct1 cells, yet were resistant to camptothecin-mediated lethality.	Camptothecin	89-101	bifunctional glycerol-3-phosphate/glycerone-phosphate O-acyltransferase SCT1	Saccharomyces cerevisiae S288C	7-11
7603986-4	1995	Mutant SCT1 cells expressed DNA topoisomerase I protein of similar specific activity and camptothecin sensitivity to that of congenic, drug-sensitive sct1 cells, yet were resistant to camptothecin-mediated lethality.	Camptothecin	184-196	bifunctional glycerol-3-phosphate/glycerone-phosphate O-acyltransferase SCT1	Saccharomyces cerevisiae S288C	7-11
7603986-5	1995	Moreover, camptothecin-treated SCT1 cells did not exhibit the G2-arrested, terminal phenotype characteristic of drug-treated wild-type cells.	Camptothecin	10-22	bifunctional glycerol-3-phosphate/glycerone-phosphate O-acyltransferase SCT1	Saccharomyces cerevisiae S288C	31-35
7603986-6	1995	SCT1 cell sensitivity to other DNA-damaging agents suggests that alterations in SCT1 function suppress camptothecin-induced DNA damage produced in the presence of yeast DNA topoisomerase I.	Camptothecin	103-115	bifunctional glycerol-3-phosphate/glycerone-phosphate O-acyltransferase SCT1	Saccharomyces cerevisiae S288C	0-4
7603986-6	1995	SCT1 cell sensitivity to other DNA-damaging agents suggests that alterations in SCT1 function suppress camptothecin-induced DNA damage produced in the presence of yeast DNA topoisomerase I.	Camptothecin	103-115	bifunctional glycerol-3-phosphate/glycerone-phosphate O-acyltransferase SCT1	Saccharomyces cerevisiae S288C	80-84
7766631-2	1995	Two water-soluble camptothecin derivatives are in clinical trial, and their anticancer activity appears promising: topotecan and CPT-11.	Camptothecin	18-30	choline phosphotransferase 1	Homo sapiens	129-132
7540951-2	1995	Proliferating E2F1d87-expressing cells exhibit a significant lengthening of S phase relative to control and E2F1 cell lines and are hypersensitive to the cytotoxic effects of the S phase-specific antitumor drug camptothecin.	Camptothecin	211-223	E2F transcription factor 1 L homeolog	Xenopus laevis	14-18
7540951-6	1995	Consistent with this relative increase in DNA synthesis, the E2F1d87 cell line undergoes camptothecin-induced apoptosis when cultured under conditions of serum starvation, while the control and E2F1 cell lines are unaffected by drug treatment under the same conditions.	Camptothecin	89-101	E2F transcription factor 1 L homeolog	Xenopus laevis	61-65
7772597-10	1995	The level of NPM oligomer remains unchanged in HeLa cells after treatment with the cytotoxic agents, actinomycin D, toyocamycin and camptothecin.	Camptothecin	132-144	nucleophosmin 1	Homo sapiens	13-16
7812949-1	1995	We have studied changes in cyclin A- and B1-dependent kinases during apoptosis induced in human promyelocytic leukemia (HL60) cells treated with the topoisomerase I inhibitor camptothecin.	Camptothecin	175-187	cyclin A2	Homo sapiens	27-35
7699706-2	1995	The activity of these compounds may be attributed to their rigid, planar geometry, and an attempt was made to correlate the SAR in this series to known attributes of camptothecin.	Camptothecin	166-178	sarcosine dehydrogenase	Homo sapiens	124-127
7812949-2	1995	We found that cyclin B1/Cdc2 kinase activity transiently increases within 30 min after camptothecin treatment.	Camptothecin	87-99	cyclin B1	Homo sapiens	14-23
7812949-2	1995	We found that cyclin B1/Cdc2 kinase activity transiently increases within 30 min after camptothecin treatment.	Camptothecin	87-99	cyclin dependent kinase 1	Homo sapiens	24-28
7812949-4	1995	The DNA polymerase inhibitor aphidicolin abrogates camptothecin-induced changes in cyclin B1/Cdc2 kinase activity, indicating that DNA replication-induced DNA damage is essential for both Cdc2 alterations and apoptosis activation.	Camptothecin	51-63	cyclin B1	Homo sapiens	83-92
7812949-4	1995	The DNA polymerase inhibitor aphidicolin abrogates camptothecin-induced changes in cyclin B1/Cdc2 kinase activity, indicating that DNA replication-induced DNA damage is essential for both Cdc2 alterations and apoptosis activation.	Camptothecin	51-63	cyclin dependent kinase 1	Homo sapiens	93-97
7812949-4	1995	The DNA polymerase inhibitor aphidicolin abrogates camptothecin-induced changes in cyclin B1/Cdc2 kinase activity, indicating that DNA replication-induced DNA damage is essential for both Cdc2 alterations and apoptosis activation.	Camptothecin	51-63	cyclin dependent kinase 1	Homo sapiens	188-192
8001262-0	1994	The sensitivity to camptothecin of DNA topoisomerase I in L5178Y-S lymphoma cells.	Camptothecin	19-31	topoisomerase (DNA) I	Mus musculus	35-54
7823135-3	1995	Using two-dimensional gel analysis we have identified a 30 kDa cytosolic protein (p30) whose radiolabeling was consistently increased in parallel with increases in arylalkylamine N-acetyltransferase activity and melatonin production that were induced by forskolin and/or camptothecin.	Camptothecin	271-283	centromere protein V	Homo sapiens	82-85
7823135-3	1995	Using two-dimensional gel analysis we have identified a 30 kDa cytosolic protein (p30) whose radiolabeling was consistently increased in parallel with increases in arylalkylamine N-acetyltransferase activity and melatonin production that were induced by forskolin and/or camptothecin.	Camptothecin	271-283	aralkylamine N-acetyltransferase	Homo sapiens	164-198
7510956-1	1994	Pretreatment (4h) of human HL 60 leukemia cells with the topoisomerase I-inhibitor camptothecin (7-28 x 10(-9) Mol/l, single dose) enhanced vitamin D3-responsive CD 14 expression (10(-11)-10(-8) Mol/l vitamin D3) up to twofold, as measured by fluorescence activated flow cytometry after 1-3 days.	Camptothecin	83-95	CD14 molecule	Homo sapiens	162-167
7923116-4	1994	Induction of p53 is also abnormal in AT cells following treatment with methylmethanesulfonate and bleomycin but appears relatively normal following treatment with UV-C irradiation or the topoisomerase inhibitors, etoposide and camptothecin.	Camptothecin	227-239	tumor protein p53	Homo sapiens	13-16
7847805-0	1994	Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-1 alpha against human ovarian carcinoma in vivo.	Camptothecin	56-68	interleukin 1 alpha	Homo sapiens	72-91
7847805-1	1994	Interleukin-1 alpha significantly potentiated the cytotoxicity of carboplatin (8-fold) and camptothecin (4-fold) during simultaneous drug exposure in human ovarian NIH: OVCAR-3 cancer cells in vitro.	Camptothecin	91-103	interleukin 1 alpha	Homo sapiens	0-19
8074481-1	1994	A camptothecin analog, ((4s)-4,11-diethyl-4-hydroxy-9-[(4- piperidinopiperidino)carbonyloxy]dione hydrochloride trihydrate), (CPT-11), is a recently developed topoisomerase I (Topo I) inhibitor which attracts the attention of clinicians because of its high antitumor activity.	Camptothecin	2-14	choline phosphotransferase 1	Homo sapiens	126-129
7510956-4	1994	The nuclear accumulation of [3H]-vitamin D3/receptor complexes (VDR) in a nuclear translocation assay was significantly enhanced (by 3 h) in the presence of camptothecin.	Camptothecin	157-169	vitamin D receptor	Homo sapiens	33-52
7510956-4	1994	The nuclear accumulation of [3H]-vitamin D3/receptor complexes (VDR) in a nuclear translocation assay was significantly enhanced (by 3 h) in the presence of camptothecin.	Camptothecin	157-169	vitamin D receptor	Homo sapiens	64-67
7690896-3	1993	A similar important role of BrdUrd in SCE induction has been reported in the cases of benzamide (BA) (Natarajan et al., 1981) and camptothecin (CPT) (Zhao et al., 1992), which are inhibitors of poly(ADP-ribose)polymerase and DNA topoisomerase I (topo I), respectively.	Camptothecin	130-142	poly(ADP-ribose) polymerase 1	Homo sapiens	194-220
8244980-0	1993	Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance.	Camptothecin	114-126	DNA topoisomerase 1	Cricetulus griseus	27-46
8244980-1	1993	A camptothecin-resistant (DC3F/C-10) Chinese hamster cell line that contains a catalytically altered and camptothecin (CPT)-resistant DNA topoisomerase I (top 1) (Tanizawa, A., and Pommier, Y.	Camptothecin	2-14	DNA topoisomerase 1	Cricetulus griseus	134-153
8244980-1	1993	A camptothecin-resistant (DC3F/C-10) Chinese hamster cell line that contains a catalytically altered and camptothecin (CPT)-resistant DNA topoisomerase I (top 1) (Tanizawa, A., and Pommier, Y.	Camptothecin	105-117	DNA topoisomerase 1	Cricetulus griseus	134-153
8244980-1	1993	A camptothecin-resistant (DC3F/C-10) Chinese hamster cell line that contains a catalytically altered and camptothecin (CPT)-resistant DNA topoisomerase I (top 1) (Tanizawa, A., and Pommier, Y.	Camptothecin	119-122	DNA topoisomerase 1	Cricetulus griseus	134-153
8402636-6	1993	When added simultaneously with CAM or TPT, CAF prevented both effects.	Camptothecin	31-34	lysine acetyltransferase 2B	Homo sapiens	43-46
8402636-10	1993	Thus, the ability of CAF to protect HL-60 cells against the cell kinetic effects of CAM or TPT, as in the case of DNA intercalating topoisomerase II inhibitors, is most likely due to formation of complexes between CAF and these aromatic molecules, which result in reducing the effective concentration of the free form of these drugs available to the cells.	Camptothecin	84-87	lysine acetyltransferase 2B	Homo sapiens	21-24
21566972-0	1994	Bcl-2 gene prevents induction of apoptosis in l1210 murine leukemia-cells by sn-38, a metabolite of the camptothecin derivative cpt-11.	Camptothecin	104-116	B cell leukemia/lymphoma 2	Mus musculus	0-5
8996611-3	1994	The ability of camptothecin to overcome MDR1-mediated resistance may be one important contributing factor to camptothecin"s impressive activity (Chen et al., 1991).	Camptothecin	15-27	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
8996611-3	1994	The ability of camptothecin to overcome MDR1-mediated resistance may be one important contributing factor to camptothecin"s impressive activity (Chen et al., 1991).	Camptothecin	109-121	ATP binding cassette subfamily B member 1	Homo sapiens	40-44
8060894-7	1994	However, examples of the camptothecin derivatives (topotecan and CPT-II) show that we have progressed, but that we still have a long way to travel.	Camptothecin	25-37	carnitine palmitoyltransferase 2	Homo sapiens	65-71
8070019-1	1994	The camptothecin derivative 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy camptothecin (CPT-11) has attracted the attention of clinicians because of its high antitumor activity against refractory solid cancers.	Camptothecin	4-16	choline phosphotransferase 1	Homo sapiens	97-100
8269616-3	1993	Irs2 showed moderate hypersensitivity (2-3-fold) to simple alkylating agents and oxidative mutagens but was most sensitive (8-fold) to the topisomerase I inhibitor camptothecin.	Camptothecin	164-176	insulin receptor substrate 2	Cricetulus griseus	0-4
8269616-8	1993	Camptothecin induced chromosomal aberrations in irs2 consisted almost exclusively of chromatid deletions and exchanges, whilst in irs3 1,3 butadiene diepoxide induced a 50-fold increase in chromatid exchanges compared with V79-4.	Camptothecin	0-12	insulin receptor substrate 2	Cricetulus griseus	48-52
8269616-9	1993	The nature of irs2"s camptothecin hypersensitivity was investigated.	Camptothecin	21-33	insulin receptor substrate 2	Cricetulus griseus	14-18
8231238-0	1993	p145 expression during the cell cycle in HL-60 cell line and normal human lymphocytes: effects of camptothecin, vinblastine, cycloheximide, actinomycin D, retinoic acid and DMSO.	Camptothecin	98-110	POM121 transmembrane nucleoporin	Homo sapiens	0-4
8467505-2	1993	We examined whether constitutive expression of transfected human bcl-2 conferred resistance to two different DNA damaging drugs, nitrogen mustard (HN2) and camptothecin (CPT) in a murine, IL-3 dependent cell line (FL5.12).	Camptothecin	170-173	BCL2 apoptosis regulator	Homo sapiens	65-70
8403196-5	1993	LY-S cells, deficient in the rejoining of DNA double-strand breaks, show enhanced sensitivity to topoisomerase II-targeting inhibitors, whereas LY-R cells have an increased sensitivity to UV radiation and to the topoisomerase I inhibitor, camptothecin.	Camptothecin	239-251	lymphoma resistance	Mus musculus	144-148
7689605-5	1993	The effect of TPA on c-kit expression levels was independent of TPA-mediated induction of differentiation since other compounds including IFN-gamma, vitamin D3, retinoic acid, arabinofuranosylcytosine, butyric acid, and camptothecin, which also effectively induced differentiation of HEL cells, failed to alter levels of c-kit expression.	Camptothecin	220-232	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	21-26
7688089-3	1993	When the Topo I inhibitor camptothecin was used, it showed a higher efficiency to induce both chromosomal aberrations and SCE in EM9 than in AA8.	Camptothecin	26-38	ERCC excision repair 2, TFIIH core complex helicase subunit	Homo sapiens	129-132
8485705-2	1993	Activation of p53-DNA binding was seen for treatment with radiation, hydrogen peroxide, actinomycin D, Adriamycin, etoposide, camptothecin, 5-fluorouracil, mitomycin C, and cisplatin.	Camptothecin	126-138	tumor protein p53	Homo sapiens	14-17
8485705-5	1993	The increase in p53 activation in camptothecin treated cells may result, at least in part, from an increased half-life of the protein and consequent increases in intracellular protein concentration.	Camptothecin	34-46	tumor protein p53	Homo sapiens	16-19
8099964-3	1993	In the present study, we investigated the activities of camptothecin derivatives in inhibiting acetylcholinesterase (AChE) and in binding to muscarinic acetylcholine receptors (AChR).	Camptothecin	56-68	acetylcholinesterase	Canis lupus familiaris	117-121
8099964-9	1993	These results suggest that the inhibition of AChE by camptothecin derivatives with an amino group at the C-10 position (or the C-4 position) relates to the early defecation or diarrhoea and vomiting.	Camptothecin	53-65	acetylcholinesterase	Canis lupus familiaris	45-49
8467505-0	1993	Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis.	Camptothecin	70-82	BCL2 apoptosis regulator	Homo sapiens	33-38
8467505-2	1993	We examined whether constitutive expression of transfected human bcl-2 conferred resistance to two different DNA damaging drugs, nitrogen mustard (HN2) and camptothecin (CPT) in a murine, IL-3 dependent cell line (FL5.12).	Camptothecin	156-168	BCL2 apoptosis regulator	Homo sapiens	65-70
8395887-3	1993	In uniquely end-labeled human c-myc DNA, camptothecin-induced cleavage occurred exclusively at guanines and was markedly enhanced by hot piperidine treatment.	Camptothecin	41-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	30-35
8099964-0	1993	Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats.	Camptothecin	23-35	acetylcholinesterase	Canis lupus familiaris	56-76
8099964-3	1993	In the present study, we investigated the activities of camptothecin derivatives in inhibiting acetylcholinesterase (AChE) and in binding to muscarinic acetylcholine receptors (AChR).	Camptothecin	56-68	acetylcholinesterase	Canis lupus familiaris	95-115
1602973-0	1992	Micronucleus induction by camptothecin and amsacrine in bone marrow of male and female CD-1 mice.	Camptothecin	26-38	CD1 antigen complex	Mus musculus	87-91
8382972-2	1993	Using a filter-binding assay, we observed a strong inhibition of DNA fragmentation induced by 3- and 24-hour continuous exposure to camptothecin, VP-16, VM-26, and m-AMSA in TPA-differentiated cells.	Camptothecin	132-144	plasminogen activator, tissue type	Homo sapiens	174-177
7678901-0	1993	Higher G2 sensitivity to the induction of chromosomal damage in the CHO mutant EM9 than in its parental line AA8 by camptothecin, an inhibitor of DNA topoisomerase I.	Camptothecin	116-128	DNA topoisomerase 1	Cricetulus griseus	146-165
7678901-1	1993	The induction of chromosomal alterations by camptothecin (CPT), an inhibitor of DNA topoisomerase I, in the G2 stage was studied in a CHO mutant cell line EM9, which has an elevated baseline frequency of SCEs, and in its parental cell line AA8.	Camptothecin	44-56	DNA topoisomerase 1	Cricetulus griseus	80-99
7678901-1	1993	The induction of chromosomal alterations by camptothecin (CPT), an inhibitor of DNA topoisomerase I, in the G2 stage was studied in a CHO mutant cell line EM9, which has an elevated baseline frequency of SCEs, and in its parental cell line AA8.	Camptothecin	58-61	DNA topoisomerase 1	Cricetulus griseus	80-99
1426041-4	1992	Upon removal of camptothecin, which induced B23-translocation in HeLa cells, nucleophosmin/B23 relocalized into nucleoli within 2 h. Relocation occurs in the presence of cycloheximide which inhibits new protein synthesis.	Camptothecin	16-28	nucleophosmin 1	Homo sapiens	44-47
1426041-4	1992	Upon removal of camptothecin, which induced B23-translocation in HeLa cells, nucleophosmin/B23 relocalized into nucleoli within 2 h. Relocation occurs in the presence of cycloheximide which inhibits new protein synthesis.	Camptothecin	16-28	nucleophosmin 1	Homo sapiens	77-90
1426041-4	1992	Upon removal of camptothecin, which induced B23-translocation in HeLa cells, nucleophosmin/B23 relocalized into nucleoli within 2 h. Relocation occurs in the presence of cycloheximide which inhibits new protein synthesis.	Camptothecin	16-28	nucleophosmin 1	Homo sapiens	91-94
1426041-10	1992	While actinomycin D and camptothecin cause B23-translocation in all cells, 40% of methotrexate-treated cells remain untranslocated.	Camptothecin	24-36	nucleophosmin 1	Homo sapiens	43-46
8440362-1	1993	The camptothecin derivatives 9-nitro-camptothecin (9NC) and 9-amino-camptothecin (9AC) inhibit similarly growth of HL-60, KG-1, and U-937 cells in vitro, whereas growth of THP-1 cells is inhibited by 9AC, but not by 9NC.	Camptothecin	4-16	GLI family zinc finger 2	Homo sapiens	172-177
11578320-0	1993	Interaction of interferon gamma and CPT-11, a new derivative of camptothecin, in human endometrial carcinoma cell lines.	Camptothecin	64-76	interferon gamma	Homo sapiens	15-42
1336489-1	1992	Recombinant human tumor necrosis factor (rHuTNF) synergistically potentiates the cytotoxicity of the topoisomerase I inhibitor camptothecin, and the topoisomerase II inhibitors epidoxorubicin, etoposide, mitoxantrone, ellipticine, actinomycin D and 4"-(9-acridinylamino)methanesulfon-m-anisidide on A2780 human ovarian cancer cell line.	Camptothecin	127-139	tumor necrosis factor	Homo sapiens	18-39
1383716-3	1992	These lines were also cross-resistant to the eukaryotic topoisomerase II inhibitors etoposide and adriamycin, but showed the same level of sensitivity as the parental line to the DNA topoisomerase I inhibitor camptothecin.	Camptothecin	209-221	DNA topoisomerase 1	Cricetulus griseus	179-198
1596908-10	1992	Treatment of MOLT-4 cells with pharmacological concentrations of methotrexate, camptothecin, or teniposide induced cell arrest in S or G2; expression of p120 in the arrested cells was unchanged from that of untreated MOLT-4 controls at the same phase of the cycle.	Camptothecin	79-91	catenin delta 1	Homo sapiens	153-157
1596908-12	1992	Camptothecin or teniposide induced apoptosis selectively in S phase of HL-60 cells; apoptotic cells from camptothecin-treated cultures, however, despite the marked nucleolysis, still expressed p120.	Camptothecin	105-117	catenin delta 1	Homo sapiens	193-197
1319161-1	1992	Three camptothecin-resistant sublines (V79r, IRS-1r and IRS-2r) of V79 cells and their irradiation-sensitive mutants, IRS-1 and IRS-2, were developed by stepwise, continuous exposure to camptothecin (CPT).	Camptothecin	6-18	insulin receptor substrate 1	Cricetulus griseus	45-50
1319161-1	1992	Three camptothecin-resistant sublines (V79r, IRS-1r and IRS-2r) of V79 cells and their irradiation-sensitive mutants, IRS-1 and IRS-2, were developed by stepwise, continuous exposure to camptothecin (CPT).	Camptothecin	6-18	insulin receptor substrate 2	Cricetulus griseus	56-61
21584513-3	1992	Exposure to inhibitors of DNA topoisomerase I (camptothecin: CPT-11) and II (etoposide: VP-16 and teniposide: VM-26) could efficiently induce CAT activities in both time- and dose-dependent manners.	Camptothecin	47-59	host cell factor C1	Homo sapiens	88-93
21584513-3	1992	Exposure to inhibitors of DNA topoisomerase I (camptothecin: CPT-11) and II (etoposide: VP-16 and teniposide: VM-26) could efficiently induce CAT activities in both time- and dose-dependent manners.	Camptothecin	47-59	catalase	Homo sapiens	142-145
1312349-1	1992	We have compared topoisomerase I and II cleavage sites on the actin 5C and 57A genes and the hsp70 genes in Drosophila Kc cells using the inhibitors camptothecin (topoisomerase I specific) and VM-26 (topoisomerase II specific) to assess the role of these enzymes in transcriptional regulation.	Camptothecin	149-161	Topoisomerase 1	Drosophila melanogaster	163-178
1312900-0	1992	The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B.	Camptothecin	43-55	cyclin dependent kinase 1	Homo sapiens	97-104
1312900-3	1992	Brief camptothecin treatment of early S-phase HeLa cells caused arrest at G2 phase and abolished the activation of p34cdc2 protein kinase.	Camptothecin	6-18	cyclin dependent kinase 1	Homo sapiens	115-122
1737386-4	1992	Under those conditions, camptothecin induced differentiation, as demonstrated by (a) the capacity of the cells to generate reactive oxygen species, (b) the increase in the surface expression of the leukocyte integrins CD11b/CD18 and CD11c/CD18, (c) the increase in the cellular content of the intermediate filament protein vimentin, and (d) the decrease in the surface expression of the transferrin receptor.	Camptothecin	24-36	integrin subunit alpha M	Homo sapiens	218-223
1737386-4	1992	Under those conditions, camptothecin induced differentiation, as demonstrated by (a) the capacity of the cells to generate reactive oxygen species, (b) the increase in the surface expression of the leukocyte integrins CD11b/CD18 and CD11c/CD18, (c) the increase in the cellular content of the intermediate filament protein vimentin, and (d) the decrease in the surface expression of the transferrin receptor.	Camptothecin	24-36	integrin subunit beta 2	Homo sapiens	224-228
1737386-4	1992	Under those conditions, camptothecin induced differentiation, as demonstrated by (a) the capacity of the cells to generate reactive oxygen species, (b) the increase in the surface expression of the leukocyte integrins CD11b/CD18 and CD11c/CD18, (c) the increase in the cellular content of the intermediate filament protein vimentin, and (d) the decrease in the surface expression of the transferrin receptor.	Camptothecin	24-36	integrin subunit alpha X	Homo sapiens	233-238
1737386-4	1992	Under those conditions, camptothecin induced differentiation, as demonstrated by (a) the capacity of the cells to generate reactive oxygen species, (b) the increase in the surface expression of the leukocyte integrins CD11b/CD18 and CD11c/CD18, (c) the increase in the cellular content of the intermediate filament protein vimentin, and (d) the decrease in the surface expression of the transferrin receptor.	Camptothecin	24-36	integrin subunit beta 2	Homo sapiens	239-243
1737386-4	1992	Under those conditions, camptothecin induced differentiation, as demonstrated by (a) the capacity of the cells to generate reactive oxygen species, (b) the increase in the surface expression of the leukocyte integrins CD11b/CD18 and CD11c/CD18, (c) the increase in the cellular content of the intermediate filament protein vimentin, and (d) the decrease in the surface expression of the transferrin receptor.	Camptothecin	24-36	vimentin	Homo sapiens	323-331
1737386-4	1992	Under those conditions, camptothecin induced differentiation, as demonstrated by (a) the capacity of the cells to generate reactive oxygen species, (b) the increase in the surface expression of the leukocyte integrins CD11b/CD18 and CD11c/CD18, (c) the increase in the cellular content of the intermediate filament protein vimentin, and (d) the decrease in the surface expression of the transferrin receptor.	Camptothecin	24-36	transferrin receptor	Homo sapiens	387-407
1737386-5	1992	Camptothecin also induced the expression of differentiation markers in other human myeloid cells, namely, the promonocytic THP-1 and the myelomonocytic HL-60 cell lines.	Camptothecin	0-12	GLI family zinc finger 2	Homo sapiens	123-128
1737386-6	1992	Northern blot assays revealed that camptothecin stimulated the expression of CD11b, CD11c, and vimentin at the mRNA level.	Camptothecin	35-47	integrin subunit alpha M	Homo sapiens	77-82
1737386-6	1992	Northern blot assays revealed that camptothecin stimulated the expression of CD11b, CD11c, and vimentin at the mRNA level.	Camptothecin	35-47	integrin subunit alpha X	Homo sapiens	84-89
1737386-6	1992	Northern blot assays revealed that camptothecin stimulated the expression of CD11b, CD11c, and vimentin at the mRNA level.	Camptothecin	35-47	vimentin	Homo sapiens	95-103
1309380-1	1992	PURPOSE: Camptothecin-11 (CPT-11) is a new semisynthetic derivative of CPT, and has been shown to inhibit DNA topoisomerase I and to have a strong antitumor activity with low toxicity in murine tumors.	Camptothecin	26-29	topoisomerase (DNA) I	Mus musculus	106-125
1310495-1	1992	DNA topoisomerase I, a nuclear enzyme important for solving topologic problems arising during DNA replication, has been identified as a principal target of a plant alkaloid, 20(s)-camptothecin.	Camptothecin	180-192	topoisomerase (DNA) I	Mus musculus	0-19
1680548-2	1991	We found that camptothecin, teniposide (VM-26), or genistein, specific inhibitors of topoisomerases, induced morphological as well as biochemical changes (production of tissue plasminogen activator, synthesis of laminin, and disappearance of stage-specific embryonic antigen 1) specific to F9 cell differentiation.	Camptothecin	14-26	fucosyltransferase 4	Mus musculus	242-276
1742737-0	1991	Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells.	Camptothecin	0-12	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	58-63
1742737-4	1991	The present studies demonstrate that 20(S)-camptothecin, 9-amino-20(S)-camptothecin, and 9-nitro-20(S)-camptothecin inhibit the growth of human U-937 myeloid leukemia cells and induce expression of the c-jun gene.	Camptothecin	37-55	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	202-207
1742737-7	1991	H7, a nonselective inhibitor of protein kinase C, completely blocked c-jun expression in 20(S)-camptothecin-treated cells, while another protein kinase inhibitor, HA1004, had no detectable effect.	Camptothecin	95-107	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	69-74
1682041-0	1991	Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells.	Camptothecin	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	23-27
1682041-1	1991	In order to understand the high efficacy of camptothecin derivatives against human colon tumor xenografts in nude mice, we have studied the transport properties of camptothecin derivatives across cellular membranes of MDR1-overexpressing cells.	Camptothecin	164-176	malic enzyme complex, mitochondrial	Mus musculus	218-222
1682041-4	1991	The mechanism by which camptothecin overcomes MDR1-mediated resistance has been further studied using a number of uncharged and charged camptothecin derivatives.	Camptothecin	23-35	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
1682041-7	1991	These results suggest that the charge on camptothecin can affect the drug"s sensitivity to MDR1.	Camptothecin	41-53	ATP binding cassette subfamily B member 1	Homo sapiens	91-95
1804390-0	1991	Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines.	Camptothecin	74-86	tumor necrosis factor	Homo sapiens	91-112
1650187-2	1991	Camptothecin, a DNA topoisomerase I blocker, inhibited the increase in progesterone and oestradiol production stimulated by FSH.	Camptothecin	0-12	DNA topoisomerase I	Rattus norvegicus	16-35
2032244-1	1991	20-(S)-Camptothecin (CAM), a plant alkaloid, was tested against 13 human cancer xenograft lines carried by immunodeficient (nude) mice.	Camptothecin	21-24	calmodulin 3	Homo sapiens	0-19
2012400-2	1991	An early Phase II study of CTP-11, a new derivative of Camptothecin, in gynecologic cancers was carried out by a cooperative study group of 9 institutions.	Camptothecin	55-67	SPANX family member C	Homo sapiens	27-33
1848545-1	1991	DNA topoisomerase inhibitors, camptothecin and 4"-demethylepipodophyllotoxin ethylidene-beta-D-glucoside (VP16) had strong differentiation-inducing activity for all five kinds of leukemia cells examined (human HL60, U937, ML1, and K562 cells and mouse M1 cells) as judged from measurements of various differentiation markers.	Camptothecin	30-42	interleukin 17F	Homo sapiens	222-225
1847484-2	1991	We tested the effects of camptothecin and VP16, specific inhibitors of topo I and II, respectively, on the DNA replication of parvoviruses LuIII and H-1 and found that viral DNA synthesis was suppressed by camptothecin but not by VP16.	Camptothecin	206-218	host cell factor C1	Homo sapiens	42-46
2170526-4	1990	Camptothecin, a specific inhibitor of topoisomerase I, enhanced TNF cytotoxicity 150-fold against both cell lines.	Camptothecin	0-12	tumor necrosis factor	Mus musculus	64-67
1668830-3	1991	ANF, which induces cGMP accumulation, potentiated camptothecin-induced, topoisomerase I linked DNA strand breakage and increased the specific activity of extractable topoisomerase I (maximum activity 5-15 min after treatment), but had no effect on topoisomerase II activity.	Camptothecin	50-62	natriuretic peptide A	Rattus norvegicus	0-3
2170010-1	1990	DNA topoisomerase I (topo I) has been identified as a principal target of a plant alkaloid camptothecin (CPT) and its derivative (CPT-11).	Camptothecin	91-103	choline phosphotransferase 1	Homo sapiens	105-108
2170010-1	1990	DNA topoisomerase I (topo I) has been identified as a principal target of a plant alkaloid camptothecin (CPT) and its derivative (CPT-11).	Camptothecin	91-103	choline phosphotransferase 1	Homo sapiens	130-133
2174738-1	1990	In a previous study, we established camptothecin (CPT)-resistant cell lines, A549/CPT and HT-29/CPT, from human lung cancer A549 and human colon cancer HT-29.	Camptothecin	36-48	choline phosphotransferase 1	Homo sapiens	50-53
2174738-1	1990	In a previous study, we established camptothecin (CPT)-resistant cell lines, A549/CPT and HT-29/CPT, from human lung cancer A549 and human colon cancer HT-29.	Camptothecin	36-48	choline phosphotransferase 1	Homo sapiens	82-85
2174738-1	1990	In a previous study, we established camptothecin (CPT)-resistant cell lines, A549/CPT and HT-29/CPT, from human lung cancer A549 and human colon cancer HT-29.	Camptothecin	36-48	choline phosphotransferase 1	Homo sapiens	82-85
33774201-3	2021	AlP/CPT-NPs were prepared using photosensitizer Al(III) phthalocyanine chloride disulfonic acid (AlP) and ROS-activatable camptothecin prodrug (CPT-PD).	Camptothecin	122-134	ATHS	Homo sapiens	0-3
2158396-1	1990	A combination of tumor necrosis factor (TNF) and the topoisomerase I inhibitor, camptothecin, or the topoisomerase II inhibitors, teniposide and amsacrine, produced dose-dependent synergistic cytotoxicity against the murine L929 fibrosarcoma cells.	Camptothecin	80-92	tumor necrosis factor	Mus musculus	17-38
2158396-7	1990	Preincubation of the cells with TNF for 30 min or 3 h before the addition of camptothecin or etoposide resulted in no more strand breaks than that observed in cells incubated with the drugs alone.	Camptothecin	77-89	tumor necrosis factor	Mus musculus	32-35
2308592-6	1990	Both irs1 and irs2 were found to be considerably more sensitive to the DNA topoisomerase I-inhibitor camptothecin, while irs3 was only slightly more sensitive than the parent V79 line.	Camptothecin	101-113	insulin receptor substrate 1	Cricetulus griseus	5-9
2308592-6	1990	Both irs1 and irs2 were found to be considerably more sensitive to the DNA topoisomerase I-inhibitor camptothecin, while irs3 was only slightly more sensitive than the parent V79 line.	Camptothecin	101-113	insulin receptor substrate 2	Cricetulus griseus	14-18
2302199-1	1990	Low concentrations of camptothecin induced differentiation of human and mouse myeloid leukemia cells including human HL60, U937, ML1, and K562 cells and mouse M1 cells as measured by various differentiation-associated properties.	Camptothecin	22-34	interleukin 17F	Homo sapiens	129-132
2302199-5	1990	The combination of camptothecin and rTNF synergistically induced differentiation of human ML1, U937, and M1 cells.	Camptothecin	19-31	interleukin 17F	Homo sapiens	90-93
2153054-2	1990	We show that the topoisomerase I inhibitor camptothecin can be used to measure topoisomerase I activity throughout the transcription cycle of the c-fos gene.	Camptothecin	43-55	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	146-151
2153054-3	1990	Upon induction of c-fos transcription in the presence of camptothecin, topoisomerase I cleavages spread through the gene in the 5" to 3" direction and concomitantly transcriptional elongation is retarded.	Camptothecin	57-69	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-23
33774201-9	2021	Upon 660 nm light exposure, the 1O2 generated by AlP/CPT-NPs could initiate immediate disassembly of AlP/CPT-NPs and further promote cytoplasmic delivery of the therapeutic payloads (camptothecin, CPT).	Camptothecin	183-195	ATHS	Homo sapiens	49-52
33774201-9	2021	Upon 660 nm light exposure, the 1O2 generated by AlP/CPT-NPs could initiate immediate disassembly of AlP/CPT-NPs and further promote cytoplasmic delivery of the therapeutic payloads (camptothecin, CPT).	Camptothecin	183-195	ATHS	Homo sapiens	101-104
31350527-0	2019	Correction: Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs.	Camptothecin	12-24	NFE2 like bZIP transcription factor 2	Homo sapiens	36-40
33237422-7	2021	Our array data suggest that camptothecin treatment induced DNA double-strand breaks in Jurkat cells and activated the DNA damage pathways ATM and Chk2, which then further induced apoptosis through caspase 3 and PARP.	Camptothecin	28-40	ATM serine/threonine kinase	Homo sapiens	138-141
33237422-7	2021	Our array data suggest that camptothecin treatment induced DNA double-strand breaks in Jurkat cells and activated the DNA damage pathways ATM and Chk2, which then further induced apoptosis through caspase 3 and PARP.	Camptothecin	28-40	checkpoint kinase 2	Homo sapiens	146-150
33237422-7	2021	Our array data suggest that camptothecin treatment induced DNA double-strand breaks in Jurkat cells and activated the DNA damage pathways ATM and Chk2, which then further induced apoptosis through caspase 3 and PARP.	Camptothecin	28-40	caspase 3	Homo sapiens	197-206
33237422-7	2021	Our array data suggest that camptothecin treatment induced DNA double-strand breaks in Jurkat cells and activated the DNA damage pathways ATM and Chk2, which then further induced apoptosis through caspase 3 and PARP.	Camptothecin	28-40	collagen type XI alpha 2 chain	Homo sapiens	211-215
33812400-4	2021	The effect of camptothecin (CPT) on the proliferation and chemosensitivity of THP-1 cells affected by Bmi-1 gene were detected by MTT assay.	Camptothecin	14-26	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	102-107
33812400-4	2021	The effect of camptothecin (CPT) on the proliferation and chemosensitivity of THP-1 cells affected by Bmi-1 gene were detected by MTT assay.	Camptothecin	28-31	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	102-107
24726431-6	2014	HaCaTs have impaired responses to p53/SIRT1/miR-34a axis manipulation which enhanced survival during exposure to the chemotherapeutic agent, camptothecin.	Camptothecin	141-153	tumor protein p53	Homo sapiens	34-37
24726431-6	2014	HaCaTs have impaired responses to p53/SIRT1/miR-34a axis manipulation which enhanced survival during exposure to the chemotherapeutic agent, camptothecin.	Camptothecin	141-153	sirtuin 1	Homo sapiens	38-43
24726431-6	2014	HaCaTs have impaired responses to p53/SIRT1/miR-34a axis manipulation which enhanced survival during exposure to the chemotherapeutic agent, camptothecin.	Camptothecin	141-153	microRNA 34a	Homo sapiens	44-51
24726431-7	2014	Inhibition of SIRT1 activity in this cell line increased p53 acetylation and doubled camptothecin-induced cell death.	Camptothecin	85-97	sirtuin 1	Homo sapiens	14-19
10734098-0	2000	NF-kappaB activation by camptothecin.	Camptothecin	24-36	nuclear factor kappa B subunit 1	Homo sapiens	0-9
10734098-3	2000	NF-kappaB can also be activated by the anticancer agent camptothecin (CPT), which inhibits DNA topoisomerase (Topo) I activity and causes DNA double-strand breaks during DNA replication to induce S phase-dependent cytotoxicity.	Camptothecin	70-73	nuclear factor kappa B subunit 1	Homo sapiens	0-9
10734098-3	2000	NF-kappaB can also be activated by the anticancer agent camptothecin (CPT), which inhibits DNA topoisomerase (Topo) I activity and causes DNA double-strand breaks during DNA replication to induce S phase-dependent cytotoxicity.	Camptothecin	56-68	nuclear factor kappa B subunit 1	Homo sapiens	0-9
34547508-0	2021	A camptothecin-based, albumin-binding prodrug enhances efficacy and safety in vivo.	Camptothecin	2-14	albumin	Mus musculus	22-29
34649567-13	2021	Antisense oligonucleotides (ASOs) against circIPO11 combined with TOP1 inhibitor camptothecin (CPT) exert synergistic antitumor effect.	Camptothecin	81-93	DNA topoisomerase I	Homo sapiens	66-70
34819354-4	2021	Notably, this nucleolar RPA phenotype was also observed in the presence of camptothecin (CPT)-induced genotoxic stress, as well as in SETX-deficient AOA2 patient fibroblasts.	Camptothecin	75-87	replication protein A1	Homo sapiens	24-27
34819354-4	2021	Notably, this nucleolar RPA phenotype was also observed in the presence of camptothecin (CPT)-induced genotoxic stress, as well as in SETX-deficient AOA2 patient fibroblasts.	Camptothecin	89-92	replication protein A1	Homo sapiens	24-27
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Camptothecin	117-129	apoptosis inducing factor mitochondria associated 1	Homo sapiens	137-140
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Camptothecin	117-129	apoptosis inducing factor mitochondria associated 1	Homo sapiens	199-202
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Camptothecin	117-129	peptidylprolyl isomerase A	Homo sapiens	214-218
34694772-7	2021	On the other hand, treatment with apoptosis inducers, such as paclitaxel, silibinin, doxorubicin, actinomycin D, and camptothecin caused AIF translocation to the nucleus after 4 h incubation through AIF binding to CypA, reaching saturation after 6-7 h. It was also found that Hsp70 and CypA regulate AIF translocation in a mutually exclusive manner because they do not interact with AIF simultaneously in cells undergoing apoptosis.	Camptothecin	117-129	apoptosis inducing factor mitochondria associated 1	Homo sapiens	300-303
34825166-1	2021	Camptothecin (CPT) exhibits a number of challenges for its oral administration, including a low aqueous solubility, a lactone ring susceptible to hydrolysis, and an affinity to the intestinal P-gp.	Camptothecin	0-12	phosphoglycolate phosphatase	Rattus norvegicus	192-196
34825166-1	2021	Camptothecin (CPT) exhibits a number of challenges for its oral administration, including a low aqueous solubility, a lactone ring susceptible to hydrolysis, and an affinity to the intestinal P-gp.	Camptothecin	14-17	phosphoglycolate phosphatase	Rattus norvegicus	192-196
34519602-1	2021	A novel tumor-targeted glutathione responsive Glycosylated-Camptothecin nanosupramolecular prodrug (CPT-GL NSp) was designed and fabricated via a disulfide bond.	Camptothecin	59-71	serine peptidase inhibitor Kazal type 5	Homo sapiens	107-110
34159519-0	2021	Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs.	Camptothecin	84-96	tyrosyl-DNA phosphodiesterase 1	Homo sapiens	11-15
34649567-13	2021	Antisense oligonucleotides (ASOs) against circIPO11 combined with TOP1 inhibitor camptothecin (CPT) exert synergistic antitumor effect.	Camptothecin	95-98	DNA topoisomerase I	Homo sapiens	66-70
34385682-4	2021	We demonstrate that sphingomyelin-derived camptothecin nanovesicles (camptothesomes) elicit potent granzyme-B- and perforin-mediated cytotoxic T lymphocyte (CTL) responses, potentiating PD-L1/PD-1 co-blockade to eradicate subcutaneous MC38 adenocarcinoma with developed memory immunity.	Camptothecin	42-54	granzyme B	Homo sapiens	99-109
34385682-4	2021	We demonstrate that sphingomyelin-derived camptothecin nanovesicles (camptothesomes) elicit potent granzyme-B- and perforin-mediated cytotoxic T lymphocyte (CTL) responses, potentiating PD-L1/PD-1 co-blockade to eradicate subcutaneous MC38 adenocarcinoma with developed memory immunity.	Camptothecin	42-54	CD274 molecule	Homo sapiens	186-191
34385682-4	2021	We demonstrate that sphingomyelin-derived camptothecin nanovesicles (camptothesomes) elicit potent granzyme-B- and perforin-mediated cytotoxic T lymphocyte (CTL) responses, potentiating PD-L1/PD-1 co-blockade to eradicate subcutaneous MC38 adenocarcinoma with developed memory immunity.	Camptothecin	42-54	programmed cell death 1	Homo sapiens	192-196
34205418-3	2021	The inhibition of RNA polymerase II with 5,6-dichloro-l-beta-D-ribofuranosyl benzimidazole (DRB), or actinomycin D (AD), and of topoisomerase I with camptothecin (CPT) resulted in an increase in chromatin-bound XPG, with concomitant relocation by forming nuclear clusters.	Camptothecin	149-161	ERCC excision repair 5, endonuclease	Homo sapiens	211-214
34500463-5	2021	Moreover, we show that XAB2 prevents Ku retention and abortive HR at seDSBs induced by temozolomide and camptothecin, via a pathway that operates in parallel to the ATM-CtIP-MRE11 axis.	Camptothecin	104-116	XPA binding protein 2	Homo sapiens	23-27
34500463-5	2021	Moreover, we show that XAB2 prevents Ku retention and abortive HR at seDSBs induced by temozolomide and camptothecin, via a pathway that operates in parallel to the ATM-CtIP-MRE11 axis.	Camptothecin	104-116	MRE11 homolog, double strand break repair nuclease	Homo sapiens	174-179
34572735-2	2021	Inhibition of MDM2 expression in the SKBR3 cell line (HER2 subtype) diminished the survival of cancer cells treated with doxorubicin, etoposide, and camptothecin.	Camptothecin	149-161	MDM2 proto-oncogene	Homo sapiens	14-18
34572735-2	2021	Inhibition of MDM2 expression in the SKBR3 cell line (HER2 subtype) diminished the survival of cancer cells treated with doxorubicin, etoposide, and camptothecin.	Camptothecin	149-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
34226554-7	2021	Moreover, defects in DHX9 also lead to impaired ATR-mediated damage signalling and an inability to restart DNA replication at camptothecin-induced DSB.	Camptothecin	126-138	DExH-box helicase 9	Homo sapiens	21-25
34496254-3	2021	By exploiting ATF3 reporter systems, we identify topoisomerase inhibitors as ATF3 inducers, including camptothecin.	Camptothecin	102-114	activating transcription factor 3	Homo sapiens	14-18
34496254-3	2021	By exploiting ATF3 reporter systems, we identify topoisomerase inhibitors as ATF3 inducers, including camptothecin.	Camptothecin	102-114	activating transcription factor 3	Homo sapiens	77-81
34496254-4	2021	Camptothecin increases ATF3 expression and promotes neurite outgrowth in sensory neurons in vitro and enhances axonal regeneration after sciatic nerve crush in vivo.	Camptothecin	0-12	activating transcription factor 3	Homo sapiens	23-27
34337875-9	2021	Eventually, GEO data showed that JQ1, actinomycin D1, and camptothecin could reduce the expression of AURKA gene in different cancer cell lines (logFC < 1, p < 0.01).	Camptothecin	58-70	aurora kinase A	Homo sapiens	102-107
34138544-0	2021	Correction to Bifunctional Cytochrome P450 Enzymes Involved in Camptothecin Biosynthesis.	Camptothecin	63-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
34201500-5	2021	Out of 3685 compounds tested, the alkaloid drug Camptothecin (CPT) and its derivatives 10-Hydroxycamtothecin (10-HCPT) and 7-Ethyl-10-hydroxycamtothecin (SN-38: the active metabolite of the drug Irinotecan) appeared most effective at very low nanomolar concentrations in all ALL cell lines, including models of MLL-rearranged ALL (n = 3).	Camptothecin	48-60	lysine methyltransferase 2A	Homo sapiens	311-314
34205418-3	2021	The inhibition of RNA polymerase II with 5,6-dichloro-l-beta-D-ribofuranosyl benzimidazole (DRB), or actinomycin D (AD), and of topoisomerase I with camptothecin (CPT) resulted in an increase in chromatin-bound XPG, with concomitant relocation by forming nuclear clusters.	Camptothecin	163-166	ERCC excision repair 5, endonuclease	Homo sapiens	211-214
35430566-7	2022	RESULTS: SLFN12 over-expression increased TNBC sensitivity to radiation, carboplatin, paclitaxel, zoledronic acid, and camptothecin, but not to olaparib.	Camptothecin	119-131	schlafen family member 12	Homo sapiens	9-15
34178646-0	2021	Nrf2 Down-Regulation by Camptothecin Favors Inhibiting Invasion, Metastasis and Angiogenesis in Hepatocellular Carcinoma.	Camptothecin	24-36	nuclear factor, erythroid derived 2, like 2	Mus musculus	0-4
34178646-3	2021	The chemotherapeutics such as epirubicin (EPI) could increase Nrf2 expression, while Camptothecin (CPT) could inhibit tumor growth by down-regulating the key molecule of antioxidant stress signal-Nrf2.	Camptothecin	85-97	nuclear factor, erythroid derived 2, like 2	Mus musculus	196-200
34178646-3	2021	The chemotherapeutics such as epirubicin (EPI) could increase Nrf2 expression, while Camptothecin (CPT) could inhibit tumor growth by down-regulating the key molecule of antioxidant stress signal-Nrf2.	Camptothecin	99-102	nuclear factor, erythroid derived 2, like 2	Mus musculus	196-200
35430566-8	2022	SLFN12 over-expression decreased CHK1 and CHK2 phosphorylation after treatment with the DNA damaging agent camptothecin (CPT).	Camptothecin	107-119	schlafen family member 12	Homo sapiens	0-6
35430566-8	2022	SLFN12 over-expression decreased CHK1 and CHK2 phosphorylation after treatment with the DNA damaging agent camptothecin (CPT).	Camptothecin	107-119	checkpoint kinase 1	Homo sapiens	33-37
35430566-8	2022	SLFN12 over-expression decreased CHK1 and CHK2 phosphorylation after treatment with the DNA damaging agent camptothecin (CPT).	Camptothecin	107-119	checkpoint kinase 2	Homo sapiens	42-46
35430566-8	2022	SLFN12 over-expression decreased CHK1 and CHK2 phosphorylation after treatment with the DNA damaging agent camptothecin (CPT).	Camptothecin	121-124	schlafen family member 12	Homo sapiens	0-6
35430566-8	2022	SLFN12 over-expression decreased CHK1 and CHK2 phosphorylation after treatment with the DNA damaging agent camptothecin (CPT).	Camptothecin	121-124	checkpoint kinase 1	Homo sapiens	33-37
35430566-8	2022	SLFN12 over-expression decreased CHK1 and CHK2 phosphorylation after treatment with the DNA damaging agent camptothecin (CPT).	Camptothecin	121-124	checkpoint kinase 2	Homo sapiens	42-46
35064653-3	2022	Moreover, in order to further improve its fluorescent yield and therapeutic effect, camptothecin prodrug (CPT-S-PEG) and novel immune checkpoint inhibitor AZD4635 are used to co-assemble with TST into nanoparticles for drug delivery.	Camptothecin	84-96	thiosulfate sulfurtransferase	Homo sapiens	192-195
35345325-1	2022	BACKGROUND: Inhibition of human topoisomerase I (TOP1) by camptothecin and topotecan has been shown to reduce excessive transcription of PAMP (Pathogen-Associated Molecular Pattern)-induced genes in prior studies, preventing death from sepsis in animal models of bacterial and SARS-CoV-2 infections.	Camptothecin	58-70	DNA topoisomerase I	Homo sapiens	49-53
35456987-5	2022	Noteworthy is that while direct irradiation activated only ATM, both ATM and ATR were activated by two factors known to induce the replication stress: hydroxyurea and camptothecin (with subsequent phosphorylation of gamma H2A.X).	Camptothecin	167-179	ATM serine/threonine kinase	Homo sapiens	59-62
35456987-5	2022	Noteworthy is that while direct irradiation activated only ATM, both ATM and ATR were activated by two factors known to induce the replication stress: hydroxyurea and camptothecin (with subsequent phosphorylation of gamma H2A.X).	Camptothecin	167-179	ATM serine/threonine kinase	Homo sapiens	69-72
35456987-5	2022	Noteworthy is that while direct irradiation activated only ATM, both ATM and ATR were activated by two factors known to induce the replication stress: hydroxyurea and camptothecin (with subsequent phosphorylation of gamma H2A.X).	Camptothecin	167-179	ATR serine/threonine kinase	Homo sapiens	77-80
35456987-5	2022	Noteworthy is that while direct irradiation activated only ATM, both ATM and ATR were activated by two factors known to induce the replication stress: hydroxyurea and camptothecin (with subsequent phosphorylation of gamma H2A.X).	Camptothecin	167-179	H2A.X variant histone	Homo sapiens	222-227
35219381-5	2022	Targeting PACMP alone inhibits tumor growth by causing a synthetic lethal interaction between CtIP and PARP inhibitions and confers sensitivity to PARP/ATR/CDK4/6 inhibitors, ionizing radiation, epirubicin, and camptothecin.	Camptothecin	211-223	RB binding protein 8, endonuclease	Homo sapiens	94-98
35219381-5	2022	Targeting PACMP alone inhibits tumor growth by causing a synthetic lethal interaction between CtIP and PARP inhibitions and confers sensitivity to PARP/ATR/CDK4/6 inhibitors, ionizing radiation, epirubicin, and camptothecin.	Camptothecin	211-223	poly(ADP-ribose) polymerase 1	Homo sapiens	103-107
35357810-2	2022	Here, we engineered a sequential ultrasound (US)/hypoxia-sensitive sonochemotherapeutic nanoprodrug by initially synthesizing the hypoxia-activated azo bond-containing camptothecin (CPT) prodrug (CPT2-Azo) and then immobilizing it into the mesopores of sonosensitizer-integrated metal organic frameworks (MOF NPs).	Camptothecin	168-180	carnitine palmitoyltransferase 2	Homo sapiens	196-200
35064653-4	2022	On account of the strong interaction of camptothecin and TST, the intramolecular rotation of TST is limited, thereby inhibiting non-radiation attenuation and promoting fluorescence generation when the nanoparticles are intact.	Camptothecin	40-52	thiosulfate sulfurtransferase	Homo sapiens	57-60
35064653-4	2022	On account of the strong interaction of camptothecin and TST, the intramolecular rotation of TST is limited, thereby inhibiting non-radiation attenuation and promoting fluorescence generation when the nanoparticles are intact.	Camptothecin	40-52	thiosulfate sulfurtransferase	Homo sapiens	93-96
35064653-6	2022	The released TST enhances non-radiative attenuation and expedites photothermal conversion because of the removal of the constraint of camptothecin.	Camptothecin	134-146	thiosulfate sulfurtransferase	Homo sapiens	13-16
35192728-3	2022	In this study, we used preclinical models of aggressive neuroblastoma featuring these characteristic mechanisms of primary and acquired drug resistance to experimentally evaluate a macromolecular prodrug of a structurally enhanced camptothecin analog, SN22, resisting ABCG2-mediated export, and glucuronidation.	Camptothecin	231-243	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	268-273
35192728-4	2022	Together with extended tumor exposure to therapeutically effective drug levels via reversible conjugation to Pluronic F-108 (PF108), these features translated into rapid tumor regression and long-term survival in models of both ABCG2-overexpressing and p53-mutant high-risk neuroblastomas, in contrast to a marginal effect of the clinically used camptothecin derivative, irinotecan.	Camptothecin	346-358	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	228-233
35192728-4	2022	Together with extended tumor exposure to therapeutically effective drug levels via reversible conjugation to Pluronic F-108 (PF108), these features translated into rapid tumor regression and long-term survival in models of both ABCG2-overexpressing and p53-mutant high-risk neuroblastomas, in contrast to a marginal effect of the clinically used camptothecin derivative, irinotecan.	Camptothecin	346-358	tumor protein p53	Homo sapiens	253-256
35163672-4	2022	In this study, a structurally enhanced camptothecin analog, SN22, reversibly coupled with a redox-silent tocol derivative (tocopheryl oxamate) to allow its optimally stable encapsulation and controlled release from PEGylated sub-100 nm nanoparticles (NP), exhibited strong NB cell growth inhibitory activity, translating into rapid regression and durably suppressed regrowth of orthotopic, MYCN-amplified NB tumors.	Camptothecin	39-51	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	390-394
35202387-0	2022	Camptothecin effectively treats obesity in mice through GDF15 induction.	Camptothecin	0-12	growth differentiation factor 15	Mus musculus	56-61
35202387-2	2022	Here, through in silico drug-screening methods, we found that small molecule Camptothecin (CPT), a previously identified drug with potential antitumor activity, is a GDF15 inducer.	Camptothecin	77-89	growth differentiation factor 15	Mus musculus	166-171
35291312-3	2022	Top1 is targeted by the widely used anti-cancer chemotherapeutic camptothecin (CPT) and its derivatives, which stabilize Top1 covalently attached on a DNA nick and prevent the re-ligation step.	Camptothecin	65-77	DNA topoisomerase I	Homo sapiens	0-4
35291312-3	2022	Top1 is targeted by the widely used anti-cancer chemotherapeutic camptothecin (CPT) and its derivatives, which stabilize Top1 covalently attached on a DNA nick and prevent the re-ligation step.	Camptothecin	65-77	DNA topoisomerase I	Homo sapiens	121-125
35291312-3	2022	Top1 is targeted by the widely used anti-cancer chemotherapeutic camptothecin (CPT) and its derivatives, which stabilize Top1 covalently attached on a DNA nick and prevent the re-ligation step.	Camptothecin	79-82	DNA topoisomerase I	Homo sapiens	0-4
35291312-3	2022	Top1 is targeted by the widely used anti-cancer chemotherapeutic camptothecin (CPT) and its derivatives, which stabilize Top1 covalently attached on a DNA nick and prevent the re-ligation step.	Camptothecin	79-82	DNA topoisomerase I	Homo sapiens	121-125
35053556-1	2022	To improve tumor selectivity of cytotoxic agents, we designed VIP236, a small molecule-drug conjugate consisting of an alphaVbeta3 integrin binder linked to a modified camptothecin payload (VIP126), which is released by the enzyme neutrophil elastase (NE) in the tumor microenvironment (TME).	Camptothecin	168-180	elastase, neutrophil expressed	Mus musculus	231-250
35087822-4	2021	While preferentially dependent on canonical STING, we demonstrate that genotoxic DNA damage induced by camptothecin (CPT) also drove IL-6 production through non-canonical STING signaling in selected cancer cells.	Camptothecin	103-115	interleukin 6	Homo sapiens	133-137
35087822-4	2021	While preferentially dependent on canonical STING, we demonstrate that genotoxic DNA damage induced by camptothecin (CPT) also drove IL-6 production through non-canonical STING signaling in selected cancer cells.	Camptothecin	117-120	interleukin 6	Homo sapiens	133-137
35111947-7	2022	By using the collagen-induced arthritis rat model, we demonstrate that the hydrogel-camptothecin formulation could alleviate arthritis severity as indicated by the joint size and interleukin-1beta level in the harvested joints, as well as from histological and microcomputed tomography evaluation of joints.	Camptothecin	84-96	interleukin 1 beta	Rattus norvegicus	179-196